0001437749-24-03491610-Q ZEVRA THERAPEUTICS, INC. 20241113202411131618341618351615835 0 0001437749-24-034916 10-Q 78 20240930 20241113 20241113 ZEVRA THERAPEUTICS, INC. 0001434647 2834 205894398 DE 1231 10-Q 34 001-36913 241454558 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747 (321) 939-3416 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747 KEMPHARM, INC 20130530 KEMPHARM INC 20080507 10-Q 1 zvra20240930_10q.htm FORM 10-Q zvra20240930_10q.htm 0001434647 ZEVRA THERAPEUTICS, INC. false --12-31 Q3 2024 0.0001 0.0001 10,000,000 10,000,000 0 0 0 0 0.0001 0.0001 250,000,000 250,000,000 54,803,056 53,227,364 43,110,360 41,534,668 1,545 4,619 64.5 0 0 0 20 0 0 0.9 0 0 0 0 0 0 0 0 250,000,000 10,000,000 0 0 4,900,000 0 2.5 2,462 4.7 2.0 13 0 0 6.5 6.5 6.5 6.5 6.5 6.5 October 15, 2024 Timothy J. Sangiovanni Senior Vice President, Finance and Corporate Controller true true April 15, 2025 October 15, 2024 Sven Guenther, Ph.D. Chief Scientific Officer true true October 15, 2024 Joshua Schafer Chief CommercialÂ Officer & Executive Vice President, Business Development true true April 15, 2025 October 15, 2024 Christal M.M. Mickle Chief DevelopmentÂ Officer true true April 15, 2025 October 15, 2024 R. LaDuane Clifton Chief FinancialÂ Officer and Treasurer true true April 15, 2025 October 15, 2024 Neil F. McFarlane Chief ExecutiveÂ Officer true true April 15, 2025 false false false 00014346472024-01-012024-09-30 xbrli:shares 00014346472024-11-13 thunderdome:item iso4217:USD 00014346472024-09-30 00014346472023-12-31 iso4217:USDxbrli:shares 0001434647zvra:UndesignatedPreferredStockMember2024-09-30 0001434647zvra:UndesignatedPreferredStockMember2023-12-31 00014346472024-07-012024-09-30 00014346472023-07-012023-09-30 00014346472023-01-012023-09-30 0001434647srt:ScenarioPreviouslyReportedMemberus-gaap:CommonStockMember2023-12-31 0001434647srt:ScenarioPreviouslyReportedMemberus-gaap:AdditionalPaidInCapitalMember2023-12-31 0001434647srt:ScenarioPreviouslyReportedMemberus-gaap:TreasuryStockCommonMember2023-12-31 0001434647srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember2023-12-31 0001434647srt:ScenarioPreviouslyReportedMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 0001434647srt:ScenarioPreviouslyReportedMember2023-12-31 0001434647us-gaap:CommonStockMember2024-01-012024-03-31 0001434647us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0001434647us-gaap:TreasuryStockCommonMember2024-01-012024-03-31 0001434647us-gaap:RetainedEarningsMember2024-01-012024-03-31 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-31 00014346472024-01-012024-03-31 0001434647us-gaap:CommonStockMember2024-03-31 0001434647us-gaap:AdditionalPaidInCapitalMember2024-03-31 0001434647us-gaap:TreasuryStockCommonMember2024-03-31 0001434647us-gaap:RetainedEarningsMember2024-03-31 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-31 00014346472024-03-31 0001434647us-gaap:CommonStockMember2024-04-012024-06-30 0001434647us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0001434647us-gaap:TreasuryStockCommonMember2024-04-012024-06-30 0001434647us-gaap:RetainedEarningsMember2024-04-012024-06-30 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-30 00014346472024-04-012024-06-30 0001434647us-gaap:CommonStockMember2024-06-30 0001434647us-gaap:AdditionalPaidInCapitalMember2024-06-30 0001434647us-gaap:TreasuryStockCommonMember2024-06-30 0001434647us-gaap:RetainedEarningsMember2024-06-30 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-30 00014346472024-06-30 0001434647us-gaap:CommonStockMember2024-07-012024-09-30 0001434647us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30 0001434647us-gaap:TreasuryStockCommonMember2024-07-012024-09-30 0001434647us-gaap:RetainedEarningsMember2024-07-012024-09-30 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-30 0001434647us-gaap:CommonStockMember2024-09-30 0001434647us-gaap:AdditionalPaidInCapitalMember2024-09-30 0001434647us-gaap:TreasuryStockCommonMember2024-09-30 0001434647us-gaap:RetainedEarningsMember2024-09-30 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-30 0001434647srt:ScenarioPreviouslyReportedMemberus-gaap:CommonStockMember2022-12-31 0001434647srt:ScenarioPreviouslyReportedMemberus-gaap:AdditionalPaidInCapitalMember2022-12-31 0001434647srt:ScenarioPreviouslyReportedMemberus-gaap:TreasuryStockCommonMember2022-12-31 0001434647srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember2022-12-31 0001434647srt:ScenarioPreviouslyReportedMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0001434647srt:ScenarioPreviouslyReportedMember2022-12-31 0001434647us-gaap:CommonStockMember2023-01-012023-03-31 0001434647us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0001434647us-gaap:TreasuryStockCommonMember2023-01-012023-03-31 0001434647us-gaap:RetainedEarningsMember2023-01-012023-03-31 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-31 00014346472023-01-012023-03-31 0001434647us-gaap:CommonStockMember2023-03-31 0001434647us-gaap:AdditionalPaidInCapitalMember2023-03-31 0001434647us-gaap:TreasuryStockCommonMember2023-03-31 0001434647us-gaap:RetainedEarningsMember2023-03-31 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-31 00014346472023-03-31 0001434647us-gaap:CommonStockMember2023-04-012023-06-30 0001434647us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0001434647us-gaap:TreasuryStockCommonMember2023-04-012023-06-30 0001434647us-gaap:RetainedEarningsMember2023-04-012023-06-30 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-30 00014346472023-04-012023-06-30 0001434647us-gaap:CommonStockMember2023-06-30 0001434647us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001434647us-gaap:TreasuryStockCommonMember2023-06-30 0001434647us-gaap:RetainedEarningsMember2023-06-30 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30 00014346472023-06-30 0001434647us-gaap:CommonStockMember2023-07-012023-09-30 0001434647us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0001434647us-gaap:TreasuryStockCommonMember2023-07-012023-09-30 0001434647us-gaap:RetainedEarningsMember2023-07-012023-09-30 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-30 0001434647us-gaap:CommonStockMember2023-09-30 0001434647us-gaap:AdditionalPaidInCapitalMember2023-09-30 0001434647us-gaap:TreasuryStockCommonMember2023-09-30 0001434647us-gaap:RetainedEarningsMember2023-09-30 0001434647us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-30 00014346472023-09-30 00014346472022-12-31 0001434647us-gaap:BridgeLoanMember2023-08-30 00014346472024-02-05 00014346472024-06-04 0001434647zvra:AtmAgreementSalesMember2024-06-04 0001434647zvra:UnderwritingAgreementMember2024-08-082024-08-08 0001434647zvra:UnderwritingAgreementMember2024-08-08 0001434647srt:MaximumMemberus-gaap:OverAllotmentOptionMember2024-08-082024-08-08 0001434647zvra:UnderwritingAgreementAndOverallotmentOptionMember2024-08-082024-08-12 0001434647zvra:JmpMemberzvra:AtmAgreementSalesMember2024-07-12 xbrli:pure 0001434647zvra:JmpMemberzvra:AtmAgreementSalesMember2024-01-012024-09-30 0001434647zvra:JMPAndRBCCMMemberzvra:AtmAgreementSalesMember2021-07-02 0001434647zvra:JMPAndRBCCMMemberzvra:AtmAgreementSalesMember2024-07-112024-07-11 00014346472021-12-20 0001434647zvra:ShareRepurchaseProgramMember2023-12-31 00014346472023-01-012023-12-31 0001434647zvra:PrelaunchInventoryThatQualifiedForCapitalizationMember2023-12-31 0001434647zvra:PrelaunchInventoryThatQualifiedForCapitalizationMember2024-09-30 0001434647zvra:NotesPayableExcludingSecuredPromissoryNoteMember2024-09-30 0001434647zvra:NotesPayableExcludingSecuredPromissoryNoteMember2023-12-31 0001434647zvra:NantahalaNoteMember2024-09-30 0001434647zvra:NantahalaNoteMember2023-12-31 0001434647zvra:NantahalaNoteMember2023-08-30 utr:D 0001434647zvra:NantahalaNoteMember2023-08-302023-08-30 0001434647zvra:SWKLoansMember2023-08-302023-08-30 0001434647zvra:NantahalaNoteMember2024-03-01 0001434647zvra:WellsFargoBankNaMembersrt:MinimumMember2023-01-26 0001434647zvra:WellsFargoBankNaMembersrt:MaximumMember2023-01-26 0001434647zvra:WellsFargoBankNaMemberus-gaap:PrimeRateMember2023-01-262023-01-26 0001434647zvra:WellsFargoBankNaMember2023-12-31 0001434647zvra:TermLoansUnderCreditAgreementMember2024-04-05 0001434647zvra:TermLoansUnderCreditAgreementMember2024-04-052024-04-05 0001434647zvra:TermLoansUnderCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-04-052024-04-05 0001434647zvra:TermLoansUnderCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-04-05 0001434647zvra:TermLoansUnderCreditAgreementMember2024-09-30 0001434647zvra:CommaveTherapeuticsSAMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember2021-05-07 0001434647zvra:ReliefTherapeuticsMemberus-gaap:LicenseMember2024-07-012024-09-30 0001434647zvra:ReliefTherapeuticsMemberus-gaap:LicenseMember2024-09-30 0001434647zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember2024-07-012024-09-30 0001434647zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember2024-01-012024-09-30 0001434647zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember2023-07-012023-09-30 0001434647zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember2023-01-012023-09-30 0001434647zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember2023-06-012023-06-30 0001434647zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember2012-03-202012-03-20 0001434647zvra:ReliefTherapeuticsMemberus-gaap:LicenseMember2024-01-012024-09-30 0001434647zvra:ReliefTherapeuticsMemberus-gaap:LicenseMember2023-12-31 0001434647zvra:ArimoclomolPurchaseAgreementMember2024-07-012024-09-30 0001434647zvra:ArimoclomolPurchaseAgreementMember2024-01-012024-09-30 0001434647zvra:ArimoclomolPurchaseAgreementMember2023-07-012023-09-30 0001434647zvra:ArimoclomolPurchaseAgreementMember2023-01-012023-09-30 0001434647zvra:ArimoclomolPurchaseAgreementMember2023-01-012023-12-31 0001434647zvra:XomaLicenseAgreementMember2024-09-30 0001434647zvra:ArimoclomolEapMember2024-09-30 0001434647zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember2024-09-30 0001434647zvra:ConsultingServicesMember2024-09-30 0001434647zvra:ArimoclomolEapMember2023-12-31 0001434647zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember2023-12-31 0001434647zvra:ConsultingServicesMember2023-12-31 0001434647zvra:LitigationRelatedToMergerMember2024-04-012024-06-30 0001434647zvra:AZSTARYSLicenseAgreementMember2023-12-31 0001434647us-gaap:StockCompensationPlanMember2024-09-30 0001434647us-gaap:StockCompensationPlanMember2023-12-31 0001434647us-gaap:WarrantMember2024-09-30 0001434647us-gaap:WarrantMember2023-12-31 0001434647zvra:PossibleFutureIssuancesUnderEquityIncentivePlansMember2024-09-30 0001434647zvra:PossibleFutureIssuancesUnderEquityIncentivePlansMember2023-12-31 0001434647zvra:PossibleFutureIssuancesUnderEmployeeStockPurchasePlansMember2024-09-30 0001434647zvra:PossibleFutureIssuancesUnderEmployeeStockPurchasePlansMember2023-12-31 00014346472023-11-012023-11-30 00014346472023-11-30 0001434647zvra:AcerWarrantsMemberus-gaap:CommonStockMember2023-11-30 0001434647zvra:TheInvestorWarrantMember2023-11-012023-11-30 0001434647zvra:TheInvestorWarrantMember2023-11-30 0001434647zvra:AcerWarrantsMember2023-11-012023-11-30 0001434647zvra:AcerWarrantsMember2023-11-012023-12-31 0001434647zvra:AcerWarrantsMember2024-01-012024-09-30 0001434647zvra:TwoThousandFourteenEquityIncentivePlanMember2021-06-012021-06-30 0001434647zvra:TwoThousandFourteenEquityIncentivePlanMember2024-09-30 0001434647zvra:TwoThousandFourteenEquityIncentivePlanMember2024-01-012024-01-01 0001434647zvra:TwoThousandFourteenEquityIncentivePlanMember2024-07-012024-09-30 0001434647zvra:TwoThousandFourteenEquityIncentivePlanMember2024-01-012024-09-30 0001434647zvra:TwoThousandFourteenEquityIncentivePlanMember2023-07-012023-09-30 0001434647zvra:TwoThousandFourteenEquityIncentivePlanMember2023-01-012023-09-30 00014346472021-06-30 0001434647zvra:The2023PlanMember2023-01-31 0001434647zvra:The2023PlanMember2024-02-29 0001434647us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-30 0001434647us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-30 0001434647us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-30 0001434647us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-30 0001434647us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-30 0001434647us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-30 0001434647us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-30 0001434647us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-30 0001434647us-gaap:PerformanceSharesMember2024-07-012024-09-30 0001434647us-gaap:PerformanceSharesMember2024-01-012024-09-30 0001434647us-gaap:PerformanceSharesMember2023-01-012023-09-30 0001434647zvra:CvrLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647zvra:WarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647zvra:WarrantsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647zvra:WarrantsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647zvra:WarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0001434647zvra:CvrLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647zvra:WarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647zvra:WarrantsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647zvra:WarrantsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647zvra:WarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001434647us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2024-09-30 0001434647us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2024-09-30 0001434647us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2023-12-31

0001434647us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2023-12-31 0001434647us-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2024-09-30 0001434647us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2024-09-30 0001434647us-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2023-12-31 0001434647us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2023-12-31 0001434647us-gaap:MeasurementInputExpectedDividendRateMember2024-09-30 0001434647us-gaap:MeasurementInputExpectedDividendRateMember2023-12-31 0001434647us-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2024-09-30 0001434647us-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2024-09-30 0001434647us-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2023-12-31 0001434647us-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2023-12-31 0001434647us-gaap:StockCompensationPlanMember2024-07-012024-09-30 0001434647us-gaap:StockCompensationPlanMember2023-07-012023-09-30 0001434647us-gaap:StockCompensationPlanMember2024-01-012024-06-30 0001434647us-gaap:StockCompensationPlanMember2023-01-012023-09-30 0001434647zvra:WarrantsToPurchaseCommonStockMember2024-07-012024-09-30 0001434647zvra:WarrantsToPurchaseCommonStockMember2023-07-012023-09-30 0001434647zvra:WarrantsToPurchaseCommonStockMember2024-01-012024-06-30 0001434647zvra:WarrantsToPurchaseCommonStockMember2023-01-012023-09-30 00014346472024-01-012024-06-30 utr:Y 0001434647srt:MinimumMember2024-01-012024-09-30 0001434647srt:MaximumMember2024-01-012024-09-30 0001434647zvra:PropertyAndEquipmentAtCostMember2024-09-30 0001434647zvra:PropertyAndEquipmentAtCostMember2023-12-31 0001434647zvra:AccumulatedDepreciationAndAmortizationMember2024-09-30 0001434647zvra:AccumulatedDepreciationAndAmortizationMember2023-12-31 0001434647us-gaap:BridgeLoanMemberzvra:AcerTherapeuticsIncMember2023-08-302023-08-30 0001434647us-gaap:BridgeLoanMembersrt:MinimumMember2023-08-30 0001434647us-gaap:BridgeLoanMember2023-10-31 0001434647zvra:SWKLoansMemberzvra:AcerTherapeuticsIncMember2022-03-142022-03-14 0001434647zvra:SWKLoansMemberzvra:AcerTherapeuticsIncMember2023-01-312023-01-31 0001434647zvra:SWKLoansMember2023-01-312023-01-31 0001434647zvra:NantahalaNoteMember2023-01-31 0001434647zvra:MarathonConvertibleNotesMember2023-06-162023-06-16 0001434647zvra:MarathonConvertibleNotesMember2023-06-16 0001434647zvra:ReliefMemberzvra:AcerTherapeuticsIncMembersrt:EuropeMemberzvra:LicenseAgreementAndTerminationAgreementMember2023-08-30 0001434647zvra:ReliefMemberzvra:AcerTherapeuticsIncMemberzvra:LicenseAgreementAndTerminationAgreementMember2023-08-302023-08-30 0001434647zvra:ReliefMemberzvra:AcerTherapeuticsIncMemberzvra:LicenseAgreementAndTerminationAgreementMember2023-08-30 0001434647zvra:ReliefMemberzvra:AcerTherapeuticsIncMemberzvra:WorldwideExcludingEuropeMemberzvra:LicenseAgreementAndTerminationAgreementMember2023-08-30 0001434647zvra:ReliefMemberzvra:AcerTherapeuticsIncMembersrt:MaximumMemberzvra:LicenseAgreementAndTerminationAgreementMember2023-08-30 0001434647zvra:AcerTherapeuticsIncMember2023-11-17 0001434647zvra:AcerTherapeuticsIncMember2023-11-172023-11-17 0001434647us-gaap:BridgeLoanMemberzvra:AcerTherapeuticsIncMember2023-11-172023-11-17 0001434647zvra:SwkLoansAndMarathonNotesMember2023-11-172023-11-17 0001434647zvra:NantahalaNoteMember2023-11-17 0001434647zvra:AcerTherapeuticsIncMemberzvra:AcerWarrantsMember2023-11-172023-11-17 00014346472023-11-17 0001434647zvra:TheInvestorWarrantMember2023-11-222023-11-22 0001434647zvra:TheInvestorWarrantMember2023-11-22 0001434647zvra:AcerTherapeuticsIncMember2023-12-31 0001434647zvra:AcerTherapeuticsIncMember2024-01-012024-09-30 0001434647zvra:AcerTherapeuticsIncMember2024-09-30 0001434647zvra:OlpruvaMember2024-09-30 0001434647zvra:OlpruvaMember2023-12-31 0001434647us-gaap:PatentsMember2024-09-30 0001434647us-gaap:PatentsMemberzvra:XomaLicenseAgreementMember2023-04-012023-09-30 0001434647us-gaap:PatentsMemberzvra:XomaLicenseAgreementMember2023-01-012023-09-30 0001434647zvra:ZVRATimothyJSangiovanniMember2024-07-012024-09-30 0001434647zvra:ZVRATimothyJSangiovanniMember2024-09-30 0001434647zvra:ZVRASvenGuentherPhDMember2024-07-012024-09-30 0001434647zvra:ZVRASvenGuentherPhDMember2024-09-30 0001434647zvra:ZVRAJoshuaSchaferMember2024-07-012024-09-30 0001434647zvra:ZVRAJoshuaSchaferMember2024-09-30 0001434647zvra:ZVRAChristalMMMickleMember2024-07-012024-09-30 0001434647zvra:ZVRAChristalMMMickleMember2024-09-30 0001434647zvra:ZVRARLaDuaneCliftonMember2024-07-012024-09-30 0001434647zvra:ZVRARLaDuaneCliftonMember2024-09-30 0001434647zvra:ZVRANeilFMcFarlaneMember2024-07-012024-09-30 0001434647zvra:ZVRANeilFMcFarlaneMember2024-09-30 Â Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â Â FORM 10-Q Â (Mark One) Â˜ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period endedÂ September 30, 2024 Â OR Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the Transition Period From Â toÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss Â $ (33,225) Â $ (10,367) Â $ (69,772) Â $ (26,157) Other comprehensive (loss) income: Â Foreign currency translation adjustment Â Â (536) Â Â 5 Â Â Â (72) Â Â (333) Other comprehensive (loss) income Â Â (536) Â Â 5 Â Â Â (72) Â Â (333) Comprehensive loss Â $ (33,761) Â $ (10,362) Â $ (69,844) Â $ (26,490) Â See accompanying notes to unaudited condensed consolidated financialÂ statements. Â 6 Table of Contents Â Â ZEVRA THERAPEUTICS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERSâ€™ EQUITY (in thousands) Â Â Â Â Â Â Â Additional Â Â Treasury Â Â Â Â Â Â Other Â Â Total Â Â Â Common Â Â Paid-in Â Â Stock, Â Â Accumulated Â Â Comprehensive Â Â Stockholders' Â Â Â Stock Â Â Capital Â Â at cost Â Â Deficit Â Â Income (Loss) Â Â Equity Â Balance as of January 1, 2024 Â $ 4 Â Â $ 472,664 Â Â $ (10,983) Â $ (399,778) Â $ (43) Â $ 61,864 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (16,622) Â Â â€” Â Â Â (16,622) Stock-based compensation expense Â Â â€” Â Â Â 2,119 Â Â Â â€” Â Â Â â€” Â Â Â 2,119 Â Issuance of common stock in exchange for consulting services Â Â â€” Â Â Â 56 Â Â Â â€” Â Â Â â€” Â Â Â 56 Â Issuance of common stock as part of the Employee Stock Purchase Plan Â Â â€” Â Â Â 71 Â Â Â â€” Â Â Â â€” Â Â Â 71 Â Issuance of common stock for options exercised Â Â â€” Â Â Â 1,146 Â Â Â â€” Â Â Â â€” Â Â Â 1,146 Â Other comprehensive income Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 184 Â Â Â 184 Â Balance as of March 31, 2024 Â $ 4 Â Â $ 476,056 Â Â $ (10,983) Â $ (416,400) Â $ 141 Â Â $ 48,818 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (19,925) Â Â â€” Â Â Â (19,925) Stock-based compensation expense Â Â â€” Â Â Â 2,632 Â Â Â â€” Â Â Â â€” Â Â Â 2,632 Â Issuance of common stock in exchange for consulting services Â Â â€” Â Â Â 193 Â Â Â â€” Â Â Â â€” Â Â Â 193 Â Issuance of common stock as part of the Employee Stock Purchase Plan Â Â â€” Â Â Â 480 Â Â Â â€” Â Â Â â€” Â Â Â 480 Â Other comprehensive income Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 280 Â Â Â 280 Â Balance as of June 30, 2024 Â $ 4 Â Â $ 479,361 Â Â $ (10,983) Â $ (436,325) Â $ 421 Â Â $ 32,478 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (33,225) Â Â â€” Â Â Â (33,225) Stock-based compensation expense Â Â â€” Â Â Â 6,137 Â Â Â â€” Â Â Â â€” Â Â Â 6,137 Â Issuance of common stock in public offering Â Â 1 Â Â Â 64,516 Â Â Â â€” Â Â Â â€” Â Â Â 64,517 Â Issuance of common stock in exchange for consulting services Â Â â€” Â Â Â 150 Â Â Â â€” Â Â Â â€” Â Â Â 150 Â Issuance of common stock as part of the Employee Stock Purchase Plan Â Â â€” Â Â Â 92 Â Â Â â€” Â Â Â â€” Â Â Â 92 Â Issuance of common stock for options exercised Â Â â€” Â Â Â 157 Â Â Â â€” Â Â Â â€” Â Â Â 157 Â Other comprehensive loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (536) Â Â (536) Balance as of September 30, 2024 Â $ 5 Â Â $ 550,413 Â Â $ (10,983) Â $ (469,550) Â $ (115) Â $ 69,770 Â Â See accompanying notes to unaudited condensed consolidated financialÂ statements. Â 7 Table of Contents Â ZEVRA THERAPEUTICS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERSâ€™ EQUITY, CONTINUED (in thousands) Â Â Â Â Â Â Â Additional Â Â Â Â Â Â Â Â Â Other Â Â Total Â Â Â Common Â Â Paid-in Â Â Treasury Â Â Accumulated Â Â Comprehensive Â Â Stockholders' Â Â Â Stock Â Â Capital Â Â Stock, at cost Â Â Deficit Â Â Income (Loss) Â Â Equity Â Balance as of January 1, 2023 Â $ 3 Â Â $ 436,269 Â Â $ (7,536) Â $ (353,729) Â $ 113 Â Â $ 75,120 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (13,217) Â Â â€” Â Â Â (13,217) Stock-based compensation expense Â Â â€” Â Â Â 945 Â Â Â â€” Â Â Â â€” Â Â Â 945 Â Shares repurchased as part of the Share Repurchase Program Â Â â€” Â Â Â â€” Â Â Â (3,447) Â Â â€” Â Â Â (3,447) Issuance of common stock in exchange for consulting services Â Â â€” Â Â Â 42 Â Â Â â€” Â Â Â â€” Â Â Â 42 Â Other comprehensive loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (176) Â Â (176) Balance as of March 31, 2023 Â $ 3 Â Â $ 437,256 Â Â $ (10,983) Â $ (366,946) Â $ (63) Â $ 59,267 Â Net income Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 2,151 Â Â Â 2,151 Â Issuance of common stock in exchange for consulting services Â Â â€” Â Â Â 25 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 25 Â Issuance of common stock as part of the Employee Stock Purchase Plan Â Â â€” Â Â Â 165 Â Â Â â€” Â Â Â â€” Â Â Â 165 Â Other comprehensive loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (162) Â Â (162) Balance as of June 30, 2023 Â $ 3 Â Â $ 439,597 Â Â $ (10,983) Â $ (369,519) Â $ (225) Â $ 58,873 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (10,367) Â Â â€” Â Â Â (10,367) Stock-based compensation expense Â Â â€” Â Â Â 1,440 Â Â Â â€” Â Â Â â€” Â Â Â 1,440 Â Issuance of common stock in connection with the Merger (Note L) Â Â â€” Â Â Â 11,500 Â Â Â â€” Â Â Â â€” Â Â Â 11,500 Â Issuance of common stock in exchange for consulting services Â Â â€” Â Â Â 71 Â Â Â â€” Â Â Â â€” Â Â Â 71 Â Other comprehensive income Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 5 Â Â Â 5 Â Balance as of September 30, 2023 Â $ 3 Â Â $ 452,608 Â Â $ (10,983) Â $ (379,886) Â $ (220) Â $ 61,522 Â Â See accompanying notes to unaudited condensed consolidated financial statements. Â 8 Table of Contents Â Â ZEVRA THERAPEUTICS, INC. UNAUDITED CONDENSED CONSOLIDATEDÂ STATEMENTS OF CASH FLOWS (in thousands) Â Â Â Nine months ended September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities: Â Â Â Â Â Â Â Â Net loss Â $ (69,772) Â $ (26,157) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Â Stock-based compensation expense Â Â 10,888 Â Â Â 4,482 Â Inventory obsolescence charge Â Â 5,244 Â Â Â â€” Â Non-cash interest expense Â Â 1,489 Â Â Â â€” Â Depreciation and amortization expense Â Â 4,741 Â Â Â 219 Â Fair value adjustment related to warrant and CVR liability Â Â (4,660) Â Â (4,159) Fair value adjustment related to investments Â Â (64) Â Â (451) Loss on sublease and disposal of property and equipment Â Â â€” Â Â Â 157 Â Consulting fees paid in common stock Â Â 399 Â Â Â 138 Â Loss (gain) on foreign currency exchange Â Â 147 Â Â Â (30) Change in assets and liabilities: Â Â Â Â Â Â Â Accounts and other receivables Â Â 9,587 Â Â Â (1,628) Prepaid expenses and other assets Â Â (452) Â Â 27 Â Inventories Â Â (4,159) Â Â 190 Â Operating lease right-of-use assets Â Â 389 Â Â Â 243 Â Other long-term assets Â Â â€” Â Â Â (93) Accounts payable and accrued expenses Â Â (10,590) Â Â 5,400 Â Discount and rebate liability Â Â 4,824 Â Â Â 3,895 Â Operating lease liabilities Â Â (395) Â Â (326) Other liabilities Â Â (1,031) Â Â 716 Â Net cash used in operating activities Â Â (53,415) Â Â (17,377) Â Â Â Â Â Â Â Â Cash flows from investing activities: Â Â Â Â Â Â Â Â Purchases of property and equipment Â Â â€” Â Â Â (224) Purchases of investments Â Â (41,488) Â Â (45,821) Purchases of secured corporate notes Â Â - Â Â Â (25,426) Maturities of investments Â Â 24,798 Â Â Â 43,496 Â Net cash used in investing activities Â Â (16,690) Â Â (27,975) Â Â Â Â Â Â Â Â Cash flows from financing activities: Â Â Â Â Â Â Â Â Proceeds from issuance of debt, net of lender fees Â Â 58,990 Â Â Â 38,801 Â Payment of third-party debt issuance costs Â Â (2,091) Â Â â€” Â Repayment of debt Â Â (42,700) Â Â (12,800) Proceeds from insurance financing arrangements Â Â 1,082 Â Â Â 1,256 Â Proceeds from Employee Stock Purchase Plan Â Â 643 Â Â Â 219 Â Payments of principal on insurance financing arrangements Â Â (431) Â Â (564) Payments to repurchase shares as part of the Share Repurchase Program Â Â â€” Â Â Â (3,447) Proceeds from issuance of stock Â Â 65,819 Â Â Â â€” Â Repayment of principal on finance lease liabilities Â Â â€” Â Â Â (5) Net cash provided by financing activities Â Â 81,312 Â Â Â 23,460 Â Effect of exchange rate changes on cash and cash equivalents Â Â (217) Â Â (305) Net increase (decrease) in cash and cash equivalents Â Â 10,990 Â Â Â (22,197) Cash and cash equivalents, beginning of period Â Â 43,049 Â Â Â 65,466 Â Cash and cash equivalents, end of period Â $ 54,039 Â Â $ 43,269 Â Â Â Â Â Â Â Â Supplemental cash flow information: Â Â Â Â Â Â Â Â Cash paid for interest Â $ 3,668 Â Â $ 456 Â Â See accompanying notes to unaudited condensed consolidated financial statements. Â 9 Table of Contents Â ZEVRA THERAPEUTICS, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATEDÂ FINANCIAL STATEMENTS Â Â A.Description of Business, Basis of Presentation, and Significant Transactions Â Organization Â Zevra Therapeutics, Inc. (the "Company") is a commercial-stageÂ company focused on addressing unmet needs for the treatment of rare diseases. The Company has a diverse portfolio of products and product candidates, which includes clinical stage pipeline and commercial stage assets. On September 20, 2024, the U.S. Food and Drug Administration ("FDA") approved the New Drug Application (â€œNDAâ€) forÂ MIPLYFFAâ„¢ (arimoclomol),Â an orally-delivered treatmentÂ for Niemann-Pick disease type C (â€œNPCâ€), which is anÂ ultra-rare and progressive neurodegenerative disease.Â MIPLYFFA,Â the first FDA-approved treatment for NPC, is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients twoÂ years of age and older. In addition, the Company received a transferable rare pediatric disease priority review voucherÂ in conjunction with the approval of MIPLYFFA.Â MIPLYFFAÂ has also been granted orphan medicinal product designation for the treatment of NPC by the European Commission.Â OLPRUVAÂ® (sodium phenylbutyrate) for oral suspension is approved by the FDA for the treatment of urea cycle disorders ("UCDs"). The Company also has a pipeline of investigational product candidates, including celiprololÂ for the treatment of vascular Ehlers-Danlos syndrome in patients with a confirmed type III collagen mutation.Â KP1077 is the Company'sÂ clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia ("IH"), a rare neurological sleep disorder, and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (â€œSDXâ€), the Company's proprietary prodrug of d-methylphenidate ("d-MPH"). The FDA has granted KP1077 orphan drug designation for the treatment of IH. Â The Company changed its name from KemPharm, Inc. to Zevra Therapeutics, Inc. effective as of February 21, 2023. On March 1, 2023, following its name change, the Company's common stock began trading on the Nasdaq Global Select Market under the ticker symbol "ZVRA". Â Going Concern Â The accompanying unauditedÂ condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the nineÂ months ended SeptemberÂ 30, 2024, and 2023, the Company incurred a net loss of $69.8Â million and $26.2Â million,Â respectively, andÂ as of SeptemberÂ 30, 2024, has an accumulated deficit of $469.6Â million.Â The Company has sustained operating losses for the majority of its corporate history and expects to continue to incur operating losses and negative operating cash flows until revenues reach a level sufficient to support ongoing operations. Â The Companyâ€™s ability to continue operating as a going concern is contingent upon its ability to generate revenue from approved products or obtain product candidate regulatory approvals, which would generate revenue, milestones, and cash flow sufficient to support ongoing operations and the satisfaction of financial covenants. These factors raise substantial doubt as to the Companyâ€™s ability to continue as a going concern for at least one year from the date the unaudited condensed consolidated financial statements are being issued. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Â The Company's liquidity needs will be largely determined by the success of operations through the progression of its products and product candidates in the future.Â The Company also may consider other sources to fund operations including: (1) out-licensing rights to certain of its technologies and product candidates, pursuant to which the Company would receive cash royalties and milestones; (2) raising additional capital through equity or debt financings or from other sources; (3) obtaining product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (4) reducing spending on one or more research and development programs, including by discontinuing development; and/or (5) restructuring operations to change its overhead structure. The Company is in theÂ early stages ofÂ its commercialization effortÂ for OLPRUVA and MIPLYFFA andÂ does not yet have a substantial basis to project future earnings, and itsÂ other sources of revenue are not sufficient to sustain itsÂ present activities on their own. Accordingly, the Company'sÂ ability to continue as a going concern may require itÂ to obtain additional financing to fund itsÂ operations. Â Basis of Presentation Â The Company prepared the unaudited condensed consolidated financial statements in accordance with U.S.Â GAAPÂ and the rules and regulations of the Securities and Exchange Commission ("SEC") and, in the Company's opinion, reflect all adjustments, including normal recurring items that are necessary. Â Merger Â On August 30, 2023, the Company and Aspen Z Merger Sub, Inc., a wholly-owned subsidiary of Zevra (â€œMerger Subâ€), entered into an Agreement and Plan of Merger (the â€œMerger Agreementâ€) with Acer Therapeutics Inc. (â€œAcerâ€), a pharmaceutical company focused on development and commercialization of therapies for rare and life-threatening diseases. On November 17, 2023 (the "Closing Date"), the Company completed the acquisition of Acer. Pursuant to the Merger Agreement, on the Closing Date, Merger Sub was merged with and into Acer (the "Merger"), with Acer continuing as the surviving entity and as a wholly-owned subsidiary of Zevra. In connection therewith, Zevra also purchased Acerâ€™s secured debt from Nantahala Capital Management, LLC ("NCMâ€), certain of its affiliates and certain other parties (collectively with NCM, â€œNantahalaâ€) through a series of transactions and Zevra agreed to provide Acer with a bridge loan facility for up to $18.0 million ("Bridge Loan"), subject to certain terms and conditions. The Merger expanded Zevra's rare disease portfolio, as well as increased and diversified its revenues with the addition of a U.S. commercial asset, OLPRUVA, indicated for the treatment of UCDs. See Note LÂ for further discussion related to the Merger. Â Â Â 10 Table of Contents Â Registration Statements on Form S-3 Â In connection with the Merger, Zevra and Nantahala concurrently entered into a registration rights agreement, pursuant to which Zevra agreed to file a resale registration statement with respect to the resale of the Zevra common stock issuable to Nantahala. On February 5, 2024, Zevra filed a registration statement on Form S-3 (File No. 333-276856) registering an aggregate of 2,269,721 shares of Zevraâ€™s common stock. On April 5, 2024, we filed an amendment to the registration statement on Form S-3Â (File No. 333-250945) covering the issuance of the shares of our common stock issuable upon the exercise of warrants issued in connection with the Merger (Note L) and remaining unexercised as of the date of the amendment, which was declared effective on April 8, 2024. Â On June 4, 2024, the CompanyÂ filed a registration statement on Form S-3 (File No. 333-279941) (the "June 2024 Registration Statement") under which the Company may sell securities, including as may be issuable upon conversion, redemption, repurchase, exchange or exercise of securities,Â in one or more offerings up to a total aggregate offering price of $350.0 million, $75.0 million of which was allocated to the sale of the shares of common stock issuable under the 2024 ATM Agreement (as described further below).Â Â The registration statementÂ was declared effective on June 13, 2024. Â August 2024 Offering Â On AugustÂ 8, 2024, the CompanyÂ entered into an underwriting agreement (the â€œUnderwriting Agreementâ€) with Cantor FitzgeraldÂ & Co. and William BlairÂ & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the â€œUnderwritersâ€), in connection with the offering, issuance and sale by the Company of 9,230,770 shares of the Companyâ€™s common stock at a public offering price of $6.50 per share, pursuant to the June 2024 Registration Statement and a related prospectus supplement dated August 8, 2024 filed with the SEC (the "August 2024 Offering"). Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 1,384,615 shares of its Common Stock at the public offering price, less underwriting discounts and commissions, which the Underwriters exercised in full on August 9, 2024. The August 2024 Offering closed on AugustÂ 12, 2024.Â Total shares issued were 10,615,385.Â Net proceeds from the offering were approximately $64.5Â million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the offering to support theÂ commercialÂ launch activities for MIPLYFFA, continued commercial support for OLPRUVA and the continued development of celiprolol and KP1077 through potential NDA filings and other general corporate purposes. Â Based on the planned use of proceeds, the CompanyÂ believes that the net proceeds from the August 2024 Offering and its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements intoÂ 2027, subject to continuing compliance with the Company'sÂ debt covenants. Â Entry intoÂ 2024Â ATM Agreement Â On July 12, 2024, the Company entered into an equity distribution agreement (the "2024 ATM Agreement") with Citizens JMP Securities LLC ("Citizens JMP") under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0 million through Citizens JMP as its sales agent. The issuance and sale, if any, of common stock by the Company under theÂ 2024Â ATM Agreement will be made pursuant to the June 2024 Registration Statement, the accompanying prospectus, and the related prospectus supplement dated July 12, 2024. Citizens JMP mayÂ sell the common stock by any method permitted by law deemed to be an â€œat the market offeringâ€ as defined in RuleÂ 415Â of the Securities Act. Citizens JMP will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the CompanyÂ mayÂ impose). The Company will pay Citizens JMPÂ a commission equal toÂ 3.0%Â in the aggregate of the gross sales proceeds of any common stock sold through Citizens JMPÂ under theÂ 2024Â ATM Agreement.Â As of SeptemberÂ 30, 2024,Â noÂ shares have been issued or sold under theÂ 2024Â ATM Agreement. Â Termination ofÂ 2021Â ATM Agreement Â OnÂ JulyÂ 2,Â 2021,Â the CompanyÂ entered into an equity distribution agreement (theÂ "2021Â ATM Agreement")Â with JMP Securities LLC ("JMP")Â and RBC Capital Markets, LLC ("RBCCM")Â under which the CompanyÂ mayÂ offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0Â million through JMP and RBCCM as its sales agents. The issuance and sale, if any, of common stock by the Company under theÂ 2021Â ATM Agreement will be made pursuant to the registration statement on FormÂ S-3Â (File No. 333-257661) which was declared effective on July 12, 2021, the accompanying prospectus, and the related prospectus supplement dated July 12, 2021.Â JMP and RBCCMÂ Â mayÂ sell the common stock by any method permitted by law deemed to be an â€œat the market offeringâ€ as defined in RuleÂ 415Â of the Securities Act. JMP and RBCCM will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the CompanyÂ Â mayÂ impose). The Company will pay JMP and RBCCM a commission equal toÂ 3.0%Â in the aggregate of the gross sales proceeds of any common stock sold through JMP and RBCCM under theÂ 2021Â ATM Agreement. The 2021 ATM Agreement terminated on July 11, 2024, and no shares had been issued or sold under the 2021 ATM Agreement as of the termination date. Â Share Repurchase Program Â On December 20, 2021, the CompanyÂ initiated a share repurchase program (the "Share Repurchase Program") pursuant to which the Company was able

to repurchase up to $50 million of shares of its common stock through December 31, 2023. On December 31, 2023, the Share Repurchase Program ended, and the Company had repurchased 1,575,692Â shares of its common stock for approximately $11.0Â million. Â B.Summary of Significant Accounting Policies Â Use of Estimates Â The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Â On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the useful lives of property and equipment, the recoverability of long-lived assets, the incremental borrowing rate for leases,Â and assumptions used for purposes of determining stock-based compensation, income taxes, the fair value of investments and the fair value of the warrant liabilities, contingent value rightÂ ("CVR") liabilitiesÂ andÂ discount and rebate liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Â 11 Table of Contents Â Investments Â The Company maintains investment securities that are classified as available-for-sale securities for which the Company has elected the fair value option under Accounting Standards Codification ("ASC") 825, Financial Instruments ("ASC 825"). As such, these securities are carried at fair value with unrealized gains and losses included in fair value adjustment related to investments on the unaudited condensedÂ consolidated statements of operations. The securities primarily consist of U.S. Treasury securitiesÂ andÂ corporate bonds and are included in securities at fair value in the unaudited condensedÂ consolidated balance sheets. The Company's investments in corporate bonds mature within one to five years.Â As of September 30, 2024, and December 31, 2023, the Company held securities with an aggregate fair value of $41.4Â million and $24.7Â million, respectively, that contained aggregate unrealized gainsof approximatelyÂ $0.1Â million and $0.6Â million, respectively. Applying fair value accounting to these debt securities more accurately represents the Company's investment strategy due to the fact that excess cash is currently being invested for the purpose of funding future operations.Â Interest income is recognized as earned using an effective yield method giving effect to the amortization of premium and accretion of discount and is based on the economic life of the securities. Interest income is included in interest and other income, net in the unaudited condensed consolidated statements of operations. Â Variable Interest Entities Â The primary beneficiary of a variable interest entity ("VIE") is required to consolidate the assets and liabilities of the VIE. When the Company obtains a variable interest in another entity, it assesses at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE, and if so, whether the Company is the primary beneficiary of the VIE based on its power to direct the activities of the VIE that most significantly impact the VIE's economic performance and the Company's obligation to absorb losses or the rights to receive benefits from the VIE that could potentially be significant to the VIE. Â To assess whether the Company has the power to direct the activities of the VIE that most significantly impact the VIE's economic performance, the Company considers all the facts and circumstances, including the Company's role in establishing the VIE and the Company's ongoing rights and responsibilities. The assessment includes identifying the activities that most significantly impact the VIE's economic performance and identifying which party, if any, has the power to direct those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) are deemed to have the power to direct the activities of a VIE. Â To assess whether the Company has the obligation to absorb losses of the VIE or the rights to receive benefits from the VIE that could potentially be significant to the VIE, the Company considers all of its economic interests that are deemed to be variable interests in the VIE. Â This assessment requires judgement in determining whether these interests, in the aggregate, are considered potentially significant to the VIE. As of SeptemberÂ 30, 2024, and December 31, 2023, the Company identified Acer to be the Company's sole interest in a VIE (Note L). As Zevra is the final decision maker for all of Acer's research, development, and commercialization of drug candidates that it is producing, the Company directs the activities of Acer that most significantly impact its performance. Therefore, the Company is the primary beneficiary of this VIE for accounting purposes.Â Â Revenue Recognition Â The Company recognizesÂ revenue in accordance with the provisions of ASC 606,Â Revenue from Contracts with CustomersÂ (â€œASC 606â€) and, as a result, follows the five-step model when recognizing revenue: 1) identifying a contract; 2) identifying the performance obligations; 3) determining the transaction price; 4) allocating the price to performance obligations; and 5) recognizing revenue when the performance obligations have been fulfilled. Â Licensing Agreements Â The terms of the Companyâ€™s licensing agreements typically include one or more of the following: (i)Â upfront fees; (ii)Â milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii)Â royalties on net sales of licensed products. Each of these payments may result in licensing revenues. Â As part of the accounting for these agreements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates asÂ independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilityÂ ofÂ regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the licensee which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Â Up-frontÂ Fees:Â If a license to the Companyâ€™s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Â Milestone Payments:Â At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Companyâ€™s or the licenseeâ€™s control, such asÂ non-operationalÂ developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the CompanyÂ re-evaluatesÂ the probability of achievement of milestones that are within its or the licenseeâ€™s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulativeÂ catch-upÂ basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Companyâ€™s estimate of the transaction price may also result in negative licensing revenues and earnings in the period of adjustment. Â 12 Table of Contents Â Product Revenues, Net Â Net revenues from product sales is recognized at the transaction price when the customer obtains control of the Company's products, which occurs at a point in time, typically upon receipt of the product by the customer. Our current single customer is a specialty pharmacy provider. Â The Company's net revenues represent total revenues adjusted for discounts and allowances, including estimated cash discounts, chargebacks, rebates, returns, copay assistance, data fees and wholesaler fees for services. These adjustments represent variable consideration under ASC 606 and are recorded as a reduction of revenue. These adjustments are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the factors that impact such allowances. Adjustments for variable consideration are determined based on the contractual terms with customers, historical trends, communications with customers and the levels of inventory remining in the distribution channel, as well as expectations about the market for the product and anticipated introduction of competitive products. Â Acquired IPR&D and Milestones Expenses Â In an asset acquisition, payments incurred prior to regulatory approval to acquire rights to in-process R&D projects are expensed as acquired IPR&D and milestones expense in the consolidated statements of earnings unless the project has an alternative future use. These costs include upfront and development milestone payments related to R&D collaborations, licensing arrangements, or other asset acquisitions that provide rights to develop, manufacture and/or sell pharmaceutical products. Where contingent development milestone payments are due to third parties, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Regulatory and commercial milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product. Â Inventories Â The value of inventory is recorded at its net realizable value. The Company determines the cost of its other inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. Â The Company may scale-up and make commercial quantities of its product candidates prior to the date it anticipates that such product will receive final regulatory approval. The scale-up and commercial production of pre-launch inventory involves the risk that such products may not be approved for marketing on a timely basis, or ever. This risk notwithstanding, the Company may scale-up and build pre-launch inventory of product that have not received final regulatory approval when the Company believes such action is appropriate in relation to the commercial value of the product launch opportunity. Inventory manufactured prior to regulatory approval is recorded as research and development expense until regulatory approval for the product is obtained. Inventory used in clinical trials is also expensed as research and development expense, when selected for such use. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign. The cost of finished goods inventory that is shipped to a customer to support the Companyâ€™s patient assistance programs is expensed when those shipments take place. As of SeptemberÂ 30, 2024, and December 31, 2023, the Company did not have pre-launch inventory that qualified for capitalization. Â The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded as a component of cost of product revenueÂ in the statements of operations and comprehensive loss. The determination of whether inventory costs will be realizable requires the use of estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. Additionally, the Companyâ€™s product is subject to strict quality control and monitoring that it performs throughout the manufacturing process. In the event that certain batches or units of product do not meet quality specifications, the Company will record a charge to cost of product revenue, to write-down any unsaleable inventory to its estimated net realizable value. For the three and nineÂ months ended SeptemberÂ 30, 2024, the Company recognized a charge of approximately $2.0Â million and $5.2Â million, respectively, related to write-downs for unsaleable inventory. No such write downs were recognized for the three and nineÂ months ended SeptemberÂ 30, 2023. Â Foreign currency Â Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the unaudited condensed consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in accumulated deficitÂ during the year, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income/loss in the accompanying unaudited condensed consolidated statements of stockholdersâ€™ equity. Â Debt Issuance Costs Â Debt issuance costs incurred in connection with financing arrangements are recorded as a reduction of the related debt on the balance sheet and amortized over the life of the respective financing arrangement using the effective interest method. Â Warrants Â The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity ("ASC 480") and FASB ASC Topic 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own stock and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Â For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital, on the unaudited condensed consolidated statement of stockholdersâ€™ deficit at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in other expense, net, on the unaudited condensed consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model. Â 13 Table of Contents Â New Accounting Pronouncements Not Yet Adopted Â Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures Â In November 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. This update is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that thisÂ guidance will have on the presentation of its consolidated financial statements and accompanying notes. Â Income Taxes (Topic 740): Improvements to Income Tax Disclosures Â In December 2023, the FASB issued ASU No. 2023- 09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on the presentation of its consolidated financial statements and accompanying notes.Â Â Â C. Inventories Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Raw materials Â $4,549Â Â $2,938Â Work in progress Â Â 3,084Â Â Â 1,884Â Finished goods Â Â 1,123Â Â Â 5,019Â Total inventory Â $8,756Â Â $9,841Â Â Â D. Debt Obligations Â Long-term debt consisted of the following (in thousands): Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Notes payable Â $61,035Â Â $â€”Â Secured promissory note Â Â â€”Â Â Â 5,000Â Unamortized original issue (discount) premium Â Â (959)Â Â 148Â Less: debt issuance costs Â Â (1,172)Â Â (82) Â Â $58,904Â Â $5,066Â Â Secured Promissory Note Â In connection with the Merger (Note L), on August 30, 2023, the Company and Nantahala, entered into a secured promissory note payable by Zevra to Nantahala in the original principal amount of $5.0 million (the "Nantahala Note"). The Nantahala Note initially bore interest at 9.0% per annum, payable quarterly in arrears in cash. The interest rate increased to 12.0% per annum effective March 1, 2024, as the Nantahala Note remained unpaid six months from its issue date. The additional 3.0% interest would have been paid in shares of Zevra'sÂ common stock based on the volume weighted average trading price ("VWAP") of Zevra's common stockÂ during the twentyÂ consecutive trading days ending on the date before such interest payment date. Beginning on the first interest payment date following the second anniversary of the Nantahala Note, and on each interest payment date thereafter, Zevra was required to make $0.6 million amortization payments on the Nantahala Note until it was paid in full. All principal and unpaid interest on the Nantahala Note would have beenÂ due on August 30, 2026, the third anniversary of the Nantahala Note. Zevra was entitled toÂ prepay the Nantahala Note at any time without penalty. The Nantahala Note was secured by Zevraâ€™s interest in (i) the loan assets under the Loan Purchase Agreement described in Note L; (ii) the note assets under the Note Purchase Agreement described in Note L; (iii) the Bridge Loan described in Note L; and (iv) the proceeds therefrom. The Company used the proceeds from the Nantahala Note, along with $12.0 million in cash and 98,683 shares of Zevra's common stock, to acquire Acer's term loans, as more fully described in Note L. In April 2024, the Nantahala NoteÂ was repaid in full and terminated. At the time of repayment, Nantahala elected to receive a cash payment in lieu of shares of Zevra's common stockÂ in exchange for the additional 3.0% interest accrued for the period from March 1, 2024, through April 5, 2024.Â Â Line of Credit Â On January 26, 2023, the Company and Wells Fargo, as lender, entered into a revolving margin account agreement. The Company's investments were used as collateral for the loan and the amount the Company was able to borrow was limited to 80-90% of its outstanding investment balance held with Wells Fargo. The margin account boreÂ interest at the Prime rate minus 225 basis-points. As of December 31, 2023, $37.7Â million was outstanding under the margin account. In AprilÂ 2024, the Company repaid the outstanding balance under theÂ margin account with Wells Fargo, and upon such repayment, the margin capabilities were removed from the account.Â Â 14 Table of Contents Â Term Loans Â On April 5, 2024 (the "Term Loans Closing Date"),Â the Company entered into a credit agreement (the â€œCredit Agreementâ€) withÂ HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the â€œLendersâ€), and Alter Domus (US) LLC, as administrative agent (the â€œAdministrative Agentâ€). Â Under the terms of the Credit

Agreement, the Lenders provided a senior secured loan facility to the Company in the aggregate principal amount of $100.0 million, whichÂ is divided into three tranches as follows: (i) $60.0 million which was funded in full on the Term Loans Closing Date; (ii) $20.0 million which is available to the Company in up to two drawings, each in an amount not to exceed $10.0 million, at the Companyâ€™s option until 18 months following the Term Loans Closing Date; and (iii) $20.0 million which is available to the Company upon approval by the FDAÂ of the NDAÂ for MIPLYFFAÂ for the treatment of NPC, at the Companyâ€™s option until December 31, 2024 (collectively, the â€œTerm Loansâ€).Â Â The principal amount of the Term Loans outstanding (the â€œOutstanding Principal Amountâ€) will bear interest at a rate equal to 3-Month Term SOFR plus 7.00% per annum. If the net product sales for the calendar year ending December 31, 2025, exceed $100.0 million, the Outstanding Principal Amount will bear interest at 3-Month Term SOFR plus 6.00% per annum. If the net product sales for the calendar year ending December 31, 2025, do not exceed $100.0 million, then for any subsequent period of four consecutive fiscal quarters ending on or after March 31, 2026, in which net product sales exceed $125.0 million, the Outstanding Principal Amount will bear interest at 3-Month Term SOFR plus 6.50% per annum. In all cases, the 3-Month Term SOFR rate will be subject to a floor of 4.00% per annum. Interest will be payable quarterly in arrears on the last day of each calendar quarter. The Company has the option to pay up to 25% of the interest in-kind beginning on the Term Loans Closing Date, through and including June 30, 2026. The Company has recognized approximately $0.9Â million of interest-in-kind as of SeptemberÂ 30, 2024, which is included in long-term debt in the unaudited condensed consolidated balance sheet. The Term Loans will mature on the fifth anniversary of the Term Loans Closing Date. In connection with the Credit Agreement, the Company incurred approximately $2.2Â million ofÂ costs, which primarily consisted of underwriting, legal and other professional fees, and areÂ included as a reduction to the carrying amount of the related debt liability and are deferred and amortized over the remaining life of the financing using the effective interest method. Â The Credit Agreement contains customary affirmative and negative covenants by the Company, which among other things, will require the Company to provide certain financial reports to the Lenders within 60 days after the end of each of the first three fiscal quarters of each fiscal year and 105 days after the end of each fiscal year, meet certain minimum net product sales amounts, and limit the ability of the Company to incur or guarantee additional indebtedness, engage in certain transactions, and effect a consolidation or merger without consent. In addition, as long as the line of credit remains active, the Company must maintainÂ a minimum cash balance of $20.0 millionÂ to ensure the Company can meet its immediate capital needs. The obligations of the Company under the Credit Agreement may be accelerated upon customary events of default, including non-payment of principal, interest, fees and other amounts, covenant defaults, insolvency, material judgments, or inaccuracy of representations and warranties. The Term Loans are secured by a first priority perfected lien on, and security interest in, substantially all current and future assets of the Company. The proceeds of the Term Loans wereÂ used to refinance certain existing indebtedness of the Company and its subsidiaries.Â The Company will use the remaining proceeds to pay fees and expenses related to the debt financingÂ and fund the development and commercialization of OLPRUVAÂ and MIPLYFFA. Â Future minimum principal payments under the Term LoansÂ as ofÂ Â September 30, 2024, were as follows (in thousands): Â Year Ending December 31, Â Â Â Â 2024 (excluding the nine months ending September 30, 2024) Â $â€”Â 2025 Â Â â€”Â 2026 Â Â â€”Â 2027 Â Â â€”Â 2028 Â Â â€”Â Thereafter Â Â 60,919Â Total minimum payments Â Â 60,919Â Less: unamortized debt discount, debt issuance costs and paid in kind interest Â Â (2,015) Note payable Â $58,904Â Â Â Â E.Revenue, net Â Licensing Agreements Â AZSTARYS License Agreement Â The Company entered into a Collaboration and License Agreement (theÂ â€œAZSTARYSÂ License Agreementâ€) with Commave Therapeutics SA (formerly known as Boston Pharmaceutical S.A.)Â ("Commave"), an affiliate of Gurnet Point Capital, L.P., dated September 3, 2019. Under theÂ AZSTARYS License Agreement, as amended, the CompanyÂ grantedÂ to Commave an exclusive, worldwide license to develop, manufacture and commercialize the Companyâ€™s product candidates containing SDXÂ andÂ d-MPH,Â including AZSTARYS, or any other product candidates containing SDX and developed to treat ADHD or any other central nervous system disorder.Â Corium Inc. was tasked by CommaveÂ to lead all commercialization activities for AZSTARYS under the AZSTARYS License Agreement. Pursuant to the AZSTARYS License Agreement, Commave agreed to pay milestone payments up to an aggregate of $590.0 million upon the occurrence of specified regulatory milestones related to AZSTARYS, additional fixed payments upon the achievement of specified U.S. sales milestones, and quarterly, tiered royalty payments based on a range of percentages of net sales (as defined in the AZSTARYS License Agreement). Commave is obligated to make such royalty payments on a product-by-product basis until expiration of the royalty term for the applicable product. Â The CompanyÂ concluded that these regulatory milestones, sales milestones and royalty payments each contain a significant uncertainty associated with a future event. As such, these milestone and royalty payments are constrained at contract inception and areÂ notÂ included in the transaction priceÂ as the Company couldÂ notÂ conclude that it is probable a significant reversal in the amount of cumulative revenue recognized willÂ notÂ occur surrounding these milestone paym ents. At the end of each reporting period, the CompanyÂ updates its assessment of whether the milestone and royalty payments are constrained by considering both the likelihood and magnitude of the potential revenue reversal. For the three and nineÂ months ended SeptemberÂ 30, 2024, the Company recognized $1.1Â million and $3.6Â millionÂ ofÂ revenue under the AZSTARYS License Agreement, respectively,Â primarily related to royalties.Â For the three and nineÂ months ended September 30, 2023, the Company recognized revenue under the AZSTARYS License Agreement of $0. 9Â million and $7.2Â million, respectively, which includes recognition of a $5.0 million net sales milestone that was met in JuneÂ 2023. There wasÂ noÂ deferred revenueÂ related to this agreement as of SeptemberÂ 30,Â 2024, or December 31,Â 2023. Â Â In accordance with the terms of the Companyâ€™s Termination Agreement with Aquestive TherapeuticsÂ ("Aquestive") dated March 20, 2012, Aquestive has the right to receive an amount equal to 10% of any royalty or milestone payments made to the Company related to AZSTARYS or KP1077 under the AZSTARYS License Agreement.Â Â Â TheÂ AZSTARYS LicenseÂ Agreement isÂ within the scope of ASCÂ 606,Â as the transaction represents a contract with a customer where theÂ participants function in a customer / vendor relationship and areÂ notÂ exposed equally to the risks and rewards of the activities contemplated under theÂ AZSTARYS License Agreement. Â 15 Table of Contents Â Relief Exclusive License Agreement Â As a condition to entering into the Merger Agreement, Acer and Relief Therapeutics SAÂ ("Relief") entered into an exclusive license agreement on August 30, 2023 (the â€œRelief License Agreementâ€). Pursuant to the Relief License Agreement, Relief will hold exclusive development and commercialization rights for OLPRUVA in the European Union, Liechtenstein, San Marino, Vatican City, Norway, Iceland, Principality of Monaco, Andorra, Gibraltar, Switzerland, United Kingdom, Albania, Bosnia, Kosovo, Montenegro, Serbia and North Macedonia ("Geographical Europe"). The Company will have the right to receive a royalty of up to 10% of the net sales of OLPRUVA in Geographical Europe. For the three and nineÂ monthsÂ ended SeptemberÂ 30, 2024, the Company did not recognize any revenue under the Relief License Agreement. There was no deferred revenue related to this agreement as of SeptemberÂ 30, 2024, and December 31, 2023. For further discussion of the Relief License Agreement, see Note L. Â Product Revenues, Net Â ExpandedÂ Access Program Â Net revenue includes revenue from the sale of arimoclomolÂ for the treatment of NPCÂ under the remunerated expandedÂ access compassionate use program in France (â€œFrench nATUâ€). An expandedÂ access compassionate use program is a program giving specific patients access to a drug, which is not yet approved for commercial sale. Only drugs targeting serious or rare indications and for which there is currently no appropriate treatment are considered for expandedÂ access compassionate use programs. Further, to be considered for the expandedÂ access compassionate use program, the drug must have proven efficacy and safety and must either be undergoing price negotiations or seeking marketing approval. Â In accordance with ASC 606, the Company recognizes revenue when fulfilling its performance obligation under the ExpandedÂ Access Program ("EAP") by transferring control of promised goods or services to its customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. In determining when the customer obtains control of the product, the Company considers certain indicators, including whether the Company has a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether the customer acceptance has been received. Revenue is recognized net of sales deductions, including discounts, rebates, applicable distributor fees, and revenue-based taxes. Â The French Health Authorities and the manufacturer have agreed toÂ a price for sales duringÂ the French nATU, but the final transaction price depends on the terms and conditions in the contracts with the French Health Authorities and is subject to price negotiations with the French Health AuthoritiesÂ following market approval.Â Any excess in the price charged the manufacturer compared to the price agreed with the health authorities once the drug product is approved in France must beÂ repaid. The repayment is considered in the clawback liability (rebate). An estimate of net revenue and clawback liability are recognized using the â€¯expected valueâ€™ method. Accounting for net revenue and clawback liability requires determination of the most appropriate method for the expected final transaction price. This estimate also requires assumptions with respect to inputs into the method, including current pricing of comparable marketed products within the rare disease area in France. Management has considered the expected final sales price as well as the price of similar drug products. The Company is operating within a rare disease therapeutic area where there is unmet treatment need and hence a limited number of comparable commercialized drugs products. The limited available relevant market information for directly comparable commercialized drugs within rare disease increases the uncertainty in management's estimate. Â For the three and nineÂ months ended September 30, 2024, the Company recognized revenue related to the EAP in France of $2.6Â million and $8.0Â million, respectively, which is net of a clawback liability of $1.4Â million and $4.4Â million, respectively, and other gross to net adjustments. For the three and nineÂ months ended SeptemberÂ 30, 2023, the Company recognized revenue related to the EAP in France of $2.0Â million and $7.1Â million, respectively,Â which is net of a clawback liability of $1.1Â million and $4.0 million, respectively, and other gross to net adjustments. The total estimated reserve liability as of SeptemberÂ 30,Â 2024, and December 31, 2023, w as $17.0Â million and $12.2 Â million, respectively. As of SeptemberÂ 30, 2024, and December 31, 2023, this estimated reserve liability is recorded as discount and rebate liabilities in the unaudited condensed consolidated balance sheets and is separated into current and long-term based upon the timing of the expected payment to the French regulators. Â Product Sales Â On December 27, 2022, the FDA approved OLPRUVA (sodium phenylbutyrate), a prescription medicine used along with certain therapy, including changes in diet, for the long-term management of adults and children with UCDs weighing 44 pounds (20 kg) or greater and with a body surface area of 1.2m2 or greater.Â On November 17, 2023, the Company acquired OLPRUVA in connection with the Merger (Note L). For the three and nineÂ months ended September 30, 2024, sales of OLPRUVA were de minimis. Â 16 Table of Contents Â On September 20, 2024, the NDA forÂ MIPLYFFA,Â an orally-delivered treatmentÂ for NPC, which is anÂ ultra-rare and progressive neurodegenerative disease, was approved. For the three and nineÂ months ended September 30, 2024, sales of MIPLYFFAÂ were de minimis.Â In May 2011, Orphazyme entered into an asset purchase agreement with LadRx Corporation, which was assigned to XOMA (US) LLC, a wholly-owned subsidiary of XOMA Corporation ("XOMA"), in June 2023 ("XOMAÂ License Agreement"). Under the XOMA License Agreement, XOMA is entitled toÂ certain net sales and regulatoryÂ milestone payments in addition toÂ a mid-single digit royalty with respect to sales of MIPLYFFA. For the three and nine months ended September 30, 2024, the Company recognized a regulatory milestone payment of $6.0 million due toÂ XOMA under the XOMA License Agreement, which is included in intangible assets, netÂ in the unaudited condensed consolidated balance sheet. Â The CompanyÂ currently utilizes a single specialty pharmacy provider as its sole distributor for both OLPRUVA and MIPLYFFA. The Company also enters into arrangements with health care providers and payors that provide for government mandated and/or privately negotiated rebates with respect to the purchase of its products.Â To commercialize OLPRUVA for oral suspension and MIPLYFFA in the U.S., the Company has builtÂ marketing, sales, medical affairs, distribution, managerial and other non-technical capabilities or is making arrangements with third parties to perform these services. Â Accounts and Other Receivables Â Accounts and other receivables consistÂ ofÂ receivables from product sales, receivables under theÂ AZSTARYS License Agreement andÂ EAP,Â as well as income tax receivables and other receivables due to the Company. Receivables under theÂ AZSTARYS License AgreementÂ are recorded for amounts due to the Company related to reimbursableÂ third-party costs and royalties on product sales. Receivables under the EAP are recorded for product sales under the French nATU.Â These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. As of September 30,Â 2024,Â the Company hadÂ receivables related to the EAP of $4.4Â million, AZSTARYS License Agreement of $1.1Â million, and other receivables of $2.3Â million.Â As ofÂ December 31, 2023,Â the Company hadÂ receivables related to the EAP of $4.7Â million, AZSTARYS License Agreement of $11.4Â million, andÂ other receivablesÂ of $1.3Â million. As of SeptemberÂ 30, 2024, and December 31, 2023,Â noÂ reserve or allowance for doubtful accounts hadÂ been established. Â Â Â F.Commitments and Contingencies Â From time to time, the Company is involved in various legal proceedings arising in the normal course of business. For some matters, a liability is not probable, or the amount cannot be reasonably estimated and, therefore, an accrual has not been made. However, for such matters when it is probable that the Company has incurred a liability and can reasonably estimate the amount, the Company accrues and discloses such estimates. Â Stockholder Litigation Related to the Merger Â On October 12, 2023, Brodsky & Smith, purporting to act as counsel for Jerry Beavee, who was asserted to be a stockholder of Acer, filed a complaint entitled Jerry Beavee v. Acer Therapeutics Inc., et al., No. 1:23-cv-08995 in the United States District Court for the Southern District of New York (the "Action") alleging that defendants violated Section 14(a) and 20(a) of the Securities Exchange Act of 1934 by filing the Preliminary Merger Registration Statement which allegedly omitted certain information that such counsel asserts is material to Acerâ€™s required disclosure. On October 30, 2023, Acer filed with the SEC a Schedule DEF14A that contained additional information regarding the Merger, which mooted the disclosure claims alleged in the Action. On December 8, 2023, Jerry Beavee filed with the court a notice of dismissal of the Action without prejudice. Â On October 20, 2023, Long Law, LLC and Acocelli Law, PLLC, purporting to act as counsel for Kevin Turner, who was asserted to be a stockholder of Acer, filed a complaint entitled Kevin Turner v. Acer Therapeutics Inc., et al., No. 1:23-cv-01185 in the United States District Court for the District of Delaware alleging that defendants violated Section 14(a) and 20(a) of the Securities Exchange Act of 1934 as well as SEC Rule 14a-9 by filing the Definitive Proxy Statement which allegedly omitted certain information that such counsel asserts is material to Acerâ€™s required disclosure. The complaint prays that, if asserted omissions are not adequately corrected, then Turner will seek to enjoin Acer from holding a stockholder meeting to approve theÂ Merger and, if the Merger closes, will seek to rescind it and seek an award of damages. Â On October 20, 2023, Long Law, LLC, purporting to act as counsel for Matthew Jones, who was asserted to be a stockholder of Acer, filed a complaint entitled Matthew Jones v. Acer Therapeutics Inc., et al., No. 1:23-cv-01186 in the United States District Court for the District of Delaware alleging that defendants violated Section 14(a) and 20(a) of the Securities Exchange Act of 1934 as well as SEC Rule 14a-9 by filing the Definitive Proxy Statement which allegedly omitted certain information that such counsel asserts is material to the Acerâ€™s required disclosure. The complaint prays that, if asserted omissions are not adequately corrected, then Jones will seek to enjoin Acer from holding a stockholder meeting to approve the Merger and, if the Merger closes, will seek to rescind it and seek an award of damages. Â On June 19, 2024, the Company entered into a confidential fee agreement (the "Fee Agreement") to settle the above stockholder litigation matters related to the Merger. The parties to the Fee Agreement were entitled to an aggregate payment of approximately $0.3 million, which was paid during the second quarter of 2024.Â Â Litigation Related to the AZSTARYS License Agreement Â In September 2024, the Company became engaged in a legal dispute regarding the AZSTARYS License Agreement.Â The litigation is in its early stages. We cannot predict with certainty the timing or ultimate outcome of this litigation or its potential impact on our business, financial condition, or results of operations. At this time, we have not recorded any accrual for contingent liability associated with this matter. The AZSTARYS License Agreement remains in effect during this litigation, and both parties continue to perform their respective obligations thereunder. However, there can be no assurance that this dispute will not have an adverse impact on our relationship with Commave or on the Company's business. The Company will continue to monitor developments in this matter and will assess the potential impact on our financial statements in future periods. The CompanyÂ expects to incur significant legal expenses in connection with this litigation, which may materially affect itsÂ results of operations in future periods. Â As of September 30, 2024, andÂ December 31, 2023,no accruals wereÂ made related to commitments and contingencies.Â Â 17 Table of Contents Â Â Â G.Stock and Warrants Â Authorized, Issued, and Outstanding Common Shares Â As of September 30, 2024, and December 31, 2023, the CompanyÂ had authorized shares of common stock of 250,000,000 shares. Of the authorized shares, 54,803,056Â and 43,110,360Â shares of common stock were issued as of September 30, 2024, and December 31, 2023, respectively,Â and 53,227,364Â and 41,534,668Â shares of common stock were outstanding as of September 30, 2024, and December 31, 2023, respectively. Â As ofÂ September 30, 2024,Â and December 31, 2023, the Company had reserved authorized shares of common stock for future issuance as follows: Â Â Â September 30, 2024Â Â December 31, 2023Â Outstanding awards under equity incentive plans Â Â 8,987,997Â Â Â Â 8,023,142Â Outstanding common stock warrants Â Â 5,483,537Â Â Â Â 5,603,729Â Possible future issuances under equity incentive plans Â Â 4,536,410Â Â Â Â 1,728,885Â Possible future issuances under employee stock purchase plans Â Â 1,242,425Â Â Â Â 1,340,172Â Total common shares reserved for future issuance Â Â 20,250,369Â Â Â Â 16,695,928Â Â Â Â Â Common Stock Activity Â The following table summarizes common stock activity for theÂ nine months ended September 30, 2024: Â Â Â Â Shares of Common StockÂ Balance as of January 1, 2024 Â Â 41,534,668Â Common stock issued as compensation to third parties Â Â 9,000Â Common stock issued as a result of stock options exercised Â Â 306,826Â Balance as of March 31, 2024 Â Â 41,850,494Â Common stock issued as a result of the Employee Stock Purchase Plan Â Â 97,747Â Common stock issued as compensation to third parties Â Â 41,820Â Common stock

issued as a result of stock options exercised Â Â 1,403Â Balance as of June 30, 2024 Â Â 41,991,464Â Common stock issued as compensation to third parties Â Â 32,820Â Common stock issued in connection with the Public Offering (Note B) Â Â 10,615,385Â Common stock issued as a result of stock options exercised Â Â 39,750Â Common stock issued in connection with vesting of performance-based awards Â Â 547,945Â Balance as of September 30, 2024 Â Â 53,227,364Â Â Authorized, Issued, and Outstanding Preferred Stock Â As of September 30, 2024, and December 31, 2023, the Company had 10,000,000 shares of authorized preferred stock, none of which were designated, issued, or outstanding.Â Â Â Â Warrants to Purchase Common Stock Â The Company has issued warrants to purchase common stock to various third parties, of which 5,483,537Â remain outstanding as of SeptemberÂ 30, 2024, and are immediately exercisable. These warrantsÂ qualifyÂ asÂ participating securitiesÂ under ASC TopicÂ 260,Â Earnings perÂ Share,Â and areÂ treated as such in theÂ net lossÂ per share calculation (Note J). The Company may be required to redeem these warrantsÂ for a cash amount equal to the Black-Scholes value of the portion of the warrantsÂ to be redeemed (the â€œPut Optionâ€).Â Â In connection with the Merger (Note L), in November 2023, the Company directly issued to certain investors an aggregate of 1,382,489 shares of its common stock, par value $0.0001 per share, and accompanying warrants to purchase up to 1,382,489 shares of its common stock (the "2023 Warrants") at a combined offering price of $4.34 per share of common stock and the Warrants and an aggregate of 917,934 shares of its common stock in exchange for the cancellation of a warrant to purchase 2,920,306 shares of common stock of Acer. The Warrants are immediately exercisable and expire on November 22, 2028. The Company used the net proceeds of approximately $6.0 million from the offering for general corporate purposes. These warrants are separately exercisable by the warrant holders. While the warrants are outstanding (but unexercised), the warrant holders will participate in any dividend or other distribution of the Companyâ€™s assets to its common stockholders by way of return of capital or otherwise. As of SeptemberÂ 30, 2024, and December 31, 2023, none of the warrants have been exercised. The warrants have been evaluated to determine the appropriate accounting and classification pursuant to ASC 480Â and ASC 815. Generally, freestanding warrants should be classified as (i) liabilities if the warrant terms allow settlement of the warrant exercise in cash and (ii) equity if the warrant terms only allow settlement in shares of common stock.Â Â The Company determined that its outstandingÂ warrants and the Put Option should be recorded as a liability and stated at fair value at each reporting period. Changes to the fair value of the warrant liability are recorded through the unaudited condensed consolidated statements of operations as a fair value adjustment related toÂ warrant and CVR liability.Â As of SeptemberÂ 30, 2024, and December 31, 2023, the fair value of the liability associated with these warrants and the Put Option was approximately $13.9Â million and $16.1Â million, respectively. The fair value adjustment related to these warrants and the Put Option was approximately $6.0Â million of loss and $2.2Â million of incomeÂ for the three and nineÂ months ended SeptemberÂ 30,Â 2024, respectively. The fair value adjustment related to these warrants and the Put Option was approximately $3.7Â million and $4.3Â million of income for the three and nineÂ months ended SeptemberÂ 30, 2023, respectively. Â 18 Table of Contents Â Â H.Stock-Based Compensation Â The Company maintains a stock-based compensation plan (the â€œIncentive Stock Planâ€) that governs stock awards made to employees and directors prior to completion of the IPO.Â Â Â In November 2014,Â the Board of Directors of the Company ("the Board"), and in April 2015,Â the Companyâ€™s stockholders, approved the Companyâ€™sÂ 2014Â Equity Incentive Plan (theÂ â€œ2014Â Planâ€), which became effective inÂ April 2015.Â TheÂ 2014Â Plan provides for the grant of stock options, other forms of equity compensation, and performance cash awards. InÂ June 2021,Â the Company's stockholders approved an Amended and RestatedÂ 2014Â Equity Incentive Plan (the "A&RÂ 2014Â Plan"), following its adoption by the Board in April 2021,Â which among other things addedÂ 4,900,000Â shares to the maximum number of shares of common stock to be issued under the plan and extended the annual automatic increases (discussed further below) untilÂ January 1, 2031 and eliminated individual grant limits that applied under the 2014 Plan to awards that were intended to comply with the exemption for "performance-based compensation" under Code Section 162(m).Â The maximum number of shares of common stock thatÂ mayÂ be issued under the A&RÂ 2014Â Plan is 9,932,883Â as of SeptemberÂ 30, 2024.Â The number of shares of common stock reserved for issuance under the A&R 2014Â Plan will automatically increase onÂ January 1Â of each year, untilÂ and includingÂ January 1, 2031,Â byÂ 4%Â of the total number of shares of the Companyâ€™s capital stock outstanding on December 31Â of the preceding calendar year, or a lesser number of shares determined by the Board. Pursuant to the terms of theÂ 2014Â Plan, onÂ January 1, 2024,Â the common stock reserved for issuance under theÂ 2014Â Plan automatically increased byÂ 1,661,386Â shares. Â During the three and nineÂ months ended SeptemberÂ 30,Â 2024, 27,750, and 761,500Â stock options were exercised, respectively. During the three and nineÂ months ended September 30, 2023, no stock options were exercised. Â InÂ June 2021,Â the Company's stockholders approved an Employee Stock Purchase Plan (the "ESPP"), following its adoption by the Board in April 2021. The maximum number of shares of common stock thatÂ mayÂ be issued under the ESPP isÂ 1,500,000. The first offering period under the ESPP began on October 1, 2021, and the first purchase date occurred on May 31, 2022. As of SeptemberÂ 30,Â 2024,Â 257,575Â shares have been issued under the ESPP. Â In January 2023, the Board approved the 2023 Employment Inducement Award Plan (the "2023Â Plan"). The maximum number of shares of common stock that were initially available for issuanceÂ under the 2023 Plan was 1,500,000. In February 2024, theÂ Board approved an amendment to the 2023 Plan to increase the aggregate number of shares of common stock available for issuance under the 2023 Plan from 1,500,000 to 4,500,000 shares. Â In May 2023, the Board approved the Ninth Amended and Restated Non-Employee Director Compensation Policy (the â€œNon-Employee Director Compensation Policyâ€). The equity compensation made pursuant to the Non-Employee Director Compensation Policy will be granted under the A&RÂ 2014Â Plan. Â Stock-based compensation expense recorded under the Incentive Stock Plan, A&R 2014 Plan, ESPP and 2023 Plan is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands): Â Â Â Three months ended September 30, Â Â Nine months ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $1,441Â Â $720Â Â $3,322Â Â $2,023Â Selling, general and administrative Â Â 4,696Â Â Â 667Â Â Â 7,566Â Â Â 1,058Â Total stock-based compensation expense Â $6,137Â Â $1,387Â Â $10,888Â Â $3,081Â Â Â During the three and nine months ended September 30, 2024, the Company recognized approximately $2.5 million in stock-based compensation expense related to performance-based awards. There was no stock-based compensation expense related to performance-based awards recognized during the nine months ended September 30, 2023.Â Â 19 Table of Contents Â Â Â I.Fair Value of Financial Instruments Â The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Companyâ€™s principal or, in absence of a principal, most advantageous market for the specific asset or liability. Â The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: Â Â â— Level 1â€”Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;Â Â â— Level 2â€”Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and Â â— Level 3â€”Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. Â The carrying amounts of certain financial instruments, including cash and cash equivalents, investments, and accounts payable and accrued expenses, approximate their respective fair values due to the short-term nature of such instruments.Â Â Assets and Liabilities Measured at Fair Value on a Recurring Basis Â The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2024, and December 31, 2023 (in thousands): Â Â Â Â Balance as of September 30, 2024Â Â Quoted Prices in Active Markets for Identical Assets (Level 1)Â Â Â Significant Other Observable Inputs (Level 2) Â Â Significant Unobservable Inputs (Level 3)Â CVR liability (Note L) Â $4,800Â Â $â€”Â Â $â€”Â Â $4,800Â Warrant liabilities Â Â 13,902Â Â Â Â â€”Â Â Â â€”Â Â Â 13,902Â Total liabilities Â $18,702Â Â $â€”Â Â $â€”Â Â $18,702Â Â Â Â

Nantahala. Under the loan purchase withÂ Nantahala, Zevra purchased (i) an original senior secured term loan facility made available to Acer in an aggregate amount of $6.5 million and funded on March 14, 2022, and (ii) an additional senior secured term loan made to Acer in an aggregate amount of $7.0 million in a single borrowing which funded on January 31, 2023 for (1) $12.0 million in cashÍ¾Â (2) 98,683 shares of Zevra Common StockÍ¾Â and (3) a secured Promissory Note payable by Zevra to Nantahala in the original principal amount $5.0 million. These were recorded as receivables from Acer and were treated as a settlement of a preexisting relationship in connection with the closing of the transaction and recorded as a component of purchase consideration. Â Â â— Purchase of Acerâ€™s Convertible Notes (â€œMarathon Convertible Notesâ€) - Under the Note Purchase Agreement with Nantahala, Zevra purchased the MarathonÂ Convertible Notes that Nantahala had acquired on June 16, 2023. Zevra acquired the Marathon Convertible Notes in exchange for the issuance of 2,171,038 shares of Zevra Common Stock at $5.0667 per share for a total purchase price of $11.0 million. Â Â â— Amendment to IP License Agreement and IP Termination Agreement -Â As a condition to entering into the Merger Agreement, Acer and Relief entered into the Exclusive License Agreement and the Termination Agreement terminating the collaboration and license agreement, dated March 19, 2021, by and between Acer and Relief. Pursuant to the Exclusive License Agreement, Relief holds exclusive development and commercialization rights for OLPRUVA in Geographical Europe. Acer has the right to receive a royalty of up to 10.0% of the net sales of OLPRUVA in Geographical Europe. In accordance with the terms of the Termination Agreement, Relief received an upfront payment from Acer of $10.0 million (which payment was funded with the Bridge Loan described above) with an additional payment of $1.5 million due on the first-year anniversary of the $10.0 million payment. Acer also agreed to pay a 10.0% royalty on net sales of OLPRUVA worldwide, excluding Geographical Europe, and 20.0% of any value received by Acer from certain third parties relating to OLPRUVA licensing or divestment rights, all of the foregoing which are capped at $45.0 million, for total payments to Relief of up to $56.5 million. Â In connection with the closing of the Merger on November 17, 2023, each share of common stock of Acer was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable CVRÂ to be issued by Zevra, which will represent the right to receive one or more contingent payments up to an additional $76 million upon the achievement, if any, of certain commercial and regulatory milestones for Acerâ€™s OLPRUVA and celiprolol products within specified time periods. Certain additional cash payments are also possible pursuant to the CVRs with respect to milestones involving Acerâ€™s early-stage program ACER-2820 (emetine). Â Â 24 Table of Contents Â The assets acquired and liabilities assumed were recorded based on their acquisition date fair values. Consideration for the Merger was $72.6 million and consists of (i) approximately 2.96 million shares of Zevra common stock valued at $12.8 million, (ii) the Bridge Loan advances of $17.8 million, (iii) $12.0 million in cash paid to Nantahala; (iv) 2.27 million shares of Zevra Common Stock issued to Nantahala valued at $11.5 million based on the VWAP of shares of Zevra Common Stock during the 20 consecutive trading days ending on the trading date prior to August 30, 2023; (v) a secured promissory note payable by Zevra to Nantahala in the original principal amount of $5.0 million, as disclosed in Note C, (vi) $8.5 million in the estimated fair value of contingent consideration related to the CVRs, (vii) approximately 0.9 million shares of Zevra Common Stock issued to a former holder of Acer warrants valued at $4.0 million based on Zevra's common stock price on the Effective Date and (viii) $1.0 million in notes payable paid by the Company on Acer's behalf. In addition, effective as of immediately prior to the Effective Time, all of the outstanding and unexercised Acer stock options were automatically cancelled and ceased to exist without any cash or other consideration being paid or provided in respect thereof. The following purchase price allocation reflects the preliminary estimates of and assumptions related to the fair values of assets acquired and liabilities assumed: Â Assetsï»¿ Â Â Â Â Cash Â $575Â Prepaid expensesï»¿ Â Â 278Â ï»¿Other current assets Â Â 11Â ï»¿Inventory Â Â 9,376Â ï»¿Property, plant, and equipment Â Â 35Â ï»¿Other noncurrent assets Â Â 209Â ï»¿Approved product - OLPRUVA Â Â 68,000Â ï»¿IPR&D - celiprolol Â Â 2,000Â ï»¿Goodwill acquired Â Â 4,701Â Â Â Â 85,185Â Â Â Â Â Â ï»¿Liabilities Â Â Â Â Accounts payable and accrued expenses Â $10,881Â Deferred collaboration funding Â Â 1,500Â Operating lease liabilities Â Â 175Â Â Â Â 12,556Â Fair Value of Net Assets Acquired Â $72,629Â Â The preliminary fair values assigned to the tangible and intangible assets acquired and liabilities assumed were determined using an income approach based on managementâ€™s estimates and assumptions, as well as other information compiled by management, including third-party valuations that utilize customary valuation procedures and techniques. These preliminary fair values are subject to change within the one-year measurement period. The estimated fair values were developed by discounting future net cash flows to their present value at market-based rates of return. The goodwill acquired represents the excess of the purchase price and related costs over the value assigned to the net tangible and identifiable intangible assets of the business acquired. The useful lives of the intangible assets for amortization purposes were determined by considering the period of expected cash flows used to measure the fair values of the intangible assets adjusted as appropriate for entity-specific factors including legal, regulatory, contractual, competitive, economic and other factors that may limit the useful life. The marketed product asset is amortized on a straight-line basis over its estimated useful life. As of SeptemberÂ 30, 2024, the in-process research and developmentÂ ("IPR&D") project had not been completed or abandoned and, therefore, the IPR&D intangible asset is not currently subject to amortization. Â The results of operations and changes in stockholders' equity for Acer were included in the Company's consolidated financial statements beginning November 18, 2023.Â Â The following pro forma combined results of operations present the acquisition as if it had occurred on January 1, 2023. The pro forma combined results of operations do not necessarily represent the Company's consolidated results of operations had the acquisition occurred on the date assumed, nor are these results necessarily indicative of the Company's future consolidated results of operations. The Company expects to realize certain benefits from integrating Acer into the Company and to incur certain one-time costs. The pro forma combined results of operations do not reflect these benefits or costs. Â Â Â Three Months Ended September 30, 2023 Â Â Â Nine Months Ended September 30, 2023 Â Pro forma revenue Â $3,267Â Â $14,913Â Pro forma net loss Â Â (25,900)Â Â (54,763) Â Â 25 Table of Contents Â Cancellation of Acer Warrant Â On November 22, 2023, the Company sold an aggregate of 917,934 shares of its common stock to a healthcare focused investment fund (the "Investor") to cancel a warrant held by the Investor to purchase 2,920,306 shares of common stock of Acer. The shares of common stock were offered and sold to the Investor in a registered direct offering without an underwriter or placement agent. Â Contingent Consideration Â Contingent consideration liabilities relate to our liabilities arising in connection with the CVRs issued as a result of the Merger. The contingent consideration is classified as Level 3 in the fair value hierarchy. The fair value is measured based on a Monte Carlo simulation or a scenario-based method, depending on the earn-out achievement objectives, utilizing projections about future performance. Significant inputs include volatility and projected financial information, including projections representative of a market participant's view of the expected cash payments associated with the agreed upon regulatory milestones based on probabilities of technical success, timing of the potential milestone events for the compounds, and estimated discount rates. Â The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration liabilities for the CVRs (dollars in thousands): Â Balance at December 31, 2023 Â $ 7,262 Â Change in fair value recognized in earningsÂ Â (2,462) Balance at September 30, 2024Â $4,800Â Â For thenine months ended September 30, 2024, the Company recorded a $2.5Â million gainÂ on the change in fair value of contingent consideration, primarily due to changes in market data and revenue projections. Â Â Â M. Goodwill & Intangible Assets Â The Company's goodwill balance was $4.7 million as of September 30, 2024, and December 31, 2023.Â Â As of September 30, 2024, and December 31, 2023,Â non-amortizable intangible assets include IPR&D ofÂ $2.0 million Â As of September 30, 2024, and December 31, 2023, the Company had a definite-lived intangible asset, net related to the acquisition of OLPRUVA as a result of the Merger of $62.6Â million and $67.2 million, respectively. ThisÂ is amortized on a straight-line basis over the OLPRUVA patentÂ life of thirteenÂ years and is reviewed periodically for impairment. Amortization expense is recorded as intangible asset amortizationÂ in the unaudited condensed consolidated statements of operations and was $1.5Â million and $4.6Â million for the three andÂ nine months ended September 30, 2024. No amortization expense related to definite-lived intangible assets was recognized for the three andÂ nine months ended September 30, 2023.Â Â In accordance with its policy, the Company reviews the estimated useful lives of its intangible assets on an ongoing basis. This review indicated that based on recent facts and circumstances, including detailed analysis on sales experience and prospective product strategy,Â the actual life of the definite-lived intangible asset related to OLPRUVAÂ wasÂ longer than the estimated useful life previously established at the acquisition of the asset. As a result, effective September 30, 2024,Â the Company changed its estimateÂ of the useful life of this intangible asset to better reflect the estimated periods during which thisÂ assetÂ will remain in service. The estimated useful life was previously 11 years and wasÂ increased to approximately 13Â years. The change in estimate had no effect on depreciation and amortization expense, net income, or basicÂ and diluted earnings per share for the three and nine months ended September 30, 2024. Â In connection with the XOMA License Agreement, the Company owedÂ XOMA a royalty payment of $6.0 million upon approval of MIPLYFFA in September 2024, which is included in intangible assets, net in the unaudited condensed consolidated balance sheet as of September 30, 2024.Â Â This definite-lived intangible asset is amortized on a straight-line basis over the MIPLYFFAÂ patentÂ life of approximately fiveÂ yearsÂ and is reviewed periodically for impairment. Amortization expense is recorded as intangible asset amortizationÂ in the unaudited condensed consolidated statements of operations and was de minimis for the three andÂ nine months ended September 30, 2024 . No amortization expense related to definite-lived intangible assets was recognized for the three andÂ nine months ended September 30, 2023 .Â Â For intangible assets subject to amortization, estimated amortization expense for the five fiscal years subsequent to September 30, 2024, isÂ expected to be $6.5Â million per year.Â Â Â N.Subsequent Events Â The CompanyÂ evaluated events and transactions occurring subsequent to September 30, 2024,Â through November 13, 2024, the date the accompanying unaudited condensed consolidated financial statements were issued. During this period, there were no subsequent events that required recognition in the accompanying unaudited condensed consolidated financial statements, nor were there any additional non-recognized subsequent events that required disclosure. Â 26 Table of Contents Â Â Â Item 2. Management's DiscussionÂ and AnalysisÂ of Financial ConditionÂ and ResultsÂ of Operations Â You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes thereto included elsewhere in thisÂ Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in thisÂ Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in Part II, Item 1A. "Risk Factors" of this Quarterly Report on Form 10-Q andÂ Part I, Item 1A. â€œRisk Factorsâ€ of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 1, 2024, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Â Overview Â We are a commercial-stageÂ company focused on addressing unmet needs for the treatment of rare diseases. Our mission is to bring life changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, we are overcoming complex drug development challenges to make new therapies available to the rare disease community. We have a diverse portfolio of products and product candidates, which includes a clinical stage pipeline and commercial stage assets. Our team has specialized expertise and a track record of success in advancing promising therapies that face complex clinical and regulatory challenges with an approach that balances science and data with patient need. Â Following the U.S. approval of AZSTARYSÂ® (further described below) in March 2021, we undertook a strategic process to evaluate how to leverage and potentially augment the Companyâ€™s existing capabilities while also considering where to invest in our pipeline to generate long-term shareholder value. With a track record of drug development success leading to approvals for products which had either difficult pathways to approval or where approvals were won following a complete response letter (â€œCRLâ€) from the U.S. Food and Drug Administration ("FDA"), the Company determined to focus its expertise on rare disease indications, as well as seeking value-creating opportunities by building and directly commercializing product candidates in lieu of an out-licensing model. We are executing on this balanced approach by building a culture that is patient-focused and driven by our commitment to developing and making available therapies which address the myriad unmet needs within the rare disease community. Â As part of our commitment to serving the rare disease community, in February 2023, we changed our name to Zevra Therapeutics, Inc. Our name, Zevra, is the Greek word for zebra, which is the internationally recognized symbol for rare disease. This name reflects our intense focus and dedication to developing transformational, patient-focused therapies for rare diseases with limited or no treatment options available, or treatment areas with significant unmet needs. Â In May 2022, we purchased all of the assets and operations of Orphazyme A/S ("Orphazyme") related to arimoclomol, settled all of Orphazymeâ€™s actual outstanding liabilities to its creditors with a cash payment of $12.8 million, and agreed to assume an estimated reserve clawback liability of $5.2 million related to revenue generated from Orphazymeâ€™s Expanded Access Program in France (the "EAP"). Â On November 17, 2023, Zevra completed the acquisition of Acer Therapeutics, Inc. ("Acer"). Pursuant to the Merger Agreement, Acer continues as a wholly-owned subsidiary of Zevra (theÂ â€œMerger"). The Merger included the acquisition of OLPRUVAÂ®Â (sodium phenylbutyrate) for oral suspension, which was approved by the FDAÂ on December 27, 2022, for the treatment of certain urea cycle disorders ("UCDs"). Acer also had a pipeline of investigational product candidates, including celiprolol for the treatment of Vascular Ehlers-Danlos syndrome ("VEDS") inÂ patients with a confirmed type III collagen (COL3A1) mutation. At the effective time of the Merger (the "Effective Time"), each share of common stock of Acer, par value $0.0001 per share, issued and outstanding immediately prior to the Effective Time (excluding cancelled shares and any shares held by holders who have exercised their appraisal rights) were converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right (â€œCVRâ€) issued by Zevra, which represents the right to receive one or more contingent payments up to an additional $76.0 million upon the achievement, if any, of certain commercial and regulatory milestones for Acerâ€™s OLPRUVA and celiprolol products within specified time periods. Certain additional cash payments are also possible pursuant to the CVRs with respect to milestones involving Acerâ€™s early-stage program ACER-2820 (emetine). Â On September 20, 2024, the FDA approved the New Drug Application (â€œNDA") for MIPLYFFAâ„¢Â (arimoclomol), an orally-delivered treatment for Niemann-Pick disease type C (â€œNPC"), which is an ultra-rare and progressive neurodegenerative disease. MIPLYFFA, the first FDA-approved treatment for NPC, is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients two years of age and older. In addition, weÂ received a transferable rare pediatric disease priority review voucher in conjunction with the approval. MIPLYFFA has also been granted orphan medical product designation for the treatment of NPC by the European Commission. Â Now focused on late-stage clinical development and commercial opportunities, Zevra has discontinued its in-house drug discovery activities and is closing its laboratory facilities in Iowa and Virginia at the end of the third quarter.Â Future early research and development activities will be outsourced. Â To accomplish our mission, we are seeking to further expand our pipeline through both internal development and through our business development activities to collaborate, partner, and potentially acquire additional assets. We intend to target assets that will allow us to leverage the expertise and infrastructure that we have built to help mitigate risk and enhance our probability of success. In addition, we may consider external opportunities within neurology and neurodegenerative diseases, psychiatric disorders, and other rare diseases, along with adjacent or related therapeutic categories. If we are successful, expanding our pipeline could be accretive to our value proposition and has the potential to create incremental long-term value for stockholders. Â Our recurring operating losses and negative cash flows from operations raise substantial doubt about our ability to continue as a going concern. The Companyâ€™s ability to continue operating as a going concern is contingent upon its ability to generate revenue from approved products or obtain product candidate regulatory approvals, which would generate revenue, milestones, and cash flow sufficient to support ongoing operations and the satisfaction of financial covenants.Â We are early in our commercialization effort for OLPRUVA and MIPLYFFA and do not yet have a substantial basis to project future earnings, and our other sources of revenue are not sufficient to sustain our present activities on their own. Accordingly, our ability to continue as a going concern may require us to obtain additional financing to fund our operations. The perception of our inability to continue as a going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the loss of confidence by investors, suppliers and employees. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or debt, the terms of these securities may restrict our ability to operate. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether cease our research and development programs or future commercialization efforts. Â 27 Table of Contents Â Our Product Candidates and Approved Products Â We have built a diverse portfolio of products and product candidates through a combination of internal development and strategic investments through acquisition. For example, we have employed our proprietary Ligand Activated Technology ("LAT") platform to develop approved products (e.g., AZSTARYS), and clinical development candidateÂ (KP1077IH and KP1077N). Through our business development efforts, we have added commercial products (OLPRUVA and MIPLYFFA), and a clinical development candidateÂ (celiprolol). We furthermore have a variety of product candidates and compounds that are clinical-stage and designed to address a variety of rare diseases and other indications. Â Currently active commercial products and development assets are

summarized in the table below: Â Active Zevra CommercialÂ and Development Assets Â Parent Drug Indication Product / Candidate Development Status Next Milestone(s) Sodium phenylbutyrate Urea Cycle Disorders (UCD) OLPRUVA FDA Approved Tracking Commercial Progress Arimoclomol Niemann Pick disease type C (NPC) MIPLYFFA FDA Approved Tracking Commercial Progress Celiprolol Vascular Ehlers Danlos Syndrome (VEDS) Celiprolol Clinical - Phase 3 Phase 3 ongoing Serdexmethylphenidate Idiopathic Hypersomnia (IH) KP1077IH Clinical - Phase 2 Evaluation of potential Phase 3 Trial Serdexmethylphenidate Narcolepsy KP1077N Clinical - Phase 1/2 Evaluation of next steps basedÂ on potential Phase 3 Trial for KP1077IH Serdexmethylphenidate and dexmethylphenidate Attention Deficit and Hyperactivity Disorder (ADHD) AZSTARYS FDA Approved and Partnered Collecting royalties and milestones Â These anticipated milestones are based on information currently available to us. Our current plans and expectations are subject to a number of uncertainties, risks and other important factors that could materially impact our plans, including risks which are not solely within our control. See Part I, Item 1A. â€œRisk Factorsâ€ of ourÂ Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 1, 2024, as updated by Part II, Item 1A. "Risk Factors" of this Quarterly Report on Form 10-Q. Â OLPRUVA Â OLPRUVAÂ (sodium phenylbutyrate) for oral suspension is approved in the U.S. as adjunctive therapy to standard ofÂ care, which includes dietary management, for the chronic management of UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), orargininosuccinic acid synthetase (AS). OLPRUVAÂ is a proprietary and novel formulation of sodium phenylbutyrate powder, packaged in pre-measured single-dose envelopes, that has shown bioequivalence to existing sodium phenylbutyrate powder but with a pH-sensitive polymer coating that is designed to minimize dissolution of the coating for up to five minutes after preparation. Â UCDs are a group of rare, genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels are not controlled. Any increase in ammonia over time is serious. Therefore, it is important to adhere to any dietary protein restrictions and have alternative medication options to help control ammonia levels. Approximately 1 in 100,000 people have UCD, and there are an estimated 800 patients who are actively treated with nitrogen scavenging therapy in the U.S. While there are therapies currently approved for the treatment of UCDs - specifically RAVICTIÂ®, marketed by Amgen, Inc. (formerly Horizon Therapeutics) and PHEBURANEÂ®, marketed by Medunik USA - there remain unmet needs for this community of patients. OLPRUVA offers benefits over other UCD treatments by eliminating issues with palatability, offering improved portability with its single-dose envelopes, and it comes in a dosage that is personalized to the patient based on weight. Â To commercialize OLPRUVA for oral suspension in the U.S. we have builtÂ marketing, sales, medical affairs, distribution, managerial and other non-technical capabilities or is making arrangements with third parties to perform these services. During the quarter ended December 31, 2023, we began generating revenue from the sale of OLPRUVA in the U.S. For additional information regarding the Merger, see Note LÂ of our unaudited condensed consolidated financial statements included elsewhere in this QuarterlyÂ Report on Form 10-Q.Â Zevra has a partnership with Relief Therapeutics who has rights to commercialize OLPRUVA in various European Union [EU]Â countries, if approved. In addition, Zevra pays royalties of 10% of U.S. net sales plus milestonesÂ to Relief Therapeutics. Â During the first halfÂ of 2024, we initiated theÂ commercial launch of OLPRUVA in the U.S.Â We have focusedÂ our initial efforts on the approximately 40 metabolic treatment centers of excellence across the United States which treat the majority of UCD patientsÂ to build awareness with physicians regarding the benefitsÂ of OLPRUVA.Â In theÂ months since launch, our team has been able to engage with more than 90% of our customers.Â We have seen meaningful growth in reimbursement coverage, which was approximately 55% of U.S. covered lives at the time of acquisition, to now approximately 76%. Zevra is refining its commercial strategy for OLPRUVA to focus on specific patient segments where there are fewer access barriers, and, to increase awareness through targeted patient education campaigns. Â OLPRUVA summary: Â Â â— OLPRUVA is available in the U.S for the treatment of UCD.Â OLPRUVA is an adjunctive therapy for long-term management of adults and children weighing 20kg or greater with UCD from deficiencies of CPS, OTC, or AS. Â Â Â Â â— OLPRUVA is differentiated from currently available forms of phenylbutyrate.Â OLPRUVA is formulated to improve palatability while providing patients with a portable and discrete pre-measured dose. Â Â Â Â â— Zevra has assembled a team to support OLPRUVA and additional future commercial products. We have established an efficient commercial team which is designed to fully service the patients and prescribers within the rare disease indicationsÂ we are pursuing.Â Â 28 Table of Contents Â MIPLYFFA (arimoclomol) Â On September 20, 2024, the FDAÂ approved the NDAÂ forÂ MIPLYFFA,Â an orally-delivered treatmentÂ for NPC, which is anÂ ultra-rare and progressive neurodegenerative disease. MIPLYFFA, the first FDA-approved treatment for NPC, is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients twoÂ years of age and older. In addition, weÂ received a transferable rare pediatric disease priority review voucher (â€œPRVâ€) in conjunction with the approval.Â MIPLYFFAÂ has also been granted orphan medical product designationÂ for the treatment of NPC by the European Commission.Â Â NPC is characterized by an inability of the body to transport cholesterol and lipids inside of cells. Symptoms of NPC include a progressive impairment of mobility, cognition, speech, and swallowing, often culminating in premature death. The incidence of NPC is estimated to be one in 100,000 to 130,000 live births. We estimate that there are approximately 1,800 individuals with NPC in the U.S. and Europe, of these, approximately 300 have been diagnosed in the U.S. However, diagnostic challenges may affect the number of potential patients, and we believe that the availability of treatment options could increase awareness of the disease and assist in more accurately identifying patients. Effective therapies to treat NPC are desperately needed, and for this reason, MIPLYFFAÂ is currently being made available to NPC patients inÂ France, Germany, and other EU member statesÂ under various expanded access programsÂ ("EAPs"). Â Zevra holds global rights to develop and commercialize MIPLYFFA.Â We intend to seek regulatory approval in the E.U., and we are currentlyÂ evaluating the potential toÂ commercializeÂ outside of the U.S., and/or to seek additional regulatory approvals to support future global commercialization opportunities. Â MIPLYFFA summary: Â Â â— Demonstrated halting of disease progression.Â MIPLYFFAÂ in combination with miglustat has demonstrated a halting of progression of the disease through 12 months of treatment.Â Â Â Â Â â— Ease of flexible administration as an oral treatment. MIPLYFFAÂ is administered as an oral capsule that can be swallowed whole, opened and contents mixed with foods or liquids, or delivered through a feeding tube. Â Â Â Â â— Extensive clinical experience with favorable safety data. No significant safety findings have been reported with more than 600 patients treated in various clinical trials and through our EAPs. Â Â Â Â â— Advantageous regulatory designations.Â MIPLYFFAÂ has been granted orphan medical product designationÂ for the treatment of NPC by the European Commission. We received aÂ transferable PRVÂ upon approval of MIPLYFFA. Â Celiprolol Â The Merger with Acer included the acquisition of celiprolol. We are advancing celiprolol as an investigational product candidate for the treatment of VEDS in patients with a confirmed type III collagen (COL3A1) mutation.Â Celiprolol is a selective adrenergic modulator (â€œSAMâ€œ) and, if we receive the first approval in the U.S. for celiprolol, we believe it would be deemed a new chemical entity (â€œNCEâ€) in the U.S. Celiprolol is currently approved in the EUÂ for the treatment of hypertension and angina. Â Ehlers-Danlos Syndrome is an inherited disorder caused by mutations in the genes responsible for the structure, production, or processing of collagen, an important component of the connective tissues in the human body, or proteins that interact with collagen. VEDS causes abnormal fragility in blood vessels, which can give rise to aneurysms, abnormal connections between blood vessels known as arteriovenous fistulas, arterial dissections, and spontaneous vascular ruptures, all of which can be potentially life-threatening. The incidence of VEDS is estimated to be one in 50,000 to 200,000 people.Â There are approximately 7,500 patients in the U.S. Â Currently, there are no approved therapies anywhere in the world for VEDS. However, celiprolol, prescribed off label, has become the standard of care therapy for VEDS in some European countries. Medical intervention for VEDS focuses on surgery, symptomatic treatment, genetic counseling, and prophylactic measures, such as avoiding intense physical activity, scuba diving, and violent sports.Â Therefore, patients must adopt a â€œwatch and waitâ€ approach following any confirmed diagnosis. Unfortunately, many of these arterial events have high mortality associated with them, and thus, a pharmacologic intervention that reduces the rate of events would be clinically meaningful. Â Celiprolol received orphan drug designation from the FDA for the treatment of VEDS in 2015. In October 2018, a new celiprolol NDA was submitted to the FDA by Acer based on data obtained from the BBEST trial and was subsequently accepted by the FDA in October 2018 with priority review status. Following FDA review, Acer received a CRL from the FDA stating that it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with VEDS. Subsequently, Acer appealed the FDA decision, and while the FDA denied the appeal, it described possible paths forward toward approval. In a May 2021 Type B meeting with the FDA, Acer discussed the conduct of an U.S.-based prospective, randomized, double-blind, placebo-controlled, decentralized clinical trial in patients with COL3A1 positive VEDS, and sought the FDAâ€™s opinion on various proposed design features of the study. Â 29 Table of Contents Â Based on FDA's feedback during theÂ Type B meeting, we adoptedÂ a decentralized (virtual) event-based clinical trial design and use of an independent centralized adjudication committee withÂ a primary endpoint based on clinical events associated with disease outcome. In April 2022, the FDA granted celiprolol Breakthrough Therapy designation (â€œBTDâ€) in the U.S. for the treatment of patients with COL3A1-positive VEDS. Â In July 2022, Acer initiated enrollment in a Phase 3 long-term event-driven clinical trial designed based on the discussions from the May 2021 Type B meeting with the FDA, also known as the DiSCOVER trial.Â The DiSCOVER trial intends to enroll 150 VEDS patients, with 100 patients receiving celiprolol and 50 patients receiving placebo. Recruitment in the Phase-3 trial was restarted earlier this year after a brief hiatus and the trial is actively enrolling patients.Â We believe that celiprolol could address significant unmet needs as there are currently no approved treatments for VEDS in the U.S. Â Celiprolol summary: Â Â â— Currently, no approved treatments for VEDS in the U.S.Â There are currently no approvedÂ treatments of VEDS in the U.S. and we believe that celiprolol, if approved, could be a significant innovation in the treatment of VEDS in the U.S. where current treatment options are focused primarily on surgical intervention. Â Â Â Â â— Unique pharmacological profile.Â Mechanism of action in VEDS patients is thought to be through vascular dilatation and smooth muscle relaxation, the effect of which is to reduce the mechanical stress on collagen fibers in the arterial wall, and thereby potentially less incidence of vascular ruptures. Â Â Â Â â— Evidence of efficacy in the EU and extensive clinical experience from multiple trials.Â Celiprolol has become the primary treatment for VEDS patients in several European countries. BBEST Clinical Trial data showed 76% reduction in risk of arterial events observed in COLA3A1+ subpopulation, with additional data from a long-term observational study in France. Â Â Â Â â— Regulatory designations.Â Celiprolol for VEDS would be considered an NCEÂ in the U.S. and has been granted Orphan Drug designation and Breakthrough Therapy designation. Â Â Â Â â— SolidÂ patent protection through 2038.Â Celiprolol is generally protected by U.S. patents that will expire, after utilizing all appropriate patent term adjustments but excluding possible term extensions, in 2038. Â KP1077 Â KP1077 is being developed and evaluated for the treatmentÂ of IH and narcolepsy. IH is a rare neurological sleep disorder affecting approximately 37,000 patients in the United States.Â The cardinal feature of IH is excessive daytime sleepinessÂ ("EDS"), characterized by daytime lapses into sleep, or an irrepressible need to sleep that persists even with adequate or prolonged nighttime sleep.Â Additionally, those with IH have extreme difficulty waking, otherwise known as â€œsleep inertia,â€ suffer from severe and debilitating brain fog, and may fall asleep unintentionally or at inappropriate times, also known as narcolepsy.Â These symptoms often further lead to reported memory problems, difficulty maintaining focus, and depression. Â There is currently only one approved product for the treatment of IH, XYWAVÂ®, developed by Jazz Pharmaceuticals.Â A second product, WAKIXÂ®, developed by Harmony Biosciences and originally approved for the treatment of EDS or cataplexy in adult patients with narcolepsy, but in October 2023, Harmony announced that the difference in outcome for EDS when comparingÂ WAKIXÂ and placebo in its Phase 3 trial with IH patients did not reach statistical significance.Â Prescribers also utilize narcolepsy medications and various stimulant products â€œoff-labelâ€ to treat IH symptoms, with methylphenidate, a stimulant which has been classified by the DEA as a Schedule II controlled substance, being one of the most commonly used stimulants for treating IH.Â While each of these medications can help to address certain IH symptoms, there are also potential shortcomings, including dosing inconvenience, serious adverse events, such as elevated blood pressure and heart rate, and significant drug-to-drug interactionsÂ ("DDIs"), including with medications used to manage contraception and depression.Â In addition, patients have indicated that the effectiveness of their current medication was poor. Â Narcolepsy is a rare, chronic, debilitating neurologic disorder of sleep-wake state instability that impacts up to 200,000 Americans and is primarily characterized by EDS and cataplexy (sudden loss of muscle tone while a person is awake) along with other manifestations of rapid eye movementÂ ("REM"), sleep dysregulation, which intrude into wakefulness. In most patients, narcolepsy is caused by the loss of hypocretin, a neuropeptide in the brain that supports sleep-wake state stability. Typical symptom onset occurs in adolescence or young adulthood, but it can take up to a decade to be properly diagnosed. Although there are several approved medications for narcolepsy, we believe a treatment option based onÂ serdexmethylphenidate (â€œSDXâ€), our proprietary prodrug of d-MPHÂ which has previously been classified as a Schedule IV controlled substance,Â with superior exposure/duration characteristics and low abuse potential may be beneficial. Â We reported top-line data from a Phase 1 proof-of-concept study of SDX in the fourth quarter of 2021 and final data for the Phase 1 proof-of-concept study of SDX in the first quarter of 2022. The proof-of-concept study was a dose-escalation study to evaluate the pharmacokinetics, pharmacodynamic stimulant effects, and safety of single oral doses of SDX in subjects with a history of high-dose stimulant use. In the trial,Â 240 mg and 360 mg doses of SDX were observed to be well-tolerated and produced d-MPH exposure that appeared to increase proportionally with dose. Mean d-MPH plasma concentrations showed a gradual increase after SDX administration, reaching a broad peak from eight to twelve hours post-dose, followed by a shallow decline thereafter. Increased wakefulness, alertness, hypervigilance, and insomnia effects were reported by study participants, which we believe suggests that SDX produced targeted pharmacodynamic effects that have the potential toÂ benefit patients with IH and other sleep disorders. In November 2022, we announced that the FDA has granted the orphan drug designation to SDX for the treatment of IH. Â In January 2022, we announced that we had selected KP1077 for the treatment of IH and narcolepsy as our leadÂ clinical development candidate. KP1077 utilizes SDX, our prodrug of d-MPH, as its API. During the first quarter of 2022, we initiated a Phase 1 clinical trial comparing the cardiovascular safety of SDX to immediate-release and long-acting formulations of RITALINÂ®, a commonly prescribed central nervous system ("CNS") stimulant. In September 2022, we announced topline data from our exploratory Phase 1 clinical trial, which showed the potential for higher dose formulations of SDX to be safe and well tolerated while avoiding the potential for greater cardiovascular safety riskÂ compared to immediate-release and long-acting formulations of Ritalin. Â 30 Table of Contents Â Based on the data, in December 2022, we announced the initiation of a double-blind, placebo-controlled, randomized-withdrawal, dose-optimizing, multi-center Phase 2 clinical trial evaluating the efficacy and safety of KP1077 for the treatment of IH. The trial concluded in March 2024 and provided meaningful information of the optimal dose and dosing regimen to inform Phase 3 trial design. Â WeÂ enrolled 48 adult patients with IH in more than 30 centers inÂ the United States. Part 1 of the trial consisted of a five-week open-label titration phase during which patients were optimized to one of four doses of SDX (80, 160, 240, or 320 mg/day). Part 2 of the trial entailed a two-week randomized, double-blind, withdrawal phase, during which two-thirds of the trial participants will continueÂ to receive their optimized dose while the remaining one-third will receiveÂ placebo. Participants were further assigned into two evenly divided cohorts. The first cohort received a single daily dose just before bedtime, and the second cohort received half the daily dose shortly after awakening and half the daily dose prior to bedtime. Â Clinically meaningful improvements were observed across all studied endpoints.Â The trial was not powered for statistical significance, and this was not the primary endpoint. The exploratory endpoints of sleep inertia and brain fog performed in-line with expectations and were stable when compared across a variety of other endpoints.Â Symptom improvements in patients receiving KP1077 were similar after both once-per-day, and twice-per-day dosing.Â Â In the Phase 2 trial, KP1077 was observed to be well-tolerated at all dose levels and both dosing regimens, with adverse events that are typical for stimulants and mostly mild in severity.Â These results are consistent with data from the Phase 1 trial with SDXÂ that indicated no greater cardiovascular safety risk despite higher overall exposure levels when compared to both immediate and long-acting methylphenidate products currently used off-label for the treatment of IH.Â The trial concluded in March 2024 and provided meaningful information of the optimal dose and dosing regimen to inform Phase 3 trial design. On June 3, 2024, weÂ announced final results from theÂ Phase 2 Clinical Trial of KP1077 for IH. The proof-of-conceptÂ study was designed to demonstrate safety and tolerability and was not powered to demonstrate statistical significance. However, the trial included several important secondary and exploratory endpoints, such as the change in Epworth Sleepiness Scale ("ESS") total score, the IH Severity Scale ("IHSS"), the Sleep Inertia Visual Analog Scale ("SIVAS"), and a new scale to assess the symptoms and severity of brain fog. These data gathered from the secondary endpoints will help inform the study design for a potential Phase 3 clinical trial of KP1077. We held the end-of-Phase 2 meeting with the FDA in September 2024, to discuss the design of a pivotal Phase 3 trial to study KP1077 in IH. Â Key Takeaways from Phase 2 Clinical Trial of KP 1077 for Idiopathic Hypersomnia include: Â â— KP1077 was well tolerated at all dose levels evaluated in the trial, including the highest dose of 320 mg daily, regardless of the dosing regimen: once daily (QD) or twice daily (BID). Â o Adverse events (AEs) were similar to other methylphenidate products Â o Most common AEs included insomnia, headache, anxiety, decreased appetite, and nausea Â o Most AEs occurred during the titration period, were mild, and did not lead to early discontinuation Â â— KP1077 produced clinically meaningful improvements in EDS as assessed by change from baseline in the ESS during both the 5-week open-label (OL) titration period which was maintained during the 2-week double-blind withdrawal period for both dosing regimens. Â o Mean total ESS scores decreased by approximately 9 points after 5 weeks of OL treatment. Â â— At the end of 7 weeks of treatment, patients administered KP1077 showed

clinically meaningful benefits in change from baseline for the ESS, IHSS, SIVAS, and Brain Fog Scale (BFS): Â o Mean total ESS score decreased by 9.4 (QD) and 8.8 (BID) Â o Mean total IHSS score decreased by 16.1 (QD) and 12.3 (BID) Â o Mean SIVAS score decreased by 25.9 (QD) and 17.2 (BID) Â o Mean total BFS symptom score decreased by 23.8 (QD) and 22.3 (BID) Â â— The study successfully fulfilled the objectives of providing key information for the design of a pivotal efficacy trial, and the results of the secondary efficacy endpoints were supportive of initiating a Phase 3 trial of KP1077. Â We completed a Phase 1 clinical trial in healthy volunteers to assess proposed dosing regimen for the narcolepsy indication. We are leveraging the data from the study and the IH program in evaluating the potential to initiate a Phase 3 trial in narcolepsy. Â As discussed above, we recently completed an End-of-Phase 2 meeting with the FDA who indicated that a single pivotal study with appropriate confirmatory evidence will be sufficient to submit a new NDA. We are evaluating strategic alternatives to advance clinical development toward NDA submission and later, commercialization. Â KP1077 is subject to the terms and conditions of the AZSTARYS License Agreement (as defined below) but is not currently licensed to Commave thereunder. Â KP1077 Summary: Â Â â— No drug-to-drug interactions.Â We have not observedÂ drug-to-drug interactions in clinical drug-drug interaction studies. Â Â Â Â â— Potential for reduced abuse potential as a Schedule IV controlled substance. All other methylphenidate-based products have been designated as Schedule II controlled substances, which indicates stricter control over the prescribing and use of such products.Â Â KP1077 is based on SDX, which has been designated a Schedule IV controlled substance. Â Â Â Â â— No currently approved generic equivalent product. KP1077 contains SDX, our proprietary prodrug of d-methylphenidate, also known as the new chemical name, serdexmethylphenidate, by the U.S. Adopted Names Council of the American Medical Association (â€œUSANâ€), which means that there may be no generic equivalent product for KP1077 in most U.S. states, making drug-equivalent substitution potentially difficult at the pharmacy.Â Â Â Â Â Â â— Orphan drug designation.Â Because small size of the IH patient population, the FDA hasÂ granted KP1077 orphan drug designation for the treatment of IH. We believe KP1077 may potentiallyÂ be eligible for fast-track and breakthrough therapy designation, which may provide various regulatory benefits for the development program. Â 31 Table of Contents Â AZSTARYS (Partnered product) Â AZSTARYS contains d-MPHÂ and our prodrug of dexmethylphenidate, SDX. On March 2, 2021, the FDA approved AZSTARYS as a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients ageÂ six years and older. AZSTARYS is currently being marketed in the U.S. under our September 2019 collaboration and license agreement, or the AZSTARYS License Agreement, with Commave. Under the AZSTARYS License Agreement, we granted to Commave an exclusive, worldwide license, to develop, manufacture, and commercialize AZSTARYS and any of our product candidates containing SDX and used to treat ADHD or any other CNSÂ disease. In July 2020, we entered into the consulting agreement with Corium, Inc. ("Corium") (the â€œCorium Consulting Agreementâ€), under which Corium and Commave, respectively, engaged us to guide the product development and regulatory activities for certain current and potential future products in their portfolio, as well as continue supporting preparation for the potential commercial launch of AZSTARYS. Â Commave has tasked Corium, another affiliate of Gurnet Point Capital, L.P., to lead all commercialization activities for AZSTARYS in the U.S.Â Corium commercially launched AZSTARYS in the U.S. during the third quarter of 2021. In December 2021, Commave entered into a sublicense of commercialization rights for AZSTARYS in greater China to Shanghai Ark Biopharmaceutical Ltd. Â Pursuant to the AZSTARYS License Agreement, CommaveÂ agreed to pay up to $63.0 million in milestone payments upon the occurrence of specified regulatory milestones related to AZSTARYS, including FDA approval and specified conditions with respect to the final approval label. In addition, Corium agreed to make additional payments upon the achievement of specified U.S. sales milestones of up to $420 million in the aggregate. Further, CommaveÂ will pay us quarterly, tiered royalty payments based on a percentage of net sales on a product-by-product basis. Corium also agreed to be responsible for and reimburse us for all of development, commercialization and regulatory expenses for any products or product candidates containing SDX, subject to certain limitations as set forth in the AZSTARYS License Agreement, including consultation fees to be paid to us for services provided to Corium in performing such activities. Â In April 2021, we entered into the AZSTARYS Amendment. Pursuant to the AZSTARYS Amendment, we and Commave agreed to modify the compensation terms of the AZSTARYS License Agreement. Commave paid us $10.0 million in connection with the execution of the AZSTARYS Amendment following the FDA approval of AZSTARYS in the United States. Corium also paid us $10.0 million following the SDX scheduling determination by the DEA, which occurred on May 7, 2021. In addition, the AZSTARYS Amendment increased the total remaining future regulatory and sales milestone payments related to AZSTARYS up to an aggregate of $590.0 million. The AZSTARYS License Agreement will continue on a product-by-product basis (i) until expiration of the royalty term for the applicable product candidate in the United States and (ii) perpetually for all other countries. Â In May 2021, we announced that SDX, our proprietary prodrug of d-MPH and the primary active pharmaceutical ingredientÂ ("API")Â in AZSTARYS, was classified as a Schedule IV controlled substance by the DEA. AZSTARYS is classified as a Schedule II controlled substance as its formulation includes a 70:30 mixture of SDX (Schedule IV) and d-MPH (Schedule II), respectively. Â During the first half of 2023, annual net sales of AZSTARYS surpassed $25 million, triggering the first annual net sales milestone payment of $5.0 million under the AZSTARYS License Agreement, which was earned and recognized as revenue in the second quarter of 2023, and received after quarter-end. DuringÂ the second halfÂ of 2023, annual net sales of AZSTARYS surpassed $50 million, triggering the second net sales milestone payment of $10.0 million under the AZSTARYS License Agreement, which was earned and recognized in the fourth quarter of 2023. Â 32 Table of Contents Â Other Third-Party Agreements Â Aquestive Termination Agreement Â Under our March 2012 termination agreement with Aquestive TherapeuticsÂ ("Aquestive")Â has the right to receive a royaltyÂ amount equal to 10% of any value generated by AZSTARYS and any product candidates containing SDX. In connection with the AZSTARYS License Agreement, we paid Aquestive a royalty equal to 10% of the quarterlyÂ royaltyÂ paymentsÂ and of the regulatory and net sales milestones earned in 2020, 2021, and 2023. Â Distributor Agreement Â Our current single distributorÂ for sales of our approved products, OLPRUVA and MIPLYFFA, is a specialty pharmacy provider, however, the Company mayÂ establish additional specialty distributors orÂ other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements, weÂ enterÂ into arrangements with health care providers and payors that provide for government mandated and/or privately negotiated rebates with respect to the purchase of our products. Â Relief Exclusive License Agreement Â As a condition to entering into the Merger Agreement, Acer and Relief Therapeutics SA ("Relief") entered into an exclusiveÂ license agreement on August 30, 2023 (the "Relief License Agreement"). Pursuant to the Relief License Agreement, Relief will hold exclusive development and commercialization rights for OLPRUVA in the EU, Liechtenstein, San Marino, Vatican City, Norway, Iceland, Principality of Monaco, Andorra, Gibraltar, Switzerland, United Kingdom, Albania, Bosnia, Kosovo, Montenegro, Serbia and North Macedonia ("Geographical Europe"). The Company will have the right to receive a royalty of up to 10% of the net sales of OLPRUVA in Geographical Europe.Â Â XOMA Agreement Â In May 2011, Orphazyme entered into an asset purchase agreement with LadRx Corporation, which was assigned to XOMA (US) LLC, a wholly-owned subsidiary of XOMA Corporation ("XOMA"), in June 2023 ("Xoma License Agreement"). Under the XOMA License Agreement, XOMA is entitled toÂ certain net sales and regulatoryÂ milestone payments in addition toÂ a mid-single digit royalty with respect to sales of MIPLYFFA. Â Results of Operations Â Comparison of the threeÂ months endedÂ September 30, 2024, and 2023Â (in thousands): Â Â Â Three months ended September 30, Â Â Â Period-to- Â Â Â Â 2024 Â Â 2023 Â Â Period Change Â Revenue, net Â $ 3,695 Â Â $ 2,895 Â Â $ 800 Â Cost of product revenue (excluding $1,545 in intangible asset amortization for the three months ended September 30, 2024, shown separately below) Â Â 2,303 Â Â Â 144 Â Â Â 2,159 Â Intangible asset amortization Â Â 1,545 Â Â Â â€” Â Â Â 1,545 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 10,945 Â Â Â 12,297 Â Â Â (1,352) Selling, general and administrative Â Â 16,208 Â Â Â 5,818 Â Â Â 10,390 Â Total operating expenses Â Â 27,153 Â Â Â 18,115 Â Â Â 9,038 Â Loss from operations Â Â (27,306) Â Â (15,364) Â Â (11,942) Other (expense) income: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest expense Â Â (2,312) Â Â (366) Â Â (1,946) Fair value adjustment related to warrant and CVR liability Â Â (4,746) Â Â 3,678 Â Â Â (8,424) Fair value adjustment related to investments Â Â 90 Â Â Â 124 Â Â Â (34) Interest and other income (expense), net Â Â 1,049 Â Â Â 1,738 Â Â Â (689) Total other (expense) income Â Â (5,919) Â Â 5,174 Â Â Â (11,093) Loss before income taxes Â Â (33,225) Â Â (10,190) Â Â (23,035) Income tax expense Â Â â€” Â Â Â (177) Â Â 177 Â Net loss Â $ (33,225) Â $ (10,367) Â $ (22,858) Â Net Loss Â Net loss for the threeÂ months ended September 30, 2024, was $33.2Â million,Â compared toÂ netÂ loss of $10.4Â million for the three months ended September 30, 2023, an increase in net loss of $22.8Â million. The change was primarily attributable to an increaseÂ in lossÂ from operations of $11.9Â million and a decrease inÂ other income of$11.1Â million.Â Â Revenue Â Revenue for the threeÂ months ended September 30, 2024, was $3.7 million, compared to revenue of $2.9Â millionÂ for the threeÂ monthsÂ ended September 30, 2023,Â an increaseÂ of $0.8Â million. The increase wasÂ primarily due to an increase in royalties and other reimbursements under the AZATARYS License Agreement of $0.3Â million and an increaseÂ in French EAP reimbursements of $0.5Â million. OLPRUVA revenue was de minimis for the period. Â Cost of product revenue Â Cost of productÂ revenueÂ for the threeÂ months ended September 30, 2024,Â increased by approximately $2.2Â million compared to the cost of product revenue for the three months ended SeptemberÂ 30, 2023, primarily due to recognition of $2.0Â million of inventory obsolescence. Â Â Â 33 Table of Contents Â Â Intangible asset amortization Â Intangible asset amortization for the three months ended September 30, 2024 , wasÂ due to $1.5 million in amortization expense related toÂ definite-lived intangible assets acquired in the Merger. Â Research and Development Â Research and development expenses decreased by$1.4Â million, from $12.3Â million for the threeÂ monthsÂ endedSeptember 30, 2023, to $10.9Â million for the threeÂ months ended September 30, 2024. This decrease was primarily driven byÂ aÂ decrease in spending for the ongoing Phase 2 clinical study in KP1077, partially offset by an increase in personnel-related costs and an increase in third-party costs related to MIPLYFFA.Â Â Â Selling, General and Administrative Â Selling, general and administrative expenses increased by$10.4Â million, from $5.8Â million for the threeÂ monthsÂ ended September 30, 2023, to $16.2Â million for the threeÂ months ended September 30, 2024. The period-over-period increase was primarily related to an increase in personnel costs due to an increase in headcount and an increase in other expenses as we builtÂ our commercial organization.Â Â Other (Expense) IncomeÂ Â Other expense for the three months ended September 30, 2024,Â was $5.9Â million compared to other income ofÂ $5.2 millionÂ for the threeÂ months ended September 30, 2023.Â This change wasÂ primarily attributable toÂ a decrease inÂ the fair value adjustment related to warrant and CVR liability of $8.4Â million, an increase inÂ interest expense of $1.9Â million, andÂ a decrease in interest and other income of $0.7Â million. Â Comparison of the nine months endedÂ September 30, 2024, and 2023 (in thousands): Â Â Â Nine months ended September 30, Â Â Period-to- Â Â Â Â 2024 Â Â 2023 Â Â Period Change Â Revenue, net Â $ 11,569 Â Â $ 14,541 Â Â Â $ (2,972) Cost of product revenue (excluding $4,619 in intangible asset amortization for the nine months ended September 30, 2024, shown separately below) Â Â 6,051 Â Â Â 946 Â Â Â 5,105 Â Intangible asset amortization Â Â 4,619 Â Â Â â€” Â Â Â 4,619 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 33,743 Â Â Â 28,385 Â Â Â 5,358 Â Selling, general and administrative Â Â 38,743 Â Â Â 19,657 Â Â Â 19,086 Â Total operating expenses Â Â 72,486 Â Â Â 48,042 Â Â Â 24,444 Â Loss from operations Â Â (71,587) Â Â (34,447) Â Â (37,140) Other (expense) income: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest expense Â Â (5,157) Â Â (745) Â Â (4,412) Fair value adjustment related to warrant and CVR liability Â Â 4,660 Â Â Â 4,253 Â Â Â 407 Â Fair value adjustment related to investments Â Â 64 Â Â Â 451 Â Â Â (387) Interest and other income (expense), net Â Â 2,248 Â Â Â 4,331 Â Â Â (2,083) Total other (expense) income Â Â 1,815 Â Â Â 8,290 Â Â Â (6,475) Loss before income taxes Â Â (69,772) Â Â (26,157) Â Â (43,615) Income tax expense Â Â â€” Â Â Â â€” Â Â Â â€” Â Net loss Â $ (69,772) Â $ (26,157) Â $ (43,615) Â Net Loss Â Net loss for the nine months ended September 30, 2024, was $69.8Â million,Â compared toÂ netÂ loss of $26.2Â million for the nine months ended September 30, 2023, an increase in net loss of$43.6Â million. The change was primarily attributable to an increaseÂ in lossÂ from operations of $37.1Â million andÂ a decreaseÂ in other income of $6.5Â million.Â Â Revenue Â Revenue for the nineÂ months ended September 30, 2024, was $11.6Â million, compared to revenue of $14.5Â millionÂ for the nineÂ monthsÂ ended September 30, 2023, a decrease of $2.9Â million. This decrease was primarily due to a decrease in net sales milestones under the AZSTARYS License Agreement of $5.0 million and aÂ decrease in consulting revenue of $1.5 million,Â partially offset by an increase in royalties and other reimbursements under theÂ AZSTARYS License Agreement of $2.4Â millionÂ and an increase in French EAP reimbursements of $1.2 million.Â OLPRUVA revenue was de minimis for the nineÂ months ended SeptemberÂ 30, 2024. Â Cost of product revenue Â Cost of productÂ revenueÂ for the nineÂ months ended September 30, 2024,Â increased by approximately $5.1Â millionÂ compared to cost of product revenueÂ for the nine months ended September 30, 2023,Â primarily due to recognition of $5.2Â million of inventory obsolescence. Â Intangible asset amortization Â Intangible asset amortization for the nine months ended September 30, 2024, wasÂ due to $4.6Â million in amortization expense related toÂ definite-lived intangible assets acquired in the Merger. Â Â 34 Table of Contents Â Research and Development Â Research and development expenses increased by $5.3Â million, from $28.4Â million for the nineÂ monthsÂ ended September 30, 2023, to $33.7Â million for the nineÂ months ended September 30, 2024. This increase was primarily driven by an increase in personnel-related costsÂ and an increase in third-party research and development costs related to celiprolol, partially offset by a decrease in research and development costs related to a product for which the NDA was withdrawn during the nine months ended September 30, 2023. Â Â Selling, General and Administrative Â Selling, general and administrative expenses increased by $19.0Â million, from $19.7Â million for the nineÂ monthsÂ ended September 30, 2023, to $38.7Â million for the nineÂ months ended September 30, 2024. The period-over-period increase was primarily related to an increase in personnel costs and fees associated with our commercial and business development activities.Â Â Other IncomeÂ Â Other income decreased by $6.5Â million, from $8.3Â million for the nineÂ months ended September 30, 2023, toÂ $1.8Â millionÂ for the nineÂ months ended September 30, 2024.Â This decreaseÂ was primarilyÂ attributable to an increase in interest expense of $4.4 million, a decrease in interest and other income of $2.1 million, and a decrease in the fair value adjustment related to investments of $0.4 million, partially offset by an increase inÂ fair value adjustment related to warrant and CVR liability of $0.4Â million. Â Liquidity and Capital Resources Â Sources of Liquidity Â Through SeptemberÂ 30, 2024, we have funded our research and development and operating activities primarily through the issuance of debt and equity and from revenue received under the EAP, AZSTARYS License Agreement, OLPRUVA product sales and consulting arrangements. As of SeptemberÂ 30, 2024, we had cash, cash equivalents and investments of $95.5Â million. Â To date, we haveÂ generated revenue from the EAP, AZSTARYS License Agreement, reimbursementÂ ofÂ out-of-pocketÂ third-party costs,Â the performance of consulting services, and sales of OLPRUVA. Â We haveÂ had recurring negative netÂ operating cash flows and we anticipate that we mayÂ continue to incur minimal positive net cash flows from operations or negative net cash flows from operations for at least the next several years. We expect that our sources of revenueÂ will be through payments arising from our license agreementÂ with Commave, theÂ EAP, sales of OLPRUVA and MIPLYFFA and otherÂ potential consulting arrangements and any other future arrangements related to one of ourÂ product candidates. Â We filed a registration statement on Form S-3 covering the sale of the shares of our common stock up to $350.0 million, $75.0 million of which was allocated to the sales of the shares of common stock issuable under the Equity Distribution Agreement (described below). The Form S-3 was declared effective on July 12, 2021. As of SeptemberÂ 30,Â 2024, no shares had been issued or sold under the Equity Distribution Agreement and this registration statement under S-3 expired on July 12, 2024. Â On June 4, 2024, we filed a registration statement on Form S-3 (File No. 333-279941) (the "June 2024 Registration Statement") under which we may sell securities, including as may be issuable upon conversion, redemption, repurchase, exchange or exercise of securities, in one or more offerings up to a total aggregate offering price of $350.0 million, $75.0Â million of which was allocated to the sales of the shares of common stockÂ issuable under theÂ 2024Â ATM Agreement (as described further below).Â The registration statementÂ was declared effective on June 13, 2024.Â Â On AugustÂ 8, 2024, weÂ entered into an underwriting agreement {the "Underwriting Agreement") with Cantor Fitzgerald & Co. and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the "Underwriters"),Â in connection with the August offering.Â Under the terms of the Underwriting Agreement, weÂ also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 1,384,615 shares of ourÂ common stock at the public offering price, less underwriting discounts and commissions, which the Underwriters exercised in full on August 9, 2024. The August 2024 Offering closed on AugustÂ 12, 2024.Â Total shares issued were 10,615,385.Â Net proceeds from the offering were approximately $64.5Â million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. WeÂ intendÂ to use the net proceeds of the offering to support theÂ commercialÂ launch activities for MIPLYFFA, continued commercial support for OLPRUVA and the continued development of celiprolol and KP1077 through potential NDA filings and other general corporate purposes.Â Â We have incurred operating losses since our inception and, as of SeptemberÂ 30, 2024, had an accumulated deficit of $469.6Â million. Our recurring operating losses and negative cash flows from operations raise substantial doubt about our ability to continue as a going concern. The Companyâ€™s ability to continue operating as a going concern is contingent upon its ability to generate revenue from approved products or obtain product candidate regulatory approvals, which would generate revenue, milestones, and cash flow sufficient to support ongoing operations and the satisfaction of financial covenants. We are early in our commercialization effort for OLPRUVA and MIPLYFFA and do not yet have a substantial basis to project future earnings, and our other sources of revenue are not sufficient to sustain our present activities on their own. Accordingly, our ability to continue as a going concern may require us to obtain additional financing to fund our operations. The perception of our

inability to continue as a going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the loss of confidence by investors, suppliers and employees. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or debt, the terms of these securities may restrict our ability to operate. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether cease our research and development programs or future commercialization efforts. Â 35 Table of Contents Â Equity Distribution Agreements Â On July 12, 2024, weÂ entered into an equity distribution agreement (the "2024 ATM Agreement") with Citizens JMP Securities LLC ("Citizens JMP")Â under which weÂ may offer and sell, from time to time in ourÂ sole discretion, shares of ourÂ common stock having an aggregate offering price of up to $75.0 million through Citizens JMP as ourÂ sales agent. The issuance and sale, if any, of common stock by usÂ under theÂ 2024Â ATM Agreement will be made pursuant to a registration statement on FormÂ S-3. Citizens JMP mayÂ sell the common stock by any method permitted by law deemed to be an â€œat the market offeringâ€ as defined in RuleÂ 415Â of the Securities Act. Citizens JMP will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from usÂ (including any price, time or size limits or other customary parameters or conditions weÂ mayÂ impose). WeÂ will pay Citizens JMPÂ a commission equal toÂ 3.0%Â in the aggregate of the gross sales proceeds of any common stock sold through Citizens JMPÂ under theÂ 2024Â ATM Agreement. In connection with the 2024 ATM Agreement, weÂ filed the June 2024 Registration Statement, the accompanying prospectus, and the related prospectus supplement dated July 12, 2024, covering the sale of the shares of ourÂ common stock up to $350.0Â million, $75.0Â million of which was allocated to the sales of the shares of common stockÂ issuable under theÂ 2024Â ATM Agreement. Â On JulyÂ 2, 2021, we entered into an equity distribution agreement ("2021 ATM Agreement") with JMP Securities LLC ("JMP")Â and RBC Capital Markets, LLC ("RBCCM"), under which we had the ability to offer and sellÂ shares of our common stockÂ having an aggregate offering price of up to $75.0 millionÂ through JMP and RBCCM as our sales agents.Â The 2021 ATMÂ Agreement expired on July 12, 2024. Â Merger Transactions and Documents Â On August 30, 2023, in connection with the Merger Agreement with Acer, the following transactions occurred prior to Closing:Â Â Â Â â— Bridge LoanÂ â€“Â Zevra and Acer entered into a bridge loan facility for up to $18.0 million ("Bridge Loan"),Â providing for Zevra to make the Bridge LoanÂ to Acer up to an aggregate principal amount of $16.5 million. The Bridge Loan was provided to Acer to support its termination agreement with Relief and to provide Acer with working capital, including for payments of accounts payable to support the commercial launch of OLPRUVA and the development of celiprololÂ pending the Mergerâ€™s closure.Â On October 31, 2023, the Company and Acer entered into an amendment to the Bridge Loan Agreement, which increased the aggregate principalÂ amount available under the loanÂ from $16.5 million to $18.0Â million.Â Â Â Â â— Purchase of Acerâ€™s Term LoansÂ â€“Â Zevra purchased certain indebtedness of Acer held by Nantahala Capital Management, LLC ("NCM"). Under the loan purchase with Nantahala, certain of its affiliates and certain other parties (collectively with Nantahala, Â â€œNantahala HoldersÂ â€)Â Zevra purchased (i) an original senior secured term loan facility made available to Acer in an aggregate amount of $6.5 million and funded on March 14, 2022, andÂ (ii) an additional senior secured term loan made to Acer in an aggregate amount of $7.0 million in a single borrowing which funded on January 31, 2023 for (1) $12.0 million in cashÎ¾Â (2) 98,683 shares of Zevra Common StockÎ¾Â and (3) a secured Promissory Note payable by Zevra to Nantahala in the original principal amount $5.0 million (the â€œNantahala Noteâ€). These were recorded as receivables from Acer and were treated as a settlement of a preexisting relationshipÂ in connection with the closing of the transaction and recorded as a component of purchase consideration. In April 2024, the Nantahala Note was repaid in full and terminated. Â Â Â â— Purchase of Acerâ€™s Convertible Notes (â€œMarathon Convertible Notesâ€) â€“Â Under the Note Purchase Agreement with the Nantahala Holders, Zevra purchased the Marathon Convertible Notes that Nantahala had acquired on June 16, 2023. Zevra acquired the Marathon Convertible Notes in exchange for the issuance of 2,171,038 shares of Zevra Common Stock at $5.0667 per share for a total purchase price of $11.0 million. Â Â Â â— Amendment to IP License Agreement and IP Termination Agreement:Â As a condition to entering into the Merger Agreement, Acer andÂ Relief entered into the Exclusive License Agreement and the Termination Agreement terminating the collaboration and license agreement, dated March 19, 2021, by and between Acer and Relief. Pursuant to the Exclusive License Agreement, Relief holds exclusive development and commercialization rights for OLPRUVA in Geographical Europe. Acer hasÂ the right to receive a royalty of up to 10% of the net sales of OLPRUVA in Geographical Europe. In accordance with the terms of the Termination Agreement, Relief received an upfront payment from Acer of $10.0 million (which payment was funded with the Bridge Loan described above) with an additional payment of $1.5 million due on the first-year anniversary of the $10.0 million payment. Acer has also agreed to pay a 10% royalty on net sales of OLPRUVA worldwide, excluding Geographical Europe, and 20.0% of any value received by Acer from certain third parties relating to OLPRUVA licensing or divestment rights, all of the foregoing which are capped at $45.0 million, for total payments to Relief of up to $56.5 million. Â In connection with the closing of the Merger on November 17, 2023, each share of common stock of Acer was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable CVRÂ to be issued by Zevra, which will represent the right to receive one or more contingent payments up to an additional $76 millionÂ upon the achievement, if any, of certain commercial and regulatory milestones for Acerâ€™s OLPRUVAÂ and celiprololÂ products within specified time periods. Certain additional cash payments are also possible pursuant to the CVRs with respect to milestones involving Acerâ€™s early-stage program ACER-2820 (emetine). Â 36 Table of Contents Â Registration Rights Agreement Â Zevra and Nantahala concurrently entered into a registration rights agreement (the â€œRegistration Rights Agreementâ€), pursuant to which Zevra agreed to file a resale registration statement with respect to the resale of the Zevra common stock issuable under the Loan and Note Purchase Agreements and the Nantahala Note. On February 5, 2024, Zevra filed a registration statement on Form S-3 (File No. 333-276856) registering an aggregate of 2,269,721 shares of Zevraâ€™s common stock that were issued pursuant to the Loan and Note Purchase Agreements. On April 5, 2024, we filed an amendment to the registration statement on Form S-3Â (File No. 333-250945) covering the issuance of the shares of our common stock issuable upon the exercise of warrants issued in connection with the Merger and remaining unexercised as of the date of the amendment, which was declared effective on April 8, 2024. Â Cancellation of Acer Warrant Â On November 22, 2023, weÂ sold an aggregate of 1,382,489 shares of our common stock and accompanying warrants to purchase up to 1,382,489 shares of our common stock at a price of $4.34 per share to a healthcare focused investment fund (the â€œInvestorÂ â€) for gross proceeds of approximately $6.0 million and an aggregate of 917,934 shares of our common stock to cancel a warrant held by the Investor to purchase 2,920,306 shares of common stock of Acer. The shares of common stock and warrants were offered and sold to the Investor in a registered direct offering without an underwriter or placement agent. Â Line of Credit Â On January 26, 2023, weÂ and Wells Fargo, as lender, entered into a margin account agreement. OurÂ investments wereÂ used as collateral for the loan and the amount we wereÂ able to borrow was limited to 80-90% of ourÂ outstanding investment balance held with Wells Fargo. The margin account boreÂ interest at the Prime Rate minus 225 basis-points. This facility was paid off on April 5, 2024, andÂ the margin capabilityÂ wasÂ removed from the account. Â Term Loans Â On April 5, 2024 (the "Term Loans Closing Date"), weÂ entered into a credit agreement (the â€œCredit Agreementâ€) withÂ HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the â€œLendersâ€), and Alter Domus (US) LLC, as administrative agent (the â€œAdministrative Agentâ€). Â Under the terms of the Credit Agreement, the Lenders provided a senior secured loan facility to usÂ in the aggregate principal amount of $100.0 million, whichÂ is divided into three tranches as follows: (i) $60.0 million which was funded in full on the Term Loans Closing Date; (ii) $20.0 million which is available to us in up to two drawings, each in an amount not to exceed $10.0 million, at the Companyâ€™s option until 18 months following the Term Loans Closing Date; and (iii) $20.0 million which is available to usÂ upon approval by the FDAÂ of the NDAÂ for MIPLYFFA for the treatment of NPC, at ourÂ option until December 31, 2024 (collectively, the â€œTerm Loansâ€).Â Â Â The principal amount of the Term Loans outstanding (the â€œOutstanding Principal Amountâ€) will bear interest at a rate equal to 3-Month Term SOFR plus 7.00% per annum. If the net product sales for the calendar year ending December 31, 2025, exceed $100.0 million, the Outstanding Principal Amount will bear interest at 3-Month Term SOFR plus 6.00% per annum. If the net product sales for the calendar year ending December 31, 2025, do not exceed $100.0 million, then for any subsequent period of four consecutive fiscal quarters ending on or after March 31, 2026, in which net product sales exceed $125.0 million, the Outstanding Principal Amount will bear interest at 3-Month Term SOFR plus 6.50% per annum. In all cases, the 3-Month Term SOFR rate will be subject to a floor of 4.00% per annum. Interest will be payable quarterly in arrears on the last day of each calendar quarter. We haveÂ the option to pay up to 25% of the interest in-kind beginning on the Term Loans Closing Date, through and including June 30, 2026.Â The Term Loans will mature on the fifth anniversary of the Term Loans Closing Date. In connection with the Credit Agreement, weÂ incurred approximately $2. 2Â million ofÂ costs, which primarily consisted of underwriting, legal and other professional fees, and areÂ included as a reduction to the carrying amount of the related debt liability and are deferred and amortized over the remaining life of the financing using the effective interest method. Â The Credit Agreement contains customary affirmative and negative covenants by us, which among other things, will require usÂ to provide certain financial reports to the Lenders, meet certain minimum net product sales amounts, and limit ourÂ ability to incur or guarantee additional indebtedness, engage in certain transactions, and effect a consolidation or mergerÂ without consent. In addition, as long as the line of credit remains active, we must maintain a minimum cash balance of $20.0 million to ensure that we can meet our immediate capital needs. OurÂ obligations under the Credit Agreement may be accelerated upon customary events of default, including non-payment of principal, interest, fees and other amounts, covenant defaults, insolvency, material judgments, or inaccuracy of representations and warranties. The Term Loans are secured by a first priority perfected lien on, and security interest in, substantially all of our current and future assets. The proceeds of the Term Loans wereÂ used to refinance certain of our previously existing indebtedness. WeÂ will use the remaining proceeds to pay fees and expenses related to the debt financingÂ and fund the development and commercialization of OLPRUVAÂ and MIPLYFFA. Â Â Â 37 Table of Contents Â Cash Flows Â The following table summarizes our cash flows for theÂ nine months ended September 30, 2024, and 2023 (in thousands): Â Â Â Nine months ended September 30, Â Â Â 2024 Â Â 2023 Â Net cash used in operating activities Â $ (53,415) Â $ (17,377) Net cash used in investing activities Â Â (16,690) Â Â (27,975) Net cash provided by financing activities Â Â 81,312 Â Â Â Â 23,460 Â Effect of exchange rates on cash and cash equivalents Â Â (217) Â Â (305) Net increase (decrease) in cash and cash equivalents Â $ 10,990 Â Â $ (22,197) Â Operating Activities Â For the nineÂ months ended SeptemberÂ 30,Â 2024, net cash used inÂ operating activities of $53.4Â million consisted of a net loss of $69.8Â million, changes in working capital of $1.8Â million, partially offset byÂ $18.2Â million in adjustments forÂ non-cashÂ items. Net loss was primarily attributable to our spending on research and development programs and operating costs;Â partially offset by revenue received under the AZSTARYS License Agreement, and theÂ EAP. The changes in working capitalÂ consisted ofÂ $10.6Â million related to a change in accounts payable and accrued expenses, $4.2Â million change in inventories, $0.4Â million related to a change in operating lease liabilities, an increase ofÂ $0.5Â million in prepaids and other assetsÂ and $1.0Â million related to a change in other liabilities, partially offset byÂ $9.6Â million related to a change in accounts and other receivables,Â $0.4Â million related to a change in operating leaseÂ right-of-use assets, andÂ $4.8Â million related to a change in discount and rebate liabilities.Â The adjustments forÂ non-cashÂ itemsÂ primarilyÂ consisted of stock-based compensation expense of $10.9Â million, an inventory obsolescence charge of $5.2Â million, interest expense of $1.5 million, andÂ $5.3Â million related to depreciation, amortization and other items,Â partially offset by a change in the fair value of warrant and CVR liability of $4.7Â million.Â Â For the nineÂ months ended SeptemberÂ 30, 2023,Â net cash used in operating activities of $17.4 million consisted of a net loss of $26.2Â million; partially offset by $0.4Â million in adjustments for non-cash items and $8.4Â million in changes in working capital. Net loss was primarily attributable to our spending on research and development programs and operating costs; partially offset by revenue received under the AZSTARYS License Agreement, Arimoclomol EAP and the Corium Consulting Agreement. The changes in working capital consisted of $3.9 million related to a change in discount and rebate liabilities, $5.4Â million related to a change in accounts payable and accrued expenses, $0.2 million related to a change in operating lease right-of-use assets, $0.2 million related to a change in inventories, $0.7 million related to a change in other liabilities; partially offset by $1.6 million related to a change in accounts and other receivables and $0.3 million related to a change in operating lease liabilities. The adjustments for non-cash items primarily consisted of stock-based compensation expense of $3.1 million, non-cash severance expense of $1.4 million, and $0.5 million related to depreciation, amortization and other items; partially offset by a change in the fair value adjustment related to warrant and CVR liability of $4.2 million and a change in fair value adjustment related to investments of $0.5 million. Â Investing Activities Â For the nineÂ months ended SeptemberÂ 30, 2024, net cash used in investing activities was $16.7Â million, which was primarily attributable to purchases of investments of $41.5 million, partially offset by $24.8 million in maturities of investments. Â For the nineÂ months ended SeptemberÂ 30, 2023, net cash used inÂ investing activities was $28.0Â million, which was primarily attributable to purchases of investments of $45.8Â million, purchases of secured corporate notes of $25.4 million, and purchases of property and equipment of $0.2 million; partially offset by maturities of investments of $43.4 million. Â Financing Activities Â For the nineÂ months ended SeptemberÂ 30, 2024, net cash provided byÂ financing activities was $81.3Â million, which was primarily attributable to proceeds from the issuance of debt of $59.0 million andÂ proceeds from the issuance of stock of $65.8Â million, partially offset by repayments of debt of $42.7Â million. Â For the nineÂ months ended September 30, 2023, net cash provided byÂ financing activities wasÂ $23.5 million, which was primarily attributable to proceeds from the issuance of debt of $38.8 million, proceeds from insurance financing programs of $1.3 million and proceeds from the Employee Stock Purchase Plan of $0.2Â million; partially offset by repayment of debt of $12.8 million, payments to repurchase shares as part of the Share Repurchase Program of $3.4 million, and payments of principal on insurance financing arrangements of $0.5 million. Â 38 Table of Contents Â Future Funding Requirements Â While under applicable accounting principles factors exist that raise substantial doubt about our ability to continue as a going concern,Â based on our current operating forecast and the net proceeds from the AugustÂ 2024 Offering (as described above), we believeÂ that our existing cash, cash equivalents and investments will be sufficient to fund our operations into 2027, subject to continuing compliance with our debt covenants. This estimateÂ includes anticipated revenue from MIPLYFFA sales, reimbursements from the EAP, royalties under the AZSTARYS License Agreement, and accounts for continued investments into our development pipeline programs. This estimate does not include potential proceeds from a PRV sale. Certain of the milestones are associated with regulatory matters that are outside our control. In addition, we maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of a failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. Â Potential near-term sources of additional funding include: Â Â Â â— any royalties or net sales milestone paymentsÂ generated under the AZSTARYS License Agreement; Â Â Â Â Â â— any product sales under the EAP; Â Â Â Â Â â— any product sales of OLPRUVA; Â Â Â Â Â â— any product sales of MIPLYFFA; and Â Â Â Â Â â— any consulting services revenue generated under other potential consulting agreements; Â We cannot guarantee that we will be able to generate sufficient proceeds from any of these potential sources to fund our operating expenses. We anticipate that our expenses will fluctuate substantially as we: Â Â Â â— continue our ongoingÂ clinical trials and our product development activities for our pipeline of product candidates; Â Â Â Â Â â— seek regulatory approvals for any product candidates that successfully complete clinical trials; Â Â Â Â Â â— continue research and development and clinical trials of our product candidates; Â Â Â Â Â â— seek to discover and develop additional product candidates either internally or in partnership with other pharmaceutical companies; Â Â Â Â Â â— adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products; Â Â Â Â Â â— maintain, expand and protect our intellectual property portfolio; and Â Â Â Â Â â— incur additional legal, accounting and other expenses in operating as a public company. Â To date, we haveÂ generated revenue from the AZSTARYS License Agreement, reimbursements ofÂ out-of-pocketÂ third-party costs, the performance of consulting services, OLPRUVA product sales, and product sales under the EAP.Â We expect that, for the foreseeable future, our only sources of revenues will be through payments arising from the AZSTARYS License Agreement, product sales of OLPRUVA and MIPLYFFA, through potential consulting arrangements andÂ any other future arrangements related to one of our product candidates and product sales under theÂ EAP.Â While we have entered into the AZSTARYS License Agreement to develop, manufacture and commercialize AZSTARYS,Â we cannot guarantee that this, orÂ any strategy we adopt in the future,Â will be successful. For instance, we received milestone payments under the AZSTARYS License Agreement, but we cannot guarantee that we will earn any additional milestone or royalty payments under this agreement in the future. We also cannot guarantee that we will continue to generate revenue under the EAP or successfully commercialize OLPRUVA or MILYFFA. We also expect to continue toÂ incur additional costs associated with operating as a public company. Â Â 39 Table of Contents Â We have based our estimates of our cash needs andÂ cash runwayÂ on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect and we cannot guarantee that we will be able to generate sufficient proceeds from the AZSTARYS License Agreement, product reimbursementsÂ under the EAP, product sales of OLPRUVA and

MILYFFA,Â potential consulting arrangements or other funding transactions to fund our operating expenses. To meet any additional cash requirements, we may seek to sell additional equity or convertible securities that may result in dilution to our stockholders, issue additional debt or seek other third-party funding, including potential strategic transactions, such as licensing or collaboration arrangements. Because of the numerous risks and uncertainties associated with the development and commercialization ofÂ product candidates and products, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the commercialization and development of our partnered product or product candidates, should they obtain regulatory approval. Â Critical Accounting Estimates Â This managementâ€™s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. The preparation of our unaudited condensed consolidatedÂ financial statements requires us to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our unaudited condensed consolidated financial statements, as well as the reported revenues and expensesÂ during the reported periods. We evaluate these estimatesÂ on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Â Our critical accounting policies have not changed materially from those described in Part II,Â Item 7 â€“ Managementâ€™sÂ Discussion and Analysis of Financial Condition and Results of OperationsÂ of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 1, 2024. Â Item 3. QuantitativeÂ and Qualitative Disclosures About Market Risk Â Not applicable. Â Item 4. ControlsÂ and Procedures Â Limitations on Effectiveness of Controls and Procedures Â In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Â Evaluation of Disclosure Controls and Procedures Â Our management, with the participation of our chief executive officer and our chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. Based on the evaluation of our disclosure controls and procedures as of September 30, 2024, our chief executive officer and our chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. Â Changes in Internal Control Over Financial Reporting Â ThereÂ was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred duringÂ our fiscal quarter ended September 30,Â 2024, that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Â 40 Table of Contents Â PART II OTHER INFORMATION Â Item 1. Legal Proceedings Â From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business.Â In connection with the AZSTARYS License Agreement with Commave, a dispute has arisen with Commave concerning the interpretation of certain provisions under the AZSTARYS License Agreement. On September 4, 2024, Commave filed a complaint against Zevra in the Court of Chancery of the State of Delaware (Case No. 2024-0920-LWW) alleging breach of contract and seeking injunctive relief, specific performance, declaratory relief, and damages regarding the parties' respective rights and obligations under the Agreement. Â We strongly disagree with Commave's allegations and believe this lawsuit is without merit.Â We filed a motion to dismiss the complaint on October 7, 2024. Commaveâ€™s opposition to the motion to dismiss is due November 21, 2024, and Zevraâ€™s reply in support of the motion to dismiss is due December 20, 2024. All discovery in the litigation has been stayed pending resolution of Zevraâ€™s motion to dismiss. Â The litigation is in its early stages. While we intend to vigorously defend against Commave's claims, the outcome of this matter is inherently uncertain. We cannot predict with certainty the timing or ultimate outcome of this litigation or its potential impact on our business, financial condition, or results of operations. At this time, we have not recorded any accrual for contingent liability associated with this matter. Â The AZSTARYS License Agreement remains in effect during this litigation, and both parties continue to perform their respective obligations thereunder. However, there can be no assurance that this dispute will not have an adverse impact on our relationship with Commave or on Zevraâ€™s business. Â We will continue to monitor developments in this matter and will assess the potential impact on our financial statements in future periods. We expect to incur significant legal expenses in connection with this litigation, which may materially affect our results of operations in future periods. Â Other than disclosed herein, weÂ believe there is no litigation pending that would reasonably be expected to, individually or in the aggregate, have a material adverse effect on our results of operations or financial condition. Â Item 1A. Risk Factors Â In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider all the risk factors and uncertainties described in Part I, Item 1A. â€œRisk Factorsâ€ of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 1, 2024, before investing in our common stock. Other than as described below, thereÂ have been no material changes to the risk factors described in that report. If any of those risks materialize, our business, financial condition and results of operations could be seriously harmed. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements because of theÂ risk factors in our Annual Report on Form 10-K and below, and the other factors described in in this Quarterly Report on Form 10-Q. Â If we experience additional material weaknesses or otherwise fail to maintain effective internal control over financial reporting and disclosure controls and procedures, we may not be able to accurately report our financial results or report them in a timely manner, which may adversely affect investor confidence in us and, as a result, the value of our common stock. Â Our management is required to report annually on the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. Â A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Companyâ€™s annual or interim financial statements will not be prevented or detected on a timely basis. We previously identified and disclosed a material weakness in our internal control over financial reporting in our Annual Report on Form 10-K for the year ended December 31, 2023, and our Quarterly Report on Form 10-Q for the three months ended March 31, 2024. This material weakness has since been remediated. Â Our failure to certify the effectiveness of our internal control over financial reporting or our disclosure controls and procedures, or the identification of the material weakness, could subject us to regulatory scrutiny and a loss of public confidence, which could have a material adverse effect on our business and our stock price. In the future, we may identify additional material weaknesses or significant deficiencies, and we may not be able to remediate them in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. In addition, we may encounter problems or delays in completing the implementation of any requested improvements and, if and when such a report is required, receiving a favorable attestation report from our independent registered public accounting firm. If we do not maintain adequate financial and management personnel, processes and controls, we may not be able to manage our business effectively or accurately report our financial performance on a timely basis, which could cause a decline in our common stock price and adversely affect our results of operations and financial condition. Â 41 Table of Contents Â Item 2. UnregisteredÂ SalesÂ of EquityÂ Securities ANDÂ UseÂ of Proceeds Â Recent Sales of Unregistered Securities Â None. Â Purchases of Equity Securities By the Issuer and Affiliated Purchasers Â None. Â Item 3. Defaults Upon Senior Securities Â Not applicable. Â Item 4. Mine Safety Disclosures Â Not applicable. Â Â Item 5. Other Information Â (a) Disclosure in lieu of reporting on a Current Report on Form 8-K. Â Â None. Â (b) Material changes to the procedures by which security holders may recommend nominees to the board of directors. Â Â Â Â None. Â (c) Insider Trading Arrangements and Policies. Â On October 15, 2024, Timothy J. Sangiovanni, Senior Vice President, Finance and Corporate Controller, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 3,000Â shares of the Companyâ€™s common stock until April 15, 2025. Â On October 15, 2024, Sven Guenther, Ph.D., Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 8,000Â shares of the Companyâ€™s common stock until April 15, 2025. Â On October 15, 2024, Joshua Schafer, Chief CommercialÂ Officer & Executive Vice President, Business Development, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 10,500Â shares of the Companyâ€™s common stock until April 15, 2025. Â On October 15, 2024, Christal M.M. Mickle, Chief DevelopmentÂ Officer,Â adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 6,300Â shares of the Companyâ€™s common stock until April 15, 2025. Â On October 15, 2024, R. LaDuane Clifton, Chief FinancialÂ Officer and Treasurer,Â adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 11,000Â shares of the Companyâ€™s common stock until April 15, 2025. Â On October 15, 2024, Neil F. McFarlane, Chief ExecutiveÂ Officer,Â adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 91,817Â shares of the Companyâ€™s common stock until April 15, 2025. Â Other than as disclosed above, during the three months ended SeptemberÂ 30, 2024, no director or officer of the Company adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408(a) of Regulation S-K. Â 42 Table of Contents Â Â Item 6. Exhibits Â The following is a list of exhibits filed as part of this Form 10-Q (the SEC file number for all items incorporated by reference herein from reports on Forms 10-K, 10-Q, and 8-K is 001-36913): Â ExhibitÂ No. Â Description 3.1 Â Amended and Restated Certificate of Incorporation of Zevra Therapeutics, Inc. (incorporated herein by reference to the Registrantâ€™s Current Report on Form 8-K as filed with the SEC on April 21, 2015). 3.1.1 Â Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant, effective as of December 23, 2020 (incorporated herein by reference to Registrant's Current Report on Form 8-K as filed with the SEC on December 23, 2020). 3.1.2 Â Certificate of Amendment of Amended and Restated Certificate of Incorporation of Zevra Therapeutics, Inc. (incorporated herein by reference to the Registrant's Current Report on Form 8-K as filed with the SEC on February 24, 2023). 3.2 Â Amended and Restated Bylaws, as currently in effect, of Zevra Therapeutics, Inc. (incorporated herein by reference to the Registrant's Current Report on Form 8-K as filed with the SEC on February 28, 2024). 4.1 Â Specimen stock certificate evidencing shares of Common Stock (incorporated herein by reference to the Registrant's Annual Report on Form 10-K as filed with the SEC on March 12, 2021). 31.1* Â Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. 31.2* Â Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. 32.1** Â Certification of the Principal Executive Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, andÂ 18. U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act ofÂ 2002. 32.2** Â Certification of the Principal FinancialÂ Officer pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, andÂ 18. U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act ofÂ 2002. 101.INS* Â Inline XBRL Instance Document 101.SCH* Â Inline XBRL Taxonomy Extension Schema Document 101.CAL* Â Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF* Â Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB* Â Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE* Â Inline XBRL Taxonomy Extension Presentation Linkbase Document 104** Â Cover page Interactive Data File (embedded within the Inline XBRL and combined in Exhibit 101) Â * Filed herewith ** Furnished herewith Â 43 Table of Contents Â SIGNATURES Â Pursuant to the requirements ofÂ the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â Zevra Therapeutics, Inc. Â Â Date:Â Â Â November 13, 2024 By: /s/ Neil F. McFarlane Â Â Neil F. McFarlane Â Â President and Chief Executive Officer (Principal Executive Officer) Â Â Â Date:Â Â Â November 13, 2024 By: /s/ R. LaDuane Clifton Â Â R. LaDuane Clifton, MBA, CPA Â Â Chief Financial OfficerÂ and Treasurer (Principal Financial Officer) Â 44 EX-31.1 2 ex_716263.htm EXHIBIT 31.1 ex_716263.htm Exhibit 31.1 Â CERTIFICATION Â I, Neil F. McFarlane, certify that: Â Â 1. I have reviewed this Quarterly Report on Form 10-Q of Zevra Therapeutics, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))Â for the registrant and have: Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â NovemberÂ 13, 2024 Â /s/ Neil F. McFarlane Â Â Name: Neil F. McFarlane Â Â Title: President and Chief Executive Officer (Principal Executive Officer) Â Â EX-31.2 3 ex_716264.htm EXHIBIT 31.2 ex_716264.htm Exhibit 31.2 Â CERTIFICATION Â I, R. LaDuane Clifton, certify that: Â Â 1. I have reviewed this Quarterly Report on Form 10-Q of Zevra Therapeutics, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â November 13, 2024 Â /s/ R. LaDuane Clifton Â Â Name: R. LaDuane Clifton, MBA, CPA Â Â Title: Chief Financial OfficerÂ and

Treasurer (Principal Financial Officer) Â Â EX-32.1 4 ex_716265.htm EXHIBIT 32.1 ex_716265.htm Exhibit 32.1 Â CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report on Form 10-QÂ of Zevra Therapeutics, Inc., (the â€œCompanyâ€) for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Neil F. McFarlane, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: Â Â 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â November 13, 2024 Â /s/ Neil F. McFarlane Â Â Name: Neil F. McFarlane Â Â Title: President andÂ Chief Executive Officer (Principal Executive Officer) Â The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350, is not being "filed" by the Company as part of the Report or as a separate disclosure document and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing. Â Â EX-32.2 5 ex_716266.htm EXHIBIT 32.2 ex_716266.htm Exhibit 32.2 Â CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report onÂ Form 10-QÂ of Zevra Therapeutics, Inc., (the â€œCompanyâ€) for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, R. LaDuane Clifton, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: Â Â 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â November 13, 2024 Â /s/ R. LaDuane Clifton Â Â Name: R. LaDuane Clifton, MBA, CPA Â Â Title: Chief Financial OfficerÂ and Treasurer (Principal Financial Officer) Â Â Â Â The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350, is not being "filed" by the Company as part of the Report or as a separate disclosure document and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing. Â Â EX-101.SCH 6 zvra-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Unaudited Condensed Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Unaudited Condensed Consolidated Statements of Operations link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Unaudited Condensed Consolidated Statements of Operations (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note A - Description of Business, Basis of Presentation and Significant Transactions link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note B - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note C - Inventories link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note D - Debt Obligations link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note E - Revenue, Net link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note F - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note G - Stock and Warrants link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note H - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note I - Fair Value of Financial Instruments link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note J - Net Loss Per Share link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note K - Leases link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note L - Merger link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note M - Goodwill & Intangible Assets link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note N - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note C - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note D - Debt Obligations (Tables) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note G - Stock and Warrants (Tables) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note H - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note I - Fair Value of Financial Instruments (Tables) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note J - Net Loss Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note K - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note L - Merger (Tables) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note A - Description of Business, Basis of Presentation and Significant Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note B - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note C - Inventories - Summary of Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note D - Debt Obligations (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note D - Debt Obligations - Aggregate Principal Amount (Details) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note D - Debt Obligations - Future Minimum Principal Payments (Details) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note E - Revenue, Net (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note F - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note G - Stock and Warrants (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note G - Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note G - Stock and Warrants - Common Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note H - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note H - Stock-based Compensation - Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note I - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note I - Fair Value of Financial Instruments - Fair Value Assumptions for Warrant Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note I - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note J - Net Loss Per Share - Anti-dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note J - Net Loss Per Share - Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note K - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note K - Leases - Lease Cost (Details) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note K - Leases - Supplement Cash Flow Information Related to Leases (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note K - Leases - Supplement Balance Sheet Information Related to Lease (Details) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note K - Leases - Maturities of Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note L - Merger (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note L - Merger - Estimates and Assumptions Related to Fair Value of Assets and Liabilities Acquired (Details) link:calculationLink link:definitionLink link:presentationLink 995502 - Disclosure - Note L - Merger - Pro Forma Combined Results of Operations (Details) link:calculationLink link:definitionLink link:presentationLink 995503 - Disclosure - Note L - Merger - Reconciliation of Contingent Consideration Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995504 - Disclosure - Note M - Goodwill & Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 zvra-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 zvra-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 zvra-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information ?IPR&D - celiprolol Note To Financial Statement Details Textual Significant Accounting Policies Maturities of investments Note C - Inventories Note D - Debt Obligations Note G - Stock and Warrants Note H - Stock-based Compensation Note I - Fair Value of Financial Instruments Note J - Net Loss Per Share Note K - Leases Prepaid expenses Note L - Merger Other current assets Note C - Inventories - Summary of Inventory (Details) zvra_EmployeeStockPurchasePlanMaximumNumberOfIssuableShares Employee Stock Purchase Plan, Maximum Number of Issuable Shares (in shares) Maximum number of shares that may be issued under Employee Stock Purchase Plan. Note D - Debt Obligations - Aggregate Principal Amount (Details) Note D - Debt Obligations - Future Minimum Principal Payments (Details) us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Cash Note G - Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details) Inventory Note G - Stock and Warrants - Common Stock Activity (Details) us-gaap_LiabilitiesCurrent Total current liabilities Schedule of Maturities of Long-Term Debt [Table Text Block] Note H - Stock-based Compensation - Stock-based Compensation Expense (Details) Note I - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Note I - Fair Value of Financial Instruments - Fair Value Assumptions for Warrant Liabilities (Details) Note I - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) Other current liabilities us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Note J - Net Loss Per Share - Anti-dilutive Securities (Details) Note J - Net Loss Per Share - Earnings Per Share (Details) us-gaap_BusinessCombinationConsiderationTransferred1 Business Combination, Consideration Transferred Note K - Leases - Lease Cost (Details) Note K - Leases - Supplement Cash Flow Information Related to Leases (Details) Note K - Leases - Supplement Balance Sheet Information Related to Lease (Details) Note K - Leases - Maturities of Lease Liabilities (Details) us-gaap_BusinessCombinationConsiderationTransferredOther1 Business Combination, Consideration Transferred, Other Note L - Merger - Estimates and Assumptions Related to Fair Value of Assets and Liabilities Acquired (Details) Note L - Merger - Pro Forma Combined Results of Operations (Details) Note L - Merger - Reconciliation of Contingent Consideration Liabilities (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] us-gaap_BusinessAcquisitionSharePrice Business Acquisition, Share Price (in dollars per share) Arimoclomol Purchase Agreement [Member] Represents Arimoclomol Purchase Agreement. US Treasury Securities [Member] Foreign currency translation adjustment zvra_AssetAcquisitionConsiderationTransferredEstimatedReserveLiability Asset Acquisition, Consideration Transferred, Estimated Reserve Liability Represents estimated reserve liability for asset acquisition consideration transferred. zvra_ContractWithCustomerClawbackLiability Contract with Customer, Clawback Liability Represents clawback liability for contract with customer Other comprehensive (loss) income: us-gaap_PaymentsToAcquireOtherInvestments Purchases of investments Pro forma net loss Business Acquisition, Pro Forma Information [Table Text Block] Pro forma revenue us-gaap_PaymentsToAcquireNotesReceivable Payments to Acquire Notes Receivable Line of credit payable us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Purchases of secured corporate notes zvra_SharesAndWarrantsIssuedPricePerShare Shares and Warrants Issued, Price Per Share (in dollars per share) The price per share of shares and warrants issued. us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Accounts payable and accrued expenses JMP and RBCCM [Member] Represents JMP Securities LLC ("JMP") and RBC Capital Markets, LLC ("RBCCM"). Goodwill and Intangible Assets Disclosure [Text Block] zvra_EquityDistributionAgreementMaximumAggregateOfferingPrice Equity Distribution Agreement, Maximum Aggregate Offering Price The maximum aggregate offering price under the equity distribution agreement. zvra_EquityDistributionAgreementCommissionFeePercentageOfGrossSales Equity Distribution Agreement, Commission Fee, Percentage of Gross Sales The percentage of gross sales for commission fee under the equity distribution agreement. Proceeds from insurance financing arrangements Represents proceeds from insurance financing arrangements. Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] zvra_PaymentsOfPrincipalOnInsuranceFinancingArrangements Payments of principal on insurance financing arrangements Represents payments of principal on insurance financing arrangements. us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Liabilities and stockholders' equity us-gaap_LossContingencyAccrualAtCarryingValue Loss Contingency Accrual Weighted average number of shares of common stock outstanding: Operating lease liabilities us-gaap_Assets Total assets Supplemental cash flow information: Patents [Member] Plan Name [Axis] Plan Name [Domain] us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net loss us-gaap_SubleaseIncome Less: sublease income Mergers, Acquisitions and Dispositions Disclosures [Text Block] Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] ATM Agreement Sales [Member] Represents for At-the-Market Agreement Sales. Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Business Description and Basis of Presentation [Text Block] Award Type [Domain] Net Income (loss) Net loss Net Income (Loss) Attributable to Parent Net loss Award Type [Axis] us-gaap_FiniteLivedIntangibleAssetsNet Finite-Lived Intangible Assets, Net Intangible assets, net Performance Shares [Member] Share-Based Payment Arrangement [Member] Warrant [Member] Inventory [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Inventory [Domain] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Underwriting Agreement [Member] Represents the information pertaining to the underwriting agreement. us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Indefinite-Lived Intangible Assets (Excluding Goodwill) zvra_ProceedsFromIssuanceOfCommonStockNet Proceeds from Issuance of Common Stock, Net The cash inflow from issuance of common stock, net of cash paid for issuance cost. Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment less: accumulated depreciation and amortization Property and equipment, net Goodwill acquired Goodwill Derivative Instrument [Axis] Derivative Contract [Domain] Cash flows from investing activities: zvra_FinancingReceivableMaximumLimit Financing Receivable, Maximum Limit The maximum limit of the financing receivable. Acer Therapeutics Inc [Member] Represents Acer Therapeutics Inc. Bridge Loan [Member] Earnings Per Share [Text Block] zvra_ClassOfWarrantsOrRightExercisedDuringPeriod Class of Warrants or Right, Exercised During Period (in shares) The number of warrants or rights exercised during period. Arimoclomol EAP [Member] Related to Arimoclomol EAP. us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Accounts payable and accrued expenses us-gaap_IncomeTaxExpenseBenefit Income tax expense Consolidation, Variable Interest Entity, Policy [Policy Text Block] SWK Loans [Member] Represents the SWK Loans. zvra_DebtInstrumentInterestRateStatedPercentageIfUnpaidWithinSixMonths Debt Instrument, Interest Rate, Stated Percentage, If Unpaid Within Six Months Contractual interest rate for funds borrowed, under the debt agreement, if unpaid within six months. Nantahala Note [Member] Represents the Nantahala Note. zvra_DebtInstrumentInterestSharesConsecutiveTradingDaysForCalculationOfVWAP Debt Instrument, Interest, Shares, Consecutive Trading Days For Calculation of VWAP (Day) The consecutive trading days for calculation of VWAP for interest to be paid in shares on debt instrument. zvra_DebtInstrumentInterestRateIncreaseInStatedPercentageIfUnpaidWithinSixMonths Debt Instrument, Interest Rate, Increase in Stated Percentage, If Unpaid Within Six Months Increase in the contractual interest rate for funds borrowed, under the debt agreement, if unpaid within six months. zvra_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableConversionRatio Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Conversion Ratio Conversion ratio of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. XOMA License Agreement [Member] Information pertaining to the type of arrangement. zvra_VwapConsecutiveTradingDays VWAP, Consecutive Trading Days (Year) The consecutive trading

days for VWAP. Warrants [Policy Text Block] Represents the policy for warrants. Aquestive Therapeutics [Member] Represents Aquestive Therapeutics (formerly known as MonoSol Rx, LLC). AZSTARYS License Agreement [Member] Information pertaining to the litigation. zvra_AssetAcquisitionSharePrice Asset Acquisition, Share Price (in dollars per share) The share price of equity interest issued in asset acquisition. Wells Fargo Bank, N.A. [Member] Represents the "Wells Fargo Bank, N.A." License Agreement and Termination Agreement [Member] Represents License Agreement and Termination Agreement. Marathon Convertible Notes [Member] Represents the Marathon Convertible Notes. zvra_MaximumRoyaltyObligation Maximum Royalty Obligation Amount of maximum royalty obligation. Worldwide, Excluding Europe [Member] Represents worldwide, excluding Europe. SWK Loans and Marathon Notes [Member] Represents the SWK Loans and Marathon Notes. Cash and cash equivalents Relief [Member] Represents Relief. us-gaap_InterestExpenseNonoperating Interest expense zvra_MaximumRoyaltyPercentage Maximum Royalty Percentage Percentage of maximum royalty. zvra_AddiitonalPaymentOnFirstAnniversary Addiitonal Payment on First Anniversary Amount of additional payment on first anniversary. us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Other liabilities zvra_UpfrontPayment Upfront Payment Amount of upfront payment. ZVRA_ Timothy J. Sangiovanni [Member] Information pertaining to insider trading. Stock based compensation expense Share-Based Payment Arrangement, Expense ZVRA_ Sven Guenther, Ph.D [Member] Information pertaining to insider trading. zvra_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfInvestments Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Investments Percentage of investments outstanding for maximum borrowing capacity of the debt instrument. ZVRA_R. LaDuane Clifton [Member] Information pertaining to insider trading. ZVRA_ Neil F. McFarlane [Member] Information pertaining to insider trading. ZVRA_ Joshua Schafer [Member] Information pertaining to insider trading. ZVRA_Christal M.M. Mickle [Member] Information pertaining to insider trading. Amendment Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_DebtInstrumentPeriodicPaymentInterest Debt Instrument, Periodic Payment, Interest Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding (in shares) Balance (in shares) Balance (in shares) Commave Therapeutics SA [Member] Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution. Preferred stock, shares outstanding (in shares) Possible Future Issuances Under Employee Stock Purchase Plans [Member] Represents possible future issuances under employee stock purchase plans. Warrant liability Derivative and Warrant Liability, Noncurrent Noncurrent Carrying amount of derivative and warrant liability. Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Variable lease cost us-gaap_LeaseCost Total lease costs us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other assets Operating leases Document Fiscal Period Focus Operating lease cost Document Fiscal Year Focus Short-term lease cost Lease, Cost [Table Text Block] us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Finance leases Document Period End Date us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Operating leases Operating leases (in years) (Year) Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Variable Rate [Domain] Change in fair value measurement Amount of cumulative effect adjustment for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Prime Rate [Member] zvra_FairValueAdjustmentOfPutOptionNetOfTax Fair Value Adjustment of Put Option, Net of Tax After tax amount of expense (income) related to adjustment to fair value of put option. Schedule of Long-Term Debt Instruments [Table Text Block] Variable Rate [Axis] Stock-based compensation expense us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Accounts and other receivables Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Entity [Domain] Legal Entity [Axis] Entity Address, Address Line One Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Amortization of intangible assets Amortization of Intangible Assets ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] us-gaap_TreasuryStockValueAcquiredCostMethod Shares repurchased as part of the Share Repurchase Program Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code us-gaap_TreasuryStockCommonValue Treasury Stock, Common, Value Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss Material Terms of Trading Arrangement [Text Block] us-gaap_TreasuryStockValue Treasury stock, at cost ecd_TrdArrIndTitle Trading Arrangement, Individual Title ecd_TrdArrIndName Trading Arrangement, Individual Name ecd_TrdArrTerminationDate Trading Arrangement Termination Date ecd_TrdArrSecuritiesAggAvailAmt Trading Arrangement, Securities Aggregate Available Amount Entity Common Stock, Shares Outstanding ecd_TrdArrAdoptionDate Trading Arrangement Adoption Date us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Other long-term assets us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol us-gaap_StockIssuedDuringPeriodSharesAcquisitions Stock Issued During Period, Shares, Acquisitions (in shares) Common stock issued as a result of the Employee Stock Purchase Plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) Local Phone Number Issuance of common stock in connection with the Merger (Note L) Common stock issued as a result of stock options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) us-gaap_TableTextBlock Notes Tables Issuance of common stock as part of the Employee Stock Purchase Plan Issuance of common stock for options exercised Litigation Related to Merger [Member] Represent litigation related to merger. Common stock issued in connection with vesting of performance-based awards (in shares) Selling, general and administrative zvra_DebtInstrumentMinimumCashBalance Debt Instrument, Minimum Cash Balance Minimum cash balance required for debt instrument to be active. Secured Overnight Financing Rate (SOFR) [Member] Risk-free interest rate Line of Credit Facility, Lender [Domain] zvra_CommonStockRegisteredMaximumOfferingPrice Common Stock Registered, Maximum Offering Price Represents maximum offering price under common stock registered. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] JMP [Member] Represents JMP. Common stock issued in connection with the Public Offering (Note B) (in shares) Stock Issued During Period, Shares, New Issues (in shares) Issuance of common stock in exchange for consulting services Common stock issued as compensation to third parties (in shares) Common stock issued as compensation to third parties (in shares) Notes Payable Excluding Secured Promissory Note [Member] Represents Notes Payable Excluding Secured Promissory Note Lender Name [Axis] Thereafter Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders' equity Issuance of common stock in public offering Stock Issued During Period, Value, New Issues Underwriting Agreement and Over-allotment Option [Member] Represents Underwriting Agreement and Over-allotment Option. zvra_StockIssuableDuringThePeriod Stock Issuable During the Period (in shares) Number of stock issuable during the period. Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income (loss) Research and development Debt Disclosure [Text Block] Measurement Input, Price Volatility [Member] Change in assets and liabilities: Measurement Input, Risk Free Interest Rate [Member] Schedule of Authorized Shares of Common Stock Reserved for Future Issuance [Table Text Block] Tabular disclosure of authorized shares of common stock reserved for future issuance. us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Inventory Disclosure [Text Block] Measurement Input, Expected Dividend Rate [Member] Operating lease liabilities, less current portion Measurement Input, Expected Term [Member] Possible Future Issuances Under Equity Incentive Plans [Member] Represents possible future issuances under equity incentive plans. us-gaap_OperatingLeaseLiability Lease liabilities, operating leases Total operating lease liabilities Non-cash interest expense Current portion of operating lease liabilities us-gaap_FinanceLeaseLiabilityCurrent Other current liabilities us-gaap_FinanceLeaseLiabilityNoncurrent Other long-term liabilities Subsequent Events [Text Block] Total operating lease right-of-use assets Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total lease payments, operating leases zvra_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesReservedForIssuanceIncrementalPercentageOfCapitalStockOutstanding Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Reserved for Issuance, Incremental Percentage of Capital Stock Outstanding Represents the share based compensation arrangement by share based payment award number of shares reserved for issuance incremental percentage of capital stock outstanding. Financing cash flows from finance leases Repayment of principal on finance lease liabilities us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: future interest expense, operating leases us-gaap_FinanceLeaseLiability Lease liabilities, finance leases 2014 Equity Incentive Plan [Member] Represents the two thousand fourteen equity incentive plan. zvra_IncreaseInCommonStockReservedForIssuance Increase in Common Stock Reserved for Issuance (in shares) Amount of increase in common stock reserved for issuance. Measurement Input Type [Axis] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2027, operating leases us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Measurement Input Type [Domain] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2028, operating leases us-gaap_UnrealizedGainLossOnInvestments Unrealized Gain (Loss) on Investments us-gaap_FinanceLeaseRightOfUseAsset Property and equipment, net Acer Warrants [Member] Represents the Acer warrants. us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Finite-Lived Intangible Asset, Expected Amortization, Year Two zvra_CommonStockRegisteredShares Common Stock Registered, Shares (in shares) Shares registered as apart of an S-3 filing. us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Finite-Lived Intangible Asset, Expected Amortization, Year Three zvra_GainLossOnContingentConsiderationChangeInFairValue Gain (Loss) on Contingent Consideration, Change in Fair Value Represents the gain/(loss) on contingent consideration from the changes in fair value over the period. us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Finite-Lived Intangible Asset, Expected Amortization, Year Four us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2025, operating leases us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2026, operating leases us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Finite-Lived Intangible Asset, Expected Amortization, Year One us-gaap_FairValueAdjustmentOfWarrants Fair value adjustment related to warrant and CVR liability The Investor Warrant [Member] Represents the warrant held by the investor. Foreign Currency Transactions and Translations Policy [Policy Text Block] Relief Therapeutics [Member] Relates to Relief Therapeutics. Warrants to Purchase Common Stock [Member] Represents warrants to purchase common stock. Other long-term assets us-gaap_ShareBasedCompensation Stock-based compensation expense us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear 2024 (excluding the three months ended March 31, 2024), operating leases Deferred collaboration funding Amount of liabilities incurred for deferred collaboration funding assumed on the acquisition date. Accounts payable and accrued expenses Amount of liability incurred for accounts payable and accrued expenses assumed at acquisition date. us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) zvra_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities Operating lease liabilities Amount of liabilities incurred for operating leases assumed at the acquisition date. Approved product - OLPRUVA Amount of the approved product, OLPRUVA, acquired at the acquisition date. Operating expenses: zvra_RoyaltyRevenuePercent Royalty Revenue, Percent Represents the royalty revenue expressed as a percentage. Total assets zvra_RevenueRecognitionMilestoneMethodAdditionalRevenueToBeRecognized Revenue Recognition, Milestone Method, Additional Revenue to be Recognized The amount of additional consideration to be recognized for the milestone or milestones. Consulting Services [Member] Information pertaining to consulting services. Research and Development Expense, Policy [Policy Text Block] Securities at fair value, long-term Depreciation and amortization expense CVR Liability [Member] Represents the CVR liability. us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) Inventories Total inventory us-gaap_AssetsCurrent Total current assets zvra_FinanceLeaseCostTotal Total finance lease cost Represents total cost of fiance lease. us-gaap_InvestmentsFairValueDisclosure Investments, Fair Value Disclosure Equity [Text Block] zvra_LesseeLeaseRemainingTermOfContract Lessee, Lease, Remaining Term of Contract (Year) Remaining term of lessee's lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Lease Disclosure [Text Block] The entire disclosure for operating, finance, sale leaseback leases. Weighted average fair value (in dollars per share) Represents the weighted average fair value under fair value assumptions for warrant liabilities. us-gaap_TreasuryStockCommonShares Treasury Stock, Common, Shares (in shares) Change in fair value recognized in earnings Share Repurchase Program [Member] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Common stock, $0.0001 par value, 250,000,000 shares authorized, 54,803,056 shares issued and 53,227,364 shares outstanding as of September 30, 2024; 43,110,360 shares issued and 41,534,668 shares outstanding as of December 31, 2023 Measurement Frequency [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized (in shares) Common stock, shares issued (in shares) Common Stock, Shares, Issued (in shares) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Schedule of Leases Cash Flow Information [Table Text Block] Tabular disclosure of leases related to cash flow information. Revenue from Contract with Customer [Policy Text Block] Revision of Prior Period [Axis] zvra_FinanceLeaseRightofuseAssetGross Property and equipment, at cost Gross amount of lessee's right to use underlying asset under finance lease. Revision of Prior Period [Domain] Previously Reported [Member] Schedule of Leases Balance Sheet Information [Table Text Block] Tabular disclosure of leases related to balance sheet. Common shares reserved for future issuance (in shares) Statistical Measurement [Domain] Term Loans Under Credit Agreement [Member Represents term loans under credit agreement. Operating cash flows from operating leases Accumulated Depreciation and Amortization [Member] Primary financial statement caption encompassing accumulated depreciation and amortization. Maximum [Member] zvra_DebtInstrumentAvailableAmountUntilDecember312024 Debt Instrument, Available Amount Until December 31, 2024 Amount of debt available to be drawn until December 31, 2024. Property and Equipment, At Cost [Member] Primary financial statement caption encompassing property and plant at cost. Minimum [Member] zvra_DebtInstrumentNetProductSalesPerformanceBenchmark Debt Instrument, Net Product Sales Performance Benchmark Amount of performance benchmark of net product sales under debt instrument. zvra_DebtInstrumentBasisSpreadOnVariableRateWhenPerformanceBenchmarkMeet Debt Instrument, Basis Spread on Variable Rate When Performance Benchmark Meet Percentage points added to the reference rate to compute the variable rate on the debt instrument when performance benchmark meet. Product and Service [Axis] us-gaap_PaymentsForLegalSettlements Payments for Legal Settlements Operating cash flows from short-term leases zvra_DebtInstrumentAvailableAmountUntil18MonthsFollowingClosingDateMaximumEachDrawing Debt Instrument, Available Amount Until 18 Months Following Closing Date, Maximum Each Drawing Maximum each drawing for amount available under debt instrument to draw after 18 months of debt closing date. Product and Service [Domain] Fair value adjustment related to warrant and CVR liability Amount of expense (income) related to adjustment to fair value of warrant liability and CVR Liability Operating cash flows from variable lease costs Statistical Measurement [Axis] zvra_DebtInstrumentAvailableAmountUntil18MonthsFollowingClosingDate Debt Instrument, Available Amount Until 18 Months Following Closing Date Amount of debt available until 18 months following closing date under debt instrument. Litigation Case [Axis] Litigation Case [Domain] Operating and Finance Lease, Liability, Maturity [Table Text Block] Tabular disclosure of undiscounted cash flows of operating and finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating and finance lease liability recognized in statement of financial position. Debt, Policy [Policy Text Block] Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of September 30, 2024, or December 31, 2023 zvra_DebtInstrumentBasisSpreadOnVariableRateWhenPerformanceBenchmarkMeetInNextYear Debt Instrument, Basis Spread on Variable Rate When Performance Benchmark Meet in Next Year Percentage points added to the reference rate to compute the variable rate on the debt instrument when performance benchmark meet in next year. Preferred stock, shares issued (in shares) zvra_DebtInstrumentNetProductSalesPerformanceBenchmarkInNextYear Debt Instrument, Net Product Sales Performance Benchmark in Next Year Amount of performance benchmark of net product sales in next year under debt instrument. zvra_DebtInstrumentMaximumInterestPaymentPercentage Debt Instrument, Maximum Interest Payment, Percentage Maximum amount of interest payment allowed under debt instrument as a percentage. Cash paid for interest zvra_DebtInstrumentFloorRate Debt Instrument, Floor Rate Floor rate of debt instrument. Geographical [Axis] Geographical [Domain] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized (in shares) Europe [Member] zvra_LesseeLeaseOptionToTerminateTerm Lessee, Lease, Option to Terminate, Term (Year) Represents the terms of option to terminate lessee's lease. OLPRUVA [Member] Represents OLPRUVA. us-gaap_InventoryNet Inventory, Net zvra_LesseeLeaseOptionToExtendMaximumTerm Lessee, Lease, Option to Extend, Maximum

Term (Year) Represents maximum terms of option to extend lessee's lease. Preferred stock, par value (in dollars per share) Work in progress Revenue, net Fair Value, Inputs, Level 3 [Member] us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Loss (gain) on foreign currency exchange Finished goods Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Raw materials Cash flows from operating activities: Accounts and other receivables Statement [Line Items] us-gaap_AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current Additional paid-in capital AOCI Attributable to Parent [Member] Stockholdersâ€™ equity: Securities at fair value, current us-gaap_NonoperatingIncomeExpense Total other (expense) income Other (expense) income: Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Inventory, Policy [Policy Text Block] Assets License [Member] Effect of exchange rate changes on cash and cash equivalents us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase (decrease) in cash and cash equivalents Over-Allotment Option [Member] us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Commitments and contingencies (Note D) Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Loss from operations us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Counterparty Name [Axis] Counterparty Name [Domain] Inventory obsolescence charge Inventory Write-down us-gaap_ContractWithCustomerLiability Contract with Customer, Liability Total liabilities us-gaap_InterestPayableCurrentAndNoncurrent Interest Payable Intangible asset amortization Investment, Policy [Policy Text Block] us-gaap_CostsAndExpenses Total operating expenses us-gaap_AccruedRoyaltiesCurrentAndNoncurrent Accrued Royalties us-gaap_PaymentsForRepurchaseOfCommonStock Payments to repurchase shares as part of the Share Repurchase Program Proceeds from Employee Stock Purchase Plan us-gaap_ProceedsFromWarrantExercises Proceeds from Warrant Exercises Retained Earnings [Member] Undesignated Preferred Stock [Member] Preferred stock that has been classified as undesignated. Proceeds from issuance of stock Treasury Stock, Common [Member] Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Note payable us-gaap_NotesPayable Notes Payable us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding (in shares) us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income taxes us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) us-gaap_LineOfCredit Long-Term Line of Credit us-gaap_PaymentsOfDebtIssuanceCosts Payment of third-party debt issuance costs us-gaap_DeferredFinanceCostsNet Debt Issuance Costs, Net Less: debt issuance costs us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Less: unamortized debt discount, debt issuance costs and paid in kind interest Revenue from Contract with Customer [Text Block] us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet Unamortized original issue (discount) premium Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Document Quarterly Report Entity Incorporation, State or Country Code Notes payable us-gaap_DebtInstrumentCarryingAmount Total minimum payments General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report Entity Interactive Data Current Security Exchange Name Title of 12(b) Security us-gaap_ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-Term Debt Receivable Type [Axis] Receivable [Domain] All Individuals [Member] Research and Development Expense [Member] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Individual [Axis] us-gaap_ContractualObligation Contractual Obligation us-gaap_RepaymentsOfNotesPayable Repayments of Notes Payable Antidilutive securities (in shares) Asset Class [Axis] Asset Class [Domain] Statement [Table] Statement of Financial Position [Abstract] Basic and diluted (in shares) Weighted average number of shares of common stock outstanding, basic and diluted (in shares) Cost of product revenue (excluding $1,545 and $4,619 in intangible asset amortization for the three and nine months ended September 30, 2024, respectively shown separately below) Business Acquisition [Axis] Basic and diluted net loss per share of common stock (in dollars per share) Net loss (in dollars per share) Business Acquisition, Acquiree [Domain] Basic and diluted net loss per share of common stock: Statement of Cash Flows [Abstract] 2024 (excluding the nine months ending September 30, 2024) us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Other comprehensive income Other comprehensive (loss) income 2027 The 2023 Plan [Member] Represents the 2023 Employment Inducement Award Plan. 2028 us-gaap_BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability Balance Balance Proceeds from issuance of debt, net of lender fees Proceeds from Issuance of Debt Pre-launch Inventory that Qualified for Capitalization [Member] Represents pre-launch inventory that qualified for capitalization. us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2025 us-gaap_RepaymentsOfDebt Repayment of debt us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2026 Interest on lease liabilities us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) Loss on sublease and disposal of property and equipment Represents the loss on sublease and disposal of property and equipment recognized during the period. us-gaap_FinanceLeaseLiabilityPaymentsDue Total lease payments, finance leases Schedule of Inventory, Noncurrent [Table Text Block] Amortization of right-of-use assets us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Less: future interest expense, finance leases us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths 2025, finance leases us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo 2026, finance leases us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree 2027, finance leases us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour 2028, finance leases Asset Acquisition [Axis] srt_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount us-gaap_AssetAcquisitionConsiderationTransferred Asset Acquisition, Consideration Transferred Interest and other income (expense), net Represents the amount of interest and other income (expense), net, recognized during the period. Finance leases Share Repurchase Program [Domain] Share Repurchase Program [Axis] us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear 2024 (excluding the three months ended March 31, 2024), finance leases Cash flows from financing activities: us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Warrants [Member] Information pertaining to warrants. Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Other long-term liabilities Asset Acquisition [Domain] Consulting fees paid in common stock The amount of consulting fees are paid in stock. Corporate Bond Securities [Member] Fair value adjustment related to investments Fair value adjustment related to investments Amount of expense (income) related to adjustment to fair value of investments. zvra_IncreaseDecreaseInOperatingLeaseRightofuseAsset Operating lease right-of-use assets The amount of increase (decrease) in operating lease right-of-use assets. zvra_FinanceLeaseLiabilityToBePaidAfterYearFour Thereafter, finance leases Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Fair Value of Net Assets Acquired zvra_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Thereafter, operating leases Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Current portion of discount and rebate liabilities Current portion of discount and rebate liabilities. Discount and rebate liabilities, less current portion Noncurrent portion of discount and rebate liabilities. us-gaap_StockholdersEquity Total stockholders' equity Balance Balance us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Class of Stock [Axis] Class of Stock [Domain] Long-term debt Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Discount and rebate liability Increase (decrease) in discount and rebate liabilities. Property, plant, and equipment Other noncurrent assets Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] EX-101.PRE 10 zvra-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 13, 2024 Document Information [Line Items] Â Â Entity Central Index Key 0001434647 Â Entity Registrant Name ZEVRA THERAPEUTICS, INC. Â Amendment Flag false Â Current Fiscal Year End Date --12-31 Â Document Fiscal Period Focus Q3 Â Document Fiscal Year Focus 2024 Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-36913 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 20-5894398 Â Entity Address, Address Line One 1180Â Celebration Boulevard, Suite 103 Â Entity Address, City or Town Celebration Â Entity Address, State or Province FL Â Entity Address, Postal Zip Code 34747 Â City Area Code 321 Â Local Phone Number 939-3416 Â Title of 12(b) Security Common Stock, $0.0001 par value per share Â Trading Symbol ZVRA Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 53,375,932 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting

Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Assets Â Â Cash and cash equivalents $ 54,039 $ 43,049 Securities at fair value, current 35,337 24,688 Accounts and other receivables 7,790 17,377 Prepaid expenses and other current assets 2,276 1,824 Total current assets 99,442 86,938 Inventories 8,756 9,841 Securities at fair value, long-term 6,105 0 Property and equipment, net 607 736 Operating lease right-of-use assets 820 790 Goodwill acquired 4,701 4,701 Intangible assets, net 70,608 69,227 Other long-term assets 512 94 Total assets 191,551 172,327 Liabilities and stockholders' equity Â Â Accounts payable and accrued expenses 24,464 28,403 Line of credit payable 0 37,700 Current portion of operating lease liabilities 540 543 Current portion of discount and rebate liabilities 8,547 4,550 Other current liabilities 930 2,524 Total current liabilities 34,481 73,720 Long-term debt 58,904 5,066 Warrant liability 13,902 16,100 Operating lease liabilities, less current portion 483 456 Discount and rebate liabilities, less current portion 8,490 7,663 Other long-term liabilities 5,521 7,458 Total liabilities 121,781 110,463 Commitments and contingencies (Note D) Stockholdersâ€™ equity: Â Â Common stock, $0.0001 par value, 250,000,000 shares authorized, 54,803,056 shares issued and 53,227,364 shares outstanding as of September 30, 2024; 43,110,360 shares issued and 41,534,668 shares outstanding as of December 31, 2023 5 4 Additional paid-in capital 550,413 472,664 Treasury stock, at cost (10,983) (10,983) Accumulated deficit (469,550) (399,778) Accumulated other comprehensive income (loss) (115) (43) Total stockholders' equity 69,770 61,864 Total liabilities and stockholders' equity 191,551 172,327 Undesignated Preferred Stock [Member] Â Â Stockholdersâ€™ equity: Â Â Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of September 30, 2024, or December 31, 2023 $ 0 $ 0 X - DefinitionAmount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsAndOtherReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value

recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_LinesOfCreditCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNoncurrent Carrying amount of derivative and warrant liability. + ReferencesNo definition available. + Details Name: zvra_DerivativeAndWarrantLiabilityNoncurrent Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X -

DefinitionCurrent portion of discount and rebate liabilities. + ReferencesNo definition available. + Details Name: zvra_DiscountAndRebateLiabilitiesCurrent Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNoncurrent portion of discount and rebate liabilities. + ReferencesNo definition available. + Details Name: zvra_DiscountAndRebateLiabilitiesNoncurrent Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=zvra_UndesignatedPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Preferred stock, shares authorized (in shares) 10,000,000 10,000,000 Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Common stock, shares authorized (in shares) 250,000,000 250,000,000 Common stock, shares issued (in shares) 54,803,056 43,110,360 Common stock, shares outstanding (in shares) 53,227,364 41,534,668 Undesignated Preferred Stock [Member] Â Â Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred stock, shares authorized (in shares) 10,000,000 10,000,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=zvra_UndesignatedPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue, net $ 3,695 $ 2,895 $ 11,569 $ 14,541 Cost of product revenue (excluding $1,545 and $4,619 in intangible asset amortization for the three and nine months ended September 30, 2024, respectively shown separately below) 2,303 144 6,051 946 Intangible asset amortization 1,545 0 4,619 0 Operating expenses: Â Â Â Â Research and development 10,945 12,297 33,743 28,385 Selling, general and administrative 16,208 5,818 38,743 19,657 Total operating expenses 27,153 18,115 72,486 48,042 Loss from operations (27,306) (15,364) (71,587) (34,447) Other (expense) income: Â Â Â Â Interest expense (2,312) (366) (5,157) (745) Fair value adjustment related to warrant and CVR liability (4,746) 3,678 4,660 4,253 Fair value adjustment related to investments 90 124 64 451 Interest and other income (expense), net 1,049 1,738 2,248 4,331 Total other (expense) income (5,919) 5,174 1,815 8,290 Loss before income taxes (33,225) (10,190) (69,772) (26,157) Income tax expense 0 (177) 0 0 Net loss $ (33,225) $ (10,367) $ (69,772) $ (26,157) Basic and diluted net loss per share of common stock: Â Â Â Â Net loss (in dollars per share) $ (0.69) $ (0.3) $ (1.59) $ (0.76) Weighted average number of shares of common stock outstanding: Â Â Â Â Basic and diluted (in shares) 47,808,817 34,724,614 43,843,851 34,364,075 X - DefinitionCost of product sold and service rendered, excluding depreciation, depletion, and amortization. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSoldAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherNonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic

10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of investments. + ReferencesNo definition available. + Details Name: zvra_FairValueAdjustmentOfInvestments Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the amount of interest and other income (expense), net, recognized during the period. + ReferencesNo definition available. + Details Name: zvra_InterestAndOtherIncomeExpenseNet Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Statements of Operations (Parentheticals) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Amortization of intangible assets $ 1,545 $ 0 $ 4,619 $ 0 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net loss $ (33,225) $ (10,367) $ (69,772) $ (26,157) Other comprehensive (loss) income: Â Â Â Â Foreign currency translation adjustment (536) 5 (72) (333) Other comprehensive (loss) income (536) 5 (72) (333) Comprehensive loss $ (33,761) $ (10,362) $ (69,844) $ (26,490) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12 + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands Previously Reported [Member] Common Stock [Member] Previously Reported [Member] Additional Paid-in Capital [Member] Previously Reported [Member] Treasury Stock, Common [Member] Previously Reported [Member] Retained Earnings [Member] Previously Reported [Member] AOCI Attributable to Parent [Member] Previously Reported [Member] Common Stock [Member] Additional Paid-in Capital [Member] Treasury Stock, Common [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Total Balance at Dec. 31, 2022 $ 3 $ 436,269 $ (7,536) $ (353,729) $ 113 $ 75,120 Â Â Â Â Â Â Net Income (loss) Â Â Â Â Â Â $ 0 $ 0 $ 0 $ (13,217) $ 0 $ (13,217) Stock-based compensation expense Â Â Â Â Â Â 0 945 0 0 0 945 Issuance of common stock in exchange for consulting services Â Â Â Â Â Â 0 42 0 0 0 42 Other comprehensive income Â Â Â Â Â Â 0 0 0 0 (176) (176) Net loss Â Â Â Â Â Â 0 0 0 (13,217) 0 (13,217) Balance at Mar. 31, 2023 Â Â Â Â Â Â 3 437,256 (10,983) (366,946) (63) 59,267 Shares repurchased as part of the Share Repurchase Program Â Â Â Â Â Â 0 0 (3,447) 0 0 (3,447) Balance at Dec. 31, 2022 3 436,269 (7,536) (353,729) 113 75,120 Â Â Â Â Â Â Net Income (loss) Â Â Â Â Â Â Â Â Â Â (26,157) Other comprehensive income Â Â Â Â Â Â Â Â Â Â (333) Net loss Â Â Â Â Â Â Â Â Â Â (26,157) Balance at Sep. 30, 2023 Â Â Â Â Â Â 3 452,608 (10,983) (379,886) (220) 61,522 Balance at Mar. 31, 2023 Â Â Â Â Â Â 3 437,256 (10,983) (366,946) (63) 59,267 Net Income (loss) Â Â Â Â Â Â 0 0 0 (2,573) 0 (2,573) Stock-based compensation expense Â Â Â Â Â Â 0 2,151 0 0 0 2,151 Issuance of common stock in exchange for consulting services Â Â Â Â Â Â 0 25 0 0 0 25 Issuance of common stock as part of the Employee Stock Purchase Plan Â Â Â Â Â Â 0 165 0 0 0 165 Other comprehensive income Â Â Â Â Â Â 0 0 0 0 (162) (162) Net loss Â Â Â Â Â Â 0 0 0 (2,573) 0 (2,573) Balance at Jun. 30, 2023 Â Â Â Â Â Â 3 439,597 (10,983) (369,519) (225) 58,873 Net Income (loss) Â Â Â Â Â Â 0 0 0 (10,367) 0 (10,367) Stock-based compensation expense Â Â Â Â Â Â 0 1,440 0 0 0 1,440 Issuance of common stock in exchange for consulting services Â Â Â Â Â Â 0 71 0 0 0 71 Other comprehensive income Â Â Â Â Â Â 0 0 0 0 5 5 Net loss Â Â Â Â Â Â 0 0 0 (10,367) 0 (10,367) Balance at Sep. 30, 2023 Â Â Â Â Â Â 3 452,608 (10,983) (379,886) (220) 61,522 Issuance of common stock in connection with the Merger (Note L) Â Â Â Â Â Â 0 11,500 0 0 0 11,500 Balance at Dec. 31, 2023 4 472,664 (10,983) (399,778) (43) 61,864 Â Â Â Â Â 61,864 Net Income (loss) Â Â Â Â Â Â 0 0 0 (16,622) 0 (16,622) Stock-based compensation expense Â Â Â Â Â Â 0 2,119 0 0 0 2,119 Issuance of common stock in exchange for consulting services Â Â Â Â Â Â 0 56 0 0 0 56 Issuance of common stock as part of the Employee Stock Purchase Plan Â Â Â Â Â Â 0 71 0 0 0 71 Issuance of common stock for options exercised Â Â Â Â Â Â 0 1,146 0 0 0 1,146 Other comprehensive income Â Â Â Â Â Â 0 0 0 0 184 184 Net loss Â Â Â Â Â Â 0 0 0 (16,622) 0 (16,622) Balance at Mar. 31, 2024 Â Â Â Â Â Â 4 476,056 (10,983) (416,400) 141 48,818 Balance at Dec. 31, 2023 $ 4 $ 472,664 $ (10,983) $ (399,778) $ (43) $ 61,864 Â Â Â Â Â 61,864 Net Income (loss) Â Â Â Â Â Â Â Â Â Â (69,772) Other comprehensive income Â Â Â Â Â Â Â Â Â Â (72) Net loss Â Â Â Â Â Â Â Â Â Â (69,772) Balance at Sep. 30, 2024 Â Â Â Â Â Â 5 550,413 (10,983) (469,550) (115) 69,770 Balance at Mar. 31, 2024 Â Â Â Â Â Â 4 476,056 (10,983) (416,400) 141 48,818 Net Income (loss) Â Â Â Â Â Â 0 0 0 (19,925) 0 (19,925) Stock-based compensation expense Â Â Â Â Â Â 0 2,632 0 0 0 2,632 Issuance of common stock in exchange for consulting services Â Â Â Â Â Â 0 193 0 0 0 193 Issuance of common stock as part of the Employee Stock Purchase Plan Â Â Â Â Â Â 0 480 0 0 0 480 Other comprehensive income Â Â Â Â Â Â 0 0 0 0 280 280 Net loss Â Â Â Â Â Â 0 0 0 (19,925) 0 (19,925) Balance at Jun. 30, 2024 Â Â Â Â Â Â 4 479,361 (10,983) (436,325) 421 32,478 Net Income (loss) Â Â Â Â Â Â 0 0 0 (33,225) 0 (33,225) Stock-based compensation expense Â Â Â Â Â Â 0 6,137 0 0 0 6,137 Issuance of common stock in exchange for consulting services Â Â Â Â Â Â 0 150 0 0 0 150 Issuance of common stock as part of the Employee Stock Purchase Plan Â Â Â Â Â Â 0 92 0 0 0 92 Issuance of common stock for options exercised Â Â Â Â Â Â 0 157 0 0 0 157 Other comprehensive income Â Â Â Â Â Â 0 0 0 0 (536) (536) Net loss Â Â Â Â Â Â 0 0 0 (33,225) 0 (33,225) Issuance of common stock in public offering Â Â Â Â Â Â 1 64,516 0 0 0 64,517 Balance at Sep. 30, 2024 Â Â Â Â Â Â $ 5 $ 550,413 $ (10,983) $ (469,550) $ (115) $ 69,770 X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (69,772) $ (26,157) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Stock-based compensation expense 10,888 4,482 Inventory obsolescence charge 5,244 0 Non-cash interest expense 1,489 0 Depreciation and amortization expense 4,741 219 Fair value adjustment related to warrant and CVR liability (4,660) (4,159) Fair value adjustment related to investments (64) (451) Loss on sublease and disposal of property and equipment 0 157 Consulting fees paid in common stock 399 138 Loss (gain) on foreign currency exchange 147 (30) Change in assets and liabilities: Â Â Accounts and other receivables 9,587 (1,628) Prepaid expenses and other assets (452) 27 Inventories (4,159) 190 Operating lease right-of-use assets 389 243 Other long-term assets 0 (93) Accounts payable and accrued expenses (10,590) 5,400 Discount and rebate liability 4,824 3,895 Operating lease liabilities (395) (326) Other liabilities (1,031) 716 Net cash used in operating activities (53,415) (17,377) Cash flows from investing activities: Â Â Purchases of property and equipment 0 (224) Purchases of investments (41,488) (45,821) Purchases of secured corporate notes 0 (25,426) Maturities of investments 24,798 43,496 Net cash used in investing activities (16,690) (27,975) Cash flows from financing activities: Â Â Proceeds from issuance of debt, net of lender fees 58,990 38,801 Payment of third-party debt issuance costs (2,091) 0 Repayment of debt (42,700) (12,800) Proceeds from insurance financing arrangements 1,082 1,256 Proceeds from Employee Stock Purchase Plan 643 219 Payments of principal on insurance financing arrangements (431) (564) Payments to repurchase shares as part of the Share Repurchase Program 0 (3,447) Proceeds from issuance of stock 65,819 0 Repayment of principal on finance lease liabilities 0 (5) Net cash provided by financing activities 81,312 23,460 Effect of exchange rate changes on cash and cash equivalents (217) (305) Net increase (decrease) in cash and cash equivalents 10,990 (22,197) Cash and cash equivalents, beginning of period 43,049 65,466 Cash and cash equivalents, end of period 54,039 43,269 Supplemental cash flow information: Â Â Cash paid for interest $ 3,668 $ 456 X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent operating liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_PaidInKindInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investments classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireOtherInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of consulting fees are paid in stock. + ReferencesNo definition available. + Details Name: zvra_ConsultingFeesPaidInStock Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of investments. + ReferencesNo definition available. + Details Name: zvra_FairValueAdjustmentOfInvestments Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability and CVR Liability + ReferencesNo definition available. + Details Name: zvra_FairValueAdjustmentOfWarrantsAndCvrLiability Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (decrease) in discount and rebate liabilities. + ReferencesNo definition available. + Details Name: zvra_IncreaseDecreaseInDiscountAndRebateLiabilities Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of increase (decrease) in operating lease right-of-use assets. + ReferencesNo definition available. + Details Name: zvra_IncreaseDecreaseInOperatingLeaseRightofuseAsset Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the loss on sublease and disposal of property and equipment recognized during the period. + ReferencesNo definition available. + Details Name: zvra_LossOnSubleaseAndDisposalOfPropertyAndEquipment Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents payments of principal on insurance financing arrangements. + ReferencesNo definition available. + Details Name: zvra_PaymentsOfPrincipalOnInsuranceFinancingArrangements Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents proceeds from insurance financing arrangements. + ReferencesNo definition available. + Details Name: zvra_ProceedsFromInsuranceFinancingArrangements Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Note A - Description of Business, Basis of Presentation and Significant Transactions 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Business Description and Basis of Presentation [Text Block] A.Description of Business, Basis of Presentation, and Significant Transactions Â Organization Â Zevra Therapeutics, Inc. (the "Company") is a commercial-stageÂ company focused on addressing unmet needs for the treatment of rare diseases. The Company has a diverse portfolio of products and product candidates, which includes clinical stage pipeline and commercial stage assets. On September 20, 2024, the U.S. Food and Drug Administration ("FDA") approved the New Drug Application (â€œNDAâ€) forÂ MIPLYFFAâ„¢ (arimoclomol),Â an orally-delivered treatmentÂ for Niemann-Pick disease type C (â€œNPCâ€), which is anÂ ultra-rare and progressive neurodegenerative disease.Â MIPLYFFA,Â the first FDA-approved treatment for NPC, is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients twoÂ years of age and older. In addition, the Company received a transferable rare pediatric disease priority review voucherÂ in conjunction with the approval of MIPLYFFA.Â MIPLYFFAÂ has also been granted orphan medicinal product designation for the treatment of NPC by the European Commission.Â OLPRUVAÂ® (sodium phenylbutyrate) for oral suspension is approved by the FDA for the treatment of urea cycle disorders ("UCDs"). The Company also has a pipeline of investigational product candidates, including celiprololÂ for the treatment of vascular Ehlers-Danlos syndrome in patients with a confirmed type III collagen mutation.Â KP1077 is the Company'sÂ clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia ("IH"), a rare neurological sleep disorder, and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (â€œSDXâ€), the Company's proprietary prodrug of d-methylphenidate ("d-MPH"). The FDA has granted KP1077 orphan drug designation for the treatment of IH. Â The Company changed its name from KemPharm, Inc. to Zevra Therapeutics, Inc. effective as of February 21, 2023. On March 1, 2023, following its name change, the Company's common stock began trading on the Nasdaq Global Select Market under the ticker symbol "ZVRA". Â Going Concern Â The accompanying unauditedÂ condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the nineÂ months ended SeptemberÂ 30, 2024, and 2023, the Company incurred a net loss of $69.8Â million and $26.2Â million,Â respectively, andÂ as of SeptemberÂ 30, 2024, has an accumulated deficit of $469.6Â million.Â The Company has sustained operating losses for the majority of its corporate history and expects to continue to incur operating losses and negative operating cash flows until revenues reach a level sufficient to support ongoing operations. Â The Companyâ€™s ability to continue operating as a going concern is contingent upon its ability to generate revenue from approved products or obtain product candidate regulatory approvals, which would generate revenue, milestones, and cash flow sufficient to support ongoing operations and the satisfaction of financial covenants. These factors raise substantial doubt as to the Companyâ€™s ability to continue as a going concern for at least one year from the date the unaudited condensed consolidated financial statements are being issued. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of

these uncertainties. Â The Company's liquidity needs will be largely determined by the success of operations through the progression of its products and product candidates in the future.Â The Company also may consider other sources to fund operations including: (1) out-licensing rights to certain of its technologies and product candidates, pursuant to which the Company would receive cash royalties and milestones; (2) raising additional capital through equity or debt financings or from other sources; (3) obtaining product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (4) reducing spending on one or more research and development programs, including by discontinuing development; and/or (5) restructuring operations to change its overhead structure. The Company is in theÂ early stages ofÂ its commercialization effortÂ for OLPRUVA and MIPLYFFA andÂ does not yet have a substantial basis to project future earnings, and itsÂ other sources of revenue are not sufficient to sustain itsÂ present activities on their own. Accordingly, the Company'sÂ ability to continue as a going concern may require itÂ to obtain additional financing to fund itsÂ operations. Â Basis of Presentation Â The Company prepared the unaudited condensed consolidated financial statements in accordance with U.S.Â GAAPÂ and the rules and regulations of the Securities and Exchange Commission ("SEC") and, in the Company's opinion, reflect all adjustments, including normal recurring items that are necessary. Â Merger Â On August 30, 2023, the Company and Aspen Z Merger Sub, Inc., a wholly-owned subsidiary of Zevra (â€œMerger Subâ€), entered into an Agreement and Plan of Merger (the â€œMerger Agreementâ€) with Acer Therapeutics Inc. (â€œAcerâ€), a pharmaceutical company focused on development and commercialization of therapies for rare and life-threatening diseases. On November 17, 2023 (the "Closing Date"), the Company completed the acquisition of Acer. Pursuant to the Merger Agreement, on the Closing Date, Merger Sub was merged with and into Acer (the "Merger"), with Acer continuing as the surviving entity and as a wholly-owned subsidiary of Zevra. In connection therewith, Zevra also purchased Acerâ€™s secured debt from Nantahala Capital Management, LLC ("NCMâ€), certain of its affiliates and certain other parties (collectively with NCM, â€œNantahalaâ€) through a series of transactions and Zevra agreed to provide Acer with a bridge loan facility for up to $18.0 million ("Bridge Loan"), subject to certain terms and conditions. The Merger expanded Zevra's rare disease portfolio, as well as increased and diversified its revenues with the addition of a U.S. commercial asset, OLPRUVA, indicated for the treatment of UCDs. See Note LÂ for further discussion related to the Merger. Â Â Â Registration Statements on Form S-3 Â In connection with the Merger, Zevra and Nantahala concurrently entered into a registration rights agreement, pursuant to which Zevra agreed to file a resale registration statement with respect to the resale of the Zevra common stock issuable to Nantahala. On February 5, 2024, Zevra filed a registration statement on Form S-3 (File No. 333-276856) registering an aggregate of 2,269,721 shares of Zevraâ€™s common stock. On April 5, 2024, we filed an amendment to the registration statement on Form S-3Â (File No. 333-250945) covering the issuance of the shares of our common stock issuable upon the exercise of warrants issued in connection with the Merger (Note L) and remaining unexercised as of the date of the amendment, which was declared effective on April 8, 2024. Â On June 4, 2024, the CompanyÂ filed a registration statement on Form S-3 (File No. 333-279941) (the "June 2024 Registration Statement") under which the Company may sell securities, including as may be issuable upon conversion, redemption, repurchase, exchange or exercise of securities,Â in one or more offerings up to a total aggregate offering price of $350.0 million, $75.0 million of which was allocated to the sale of the shares of common stock issuable under the 2024 ATM Agreement (as described further below).Â Â The registration statementÂ was declared effective on June 13, 2024. Â August 2024 Offering Â On AugustÂ 8, 2024, the CompanyÂ entered into an underwriting agreement (the â€œUnderwriting Agreementâ€) with Cantor FitzgeraldÂ & Co. and William BlairÂ & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the â€œUnderwritersâ€), in connection with the offering, issuance and sale by the Company of 9,230,770 shares of the Companyâ€™s common stock at a public offering price of $6.50 per share, pursuant to the June 2024 Registration Statement and a related prospectus supplement dated August 8, 2024 filed with the SEC (the "August 2024 Offering"). Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 1,384,615 shares of its Common Stock at the public offering price, less underwriting discounts and commissions, which the Underwriters exercised in full on August 9, 2024. The August 2024 Offering closed on AugustÂ 12, 2024.Â Total shares issued were 10,615,385.Â Net proceeds from the offering were approximately $64.5Â million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the offering to support theÂ commercialÂ launch activities for MIPLYFFA, continued commercial support for OLPRUVA and the continued development of celiprolol and KP1077 through potential NDA filings and other general corporate purposes. Â Based on the planned use of proceeds, the CompanyÂ believes that the net proceeds from the August 2024 Offering and its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements intoÂ 2027, subject to continuing compliance with the Company'sÂ debt covenants. Â Entry intoÂ 2024Â ATM Agreement Â On July 12, 2024, the Company entered into an equity distribution agreement (the "2024 ATM Agreement") with Citizens JMP Securities LLC ("Citizens JMP") under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0 million through Citizens JMP as its sales agent. The issuance and sale, if any, of common stock by the Company under theÂ 2024Â ATM Agreement will be made pursuant to the June 2024 Registration Statement, the accompanying prospectus, and the related prospectus supplement dated July 12, 2024. Citizens JMP mayÂ sell the common stock by any method permitted by law deemed to be an â€œat the market offeringâ€ as defined in RuleÂ 415Â of the Securities Act. Citizens JMP will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the CompanyÂ mayÂ impose). The Company will pay Citizens JMPÂ a commission equal toÂ 3.0%Â in the aggregate of the gross sales proceeds of any common stock sold through Citizens JMPÂ under theÂ 2024Â ATM Agreement.Â As of SeptemberÂ 30, 2024,Â noÂ shares have been issued or sold under theÂ 2024Â ATM Agreement. Â Termination ofÂ 2021Â ATM Agreement Â OnÂ JulyÂ 2,Â 2021,Â the CompanyÂ entered into an equity distribution agreement (theÂ "2021Â ATM Agreement")Â with JMP Securities LLC ("JMP")Â and RBC Capital Markets, LLC ("RBCCM")Â under which the CompanyÂ mayÂ offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0Â million through JMP and RBCCM as its sales agents. The issuance and sale, if any, of common stock by the Company under theÂ 2021Â ATM Agreement will be made pursuant to the registration statement on FormÂ S-3Â (File No. 333-257661) which was declared effective on July 12, 2021, the accompanying prospectus, and the related prospectus supplement dated July 12, 2021.Â JMP and RBCCMÂ mayÂ sell the common stock by any method permitted by law deemed to be an â€œat the market offeringâ€ as defined in RuleÂ 415Â of the Securities Act. JMP and RBCCM will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the CompanyÂ mayÂ impose). The Company will pay JMP and RBCCM a commission equal toÂ 3.0%Â in the aggregate of the gross sales proceeds of any common stock sold through JMP and RBCCM under theÂ 2021Â ATM Agreement. The 2021 ATM Agreement terminated on July 11, 2024, and no shares had been issued or sold under the 2021 ATM Agreement as of the termination date. Â Share Repurchase Program Â On December 20, 2021, the CompanyÂ initiated a share repurchase program (the "Share Repurchase Program") pursuant to which the Company was able to repurchase up to $50 million of shares of its common stock through December 31, 2023. On December 31, 2023, the Share Repurchase Program ended, and the Company had repurchased 1,575,692Â shares of its common stock for approximately $11.0Â million. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Note B - Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Significant Accounting Policies [Text Block] B.Summary of Significant Accounting Policies Â Use of Estimates Â The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Â On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the useful lives of property and equipment, the recoverability of long-lived assets, the incremental borrowing rate for leases,Â and assumptions used for purposes of determining stock-based compensation, income taxes, the fair value of investments and the fair value of the warrant liabilities, contingent value rightÂ ("CVR") liabilitiesÂ andÂ discount and rebate liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Â Investments Â The Company maintains investment securities that are classified as available-for-sale securities for which the Company has elected the fair value option under Accounting Standards Codification ("ASC") 825, Financial Instruments ("ASC 825"). As such, these securities are carried at fair value with unrealized gains and losses included in fair value adjustment related to investments on the unaudited condensedÂ consolidated statements of operations. The securities primarily consist of U.S. Treasury securitiesÂ andÂ corporate bonds and are included in securities at fair value in the unaudited condensedÂ consolidated balance sheets. The Company's investments in corporate bonds mature within one to five years.Â As of September 30, 2024, and December 31, 2023, the Company held securities with an aggregate fair value of $41.4Â million and $24.7Â million, respectively, that contained aggregate unrealized gainsof approximatelyÂ $0.1Â million and $0.6Â million, respectively. Applying fair value accounting to these debt securities more accurately represents the Company's investment strategy due to the fact that excess cash is currently being invested for the purpose of funding future operations.Â Interest income is recognized as earned using an effective yield method giving effect to the amortization of premium and accretion of discount and is based on the economic life of the securities. Interest income is included in interest and other income, net in the unaudited condensed consolidated statements of operations. Â Variable Interest Entities Â The primary beneficiary of a variable interest entity ("VIE") is required to consolidate the assets and liabilities of the VIE. When the Company obtains a variable interest in another entity, it assesses at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE, and if so, whether the Company is the primary beneficiary of the VIE based on its power to direct the activities of the VIE that most significantly impact the VIE's economic performance and the Company's obligation to absorb losses or the rights to receive benefits from the VIE that could potentially be significant to the VIE. Â To assess whether the Company has the power to direct the activities of the VIE that most significantly impact the VIE's economic performance, the Company considers all the facts and circumstances, including the Company's role in establishing the VIE and the Company's ongoing rights and responsibilities. The assessment includes identifying the activities that most significantly impact the VIE's economic performance and identifying which party, if any, has the power to direct those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) are deemed to have the power to direct the activities of a VIE. Â To assess whether the Company has the obligation to absorb losses of the VIE or the rights to receive benefits from the VIE that could potentially be significant to the VIE, the Company considers all of its economic interests that are deemed to be variable interests in the VIE. Â This assessment requires judgement in determining whether these interests, in the aggregate, are considered potentially significant to the VIE. As of SeptemberÂ 30, 2024, and December 31, 2023, the Company identified Acer to be the Company's sole interest in a VIE (Note L). As Zevra is the final decision maker for all of Acer's research, development, and commercialization of drug candidates that it is producing, the Company directs the activities of Acer that most significantly impact its performance. Therefore, the Company is the primary beneficiary of this VIE for accounting purposes.Â Â Revenue Recognition Â The Company recognizesÂ revenue in accordance with the provisions of ASC 606,Â Revenue from Contracts with CustomersÂ (â€œASC 606â€) and, as a result, follows the five-step model when recognizing revenue: 1) identifying a contract; 2) identifying the performance obligations; 3) determining the transaction price; 4) allocating the price to performance obligations; and 5) recognizing revenue when the performance obligations have been fulfilled. Â Licensing Agreements Â The terms of the Companyâ€™s licensing agreements typically include one or more of the following: (i)Â upfront fees; (ii)Â milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii)Â royalties on net sales of licensed products. Each of these payments may result in licensing revenues. Â As part of the accounting for these agreements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates asÂ independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilityÂ ofÂ regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the licensee which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Â Up-frontÂ Fees:Â If a license to the Companyâ€™s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Â Milestone Payments:Â At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Companyâ€™s or the licenseeâ€™s control, such asÂ non-operationalÂ developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the CompanyÂ re-evaluatesÂ the probability of achievement of milestones that are within its or the licenseeâ€™s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulativeÂ catch-upÂ basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Companyâ€™s estimate of the transaction price may also result in negative licensing revenues and earnings in the period of adjustment. Â Product Revenues, Net Â Net revenues from product sales is recognized at the transaction price when the customer obtains control of the Company's products, which occurs at a point in time, typically upon receipt of the product by the customer. Our current single customer is a specialty pharmacy provider. Â The Company's net revenues represent total revenues adjusted for discounts and allowances, including estimated cash discounts, chargebacks, rebates, returns, copay assistance, data fees and wholesaler fees for services. These adjustments represent variable consideration under ASC 606 and are recorded as a reduction of revenue. These adjustments are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the factors that impact such allowances. Adjustments for variable consideration are determined based on the contractual terms with customers, historical trends, communications with customers and the levels of inventory remining in the distribution channel, as well as expectations about the market for the product and anticipated introduction of competitive products. Â Acquired IPR&D and Milestones Expenses Â In an asset acquisition, payments incurred prior to regulatory approval to acquire rights to in-process R&D projects are expensed as acquired IPR&D and milestones expense in the consolidated statements of earnings unless the project has an alternative future use. These costs include upfront and development milestone payments related to R&D collaborations, licensing arrangements, or other asset acquisitions that provide rights to develop, manufacture and/or sell pharmaceutical products. Where contingent development milestone payments are due to third parties, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Regulatory and commercial milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product. Â Inventories Â The value of inventory is recorded at its net realizable value. The Company determines the cost of its other inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. Â The Company may scale-up and make commercial quantities of its product candidates prior to the date it anticipates that such product will receive final regulatory approval. The scale-

up and commercial production of pre-launch inventory involves the risk that such products may not be approved for marketing on a timely basis, or ever. This risk notwithstanding, the Company may scale-up and build pre-launch inventory of product that have not received final regulatory approval when the Company believes such action is appropriate in relation to the commercial value of the product launch opportunity. Inventory manufactured prior to regulatory approval is recorded as research and development expense until regulatory approval for the product is obtained. Inventory used in clinical trials is also expensed as research and development expense, when selected for such use. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign. The cost of finished goods inventory that is shipped to a customer to support the Companyâ€™s patient assistance programs is expensed when those shipments take place. As of SeptemberÂ 30, 2024, and December 31, 2023, the Company did not have pre-launch inventory that qualified for capitalization. Â The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded as a component of cost of product revenueÂ in the statements of operations and comprehensive loss. The determination of whether inventory costs will be realizable requires the use of estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. Additionally, the Companyâ€™s product is subject to strict quality control and monitoring that it performs throughout the manufacturing process. In the event that certain batches or units of product do not meet quality specifications, the Company will record a charge to cost of product revenue, to write-down any unsaleable inventory to its estimated net realizable value. For the three and nineÂ months ended SeptemberÂ 30, 2024, the Company recognized a charge of approximately $2.0Â million and $5.2Â million, respectively, related to write-downs for unsaleable inventory. No such write downs were recognized for the three and nineÂ months ended SeptemberÂ 30, 2023. Â Foreign currency Â Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the unaudited condensed consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in accumulated deficitÂ during the year, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income/loss in the accompanying unaudited condensed consolidated statements of stockholdersâ€™ equity. Â Debt Issuance Costs Â Debt issuance costs incurred in connection with financing arrangements are recorded as a reduction of the related debt on the balance sheet and amortized over the life of the respective financing arrangement using the effective interest method. Â Warrants Â The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity ("ASC 480") and FASB ASC Topic 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own stock and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Â For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital, on the unaudited condensed consolidated statement of stockholdersâ€™ deficit at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in other expense, net, on the unaudited condensed consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model. Â New Accounting Pronouncements Not Yet Adopted Â Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures Â In November 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. This update is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that thisÂ guidance will have on the presentation of its consolidated financial statements and accompanying notes. Â Income Taxes (Topic 740): Improvements to Income Tax Disclosures Â In December 2023, the FASB issued ASU No. 2023- 09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on the presentation of its consolidated financial statements and accompanying notes.Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Note C - Inventories 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Inventory Disclosure [Text Block] C. Inventories Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Raw materials Â $4,549Â Â $2,938Â Work in progress Â Â 3,084Â Â Â 1,884Â Finished goods Â Â 1,123Â Â Â 5,019Â Total inventory Â $8,756Â Â $9,841Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Note D - Debt Obligations 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Debt Disclosure [Text Block] D. Debt Obligations Â Long-term debt consisted of the following (in thousands): Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Notes payable Â $61,035Â Â $â€”Â Secured promissory note Â Â â€”Â Â Â 5,000Â Unamortized original issue (discount) premium Â Â (959)Â Â 148Â Less: debt issuance costs Â Â (1,172)Â Â (82) Â Â $58,904Â Â $5,066Â Â Secured Promissory Note Â In connection with the Merger (Note L), on August 30, 2023, the Company and Nantahala, entered into a secured promissory note payable by Zevra to Nantahala in the original principal amount of $5.0 million (the "Nantahala Note"). The Nantahala Note initially bore interest at 9.0% per annum, payable quarterly in arrears in cash. The interest rate increased to 12.0% per annum effective March 1, 2024, as the Nantahala Note remained unpaid six months from its issue date. The additional 3.0% interest would have been paid in shares of Zevra'sÂ common stock based on the volume weighted average trading price ("VWAP") of Zevra's common stockÂ during the twentyÂ consecutive trading days ending on the date before such interest payment date. Beginning on the first interest payment date following the second anniversary of the Nantahala Note, and on each interest payment date thereafter, Zevra was required to make $0.6 million amortization payments on the Nantahala Note until it was paid in full. All principal and unpaid interest on the Nantahala Note would have beenÂ due on August 30, 2026, the third anniversary of the Nantahala Note. Zevra was entitled toÂ prepay the Nantahala Note at any time without penalty. The Nantahala Note was secured by Zevraâ€™s interest in (i) the loan assets under the Loan Purchase Agreement described in Note L; (ii) the note assets under the Note Purchase Agreement described in Note L; (iii) the Bridge Loan described in Note L; and (iv) the proceeds therefrom. The Company used the proceeds from the Nantahala Note, along with $12.0 million in cash and 98,683 shares of Zevra's common stock, to acquire Acer's term loans, as more fully described in Note L. In April 2024, the Nantahala NoteÂ was repaid in full and terminated. At the time of repayment, Nantahala elected to receive a cash payment in lieu of shares of Zevra's common stockÂ in exchange for the additional 3.0% interest accrued for the period from March 1, 2024, through April 5, 2024.Â Â Line of Credit Â On January 26, 2023, the Company and Wells Fargo, as lender, entered into a revolving margin account agreement. The Company's investments were used as collateral for the loan and the amount the Company was able to borrow was limited to 80-90% of its outstanding investment balance held with Wells Fargo. The margin account boreÂ interest at the Prime rate minus 225 basis-points. As of December 31, 2023, $37.7Â million was outstanding under the margin account. In AprilÂ 2024, the Company repaid the outstanding balance under theÂ margin account with Wells Fargo, and upon such repayment, the margin capabilities were removed from the account.Â Â Term Loans Â On April 5, 2024 (the "Term Loans Closing Date"),Â the Company entered into a credit agreement (the â€œCredit Agreementâ€) withÂ HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the â€œLendersâ€), and Alter Domus (US) LLC, as administrative agent (the â€œAdministrative Agentâ€). Â Under the terms of the Credit Agreement, the Lenders provided a senior secured loan facility to the Company in the aggregate principal amount of $100.0 million, whichÂ is divided into three tranches as follows: (i) $60.0 million which was funded in full on the Term Loans Closing Date; (ii) $20.0 million which is available to the Company in up to two drawings, each in an amount not to exceed $10.0 million, at the Companyâ€™s option until 18 months following the Term Loans Closing Date; and (iii) $20.0 million which is available to the Company upon approval by the FDAÂ of the NDAÂ for MIPLYFFAÂ for the treatment of NPC, at the Companyâ€™s option until December 31, 2024 (collectively, the â€œTerm Loansâ€).Â Â The principal amount of the Term Loans outstanding (the â€œOutstanding Principal Amountâ€) will bear interest at a rate equal to 3-Month Term SOFR plus 7.00% per annum. If the net product sales for the calendar year ending December 31, 2025, exceed $100.0 million, the Outstanding Principal Amount will bear interest at 3-Month Term SOFR plus 6.00% per annum. If the net product sales for the calendar year ending December 31, 2025, do not exceed $100.0 million, then for any subsequent period of four consecutive fiscal quarters ending on or after March 31, 2026, in which net product sales exceed $125.0 million, the Outstanding Principal Amount will bear interest at 3-Month Term SOFR plus 6.50% per annum. In all cases, the 3-Month Term SOFR rate will be subject to a floor of 4.00% per annum. Interest will be payable quarterly in arrears on the last day of each calendar quarter. The Company has the option to pay up to 25% of the interest in-kind beginning on the Term Loans Closing Date, through and including June 30, 2026. The Company has recognized approximately $0.9Â million of interest-in-kind as of SeptemberÂ 30, 2024, which is included in long-term debt in the unaudited condensed consolidated balance sheet. The Term Loans will mature on the fifth anniversary of the Term Loans Closing Date. In connection with the Credit Agreement, the Company incurred approximately $2.2Â million ofÂ costs, which primarily consisted of underwriting, legal and other professional fees, and areÂ included as a reduction to the carrying amount of the related debt liability and are deferred and amortized over the remaining life of the financing using the effective interest method. Â The Credit Agreement contains customary affirmative and negative covenants by the Company, which among other things, will require the Company to provide certain financial reports to the Lenders within 60 days after the end of each of the first three fiscal quarters of each fiscal year and 105 days after the end of each fiscal year, meet certain minimum net product sales amounts, and limit the ability of the Company to incur or guarantee additional indebtedness, engage in certain transactions, and effect a consolidation or mergerÂ without consent. In addition, as long as the line of credit remains active, the Company must maintainÂ a minimum cash balance of $20.0 millionÂ to ensure the Company can meet its immediate capital needs. The obligations of the Company under the Credit Agreement may be accelerated upon customary events of default, including non-payment of principal, interest, fees and other amounts, covenant defaults, insolvency, material judgments, or inaccuracy of representations and warranties. The Term Loans are secured by a first priority perfected lien on, and security interest in, substantially all current and future assets of the Company. The proceeds of the Term Loans wereÂ used to refinance certain existing indebtedness of the Company and its subsidiaries.Â The Company will use the remaining proceeds to pay fees and expenses related to the debt financingÂ and fund the development and commercialization of OLPRUVAÂ and MIPLYFFA. Â Future minimum principal payments under the Term LoansÂ as ofÂ Â September 30, 2024, were as follows (in thousands): Â Year Ending December 31, Â Â Â Â 2024 (excluding the nine months ending September 30, 2024) Â $â€”Â 2025 Â Â â€”Â 2026 Â Â â€”Â 2027 Â Â â€”Â 2028 Â Â â€”Â Thereafter Â Â 60,919Â Total minimum payments Â Â 60,919Â Less: unamortized debt discount, debt issuance costs and paid in kind interest Â Â (2,015) Note payable Â $58,904Â Â X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -

SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Note E - Revenue, Net 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Revenue from Contract with Customer [Text Block] E.Revenue, net Â Licensing Agreements Â AZSTARYS License Agreement Â The Company entered into a Collaboration and License Agreement (theÂ â€œAZSTARYSÂ License Agreementâ€) with Commave Therapeutics SA (formerly known as Boston Pharmaceutical S.A.)Â ("Commave"), an affiliate of Gurnet Point Capital, L.P., dated September 3, 2019. Under theÂ AZSTARYS License Agreement, as amended, the CompanyÂ grantedÂ to Commave an exclusive, worldwide license to develop, manufacture and commercialize the Companyâ€™s product candidates containing SDXÂ andÂ d-MPH,Â including AZSTARYS, or any other product candidates containing SDX and developed to treat ADHD or any other central nervous system disorder.Â Corium Inc. was tasked by CommaveÂ to lead all commercialization activities for AZSTARYS under the AZSTARYS License Agreement. Pursuant to the AZSTARYS License Agreement, Commave agreed to pay milestone payments up to an aggregate of $590.0 million upon the occurrence of specified regulatory milestones related to AZSTARYS, additional fixed payments upon the achievement of specified U.S. sales milestones, and quarterly, tiered royalty payments based on a range of percentages of net sales (as defined in the AZSTARYS License Agreement). Commave is obligated to make such royalty payments on a product-by-product basis until expiration of the royalty term for the applicable product. Â The CompanyÂ concluded that these regulatory milestones, sales milestones and royalty payments each contain a significant uncertainty associated with a future event. As such, these milestone and royalty payments are constrained at contract inception and areÂ notÂ included in the transaction priceÂ as the Company couldÂ notÂ conclude that it is probable a significant reversal in the amount of cumulative revenue recognized willÂ notÂ occur surrounding these milestone paym ents. At the end of each reporting period, the CompanyÂ updates its assessment of whether the milestone and royalty payments are constrained by considering both the likelihood and magnitude of the potential revenue reversal. For the three and nineÂ months ended SeptemberÂ 30, 2024, the Company recognized $1.1Â million and $3.6Â millionÂ ofÂ revenue under the AZSTARYS License Agreement, respectively,Â primarily related to royalties.Â For the three and nineÂ months ended September 30, 2023, the Company recognized revenue under the AZSTARYS License Agreement of $0. 9Â million and $7.2Â million, respectively, which includes recognition of a $5.0 million net sales milestone that was met in JuneÂ 2023. There wasÂ noÂ deferred revenueÂ related to this agreement as of SeptemberÂ 30,Â 2024, or December 31,Â 2023. Â Â In accordance with the terms of the Companyâ€™s Termination Agreement with Aquestive TherapeuticsÂ ("Aquestive") dated March 20, 2012, Aquestive has the right to receive an amount equal to 10% of any royalty or milestone payments made to the Company related to AZSTARYS or KP1077 under the AZSTARYS License Agreement.Â Â Â TheÂ AZSTARYS LicenseÂ Agreement isÂ within the scope of ASCÂ 606,Â as the transaction represents a contract with a customer where theÂ participants function in a customer / vendor relationship and areÂ notÂ exposed equally to the risks and rewards of the activities contemplated under theÂ AZSTARYS License Agreement. Â Relief Exclusive License Agreement Â As a condition to entering into the Merger Agreement, Acer and Relief Therapeutics SAÂ ("Relief") entered into an exclusive license agreement on August 30, 2023 (the â€œRelief License Agreementâ€). Pursuant to the Relief License Agreement, Relief will hold exclusive development and commercialization rights for OLPRUVA in the European Union, Liechtenstein, San Marino, Vatican City, Norway, Iceland, Principality of Monaco, Andorra, Gibraltar, Switzerland, United Kingdom, Albania, Bosnia, Kosovo, Montenegro, Serbia and North Macedonia ("Geographical Europe"). The Company will have the right to receive a royalty of up to 10% of the net sales of OLPRUVA in Geographical Europe. For the three and nineÂ monthsÂ ended SeptemberÂ 30, 2024, the Company did not recognize any revenue under the Relief License Agreement. There was no deferred revenue related to this agreement as of SeptemberÂ 30, 2024, and December 31, 2023. For further discussion of the Relief License Agreement, see Note L. Â Product Revenues, Net Â ExpandedÂ Access Program Â Net revenue includes revenue from the sale of arimoclomolÂ for the treatment of NPCÂ under the remunerated expandedÂ access compassionate use program in France (â€œFrench nATUâ€). An expandedÂ access compassionate use program is a program giving specific patients access to a drug, which is not yet approved for commercial sale. Only drugs targeting serious or rare indications and for which there is currently no appropriate treatment are considered for expandedÂ access compassionate use programs. Further, to be considered for the expandedÂ access compassionate use program, the drug must have proven efficacy and safety and must either be undergoing price negotiations or seeking marketing approval. Â In accordance with ASC 606, the Company recognizes revenue when fulfilling its performance obligation under the ExpandedÂ Access Program ("EAP") by transferring control of promised goods or services to its customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. In determining when the customer obtains control of the product, the Company considers certain indicators, including whether the Company has a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether the customer acceptance has been received. Revenue is recognized net of sales deductions, including discounts, rebates, applicable distributor fees, and revenue-based taxes. Â The French Health Authorities and the manufacturer have agreed toÂ a price for sales duringÂ the French nATU, but the final transaction price depends on the terms and conditions in the contracts with the French Health Authorities and is subject to price negotiations with the French Health AuthoritiesÂ following market approval.Â Any excess in the price charged the manufacturer compared to the price agreed with the health authorities once the drug product is approved in France must beÂ repaid. The repayment is considered in the clawback liability (rebate). An estimate of net revenue and clawback liability are recognized using the â€˜expected valueâ€™ method. Accounting for net revenue and clawback liability requires determination of the most appropriate method for the expected final transaction price. This estimate also requires assumptions with respect to inputs into the method, including current pricing of comparable marketed products within the rare disease area in France. Management has considered the expected final sales price as well as the price of similar drug products. The Company is operating within a rare disease therapeutic area where there is unmet treatment need and hence a limited number of comparable commercialized drugs products. The limited available relevant market information for directly comparable commercialized drugs within rare disease increases the uncertainty in management's estimate. Â For the three and nineÂ months ended September 30, 2024, the Company recognized revenue related to the EAP in France of $2.6Â million and $8.0Â million, respectively, which is net of a clawback liability of $1.4Â million and $4.4Â million, respectively, and other gross to net adjustments. For the three and nineÂ months ended SeptemberÂ 30, 2023, the Company recognized revenue related to the EAP in France of $2.0Â million and $7.1Â million, respectively,Â which is net of a clawback liability of $1.1Â million and $4.0 million, respectively, and other gross to net adjustments. The total estimated reserve liability as of SeptemberÂ 30,Â 2024, and December 31, 2023, w as $17.0Â million and $12.2 Â million, respectively. As of SeptemberÂ 30, 2024, and December 31, 2023, this estimated reserve liability is recorded as discount and rebate liabilities in the unaudited condensed consolidated balance sheets and is separated into current and long-term based upon the timing of the expected payment to the French regulators. Â Product Sales Â On December 27, 2022, the FDA approved OLPRUVA (sodium phenylbutyrate), a prescription medicine used along with certain therapy, including changes in diet, for the long-term management of adults and children with UCDs weighing 44 pounds (20 kg) or greater and with a body surface area of 1.2m2 or greater.Â On November 17, 2023, the Company acquired OLPRUVA in connection with the Merger (Note L). For the three and nineÂ months ended September 30, 2024, sales of OLPRUVA were de minimis. Â On September 20, 2024, the NDA forÂ MIPLYFFA,Â an orally-delivered treatmentÂ for NPC, which is anÂ ultra-rare and progressive neurodegenerative disease, was approved. For the three and nineÂ months ended September 30, 2024, sales of MIPLYFFAÂ were de minimis.Â In May 2011, Orphazyme entered into an asset purchase agreement with LadRx Corporation, which was assigned to XOMA (US) LLC, a wholly-owned subsidiary of XOMA Corporation ("XOMA"), in June 2023 ("XOMAÂ License Agreement"). Under the XOMA License Agreement, XOMA is entitled toÂ certain net sales and regulatoryÂ milestone payments in addition toÂ a mid-single digit royalty with respect to sales of MIPLYFFA. For the three and nine months ended September 30, 2024, the Company recognized a regulatory milestone payment of $6.0 million due toÂ XOMA under the XOMA License Agreement, which is included in intangible assets, netÂ in the unaudited condensed consolidated balance sheet. Â The CompanyÂ currently utilizes a single specialty pharmacy provider as its sole distributor for both OLPRUVA and MIPLYFFA. The Company also enters into arrangements with health care providers and payors that provide for government mandated and/or privately negotiated rebates with respect to the purchase of its products.Â To commercialize OLPRUVA for oral suspension and MIPLYFFA in the U.S., the Company has builtÂ marketing, sales, medical affairs, distribution, managerial and other non-technical capabilities or is making arrangements with third parties to perform these services. Â Accounts and Other Receivables Â Accounts and other receivables consistÂ ofÂ receivables from product sales, receivables under theÂ AZSTARYS License Agreement andÂ EAP,Â as well as income tax receivables and other receivables due to the Company. Receivables under theÂ AZSTARYS License AgreementÂ are recorded for amounts due to the Company related to reimbursableÂ third-party costs and royalties on product sales. Receivables under the EAP are recorded for product sales under the French nATU.Â These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. As of September 30,Â 2024,Â the Company hadÂ receivables related to the EAP of $4.4Â million, AZSTARYS License Agreement of $1.1Â million, and other receivables of $2.3Â million.Â As ofÂ December 31, 2023,Â the Company hadÂ receivables related to the EAP of $4.7Â million, AZSTARYS License Agreement of $11.4Â million, andÂ other receivablesÂ of $1.3Â million. As of SeptemberÂ 30, 2024, and December 31, 2023,Â noÂ reserve or allowance for doubtful accounts hadÂ been established. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Note F - Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Commitments and Contingencies Disclosure [Text Block] F.Commitments and Contingencies Â From time to time, the Company is involved in various legal proceedings arising in the normal course of business. For some matters, a liability is not probable, or the amount cannot be reasonably estimated and, therefore, an accrual has not been made. However, for such matters when it is probable that the Company has incurred a liability and can reasonably estimate the amount, the Company accrues and discloses such estimates. Â Stockholder Litigation Related to the Merger Â On October 12, 2023, Brodsky & Smith, purporting to act as counsel for Jerry Beavee, who was asserted to be a stockholder of Acer, filed a complaint entitled Jerry Beavee v. Acer Therapeutics Inc., et al., No. 1:23-cv-08995 in the United States District Court for the Southern District of New York (the "Action") alleging that defendants violated Section 14(a) and 20(a) of the Securities Exchange Act of 1934 by filing the Preliminary Merger Registration Statement which allegedly omitted certain information that such counsel asserts is material to Acerâ€™s required disclosure. On October 30, 2023, Acer filed with the SEC a Schedule DEF14A that contained additional information regarding the Merger, which mooted the disclosure claims alleged in the Action. On December 8, 2023, Jerry Beavee filed with the court a notice of dismissal of the Action without prejudice. Â On October 20, 2023, Long Law, LLC and Acocelli Law, PLLC, purporting to act as counsel for Kevin Turner, who was asserted to be a stockholder of Acer, filed a complaint entitled Kevin Turner v. Acer Therapeutics Inc., et al., No. 1:23-cv-01185 in the United States District Court for the District of Delaware alleging that defendants violated Section 14(a) and 20(a) of the Securities Exchange Act of 1934 as well as SEC Rule 14a-9 by filing the Definitive Proxy Statement which allegedly omitted certain information that such counsel asserts is material to Acerâ€™s required disclosure. The complaint prays that, if asserted omissions are not adequately corrected, then Turner will seek to enjoin Acer from holding a stockholder meeting to approve theÂ Merger and, if the Merger closes, will seek to rescind it and seek an award of damages. Â On October 20, 2023, Long Law, LLC, purporting to act as counsel for Matthew Jones, who was asserted to be a stockholder of Acer, filed a complaint entitled Matthew Jones v. Acer Therapeutics Inc., et al., No. 1:23-cv-01186 in the United States District Court for the District of Delaware alleging that defendants violated Section 14(a) and 20(a) of the Securities Exchange Act of 1934 as well as SEC Rule 14a-9 by filing the Definitive Proxy Statement which allegedly omitted certain information that such counsel asserts is material to the Acerâ€™s required disclosure. The complaint prays that, if asserted omissions are not adequately corrected, then Jones will seek to enjoin Acer from holding a stockholder meeting to approve the Merger and, if the Merger closes, will seek to rescind it and seek an award of damages. Â On June 19, 2024, the Company entered into a confidential fee agreement (the "Fee Agreement") to settle the above stockholder litigation matters related to the Merger. The parties to the Fee Agreement were entitled to an aggregate payment of approximately $0.3 million, which was paid during the second quarter of 2024.Â Â Litigation Related to the AZSTARYS License Agreement Â In September 2024, the Company became engaged in a legal dispute regarding the AZSTARYS License Agreement.Â The litigation is in its early stages. We cannot predict with certainty the timing or ultimate outcome of this litigation or its potential impact on our business, financial condition, or results of operations. At this time, we have not recorded any accrual for contingent liability associated with this matter. The AZSTARYS License Agreement remains in effect during this litigation, and both parties continue to perform their respective obligations thereunder. However, there can be no assurance that this dispute will not have an adverse impact on our relationship with Commave or on the Company's business. The Company will continue to monitor developments in this matter and will assess the potential impact on our financial statements in future periods. The CompanyÂ expects to incur significant legal expenses in connection with this litigation, which may materially affect itsÂ results of operations in future periods. Â As of September 30, 2024, andÂ December 31, 2023,no accruals wereÂ made related to commitments and contingencies.Â Â Â X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Note G - Stock and Warrants 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Equity [Text Block] G.Stock and Warrants Â Authorized, Issued, and Outstanding Common Shares Â As of September 30, 2024, and December 31, 2023, the CompanyÂ had authorized shares of common stock of 250,000,000 shares. Of the authorized shares, 54,803,056Â and 43,110,360Â shares of common stock were issued as of September 30, 2024, and December 31, 2023, respectively,Â and 53,227,364Â and 41,534,668Â shares of common stock were outstanding as of September 30, 2024, and December 31, 2023, respectively. Â As ofÂ September 30, 2024,Â and December 31, 2023, the Company had reserved authorized shares of common stock for future issuance as follows: Â Â Â September 30, 2024Â Â December 31, 2023Â Outstanding awards under equity incentive plans Â Â 8,987,997Â Â Â 8,023,142Â Outstanding common stock warrants Â Â 5,483,537Â Â Â 5,603,729Â Possible future issuances under equity incentive plans Â Â 4,536,410Â Â Â 1,728,885Â Possible future issuances under employee stock purchase plans Â Â 1,242,425Â Â Â 1,340,172Â Total common shares reserved for future issuance Â Â 20,250,369Â Â Â 16,695,928Â Â Â Â Common Stock Activity Â The following table summarizes common stock activity for theÂ nine months ended September 30, 2024: Â Â Â Shares of Common StockÂ Balance as of January 1, 2024 Â Â 41,534,668Â Common stock issued as compensation to third parties Â Â 9,000Â Common stock issued as a result of stock options exercised Â Â 306,826Â Balance as of March 31, 2024 Â Â 41,850,494Â Common stock issued as a result of the Employee Stock Purchase Plan Â Â 97,747Â Common stock issued as compensation to third parties Â Â 41,820Â Common stock issued as a result of stock options exercised Â Â 1,403Â Balance as of June 30, 2024 Â Â 41,991,464Â Common stock issued as compensation to third parties Â Â 32,820Â Common stock issued in connection with the Public Offering (Note B) Â Â 10,615,385Â Common stock issued as a result of stock options exercised Â Â 39,750Â Common stock issued in connection with vesting of performance-based awards Â Â 547,945Â Balance as of September 30, 2024 Â Â 53,227,364Â Â Authorized, Issued, and Outstanding Preferred Stock Â As of September 30, 2024, and December 31, 2023, the Company had 10,000,000 shares of authorized preferred stock, none of which were designated, issued, or outstanding.Â Â Â Â Warrants to Purchase Common Stock Â The Company has issued warrants to purchase common stock to various third parties, of which 5,483,537Â remain outstanding as of SeptemberÂ 30, 2024, and are immediately exercisable. These warrantsÂ qualifyÂ asÂ participating securitiesÂ under ASC TopicÂ 260,Â Earnings perÂ Share,Â and areÂ treated as such in theÂ net lossÂ per share calculation (Note J). The Company may be required to redeem these warrantsÂ for a cash amount equal to the Black-Scholes value of the portion of the warrantsÂ to be redeemed (the â€œPut Optionâ€).Â Â In connection with the Merger (Note L), in November 2023, the Company directly issued to certain investors an aggregate of 1,382,489 shares of its common stock, par value $0.0001 per share, and accompanying warrants to purchase up to 1,382,489 shares of its common stock (the "2023 Warrants") at a combined offering price of $4.34 per share of common stock and the Warrants and an aggregate of 917,934 shares of its common stock in exchange for the cancellation of a warrant to purchase 2,920,306 shares of common stock of Acer. The Warrants are immediately exercisable and expire on November 22, 2028. The Company used the net proceeds of approximately $6.0 million from the offering for general corporate purposes. These warrants are separately exercisable by the warrant holders. While the warrants are outstanding (but unexercised), the warrant holders will participate in any dividend or other distribution of the Companyâ€™s assets to its common stockholders by way of return of capital or otherwise. As of SeptemberÂ 30, 2024, and December 31, 2023, none of the warrants have been exercised. The warrants have been evaluated to determine the appropriate accounting and classification pursuant to ASC 480Â and ASC 815. Generally, freestanding warrants should be classified as (i) liabilities if the warrant terms allow settlement of the warrant exercise in cash and (ii) equity if the warrant terms only allow settlement in shares of common stock.Â Â The Company determined that its outstandingÂ warrants and the Put Option should be recorded as a liability and stated at fair value at each reporting period. Changes to the fair value of the warrant liability are recorded through the unaudited condensed consolidated statements of operations as a fair value adjustment related toÂ warrant and CVR liability.Â As of SeptemberÂ 30, 2024, and December 31, 2023, the fair value of the liability associated with these warrants and the Put Option was approximately $13.9Â million and $16.1Â million, respectively. The fair value adjustment related to these warrants and the Put Option was approximately $6.0Â million of loss and $2.2Â million of incomeÂ for the three and nineÂ months ended SeptemberÂ 30,Â 2024, respectively. The fair value adjustment related to these warrants and the Put Option was approximately $3.7Â million and $4.3Â million of income for the three and nineÂ months ended SeptemberÂ 30, 2023, respectively. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Note H - Stock-based Compensation 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Share-Based Payment Arrangement [Text Block] H.Stock-Based Compensation Â The Company maintains a stock-based compensation plan (the â€œIncentive Stock Planâ€) that governs stock awards made to employees and directors prior to completion of the IPO.Â Â Â In November 2014,Â the Board of Directors of the Company ("the Board"), and in April 2015,Â the Companyâ€™s stockholders, approved the Companyâ€™sÂ 2014Â Equity Incentive Plan (theÂ â€œ2014Â Planâ€), which became effective inÂ April 2015.Â TheÂ 2014Â Plan provides for the grant of stock options, other forms of equity compensation, and performance cash awards. InÂ June 2021,Â the Company's stockholders approved an Amended and RestatedÂ 2014Â Equity Incentive Plan (the "A&RÂ 2014Â Plan"), following its adoption by the Board in April 2021,Â which among other things addedÂ 4,900,000Â shares to the maximum number of shares of common stock to be issued under the plan and extended the annual automatic increases (discussed further below) untilÂ January 1, 2031 and eliminated individual grant limits that applied under the 2014 Plan to awards that were intended to comply with the exemption for "performance-based compensation" under Code Section 162(m).Â The maximum number of shares of common stock thatÂ mayÂ be issued under the A&RÂ 2014Â Plan is 9,932,883Â as of SeptemberÂ 30, 2024.Â The number of shares of common stock reserved for issuance under the A&R 2014Â Plan will automatically increase onÂ January 1Â of each year, untilÂ and includingÂ January 1, 2031,Â byÂ 4%Â of the total number of shares of the Companyâ€™s capital stock outstanding on December 31Â of the preceding calendar year, or a lesser number of shares determined by the Board. Pursuant to the terms of theÂ 2014Â Plan, onÂ January 1, 2024,Â the common stock reserved for issuance under theÂ 2014Â Plan automatically increased byÂ 1,661,386Â shares. Â During the three and nineÂ months ended SeptemberÂ 30,Â 2024, 27,750, and 761,500Â stock options were exercised, respectively. During the three and nineÂ months ended September 30, 2023, no stock options were exercised. Â InÂ June 2021,Â the Company's stockholders approved an Employee Stock Purchase Plan (the "ESPP"), following its adoption by the Board in April 2021. The maximum number of shares of common stock thatÂ mayÂ be issued under the ESPP isÂ 1,500,000. The first offering period under the ESPP began on October 1, 2021, and the first purchase date occurred on May 31, 2022. As of SeptemberÂ 30,Â 2024,Â 257,575Â shares have been issued under the ESPP. Â In January 2023, the Board approved the 2023 Employment Inducement Award Plan (the "2023Â Plan"). The maximum number of shares of common stock that were initially available for issuanceÂ under the 2023 Plan was 1,500,000. In February 2024, theÂ Board approved an amendment to the 2023 Plan to increase the aggregate number of shares of common stock available for issuance under the 2023 Plan from 1,500,000 to 4,500,000 shares. Â In May 2023, the Board approved the Ninth Amended and Restated Non-Employee Director Compensation Policy (the â€œNon-Employee Director Compensation Policyâ€). The equity compensation made pursuant to the Non-Employee Director Compensation Policy will be granted under the A&RÂ 2014Â Plan. Â Stock-based compensation expense recorded under the Incentive Stock Plan, A&R 2014 Plan, ESPP and 2023 Plan is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands): Â Â Â Three months ended September 30, Â Â Nine months ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $1,441Â Â $720Â Â $3,322Â Â $2,023Â Selling, general and administrative Â Â 4,696Â Â Â 667Â Â Â 7,566Â Â Â 1,058Â Total stock-based compensation expense Â $6,137Â Â $1,387Â Â $10,888Â Â $3,081Â Â Â During the three and nine months ended September 30, 2024, the Company recognized approximately $2.5 million in stock-based compensation expense related to performance-based awards. There was no stock-based compensation expense related to performance-based awards recognized during the nine months ended September 30, 2023.Â Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Note I - Fair Value of Financial Instruments 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Fair Value Disclosures [Text Block] I.Fair Value of Financial Instruments Â The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Companyâ€™s principal or, in absence of a principal, most advantageous market for the specific asset or liability. Â The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: Â Â â— Level 1â€”Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;Â Â â— Level 2â€”Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and Â â— Level 3â€”Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. Â The carrying amounts of certain financial instruments, including cash and cash equivalents, investments, and accounts payable and accrued expenses, approximate their respective fair values due to the short-term nature of such instruments.Â Â Assets and Liabilities Measured at Fair Value on a Recurring Basis Â The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2024, and December 31, 2023 (in thousands): Â Â Â Balance as of September 30, 2024Â Â Quoted Prices in Active Markets for Identical Assets (Level 1)Â Â Significant Other Observable Inputs (Level 2) Â Â Significant Unobservable Inputs (Level 3)Â CVR liability (Note L) Â $4,800Â Â $â€”Â Â $â€”Â Â $4,800Â Warrant liabilities Â Â 13,902Â Â Â â€”Â Â Â â€”Â Â Â 13,902Â Total liabilities Â $18,702Â Â $â€”Â Â $â€”Â Â $18,702Â Â Â

disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Note J - Net Loss Per Share 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Earnings Per Share [Text Block] J.Net Loss Per Share Â For all periods presented herein, the Company did not use the two-class method to compute net loss per share of common stock, even though it had issued securities, other than common stock, that contractually entitled the holders to participate in dividends and earnings, because these holders are not obligated to participate in a loss. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Â UnderÂ theÂ two-classÂ method, for periods with net income, basic net income per share of common stock is computed by dividing the undistributed net income by the weighted average number of shares of common stock outstanding during the period. Undistributed net income is computed by subtracting from net income the portion of current period earnings that participating securities would have been entitled to receive pursuant to their dividend rights had all of the periodâ€™s earnings been distributed and subtracting the actual or deemed dividends declared.Â NoÂ such adjustment to earnings is made during periods with a net loss as the holders of the participating securities haveÂ noÂ obligation to fund losses. Diluted net income per share of common stock is computed underÂ theÂ two-classÂ method by using the weighted average number of shares of common stock outstanding plus the potential dilutive effects of stock options, warrants and other outstanding convertible securities. In addition to analyzing under the two-class method, the Company analyzes the potential dilutive effect of stock options and warrants, under the treasury-stock method and other outstanding convertible securities under theÂ if-convertedÂ method when calculating diluted income (loss) per share of common stock, in which it is assumedÂ that the stock options, warrants and other outstanding convertibleÂ securities convert into common stock at the beginning of the period or date of issuance, if the stock option, warrant or other outstanding convertible security was issued during the period. The Company reports the more dilutive of the approachesÂ (two-classÂ orÂ treasury-stock/if-converted)Â as its diluted net income (loss) of common stock during the period. Â As noted above, for all periods presented herein, the Company did not utilize the two-class approach as the Company was in a net loss position and the holders of the participating securities have no obligation to fund losses. The Company did analyze diluted net loss per share of common stock under the treasury-stock/if-converted method and noted that all outstanding stock options and warrants were anti-dilutive for the periods presented. For all periods presented,Â basic net loss per share of common stock was the same as diluted net loss per share of common stock.Â Â The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average number of shares of common stock outstanding because their effect is anti-dilutive: Â Â Â Three months ended September 30, Â Â Nine months ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Awards under equity incentive plans Â Â 8,987,997Â Â Â 7,262,039Â Â Â 8,987,997Â Â Â 7,262,039Â Common stock warrants Â Â 5,483,537Â Â Â 4,252,490Â Â Â 5,483,537Â Â Â 4,252,490Â Total securities excluded from the calculation of weighted average number of shares of common stock outstanding Â Â 14,471,534Â Â Â 11,514,529Â Â Â 14,471,534Â Â Â 11,514,529Â Â A reconciliation from net lossÂ to basic and diluted net lossÂ per share of common stock for the three andÂ nine months ended September 30, 2024, and 2023, is as follows (in thousands): Â Â Â Three months ended September 30, Â Â Nine months ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Basic and diluted net loss per share of common stock: Â Â Â

are subject to change within the one-year measurement period. The estimated fair values were developed by discounting future net cash flows to their present value at market-based rates of return. The goodwill acquired represents the excess of the purchase price and related costs over the value assigned to the net tangible and identifiable intangible assets of the business acquired. The useful lives of the intangible assets for amortization purposes were determined by considering the period of expected cash flows used to measure the fair values of the intangible assets adjusted as appropriate for entity-specific factors including legal, regulatory, contractual, competitive, economic and other factors that may limit the useful life. The marketed product asset is amortized on a straight-line basis over its estimated useful life. As of SeptemberÂ 30, 2024, the in-process research and developmentÂ ("IPR&D") project had not been completed or abandoned and, therefore, the IPR&D intangible asset is not currently subject to amortization. Â The results of operations and changes in stockholders' equity for Acer were included in the Company's consolidated financial statements beginning November 18, 2023.Â Â The following pro forma combined results of operations present the acquisition as if it had occurred on January 1, 2023. The pro forma combined results of operations do not necessarily represent the Company's consolidated results of operations had the acquisition occurred on the date assumed, nor are these results necessarily indicative of the Company's future consolidated results of operations. The Company expects to realize certain benefits from integrating Acer into the Company and to incur certain one-time costs. The pro forma combined results of operations do not reflect these benefits or costs. Â Â Â Three Months Ended September 30, 2023 Â Â Â Nine Months Ended September 30, 2023 Â Pro forma revenue Â $3,267Â Â $14,913Â Pro forma net loss Â Â (25,900)Â Â (54,763) Â Â Cancellation of Acer Warrant Â On November 22, 2023, the Company sold an aggregate of 917,934 shares of its common stock to a healthcare focused investment fund (the "Investor") to cancel a warrant held by the Investor to purchase 2,920,306 shares of common stock of Acer. The shares of common stock were offered and sold to the Investor in a registered direct offering without an underwriter or placement agent. Â Contingent Consideration Â Contingent consideration liabilities relate to our liabilities arising in connection with the CVRs issued as a result of the Merger. The contingent consideration is classified as Level 3 in the fair value hierarchy. The fair value is measured based on a Monte Carlo simulation or a scenario-based method, depending on the earn-out achievement objectives, utilizing projections about future performance. Significant inputs include volatility and projected financial information, including projections representative of a market participant's view of the expected cash payments associated with the agreed upon regulatory milestones based on probabilities of technical success, timing of the potential milestone events for the compounds, and estimated discount rates. Â The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration liabilities for the CVRs (dollars in thousands): Â Balance at December 31, 2023 Â $ 7,262 Â Change in fair value recognized in earningsÂ Â (2,462) Balance at September 30, 2024Â $4,800Â Â For thenine months ended September 30, 2024, the Company recorded a $2.5Â million gainÂ on the change in fair value of contingent consideration, primarily due to changes in market data and revenue projections. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContent + Details Name: us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Note M - Goodwill & Intangible Assets 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Goodwill and Intangible Assets Disclosure [Text Block] M. Goodwill & Intangible Assets Â The Company's goodwill balance was $4.7 million as of September 30, 2024, and December 31, 2023.Â Â As of September 30, 2024, and December 31, 2023,Â non-amortizable intangible assets include IPR&D ofÂ $2.0 million Â As of September 30, 2024, and December 31, 2023, the Company had a definite-lived intangible asset, net related to the acquisition of OLPRUVA as a result of the Merger of $62.6Â million and $67.2 million, respectively. ThisÂ is amortized on a straight-line basis over the OLPRUVA patentÂ life of thirteenÂ years and is reviewed periodically for impairment. Amortization expense is recorded as intangible asset amortizationÂ in the unaudited condensed consolidated statements of operations and was $1.5Â million and $4.6Â million for the three andÂ nine months ended September 30, 2024. No amortization expense related to definite-lived intangible assets was recognized for the three andÂ nine months ended September 30, 2023.Â Â In accordance with its policy, the Company reviews the estimated useful lives of its intangible assets on an ongoing basis. This review indicated that based on recent facts and circumstances, including detailed analysis on sales experience and prospective product strategy,Â the actual life of the definite-lived intangible asset related to OLPRUVAÂ wasÂ longer than the estimated useful life previously established at the acquisition of the asset. As a result, effective September 30, 2024,Â the Company changed its estimateÂ of the useful life of this intangible asset to better reflect the estimated periods during which thisÂ assetÂ will remain in service. The estimated useful life was previously 11 years and wasÂ increased to approximately 13Â years. The change in estimate had no effect on depreciation and amortization expense, net income, or basicÂ and diluted earnings per share for the three and nine months ended September 30, 2024. Â In connection with the XOMA License Agreement, the Company owedÂ XOMA a royalty payment of $6.0 million upon approval of MIPLYFFA in September 2024, which is included in intangible assets, net in the unaudited condensed consolidated balance sheet as of September 30, 2024.Â Â This definite-lived intangible asset is amortized on a straight-line basis over the MIPLYFFAÂ patentÂ life of approximately fiveÂ yearsÂ and is reviewed periodically for impairment. Amortization expense is recorded as intangible asset amortizationÂ in the unaudited condensed consolidated statements of operations and was de minimis for the three andÂ nine months ended September 30, 2024 . No amortization expense related to definite-lived intangible assets was recognized for the three andÂ nine months ended September 30, 2023 .Â Â For intangible assets subject to amortization, estimated amortization expense for the five fiscal years subsequent to September 30, 2024, isÂ expected to be $6.5Â million per year.Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Note N - Subsequent Events 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Subsequent Events [Text Block] N.Subsequent Events Â The CompanyÂ evaluated events and transactions occurring subsequent to September 30, 2024,Â through November 13, 2024, the date the accompanying unaudited condensed consolidated financial statements were issued. During this period, there were no subsequent events that required recognition in the accompanying unaudited condensed consolidated financial statements, nor were there any additional non-recognized subsequent events that required disclosure. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 shares Trading Arrangements, by Individual Â Non-Rule 10b5-1 Arrangement Adopted [Flag] false Non-Rule 10b5-1 Arrangement Terminated [Flag] false ZVRA_ Timothy J. Sangiovanni [Member] Â Trading Arrangements, by Individual Â Trading Arrangement Adoption Date October 15, 2024 Trading Arrangement, Individual Name Timothy J. Sangiovanni Trading Arrangement, Individual Title Senior Vice President, Finance and Corporate Controller Rule 10b5-1 Arrangement Adopted [Flag] true Rule 10b5-1 Arrangement Terminated [Flag] true Trading Arrangement, Securities Aggregate Available Amount 3,000 Trading Arrangement Termination Date April 15, 2025 ZVRA_ Sven Guenther, Ph.D [Member] Â Trading Arrangements, by Individual Â Trading Arrangement Adoption Date October 15, 2024 Trading Arrangement, Individual Name Sven Guenther, Ph.D. Trading Arrangement, Individual Title Chief Scientific Officer Rule 10b5-1 Arrangement Adopted [Flag] true Rule 10b5-1 Arrangement Terminated [Flag] true Trading Arrangement, Securities Aggregate Available Amount 8,000 Trading Arrangement Termination Date April 15, 2025 ZVRA_ Joshua Schafer [Member] Â Trading Arrangements, by Individual Â Trading Arrangement Adoption Date October 15, 2024 Trading Arrangement, Individual Name Joshua Schafer Trading Arrangement, Individual Title Chief CommercialÂ Officer & Executive Vice President, Business Development Rule 10b5-1 Arrangement Adopted [Flag] true Rule 10b5-1 Arrangement Terminated [Flag] true Trading Arrangement, Securities Aggregate Available Amount 10,500 Trading Arrangement Termination Date April 15, 2025 ZVRA_Christal M.M. Mickle [Member] Â Trading Arrangements, by Individual Â Trading Arrangement Adoption Date October 15, 2024 Trading Arrangement, Individual Name Christal M.M. Mickle Trading Arrangement, Individual Title Chief DevelopmentÂ Officer Rule 10b5-1 Arrangement Adopted [Flag] true Rule 10b5-1 Arrangement Terminated [Flag] true Trading Arrangement, Securities Aggregate Available Amount 6,300 Trading Arrangement Termination Date April 15, 2025 ZVRA_R. LaDuane Clifton [Member] Â Trading Arrangements, by Individual Â Trading Arrangement Adoption Date October 15, 2024 Trading Arrangement, Individual Name R. LaDuane Clifton Trading Arrangement, Individual Title Chief FinancialÂ Officer and Treasurer Rule 10b5-1 Arrangement Adopted [Flag] true Rule 10b5-1 Arrangement Terminated [Flag] true Trading Arrangement, Securities Aggregate Available Amount 11,000 Trading Arrangement Termination Date April 15, 2025 ZVRA_ Neil F. McFarlane [Member] Â Trading Arrangements, by Individual Â Trading Arrangement Adoption Date October 15, 2024 Trading Arrangement, Individual Name Neil F. McFarlane Trading Arrangement, Individual Title Chief ExecutiveÂ Officer Rule 10b5-1 Arrangement Adopted [Flag] true Rule 10b5-1 Arrangement Terminated [Flag] true Trading Arrangement, Securities Aggregate Available Amount 91,817 Trading Arrangement Termination Date April 15, 2025 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrTerminationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: ecd_IndividualAxis=zvra_ZVRATimothyJSangiovanniMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=zvra_ZVRASvenGuentherPhDMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=zvra_ZVRAJoshuaSchaferMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=zvra_ZVRAChristalMMMickleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=zvra_ZVRARLaDuaneCliftonMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=zvra_ZVRANeilFMcFarlaneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Use of Estimates, Policy [Policy Text Block] Use of Estimates Â The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Â On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the useful lives of property and equipment, the recoverability of long-lived assets, the incremental borrowing rate for leases,Â and assumptions used for purposes of determining stock-based compensation, income taxes, the fair value of investments and the fair value of the warrant liabilities, contingent value rightÂ ("CVR") liabilitiesÂ andÂ discount and rebate liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Â Investment, Policy [Policy Text Block] Investments Â The Company maintains investment securities that are classified as available-for-sale securities for which the Company has elected the fair value option under Accounting Standards Codification ("ASC") 825, Financial Instruments ("ASC 825"). As such, these securities are carried at fair value with unrealized gains and losses included in fair value adjustment related to investments on the unaudited condensedÂ consolidated statements of operations. The securities primarily consist of U.S. Treasury securitiesÂ andÂ corporate bonds and are included in securities at fair value in the unaudited condensedÂ consolidated balance sheets. The Company's investments in corporate bonds mature within one to five years.Â As of September 30, 2024, and December 31, 2023, the Company held securities with an aggregate fair value of $41.4Â million and $24.7Â million, respectively, that contained aggregate unrealized gainsof approximatelyÂ $0.1Â million and $0.6Â million, respectively. Applying fair value accounting to these debt securities more accurately represents the Company's investment strategy due to the fact that excess cash is currently being invested for the purpose of funding future operations.Â Interest income is recognized as earned using an effective yield method giving effect to the amortization of premium and accretion of discount and is based on the economic life of the securities. Interest income is included in interest and other income, net in the unaudited condensed consolidated statements of operations. Â Consolidation, Variable Interest Entity, Policy [Policy Text Block] Variable Interest Entities Â The primary beneficiary of a variable interest entity ("VIE") is required to consolidate the assets and liabilities of the VIE. When the Company obtains a variable interest in another entity, it assesses at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE, and if so, whether the Company is the primary beneficiary of the VIE based on its power to direct the activities of the VIE that most significantly impact the VIE's economic performance and the Company's obligation to absorb losses or the rights to receive benefits from the VIE that could potentially be significant to the VIE. Â To assess whether the Company has the power to direct the activities of the VIE that most significantly impact the VIE's economic performance, the Company considers all the facts and circumstances, including the Company's role in establishing the VIE and the Company's ongoing rights and responsibilities. The assessment includes identifying the activities that most significantly impact the VIE's economic performance and identifying which party, if any, has the power to direct those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) are deemed to

have the power to direct the activities of a VIE. Â To assess whether the Company has the obligation to absorb losses of the VIE or the rights to receive benefits from the VIE that could potentially be significant to the VIE, the Company considers all of its economic interests that are deemed to be variable interests in the VIE. Â This assessment requires judgement in determining whether these interests, in the aggregate, are considered potentially significant to the VIE. As of SeptemberÂ 30, 2024, and December 31, 2023, the Company identified Acer to be the Company's sole interest in a VIE (Note L). As Zevra is the final decision maker for all of Acer's research, development, and commercialization of drug candidates that it is producing, the Company directs the activities of Acer that most significantly impact its performance. Therefore, the Company is the primary beneficiary of this VIE for accounting purposes.Â Â Revenue from Contract with Customer [Policy Text Block] Revenue Recognition Â The Company recognizesÂ revenue in accordance with the provisions of ASC 606,Â Revenue from Contracts with CustomersÂ (â€œASC 606â€) and, as a result, follows the five-step model when recognizing revenue: 1) identifying a contract; 2) identifying the performance obligations; 3) determining the transaction price; 4) allocating the price to performance obligations; and 5) recognizing revenue when the performance obligations have been fulfilled. Â Licensing Agreements Â The terms of the Companyâ€™s licensing agreements typically include one or more of the following: (i)Â upfront fees; (ii)Â milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii)Â royalties on net sales of licensed products. Each of these payments may result in licensing revenues. Â As part of the accounting for these agreements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates asÂ independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probabilityÂ ofÂ regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the licensee which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Â Up-frontÂ Fees:Â If a license to the Companyâ€™s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Â Milestone Payments:Â At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Companyâ€™s or the licenseeâ€™s control, such asÂ non-operationalÂ developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the CompanyÂ re-evaluatesÂ the probability of achievement of milestones that are within its or the licenseeâ€™s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulativeÂ catch-upÂ basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Companyâ€™s estimate of the transaction price may also result in negative licensing revenues and earnings in the period of adjustment. Â Product Revenues, Net Â Net revenues from product sales is recognized at the transaction price when the customer obtains control of the Company's products, which occurs at a point in time, typically upon receipt of the product by the customer. Our current single customer is a specialty pharmacy provider. Â The Company's net revenues represent total revenues adjusted for discounts and allowances, including estimated cash discounts, chargebacks, rebates, returns, copay assistance, data fees and wholesaler fees for services. These adjustments represent variable consideration under ASC 606 and are recorded as a reduction of revenue. These adjustments are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the factors that impact such allowances. Adjustments for variable consideration are determined based on the contractual terms with customers, historical trends, communications with customers and the levels of inventory remining in the distribution channel, as well as expectations about the market for the product and anticipated introduction of competitive products. Â Research and Development Expense, Policy [Policy Text Block] Acquired IPR&D and Milestones Expenses Â In an asset acquisition, payments incurred prior to regulatory approval to acquire rights to in-process R&D projects are expensed as acquired IPR&D and milestones expense in the consolidated statements of earnings unless the project has an alternative future use. These costs include upfront and development milestone payments related to R&D collaborations, licensing arrangements, or other asset acquisitions that provide rights to develop, manufacture and/or sell pharmaceutical products. Where contingent development milestone payments are due to third parties, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Regulatory and commercial milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product. Â Inventory, Policy [Policy Text Block] Inventories Â The value of inventory is recorded at its net realizable value. The Company determines the cost of its other inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. Â The Company may scale-up and make commercial quantities of its product candidates prior to the date it anticipates that such product will receive final regulatory approval. The scale-up and commercial production of pre-launch inventory involves the risk that such products may not be approved for marketing on a timely basis, or ever. This risk notwithstanding, the Company may scale-up and build pre-launch inventory of product that have not received final regulatory approval when the Company believes such action is appropriate in relation to the commercial value of the product launch opportunity. Inventory manufactured prior to regulatory approval is recorded as research and development expense until regulatory approval for the product is obtained. Inventory used in clinical trials is also expensed as research and development expense, when selected for such use. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign. The cost of finished goods inventory that is shipped to a customer to support the Companyâ€™s patient assistance programs is expensed when those shipments take place. As of SeptemberÂ 30, 2024, and December 31, 2023, the Company did not have pre-launch inventory that qualified for capitalization. Â The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded as a component of cost of product revenueÂ in the statements of operations and comprehensive loss. The determination of whether inventory costs will be realizable requires the use of estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. Additionally, the Companyâ€™s product is subject to strict quality control and monitoring that it performs throughout the manufacturing process. In the event that certain batches or units of product do not meet quality specifications, the Company will record a charge to cost of product revenue, to write-down any unsaleable inventory to its estimated net realizable value. For the three and nineÂ months ended SeptemberÂ 30, 2024, the Company recognized a charge of approximately $2.0Â million and $5.2Â million, respectively, related to write-downs for unsaleable inventory. No such write downs were recognized for the three and nineÂ months ended SeptemberÂ 30, 2023. Â Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign currency Â Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the unaudited condensed consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in accumulated deficitÂ during the year, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income/loss in the accompanying unaudited condensed consolidated statements of stockholdersâ€™ equity. Â Debt, Policy [Policy Text Block] Debt Issuance Costs Â Debt issuance costs incurred in connection with financing arrangements are recorded as a reduction of the related debt on the balance sheet and amortized over the life of the respective financing arrangement using the effective interest method. Â Warrants [Policy Text Block] Warrants Â The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity ("ASC 480") and FASB ASC Topic 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own stock and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Â For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital, on the unaudited condensed consolidated statement of stockholdersâ€™ deficit at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in other expense, net, on the unaudited condensed consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model. Â New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements Not Yet Adopted Â Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures Â In November 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. This update is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that thisÂ guidance will have on the presentation of its consolidated financial statements and accompanying notes. Â Income Taxes (Topic 740): Improvements to Income Tax Disclosures Â In December 2023, the FASB issued ASU No. 2023- 09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on the presentation of its consolidated financial statements and accompanying notes.Â Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Paragraph 2AA -Subparagraph (a) -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AAReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A + Details Name: us-gaap_ConsolidationVariableInterestEntityPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_DebtPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 +

Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionRepresents the policy for warrants. + ReferencesNo definition available. + Details Name: zvra_WarrantsPolicyTextBlock Namespace Prefix: zvra_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Note C - Inventories (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Inventory, Noncurrent [Table Text Block] Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Raw materials Â $4,549Â Â $2,938Â Work in progress Â Â 3,084Â Â Â 1,884Â Finished goods Â Â 1,123Â Â Â 5,019Â Total inventory Â $8,756Â Â $9,841Â X - DefinitionTabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Note D - Debt Obligations (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Long-Term Debt Instruments [Table Text Block] Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Notes payable Â $61,035Â Â $â€”Â Secured promissory note Â Â â€”Â Â Â 5,000Â Unamortized original issue (discount) premium Â Â (959)Â Â 148Â Less: debt issuance costs Â Â (1,172)Â Â (82) Â Â $58,904Â Â $5,066Â Schedule of Maturities of Long-Term Debt [Table Text Block] Year Ending December 31, Â Â Â Â 2024 (excluding the nine months ending September 30, 2024) Â $â€”Â 2025 Â Â â€”Â 2026 Â Â â€”Â 2027 Â Â â€”Â 2028 Â Â â€”Â Thereafter Â Â 60,919Â Total minimum payments Â Â 60,919Â Less: unamortized debt discount, debt issuance costs and paid in kind interest Â Â (2,015) Note payable Â $58,904Â X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Note G - Stock and Warrants (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Authorized Shares of Common Stock Reserved for Future Issuance [Table Text Block] Â Â September 30, 2024Â Â December 31, 2023Â Outstanding awards under equity incentive plans Â Â 8,987,997Â Â Â 8,023,142Â Outstanding common stock warrants Â Â 5,483,537Â Â Â 5,603,729Â Possible future issuances under equity incentive plans Â Â 4,536,410Â Â Â 1,728,885Â Possible future issuances under employee stock purchase plans Â Â 1,242,425Â Â Â 1,340,172Â Total common shares reserved for future issuance Â Â 20,250,369Â Â Â 16,695,928Â Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Â Â Shares of Common StockÂ Balance as of January 1, 2024 Â Â 41,534,668Â Common stock issued as compensation to third parties Â Â 9,000Â Common stock issued as a result of stock options exercised Â Â 306,826Â Balance as of March 31, 2024 Â Â 41,850,494Â Common stock issued as a result of the Employee Stock Purchase Plan Â Â 97,747Â Common stock issued as compensation to third parties Â Â 41,820Â Common stock issued as a result of stock options exercised Â Â 1,403Â Balance as of June 30, 2024 Â Â 41,991,464Â Common stock issued as compensation to third parties Â Â 32,820Â Common stock issued in connection with the Public Offering (Note B) Â Â 10,615,385Â Common stock issued as a result of stock options exercised Â Â 39,750Â Common stock issued in connection with vesting of performance-based awards Â Â 547,945Â Balance as of September 30, 2024 Â Â 53,227,364Â X - DefinitionTabular disclosure of the change in common stock outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of authorized shares of common stock reserved for future issuance. + ReferencesNo definition available. + Details Name: zvra_ScheduleOfAuthorizedSharesOfCommonStockReservedForFutureIssuanceTableTextBlock Namespace Prefix: zvra_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Note H - Stock-based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Â Â Three months ended September 30, Â Â Nine months ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $1,441Â Â $720Â Â $3,322Â Â $2,023Â Selling, general and administrative Â Â 4,696Â Â Â 667Â Â Â 7,566Â Â Â 1,058Â Total stock-based compensation expense Â $6,137Â Â $1,387Â Â $10,888Â Â $3,081Â X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Note I - Fair Value of Financial Instruments (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Â Â Balance as of September 30, 2024Â Â Quoted Prices in Active Markets for Identical Assets (Level 1)Â Â Significant Other Observable Inputs (Level 2) Â Â Significant Unobservable Inputs (Level 3)Â CVR liability (Note L) Â $4,800Â Â $â€”Â Â $â€”Â Â $4,800Â Warrant liabilities Â Â 13,902Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â 13,902Â Total liabilities Â $18,702Â Â $â€”Â Â $â€”Â Â $18,702Â Â Â Â

https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Note J - Net Loss Per Share (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Â Â Three months ended September 30, Â Â Nine months ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Awards under equity incentive plans Â Â 8,987,997Â Â Â 7,262,039Â Â Â 8,987,997Â Â Â 7,262,039Â Common stock warrants Â Â 5,483,537Â Â Â 4,252,490Â Â Â 5,483,537Â Â Â 4,252,490Â Total securities excluded from the calculation of weighted average number of shares of common stock outstanding Â Â 14,471,534Â Â Â 11,514,529Â Â Â 14,471,534Â Â Â 11,514,529Â Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Â Â Three months ended September 30, Â Â Nine months ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Basic and diluted net loss per share of common stock: Â Â Â

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents maximum offering price under common stock registered. + ReferencesNo definition available. + Details Name: zvra_CommonStockRegisteredMaximumOfferingPrice Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionShares registered as apart of an S-3 filing. + ReferencesNo definition available. + Details Name: zvra_CommonStockRegisteredShares Namespace Prefix: zvra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe percentage of gross sales for commission fee under the equity distribution agreement. + ReferencesNo definition available. + Details Name: zvra_EquityDistributionAgreementCommissionFeePercentageOfGrossSales Namespace Prefix: zvra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe maximum aggregate offering price under the equity distribution agreement. + ReferencesNo definition available. + Details Name: zvra_EquityDistributionAgreementMaximumAggregateOfferingPrice Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe maximum limit of the financing receivable. + ReferencesNo definition available. + Details Name: zvra_FinancingReceivableMaximumLimit Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow from issuance of common stock, net of cash paid for issuance cost. + ReferencesNo definition available. + Details Name: zvra_ProceedsFromIssuanceOfCommonStockNet Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of stock issuable during the period. + ReferencesNo definition available. + Details Name: zvra_StockIssuableDuringThePeriod Namespace Prefix: zvra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ShareRepurchaseProgramAxis=zvra_ShareRepurchaseProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=zvra_AtmAgreementSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=zvra_JmpMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=zvra_JMPAndRBCCMMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=zvra_UnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=zvra_UnderwritingAgreementAndOverallotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_BridgeLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Note B - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Investments, Fair Value Disclosure $ 41,400 Â $ 41,400 Â $ 24,700 Unrealized Gain (Loss) on Investments Â Â 100 Â 600 Inventory Write-down 2,000 $ 0 5,244 $ 0 Â Pre-launch Inventory that Qualified for Capitalization [Member] Â Â Â Â Â Inventory, Net $ 0 Â $ 0 Â $ 0 X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized gain (loss) on investment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_UnrealizedGainLossOnInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_PublicUtilitiesInventoryAxis=zvra_PrelaunchInventoryThatQualifiedForCapitalizationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Note C - Inventories - Summary of Inventory (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Raw materials $ 4,549 $ 2,938 Work in progress 3,084 1,884 Finished goods 1,123 5,019 Total inventory $ 8,756 $ 9,841 X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Note D - Debt Obligations (Details Textual) - USD ($) $ in Thousands 1 Months Ended 9 Months Ended Apr. 05, 2024 Aug. 30, 2023 Jan. 31, 2023 Jan. 26, 2023 Nov. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 01, 2024 Dec. 31, 2023 Nov. 17, 2023 Stock Issued During Period, Shares, Acquisitions (in shares) Â Â Â Â 1,382,489 Â Â Â Â Â Proceeds from Issuance of Debt Â Â Â Â Â $ 58,990 $ 38,801 Â Â Â Debt Issuance Costs, Net Â Â Â Â Â 1,172 Â Â $ 82 Â Wells Fargo Bank, N.A. [Member] Â Â Â Â Â Â Â Â Â Â Long-Term Line of Credit Â Â Â Â Â Â Â Â Â $ 37,700 Â Wells Fargo Bank, N.A. [Member] | Prime Rate [Member] Â Â Â Â Â Â Â Â Â Â Debt Instrument, Basis Spread on Variable Rate Â Â Â 2.25% Â Â Â Â Â Â Wells Fargo Bank, N.A. [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Investments Â Â Â 80.00% Â Â Â Â Â Â Wells Fargo Bank, N.A. [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Investments Â Â Â 90.00% Â Â Â Â Â Â Â SWK Loans [Member] Â Â Â Â Â Â Â Â Â Â Payments to Acquire Notes Receivable Â $ 12,000 $ 12,000 Â Â Â Â Â Â Â Stock Issued During Period, Shares, Acquisitions (in shares) Â 98,683 98,683 Â Â Â Â Â Â Â Nantahala Note [Member] Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â $ 5,000 $ 5,000 Â Â Â Â Â Â $ 5,000 Debt Instrument, Interest Rate, Stated Percentage Â 9.00% Â Â Â Â Â Â Â Â Debt Instrument, Interest Rate, Stated Percentage, If Unpaid Within Six Months Â 12.00% Â Â Â Â Â Â Â Â Debt Instrument, Interest Rate, Increase in Stated Percentage, If Unpaid Within Six Months Â 3.00% Â Â Â Â Â 3.00% Â Debt Instrument, Interest, Shares, Consecutive Trading Days For Calculation of VWAP (Day) Â 20 days Â Â Â Â Â Â Â Â Debt Instrument, Periodic Payment, Interest Â $ 600 Â Â Â Â Â Â Â Â Term Loans Under Credit Agreement [Member

Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount $ 100,000 Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from Issuance of Debt 60,000 Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Available Amount Until 18 Months Following Closing Date 20,000 Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Available Amount Until 18 Months Following Closing Date, Maximum Each Drawing 10,000 Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Available Amount Until December 31, 2024 20,000 Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Net Product Sales Performance Benchmark 100,000 Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Net Product Sales Performance Benchmark in Next Year $ 125,000 Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Maximum Interest Payment, Percentage 25.00% Â Â Â Â Â Â Â Â Â Â Â Â Interest Payable Â Â Â Â Â Â 900 Â Â Â Â Â Debt Issuance Costs, Net Â Â Â Â Â 2,200 Â Â Â Â Â Debt Instrument, Minimum Cash Balance Â Â Â Â Â $ 20,000 Â Â Â Â Â Term Loans Under Credit Agreement [Member | Secured Overnight Financing Rate (SOFR) [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Basis Spread on Variable Rate 7.00% Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Basis Spread on Variable Rate When Performance Benchmark Meet 6.00% Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Basis Spread on Variable Rate When Performance Benchmark Meet in Next Year 6.50% Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Floor Rate 4.00% Â Â Â Â Â Â Â Â Â Â Â Â X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of the required periodic payments applied to interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentPeriodicPaymentInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireNotesReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of debt available until 18 months following closing date under debt instrument. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentAvailableAmountUntil18MonthsFollowingClosingDate Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum each drawing for amount available under debt instrument to draw after 18 months of debt closing date. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentAvailableAmountUntil18MonthsFollowingClosingDateMaximumEachDrawing Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of debt available to be drawn until December 31, 2024. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentAvailableAmountUntilDecember312024 Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument when performance benchmark meet. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentBasisSpreadOnVariableRateWhenPerformanceBenchmarkMeet Namespace Prefix: zvra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument when performance benchmark meet in next year. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentBasisSpreadOnVariableRateWhenPerformanceBenchmarkMeetInNextYear Namespace Prefix: zvra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFloor rate of debt instrument. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentFloorRate Namespace Prefix: zvra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionIncrease in the contractual interest rate for funds borrowed, under the debt agreement, if unpaid within six months. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentInterestRateIncreaseInStatedPercentageIfUnpaidWithinSixMonths Namespace Prefix: zvra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement, if unpaid within six months. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentInterestRateStatedPercentageIfUnpaidWithinSixMonths Namespace Prefix: zvra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe consecutive trading days for calculation of VWAP for interest to be paid in shares on debt instrument. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentInterestSharesConsecutiveTradingDaysForCalculationOfVWAP Namespace Prefix: zvra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionMaximum amount of interest payment allowed under debt instrument as a percentage. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentMaximumInterestPaymentPercentage Namespace Prefix: zvra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionMinimum cash balance required for debt instrument to be active. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentMinimumCashBalance Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of performance benchmark of net product sales under debt instrument. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentNetProductSalesPerformanceBenchmark Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of performance benchmark of net product sales in next year under debt instrument. + ReferencesNo definition available. + Details Name: zvra_DebtInstrumentNetProductSalesPerformanceBenchmarkInNextYear Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of investments outstanding for maximum borrowing capacity of the debt instrument. + ReferencesNo definition available. + Details Name: zvra_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfInvestments Namespace Prefix: zvra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_LineOfCreditFacilityAxis=zvra_WellsFargoBankNaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_PrimeRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=zvra_SWKLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=zvra_NantahalaNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=zvra_TermLoansUnderCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Note D - Debt Obligations - Aggregate Principal Amount (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Unamortized original issue (discount) premium $ (959) $ 148 Less: debt issuance costs (1,172) (82) Notes Payable 58,904 5,066 Notes Payable Excluding Secured Promissory Note [Member] Â Â Notes payable 61,035 0 Nantahala Note [Member] Â Â Notes payable $ 0 $ 5,000 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt discount (premium). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_NotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=zvra_NotesPayableExcludingSecuredPromissoryNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=zvra_NantahalaNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Note D - Debt Obligations - Future Minimum Principal Payments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Note payable $ 58,904 $ 5,066 Term Loans Under Credit Agreement [Member Â Â 2024 (excluding the nine months ending September 30, 2024) 0 Â 2025 0 Â 2026 0 Â 2027 0 Â 2028 0 Â Thereafter 60,919 Â Total minimum payments 60,919 Â Less: unamortized debt discount, debt issuance costs and paid in kind interest (2,015) Â Note payable $ 58,904 Â X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_NotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: zvra_LongtermDebtMaturityAfterYearFour Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=zvra_TermLoansUnderCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Note E - Revenue, Net (Details Textual) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Mar. 20, 2012 Jun. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 May 07, 2021 Accounts Receivable, Allowance for Credit Loss Â Â $ 0 Â $ 0 Â $ 0 Â Arimoclomol Purchase Agreement [Member] Â Â Â Â Â Â Â Â Contract with Customer, Liability, Revenue Recognized Â Â 2,600 $ 2,000 8,000 $ 7,100 Â Â Contract with Customer, Clawback Liability Â Â 1,400 1,100 4,400 4,000 Â Â Asset Acquisition, Consideration Transferred, Estimated Reserve Liability Â Â Â Â 17,000 Â 12,200 Â XOMA License Agreement [Member] Â Â Â Â Â Â Â Â Accrued Royalties Â Â 6,000 Â 6,000 Â Â Â Consulting Services [Member] Â Â Â Â Â Â Â Â Â Accounts Receivable, after Allowance for Credit Loss, Current Â Â 2,300 Â 2,300 Â 1,300 Â Commave Therapeutics SA [Member] | License [Member] | AZSTARYS License Agreement [Member] Â Â Â Â Â Â Â Â Revenue Recognition, Milestone Method, Additional Revenue to be Recognized Â Â Â Â Â Â Â Â $ 590,000 Relief Therapeutics [Member] | License [Member] Â Â Â Â Â Â Â Â Contract with Customer, Liability, Revenue Recognized Â Â 0 Â 0 Â Â Â Contract with Customer, Liability Â Â 0 Â $ 0 Â 0 Â Royalty Revenue, Percent Â Â Â Â 10.00% Â Â Â Aquestive Therapeutics [Member] | License [Member] | AZSTARYS License Agreement [Member] Â Â Â Â Â Â Â Â Contract with Customer, Liability, Revenue Recognized Â $ 5,000 1,100 $ 900 $ 3,600 $ 7,200 Â Â Royalty Revenue, Percent 10.00% Â Â Â Â Â Â Â Â Accounts Receivable, after Allowance for Credit Loss, Current Â Â 1,100 Â 1,100 Â 11,400 Â Arimoclomol EAP [Member] Â Â Â Â Â Â Â Â Â Accounts Receivable, after Allowance for Credit Loss, Current Â Â $ 4,400 Â $ 4,400 Â $ 4,700 Â X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedRoyaltiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents estimated reserve liability for asset acquisition consideration transferred. + ReferencesNo definition available. + Details Name: zvra_AssetAcquisitionConsiderationTransferredEstimatedReserveLiability Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents clawback liability for contract with customer + ReferencesNo definition available. + Details Name: zvra_ContractWithCustomerClawbackLiability Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of additional consideration to be recognized for the milestone or milestones. + ReferencesNo definition available. + Details Name: zvra_RevenueRecognitionMilestoneMethodAdditionalRevenueToBeRecognized Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the royalty revenue expressed as a percentage. + ReferencesNo definition available. + Details Name: zvra_RoyaltyRevenuePercent Namespace Prefix: zvra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=zvra_ArimoclomolPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=zvra_XomaLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=zvra_ConsultingServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=zvra_CommaveTherapeuticsSAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-

gaap_LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=zvra_AZSTARYSLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=zvra_ReliefTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=zvra_AquestiveTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=zvra_ArimoclomolEapMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Note F - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands 3 Months Ended Jun. 30, 2024 Sep. 30, 2024 Dec. 31, 2023 Loss Contingency Accrual Â $ 0 $ 0 Litigation Related to Merger [Member] Â Â Â Payments for Legal Settlements $ 300 Â Â AZSTARYS License Agreement [Member] Â Â Â Loss Contingency Accrual Â Â $ 0 X - DefinitionAmount of loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10 + Details Name: us-gaap_LossContingencyAccrualAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of cash paid for the settlement of litigation or for other legal issues during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForLegalSettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_LitigationCaseAxis=zvra_LitigationRelatedToMergerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=zvra_AZSTARYSLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Note G - Stock and Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended Nov. 22, 2023 Nov. 30, 2023 Dec. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 Mar. 31, 2024 Common Stock, Shares Authorized (in shares) Â Â 250,000,000 250,000,000 Â 250,000,000 Â Â Â Common Stock, Shares, Issued (in shares) Â Â 43,110,360 54,803,056 Â 54,803,056 Â Â Â Common Stock, Shares, Outstanding (in shares) Â Â 41,534,668 53,227,364 Â 53,227,364 Â 41,991,464 41,850,494 Preferred Stock, Shares Authorized (in shares) Â Â 10,000,000 10,000,000 Â 10,000,000 Â Â Â Class of Warrant or Right, Outstanding (in shares) Â Â Â 5,483,537 Â 5,483,537 Â Â Â Stock Issued During Period, Shares, Acquisitions (in shares) Â 1,382,489 Â Â Â Â Â Â Â Common Stock, Par or Stated Value Per Share (in dollars per share) Â $ 0.0001 $ 0.0001 $ 0.0001 Â $ 0.0001 Â Â Â Stock Issued During Period, Shares, New Issues (in shares) Â Â Â 10,615,385 Â Â Â Â Â Derivative and Warrant Liability, Noncurrent Â Â $ 16,100 $ 13,902 Â $ 13,902 Â Â Â Fair Value Adjustment of Put Option, Net of Tax Â Â Â $ 6,000 $ 3,700 $ 2,200 $ 4,300 Â Â Acer Warrants [Member] Â Â Â Â Â Â Â Â Â Proceeds from Warrant Exercises Â $ 6,000 Â Â Â Â Â Â Â Class of Warrants or Right, Exercised During Period (in shares) Â Â 0 Â Â 0 Â Â Â Acer Warrants [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â 1,382,489 Â Â Â Â Â Â Â Â Shares and Warrants Issued, Price Per Share (in dollars per share) Â $ 4.34 Â Â Â Â Â Â Â Â The Investor Warrant [Member] Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 2,920,306 2,920,306 Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) 917,934 917,934 Â Â Â Â Â Â Â Â X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants or rights exercised during period. + ReferencesNo definition available. + Details Name: zvra_ClassOfWarrantsOrRightExercisedDuringPeriod Namespace Prefix: zvra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNoncurrent Carrying amount of derivative and warrant liability. + ReferencesNo definition available. + Details Name: zvra_DerivativeAndWarrantLiabilityNoncurrent Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAfter tax amount of expense (income) related to adjustment to fair value of put option. + ReferencesNo definition available. + Details Name: zvra_FairValueAdjustmentOfPutOptionNetOfTax Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe price per share of shares and warrants issued. + ReferencesNo definition available. + Details Name: zvra_SharesAndWarrantsIssuedPricePerShare Namespace Prefix: zvra_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=zvra_AcerWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=zvra_TheInvestorWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Note G - Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details) - shares Sep. 30, 2024 Dec. 31, 2023 Common shares reserved for future issuance (in shares) 20,250,369 16,695,928 Warrant [Member] Â Â Common shares reserved for future issuance (in shares) 5,483,537 5,603,729 Share-Based Payment Arrangement [Member] Â Â Common shares reserved for future issuance (in shares) 8,987,997 8,023,142 Possible Future Issuances Under Equity Incentive Plans [Member] Â Â Common shares reserved for future issuance (in shares) 4,536,410 1,728,885 Possible Future Issuances Under Employee Stock Purchase Plans [Member] Â Â Common shares reserved for future issuance (in shares) 1,242,425 1,340,172 X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=zvra_PossibleFutureIssuancesUnderEquityIncentivePlansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=zvra_PossibleFutureIssuancesUnderEmployeeStockPurchasePlansMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Note G - Stock and Warrants - Common Stock Activity (Details) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2024 Balance (in shares) 41,991,464 41,850,494 41,534,668 41,534,668 Common stock issued as compensation to third parties (in shares) 32,820 41,820 9,000 Â Common stock issued as a result of stock options exercised (in shares) 39,750 1,403 306,826 Â Common stock issued as a result of the Employee Stock Purchase Plan (in shares) Â 97,747 Â 257,575 Common stock issued as compensation to third parties (in shares) 32,820 41,820 9,000 Â Common stock issued in connection with the Public Offering (Note B) (in shares) 10,615,385 Â Â Â Common stock issued in connection with vesting of performance-based awards (in shares) 547,945 Â Â Â Balance (in shares) 53,227,364 41,991,464 41,850,494 53,227,364 X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478848/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Note H - Stock-based Compensation (Details Textual) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Jan. 01, 2024 Jun. 30, 2021 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Feb. 29, 2024 Jan. 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) Â Â 39,750 1,403 306,826 Â Â Â Â Â Â Employee Stock Purchase Plan, Maximum Number of Issuable Shares (in shares) Â 1,500,000 Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) Â Â Â 97,747 Â Â 257,575 Â Â Â Share-Based Payment Arrangement, Expense Â Â $ 6,137 Â Â $ 1,387 $ 10,888 $ 3,081 Â Â Performance Shares [Member] Â Â Â Â Â Â Â Â Â Â Share-Based Payment Arrangement, Expense Â Â $ 2,500 Â Â Â Â $ 2,500 $ 0 Â Â 2014 Equity Incentive Plan [Member] Â Â Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) Â 4,900,000 Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Â Â 9,932,883 Â Â Â 9,932,883 Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Reserved for Issuance, Incremental Percentage of Capital Stock Outstanding Â 4.00% Â Â Â Â Â Â Â Â Increase in Common Stock Reserved for Issuance (in shares) 1,661,386 Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) Â Â 27,750 Â Â 0 761,500 0 Â Â The 2023 Plan [Member] Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Â Â Â Â Â Â Â Â 4,500,000 1,500,000 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionMaximum number of shares that may be issued under Employee Stock Purchase Plan. + ReferencesNo definition available. + Details Name: zvra_EmployeeStockPurchasePlanMaximumNumberOfIssuableShares Namespace Prefix: zvra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of increase in common stock reserved for issuance. + ReferencesNo definition available. + Details Name: zvra_IncreaseInCommonStockReservedForIssuance Namespace Prefix: zvra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents the share based compensation arrangement by share based payment award number of shares reserved for issuance incremental percentage of capital stock outstanding. + ReferencesNo definition available. + Details Name: zvra_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesReservedForIssuanceIncrementalPercentageOfCapitalStockOutstanding Namespace Prefix: zvra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=zvra_TwoThousandFourteenEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=zvra_The2023PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Note H - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stock based compensation expense $ 6,137 $ 1,387 $ 10,888 $ 3,081 Research and Development Expense [Member] Â Â Â Â Stock based compensation expense 1,441 720 3,322 2,023 General and Administrative Expense [Member] Â Â Â Â Stock based compensation expense $ 4,696 $ 667 $ 7,566 $ 1,058 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Note I - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Total liabilities $ 18,702 $ 23,362 Total assets 41,442 24,688 US Treasury Securities [Member] Â Â Total assets 35,337 24,688 Corporate Bond Securities [Member] Â Â Total assets 6,105 Â Fair Value, Inputs, Level 1 [Member] Â Â Total liabilities 0 0 Total assets 35,337 24,688 Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member] Â Â Total assets 35,337 24,688 Fair Value, Inputs, Level 1 [Member] | Corporate Bond Securities [Member] Â Â Total assets 0 Â Fair Value, Inputs, Level 2 [Member] Â Â Total liabilities 0 0 Total assets 6,105 0 Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member] Â Â Total assets 0 0 Fair Value, Inputs, Level 2 [Member] | Corporate Bond Securities [Member] Â Â Total assets 6,105 Â Fair Value, Inputs, Level 3 [Member] Â Â Total liabilities 18,702 23,362 Total assets 0 0 Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member] Â Â Total assets 0 0 Fair Value, Inputs, Level 3 [Member] | Corporate Bond Securities [Member] Â Â Total assets 0 Â CVR Liability [Member] Â Â Total liabilities 4,800 7,262 CVR Liability [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Total liabilities 0 0 CVR Liability [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Total liabilities 0 0 CVR Liability [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Total liabilities 4,800 7,262 Warrants [Member] Â Â Total liabilities 13,902 16,100 Warrants [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Total liabilities 0 0 Warrants [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Total liabilities 0 0 Warrants [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Total liabilities $ 13,902 $ 16,100 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 16:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 28: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=zvra_CvrLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=zvra_WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Note I - Fair Value of Financial Instruments - Fair Value Assumptions for Warrant Liabilities (Details) 9 Months Ended 12 Months Ended Sep. 30, 2024 $ / shares Dec. 31, 2023 $ / shares Weighted average fair value (in dollars per share) $ 2.54 $ 2.94 Measurement Input, Expected Dividend Rate [Member] Â Â Risk-free interest rate 0 0 Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Risk-free interest rate 0.0351 0.0376 Minimum [Member] | Measurement Input, Price Volatility [Member] Â Â Risk-free interest rate 0.6176 0.6201 Minimum [Member] | Measurement Input, Expected Term [Member] Â Â Risk-free interest rate 1.27 2 Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] Â Â Risk-free interest rate 0.0381 0.0412 Maximum [Member] | Measurement Input, Price Volatility [Member] Â Â Risk-free interest rate 0.8244 0.9242 Maximum [Member] | Measurement Input, Expected Term [Member] Â Â Risk-free interest rate 4.14 4.9 X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionRepresents the weighted average fair value under fair value assumptions for warrant liabilities. + ReferencesNo definition available. + Details Name: zvra_ClassOfWarrantOrRightLiabilityWeightedAverageFairValue Namespace Prefix: zvra_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Note I - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Balance $ 16,100 Change in fair value measurement (2,198) Balance $ 13,902 X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cumulative effect adjustment for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesNo definition available. + Details Name: zvra_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCumulativeEffectAdjustment Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Note J - Net Loss Per Share - Anti-dilutive Securities (Details) - shares 3 Months Ended 6 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 Sep. 30, 2023 Antidilutive securities (in shares) 14,471,534 11,514,529 14,471,534 11,514,529 Share-Based Payment Arrangement [Member] Â Â Â Â Antidilutive securities (in shares) 8,987,997 7,262,039 8,987,997 7,262,039 Warrants to Purchase Common Stock [Member] Â Â Â Â Antidilutive securities (in shares) 5,483,537 4,252,490 5,483,537 4,252,490 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=zvra_WarrantsToPurchaseCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Note J - Net Loss Per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Net Income (Loss) Attributable to Parent $ (33,225) $ (19,925) $ (16,622) $ (10,367) $ (2,573) $ (13,217) $ (69,772) $ (26,157) Weighted average number of shares of common stock outstanding, basic and diluted (in shares) 47,808,817 Â Â 34,724,614 Â Â 43,843,851 34,364,075 Basic and diluted net loss per share of common stock (in dollars per share) $ (0.69) Â Â $ (0.3) Â Â $ (1.59) $ (0.76) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Note K - Leases (Details Textual) 9 Months Ended Sep. 30, 2024 Lessee, Lease, Option to Extend, Maximum Term (Year) 5 years Lessee, Lease, Option to Terminate, Term (Year) 1 year Minimum [Member] Â Lessee, Lease, Remaining Term of Contract (Year) 1 year Maximum [Member] Â Lessee, Lease, Remaining Term of Contract (Year) 3 years X - DefinitionRepresents maximum terms of option to extend lessee's lease. + ReferencesNo definition available. + Details Name: zvra_LesseeLeaseOptionToExtendMaximumTerm Namespace Prefix: zvra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the terms of option to terminate lessee's lease. + ReferencesNo definition available. + Details Name: zvra_LesseeLeaseOptionToTerminateTerm Namespace Prefix: zvra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRemaining term of lessee's lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: zvra_LesseeLeaseRemainingTermOfContract Namespace Prefix: zvra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Note K - Leases - Lease Cost (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Amortization of right-of-use assets $ 12 $ 26 $ 36 $ 90 Interest on lease liabilities 0 0 0 0 Total finance lease cost 12 26 36 90 Operating lease cost 119 113 330 340 Short-term lease cost 59 55 177 165 Variable lease cost 26 13 39 39 Less: sublease income (50) (39) (128) (117) Total lease costs $ 166 $ 168 $ 454 $ 517 X - DefinitionAmount of interest expense on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of sublease income excluding finance and operating lease expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_SubleaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents total cost of fiance lease. + ReferencesNo definition available. + Details Name: zvra_FinanceLeaseCostTotal Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Note K - Leases - Supplement Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Financing cash flows from finance leases $ (0) $ 5 Operating cash flows from operating leases 405 426 Operating cash flows from short-term leases 177 165 Operating cash flows from variable lease costs 39 39 Finance leases 0 0 Operating leases $ 419 $ 0 X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term lease payment excluded from lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_ShortTermLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for variable lease payment excluded from lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_VariableLeasePayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Note K - Leases - Supplement Balance Sheet Information Related to Lease (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property and equipment, net $ 114 $ 149 Other current liabilities 0 0 Other long-term liabilities 0 0 Lease liabilities, finance leases 0 0 Operating lease right-of-use assets 820 790 Total operating lease right-of-use assets 820 790 Current portion of operating lease liabilities 540 543 Operating lease liabilities, less current portion 483 456 Total operating lease liabilities $ 1,023 $ 999 Operating leases (in years) (Year) 2 years 2 years Finance leases 0.00% 14.30% Operating leases 9.60% 7.60% Property and Equipment, At Cost [Member] Â Â Property and equipment, at cost $ 1,031 $ 1,031 Accumulated Depreciation and Amortization [Member] Â Â less: accumulated depreciation and amortization $ (917) $ (882) X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-

gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for finance lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionGross amount of lessee's right to use underlying asset under finance lease. + ReferencesNo definition available. + Details Name: zvra_FinanceLeaseRightofuseAssetGross Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BalanceSheetLocationAxis=zvra_PropertyAndEquipmentAtCostMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=zvra_AccumulatedDepreciationAndAmortizationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Note K - Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 2024 (excluding the three months ended March 31, 2024), finance leases $ 0 Â 2024 (excluding the three months ended March 31, 2024), operating leases 167 Â 2025, finance leases 0 Â 2025, operating leases 536 Â 2026, finance leases 0 Â 2026, operating leases 146 Â 2027, finance leases 0 Â 2027, operating leases 136 Â 2028, finance leases 0 Â 2028, operating leases 161 Â Thereafter, finance leases 0 Â Thereafter, operating leases 49 Â Total lease payments, finance leases 0 Â Total lease payments, operating leases 1,195 Â Less: future interest expense, finance leases 0 Â Less: future interest expense, operating leases (172) Â Lease liabilities, finance leases 0 $ 0 Lease liabilities, operating leases $ 1,023 $ 999 X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: zvra_FinanceLeaseLiabilityToBePaidAfterYearFour Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: zvra_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Note L - Merger (Details Textual) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Nov. 22, 2023 shares Nov. 17, 2023 USD ($) $ / shares shares Aug. 30, 2023 USD ($) shares Jun. 16, 2023 USD ($) $ / shares shares Jan. 31, 2023 USD ($) shares Mar. 14, 2022 USD ($) Nov. 30, 2023 shares Sep. 30, 2024 USD ($) shares Sep. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Oct. 31, 2023 USD ($) Stock Issued During Period, Shares, Acquisitions (in shares) | shares Â Â Â Â Â Â 1,382,489 Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) | shares Â Â Â Â Â Â Â 10,615,385 Â Â Â Stock Issued During Period, Value, New Issues Â Â Â Â Â Â Â $ 64,517 Â Â Â The Investor Warrant [Member] Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) | shares 917,934 Â Â Â Â Â 917,934 Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares 2,920,306 Â Â Â Â Â 2,920,306 Â Â Â Â SWK Loans [Member] Â Â Â Â Â Â Â Â Â Â Payments to Acquire Notes Receivable Â Â $ 12,000 Â $ 12,000 Â Â Â Â Â Â Stock Issued During Period, Shares, Acquisitions (in shares) | shares Â Â 98,683 Â 98,683 Â Â Â Â Â Â Marathon Convertible Notes [Member] Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, Acquisitions (in shares) | shares Â Â Â 2,171,038 Â Â Â Â Â Â Â Asset Acquisition, Share Price (in dollars per share) | $ / shares Â Â Â $ 5.0667 Â Â Â Â Â Â Â Asset Acquisition, Consideration Transferred Â Â Â $ 11,000 Â Â Â Â Â Â Â SWK Loans and Marathon Notes [Member] Â Â Â Â Â Â Â Â Â Â Payments to Acquire Notes Receivable Â $ 12,000 Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, Acquisitions (in shares) | shares Â 2,270,000 Â Â Â Â Â Â Â Â Asset Acquisition, Consideration Transferred, Equity

Interest Issued and Issuable Â $ 11,500 Â Â Â Â Â Â Â Â Â VWAP, Consecutive Trading Days (Year) Â 20 years Â Â Â Â Â Â Â Â Â Nantahala Note [Member] Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â $ 5,000 $ 5,000 Â $ 5,000 Â Â Â Â Â Â Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member] Â Â Â Â Â Â Â Â Â Â Maximum Royalty Percentage Â Â 20.00% Â Â Â Â Â Â Â Â Upfront Payment Â Â $ 10,000 Â Â Â Â Â Â Â Â Addiitonal Payment on First Anniversary Â Â 1,500 Â Â Â Â Â Â Â Â Â Maximum Royalty Obligation Â Â $ 45,000 Â Â Â Â Â Â Â Â Â Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member] | Europe [Member] Â Â Â Â Â Â Â Â Â Â Maximum Royalty Percentage Â Â 10.00% Â Â Â Â Â Â Â Â Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member] | Worldwide, Excluding Europe [Member] Â Â Â Â Â Â Â Â Â Â Maximum Royalty Percentage Â Â 10.00% Â Â Â Â Â Â Â Â Â Acer Therapeutics Inc [Member] | SWK Loans [Member] Â Â Â Â Â Â Â Â Â Â Proceeds from Issuance of Long-Term Debt Â Â Â Â $ 7,000 $ 6,500 Â Â Â Â Â Maximum [Member] | Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member] Â Â Â Â Â Â Â Â Â Â Contractual Obligation Â Â $ 56,500 Â Â Â Â Â Â Â Â Bridge Loan [Member] Â Â Â Â Â Â Â Â Â Â Financing Receivable, Maximum Limit Â Â 18,000 Â Â Â Â Â Â Â Â $ 18,000 Bridge Loan [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Â Â Financing Receivable, Maximum Limit Â Â 16,500 Â Â Â Â Â Â Â Â Â Acer Therapeutics Inc [Member] Â Â Â Â Â Â Â Â Â Â Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Conversion Ratio Â 0.121 Â Â Â Â Â Â Â Â Â Business Acquisition, Share Price (in dollars per share) | $ / shares Â $ 0.0001 Â Â Â Â Â Â Â Â Â Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Â $ 76,000 Â Â Â Â Â Â Â Â Â Business Combination, Consideration Transferred Â $ 72,600 Â Â Â Â Â Â Â Â Â Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares Â 2,960,000 Â Â Â Â Â Â Â Â Â Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Â $ 12,800 Â Â Â Â Â Â Â Â Â Business Combination, Contingent Consideration, Liability Â 8,500 Â Â Â Â Â Â Â $ 4,800 $ 4,800 $ 7,262 Â Repayments of Notes Payable Â $ 1,000 Â Â Â Â Â Â Â Â Â Gain (Loss) on Contingent Consideration, Change in Fair Value Â Â Â Â Â Â Â Â $ 2,500 Â Â Acer Therapeutics Inc [Member] | Acer Warrants [Member] Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) | shares Â 900,000 Â Â Â Â Â Â Â Â Â Stock Issued During Period, Value, New Issues Â $ 4,000 Â Â Â Â Â Â Â Â Â Acer Therapeutics Inc [Member] | Bridge Loan [Member] Â Â Â Â Â Â Â Â Â Business Combination, Consideration Transferred, Other Â $ 17,800 $ 16,500 Â Â Â Â Â Â Â Â Â X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of equity interests issued or issuable to acquire entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionSharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessCombinationConsiderationTransferredOther1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFor contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_ContractualObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireNotesReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of additional payment on first anniversary. + ReferencesNo definition available. + Details Name: zvra_AddiitonalPaymentOnFirstAnniversary Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe share price of equity interest issued in asset acquisition. + ReferencesNo definition available. + Details Name: zvra_AssetAcquisitionSharePrice Namespace Prefix: zvra_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionConversion ratio of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + ReferencesNo definition available. + Details Name: zvra_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableConversionRatio Namespace Prefix: zvra_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionThe maximum limit of the financing receivable. + ReferencesNo definition available. + Details Name: zvra_FinancingReceivableMaximumLimit Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the gain/(loss) on contingent consideration from the changes in fair value over the period. + ReferencesNo definition available. + Details Name: zvra_GainLossOnContingentConsiderationChangeInFairValue Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of maximum royalty obligation. + ReferencesNo definition available. + Details Name: zvra_MaximumRoyaltyObligation Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of maximum royalty. + ReferencesNo definition available. + Details Name: zvra_MaximumRoyaltyPercentage Namespace Prefix: zvra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of upfront payment. + ReferencesNo definition available. + Details Name: zvra_UpfrontPayment Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consecutive trading days for VWAP. + ReferencesNo definition available. + Details Name: zvra_VwapConsecutiveTradingDays Namespace Prefix: zvra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=zvra_TheInvestorWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=zvra_SWKLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=zvra_MarathonConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=zvra_SwkLoansAndMarathonNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=zvra_NantahalaNoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=zvra_AcerTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=zvra_LicenseAgreementAndTerminationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=zvra_ReliefMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=zvra_WorldwideExcludingEuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=zvra_SWKLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_BridgeLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=zvra_AcerTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=zvra_AcerWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Note L - Merger - Estimates and Assumptions Related to Fair Value of Assets and Liabilities Acquired (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Nov. 17, 2023 Cash Â Â $ 575 Prepaid expenses Â Â 278 Other current assets Â Â 11 Inventory Â Â 9,376 Property, plant, and equipment Â Â 35 Other noncurrent assets Â Â 209 Approved product - OLPRUVA Â Â 68,000 ? IPR&D - celiprolol Â Â 2,000 Goodwill acquired $ 4,701 $ 4,701 Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Â Â 85,185 Accounts payable and accrued expenses Â Â 10,881 Deferred collaboration funding Â Â 1,500 Operating lease liabilities Â Â 175 Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Â Â 12,556 Fair Value of Net Assets Acquired Â Â 72,629 Acer Therapeutics Inc [Member] Â Â Â Goodwill acquired Â Â $ 4,701 X - DefinitionAmount of assets acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of identifiable intangible assets recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of inventory recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of property, plant, and equipment recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability incurred for accounts payable and accrued expenses assumed at acquisition date. + ReferencesNo definition available. + Details Name: zvra_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the approved product, OLPRUVA, acquired at the acquisition date. + ReferencesNo definition available. + Details Name: zvra_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedApprovedProductOlpruva Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities incurred for deferred collaboration funding assumed on the acquisition date. + ReferencesNo definition available. + Details Name: zvra_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredCollaborationFunding Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities incurred for operating leases assumed at the acquisition date. + ReferencesNo definition available. + Details Name: zvra_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities Namespace Prefix: zvra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=zvra_AcerTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Note L - Merger - Pro Forma Combined Results of Operations (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2023 Sep. 30, 2023 Pro forma revenue $ 3,267 $ 14,913 Pro forma net loss $ (25,900) $ (54,763) X - DefinitionThe pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Note L - Merger - Reconciliation of Contingent Consideration Liabilities (Details) - Acer Therapeutics Inc [Member] $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Balance $ 7,262 Change in fair value recognized in earnings (2,462) Balance $ 4,800 X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -

Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=zvra_AcerTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Note M - Goodwill & Intangible Assets (Details Textual) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Goodwill $ 4,701 Â Â $ 4,701 Â $ 4,701 Indefinite-Lived Intangible Assets (Excluding Goodwill) $ 2,000 Â Â $ 2,000 Â $ 2,000 Finite-Lived Intangible Asset, Useful Life (Year) 13 years Â Â 13 years Â 11 years Amortization of Intangible Assets $ 1,545 $ 0 Â $ 4,619 $ 0 Â Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year 6,500 Â Â 6,500 Â Â Finite-Lived Intangible Asset, Expected Amortization, Year One 6,500 Â Â 6,500 Â Â Finite-Lived Intangible Asset, Expected Amortization, Year Two 6,500 Â Â 6,500 Â Â Finite-Lived Intangible Asset, Expected Amortization, Year Three 6,500 Â Â 6,500 Â Â Finite-Lived Intangible Asset, Expected Amortization, Year Four 6,500 Â Â 6,500 Â Â XOMA License Agreement [Member] Â Â Â Â Â Â Accrued Royalties $ 6,000 Â Â $ 6,000 Â Â Patents [Member] Â Â Â Â Â Â Finite-Lived Intangible Asset, Useful Life (Year) 13 years Â Â Patents [Member] | XOMA License Agreement [Member] Â Â Â Â Â Â Amortization of Intangible Assets Â Â $ 0 Â $ 0 Â OLPRUVA [Member] Â Â Â Â Â Â Finite-Lived Intangible Assets, Net $ 62,600 Â Â $ 62,600 Â $ 67,200 X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedRoyaltiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteOfArrangementAxis=zvra_XomaLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=zvra_OlpruvaMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

MY8OV\(WU,P1":-LZ\>GC9>T+X87*N2!_],8%8?7J^UUV*_[8\IM7:#GTO>K7 M=Y?KQDX(;%D(&POA00LC7A3Z]:CUEUB@):8+L+HS3BD6$I4@*@\[+53\W3SE M7D?+\C<,' UKR8\:^=$9\L].?[25U2#>G?]3(EL.XL9!?+X#(N7BN/IX2U,< M];S0BY,-\=N!4>C[7ICLT9XTVI/SM>OB+Q5F&6'S8P:2;0-A$'3#)-HPL!T8 M^7$8)4EOMX%N8Z!
[T,"#KF&2S)DM72]O\\080C_NH)B"^+E+^4%:\RV]EB5. M8>#HCZ4$L01G^.Z-GW@?=Q6M?T36RD"OR4#OO!+VFA+0.ZT$' UK.;AJ'%S]
MYR)\=6H1/B&P9<'W7CZKWJM,G%8(:O)U89O2#X:T1: U OZK1)1]+H3#BH_M%%(I=]<:&M--WF$Q)TPB"C.-\3I=#195@U9-%"]MCS/E2G=,=ICKIA:$"=#[M,\[5\\2T34V;//P+4$L#!!0 (
$V";5FX.=PII@8 T= 8 >&PO M=V]R:W-H965T&ULK5EM]LV$/XKA!<,+9#4(O6>)086V\4* MK%N1].4S8]&V5DGT1-I)]^MWE&S9)L]*N[EH:UE^[LCG[GA*-T\R?JK6@JA MR7-95.IVL-1Z=3T9?=
M#CPS(U&(F38N.'QLQ%@4A?$$_A[ZW30C6D,#Z]WWM\VY(',(U=B+(LO>::7 MMX-D0#(QY^M"W\NGW\264&C\S62AFO_)TQ;K#$<*M04-]V')O C?AFNJ]N:OE$:H,& M;^:BB7YC#?'**U,H#
[J&7W.PTZ-/%5]GN189&! _MG.X:^? M3LS!)^]EI9>*3&$&&6(_Z;=/>^R'$(\N*&P7E#O6Z_!!K-X0WL[O&,!,I_Q M]YO[O&)W_-KT!X]~%P9 R_J2" \1><\'4!A&>AK!+0]B; MAG=]X<08ARX92)+%V
5Y%E\7$4""+;Y];H[81AW;J#'Q3[#=-.E-H+?&\,JU7 M76,8K%W46%" M+=#$!?F)2QX9,(W"&">?=N337O(?I0;&TEE_&./4C7Y,0[NKNBB:P.YE4791 M,0N2R*+LHH+$"QA.F7I[I>?
UDOY=*D7FM2QWQ$'%H6+-<\:_8K'O6=,<8S@(M3&1O)A@.(IA8BV&*X?P@"$[DFAY(7-K?9V$/KLU6WB3Y-6S:,UD*M-=N/9VI MV9[5V^2LWJ;G\G:<$[;/"7MIIQ?@5^^6'IH,AA2B3YE=APC,CR*
["A%42$.G M"!%8'}SHM72OH6F_B'[+\YIL> &2DF=_P;'.["Z@\XKFC*4E>>)US>&6Z-<+C MS_>DR/EC7N3Z&QH8WYUD$?. G5A?A3;;1A!!5'DV7%!4.8A@"Q[*92"[:;_N M?
C$N>;41[5V\5R$BU+/#@"A>YC0I1/(&=@Q<3!">.'C0O>2E+VK>=B68U,NF M5;4-:M^Q3IZ]**)_O2"U X"@8M^I Q?%8'.R8X!(9=_%82]$]:]\FZW(:.- M&B4>(:LYM27[&(&%-
'9R[Z)@\PYMYBXJ8>F)(P#=*T_:+SV;??E1P%%1[/*N M^3,N1:BK!*]\GS%;?&(XZE%[94PP7)3&,,.I(S@6T5,JC.XU*.T7H>\ZPKW[M@*L!G37N0JFV;,OMEQU->R''+/=BD_:KS3_@(%M FE%NJ?_X
T\I@J,>M'.; M(H)#4XK@>E+*]BJ3>;UBZXZK?-:>H_)B;;IXM:5/0'42M>10Z'). (/&EK(C2 MDP.J\=[$R7IT1^KA+=&Z&1=9":8*[IF]!^&///(#[Q_(GM=2ECO>7[I7FS M %7+-W!&6@A2K9N'IN?R
M=IRZO<9F_1K;[3RFH-NLX56,:-HX\9*$QG;I(DHZ@*-[1&TM@?GT$_CK/#Y% M?<+IV8OMT\;PX/5.*>I%\UY-016N*]T^Q^_N=N_N?FW>6%GW[^CUF'+W)_1Z
MVKZ9V[MO7Q2^Y_4BKQ0IQ!R&@@4&TZW=V_M%RU7S"9J T M?I]+J7=?S #=&]#1OU!+ P04 " !-@FU9??_:6FL" !>!@ & 'AL M+W=OU9L)A8J2YXD-]V^?
I3L>$F;!L7V8E$4S^%%%)UNE7XP)8 E3Y60 M9AR4UM8C2DU>0L7,I:I!XLE:Z8I9W.H--;4&5GA0)6@4AE>T8EP&6>IU"YVE MJK&"2UAH8IJ8OK7!(3:CH-!L%/<\4UIG8)F:&'+/+E3#^
M2[:=;1B0O#%651T8(ZBX;%?VU-5A#X \QP%!!XB> Y)7 '$'B-_J(>D R5L] M##N 3YVVN?O"S9AE6:K5EFAGC6Q.\-7W:*P7EZY/EE;C*4>XE:PINH2!3 M)0N_U8R2O""?
72XH*-80U1: *U!LW<#1MROF :U258GC-A+LA[O?'6\LI3NMGUF V&R3*EC_M5?&D4'EK, M7EHD5X/K0Z/Y*9HV8[KW8"K0&S^I#,E5(VU;B%[;#\,;/P.>Z2>#T71P1#_# MX=G.NK_T[>2]97K#\?
D(6*.K\(/#OF?=3K-V8U7MQ>M*67S\7BSQ!P#:&>#Y M6BF[VS@' _2\E^P-02P,$% @ 38)M60\PY PH P @H ! @ !X;"]W M;W)KWW,^G6^P9OQ19(1(]%065 R-
M3,I%WS1%DI$2BTNV(!1V9HR76,*4STVQX 2G%:@L3,>R K/$.36B0;5VRZ,! M6\HBI^26([$L2\R1Z1@ZZ%A&YN%NWR>2;5@1H,%GI,ID?>+6PXSLV5)\Y)0 MD3.*.)D-C6N[/PF5?
67P(R=KL35&2LD#8X]]\CD=&I9RB!0DD8H!PV]%QJ0H M%!&X\;OA--HC%7![O&' 6&D'+0]8D#$K?N:IS(;&E8%2,L/+0MZQ]22?Z/$5 M7\(*47W1NK&U#)0LA61E P8/RIS6?_S4Q&$+ #QZ@-, G"
[.P!P&X![Z@E> M _!./<%O)5TL]9>!2[&$D<#SM:(*VM@4X,J^A4:XI53E2=3R6$W!YR,[BE> MIKDD*1HSFL+]UR!BCS%:GDJX0>)(05B,]@(1TSE2QI_QZ7!7)^?_3I_\\^D[P7#;3'$K/N\
MWU:V10(55E6D47KNLX_L!<;8=+8V9;,A#NFL4:LZ 7ALZNV41C MY@2V_*V(]-K97H5SCT@\YO,"$?)3IZ?*]WO(+MAF?1U ?".A4[5^KY8X(0, M#6 5A*^($;U]8P?6!UU6O299)IDDU2-NIHU-
'N:-38'-8>MYO"HYMV'YE#="75U)PSLCDR-F:H[M'1VQQBSH77E>1Z[&S F\GM41;&X]RB7A\ZH;$G"-2RKKJMNNM@W7==5G=-9' M=G]L:]9C:-#J?NJ%ON[N;C"?YU2@#LS@*.LRA+OA=
<=43R1;5"W! Y/08%3# M#)I,PI4![,\8DYN),J!M6Z, 4$L#!!0 ($V";5DRA]^0(A !## 8 M >&PO=V]R:W-H965T&ULM9UM M)64]KDI, ^(EF9I)=C]L[0=&PK8JDE CS/_?D'6"--<^AKY[)?QV^F'EM0'
MZ#ZWF>NGO/BC?,BR2OMKN]F5[RX>JFK_X]55N7S(MFGY0[[/=O5?[O)BFU;U MC\7]5;DOLG1U:+3=7!F3B7.U3=>[BYOKP^_>%S?7<6.U6>^R]X56/FZW:?'E
MYVR3/[V[T"^^_N+#^OZA:GYQ=7.]3^^SCUGU^_Y]4?]T=:*LUMML5Z[SG59D M=\N?M) 3)QJT^"@^-RI??*\UL+*53GO_1 +!8O;N8-#W*-MFR:A!I _>5S M=IMM-@VI[L>?1^C%Z9A-PY???
Z5[AQ=?OYA/:9G=YIM_KU?5P[N+V86VRN[2 MQTWU(7*LN,+LAO>,M^4AW^UIZ-V\YIN#&P[MZ_&[WC7& M_5@5]5_7=;QJYO=^KA:5]E*N\UWJ]J0S]^5^6:J2IM??ZSJ+[53JU++[[3;
MAW1WGY7:>E?_(5_^\9!O5EE1_D,3?SZNJR.:I?;[1U?[]IOOM&\:S6\/^6.9 M[E;E]555=[8YY-7RV+&?GSMF#'3L?9%]7M>M-U^T#]D^+YJ^_"?)MI^RKDJ U M#[?;_-
B%TV^}8]R^X1@_K>KWI3ZW!!OM?;I>7=8OYS;=KZOZ9\41W3<<\;?Z MS%L^%E^>7]?W7U^EXFCB#4?[D%7U>;W^C4B+W7IW7ZH.Y+WEC?SU=J']5%7% M^M-
CE7[:9%J5UV]I48\IU2'\P])T (U[;4#:]'&G#=F0C5T_+"(U,!1GWS, MO.+S/MR$>3/H*RW0,9]Z5N7W9Y=0VG:Y*$"K3-J>& M1//Z.EV7.N;W-5-;-R9=5:!\[YH;Q[_+?;K,WEW4=X!E5GS.+F[^_C?=F?
R3 M\@$2%B)A$1(6(V$)"-9Q@GER@JETPB_U'&"Q6^;;3/MVDY?E=Y0%E(B1K_86 M"7.1,(&$>4B8CX0%9N^L()T1%JPB9!517W&IFX8^[O37\]TR//A'JB>O2V?[QS+PUWNNO' M\C"?
T^[RHO[CKGS<5/7]H-:\I^ME1L[:E$<;:PXDS$7"!!+F(6$^$A;8K#GZ M"LN0O,%("(E81LXI$V9&-.9R3-1RE-7ZM'K+B<%4HLH=F+?)S5KNBN4>B!KZ2 M-7;@(VNB:0,
\0\Y&PP&$'/JL(647$*N*^XE*?2G/%A!%U!O_T-/BG[(2@ MF0A00UW9&O(T=_DB8BX0)),Q#PGPD+)CUQI.T?+;H*RQS:MC263CL
MRR[UR7PFT2)"9CK.W))P,:%S)%;2U]ASPQFPPOQDA;EZ2OR0UF^;5F3[QZ*^ M_V]FQFFI[=.B:N8(]3V1=E TR^I'@?;^R_^+=$N917FLL69!PEPD3"!A'A+F
M(V'!G+U6L(JPK[@T+4NZ$$0L)V85"7>DCCWT21N)3F"IP1&E.+W<$A(R-R!T M5'! RX:@9HR] M(${!I+I0FH#0/2O.AM !*6T!I(90606DQE)8<:9T3O^'H]M#UK@W)=75*/FX= M3 T;;7
DS872!)3F06D^E!9 :0LH+832(B@MAM*2(ZU[9V>: _9NDW^=C_Z' M5OK434>;&9KY0VD"2O.@-!]*"Z"T!9060FD1E!9#:R52C1ML;6LL I0DHS8/2?"@MT/M% O*")B&Q,.9S*25&D)'
M+FE2.G,ZG\WD-4U*:,B+"0FAJHUA#*2Y>EOIH*M+'<:L\:M1HYT!+62 T@24 MYD%/I06Z/T2@9XSB"H":JV?T-'.('3D:C\E["WW$R+%>K_>UCGHZD*'URW< M0 LE^5!:H/-
E#KPDY"41(;DT[*DINX E)2RIZX&VW$%7USN< M4PBJ1HZV!+02 DH34)H'I?E06J#SY1*$Q-!M778%7Q/!2V)>DG#=Z1JB+8C0 MU141Z,)0]>%&FP5:-P&E"2C-
@])*"W0^P4(;/T)898UA.Q$MB7I(PO>GNNFPK* QU!<6X1$D-&VL$*,V%T@24YD%I M/I06&/VZ$MD(O"3D)1$OB0G)I>Y(NQ@23M6U0ELT8?!%$T/IB[KIZ($/K96 MT@24YD%I/I06&/V4OC?
P64G(2R)"0DVY>5+"DKI#OZTX,%Z]^SY\W*F3"C5J MM!6@5050FH#2/"C-A](*HY]GR^NQA,0RY_9*ON!B,:I]5A*9SIS6Y_+MB$ MACQQ20B5/9L-.J.-Y W ;GPU8[0EH-D\E*:@-]*\Z&TP.BGPKVK
RL)>4E$ M2&K#F(Z\'X=')3RJZX(VR3;42?8Y2(]JY&A30!-M*$U :1Z4YD-I@=/@WNF MZ$MTR^KY@@5%O"3F)0G7G:XAV@#;4 ?8Z"59]>%&FP4: M$0.2A.U/]\FH;5IMGK7?G[R6F,1F?
FF_/R69&HXCZ5Q*1YUW!*4SY_/I5#J1 M>930DC?\$R)'G\F="]1OV=A-1%!:'*5%4%H,I27LA]4=\6TH;0)V\JL98_Z M4)H+I0DHS8/2?"@M,/ETFI>$O"0B))>ZXQA2U47,HQ(>U75!FT^;ZGSZG/Q!
MC1QM"FA.#:4)*,V#TGPH+3#[*6_/%'V)H$:^. MI='Y@_IPH\V":?:(\]I'RV&?*8Q\JCWVJ)]@$Y+>!CL>$_&2F)4G"=:=KCS;/-I%YMAHVV@K0/!M*$U":!Z7Y4%I@\GDV+PEY
M2<1+8D*BSRS9*6I1UPAMIFV>GVFKFXX>]M!,&TH34)H'I?E06F#RF38O"7E) M1$CH]2@^T^91W<'?9MKF6<^HMT@S0#-M*,V%T@24YD%I/I06F$1@+9N!D$R= M27]Z_$M)
MR("NKZ,#.D)'!W2$L!_0)45D0(=,@Q=06@BE15!:#*4E9C^25@1T5AM)6^I(M^E4!G9HQ]AH I;E0FH#2/"C-A](*&T!I8506@2EQ5!:8A&5%$Y]0A^XQ;/: MX-U2!^_C)OIJV&B#0Q-X*$U :1Z4YD-
I 92V@-)"*"V"TF(H+;&(FH)!=[<% M!9:ZH$"U>]%N.MK+T,(!*$U :1Z4YD-I 92V@-)"*"V"TF(H+;&(K?RJBW>E]AB0ZS%JU&A[0TL=H#0!I7E0F@^E!191.B"MQU 2>V+)_\U62.C(
M]1A*9SGSFBFMQY! 7=YV1]@:9PQ43%MM_8.EKG\8LU*I1HUV!K2F 4H34)H' MI?E06F#U:P3DE4I*0JU4$CK:&82.7*DDA/V52JIWPRN55EOG8*GK'%ZW;@,M M98#27"A-
0&D>E.9#:8'%ES+PDI"71(3D4I_/Y4<7Q3PJX5%=%[3E#):ZG.&< MPFHU$O.2A.M.UQ!M68.E M+FM %U:K#S?:+-!2"""A-0&D>E.9#:8'%ET(0$GW>FVKPQ1"\).8E"=.;KE7: M(@CKS,?
2O[&T6GW8T9:!%DQ :0)*\Z T'TH++/[Q](3$FO5NN_CGT_.2F)<3(4 FZF1]* MA](&E.9!:3Z4YD-MC\OGY>$O*2B)!E.9!#:8'-!^&$9"XG?CPFXB4Q+TG4G>D:I@W M7#4 _O;'7:@;,-H:T#@<2A-
0F@>E^5!:8/-Q."'1[=Z=%Y^&\Y*8ER1,;[KF M:,-P6QVE&CXLKU+#11H!&W5":@-(*,V'T@*;C[IY2$O*2B)#0*U)\9LVCNH._ MC:WM\Q]4OW_\M%DOZ[_<944]\2;] E^5!:8!-/>)?]0>RX
MMVQ=+BLG9#V/\%DV+TD&^C-PE^2T6;;SZH?2LYN/U*BQ5H#27"A-0&D>E.9# M:<&1]O(Q(/+F(TI";3XB=&2<1^G(S4'F^RN[K=Y(=I;:UB??]P^J'*]^\N] OM4UY5^?;P[4.6KK*B$=1_
MO\OSZNL/5S7_*2_^.!SCYG]02P,$% @ 38)M65)YH"7" JB8 !@ M !X;"]W;W)KQF^MKB(0D-A3! RD[[]?O J0(B?@CN_6;F**6R&\7V'T6 M$*\>A?
S1[#AOT<]]6377DUW;UA]FLR;;\3UKWHN:5_#-1L@]:^&CW,Z:6G*6 MZX?VY0Q'43K;LZ*:K*[TO5NYNA*'MBPJ?BM1<]COF7SZQ$OQ>#V))\<;=\5V MUZH;L]55S;;\GK??ZUL)GV;#*'FQYU53B
I)OKF>?(P_W-"%>D!;_%'PQ^;D M&BE7UD+\4!]^RZ\GD5+$2YZU:@@&?Q[X#2]+-1+H^+,?=##+\G^K!T^OCZ%^U M\^#D,FC7\1I3_*O)V=SU93%#.-^Q0MG?B\5?>.Y2H\3)1-OI?]-C;1A.4'9I6
M[/N'0<&^J+J_[&-]*^; IYK5]\K=LB+EN?H1E0Y3$]WU8BRR)FZ?=_" M'YBWMD%B@VY8LT-?8>X;-$??[S^C-[^\1;^@HD+_W(E#PZ]\N9JUH$N-/LMZ M#9\Z#=BC88F^B:K=-><@+*,C/GY^!/X-
3^.C4)QP<\)[7[Q&)WB$<8>K0<_/\ MQTE #AEB3/1XQ#.>#MI&!VTCQ1Y!#DK6%M6V6\1%6_#F@RMLW;#4/:Q*\ ]- MS3)^/8$,;KA\X)/57_\2I]'?7#Z_TF!G$:!#!&AH]-4_H!Z5HGKNC>[)5#^I
MBL[#:IHNYW-\-7LXE>)PVFRS,V')("P)3LW` -^08]WR;@74I4Q465%R M5/6*U5UUG:DY/*CL@+7^[E,7G,"7VFPLSBE0YS2X 3>MR+[,57U,D>9V -$ M&J+,/^IKKG+^6[$Y&3&XFBQ6(SFU;:B=
('=LSH?U,Z#:G^K'F!&A7Q"8@V5 MC#<9KS*.LAV36Z?4N24BP92.E-I&D5OF8I"Y"&>%J*9Z7155RV'.VE T%W8T MZ6(YDF@;>20N!XG+H,3/'!935G1S#=4=L;V0;?&?BY._M*=U3N.17-L(QTNW
MX#@R0(N"DK^R0J('5AXX8D-V0V:7&F>0SH],2@:WE#LW?]RALF#KHBS:)R>Y MDOCE*9I-/+$:18G/F=.Z!S_?\X4L-3[N:4']NZTO'"=AG1)/9HQT8[#FK_ MNRJ?L$]:P[KD4#ETP/.BJ47#2M5,U%
(5TO9)?\' /!2U\L/!@XL[-X)V\1+ MA]B0.PYB<:5:(6@(5:G?<-ZG FA6: % #]\HU51:=@HFEABS'V>HPBLG"(]F@ M-@ZS5H?]S18Z^+=4;*8'53?]T;0)2]RFP&&$*7$KQ@:S.
(S9W_5$EZ+:3]%YV0=$8IN-X^+M M,)DN?1(-/'$8GD-"U>Q)Y5#7P&29/"'S:IV*'4",HV1IR;,M$AIY%@,VX,1A M<'XN&BUM0:1.(S(\=(]]=E.K3;TIN1$
M1:_59853CU;#1AQF8[]H+RAT\"V.R+AY=9C-8Y]"@T$*5_<:SI5)[;] MA$!&\MVV,5S,O>45VSPA=,7G7)TG>DS-LDXB,670ORU1CN/@H$BO@#%@X3V M2M'P10TN#FTN>_<^(
M,+%!B.E\.0ZPPXP2NO1I-<0D86):U<>5Q${=+F*FJ45,EQV>+^<>"A'#3()? M5'TV1<6][#EGK$$6O_B0]95&.X_"R4%SF,6W4F29*D50X<5#M:9TAL^":+I3V7CCWN8A%YDIP82),PI&_9DS[E
*'MKI#Y MM&;JABH/C$N9:#P9Y* WCI9C>CO,/"T;,>PF87;?P7YHD*[D.O4Y^$OQ/+*B MZ^(T7OBZ2V(X3<+;S-$:J9J#U!$]R1AU/K;E_B+E/-D=[^%<5COZ@#6')I MUWDJ_\N^+L43YT@?
4*,C']!MR2JG=!NBZJ%?NV'WZSB6) 2VY -IN;?2- M00&AKM4Q6/6_38&+L%:+ZK)*4D_+0 R%R04*'SW1OYC4QY@W.R;5*8#:,\D^ M?6%BU%UT9\Q@ K>2[9U>7<:TPV1**/5TK]10FH8I[:^/OM
M,//D,#6G>L[O6!][: M-=7RZPO5]S^PTI?)U+'3Q?'X#,]E12+?1)S\+'OY=UE8/%(OECZA/N M%SGA.#>.
([[!809;F'CIRUY#7AHF[XU[#NTYMNBJM2R4JG"92%RIPE)A54H.S8AL,2ZMXQ*D3E[+MI$/,O[;M?:[3S&!BVTS#;]?3IPW!P>O@Y MU^EV-]#I>PPD3A%;5^MV@MVE;L]>6. M,]A<* /X?B-
@2]Y_4/ _\'K:ZK]02P,$% @ 38)M67'_^HE6!P +A$ M ! @ !X;"]W;W)K6YJ7R@M;RRYNBR%?;R2A=E>]))>NW"K-KGG MA>'E>24V(GES-67]H/";DENW]YTXDI4Q MW_CA8W;1&[%#LI"I9PL"'_?
R6A8%&X(;OSJV1O'' >VO]0X@=L:R$D]>F M^)O*?'[1.^U1)M>B+ORMV?XLFWAF;"\UA0O_:=OEG]4ULZ;LMD,#TJEXZ=X M:/+P9S:,FPWCX'<*'CY3GAQ>6[-
EBQKPQI_":&&W7!.2[*TEM(%?;YR\ & M2UK0:WHG76I5%5)EUG15.V@ZUZQ&SJC)9JH]5:I4][NK-" M.Q$R['$5O1@_X<49?3+:YX[>ZTQFA_N'B*@+:]R&=35^UN!2
M5@.:C/HT'HVGS]B;=&F:!'N39]+DR!OZH+30J1(%+9$)"7CZH_%&<]/CYKC3 MWKA*I/*B5W%6[;WL7?[X0S(?O7W&V6GG[/0YZY=M[0YJR@4[7LI_W,D'3U>%
M2;]\U@HSQ^V&/R/T.D BQWZ8C="JW']U_XN[ZV@NUQ:4\(Q@E)3EM)R<5X[#'T;A!9;3VJ"39$:#=@-:DF5L7YM"I&0C%.DF5L7YM"5X5V5- M5]?>A3";!T* MW'[];8%MR)"B94JE%?8
MK710T3Q?"ABN&4W0634MA-ZJ+3L2M!@5NZI/NJK']&#;B_G9X)3*HTHOIA#. M,4+VR\AX24[>PMG@TB-7C,-3NH8?%8KF^?0]L., %-1<(C:&P9P<"
MWL_IN9=L+R!$5&B)>YGMV@1(-2N/Z\WS8*MFQIY-H!%W"B*K@Q;4Q?9=Z?T M6A,38UMUKH(>%R6N/R@8O'&HRCV&'XY^J*^Q;ECI$UX3('/56Z'8)2Q(#O M/M("BL9:QCIP!O@"ME? &-
(#U]I;OKS&;(.^W2=D5RU2@?9Z&N(7R%16Y*3"= _H4K M7 "QWTP(QD##Y;/#'2 @NNP#!,TI+KB+($YPI46O+\V%1;V"K90 0Q&=@ M-I!" _/6;P[&R: M4" (61@Z@_],NP
124HFK;6FVD&V*.YI:WMGZ5!"O?V-DU$K/CMFM_F>C%OA MB_ET,&MO!VC<.#P#;11",_4<9Z!)5*FI/Y*$X":"@76;H <1APN9*UNG!>\ MNN^#X0_@][WV*$9 5/3M[A,M6A#%W)YK:M]ZG5I;-
/7)7)/;Q TILELI_G$_MP)W27>#2;NIC+7G"BV@\B4XDK>GD "$G\WERX$Q2/WS\SK4D_HM*R9YK"2US M9H5;B58"+:$$-\SBHF2/WH$K]F^-V-DM3;JKUW=+?;[RHJ!)?W8RZ\ /QN3X M$-
<.A8,V"K.*Y_6#PGLSCYX723(8\6C&)5D/CKWC#/?>84MF%GY39[NU]O%U MMEOM?@Q8Q'?@G7K\)0'WQHT"51=RC:VCP&ULO5I;;]M&%G[OKQBH13<%9%F6 MG4MS,6
[26N@\1]VDSXL]F%$CJ1!2 X[0TI6?_U^YYP9BE)D)\5B%_"%(F?. MG.MW+M3KE?.?P*81MV7117>#!9-4[\\/ S9PI0ZC%QM*CR9.5_J!A_] ,##4 MWNB<-Y7%X60\?G98:EL-
3E_SO6M_^MJU36$K<^U5:,M2^_6Y*=SJS>!MD&[< MV/FBH1N'IZ]K/3>WIOE87WM\.NRHY+8T5;"N4M[,W@S.CEZ>G]!Z7O#)FE7H M72N29.K<9_IPF;\9C(DA4YBL(0H:_Y;FPA0%$0(;?
T::@^Y(VMB_3M3?L^R0 M9:J#N7#%[S9O%F\&+P8J-S/=%LV-6_UJHCQ/B5[FBL!_U4K6/IT,5-:&QI5Q M,S@H;27_]7W40V_#B_$#&R9QPX3YEH.8R>ZT:>OO5LI3ZM!C2Y85-X-YFQ%
M1KEM//)Y:[&M.KUQCU+DZ4++=B%>5FZM;.*SNSF:X:=99EKJT:6\W5M2ML9DUX M?=C@8-I^F,5#SN60R.0.' *P^N*I9!/6NRDV^O?\0#'=<3Q+7YY-'"=Z:>]2.
MQT,U&4].'J%WW&GAF.D=/Z*%H!JGWMM*5YG5A;IM=&/@?>87IGX_^ABNHC\0LG>AL8@0W+A;& 69;^TU1QT>SCJ=ADZGRE8JVR/U3X 1-%/-'9$!IM@P MW!+5+'71LH@6%!\4>
B!L@*B@(H64M;5X:KZ>V(#-A=0&V#V@O1[6O^L9F@3;-3*" M9F$AMT?4%53A%1N=%%&53&_M\I4AR!^>O)/5*7 M/1/TI:9:H<%OZ!E)9.U7I0J<>QQ5 '2@!]V-J67VA8DQ@$X/ BZ,/U-Q+6(
MTX^D!?9Q!6"^] #6&L @AQI[V ;@KW+M\P B.6,?KWLR.+N]@/5?3)X,>VGB ML@]-;T5&/!HH&)@4W@(_>]R)[7 ^(DP%4IC@VI;"A>FNR>.N(;QT/5:E^ M&(^.D/1Q""("BDI.;T,*Z[]$-4;["E=M(&
+89!D.Y:6P.X*@WP(5=SNZ0% M)D*D2RCI&_M7!= [!*Y9<([;]*#+3\"Q*5>-:H3_!)LLR&TW=0)DLN'<%R M0IF:RD^A-B87S;[.^VS:9VC?&MK^=/D.VF9).1DPJ/506GC?ZWDIN$%BI'Y?
MF&K+)=Q4?&_?Z9:060)+&!E2/-$I]*-TD\#.U$DKE%JR\L;,W.M#4]S&!^ MSZ&++=1DP%N>]PJ,NH!-%@?[4P?"21BO);&Q_\"V3:F0INN+4N26.E23Z@X:B%
MC:D(:FJW(B(.!O5=JB1OV56>!&+IH)@>UP4.Q=EQ(Y;]_X'PJC29@I@Q8U"_MPJL>JUCFIH6=BZ/A>#T-SD^145BW3N1B]_V2P#)#'BPBX5Y,ICW6)-?6R,/0 MFBX*DG]+P='%V1'N7#3D7CT24+
B_S_*V<[WY-86, 2C%T7$]2SZ=69]UI:H M0!'K)^/W5>L=^:$;BTA2?&)<3]'DO$XB,J6S)7J(F/#7[?Q0@+@1%:CJ9\ MEY9._9^MT1$_ [W'](D+GJ.6Y$ $8%3X_["E]_+:\$+Y1R&)HWPI1-U$:,,D
MU9)T=Y=;U!^9#9Q0I9:L;_()&$6ORH0I7&!CW0F>"!0<^Z0\A7WC)KSH>?_M.) E!CL9R!9Z:;[1W_3?<=]'(VSCN__C8'O,NZDT:WKV3]C;2_L;->&$+T Z_MI#)>U+(@]-
PX:=U6$BJ^=S;Z!#Q"C7()%[LRW[0RAS MQGK^M@$_W4VLT6\V-?I6H=0E^=*"5\Y2A4*OXG_&^R:!?[>,3HOC4:FH9^-G M0Y4.8&M>H*SUC"N\
[8*'"V06+/WQ^O>3R=$KJ4^..)O[/U5/UF,YJ_0&MG M4(K9E'*DSLZC(KM$X^CYJX!4G';IS:YF75-!2U@@.,+U4*G7I#**S$1-;TJQ MF4MFVA#:]JT20L"Z2U.X^FN=872-
KJCE[(N.86)C"$,7:VD\0.- %\1D,$5! M]Y!D,^EGC"9F-2!U*)[C4_>9*X A-5JSD M+Z]O M+E_>HMG]KY85#0[JG#Q\4ECTBXO <@8%N($XPZNBJI@ZR4DR\Y+SEL
MWJ(.=RA]=4TF@9(["4HK.W8IB?(WXX4CD"0GJU0(Z[I&C<'W -BGB(FU:]>8_U&]8+^5?B&I+ MZFD6]"5414E_GZ886I$U?IB.QJI4%EF4+ #V?G@ZFI 7%HQ$U"_)D(7R<<^J M+.
!R2<(VE8$]:&&C7*-U53H06WO%K)ZA5Y?RISOOKG48Z/1^J]\P:;E$Q: M&554>\E1+:D(&[+5G;F//YHDAO2 MPC5PMXO&T!NI)M>.4[4.K#M.I%3A3#']:FD>DT?,?XC_C?I6_%J01*+@F>_H
ML\^FN+$ 3I2'LD"2EW[N180ZU"%$NNL"*$KB2(S>NT2W".T4*=EJGWR@ [X= MW0F&T9C=FP4E@V72S2&UD%V#U"\)\E7S;Z= GN>CRJ!V./8+_,ZA042\-=-& M7:)J9W>YX%S'JVRZU^4_R?
SR#]F*[W=9"_'-S4X6VY::,BT^4&Q TT[MW]YV72[(9%A*REK&%KRP,[,ADC!A/R?]N.I&M-WT4;:TR(+R4F)[:-ZY&@^Z MTP]:_5J95[(6#WHC!>S(_'=(T=E[Z(K]C^L4+J&I4#
M@YMNP3[03/QVWEKI46&EV>WYUP%WCG4Y,KD!:#K+>(;NFCCJ,JW'DYQ1Q$1 MXH3>@[\>DH9S-LETY:3?S7YG';BX4!(\A]>^[ZO(QGWL 5?2%MTBZTL?) M(4DYF=Z\)MNHF'UG,X.>
[KH210,J$E&;SG,NCJBLT38_(!^5/#G\9L3< -$# M$9- +G56Z'>X#HEQ,MHC?^XX]UV9U=9[7!20N,YBF%QO\2#-\4V7%)Z(U28O MQE267\'O.?I($'7'E1GREQL^'7]E;4J68I@$N+F+/2?
O@$QF0LJ7Y35>PD#WE MK-U:)S3B8^B^H[> Z;#G)^/O+]OONM6[C\X\?&C;GA/VO:\['W= FWAG+]4 MPF]^]T:^>=']=[:ZW MF+H&/2A?4E5H/"W \YES3?I !W3?YCG]#U!+ P04 " !-@FU9T0V
DWD" M !?!0 &0 'AL+W=O-+ M\U:J9UTB&GBM*Z$73FE,<^EY.BNQ9GHB&Q1TLY6J9H9$57BZ4&D\TYWK]*YW)F*"[Q7H'=US=3;$BO9+IS V2L>>%$:]_#2>=,*7*/Y MV=PKDKP1>NE
[;R+'A2W*VBBZY>1GTA_2(*S@"]R*%Q1&*HYZ M[AE"MO=>-J L>Y3P Y09W$EA2@W?1((Y__X>,1IIA7M:R_ DX!]:"42^"Z$? MQB?
PHC'J,.+3H2IP4BXX8*)C+,*UH89I/8R1^/MX>+C<'92+G7#,EPX- H: MU0LZZ>=/P;G_]039>"0;GT)/lZ5X@VNNLTKJG4+X_8BO!I;5S)[_'"-\$O(X MX=7DL.I
.:>$;%!UB;_&;!""O@IVB>"!M=1^!A6E4,,9Q.XTGM$>NK,H@2>: M0. "&B4+>D9#Y/I)#(&;T$JIY]2H.112YIJ4 >%-73^8P:,T5!$^QGT&B7LQ M/:=]YB9Q_>2ZATT?
8VJZ$9;0R9WPO3]/VK'W^,J'YI_YOW7<\=4P86&"K?D MZD\NI@ZH?IQ[P&UL?5=M;]LX#/XK1*XWI(",.$Z3)7T)T)<5MZ&]%6MWP^%P'Q1;283)EB?) M37N__A[*3NIV6;^DED12Y,.'I'JR-O:
[6TGIZ3'7A3OMK+POC_I]EZYD+ES/ ME++ R<+87'@L[-+02BM%%I1RW4_B>-S/A2HZLY,P=VMG)Z;R6A7RUI*K\ES8 MIW.IS?]T_?AL-KZHYIOK60JEX53IB K%Z>=L\'1
M^2'+!X&_E%R[UC=Q)'COO/B8W;;B=DAJ67JV8+ GP=Y(;5F0W#C1V.SL[V2 M%=O?&^M7(7;$,A=.7ACJ365^==]9="B3"U%I_\6L_Y!-/".VEQKMPB^M:!8 EA MW*&TXE1!S_^-%
[2)1W0I9Q[^CS7:BD8+G?2]S#/0OVT,75>FTI^ M86I*-Z;P*T@F-^9[RUNS]EG;Y- ML3SPTN:@-HY2["GG949F07XE:6$TZE@52^]J CNFSVV;%0.Q\+ M!]EHFLQ:^57 Z4;:);+O!IGK_8AP>%8M4=
;1@\CNA$V75$#4$1./9)?@XQ/ MM% 6DD["=/9*;OSA F6O7S]E&]57ENJC4;WLT378P F\0 *^2[HDR@]]&!B M:[4O@& MP;/*(4CA$)36] T+8-'Z0TS:"+11_,0+) @A\\+DY>B>*(UU>S)
M46)S8YGPXP55KIA!V)W$!]X=W9%X3[."=AC]FDB@?I/%5E)G=6 M?D/3=G0E[-+TZ!XW8GX@YVCI(=-\F80%> L;&]O;BV&!UG$P'VS.77E-U6'T MI[+H9KA.X8N!?(4A=,S&2-#A>-
VY1)@_39TLK0 M7J*P>RU9VC&Y'U3&,"/%A0*\KF%7@'@A4J456 #$VOB&@@/R2UA=)&:!XE1A%J8/[53 MO4D:,_=X!B?,,0#IHAHQ"V@42-^F!W!JB$6IM.P# -X,.BM+-$RWH=2&B5Q>
MD!O'3<>I>3&(1RBQ31>ZZI(/(!21RM%-GOF!-AY&)U7;(FC10H1^]E-BNI& M\S9 >S%N+!ZW%Y/M NG$ MNW8!&@*0:#J8TKWQB',;^2;>YK>)E5K%H7!LAE T(ZI_^JR)YY MWTVB>#*"[
DSXWE&-H-HUYNBWWKXY3QQ+D*G#-?7;\#M[O8%?58_')_%Z^?W M36BIZ-9R =6X]W[4(5L_:>N%-V5X1LZ:IZW#YPK_!4C+ CA?&+C=+/B"[?\5 ML_\!4$L#!!0 ($V";5F2>WF);PD "88 9
>&PO=V]R:W-H965T M>>\$]O+7NVB^4"N*N M*HT_ZBU"]-_O[/A\H2KLJULK@Y69=94,^.GF,]YV2A9\["IW1H/!_DXEM>D= M'_*
[B3L^M$THM5$3)WQ35=+=GZC2WA[UAKWVQ:6>+P*]V#D^K.5<7:GPK9XX M_-KII!2Z4L9K:X13LZ/>>/C^9(_V\X;?M;KU*\^")E:>TT_/A9'O0$9I$J5
M!Y(@\>=&G;]R)$PXWN2V>M4TL'5YU;Z.?L.7Z;2[U=;_D,787'4>]L3A9K) MI@R7]O8WE?QY0_)R6WK^5]S&O7OO>B)O?+!5.@P+*FWB7WF7XK!RX.W@D0.

[S$\\H;CI6S][(,]Z*6]YP$H62^(+$!K(OH>CTW M>@9_8&!CAC5W'CX*BRBXX55L7"&&U%U (O5.+N)"84E^K4B^L+5A. M)1'2@*21.EJO02 F$&^X5)WTUR%?F4! X#UA 9 *SUB!1*)O/[/+@,XKP:9 M>"=>O(X$9IOZH\O1I&"=G61^IRN74%&$[%E+-9RE6^]2,% ME\IH>/#!BZ]8!"5R[I:UR&?'WQM$5O^YO+9[W4+O=:J "^F0SA$;-QSUO=\G MP\'! 5?!XZ4LM&=%P#!9YG.,&F3F^.I4[V^X2=K4MD1+!C67N-ISR]XZNT-:B6/&>8Y*$=@U M=[*BM0ZQ.O*0[UYP@^'8@W8H]-+IRN:EK3"(S%I48]@+;>5]GIR"8HI4>TY5 MP*ECAE&M 3(:D!/0/ UOQ*.-@E0GDY#O<\<0W4YT?^Z4 7[,^.SMUNF_!%^9' M9!(&VA|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|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lS>V MT]+E2J7]4.Z76[7D0J+S$AJF>:)'3R4+(MAFE:RF6@6HFLL$I-'<1AF 4-J[@W&=F]F9R.Q$K7% <>9!+5J&B8W4ZS%>NQ% MWG;CL5J6VFP$DU'+ECA' :.=25H%2L"K2G"0N!A[E']Y-#7R5N#/"M=] M.P[&DV:.(##ZO.(5UK4!AK _IC>$J11W)]OT6^LJ^3+ M,U-X)>]_JD*78V_H08$+MJKUHUC?8N=/W^#EHE9VA+633?L>Y"NE1=,I$X.F MXN[+WKHX["D,PT\4XDXAMKR=(@0OV?F<6+SDB,*M("BC.> M5ZPF[YE&IC6M#OGKX-+# <.,:G*N6Y3CVZ%XHE*_H34Z^1%EX<81LNB.,'D.? MS$LF\71J\S)C&\,1+J5D?&GYPM|/^*9A6E/V_CG$_2CZ8>ZWO:X;IO^K!G@J MT6XPO@%SYS7]%#!0>^63[RNT->/PFR:UDR_#. XO[GA.O.DJ.B,P(P%[%%W\ M#KID&I;B%26A6DQ@:R8+1<8*-#G#IJW%!BF!C!=05)*NMY *6ED):02,]1JM M:;$ 8_AN]KT=QP>"+=Y1DEU%*4^7))*;>9]W^YL"=KY^V'/'7Y;<30%&'7" M/TF9W=0 "T, #$/0M/>-\14]L MXM**@W?*1%&RY&AT6W?DT#B]N+>0=MO?^#W!WU05.K64N>5,VU&\,QHAQM\ MEMOCM#NV VG>LW MK#W9@#7NI4/STGWP[<'$\LAYEW"OIL]TA5D,B]=:>,K]@[MB$,:$S^)8_K&OE&;4U.C//NP1(Z2GC.CS@IJ%Y72DEEO4C\[RR#+!D#!SC+" M"_M#>]*:Q#^]O-LX?87,CY*!I9$,[3? TA\.A91(.HU\HMs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§@9IDN87\+++ MVRS@9W1>\M> TO!&*JU)P'2O'5*6.7O.WPXN/P_G"^,:*-KS§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l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`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{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lF^$/GS>K5Z'0DRD:>O;1F+2R-QFKT@8_*LR&R M:L1YEIFV:G2U%->FT)E63CR*GWYZ>=A@/YIUF(6U7_NU9_>L_4$5G4RF>D"S>K=.*!^6FEDOK$]:1ZZ$ZF*,O0N#6G$W\ (3W:RNAY_K76$P M<.$V8^0Y)P@[V$=91"7+@%BOWFJOC/7VQ+9M[0E;_D#OTY!O>9C3N&WCJU"_M/;3X_KS)-C1@ER/]!., 1U)W9$.[OC(I!Z^%*X)O]MJGM8U3\&< M?SX_S/]#CSP1*OJ!/HS10K?D8DO3E*,O=RQ9,ME:#XP=^/F?U:7/CC%DSXY0 M^;RN? [NYY;*U5 MIF,]6[&VPG#DIT) >D@EU13 M#RHFYYT:?E26.GHH\T M:2UJ26T=74!=US$SMG-0X4>NXM;&EMP%2[F0Z#,/&+K7HT&[4"3?ZF]MJE^B M:8BNA=P{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lF^$/GS>K5Z'0DRD:>O;1F+2R-QFKT@8_*LR&R M:L1YEIFV:G2U%->FT)E63CR*GWYZ>=A@/YIUF(6U7_NU9_>L_4$5G4RF>D"S>K=.*!^6FEDOK$]:1ZZ$ZF*,O0N#6G$W\ (3W:RNAY_K76$P M<.$V8^0Y)P@[V$=91"7+@%BOWFJOC/7VQ+9M[0E;_D#OTY!O>9C3N&WCJU"_M/;3X_KS)-C1@ER/]!., 1U)W9$.[OC(I!Z^%*X)O]MJGM8U3\&< M?SX_S/]#CSP1*OJ!/HS10K?D8DO3E*,O=RQ9,ME:#XP=^/F?U:7/CC%DSXY0 M^;RN? [NYY;*U5 MIF,]6[&VPG#DIT) >D@EU13 M#RHFYYT:?E26.GHH\T M:2UJ26T=74!=US$SMG-0X4>NXM;&EMP%2[F0Z#,/&+K7HT&[4"3?ZF]MJE^B M:8BNA=P{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

EWGA6M3H%;HS[#E MZAIJX$0H6^@9F<^CP;+5OHD$=WI[?O.:R[1;@Z)9G)PBS5T"-6&T-O3"?TW0 MGTO^@+LG]+[2Z=%C8CM6W_':?N=?5+ZDF?ARY)?D_WCLVU1'OI_,K@9:G5%N M!D'SC1;_251,)OOW'7H5LY/WEUSS79\GC 'A]FJ3>J?76.UTHL/ Y MB\70 R'M/WCU:5 L#"BR[X']IXC#(^\[\U.IU0WOP/,../RM/F=F? G,7TZ M_LK*SDW3F)(_4B&D+ W]PMCFO@' M;="]/7KV:U!+ P04 " !-@FU9TDKAS'L" !;!0 &0 'AL+W=OXW-L7T^W2C^9#:*%EUI(,PLVUC:G M463*#=:,'*D&):VLE*Z9I5"O(}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

2L$$N\0 -7<:/H:]A(F2<9YCJ1.2A7[CJF_E^1VN;JC\:W.QX@[:N3DY3G4A M8CSO$?HUJ@?L35^_**1(W/S<2!![IE!,MP
**ML57RTD3,DC0Q"6WBZU=CS_7>'.SOI1$I+/;L846DAI20BL\%*K(K7^X0N!/Z M^^^#[#OB! W MK%I\EAF"/W0@2/HTSJUKC>VG3NBKK)^(Q&*(IL.Z8V" -J0Z+M0%[8("_L M1-X=E?EY2<;3YM0UX$KH%5Q3N:9=J,H^;|I/|P;)363LL?X2Z#*<"L885(YD!F M@&\!YB6;W(62AL)(2 ,'&;1+X"E&S@=YGG8!YJN,7;;DE=R9NA4K@*#
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|\?II ,_" (WOC,;P]97IR>DTF*@I.#H%<9O3/Z5:ELPX6@ MHM)<1_O!R$,8C\EJ2[Q+8.4V##P!X.0SG&) MV@'3 Q=LH32KBMBRE!F7*PC]F.C<4(9HG>8"J3*!V#HOI L*(S^,_&C&N(8' M)LI*7M=4Z3^<Z0#ZD9]$0|@CY;B5K_D^6=':7A!FCIYF2E"WI-6V2&3;))$U1ZB(X6S,B!9$$ MZW3X5.E0O]4XVD"F)3%WJ?1[Y'($6\C_N*<>0??\ 65\5YH[6[TP=SW-=7P# MU>.KVV*[VGY43.M>^F9>?Y%<,;WBE&B!2W(-COLD1%UW^7IB55%UUH6RU*>K MX9H^C% [ ]I? *FHYS<0=T'YJ3?X&4$L#!!0 ($V";5D??.0YWPP ""\ M 9 >&PO=V]R:W-H965T:>V MDBI/+) EVUG'58Z%)+X$ C)[L;471&[+5"3A 11GMO;'+^C3V*B#9MZ=BXE, M.$^#.NZC[O;!U\])~BU[%")7?LQGB^S3R6.>/WT\.LFCV(>91^2)[$H_N8A M2>=17GR93L^RIU1$]ZN@^>,Q.:[6Z9 ,H7IS<7^.>>G-=;+,9 %">*F2+>?S M*/WCLY@ESY].U)/M 3^>/N;E@;.;ZZ=H*@^1?WGRTN*KLYUR_%(HN3A9** MAT\GM^K'L+T*6)WQ6RR>LQ>OE?)6OB;)M_(+X_[32:N\(C$3D[PDHN*/[^). MS&:E5%S'[QOT9-=F&?
CR]5;OKVZ^N)FO42;NDMD_X_O\\=/)Y8ER+QZBY2SW MD^>AV-Q0I_0FR2Q;_5]YWIS;.E$FRRQ/YIO@X@KF\6+]9_1C\T:\"%#/#P1H MFP"M:4![$]!N&G"^"3A_'= Y$-#9!'2:MM#=!'2;!EQL BZ:!EQN BZ;!EQM M JZ:!JBM;<^UFKY/ZJZS&_>VNNUNM7%_]IL.5QOWN+KMU;>]KJ!X_6W_#KT:+7I1'-|=I M\JRDY?F%5[Y8#3FK^&*0B!?EZ!CD:?
&W<1&7WXR27"BWRJ!*3V23-'Y:#5G) M@_)YF15G9MFI\CG*XJP\Y*4B$XL\6H]JBWLEB*>+^"&>1(M<"=-HD46K$2]3 MWO5$'L6S3
G%CWP9S=X7_I>@I[S!Y;WRBW*F9(]182GQ0OFRB/.BC5_*U^%C MLLP*-[L^RXLI*Z_O;+*Y"WU]%]I!NV@K3K+('S-%7]R+^YIX2QY_)8D_*I[1
MW=NJ:=_6SYH4O%U./RBJ=JIH+>V\YGKN&H2W+@^&]^3AYG)6M*X>=?EX8%X M^]"T6P?#^S]K?2$-'\C#G2@MP@I?_+#YQ;=KPHWF%U\7;C:_^+IPZZ^]_9? MNW>GR3^;P_]H1PW>NM;YP7!7'MX77XOPSL%P3Q[>$Q/I.S^6A[N37!KN-_B& ME;SS08.+U];A:DUXV*#C6EI=>&7T:N^20GOEG1!*"L6G9">6 MN(5
_@BK[G2SU*Y_*S_,7N*)N+3R5.93M+OXN3F[W]3 MNZU_U(V2)-8C,7V-=5=8.0/Y?O-KNZUIG>NS[R]'RIK3U*NKUZ<-ZD[K=C6M
M>MJP[K16NWM1/^&_#.I0.>7WY>78A[18_21;R8%A]A;R>3 MY7PYB_+B:$\4GW+C_'W=>">%CQWO2*Q'8OKYV^_O\^Y5I]-Z->"1C0Y(;$AB M!HF9)&8U["B;;-0AL1&)N23FU;RW!:LB&5Y6W]LQV:A/8@&)A1!6&;$[NQ&[M(QVQ[Y+Y/%DH09Y,OBF^F,99+E)Q?ZH$Z[6%=_%BL\Q0.VI+\6-';1+KD9A. M8GT2&Y#8D.0,$C-)S"(QF\0<$AN1F+O&.B^&;$TKYB_E-/GED.V1C8Y)S">Q M@,1""*N,]W=^-_]<^._$_V(\NYXCX\B+3X**]X:3P1=3E VL"Q.8#$>B2F MDUB?Q 8D-B0Q@\1,$K-(S"8QA\1&W3>?M-
N=5O%?==1VR38]$AN3F$]B 8F% M$%9) 1>[%' A30'KL=_(LF6Y1+-<# ;%F)_L9@&GRD@\K_XZ8Q VM:QV8#$ M>B2F7[SY/*2VNFJG??
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
LIK9HF]C70JKP(^B=IHMRTB+/5H^S[0IR6\XM)^0SGJ2B?Z#Q(DRQ; MKUG5Y@NT)AK5>JBFHUH?U0:H-D0U]5,5+-0S48U9Z.5/P&YG^]\:+5?YPNT
M.!K5/%0;HYJ/:@&JA916S1?[&FE57B3=8+NB?+2___GNSI%O7*#UTJC60S4= MU?]H-D"U(:H9J&:BFH5J-JHYJ#9"-1?5/%0;HYJ/:@&JA916S2'[2FOU)Z76 M[,8%6H2-:KV-)EF6UM$&^Z@V04AJAFH9J*:A6HVJCFH-D(U%]4\5!NCFH]J M :]%E%;IQ5Z[6FM-7FOl?IBXD+=X;(I M1ZJZ:C61[4]J@U1S4 U$]4L5+-1 MS4&U$;JYJ.:AVAC5?%0+4"W<:
(>WMJII8E]^KVJOE"V^<+ M>:7VE\6]2],3."]G"OL=#-D6A5P\.V@Q=JHIJ-:']4&J#9$-0/53%2S4,U& M-0?51JCFHIJ':F-4\U$M0+60TJK98E^LK2]IM-A2NMZW;JX
M>+6UT$.;U5&MCVH#5!NBFH%J)II9J&:CFH-J(U1S4[2'^]G_)SL=A=;NOR$5F2C6@_5 M=%3KH]H U8:H9J":B6H6]MFHYJ#:"-5<5/-0;8QJ/]H%J!926C5_[(NW-7GQ M]G[Y*?HZ$!L%J/O1;!:A?KK@A%9J;[3*L^?;E<==]_B*+,E'DM5EAK;\L^^B>=UX_T>Q.?A%'IP3TMUZC6A_5 M!]@V1+4#U4Q4LU#-1C4'U4:HYJ*:AVIC5/-1+4"UD-(J*:&]K\QNRRNS/Z?Q
M_50H=A+)EY;DS+9+2ZC60S4=U?JH-D"U(:H9J&:BFH5J-JHYJ#9"-1?5/%0; MHYJ/:@&JA91631'[JNRVO"J['R^*:4*YH.2+B8B_E]O7^V=VV/$\KITMR-6C M,P9:<(U.JKU46V :D-4,U#-1#4+U6Q4; MG1:@UQ92VGJ,/\L>A&ULK5==C^(V%/TK5^FJFI%F)A\DH:6 -!#2KM19T65GJZ'J@R>Y$&L3 MF[4=F/;7U_F8+ ,A,%I>
('9\SK'/O;&OAULNOLH$4<%SEC(Y,A*EU@/3E%&" M&9%W?(U,OUERD1&EFV)ERK5 $I>@+#4=R_+-C%!FC(=EWUR,ASQ7*64X%R#S M+"/BWPFF?#LR;..EXR-=):KH,,?#-5GA M7C>BYTRVQ88IHADY0S$+@<&??V M(.P7X\L!GRENYB_#4XQ30LB/8UO-:?1 M2!; W>><7]K!D7&]MD9/QB0(Q+DJ?J(]_^@?5ZO((OXJDL?V%; MC[4,B*I>%:#]0PRRJ|_ES[L /0/.T IP8X^P#W"*!7 WKG*K@UP#U7P:L! MWC[/P+P:X!?>E^953H=$$7&0\&W((K1FJUX*,-5HK7!E!6)M5!"OZ4:I\8?
MN$*8P"TLJLP"OH0%73&ZI!%A"NZCB.=,4;;".4]I1%"'58"*T%3")WQ6.4FO M-?QQ$<#5NVMX!Y3!IX3GDK!8#DVEYU@HF5$]GTDU'^?(?'KPP)E*),Q8C'$+ M/NC&_WH*'W;C;;>#P-3F-@XI+PY/G$I&!:[OH&?=@&,Y;LN$IN?#>VU^_)CZ M[,?4PVYX>@)&&VWP5UIVFFSME7SN$;W;(-2Z7U-R1L("17PF:0Y0D!EE'*9 M"VS+N(K3+SF+C78S=FW7LH;F9C<,G7E P/)1VWOR/YRG"W,=SM-/R1Z=,JI?IA#+_K4PJN_N127H,^$G9" MT>9Y)^T;ES:)%E0D7D[/MD'@;FD8'@HZ!\+B]>$Q3OY3#%]7;]15"%MS'? MLK8H> ?2NN#83WSOC("V1@2'-)
[CNGN>G:0).]=TOJNO'/,;Q_Q.Q^8";U.2 MLRB![^:IA"CX2Y]@^K33&:[+-)B2-55%QI.R\/G[;,G%/^TF=LI^-84OR19 M<$FRV27)P@N1O4J!?
I,"_?,^FAOX@*HMHOU3*3SM5'AKF$[*S2XI%W;)58:: M.W5DAF)55OP2R@JPJ2;WN92<5_6TGO]$WLPM5OZ WLPJ^X,W^FK&\P#$2O* M)*2XU%+675]O%]*Z%50-Q==E%?
O$E:Z)R\=$7Z10% /T^R77E6S=* 2;]IGX M?U!+ P04 " !.@FU93V8K?%@" #I!0 &0 'AL+W=O9>6I1&6EJAY6%7B,+R;)II8^'8 M6=MMX.]W[(0HI1?M2^*QSSD^_,8X:Z1ZTR6 (>\5%WKFE<;4-[ZO5R545(]D M#0)7UE)5U&"H-KZN%=#"D2KN1T$P]BO*A)=G;NY!Y9G<&LX$/"BBMU5%U<>3_"FWEJ\0[P MAT&C!V-B,WF5\LT&]\7,"ZPAX+ R5H'B;P=SX-P*H8V_G:;7;VF)P_&G^IW+ M'7-YI1KFDK^PPI0$;^*1 M9TR\VC;'Y"EX\SN))R7+ V1.OI-[L0-AI&*@,5]VATKDNE_X()<+,)1Q?86 Y^6" M7%YC,-C^)*ONK;O_:=O_HQ/Y+J$?H"
M5D@/'3W>I_M8B;X<45^.R.DE)_0>:8/5-: 8Y4>S:>EC1[<=LLN3-)EF]H M^1 43>-)#]IS%O?.XK/.7K ;;*UK)3<*]%%SK4(ZV#<.)LD7@<#([9E+ M>G()67-
W3#"\@P792'G\%B2'NX;VQ/.L'8+2()P>MY;VUM*SUIZDH1P+UUWB M8!I2@^.:7*?C+]X.0=-)$G!QY@\:T3Z"OZC.;*$)AS72@M$UJJCV86D#(VO7 MFZ_28*>]88EO.2@+P/6UQ/[L MON_>N>_P-02P,$% @ 3H)M6?U"7]]P M"P HH< !D !X;"]W;W)K&ULO=U_;YM(@;P MMS+RK4ZMU(T!_^XED1+#*M)HZ9M=#K='Q,\L5$P> $GJ;0O?@%CX\%X8FX? MW?
ZQB6WF,Q/;3P>&K_'Y:O0_)PO.4_*V#,+DHK-(T]7G;C?Q%GS)DK-HQ1ZMT\ /^5U,DO5R MR>)?USR(7B\Z:F=[QS=_ODCS.[]7YRLVY_<_;&ZB[-;WT9TR\Y<\3/PH)#%_
MNNA)=G9]Y@WW?] JM/CCLS_FD25\&@4/ BQ=7'3&'3+C3VP=I-^B5XN7 M?] @][PH2(K_D]=R6Z5#O'621LNR<3:"I1]N?K*W\HG8:Z#VCS30R@:;]0UZ M98/>]0WZ98/^]0T&98-!O<'@2(-AV6!X:H-1V6!TZI#&98/QJ0TF98/)]0U4 M9?O**2;EOQ3OTZ)][LRPSQ2]VF< M/>IG[=++VRCE1">_$YT_IN3K8^#/6?Y>3\)@'G:?,#Q+RG;^E:Q9\S#;Z<:^3 M#[])+\1/R3?
%]$Z8>$L.>^FV4ARK^N5O=)-K]17E5R$X7I(B%&...SAO:F MO/U$TKZ;/0.[IT':/@W7FA2\6L5G1!E\([JB]1O&,WVG^7I^1GI*T;S7T%R7 M-
W=8F#57CS8W3FBN#8\VI_+FM|&+=/"FO/DI7^V:-SUUUNG-FWJWYY)GWGWA*=.'34U%]Z&O5T:>X77/_9DI)'W3.PD6?,9T=>Q'\[) M'8_]:/:)W"]8S)-/Y,K[8^TG?AG2+(=)\<#'AM%?
2WO+9^O/R8IY_**33<<) MCU]XY_*?_U"'RK^:(H#$="1F(#&ZP08%EN^0O%RJO;'6'T_.NR_[J4!V:B$Q M&XDY2,P%84*V^KML]:79NHLCC_-90I[B%:EDC(4>)]%3,?4UI4?
]M4T($M.1 MF('$*!(S-]AP+XJ#\62BB$&T#K?]C<>**FYE(P?F(#$7A FA&.Q_"9"&HMCK MVV5A&B5I-L/<\L8X2*6V<4!B.A(SD!A%8N;@<&921UHM#<@>;28?# YR.IX-
MW@7U)T1AN(Q"4!]%A^RP/B&4Q?.(7+/P.O2!22GRSVV6.PR5Y3Y*1^V\@A,1V@1M. M5??^%57.%$T;B/^,4F2G)A*SD)B-Q!PDYH(P(4VJ4IUL4OIF3';CA_YRO91.
M8_).VH8*JNE0S8!J%*J94,V":C9461<\/_/37 M)W+#WHKD74=QAN9GGJ8L&T?QV!V/O6S^8_.BJ1V^\"3-)\2F4[_7\@&TCB=2 MTZ&:46KY*[HW[8UKJO.[B_L$E7R(6)O*9#5IL =5TJ&9 M-0K53*AF034;JCE0S45I8L2](@Y57L5QOWX5()?U93ZF13]M,T,Z-@H5#.AF@75;*CF0#47I8DQJ0H\5'F% M!
[JZ5MY=Z_@,#\I[)NA/N>>]STF;&="Q4:AF0C4+]ME0S8%]+DH3XU/5;]CR MXHU;EAT'+5C BKE%OC<'+=Z :CI4,Z :A6HF5+.@F&W5'*CFHC0Q9U6UARHO
M]S@XZ4RSOLC5,E]'C852#AIVX4[8RH".C4,V$:A94LZ&:]7< M]UYY\4U?%5]H+2LM[##EV7#2HK(BVS]+LQ^SO>6XQB1 JRU*K;;&I4SJ48 6 M4D
U"M5,J&9!-1NJ.5#-16GB)UNKH@M-7G31.EK9%D_2I[AB_HP\^.DB.PJZ M!]_*C]PVY4X^@+:Y*[5:[M3:9P5T:*<&5*-0S81]%E2SH9H#U5R4)N:NJK30
MY)46[^7.#KV8LX3GZ4'9!]:=:$U5C8H]<4(:*<&5*-0S81]%E2S3WNQ'&BG M+DH3PU754VCR>HJCX:J6\J91F'!OG5^RA7R/V2Q?[M/9KX30*"93%GCKH+C4 M17YB]^?
#U1WYD#W:N- G'TOK;,G_,DTALVR434L7T'$84(U"-1.J65#-AFH. M5'-1FIC*JL1"DY=8'*1RL[SN>Z0\157EM#%GT/J)4ML_4AT>+&1 NS2@&H5J M)E2SH)H-
U1RHYJ(T,5)5^80F+Y_8?%JRI)_X$1VB[$-P8* M6E4!U72H9D U"M5,J&9!-1NJ.5#-16EB\JI"NV4:V.O8@2C;+'\V?4BZ[WD^>P.J&5"-0C43
MJEE0S89J#E1S49J8PZHV1&M9&W(DASKWBI60[05]FZX'?%WV]>Y4![W6!E0S MH!J%:B94LZ":#=4RFY9P%\J7\XAL< M\H.W:QYZBR6+GYL25G9U,(G5(R8?
4MN(034#JE&H9D(U"ZK94,V!:BY*$R-6 ME8/T6I:#G!BQO#SDEK^EY-^<-2[RE_V*'Z@ZK,:=RL?7.F_0T@^H1J&:"=4L MJ&9#-0>]N2A-S%M5(=)K62&R/0C;E6'MSDG+]XK+?FKE-
?5+FTWEPVD=++VBI M!U2C4,V$:A94LZ&:]5X??:#*I[QQ8T"YMJ.9 -1>EB;FIZCEZ\GJ.-M^X(*=:YP=:O@'5#*A&H9I9 M:L**D788(&A9!E1SH)J+TL0
6594O99E&=M+ADY9LB#7+,B#U9@7Z-4NH)H. MU0RH1J&:V3NLDFE8?[6@G=I0S8%]+DH3XU259_3DY1DGUQ>2/AD]]:9H^3K M"X_#_+M*"?7#+&[YB:[BXO,?
[K_2;Q^EEP:0#Z=U"]$U(%#-@&H4JIE0S8)] M-E1SH)]+TL2P5C4@O98U(*VO1U]V4/^LT$@1_E/K:QO0P@^H9D U"M5,J&9! M-
1NJ.5#-16EBS*K"CU[+P@IS,C#@H='UNYO^)$CNW%C#(?UW$$+/:": =4H M5#.AF@75;*CF0#47I8FYJPH]>LBO6WDO=^^?.&O^UI+AP%%)S\GO;N7 MQ/PIO]
[5YRNMTSVXWU0_6VI^?[=B+L]7;,YO6#WSPX0$_"DCE;/1H$/B?)%E M>R.-5EG,.N0Q2M-H6?RZR.9%'N<;9(_15&ZO9%W\!K%S\6P+_\'4$L#!!0 M ($Z";5F?B! Q] (+@(9
>&PO=V]R:W-H965T?XW'O\R'#%Q;W, 11Z*"B3(RM7JAS8MDQR*+"\X"4P M_67!18&5[HK,EJ4 G-:@@MJ>XX1V@0FSXF$]-A7QD%>*$@93@615%%@\7@/E

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l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|%:QI.VQI.^_|& MQ,IPG\L\ W2?TO+B$Y_4GHFI+2UX?,"<$RKFN7A%A.X&;T)QM%Q _Y2SC.$D M")-5]TFE'3K9I"5-?.QMOVB<*\/|@1,RJ F*LT!I-BC- :6YH#0/E.9#T9H^ MWNZF4.7;*0ISB:M.?(3C/HZY@TLWM9KQZ$#8LKU@/%8'^M[6@1MY5B>/<9 T M$Y1F@=)L4)H#2G-!:1XHS8>B-5VVW7BARG=>_.)-2_+L3A[Z(&F&>KC30YL< M[EL"#6]!TNR6+NRE[[0TF8S5P]7+XR@/-'6@DVL8=,L#*,T$I5F@-!N4YH#27%":!TKSH6A-FVTW4JC==U+\@N41T,T8MH#0#E&:"TBQ0F@U*VVS:-^2\/!7::EX?H[=Z'$A*Z*&Z4R MM$SSA)5;U^NC|&PO=R:W-H965THICC-M-E%C]W0V(5N>Q!G<4\2V:8KI MKSDD9#_53.UEX"'>1%P.Z+-)CC>P!/Z8WU/1TRN5,$XA8S'}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|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|% 2#1SZJD8NH54NYO?5^L"ZBPN&%[H.K)EO$*2S7E M.U_L.>"-.,I*/PJ"S*\PH=YL8M8>^&S"#K(D%!XX$H>]POS7/93L./5"[VGA M,]D54B_XL\D>[V)\NO^@:N9WWK9D JH((PB#MNI=Q?>+L) &QC%-P)'<3)&MN&F7%V'<|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~%R!V:,!IU.%VB<.@F#8/G3B-

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l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`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|_-3=M)VJD[T1]%G=/]ZN4VZF;^U1>)8^O M3F5H#ZK17EX&]64RT'X3JKFHYJ&:CVH!JH6H%J%:3&EJ(MM^TTC?;_(2N9?X M4YR7MJ&:CFH-J M+JIY].:C6H!J(:I%J!93FIKJMA$UUC>B=KE;|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|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|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|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|(^>)2<)X9VNE0MOI*>8 M=|(0WNF*B69N,IMB^DE#Z*<#$_X)+B9FH32$A3HQIRXF9]$TA(4Z(TQOTP;= MM0EAH4Y,=]LFQ2R4AK!09R#LM29FH?28*VM^:V(62D-8J!/3W09+,0NE(2S4 MD5: U5U,S$+I$;.?$W+I[GQB%LI"9S][FS^PKZ9V]D,LU 6PD(,YH\#F),T MC4!<3,Q"60@+>9C+>K3:Q43?'@AA(3=![QY"F(6R$!9R,&$2TH9#/;R)CEU,S$)9" MYF'=*DKFM MRD8@+B9FH2R$A3S,>Y9+D?.2V\(N)F:A+(2%L,T5+O\:8R8:-R8:[M|C*]B: M"U;[UG593N':%W$M:;%_+6[_2M^G?P%02P,$ M% @ 3H)M69@;6II[0 RR, !H !X;"]?|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end XML 73 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);

e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 295 361 1 false 80 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.kempharm.com/20240930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Unaudited Condensed Consolidated Balance Sheets Sheet http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-Unaudited Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals Unaudited Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Unaudited Condensed Consolidated Statements of Operations Sheet http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations Unaudited Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Unaudited Condensed Consolidated Statements of Operations (Parentheticals) Sheet http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations-parentheticals Unaudited Condensed Consolidated Statements of Operations (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss Unaudited Condensed Consolidated Statements of Comprehensive Loss Statements 6 false false R7.htm 006 - Statement - Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity Statements 7 false false R8.htm 007 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows Unaudited Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 008 - Disclosure - Note A - Description of Business, Basis of Presentation and Significant Transactions Sheet http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions Note A - Description of Business, Basis of Presentation and Significant Transactions Notes 9 false false R10.htm 009 - Disclosure - Note B - Summary of Significant Accounting Policies Sheet http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies Note B - Summary of Significant Accounting Policies Notes 10 false false R11.htm 010 - Disclosure - Note C - Inventories Sheet http://www.kempharm.com/20240930/role/statement-note-c-inventories Note C - Inventories Notes 11 false false R12.htm 011 - Disclosure - Note D - Debt Obligations Sheet http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations Note D - Debt Obligations Notes 12 false false R13.htm 012 - Disclosure - Note E - Revenue, Net Sheet http://www.kempharm.com/20240930/role/statement-note-e-revenue-net Note E - Revenue, Net Notes 13 false false R14.htm 013 - Disclosure - Note F - Commitments and Contingencies Sheet http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies Note F - Commitments and Contingencies Notes 14 false false R15.htm 014 - Disclosure - Note G - Stock and Warrants Sheet http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants Note G - Stock and Warrants Notes 15 false false R16.htm 015 - Disclosure - Note H - Stock-based Compensation Sheet http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation Note H - Stock-based Compensation Notes 16 false false R17.htm 016 - Disclosure - Note I - Fair Value of Financial Instruments Sheet http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments Note I - Fair Value of Financial Instruments Notes 17 false false R18.htm 017 - Disclosure - Note J - Net Loss Per Share Sheet http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share Note J - Net Loss Per Share Notes 18 false false R19.htm 018 - Disclosure - Note K - Leases Sheet http://www.kempharm.com/20240930/role/statement-note-k-leases Note K - Leases Notes 19 false false R20.htm 019 - Disclosure - Note L - Merger Sheet http://www.kempharm.com/20240930/role/statement-note-l-merger Note L - Merger Notes 20 false false R21.htm 020 - Disclosure - Note M - Goodwill & Intangible Assets Sheet http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets Note M - Goodwill & Intangible Assets Notes 21 false false R22.htm 021 - Disclosure - Note N - Subsequent Events Sheet http://www.kempharm.com/20240930/role/statement-note-n-subsequent-events Note N - Subsequent Events Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 995468 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies 24 false false R25.htm 995469 - Disclosure - Note C - Inventories (Tables) Sheet http://www.kempharm.com/20240930/role/statement-note-c-inventories-tables Note C - Inventories (Tables) Tables http://www.kempharm.com/20240930/role/statement-note-c-inventories 25 false false R26.htm 995470 - Disclosure - Note D - Debt Obligations (Tables) Sheet http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-tables Note D - Debt Obligations (Tables) Tables http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations 26 false false R27.htm 995471 - Disclosure - Note G - Stock and Warrants (Tables) Sheet http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-tables Note G - Stock and Warrants (Tables) Tables http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants 27 false false R28.htm 995472 - Disclosure - Note H - Stock-based Compensation (Tables) Sheet http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-tables Note H - Stock-based Compensation (Tables) Tables http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation 28 false false R29.htm 995473 - Disclosure - Note I - Fair Value of Financial Instruments (Tables) Sheet http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-tables Note I - Fair Value of Financial Instruments (Tables) Tables http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments 29 false false R30.htm 995474 - Disclosure - Note J - Net Loss Per Share (Tables) Sheet http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-tables Note J - Net Loss Per Share (Tables) Tables http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share 30 false false R31.htm 995475 - Disclosure - Note K - Leases (Tables) Sheet http://www.kempharm.com/20240930/role/statement-note-k-leases-tables Note K - Leases (Tables) Tables http://www.kempharm.com/20240930/role/statement-note-k-leases 31 false false R32.htm 995476 - Disclosure - Note L - Merger (Tables) Sheet http://www.kempharm.com/20240930/role/statement-note-l-merger-tables Note L - Merger (Tables) Tables http://www.kempharm.com/20240930/role/statement-note-l-merger 32 false false R33.htm 995477 - Disclosure - Note A - Description of Business, Basis of Presentation and Significant Transactions (Details Textual) Sheet http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual Note A - Description of Business, Basis of Presentation and Significant Transactions (Details Textual) Details http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions 33 false false R34.htm 995478 - Disclosure - Note B - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual Note B - Summary of Significant Accounting Policies (Details Textual) Details 34 false false R35.htm 995479 - Disclosure - Note C - Inventories - Summary of Inventory (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details Note C - Inventories - Summary of Inventory (Details) Details 35 false false R36.htm 995480 - Disclosure - Note D - Debt Obligations (Details Textual) Sheet http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual Note D - Debt Obligations (Details Textual) Details http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-tables 36 false false R37.htm 995481 - Disclosure - Note D - Debt Obligations - Aggregate Principal Amount (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details Note D - Debt Obligations - Aggregate Principal Amount (Details) Details 37 false false R38.htm 995482 - Disclosure - Note D - Debt Obligations - Future Minimum Principal Payments (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details Note D - Debt Obligations - Future Minimum Principal Payments (Details) Details 38 false false R39.htm 995483 - Disclosure - Note E - Revenue, Net (Details Textual) Sheet http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual Note E - Revenue, Net (Details Textual) Details http://www.kempharm.com/20240930/role/statement-note-e-revenue-net 39 false false R40.htm 995484 - Disclosure - Note F - Commitments and Contingencies (Details Textual) Sheet http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual Note F - Commitments and Contingencies (Details Textual) Details http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies 40 false false R41.htm 995485 - Disclosure - Note G - Stock and Warrants (Details Textual) Sheet http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual Note G - Stock and Warrants (Details Textual) Details http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-tables 41 false false R42.htm 995486 - Disclosure - Note G - Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details Note G - Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details) Details 42 false false R43.htm 995487 - Disclosure - Note G - Stock and Warrants - Common Stock Activity (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details Note G - Stock and Warrants - Common Stock Activity (Details) Details 43 false false R44.htm 995488 - Disclosure - Note H - Stock-based Compensation (Details Textual) Sheet http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual Note H - Stock-based Compensation (Details Textual) Details http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-tables 44 false false R45.htm 995489 - Disclosure - Note H - Stock-based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-stockbased-compensation-expense-details Note H - Stock-based Compensation - Stock-based Compensation Expense (Details) Details 45 false false R46.htm 995490 - Disclosure - Note I - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details Note I - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 46 false false R47.htm 995491 - Disclosure - Note I - Fair Value of Financial Instruments - Fair Value Assumptions for Warrant Liabilities (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details Note I - Fair Value of Financial Instruments - Fair Value Assumptions for Warrant Liabilities (Details) Details 47 false false R48.htm 995492 - Disclosure - Note I - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-reconciliation-of-beginning-and-ending-balances-for-derivative-and-warrant-liability-measured-at-fair-value-on-recurring-basis-details Note I - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) Details 48 false false R49.htm 995493 - Disclosure - Note J - Net Loss Per Share - Anti-dilutive Securities (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-antidilutive-securities-details Note J - Net Loss Per Share - Anti-dilutive Securities (Details) Details 49 false false R50.htm 995494 - Disclosure - Note J - Net Loss Per Share - Earnings Per Share (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-earnings-per-share-details Note J - Net Loss Per Share - Earnings Per Share (Details) Details 50 false false R51.htm 995495 - Disclosure - Note K - Leases (Details Textual) Sheet http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual Note K - Leases (Details Textual) Details http://www.kempharm.com/20240930/role/statement-note-k-leases-tables 51 false false R52.htm 995496 - Disclosure - Note K - Leases - Lease Cost (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details Note K - Leases - Lease Cost (Details) Details 52 false false R53.htm 995497 - Disclosure - Note K - Leases - Supplement Cash Flow Information Related to Leases (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details Note K - Leases - Supplement Cash Flow Information Related to Leases (Details) Details 53 false false

R54.htm 995498 - Disclosure - Note K - Leases - Supplement Balance Sheet Information Related to Lease (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details Note K - Leases - Supplement Balance Sheet Information Related to Lease (Details) Details 54 false false R55.htm 995499 - Disclosure - Note K - Leases - Maturities of Lease Liabilities (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details Note K - Leases - Maturities of Lease Liabilities (Details) Details 55 false false R56.htm 995500 - Disclosure - Note L - Merger (Details Textual) Sheet http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual Note L - Merger (Details Textual) Details http://www.kempharm.com/20240930/role/statement-note-l-merger-tables 56 false false R57.htm 995501 - Disclosure - Note L - Merger - Estimates and Assumptions Related to Fair Value of Assets and Liabilities Acquired (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details Note L - Merger - Estimates and Assumptions Related to Fair Value of Assets and Liabilities Acquired (Details) Details 57 false false R58.htm 995502 - Disclosure - Note L - Merger - Pro Forma Combined Results of Operations (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-l-merger-pro-forma-combined-results-of-operations-details Note L - Merger - Pro Forma Combined Results of Operations (Details) Details 58 false false R59.htm 995503 - Disclosure - Note L - Merger - Reconciliation of Contingent Consideration Liabilities (Details) Sheet http://www.kempharm.com/20240930/role/statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details Note L - Merger - Reconciliation of Contingent Consideration Liabilities (Details) Details 59 false false R60.htm 995504 - Disclosure - Note M - Goodwill & Intangible Assets (Details Textual) Sheet http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual Note M - Goodwill & Intangible Assets (Details Textual) Details http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets 60 false false All Reports Book All Reports zvra-20240930.xsd zvra-20240930_cal.xml zvra-20240930_def.xml zvra-20240930_lab.xml zvra-20240930_pre.xml zvra20240930_10q.htm http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 79 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "zvra20240930_10q.htm": { "nsprefix": "zvra", "nsuri": "http://www.kempharm.com/20240930", "dts": { "schema": { "local": ["zvra-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["zvra-20240930_cal.xml"] }, "definitionLink": { "local": ["zvra-20240930_def.xml"] }, "labelLink": { "local": ["zvra-20240930_lab.xml"] }, "presentationLink": { "local": ["zvra-20240930_pre.xml"] }, "inline": { "local": ["zvra20240930_10q.htm"] } }, "keyStandard": 290, "keyCustom": 71, "axisStandard": 32, "axisCustom": 0, "memberStandard": 30, "memberCustom": 46, "hidden": { "total": 96, "http://xbrl.sec.gov/ecd/2024": 37, "http://fasb.org/us-gaap/2024": 49, "http://xbrl.sec.gov/dei/2024": 6, "http://www.kempharm.com/20240930": 4 }, "contextCount": 295, "entityCount": 1, "segmentCount": 80, "elementCount": 560, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 881, "http://xbrl.sec.gov/ecd/2024": 44, "http://xbrl.sec.gov/dei/2024": 29, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.kempharm.com/20240930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-", "longName": "001 - Statement - Unaudited Condensed Consolidated Balance Sheets", "shortName": "Unaudited Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals", "longName": "002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations", "longName": "003 - Statement - Unaudited Condensed Consolidated Statements of Operations", "shortName": "Unaudited Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations-parentheticals", "longName": "004 - Statement - Unaudited Condensed Consolidated Statements of Operations (Parentheticals)", "shortName": "Unaudited Condensed Consolidated Statements of Operations (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "div", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss", "longName": "005 - Statement - Unaudited Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Unaudited Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity", "longName": "006 - Statement - Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity", "shortName": "Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "i_2022-12-31_RestatementAxis-ScenarioPreviouslyReportedMember_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R8": { "role": "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "longName": "007 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R9": { "role": "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "longName": "008 - Disclosure - Note A - Description of Business, Basis of Presentation and Significant Transactions", "shortName": "Note A - Description of Business, Basis of Presentation and Significant Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies", "longName": "009 - Disclosure - Note B - Summary of Significant Accounting Policies", "shortName": "Note B - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.kempharm.com/20240930/role/statement-note-c-inventories", "longName": "010 - Disclosure - Note C - Inventories", "shortName": "Note C - Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "longName": "011 - Disclosure - Note D - Debt Obligations", "shortName": "Note D - Debt Obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "longName": "012 - Disclosure - Note E - Revenue, Net", "shortName": "Note E - Revenue, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies", "longName": "013 - Disclosure - Note F - Commitments and Contingencies", "shortName": "Note F - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1,

"baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "longName": "014 - Disclosure - Note G - Stock and Warrants", "shortName": "Note G - Stock and Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "longName": "015 - Disclosure - Note H - Stock-based Compensation", "shortName": "Note H - Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments", "longName": "016 - Disclosure - Note I - Fair Value of Financial Instruments", "shortName": "Note I - Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share", "longName": "017 - Disclosure - Note J - Net Loss Per Share", "shortName": "Note J - Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.kempharm.com/20240930/role/statement-note-k-leases", "longName": "018 - Disclosure - Note K - Leases", "shortName": "Note K - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "zvra:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "zvra:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.kempharm.com/20240930/role/statement-note-l-merger", "longName": "019 - Disclosure - Note L - Merger", "shortName": "Note L - Merger", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "longName": "020 - Disclosure - Note M - Goodwill & Intangible Assets", "shortName": "Note M - Goodwill & Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.kempharm.com/20240930/role/statement-note-n-subsequent-events", "longName": "021 - Disclosure - Note N - Subsequent Events", "shortName": "Note N - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "i_2024-09-30_IndividualAxis-ZVRATimothyJSangiovanniMember", "name": "ecd:TrdArrSecuritiesAggAvailAmt", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_IndividualAxis-ZVRATimothyJSangiovanniMember", "name": "ecd:TrdArrSecuritiesAggAvailAmt", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies", "longName": "995468 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.kempharm.com/20240930/role/statement-note-c-inventories-tables", "longName": "995469 - Disclosure - Note C - Inventories (Tables)", "shortName": "Note C - Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-tables", "longName": "995470 - Disclosure - Note D - Debt Obligations (Tables)", "shortName": "Note D - Debt Obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-tables", "longName": "995471 - Disclosure - Note G - Stock and Warrants (Tables)", "shortName": "Note G - Stock and Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "zvra:ScheduleOfAuthorizedSharesOfCommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "zvra:ScheduleOfAuthorizedSharesOfCommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-tables", "longName": "995472 - Disclosure - Note H - Stock-based Compensation (Tables)", "shortName": "Note H - Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-tables", "longName": "995473 - Disclosure - Note I - Fair Value of Financial Instruments (Tables)", "shortName": "Note I - Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-tables", "longName": "995474 - Disclosure - Note J - Net Loss Per Share (Tables)", "shortName": "Note J - Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.kempharm.com/20240930/role/statement-note-k-leases-tables", "longName": "995475 - Disclosure - Note K - Leases (Tables)", "shortName": "Note K - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["zvra:LeaseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["zvra:LeaseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.kempharm.com/20240930/role/statement-note-l-merger-tables", "longName": "995476 - Disclosure - Note L - Merger (Tables)", "shortName": "Note L - Merger (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "longName": "995477 - Disclosure - Note A - Description of Business, Basis of Presentation and Significant Transactions (Details Textual)", "shortName": "Note A - Description of Business, Basis of Presentation and Significant Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null,

"decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-02-05", "name": "zvra:CommonStockRegisteredShares", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R34": { "role": "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual", "longName": "995478 - Disclosure - Note B - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note B - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:InvestmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:InvestmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R35": { "role": "http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details", "longName": "995479 - Disclosure - Note C - Inventories - Summary of Inventory (Details)", "shortName": "Note C - Inventories - Summary of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "longName": "995480 - Disclosure - Note D - Debt Obligations (Details Textual)", "shortName": "Note D - Debt Obligations (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "d_2023-11-01_2023-11-30", "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_LineOfCreditFacilityAxis-WellsFargoBankNaMember", "name": "us-gaap:LineOfCredit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R37": { "role": "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details", "longName": "995481 - Disclosure - Note D - Debt Obligations - Aggregate Principal Amount (Details)", "shortName": "Note D - Debt Obligations - Aggregate Principal Amount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details", "longName": "995482 - Disclosure - Note D - Debt Obligations - Future Minimum Principal Payments (Details)", "shortName": "Note D - Debt Obligations - Future Minimum Principal Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:NotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_DebtInstrumentAxis-TermLoansUnderCreditAgreementMember", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R39": { "role": "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "longName": "995483 - Disclosure - Note E - Revenue, Net (Details Textual)", "shortName": "Note E - Revenue, Net (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_AssetAcquisitionAxis-ArimoclomolPurchaseAgreementMember", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "div", "div", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R40": { "role": "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual", "longName": "995484 - Disclosure - Note F - Commitments and Contingencies (Details Textual)", "shortName": "Note F - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "longName": "995485 - Disclosure - Note G - Stock and Warrants (Details Textual)", "shortName": "Note G - Stock and Warrants (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-11-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R42": { "role": "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details", "longName": "995486 - Disclosure - Note G - Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details)", "shortName": "Note G - Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "zvra:ScheduleOfAuthorizedSharesOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "zvra:ScheduleOfAuthorizedSharesOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details", "longName": "995487 - Disclosure - Note G - Stock and Warrants - Common Stock Activity (Details)", "shortName": "Note G - Stock and Warrants - Common Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R44": { "role": "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual", "longName": "995488 - Disclosure - Note H - Stock-based Compensation (Details Textual)", "shortName": "Note H - Stock-based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-06-30", "name": "zvra:EmployeeStockPurchasePlanMaximumNumberOfIssuableShares", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R45": { "role": "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-stockbased-compensation-expense-details", "longName": "995489 - Disclosure - Note H - Stock-based Compensation - Stock-based Compensation Expense (Details)", "shortName": "Note H - Stock-based Compensation - Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R46": { "role": "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "longName": "995490 - Disclosure - Note I - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "shortName": "Note I - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "i_2024-09-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:DerivativeLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:DerivativeLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details", "longName": "995491 - Disclosure - Note I - Fair Value of Financial Instruments - Fair Value Assumptions for Warrant Liabilities (Details)", "shortName": "Note I - Fair Value of Financial Instruments - Fair Value Assumptions for Warrant Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "zvra:ClassOfWarrantOrRightLiabilityWeightedAverageFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "zvra:ClassOfWarrantOrRightLiabilityWeightedAverageFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-reconciliation-of-beginning-and-ending-balances-for-derivative-and-warrant-

liability-measured-at-fair-value-on-recurring-basis-details", "longName": "995492 - Disclosure - Note I - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details)", "shortName": "Note I - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-antidilutive-securities-details", "longName": "995493 - Disclosure - Note J - Net Loss Per Share - Anti-dilutive Securities (Details)", "shortName": "Note J - Net Loss Per Share - Anti-dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-earnings-per-share-details", "longName": "995494 - Disclosure - Note J - Net Loss Per Share - Earnings Per Share (Details)", "shortName": "Note J - Net Loss Per Share - Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual", "longName": "995495 - Disclosure - Note K - Leases (Details Textual)", "shortName": "Note K - Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "zvra:LesseeLeaseOptionToExtendMaximumTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "zvra:LeaseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "zvra:LesseeLeaseOptionToExtendMaximumTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "zvra:LeaseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details", "longName": "995496 - Disclosure - Note K - Leases - Lease Cost (Details)", "shortName": "Note K - Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "zvra:LeaseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "zvra:LeaseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details", "longName": "995497 - Disclosure - Note K - Leases - Supplement Cash Flow Information Related to Leases (Details)", "shortName": "Note K - Leases - Supplement Cash Flow Information Related to Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FinanceLeasePrincipalPayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "zvra:ScheduleOfLeasesCashFlowInformationTableTextBlock", "zvra:LeaseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R54": { "role": "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details", "longName": "995498 - Disclosure - Note K - Leases - Supplement Balance Sheet Information Related to Lease (Details)", "shortName": "Note K - Leases - Supplement Balance Sheet Information Related to Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "zvra:ScheduleOfLeasesBalanceSheetInformationTableTextBlock", "zvra:LeaseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "zvra:ScheduleOfLeasesBalanceSheetInformationTableTextBlock", "zvra:LeaseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details", "longName": "995499 - Disclosure - Note K - Leases - Maturities of Lease Liabilities (Details)", "shortName": "Note K - Leases - Maturities of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "zvra:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "zvra:LeaseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "zvra:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "zvra:LeaseDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "longName": "995500 - Disclosure - Note L - Merger (Details Textual)", "shortName": "Note L - Merger (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "d_2023-11-01_2023-11-30", "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-06-16_2023-06-16_AssetAcquisitionAxis-MarathonConvertibleNotesMember", "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "tbody", "table", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } }, "R57": { "role": "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details", "longName": "995501 - Disclosure - Note L - Merger - Estimates and Assumptions Related to Fair Value of Assets and Liabilities Acquired (Details)", "shortName": "Note L - Merger - Estimates and Assumptions Related to Fair Value of Assets and Liabilities Acquired (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "i_2023-11-17", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-11-17", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.kempharm.com/20240930/role/statement-note-l-merger-pro-forma-combined-results-of-operations-details", "longName": "995502 - Disclosure - Note L - Merger - Pro Forma Combined Results of Operations (Details)", "shortName": "Note L - Merger - Pro Forma Combined Results of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.kempharm.com/20240930/role/statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details", "longName": "995503 - Disclosure - Note L - Merger - Reconciliation of Contingent Consideration Liabilities (Details)", "shortName": "Note L - Merger - Reconciliation of Contingent Consideration Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "i_2023-12-31_BusinessAcquisitionAxis-AcerTherapeuticsIncMember", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual", "longName": "995504 - Disclosure - Note M - Goodwill & Intangible Assets (Details Textual)", "shortName": "Note M - Goodwill & Intangible Assets (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "zvra20240930_10q.htm", "unique": true } } }, "tag": { "zvra_AZSTARYSLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "AZSTARYSLicenseAgreementMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "AZSTARYS License Agreement [Member]", "documentation": "Information pertaining to the litigation." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Accounts and other receivables", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": ["r68", "r74"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "terseLabel": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r57", "r58"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsReceivableNetCurrent", "terseLabel": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r875"] }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent", "terseLabel": "Accrued Royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties." } } }, "auth_ref": ["r108"] }, "zvra_AccumulatedDepreciationAndAmortizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "AccumulatedDepreciationAndAmortizationMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation and Amortization [Member]", "documentation": "Primary financial statement caption encompassing accumulated depreciation and amortization." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details": { "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedTerseLabel": "less: accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r30", "r166", "r580"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income (loss)", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r18", "r19", "r77", "r174", "r577", "r606", "r610"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r4", "r15", "r19", "r447", "r450", "r521", "r601", "r602", "r847", "r848", "r849", "r861", "r862", "r863", "r865"] }, "zvra_AcerTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "AcerTherapeuticsIncMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details"], "lang": { "en-us": { "role": { "label": "Acer Therapeutics Inc [Member]", "documentation": "Represents Acer Therapeutics Inc." } } }, "auth_ref": [] }, "zvra_AcerWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "AcerWarrantsMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Acer Warrants [Member]", "documentation": "Represents the Acer warrants." } } }, "auth_ref": [] }, "zvra_AddiitonalPaymentOnFirstAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "AddiitonalPaymentOnFirstAnniversary", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_AddiitonalPaymentOnFirstAnniversary", "terseLabel": "Addiitonal Payment on First Anniversary", "documentation": "Amount of additional payment on first anniversary." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r69"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r622", "r861", "r862", "r863", "r865", "r941", "r1014"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r37", "r38", "r389"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]" } } }, "auth_ref": ["r812", "r813", "r814", "r816", "r817", "r818", "r821"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-stockbased-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "Stock based compensation expense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r417", "r421"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r175", "r254", "r262", "r263", "r264", "r979"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations-parentheticals"], "lang": { "en-us": { "role": { "label": "Amortization of intangible assets", "terseLabel": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r10", "r273", "r280", "r753"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Antidilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r232"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r26"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r26"] }, "zvra_AquestiveTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "AquestiveTherapeuticsMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "Aquestive Therapeutics [Member]", "documentation": "Represents Aquestive Therapeutics (formerly known as MonoSol Rx, LLC)." } } }, "auth_ref": [] }, "zvra_ArimoclomolEapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ArimoclomolEapMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "Arimoclomol EAP [Member]", "documentation": "Related to Arimoclomol EAP." } } }, "auth_ref": [] }, "zvra_ArimoclomolPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ArimoclomolPurchaseAgreementMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "Arimoclomol Purchase Agreement [Member]", "documentation": "Represents Arimoclomol Purchase Agreement." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-

assets-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r441"] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": ["r274", "r275", "r276", "r277", "r278", "r936"] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetAcquisitionConsiderationTransferred", "terseLabel": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": ["r771", "r937", "r938", "r939"] }, "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "terseLabel": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable", "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition." } } }, "auth_ref": ["r937", "r938", "r939"] }, "zvra_AssetAcquisitionConsiderationTransferredEstimatedReserveLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "AssetAcquisitionConsiderationTransferredEstimatedReserveLiability", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_AssetAcquisitionConsiderationTransferredEstimatedReserveLiability", "terseLabel": "Asset Acquisition, Consideration Transferred, Estimated Reserve Liability", "documentation": "Represents estimated reserve liability for asset acquisition consideration transferred." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": ["r274", "r275", "r276", "r277", "r278", "r936"] }, "zvra_AssetAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "AssetAcquisitionSharePrice", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_AssetAcquisitionSharePrice", "terseLabel": "Asset Acquisition, Share Price (in dollars per share)", "documentation": "The share price of equity interest issued in asset acquisition." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r106", "r117", "r169", "r201", "r236", "r240", "r247", "r248", "r257", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r442", "r444", "r480", "r573", "r664", "r749", "r750", "r782", "r807", "r902", "r903", "r967"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r161", "r178", "r201", "r257", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r442", "r444", "r480", "r782", "r902", "r903", "r967"] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Total assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r458", "r459", "r772"] }, "zvra_AtmAgreementSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "AtmAgreementSalesMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "ATM Agreement Sales [Member]", "documentation": "Represents for At-the-Market Agreement Sales." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Securities at fair value, current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r256", "r265"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Securities at fair value, long-term", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": ["r165", "r256", "r265"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r292", "r981", "r982"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r48", "r50", "r292", "r981", "r982"] }, "us-gaap_BridgeLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BridgeLoanMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Bridge Loan [Member]", "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r274", "r275", "r276", "r277", "r278", "r436", "r765", "r766"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r39", "r40", "r274", "r275", "r276", "r277", "r278", "r436", "r765", "r766"] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "terseLabel": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": ["r103"] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-tables"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": ["r827", "r828"] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionSharePrice", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessAcquisitionSharePrice", "terseLabel": "Business Acquisition, Share Price (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-pro-forma-combined-results-of-operations-details"], "lang": { "en-us": { "role": { "label": "Pro forma net loss", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": ["r434", "r435"] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-pro-forma-combined-results-of-operations-details"], "lang": { "en-us": { "role": { "label": "Pro forma revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": ["r434", "r435"] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "terseLabel": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } },

"auth_ref": ["r1", "r2", "r13"] }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "terseLabel": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": ["r1", "r2"] }, "zvra_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableConversionRatio", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableConversionRatio", "terseLabel": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Conversion Ratio", "documentation": "Conversion ratio of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferredOther1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredOther1", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationConsiderationTransferredOther1", "terseLabel": "Business Combination, Consideration Transferred, Other", "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree, Excludes cash." } } }, "auth_ref": ["r14"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details"], "lang": { "en-us": { "role": { "label": "Change in fair value recognized in earnings", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r438", "r855"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid." } } }, "auth_ref": ["r44"] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationContingentConsiderationLiability", "terseLabel": "Business Combination, Contingent Consideration, Liability", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r43", "r102", "r437", "r460", "r461", "r462"] }, "zvra_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "documentation": "Amount of liability incurred for accounts payable and accrued expenses assumed at acquisition date." } } }, "auth_ref": [] }, "zvra_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedApprovedProductOlpruva": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedApprovedProductOlpruva", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "Approved product - OLPRUVA", "documentation": "Amount of the approved product, OLPRUVA, acquired at the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r42"] }, "zvra_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredCollaborationFunding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredCollaborationFunding", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "Deferred collaboration funding", "documentation": "Amount of liabilities incurred for deferred collaboration funding assumed on the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "?IPR&D - celiprolol", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": ["r41", "r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": ["r41", "r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": ["r42"] }, "zvra_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "zvra_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities", "terseLabel": "Operating lease liabilities", "documentation": "Amount of liabilities incurred for operating leases assumed at the acquisition date." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-

details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "Other noncurrent assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "Property, plant, and equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": ["r41", "r42"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "totalLabel": "Fair Value of Net Assets Acquired", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r42"] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions"], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r54", "r90", "r91"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r25", "r164", "r739"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r25", "r87", "r197"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r3", "r87"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r126", "r171", "r172", "r173", "r201", "r225", "r226", "r229", "r231", "r238", "r239", "r257", "r303", "r305", "r306", "r307", "r310", "r311", "r341", "r342", "r345", "r348", "r354", "r480", "r617", "r618", "r619", "r620", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r652", "r673", "r692", "r716", "r717", "r718", "r719", "r720", "r825", "r856", "r866"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r35"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "zvra_ClassOfWarrantOrRightLiabilityWeightedAverageFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ClassOfWarrantOrRightLiabilityWeightedAverageFairValue", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details"], "lang": { "en-us": { "role": { "label": "Weighted average fair value (in dollars per share)", "documentation": "Represents the weighted average fair value under fair value assumptions for warrant liabilities." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r355"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "zvra_ClassOfWarrantsOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ClassOfWarrantsOrRightExercisedDuringPeriod", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_ClassOfWarrantsOrRightExercisedDuringPeriod", "terseLabel": "Class of Warrants or Right, Exercised During Period (in shares)", "documentation": "The number of warrants or rights exercised during period." } } }, "auth_ref": [] }, "zvra_CommaveTherapeuticsSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "CommaveTherapeuticsSAMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "Commave Therapeutics SA [Member]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note D)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r64", "r110", "r574", "r651"] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r93", "r294", "r295", "r723", "r892", "r897"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details"], "lang": { "en-us": { "role": { "label": "Common shares reserved for future issuance (in shares)", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r67"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r797", "r798", "r799", "r801", "r802", "r803", "r804", "r861", "r862", "r865", "r941", "r1012", "r1014"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r67"] }, "zvra_CommonStockRegisteredMaximumOfferingPrice": { "xbrltype":

"monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "CommonStockRegisteredMaximumOfferingPrice", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_CommonStockRegisteredMaximumOfferingPrice", "terseLabel": "Common Stock Registered, Maximum Offering Price", "documentation": "Represents maximum offering price under common stock registered." } } }, "auth_ref": [] }, "zvra_CommonStockRegisteredShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "CommonStockRegisteredShares", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_CommonStockRegisteredShares", "terseLabel": "Common Stock Registered, Shares (in shares)", "documentation": "Shares registered as apart of an S-3 filing." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r67", "r652"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "terseLabel": "Common Stock, Shares, Issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r67"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "terseLabel": "Common Stock, Shares, Outstanding (in shares)", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r16", "r67", "r652", "r670", "r1014", "r1015"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Common stock, $0.0001 par value, 250,000,000 shares authorized, 54,803,056 shares issued and 53,227,364 shares outstanding as of September 30, 2024; 43,110,360 shares issued and 41,534,668 shares outstanding as of December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r67", "r576", "r782"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss"], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r20", "r183", "r185", "r189", "r568", "r585", "r586"] }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": ["http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": ["r45", "r46", "r47"] }, "zvra_ConsultingFeesPaidInStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ConsultingFeesPaidInStock", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Consulting fees paid in common stock", "documentation": "The amount of consulting fees are paid in stock." } } }, "auth_ref": [] }, "zvra_ConsultingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ConsultingServicesMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "Consulting Services [Member]", "documentation": "Information pertaining to consulting services." } } }, "auth_ref": [] }, "zvra_ContractWithCustomerClawbackLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ContractWithCustomerClawbackLiability", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_ContractWithCustomerClawbackLiability", "terseLabel": "Contract with Customer, Clawback Liability", "documentation": "Represents clawback liability for contract with customer" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r357", "r358", "r377"] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r378"] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractualObligation", "terseLabel": "Contractual Obligation", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": ["r859"] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Cost of product revenue (excluding $1,545 and $4,619 in intangible asset amortization for the three and nine months ended September 30, 2024, respectively shown separately below)", "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization." } } }, "auth_ref": ["r834", "r835"] }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSoldAmortization", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Intangible asset amortization", "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service." } } }, "auth_ref": ["r850"] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total operating expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r82"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r152", "r153", "r202", "r203", "r316", "r343", "r522", "r530", "r572", "r741", "r743"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "zvra_CvrLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "CvrLiabilityMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "CVR Liability [Member]", "documentation": "Represents the CVR liability." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r94", "r199", "r287", "r288", "r289", "r290", "r291", "r301", "r302", "r312", "r318", "r319", "r320", "r321", "r322", "r323", "r328", "r335", "r336", "r337", "r496"] }, "zvra_DebtInstrumentAvailableAmountUntil18MonthsFollowingClosingDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentAvailableAmountUntil18MonthsFollowingClosingDate", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentAvailableAmountUntil18MonthsFollowingClosingDate", "terseLabel": "Debt Instrument, Available Amount Until 18 Months Following Closing Date", "documentation": "Amount of debt available until 18 months following closing date under debt instrument." } } }, "auth_ref": [] }, "zvra_DebtInstrumentAvailableAmountUntil18MonthsFollowingClosingDateMaximumEachDrawing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentAvailableAmountUntil18MonthsFollowingClosingDateMaximumEachDrawing", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label":

"zvra_DebtInstrumentAvailableAmountUntil18MonthsFollowingClosingDateMaximumEachDrawing", "terseLabel": "Debt Instrument, Available Amount Until 18 Months Following Closing Date, Maximum Each Drawing", "documentation": "Maximum each drawing for amount available under debt instrument to draw after 18 months of debt closing date." } } }, "auth_ref": [] }, "zvra_DebtInstrumentAvailableAmountUntilDecember312024": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentAvailableAmountUntilDecember312024", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentAvailableAmountUntilDecember312024", "terseLabel": "Debt Instrument, Available Amount Until December 31, 2024", "documentation": "Amount of debt available to be drawn until December 31, 2024." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r17", "r57", "r58", "r107", "r109", "r204", "r313", "r314", "r315", "r316", "r317", "r319", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r754", "r755", "r756", "r757", "r758", "r780", "r857", "r893", "r894", "r895", "r961", "r962"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "zvra_DebtInstrumentBasisSpreadOnVariableRateWhenPerformanceBenchmarkMeet": { "xbrltype": "percentItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentBasisSpreadOnVariableRateWhenPerformanceBenchmarkMeet", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentBasisSpreadOnVariableRateWhenPerformanceBenchmarkMeet", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate When Performance Benchmark Meet", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument when performance benchmark meet." } } }, "auth_ref": [] }, "zvra_DebtInstrumentBasisSpreadOnVariableRateWhenPerformanceBenchmarkMeetInNextYear": { "xbrltype": "percentItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentBasisSpreadOnVariableRateWhenPerformanceBenchmarkMeetInNextYear", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentBasisSpreadOnVariableRateWhenPerformanceBenchmarkMeetInNextYear", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate When Performance Benchmark Meet in Next Year", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument when performance benchmark meet in next year." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details": { "parentTag": "us-gaap_NotesPayable", "weight": 1.0, "order": 0.0 }, "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details"], "lang": { "en-us": { "role": { "verboseLabel": "Notes payable", "label": "us-gaap_DebtInstrumentCarryingAmount", "totalLabel": "Total minimum payments", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r17", "r109", "r338"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r313", "r496", "r497", "r755", "r756", "r780"] }, "zvra_DebtInstrumentFloorRate": { "xbrltype": "percentItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentFloorRate", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentFloorRate", "terseLabel": "Debt Instrument, Floor Rate", "documentation": "Floor rate of debt instrument." } } }, "auth_ref": [] }, "zvra_DebtInstrumentInterestRateIncreaseInStatedPercentageIfUnpaidWithinSixMonths": { "xbrltype": "percentItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentInterestRateIncreaseInStatedPercentageIfUnpaidWithinSixMonths", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentInterestRateIncreaseInStatedPercentageIfUnpaidWithinSixMonths", "terseLabel": "Debt Instrument, Interest Rate, Increase in Stated Percentage, If Unpaid Within Six Months", "documentation": "Increase in the contractual interest rate for funds borrowed, under the debt agreement, if unpaid within six months." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r60", "r314"] }, "zvra_DebtInstrumentInterestRateStatedPercentageIfUnpaidWithinSixMonths": { "xbrltype": "percentItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentInterestRateStatedPercentageIfUnpaidWithinSixMonths", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentInterestRateStatedPercentageIfUnpaidWithinSixMonths", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage, If Unpaid Within Six Months", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement, if unpaid within six months." } } }, "auth_ref": [] }, "zvra_DebtInstrumentInterestSharesConsecutiveTradingDaysForCalculationOfVWAP": { "xbrltype": "durationItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentInterestSharesConsecutiveTradingDaysForCalculationOfVWAP", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentInterestSharesConsecutiveTradingDaysForCalculationOfVWAP", "terseLabel": "Debt Instrument, Interest, Shares, Consecutive Trading Days For Calculation of VWAP (Day)", "documentation": "The consecutive trading days for calculation of VWAP for interest to be paid in shares on debt instrument." } } }, "auth_ref": [] }, "zvra_DebtInstrumentMaximumInterestPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentMaximumInterestPaymentPercentage", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentMaximumInterestPaymentPercentage", "terseLabel": "Debt Instrument, Maximum Interest Payment, Percentage", "documentation": "Maximum amount of interest payment allowed under debt instrument as a percentage." } } }, "auth_ref": [] }, "zvra_DebtInstrumentMinimumCashBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentMinimumCashBalance", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentMinimumCashBalance", "terseLabel": "Debt Instrument, Minimum Cash Balance", "documentation": "Minimum cash balance required for debt instrument to be active." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r17", "r204", "r313", "r314", "r315", "r316", "r317", "r319", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r754", "r755", "r756", "r757", "r758", "r780", "r857", "r893", "r894", "r895", "r961", "r962"] }, "zvra_DebtInstrumentNetProductSalesPerformanceBenchmark": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentNetProductSalesPerformanceBenchmark", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentNetProductSalesPerformanceBenchmark", "terseLabel": "Debt Instrument, Net Product Sales Performance Benchmark", "documentation": "Amount of performance benchmark of net product sales under debt instrument." } } }, "auth_ref": [] }, "zvra_DebtInstrumentNetProductSalesPerformanceBenchmarkInNextYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DebtInstrumentNetProductSalesPerformanceBenchmarkInNextYear", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_DebtInstrumentNetProductSalesPerformanceBenchmarkInNextYear", "terseLabel": "Debt Instrument, Net Product Sales Performance Benchmark in Next Year", "documentation": "Amount of performance benchmark of net product sales in next year under debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentPeriodicPaymentInterest", "terseLabel": "Debt Instrument, Periodic Payment, Interest", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": ["r17"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "negatedLabel": "Less: unamortized debt discount, debt issuance costs and paid in kind interest", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r324", "r339", "r495", "r496", "r497", "r755", "r756", "r780"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details": { "parentTag": "us-gaap_NotesPayable", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet", "negatedTerseLabel": "Unamortized original issue (discount) premium", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": ["r905", "r960", "r961", "r962"] }, "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtPolicyTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": ["r12"] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details": { "parentTag": "us-gaap_NotesPayable", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsNet", "terseLabel": "Debt Issuance Costs, Net", "negatedTerseLabel": "Less: debt issuance costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r905", "r960", "r961", "r962"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization expense", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r10", "r236", "r244", "r248", "r749", "r750"] }, "zvra_DerivativeAndWarrantLiabilityNoncurrent": {

"xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DerivativeAndWarrantLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Warrant liability", "terseLabel": "Derivative and Warrant Liability, Noncurrent", "documentation": "Noncurrent Carrying amount of derivative and warrant liability." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r641", "r643", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r665", "r666", "r667", "r668", "r679", "r680", "r681", "r682", "r685", "r686", "r687", "r688", "r706", "r707", "r710", "r712", "r797", "r799", "r948", "r949", "r950", "r951", "r952", "r953", "r955", "r956"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r49", "r51", "r52", "r105", "r641", "r643", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r665", "r666", "r667", "r668", "r679", "r680", "r681", "r682", "r685", "r686", "r687", "r688", "r706", "r707", "r710", "r712", "r743", "r797", "r799", "r948", "r949", "r950", "r951", "r952", "r953", "r955", "r956"] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Total liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r179", "r180", "r458", "r459", "r472", "r479", "r634", "r635", "r636", "r637", "r639", "r640", "r641", "r642", "r643", "r665", "r667", "r668", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r743", "r945", "r946", "r947", "r1013"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r388", "r390", "r418", "r419", "r420", "r768"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies", "http://www.kempharm.com/20240930/role/statement-note-c-inventories", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share", "http://www.kempharm.com/20240930/role/statement-note-k-leases", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-n-subsequent-events"], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "zvra_DiscountAndRebateLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DiscountAndRebateLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Current portion of discount and rebate liabilities", "documentation": "Current portion of discount and rebate liabilities." } } }, "auth_ref": [] }, "zvra_DiscountAndRebateLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "DiscountAndRebateLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Discount and rebate liabilities, less current portion", "documentation": "Noncurrent portion of discount and rebate liabilities." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r811"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r815"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-earnings-per-share-details", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Basic and diluted net loss per share of common stock (in dollars per share)", "terseLabel": "Net loss (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r190", "r210", "r211", "r213", "r214", "r215", "r217", "r223", "r225", "r229", "r230", "r231", "r235", "r432", "r440", "r455", "r456", "r569", "r587", "r746"] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Basic and diluted net loss per share of common stock:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r222", "r232", "r233", "r234"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r959"] }, "zvra_EmployeeStockPurchasePlanMaximumNumberOfIssuableShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "EmployeeStockPurchasePlanMaximumNumberOfIssuableShares", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_EmployeeStockPurchasePlanMaximumNumberOfIssuableShares", "terseLabel": "Employee Stock Purchase Plan, Maximum Number of Issuable Shares (in shares)", "documentation": "Maximum number of shares that may be issued under Employee Stock Purchase Plan." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r809"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-

information"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual", "http://www.kempharm.com/20240930/role/statement-note-c-inventories", "http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details", "http://www.kempharm.com/20240930/role/statement-note-c-inventories-tables", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-tables", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-tables", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-stockbased-compensation-expense-details", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-tables", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-reconciliation-of-beginning-and-ending-balances-for-derivative-and-warrant-liability-measured-at-fair-value-on-recurring-basis-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-tables", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-antidilutive-securities-details", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-earnings-per-share-details", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-tables", "http://www.kempharm.com/20240930/role/statement-note-k-leases", "http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual", "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-tables", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-pro-forma-combined-results-of-operations-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-tables", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual", "http://www.kempharm.com/20240930/role/statement-note-n-subsequent-events", "http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations-parentheticals"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r809"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r809"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r824"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r809"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r809"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r809"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r809"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r16", "r158", "r186", "r187", "r188", "r205", "r206", "r207", "r209", "r215", "r218", "r220", "r237", "r258", "r261", "r285", "r356", "r426", "r427", "r429", "r430", "r431", "r433", "r439", "r440", "r446", "r447", "r448", "r449", "r450", "r451", "r454", "r489", "r490", "r491", "r492", "r493", "r494", "r499", "r501", "r521", "r584", "r601", "r602", "r603", "r622", "r692"] }, "zvra_EquityDistributionAgreementCommissionFeePercentageOfGrossSales": { "xbrltype": "percentItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "EquityDistributionAgreementCommissionFeePercentageOfGrossSales", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_EquityDistributionAgreementCommissionFeePercentageOfGrossSales", "terseLabel": "Equity Distribution Agreement, Commission Fee, Percentage of Gross Sales", "documentation": "The percentage of gross sales for commission fee under the equity distribution agreement." } } }, "auth_ref": [] }, "zvra_EquityDistributionAgreementMaximumAggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "EquityDistributionAgreementMaximumAggregateOfferingPrice", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_EquityDistributionAgreementMaximumAggregateOfferingPrice", "terseLabel": "Equity Distribution Agreement, Maximum Aggregate Offering Price", "documentation": "The maximum aggregate offering price under the equity distribution agreement." } } }, "auth_ref": [] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Europe [Member]", "documentation": "Continent of Europe." } } }, "auth_ref": ["r836", "r837", "r838", "r839", "r1016", "r1017", "r1018", "r1019"] }, "zvra_FairValueAdjustmentOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "FairValueAdjustmentOfInvestments", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Fair value adjustment related to investments", "negatedLabel": "Fair value adjustment related to investments", "documentation": "Amount of expense (income) related to adjustment to fair value of investments." } } }, "auth_ref": [] }, "zvra_FairValueAdjustmentOfPutOptionNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "FairValueAdjustmentOfPutOptionNetOfTax", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_FairValueAdjustmentOfPutOptionNetOfTax", "terseLabel": "Fair Value Adjustment of Put Option, Net of Tax", "documentation": "After tax amount of expense (income) related to adjustment to fair value of put option." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueAdjustmentOfWarrants", "negatedLabel": "Fair value adjustment related to warrant and CVR liability", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r0", "r10"] }, "zvra_FairValueAdjustmentOfWarrantsAndCvrLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "FairValueAdjustmentOfWarrantsAndCvrLiability", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Fair value adjustment related to warrant and CVR liability", "documentation":

"Amount of expense (income) related to adjustment to fair value of warrant liability and CVR Liability" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-tables"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r460", "r461", "r776"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r463", "r464", "r465", "r466", "r467", "r468", "r473", "r774"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r463", "r464", "r465", "r466", "r467", "r468", "r473", "r774"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r326", "r381", "r382", "r383", "r384", "r385", "r386", "r457", "r459", "r460", "r461", "r462", "r471", "r472", "r474", "r525", "r526", "r527", "r755", "r756", "r762", "r763", "r764", "r772", "r776"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r458", "r459", "r460", "r462", "r772", "r946", "r957"] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r467", "r469", "r470", "r471", "r474", "r475", "r476", "r477", "r478", "r566", "r772", "r777"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r326", "r381", "r386", "r459", "r472", "r525", "r762", "r763", "r764", "r772"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r326", "r381", "r386", "r459", "r460", "r472", "r526", "r755", "r756", "r762", "r763", "r764", "r772"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r326", "r381", "r382", "r383", "r384", "r385", "r386", "r459", "r460", "r461", "r462", "r472", "r527", "r755", "r756", "r762", "r763", "r764", "r772", "r776"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r463", "r468", "r473"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r458", "r459", "r460", "r462", "r772", "r946", "r957"] }, "zvra_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCumulativeEffectAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCumulativeEffectAdjustment", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-reconciliation-of-beginning-and-ending-balances-for-derivative-and-warrant-liability-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Change in fair value measurement", "documentation": "Amount of cumulative effect adjustment for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-reconciliation-of-beginning-and-ending-balances-for-derivative-and-warrant-liability-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r463", "r473"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r326", "r381", "r382", "r383", "r384", "r385", "r386", "r457", "r459", "r460", "r461", "r462", "r471", "r472", "r474", "r525", "r526", "r527", "r755", "r756", "r762", "r763", "r764", "r772", "r776"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r772", "r943", "r944", "r945", "r946", "r947", "r957"] }, "zvra_FinanceLeaseCostTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "FinanceLeaseCostTotal", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "zvra_FinanceLeaseCostTotal", "totalLabel": "Total finance lease cost", "documentation": "Represents total cost of fiance lease." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details": { "parentTag": "zvra_FinanceLeaseCostTotal", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "Interest on lease liabilities", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": ["r504", "r509", "r781"] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiability", "terseLabel": "Lease liabilities, finance leases", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": ["r503", "r518"] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityCurrent", "terseLabel": "Other current liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": ["r503"] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityNoncurrent", "terseLabel": "Other long-term liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": ["r503"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments, finance leases", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r518"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2025, finance leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r518"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2028, finance leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r518"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2027, finance leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r518"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2026, finance leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r518"] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "terseLabel": "2024 (excluding the three months ended March 31, 2024), finance leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r964"] }, "zvra_FinanceLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "zvra_FinanceLeaseLiabilityToBePaidAfterYearFour", "terseLabel": "Thereafter, finance leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount", "negatedTerseLabel": "Less: future interest expense, finance leases", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r518"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Financing cash flows from finance leases", "negatedLabel": "Repayment of principal on finance lease liabilities", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r505", "r514"] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseRightOfUseAsset", "totalLabel": "Property and equipment, net", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": ["r502"] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details": { "parentTag": "zvra_FinanceLeaseCostTotal", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "Amortization of right-of-use assets", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": ["r504", "r509", "r781"] }, "zvra_FinanceLeaseRightofuseAssetGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "FinanceLeaseRightofuseAssetGross", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details": { "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "zvra_FinanceLeaseRightofuseAssetGross", "terseLabel": "Property and equipment, at cost", "documentation": "Gross amount of lessee's right to use underlying asset under finance lease." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "Finance leases", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": ["r517", "r781"] }, "zvra_FinancingReceivableMaximumLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "FinancingReceivableMaximumLimit", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_FinancingReceivableMaximumLimit", "terseLabel": "Financing Receivable, Maximum Limit", "documentation": "The maximum limit of the financing receivable." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r281", "r735", "r753"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r1020"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r281", "r735", "r753"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r281", "r735", "r753"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r281", "r735", "r753"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r272", "r274", "r275", "r276", "r278", "r279", "r283", "r284", "r534", "r535", "r735"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r272", "r274", "r275", "r276", "r278", "r279", "r283", "r284", "r735"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "terseLabel": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r534", "r888"] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax", "negatedLabel": "Loss (gain) on foreign currency exchange", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r482", "r484", "r486", "r487", "r689"] }, "us-

gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": ["r481"] }, "zvra_GainLossOnContingentConsiderationChangeInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "GainLossOnContingentConsiderationChangeInFairValue", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_GainLossOnContingentConsiderationChangeInFairValue", "terseLabel": "Gain (Loss) on Contingent Consideration, Change in Fair Value", "documentation": "Represents the gain/(loss) on contingent consideration from the changes in fair value over the period." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-stockbased-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r80"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 0.0 }, "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Goodwill acquired", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r167", "r271", "r567", "r750", "r752", "r773", "r782", "r880", "r881"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r879", "r882"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r78", "r112", "r116", "r570", "r582", "r748", "r749", "r869", "r870", "r871", "r872", "r873"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-stockbased-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r286", "r292", "r293", "r464", "r468", "r473", "r598", "r600", "r676", "r735", "r775", "r983"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-stockbased-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r292", "r293", "r464", "r468", "r473", "r598", "r600", "r676", "r735", "r775", "r983"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r118", "r124", "r219", "r220", "r236", "r245", "r248", "r424", "r425", "r428", "r589", "r770"] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables", "negatedLabel": "Accounts and other receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": ["r9"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r9"] }, "zvra_IncreaseDecreaseInDiscountAndRebateLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "IncreaseDecreaseInDiscountAndRebateLiabilities", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Discount and rebate liability", "documentation": "Increase (decrease) in discount and rebate liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r9"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Change in assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r830", "r855"] }, "zvra_IncreaseDecreaseInOperatingLeaseRightofuseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseRightofuseAsset", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "zvra_IncreaseDecreaseInOperatingLeaseRightofuseAsset", "negatedLabel": "Operating lease right-of-use assets", "documentation": "The amount of increase (decrease) in operating lease right-of-use assets." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets", "negatedLabel": "Other long-term assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r855"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities", "terseLabel": "Other liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r9"] }, "zvra_IncreaseInCommonStockReservedForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "IncreaseInCommonStockReservedForIssuance", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_IncreaseInCommonStockReservedForIssuance", "terseLabel": "Increase in Common Stock Reserved for Issuance (in shares)", "documentation": "Amount of increase in common stock reserved for issuance." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill", "terseLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r270", "r282", "r753"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": ["r812", "r813", "r814", "r816", "r817", "r818", "r821"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": ["r819"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets,

excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r272", "r888", "r889"] }, "zvra_InterestAndOtherIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "InterestAndOtherIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Interest and other income (expense), net", "documentation": "Represents the amount of interest and other income (expense), net, recognized during the period." } } }, "auth_ref": [] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseNonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r243", "r851"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r193", "r195", "r196"] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestPayableCurrentAndNoncurrent", "terseLabel": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": ["r108", "r976"] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-c-inventories"], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r266"] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details"], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r842"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryNet", "terseLabel": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r177", "r740", "r782"] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 }, "http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Inventories", "totalLabel": "Total inventory", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": ["r841"] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r119", "r163", "r176", "r266", "r267", "r269", "r532", "r744"] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details"], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r844"] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details"], "lang": { "en-us": { "role": { "label": "Work in progress", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r843"] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Inventory obsolescence charge", "terseLabel": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": ["r268"] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": ["r588", "r613", "r614", "r615", "r616", "r699", "r700"] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InvestmentsFairValueDisclosure", "terseLabel": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": ["r943", "r944", "r954"] }, "zvra_JMPAndRBCCMMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "JMPAndRBCCMMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "JMP and RBCCM [Member]", "documentation": "Represents JMP Securities LLC (\"JMP\") and RBC Capital Markets, LLC (\"RBCCM\")." } } }, "auth_ref": [] }, "zvra_JmpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "JmpMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "JMP [Member]", "documentation": "Represents JMP." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LeaseCost", "totalLabel": "Total lease costs", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r508", "r781"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-tables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r963"] }, "zvra_LeaseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "LeaseDisclosureTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases"], "lang": { "en-us": { "role": { "label": "Lease Disclosure [Text Block]", "documentation": "The entire disclosure for operating, finance, sale leaseback leases." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual", "http://www.kempharm.com/20240930/role/statement-note-c-inventories", "http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details", "http://www.kempharm.com/20240930/role/statement-note-c-inventories-tables", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-tables", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-tables", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-stockbased-compensation-expense-details", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-tables", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-reconciliation-of-beginning-and-ending-balances-for-derivative-and-warrant-liability-measured-at-fair-value-on-recurring-basis-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-tables", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-antidilutive-securities-details", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-earnings-per-share-details", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-tables", "http://www.kempharm.com/20240930/role/statement-note-k-leases", "http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual", "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-tables", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-pro-forma-combined-results-of-operations-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-tables", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets",

"http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual", "http://www.kempharm.com/20240930/role/statement-note-n-subsequent-events", "http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations-parentheticals"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "zvra_LesseeLeaseOptionToExtendMaximumTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "LesseeLeaseOptionToExtendMaximumTerm", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_LesseeLeaseOptionToExtendMaximumTerm", "terseLabel": "Lessee, Lease, Option to Extend, Maximum Term (Year)", "documentation": "Represents maximum terms of option to extend lessee's lease." } } }, "auth_ref": [] }, "zvra_LesseeLeaseOptionToTerminateTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "LesseeLeaseOptionToTerminateTerm", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_LesseeLeaseOptionToTerminateTerm", "terseLabel": "Lessee, Lease, Option to Terminate, Term (Year)", "documentation": "Represents the terms of option to terminate lessee's lease." } } }, "auth_ref": [] }, "zvra_LesseeLeaseRemainingTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "LesseeLeaseRemainingTermOfContract", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_LesseeLeaseRemainingTermOfContract", "terseLabel": "Lessee, Lease, Remaining Term of Contract (Year)", "documentation": "Remaining term of lessee's lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments, operating leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r518"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2025, operating leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r518"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2028, operating leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r518"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2027, operating leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r518"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2026, operating leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r518"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "terseLabel": "2024 (excluding the three months ended March 31, 2024), operating leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r964"] }, "zvra_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "zvra_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "terseLabel": "Thereafter, operating leases", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedTerseLabel": "Less: future interest expense, operating leases", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r518"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r17", "r57", "r58", "r59", "r62", "r63", "r64", "r65", "r201", "r257", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r443", "r444", "r445", "r480", "r650", "r747", "r807", "r902", "r967", "r968"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r73", "r111", "r579", "r782", "r858", "r876", "r958"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders' equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r59", "r162", "r201", "r257", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r443", "r444", "r445", "r480", "r782", "r902", "r967", "r968"] }, "zvra_LicenseAgreementAndTerminationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "LicenseAgreementAndTerminationAgreementMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "License Agreement and Termination Agreement [Member]", "documentation": "Represents License Agreement and Termination Agreement." } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": ["r908"] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LineOfCredit", "terseLabel": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r17", "r109", "r977"] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": ["r56", "r61", "r857", "r900", "r901"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r56", "r61", "r857", "r900"] }, "zvra_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfInvestments": { "xbrltype": "percentItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfInvestments", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfInvestments", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Investments", "documentation": "Percentage of investments outstanding for maximum borrowing capacity of the debt instrument." } } }, "auth_ref": [] }, "us-

gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditCurrent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Line of credit payable", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r57", "r107"] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information." } } }, "auth_ref": [] }, "zvra_LitigationRelatedToMergerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "LitigationRelatedToMergerMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Litigation Related to Merger [Member]", "documentation": "Represent litigation related to merger." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r204", "r330"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details"], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r204", "r330"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details"], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r204", "r330"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r204", "r330"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details"], "lang": { "en-us": { "role": { "label": "2024 (excluding the nine months ending September 30, 2024)", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": ["r860"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r170"] }, "zvra_LongtermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "LongtermDebtMaturityAfterYearFour", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details"], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LossContingencyAccrualAtCarryingValue", "terseLabel": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": ["r296", "r826"] }, "zvra_LossOnSubleaseAndDisposalOfPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "LossOnSubleaseAndDisposalOfPropertyAndEquipment", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Loss on sublease and disposal of property and equipment", "documentation": "Represents the loss on sublease and disposal of property and equipment recognized during the period." } } }, "auth_ref": [] }, "zvra_MarathonConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "MarathonConvertibleNotesMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Marathon Convertible Notes [Member]", "documentation": "Represents the Marathon Convertible Notes." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases", "http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r127", "r129", "r131", "r132", "r134", "r156", "r157", "r297", "r298", "r299", "r300", "r387", "r422", "r462", "r531", "r597", "r599", "r611", "r642", "r643", "r697", "r701", "r703", "r704", "r714", "r733", "r734", "r751", "r759", "r767", "r776", "r777", "r778", "r779", "r792", "r904", "r969", "r970", "r971", "r972", "r973", "r974"] }, "zvra_MaximumRoyaltyObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "MaximumRoyaltyObligation", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_MaximumRoyaltyObligation", "terseLabel": "Maximum Royalty Obligation", "documentation": "Amount of maximum royalty obligation." } } }, "auth_ref": [] }, "zvra_MaximumRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "MaximumRoyaltyPercentage", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_MaximumRoyaltyPercentage", "terseLabel": "Maximum Royalty Percentage", "documentation": "Percentage of maximum royalty." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": ["r945", "r946", "r947"] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": ["r945", "r946", "r947"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r776", "r945", "r946", "r947"] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r945", "r946", "r947"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } },

"auth_ref": ["r460", "r461", "r462", "r776"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r460", "r461", "r462", "r776"] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger"], "lang": { "en-us": { "role": { "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": ["r55", "r99"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases", "http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r127", "r129", "r131", "r132", "r134", "r156", "r157", "r297", "r298", "r299", "r300", "r387", "r422", "r462", "r531", "r597", "r599", "r611", "r642", "r643", "r697", "r701", "r703", "r704", "r714", "r733", "r734", "r751", "r759", "r767", "r776", "r777", "r778", "r792", "r904", "r969", "r970", "r971", "r972", "r973", "r974"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r820"] }, "zvra_NantahalaNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "NantahalaNoteMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Nantahala Note [Member]", "documentation": "Represents the Nantahala Note." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r194"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r194"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r87", "r88", "r89"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 }, "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-earnings-per-share-details", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "verboseLabel": "Net Income (loss)", "label": "Net loss", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r79", "r89", "r113", "r160", "r181", "r184", "r188", "r201", "r208", "r210", "r211", "r213", "r214", "r215", "r219", "r220", "r227", "r257", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r432", "r440", "r456", "r480", "r583", "r672", "r690", "r691", "r805", "r902"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss"], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "terseLabel": "Net loss", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r191", "r210", "r211", "r213", "r214", "r223", "r224", "r228", "r231", "r440"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r820"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r820"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other (expense) income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r81"] }, "zvra_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details"], "lang": { "en-us": { "role": { "verboseLabel": "Note payable", "label": "us-gaap_NotesPayable", "totalLabel": "Notes Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r17", "r109", "r977", "r978"] }, "zvra_NotesPayableExcludingSecuredPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "NotesPayableExcludingSecuredPromissoryNoteMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details"], "lang": { "en-us": { "role": { "label": "Notes Payable Excluding Secured Promissory Note [Member]", "documentation": "Represents Notes Payable Excluding Secured Promissory Note" } } }, "auth_ref": [] }, "zvra_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "zvra_OlpruvaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "OlpruvaMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "OLPRUVA [Member]", "documentation": "Represents OLPRUVA." } } }, "auth_ref": [] }, "zvra_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-tables"], "lang": { "en-us": { "role": { "label": "Operating and Finance Lease, Liability, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of operating and finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating and finance lease liability recognized in statement of financial position." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r116", "r748", "r869", "r870", "r871", "r872", "r873"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r510", "r781"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseLiability", "terseLabel": "Lease liabilities, operating leases", "totalLabel": "Total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r503"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r503"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Operating lease liabilities, less current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r503"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details"], "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r506", "r514"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "verboseLabel": "Total operating lease right-of-use assets", "label": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r502"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "Operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r517", "r781"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "Operating leases (in years) (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r516", "r781"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r168"] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss"], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustment", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r5", "r75", "r76", "r77", "r483", "r485", "r488"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss"], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "totalLabel": "Other comprehensive (loss) income", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r7", "r15", "r104", "r182", "r185", "r215"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss"], "lang": { "en-us": { "role": { "label": "Other comprehensive (loss) income:" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r58", "r782"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r63"] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Other (expense) income:" } } }, "auth_ref": [] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Non-cash interest expense", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r10"] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": ["r101", "r883", "r884", "r885", "r886", "r887", "r888", "r890", "r891"] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForLegalSettlements", "terseLabel": "Payments for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": ["r8"] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Payments to repurchase shares as part of the Share Repurchase Program", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r85"] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Payment of third-party debt issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": ["r24"] }, "zvra_PaymentsOfPrincipalOnInsuranceFinancingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "PaymentsOfPrincipalOnInsuranceFinancingArrangements", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "zvra_PaymentsOfPrincipalOnInsuranceFinancingArrangements", "negatedLabel": "Payments of principal on insurance financing arrangements", "documentation": "Represents payments of principal on insurance financing arrangements." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt", "negatedLabel": "Purchases of secured corporate notes", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r22", "r192", "r255"] }, "us-gaap_PaymentsToAcquireNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireNotesReceivable", "crdr": "credit", "presentation": [

"http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireNotesReceivable", "terseLabel": "Payments to Acquire Notes Receivable", "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": ["r22"] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireOtherInvestments", "negatedLabel": "Purchases of investments", "documentation": "Amount of cash outflow to acquire investments classified as other." } } }, "auth_ref": ["r83"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r84"] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "zvra_PossibleFutureIssuancesUnderEmployeeStockPurchasePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "PossibleFutureIssuancesUnderEmployeeStockPurchasePlansMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details"], "lang": { "en-us": { "role": { "label": "Possible Future Issuances Under Employee Stock Purchase Plans [Member]", "documentation": "Represents possible future issuances under employee stock purchase plans." } } }, "auth_ref": [] }, "zvra_PossibleFutureIssuancesUnderEquityIncentivePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "PossibleFutureIssuancesUnderEquityIncentivePlansMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details"], "lang": { "en-us": { "role": { "label": "Possible Future Issuances Under Equity Incentive Plans [Member]", "documentation": "Represents possible future issuances under equity incentive plans." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r66", "r341"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r66", "r652"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r66", "r341"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r66", "r652", "r670", "r1014", "r1015"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of September 30, 2024, or December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r66", "r575", "r782"] }, "zvra_PrelaunchInventoryThatQualifiedForCapitalizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "PrelaunchInventoryThatQualifiedForCapitalizationMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Pre-launch Inventory that Qualified for Capitalization [Member]", "documentation": "Represents pre-launch inventory that qualified for capitalization." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r846"] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrimeRateMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "zvra_ProceedsFromInsuranceFinancingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ProceedsFromInsuranceFinancingArrangements", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Proceeds from insurance financing arrangements", "documentation": "Represents proceeds from insurance financing arrangements." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r6"] }, "zvra_ProceedsFromIssuanceOfCommonStockNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockNet", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_ProceedsFromIssuanceOfCommonStockNet", "terseLabel": "Proceeds from Issuance of Common Stock, Net", "documentation": "The cash inflow from issuance of common stock, net of cash paid for issuance cost." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of debt, net of lender fees", "terseLabel": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r853"] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfLongTermDebt", "terseLabel": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r23", "r617"] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Maturities of investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": ["r21"] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Proceeds from Employee Stock Purchase Plan", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": ["r6"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromWarrantExercises", "terseLabel": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r852"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of

similar products and similar services." } } }, "auth_ref": ["r136", "r137", "r138", "r139", "r140", "r141", "r154", "r249", "r533", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r737", "r760", "r791", "r792", "r793", "r795", "r796", "r840", "r898", "r899", "r907", "r980", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": ["r136", "r137", "r138", "r139", "r140", "r141", "r154", "r249", "r533", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r737", "r760", "r791", "r792", "r793", "r795", "r796", "r840", "r898", "r899", "r907", "r980", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011"] }, "zvra_PropertyAndEquipmentAtCostMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "PropertyAndEquipmentAtCostMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details"], "lang": { "en-us": { "role": { "label": "Property and Equipment, At Cost [Member]", "documentation": "Primary financial statement caption encompassing property and plant at cost." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r11", "r519", "r571", "r581", "r782"] }, "us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Inventory [Axis]", "documentation": "Information by type of inventory held." } } }, "auth_ref": ["r845"] }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Inventory [Domain]", "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } }, "auth_ref": ["r845"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases", "http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r127", "r129", "r131", "r132", "r134", "r156", "r157", "r297", "r298", "r299", "r300", "r380", "r387", "r413", "r414", "r415", "r422", "r462", "r528", "r529", "r531", "r597", "r599", "r611", "r642", "r643", "r697", "r701", "r703", "r704", "r714", "r733", "r734", "r751", "r759", "r767", "r776", "r777", "r778", "r779", "r792", "r799", "r896", "r904", "r946", "r970", "r971", "r972", "r973", "r974"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases", "http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r127", "r129", "r131", "r132", "r134", "r156", "r157", "r297", "r298", "r299", "r300", "r380", "r387", "r413", "r414", "r415", "r422", "r462", "r528", "r529", "r531", "r597", "r599", "r611", "r642", "r643", "r697", "r701", "r703", "r704", "r714", "r733", "r734", "r751", "r759", "r767", "r776", "r777", "r778", "r779", "r792", "r799", "r896", "r904", "r946", "r970", "r971", "r972", "r973", "r974"] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": ["r68", "r74"] }, "zvra_ReliefMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ReliefMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Relief [Member]", "documentation": "Represents Relief." } } }, "auth_ref": [] }, "zvra_ReliefTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ReliefTherapeuticsMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "Relief Therapeutics [Member]", "documentation": "Relates to Relief Therapeutics." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfDebt", "negatedLabel": "Repayment of debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r854"] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfNotesPayable", "terseLabel": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": ["r86"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r152", "r153", "r202", "r203", "r316", "r343", "r522", "r530", "r572", "r742", "r743"] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r935"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-stockbased-compensation-expense-details"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r423"] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": ["r155", "r159", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r216", "r217", "r218", "r219", "r220", "r221", "r235", "r259", "r260", "r430", "r431", "r432", "r433", "r439", "r440", "r453", "r454", "r455", "r456", "r498", "r500", "r520", "r521", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r612", "r874"] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": ["r155", "r159", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r216", "r217", "r218", "r219", "r220", "r221", "r235", "r259", "r260", "r430", "r431", "r432", "r433", "r439", "r440", "r453", "r454", "r455", "r456", "r498", "r500", "r520", "r521", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r612", "r874"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r70", "r98", "r578", "r605", "r610", "r621", "r653", "r782"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r158", "r205", "r206", "r207", "r209", "r215", "r218", "r220", "r258", "r261", "r285", "r426", "r427", "r429", "r430", "r431", "r433", "r439", "r440", "r446", "r448", "r449", "r451", "r454", "r499", "r501", "r601", "r603", "r622", "r1014"] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Revenue, net", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to

customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r114", "r115", "r236", "r241", "r242", "r246", "r248", "r249", "r250", "r252", "r375", "r376", "r533"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r125", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r736"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r125", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r379"] }, "zvra_RevenueRecognitionMilestoneMethodAdditionalRevenueToBeRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "RevenueRecognitionMilestoneMethodAdditionalRevenueToBeRecognized", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_RevenueRecognitionMilestoneMethodAdditionalRevenueToBeRecognized", "terseLabel": "Revenue Recognition, Milestone Method, Additional Revenue to be Recognized", "documentation": "The amount of additional consideration to be recognized for the milestone or milestones." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details"], "lang": { "en-us": { "role": { "label": "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "terseLabel": "Finance leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": ["r515", "r781"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details"], "lang": { "en-us": { "role": { "label": "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "terseLabel": "Operating leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r515", "r781"] }, "zvra_RoyaltyRevenuePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "RoyaltyRevenuePercent", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_RoyaltyRevenuePercent", "terseLabel": "Royalty Revenue, Percent", "documentation": "Represents the royalty revenue expressed as a percentage." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r820"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r820"] }, "zvra_SWKLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "SWKLoansMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "SWK Loans [Member]", "documentation": "Represents the SWK Loans." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": ["r159", "r205", "r207", "r208", "r209", "r210", "r211", "r220", "r235", "r430", "r432", "r433", "r439", "r440", "r453", "r454", "r455", "r498", "r500", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r612", "r829", "r831", "r832", "r833", "r864", "r874", "r877", "r878", "r942", "r965", "r966"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r26"] }, "zvra_ScheduleOfAuthorizedSharesOfCommonStockReservedForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ScheduleOfAuthorizedSharesOfCommonStockReservedForFutureIssuanceTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Authorized Shares of Common Stock Reserved for Future Issuance [Table Text Block]", "documentation": "Tabular disclosure of authorized shares of common stock reserved for future issuance." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r17", "r31", "r32", "r53", "r96", "r97", "r755", "r757", "r860", "r961"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r867"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r36"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r943", "r944"] }, "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryNoncurrentTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-c-inventories-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Noncurrent [Table Text Block]", "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs." } } }, "auth_ref": [] }, "zvra_ScheduleOfLeasesBalanceSheetInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ScheduleOfLeasesBalanceSheetInformationTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Leases Balance Sheet Information [Table Text Block]", "documentation": "Tabular disclosure of leases related to balance sheet." } } }, "auth_ref": [] }, "zvra_ScheduleOfLeasesCashFlowInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ScheduleOfLeasesCashFlowInformationTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Leases Cash Flow Information [Table Text Block]", "documentation": "Tabular disclosure of leases related to cash flow information." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r12"] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": ["r100"] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": ["r940"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r808"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-

information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r810"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": ["r128", "r130", "r133", "r135", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r250", "r251", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r636", "r638", "r640", "r698", "r702", "r705", "r715", "r722", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r738", "r761", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r794", "r799", "r907", "r980", "r984", "r985", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations"], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r80"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r9"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r769"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416"] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": ["r906"] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": ["r906"] }, "zvra_ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ShareRepurchaseProgramMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Member]" } } }, "auth_ref": [] }, "zvra_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesReservedForIssuanceIncrementalPercentageOfCapitalStockOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesReservedForIssuanceIncrementalPercentageOfCapitalStockOutstanding", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesReservedForIssuanceIncrementalPercentageOfCapitalStockOutstanding", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Reserved for Issuance, Incremental Percentage of Capital Stock Outstanding", "documentation": "Represents the share based compensation arrangement by share based payment award number of shares reserved for issuance incremental percentage of capital stock outstanding." } } }, "auth_ref": [] }, "zvra_SharesAndWarrantsIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "SharesAndWarrantsIssuedPricePerShare", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_SharesAndWarrantsIssuedPricePerShare", "terseLabel": "Shares and Warrants Issued, Price Per Share (in dollars per share)", "documentation": "The price per share of shares and warrants issued." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r511", "r781"] }, "us-gaap_ShortTermLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeasePayments", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details"], "lang": { "en-us": { "role": { "label": "Operating cash flows from short-term leases", "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability." } } }, "auth_ref": ["r507"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r90", "r198"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r126", "r171", "r172", "r173", "r201", "r225", "r226", "r229", "r231", "r238", "r239", "r257", "r303", "r305", "r306", "r307", "r310", "r311", "r341", "r342", "r345", "r348", "r354", "r480", "r617", "r618", "r619", "r620", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r652", "r673", "r692", "r716", "r717", "r718", "r719", "r720", "r825", "r856", "r866"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r16", "r67", "r71", "r72", "r158", "r186", "r187", "r188", "r205", "r206", "r207", "r209", "r215", "r218", "r220", "r237", "r258", "r261", "r285", "r356", "r426", "r427", "r429", "r430", "r431", "r433", "r439", "r440", "r446", "r447", "r448", "r449", "r450", "r451", "r454", "r489", "r490", "r491", "r492", "r493", "r494", "r499", "r501", "r521", "r584", "r601", "r602", "r603", "r622", "r692"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": ["r128", "r130", "r133", "r135", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r250", "r251", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r636", "r638", "r640", "r698", "r702", "r705", "r715", "r722", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r738", "r761", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r794", "r799", "r907", "r980", "r984", "r985", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual", "http://www.kempharm.com/20240930/role/statement-note-c-inventories", "http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details", "http://www.kempharm.com/20240930/role/statement-note-c-inventories-tables", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-tables", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-tables", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-stockbased-compensation-expense-details", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-tables", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-reconciliation-of-beginning-and-ending-balances-for-derivative-and-warrant-liability-measured-at-fair-value-on-recurring-basis-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-tables",

"http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-antidilutive-securities-details", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-earnings-per-share-details", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-tables", "http://www.kempharm.com/20240930/role/statement-note-k-leases", "http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual", "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-tables", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-pro-forma-combined-results-of-operations-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-tables", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual", "http://www.kempharm.com/20240930/role/statement-note-n-subsequent-events", "http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations-parentheticals"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r205", "r206", "r207", "r237", "r501", "r533", "r613", "r633", "r644", "r645", "r646", "r647", "r648", "r649", "r652", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r665", "r666", "r667", "r668", "r669", "r671", "r674", "r675", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r692", "r800"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies", "http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual", "http://www.kempharm.com/20240930/role/statement-note-c-inventories", "http://www.kempharm.com/20240930/role/statement-note-c-inventories-summary-of-inventory-details", "http://www.kempharm.com/20240930/role/statement-note-c-inventories-tables", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-aggregate-principal-amount-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-tables", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies", "http://www.kempharm.com/20240930/role/statement-note-f-commitments-and-contingencies-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-tables", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-stockbased-compensation-expense-details", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-tables", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-reconciliation-of-beginning-and-ending-balances-for-derivative-and-warrant-liability-measured-at-fair-value-on-recurring-basis-details", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-tables", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-antidilutive-securities-details", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-earnings-per-share-details", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-tables", "http://www.kempharm.com/20240930/role/statement-note-k-leases", "http://www.kempharm.com/20240930/role/statement-note-k-leases-details-textual", "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-maturities-of-lease-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details", "http://www.kempharm.com/20240930/role/statement-note-k-leases-tables", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-pro-forma-combined-results-of-operations-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details", "http://www.kempharm.com/20240930/role/statement-note-l-merger-tables", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual", "http://www.kempharm.com/20240930/role/statement-note-n-subsequent-events", "http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-comprehensive-loss", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations-parentheticals"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r205", "r206", "r207", "r237", "r253", "r501", "r533", "r613", "r633", "r644", "r645", "r646", "r647", "r648", "r649", "r652", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r665", "r666", "r667", "r668", "r669", "r671", "r674", "r675", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r692", "r800"] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": ["r868"] }, "zvra_StockIssuableDuringThePeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "StockIssuableDuringThePeriod", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "zvra_StockIssuableDuringThePeriod", "terseLabel": "Stock Issuable During the Period (in shares)", "documentation": "Number of stock issuable during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesAcquisitions", "terseLabel": "Stock Issued During Period, Shares, Acquisitions (in shares)", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": ["r66", "r67", "r98"] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock issued as a result of the Employee Stock Purchase Plan (in shares)", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r16", "r66", "r67", "r98"] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details"], "lang": { "en-us": { "role": { "label": "Common stock issued as compensation to third parties (in shares)", "terseLabel": "Common stock issued as compensation to third parties (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock issued in connection with the Public Offering (Note B) (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r16", "r66", "r67", "r98", "r617", "r692", "r717"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details"], "lang": { "en-us": { "role": { "label": "Common stock issued in connection with vesting of performance-based awards (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r16", "r66", "r67", "r98"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-common-stock-activity-details", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock issued as a result of stock options exercised (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r16", "r66", "r67", "r98", "r399"] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with the Merger (Note L)", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": ["r16", "r67", "r71", "r72", "r98"] }, "us-

gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock as part of the Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r16", "r66", "r67", "r98"] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock in exchange for consulting services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock in public offering", "terseLabel": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r16", "r66", "r67", "r98", "r622", "r692", "r717", "r806"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock for options exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r16", "r67", "r71", "r72", "r98"] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "srt_StockRepurchaseProgramAuthorizedAmount1", "terseLabel": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": ["r906"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-", "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r67", "r71", "r72", "r92", "r654", "r670", "r693", "r694", "r782", "r807", "r858", "r876", "r958", "r1014"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r95", "r200", "r340", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r356", "r452", "r695", "r696", "r721"] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details"], "lang": { "en-us": { "role": { "label": "us-gaap_SubleaseIncome", "negatedLabel": "Less: sublease income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": ["r513", "r781"] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-n-subsequent-events"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r523", "r524"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows"], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "auth_ref": [] }, "zvra_SwkLoansAndMarathonNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "SwkLoansAndMarathonNotesMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "SWK Loans and Marathon Notes [Member]", "documentation": "Represents the SWK Loans and Marathon Notes." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-c-inventories-tables", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-tables", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-tables", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-tables", "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-tables", "http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-tables", "http://www.kempharm.com/20240930/role/statement-note-k-leases-tables", "http://www.kempharm.com/20240930/role/statement-note-l-merger-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "zvra_TermLoansUnderCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "TermLoansUnderCreditAgreementMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-future-minimum-principal-payments-details"], "lang": { "en-us": { "role": { "label": "Term Loans Under Credit Agreement [Member]", "documentation": "Represents term loans under credit agreement." } } }, "auth_ref": [] }, "zvra_The2023PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "The2023PlanMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "The 2023 Plan [Member]", "documentation": "Represents the 2023 Employment Inducement Award Plan." } } }, "auth_ref": [] }, "zvra_TheInvestorWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "TheInvestorWarrantMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants", "http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual"], "lang": { "en-us": { "role": { "label": "The Investor Warrant [Member]", "documentation": "Represents the warrant held by the investor." } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual", "terseLabel": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r821"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.kempharm.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_TrdArrAdoptionDate", "terseLabel": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r822"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_TrdArrIndName", "terseLabel": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r821"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_TrdArrIndTitle", "terseLabel": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r821"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_TrdArrSecuritiesAggAvailAmt", "terseLabel": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r823"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_TrdArrTerminationDate", "terseLabel": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r822"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r33"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockCommonShares", "terseLabel": "Treasury Stock, Common, Shares (in shares)", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r33"] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockCommonValue", "terseLabel": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r33", "r34", "r71"] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-"], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, at cost", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": ["r33", "r34", "r67", "r71"] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": ["http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-changes-in-stockholders-equity"], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockValueAcquiredCostMethod", "negatedLabel": "Shares repurchased as part of the Share Repurchase Program", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": ["r16", "r33", "r98"] }, "zvra_TwoThousandFourteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "TwoThousandFourteenEquityIncentivePlanMember", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation", "http://www.kempharm.com/20240930/role/statement-note-h-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "2014 Equity Incentive Plan [Member]", "documentation": "Represents the two thousand fourteen equity incentive plan." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.kempharm.com/20240930/role/statement-note-e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",

```
"documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } },
"auth_ref": [ "r441" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"USTreasurySecuritiesMember", "presentation": [ "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-
measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "documentation": "This category includes
information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of
treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to
thirty years)." } } } }, "auth_ref": [ "r745", "r762", "r764", "r772", "r975" ] }, "zvra_UnderwritingAgreementAndOverallotmentOptionMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.kempharm.com/20240930", "localname": "UnderwritingAgreementAndOverallotmentOptionMember", "presentation": [
"http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions",
"http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-textual" ], "lang": { "en-us": {
"role": { "label": "Underwriting Agreement and Over-allotment Option [Member]", "documentation": "Represents Underwriting Agreement and Over-allotment Option." } } },
"auth_ref": [] }, "zvra_UnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname":
"UnderwritingAgreementMember", "presentation": [ "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-
significant-transactions", "http://www.kempharm.com/20240930/role/statement-note-a-description-of-business-basis-of-presentation-and-significant-transactions-details-
textual" ], "lang": { "en-us": { "role": { "label": "Underwriting Agreement [Member]", "documentation": "Represents the information pertaining to the underwriting
agreement." } } } }, "auth_ref": [] }, "zvra_UndesignatedPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname":
"UndesignatedPreferredStockMember", "presentation": [ "http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-",
"http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Undesignated
Preferred Stock [Member]", "documentation": "Preferred stock that has been classified as undesignated." } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnInvestments":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": [
"http://www.kempharm.com/20240930/role/statement-note-b-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-
gaap_UnrealizedGainLossOnInvestments", "terseLabel": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } },
"auth_ref": [ "r10" ] }, "zvra_UpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "UpfrontPayment", "crdr":
"credit", "presentation": [ "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual" ], "lang": { "en-us": { "role": { "label": "zvra_UpfrontPayment",
"terseLabel": "Upfront Payment", "documentation": "Amount of upfront payment." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-
policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the
preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r27", "r28", "r29", "r120", "r121", "r122", "r123" ] }, "us-
gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": {
"http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.kempharm.com/20240930/role/statement-note-k-leases-lease-cost-details" ], "lang": { "en-us": { "role": { "label": "Variable lease cost", "documentation": "Amount
of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r512", "r781" ] },
"us-gaap_VariableLeasePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeasePayment", "crdr": "credit",
"presentation": [ "http://www.kempharm.com/20240930/role/statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details" ], "lang": { "en-us": { "role":
{ "label": "Operating cash flows from variable lease costs", "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability." } } },
"auth_ref": [ "r507" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [
"http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"
], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [
"http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual"
], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate
or index." } } }, "auth_ref": [] }, "zvra_VwapConsecutiveTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://www.kempharm.com/20240930", "localname":
"VwapConsecutiveTradingDays", "presentation": [ "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual" ], "lang": { "en-us": { "role": { "label":
"zvra_VwapConsecutiveTradingDays", "terseLabel": "VWAP, Consecutive Trading Days (Year)", "documentation": "The consecutive trading days for VWAP." } } }, "auth_ref": []
}, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [
"http://www.kempharm.com/20240930/role/statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details" ], "lang": { "en-us":
{ "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument,
usually upon payment of a specified amount." } } }, "auth_ref": [ "r797", "r798", "r801", "r802", "r803", "r804" ] }, "us-
gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-fair-
value-assumptions-for-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "Value of input used to measure
outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to
occur." } } }, "auth_ref": [ "r945", "r946", "r947" ] }, "zvra_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname":
"WarrantsMember", "presentation": [ "http://www.kempharm.com/20240930/role/statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-
value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Warrants [Member]", "documentation": "Information pertaining to warrants." } } }, "auth_ref": [] },
"zvra_WarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "WarrantsPolicyTextBlock", "presentation":
[ "http://www.kempharm.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Warrants [Policy Text Block]",
"documentation": "Represents the policy for warrants." } } }, "auth_ref": [] }, "zvra_WarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.kempharm.com/20240930", "localname": "WarrantsToPurchaseCommonStockMember", "presentation": [ "http://www.kempharm.com/20240930/role/statement-
note-j-net-loss-per-share-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Warrants to Purchase Common Stock [Member]", "documentation":
"Represents warrants to purchase common stock." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.kempharm.com/20240930/role/statement-note-j-net-loss-per-share-earnings-per-share-details", "http://www.kempharm.com/20240930/role/statement-unaudited-
condensed-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Basic and diluted (in shares)", "terseLabel": "Weighted average number of shares of
common stock outstanding, basic and diluted (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and
other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the
total time in that period." } } }, "auth_ref": [ "r223", "r231" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [
"http://www.kempharm.com/20240930/role/statement-unaudited-condensed-consolidated-statements-of-operations" ], "lang": { "en-us": { "role": { "label": "Weighted average
number of shares of common stock outstanding:" } } }, "auth_ref": [] }, "zvra_WellsFargoBankNaMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.kempharm.com/20240930", "localname": "WellsFargoBankNaMember", "presentation": [ "http://www.kempharm.com/20240930/role/statement-note-d-debt-
obligations", "http://www.kempharm.com/20240930/role/statement-note-d-debt-obligations-details-textual" ], "lang": { "en-us": { "role": { "label": "Wells Fargo Bank, N.A.
[Member]", "documentation": "Represents the \"Wells Fargo Bank, N.A.\"" } } }, "auth_ref": [] }, "zvra_WorldwideExcludingEuropeMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.kempharm.com/20240930", "localname": "WorldwideExcludingEuropeMember", "presentation": [ "http://www.kempharm.com/20240930/role/statement-
note-l-merger", "http://www.kempharm.com/20240930/role/statement-note-l-merger-details-textual" ], "lang": { "en-us": { "role": { "label": "Worldwide, Excluding Europe
[Member]", "documentation": "Represents worldwide, excluding Europe." } } }, "auth_ref": [] }, "zvra_XomaLicenseAgreementMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.kempharm.com/20240930", "localname": "XomaLicenseAgreementMember", "presentation": [ "http://www.kempharm.com/20240930/role/statement-note-
e-revenue-net", "http://www.kempharm.com/20240930/role/statement-note-e-revenue-net-details-textual", "http://www.kempharm.com/20240930/role/statement-note-m-
goodwill-intangible-assets", "http://www.kempharm.com/20240930/role/statement-note-m-goodwill-intangible-assets-details-textual" ], "lang": { "en-us": { "role": { "label":
"XOMA License Agreement [Member]", "documentation": "Information pertaining to the type of arrangement." } } }, "auth_ref": [] }, "zvra_ZVRAChristalMMMickleMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ZVRAChristalMMMickleMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ZVRA_Christal M.M. Mickle [Member]", "documentation": "Information
pertaining to insider trading." } } }, "auth_ref": [] }, "zvra_ZVRAJoshuaSchaferMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930",
"localname": "ZVRAJoshuaSchaferMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ZVRA_ Joshua
Schafer [Member]", "documentation": "Information pertaining to insider trading." } } }, "auth_ref": [] }, "zvra_ZVRANeilFMcFarlaneMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.kempharm.com/20240930", "localname": "ZVRANeilFMcFarlaneMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ],
"lang": { "en-us": { "role": { "label": "ZVRA_ Neil F. McFarlane [Member]", "documentation": "Information pertaining to insider trading." } } }, "auth_ref": [] },
"zvra_ZVRARLaDuaneCliftonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "ZVRARLaDuaneCliftonMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ZVRA_R. LaDuane Clifton [Member]", "documentation":
"Information pertaining to insider trading." } } }, "auth_ref": [] }, "zvra_ZVRASvenGuentherPhDMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.kempharm.com/20240930", "localname": "ZVRASvenGuentherPhDMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang":
{ "en-us": { "role": { "label": "ZVRA_ Sven Guenther, Ph.D [Member]", "documentation": "Information pertaining to insider trading." } } }, "auth_ref": [] },
"zvra_ZVRATimothyJSangiovanniMember": { "xbrltype": "domainItemType", "nsuri": "http://www.kempharm.com/20240930", "localname":
"ZVRATimothyJSangiovanniMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ZVRA_ Timothy J.
Sangiovanni [Member]", "documentation": "Information pertaining to insider trading." } } }, "auth_ref": [] }, "zvra_statement-statement-note-c-inventories-summary-of-
inventory-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-c-inventories-summary-of-
inventory-details", "lang": { "en-us": { "role": { "label": "Note C - Inventories - Summary of Inventory (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-c-
inventories-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-c-inventories-tables", "lang": {
"en-us": { "role": { "label": "Note C - Inventories" } } }, "auth_ref": [] }, "zvra_statement-statement-note-d-debt-obligations-aggregate-principal-amount-details": { "xbrltype":
"stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-d-debt-obligations-aggregate-principal-amount-details", "lang": {
"en-us": { "role": { "label": "Note D - Debt Obligations - Aggregate Principal Amount (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-d-debt-obligations-
future-minimum-principal-payments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-d-debt-
obligations-future-minimum-principal-payments-details", "lang": { "en-us": { "role": { "label": "Note D - Debt Obligations - Future Minimum Principal Payments (Details)" } }
}, "auth_ref": [] }, "zvra_statement-statement-note-d-debt-obligations-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname":
"statement-statement-note-d-debt-obligations-tables", "lang": { "en-us": { "role": { "label": "Note D - Debt Obligations" } } }, "auth_ref": [] }, "zvra_statement-statement-note-
g-stock-and-warrants-common-stock-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-
note-g-stock-and-warrants-common-stock-activity-details", "lang": { "en-us": { "role": { "label": "Note G - Stock and Warrants - Common Stock Activity (Details)" } } },
"auth_ref": [] }, "zvra_statement-statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-stock-for-future-issuance-details": { "xbrltype":
"stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-g-stock-and-warrants-reserved-authorized-shares-of-common-
stock-for-future-issuance-details", "lang": { "en-us": { "role": { "label": "Note G - Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance
(Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-g-stock-and-warrants-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930",
"localname": "statement-statement-note-g-stock-and-warrants-tables", "lang": { "en-us": { "role": { "label": "Note G - Stock and Warrants" } } }, "auth_ref": [] },
"zvra_statement-statement-note-h-stockbased-compensation-stockbased-compensation-expense-details": { "xbrltype": "stringItemType", "nsuri":
"http://www.kempharm.com/20240930", "localname": "statement-statement-note-h-stockbased-compensation-stockbased-compensation-expense-details", "lang": { "en-us": {
```

"role": { "label": "Note H - Stock-based Compensation - Stock-based Compensation Expense (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-h-stockbased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-h-stockbased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note H - Stock-based Compensation" } } }, "auth_ref": [] }, "zvra_statement-statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-i-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "lang": { "en-us": { "role": { "label": "Note I - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-i-fair-value-of-financial-instruments-fair-value-assumptions-for-warrant-liabilities-details", "lang": { "en-us": { "role": { "label": "Note I - Fair Value of Financial Instruments - Fair Value Assumptions for Warrant Liabilities (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-i-fair-value-of-financial-instruments-reconciliation-of-beginning-and-ending-balances-for-derivative-and-warrant-liability-measured-at-fair-value-on-recurring-basis-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-i-fair-value-of-financial-instruments-reconciliation-of-beginning-and-ending-balances-for-derivative-and-warrant-liability-measured-at-fair-value-on-recurring-basis-details", "lang": { "en-us": { "role": { "label": "Note I - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-i-fair-value-of-financial-instruments-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-i-fair-value-of-financial-instruments-tables", "lang": { "en-us": { "role": { "label": "Note I - Fair Value of Financial Instruments" } } }, "auth_ref": [] }, "zvra_statement-statement-note-j-net-loss-per-share-antidilutive-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-j-net-loss-per-share-antidilutive-securities-details", "lang": { "en-us": { "role": { "label": "Note J - Net Loss Per Share - Anti-dilutive Securities (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-j-net-loss-per-share-earnings-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-j-net-loss-per-share-earnings-per-share-details", "lang": { "en-us": { "role": { "label": "Note J - Net Loss Per Share - Earnings Per Share (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-j-net-loss-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-j-net-loss-per-share-tables", "lang": { "en-us": { "role": { "label": "Note J - Net Loss Per Share" } } }, "auth_ref": [] }, "zvra_statement-statement-note-k-leases-lease-cost-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-k-leases-lease-cost-details", "lang": { "en-us": { "role": { "label": "Note K - Leases - Lease Cost (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-k-leases-maturities-of-lease-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-k-leases-maturities-of-lease-liabilities-details", "lang": { "en-us": { "role": { "label": "Note K - Leases - Maturities of Lease Liabilities (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-k-leases-supplement-balance-sheet-information-related-to-lease-details", "lang": { "en-us": { "role": { "label": "Note K - Leases - Supplement Balance Sheet Information Related to Lease (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-k-leases-supplement-cash-flow-information-related-to-leases-details", "lang": { "en-us": { "role": { "label": "Note K - Leases - Supplement Cash Flow Information Related to Leases (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-k-leases-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-k-leases-tables", "lang": { "en-us": { "role": { "label": "Note K - Leases" } } }, "auth_ref": [] }, "zvra_statement-statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-l-merger-estimates-and-assumptions-related-to-fair-value-of-assets-and-liabilities-acquired-details", "lang": { "en-us": { "role": { "label": "Note L - Merger - Estimates and Assumptions Related to Fair Value of Assets and Liabilities Acquired (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-l-merger-pro-forma-combined-results-of-operations-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-l-merger-pro-forma-combined-results-of-operations-details", "lang": { "en-us": { "role": { "label": "Note L - Merger - Pro Forma Combined Results of Operations (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-l-merger-reconciliation-of-contingent-consideration-liabilities-details", "lang": { "en-us": { "role": { "label": "Note L - Merger - Reconciliation of Contingent Consideration Liabilities (Details)" } } }, "auth_ref": [] }, "zvra_statement-statement-note-l-merger-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-note-l-merger-tables", "lang": { "en-us": { "role": { "label": "Note L - Merger" } } }, "auth_ref": [] }, "zvra_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.kempharm.com/20240930", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Paragraph": "2AA", "Subparagraph": "(a)", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5",

"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":

"Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r825": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r826": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Subparagraph": "(ii)", "Footnote": "2", "Publisher": "SEC" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "1", "Publisher": "SEC" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r887": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",

"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12 (Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 80 0001437749-24-034916-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-034916-xbrl.zip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|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|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|)-DHJG%;4Y$S.M0BA\YJ*(^3" M_HQ+." MTTH!2XY$? [H:&$E*PDCB[NM]YHL>]_B9OOR 9SYYOJ;Y"5WI MDTN?-^K-Y;M@6*;S\G8Z+Y?-0NG-$^;P)$==Z6*=2\<"R[+%%0L2QJ4I"\&F M>MB+)&?A!,M?S.)4%[R? <0.#J[E0BQTR\0531G^36*MI]2U-0*1*2]WTTDW& MUS=H-SBI[Y=<%CJ^T#X!KG BW7;&=?."!0IAZWK=$1+7I|\^)/6HI-S1,TBA MV;$06AAQ0!/>J-$A_MJRW?.N6MU2D>YJC]?7P/'#A.(:B1V& MB\4VU:J+\?+4@G%(;>!YPGJ0BX;$78?3VI9Q_&'(G\--ZT[!E']"78:'G" MR)DLT%OU(7OT_HCUD&;#Y?=@^.3,+S(W%C#D=&WKEO&Y:!E_8:98GVV?!T> M#;;&)IXAQW>[XH842+?K!Z7(ZV]_B$S\W?!?4$L#!!0 (M $Z";5D!J 74G1D "XD 0 1 >G9R82TR,#(T,#DS,"YX\XPQJ33WN>^+*VTYF9ESD0"4GHD" ; &6K?_U6 M@1>1%$A1$FQ3;3U9)@M %>I#H5 BN__^A &SI0*R2+^8>_PU<&>0[D7^8R/ M/^Q]N74'M\?GYWN.5(3[)(@X_;#'H[V__OSO__;^/USW^{54}$5]9SAS[B8) M]ZDXB4+]_/WCS6?'=0[>O#LXN+YPOMP=.T<'1]^[AX?NX6O7_?G]@_3?2E] M0^(!UR^@P_V]^_O[U_=OWX5B?'^T<'!X?[?+S[?:M]C-B+$]]$ MK"CP,!3!*TF]5^-HNI^]W, <&BP*)$"!74XGL;:6(3YF9&EY4"95PU2RFLL*_M+H(2P.MJ?(UE#MR#0_?H,"l)/=_HR*_[@31H:@^C>5E@+&OYGE $V\WL?70R)I3LX)\Z2Y:OVJ4K=D MGID47E0)A2H(1T0.=? OPL$Y4Z_8R:?]J6D#%HJ%|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|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

_8.PXB<'W&)T051G+C6GIK.3>3+)LG3HDW M.1'DON2O/T*]6|R')]33H^+U(6YQ=N^CA7);T@?ZMN!M+"CQK_BO1.B%P@TH M]NN$KI"[1W@OAZ;IS!?"F. MYP=#KD:_?AU7>.[@C-*Y M3W$U L:DU.:X$'_36GKAI;1(D:FQ^%R'<:MA@_)]&^I%GQ1;=P/_MT3J5/& M8CZEZ>\" 1WH^A;&;Y?Q.E%7^E(8>"!7HSORT"JIB7J[Y,VW-<$^EZ/=K5(W ME^F_[%E2,'R+2^$'AXSA=,_*Q5LG>;OT5'Y#'F$YK' MFMO697DGK%RJMT9L49+J*;;;P&WN@&7%^@^![HY!F!YPOR_I<2M<[!3;&(7ZYN,9A^/'X^*)Z?L/T MHI?7A'X):W>!$C_+Y?6&\^?LQ*!WD:GF_&?\]K\F""&';4O%^= M$2\]39B:D8^1$.DA,1+#&S4K1TH-X38[53UGU+4%#RK[F&V6C.DN2M.9U!&P MC*P?.H_X&
9FB+N:60*\F7F0=R#LVY@N28GKPMMDJ',-PF $!R".) FN1M<" M4RZ!+%Q?=(S+L;'5B_5M.=6(X@L"A2;ZTN<4Y,"L*9A7I78@?"E5+S"<&9;; M:$8"-9M_;'HN1>/[WB*VRO/B.9N6][VTFI=0@$R@;Q _59"97_5R^8,/B5$K!\N&$:B9E! ME:N7ZZV>I4EULB)I$T4_]6GD=I 562Y7B;)W\F7WM:M@K#_LQ5Q5K)+ <3#N MNN2^U1WRNA"]6+]X7X(;V1E0B2X4
XC%X$WQI:#5 4_/8-JRCEI:X5:8L.0GZ+&RZYG M7V JXX1[$UPIT7]*1MF^RMN!l<9TI4'@.HXILI72|'.\W M-&!T5)6E]JS'?#>G\FMYWPM;QB"RX$+&=Q9C* 1O>/FLEQD:X7K[]6^?HP778.%I+Z!Y MZTVHGP1@M@<)($@@3-+SV!5#7MK8K[HVYI6#]5K[L]"8"Y9^R26[BJ6_ U0Z MP[^L5U8KW%?A\2X:?GIK9<&[%'QFH9L'-\+XAL;YBD9$8T'"VE!OI^G'P$<>M,?.Y#P,2#[BDFX5S+_7C;$Z2+88'!T3X^>V-=#P;3OSHDT%(3H+R;EOF[.N! M?Y4HG!'*.=]ZQ$_KLBG\LPOO&6Y,/4EB>LL\U>E\Y;3/FOVU+E@V./YW9\T
M41BX;M>5]&)+:'J73^SV_IN>W =X%B;=QC+L<"VEZJ7WC6<)--LZBI%NLS>< M1.A&VD\I)_3HX.BUOJ96E_[*<]]=#>)$@EV&;?\ M%:7<$$*KR;A:F5[*K"V3L'MZ8$.LO9?M*LG&7*'0BGN?9*+BO/^W=ED@AP*_W)#8G2LF% M.:;5XOF.4C1 S?Z"DGQ\GR;FZC+F51;6C,VO^[HRS#F^B_+MKE*HPZR1=M)> M6K&O- CD&1'CZ"/AWRYKV^"-
;_LI2R0"_Y[V\^,CIPF&]FLR+:/]I6Q_AVK; MOZC52M%+F?[YZ\W@>"(8K#&#BXL+YGT+:KIJI>BM3+|$]I*_-9W*2 *?' 1NINL_=1M!;B6ZGE'I*@&Q" MQ?7D9%&B)H+>2G3'PDA-9K_S;_TFLIOIZK>G<7K*)9"KE?MBZ+0]DB-WQ ?*C(I-F>ING=>]"XIS@ZX MZ;9-^GWQDO"C2.1CB66[?9MUK;6VMUP'<=M>]GMZ8-)*H?>6T8M%_O/C<]I
MFA2B,]ILM/!GZ,^.P.I0P?;T!G-'A EWBFFT(R,\OLN+BM2^\K\X_8XE()Y MUAPW3#.XY.S\V45LZE6HXV*HL*9H[Q*QHG;'XY.S\!VS;LX<'I@0LB,8*7+
M[.IE[<;_;%H0E0R!2#>D8\BQXX5&+=7'>=QLLRCM(;]()%V>LHH.FSW;;.N- M,\'VE'2<;U:L;'MZZ3>74\!$)*4+C:2^+,!%,9\%>D_3Q\U M2@2.Q_*CC3JLM;XM[ZN.PZZ]
[/;TP3=7)^V0Z1]P6&7WZ%I[V2WL@S"]%:'XUV19O5Q592)OW(?;MK,=O>L M1^3$'071?:NX;T!SHS:VL$\[VO5%^NV1-0"_&5-GN10X!"W2=!%<7FR5E%IU M&QL6S23[7GIG?#T-#UNHDUA$KAY<&!0:,@]R"(J?$=930Q1GV9>[C^1-;M[" M_EM<9WI%_FK\.4]@O=:4;:^=+>S;CK9QD7XK9,43R6S' PQ$$ IQG^<;X08S' M,U%U^8\V^5>HX\GZY/T^=HGT)C0D\.__
U!+ P04 " !.@FU91/X,(L81 M /%0$ %0 'IV]_>_^(//B$$\Q0BJ(>:-D;3K,DPNR:SG#O[\ON[U0 M._OQW=G9X'/OZ_"J]_KL]0_!^7EP_B8(?GX?D^3;_G7"'"<$T0D//_XX62: MIO-
WIZ>/CX^OGD8L?D79Y/3UV=F;TU7KD[*Y_#5*UQVV&_]X6ORX;KHW]..; MO.WYV[=O3_-?UTTYJ6HH!CT__?WSW4,XQ3,4D$1R))2TT1"E.1N-
M$'K*%O)3L&H6R*^"\]?!F_-73SPZ$5SOl0K6,1KC>SSNR7^_WM\^>^8W/)M/ M$9N!"NGL5++![.V;LU/9\E10G>(93M(@H2D.HB#"HS2@HYA.#%=-ODR^"L<-'"_P9YJD4ZX
VI5(JZ(_OB%+&O]N0W.2GIA#)+,BT8L/Y<;/!8M;:2%^'OHR^#A@0NN1Z./3'"<*IQTMYW*I\X4FX;9L\L!#[7./EIL# M1N>8I-SSX&KGZB-'HD<5R\\ MNF8^V3_/*N151"JB[
M/[<0/6[5C0E#&8C@ [3,>R3R&Y;AE:&S*UNZ(P :X^9S1A?Y,HZR,.W'$A;!=[Y: MY@M]%M9E"XC5"L=QA%O IEI5=]@5R=4?V4NC6 MC#A/!6LKC;*RC\1,P\)EE?
$L,3U+@TJ1#W+JZS61I=236^O!#IO#"+X19K,L MKY#,>2^$Q9SAJ9AE9(%O$S$O\1WEJCWTQT/TI$999Q2_?.QB,1Z1/% F/.W
MR16:DQ3%@M0931Y2&GY3@;/NZ!>/KLZAPV*$XM&&55'5QB^5"T1BN2)O*'M M,7[85E6+HO,-Y\,..J- A+I)HS;$.S^0%
[QEB%3^<16V/1BOFEGJNVW6"@,/X*]S[=8CF7@:E^N.OO% \5D@4 M??RBV"1*S.I!U]8_U=8BT]"Z4\KMF*[MX)7^ 2L30$8S5]/2-\7*W*!^WCCT M](Q(41*AKERWZ>
(5P[W*QMCZ!V)M# M)C10QI;&9:QNV$(=\C5FPH%/R4*NKM^$ R]FI]DNJ-.U#6()S^/$XGGW>"0F MG%$!N78[,)$&ACKUA%E;72V;::/@$:0Z!B.^&FD:2(4#9GQ-@KF0ZHB-2)V-
M#TB5">H2, TMK'H?Q>6: M56^.'$ JX-:\B8;Y-4@5U3H98$A!0-(U&G-:]7^5B^ M,9NH'23=HX=5SQ>$I)_L7EOM8BJ@,L5F:685PVSB%B=.T;(K-
LT"IE(X6J3R@ M@]1:V!^ES'#0RDU?D@IC5[N>ZL0F:\B_PY7 :Z+46Z_/%!N&)/_L$+G6D4*2 M@G8(]=5GD,2@Y1MK4M8,253:P75-?T$2F78(C7ECH(:BOI:L6G_#%9=U@)E2
MFZ#V(:V;/[%5LN!,+NH4-JA-$OP-2[^%9^+Z/7'IW"*D@F^%W@_CL M4X[B3XQF<]$C]Y@3X;EDZYW#8DTI. :',*_OXX8DMR;LRBI-%8$"
M8ZTQ@*#412]=X=H,UC'N57;'15Y%GXY1*$)'UH@,_;M&YW!>M-O6,CJK#7S M$!UC+&MW5F?EN%P$T6RP;K:T_<;$?W%-'U46H[JA5WIE 9RPH@:,+HCP9"Z7
M7[D\^:PP.>3=5D(G+W0ST7T "/@D]WG:)]F CXUH*\+CI- +[Q:>*5:@CI M;?QN/LCCXO\AB3P.%S,Q,Q2DJAMZIK=P'H05?H_G&1,N&,?]L?E("?N.G>#I MC_.;^CC/I,-T1;E2I5CTZ
3!D);'&>F+J@RH'$?I%FFNL@MYJO."K?MUB\;U M&A+W 7QOJPHQCO@-H[/5*K$2%+;] *#1+2ACA\[HE\MY?7MNDI\]B?, BI!I M%]NI_DC=(9;S1BX+*U!['C3UOY9L_TS *BE7-_&
[3FR*&+XBCV2>6#A2NDBW MOG$+F[6NQ+S+8FEZWF#,"X.I2M+8-6Z!H!M$6)YQO8C^EQ5K0;?"G/H&]NE71 M$# _8OS>[+UQQGC&IF#[W UM,U?^B4V5?>YX\GZY/T^=HGT)C0D\.__
(M9N=>=E T$'V-/"9K+L W_&SB+]9P@=MZ33Q\:Q[M?4L M\IO6*'ULUCB4IKT%KE 4]6]SUDKXUXE='PP*74H4:L:RCX8.^K.$((EBVP)MF MH(]'NC*()M8-
6E@8]AU5L"M2Z[.H)HM2UDBZ*$(UC5!K2-34JT1LP;&!]>:L6.(3UM"=MBA6",^#12T8XEC#7/E8, [VLR] MQ3QHVW\A509T_W;J;@]!9+6!Y:)Q:Q0D:Q L%XT;L#9P"MT30JT?K++_
M"(@'JZBH|'6PBO [^V-Y"9^G@|F"Q+B|<'>#8X#:6]@KX7@E63S!QK7QJSL M[!V7)*JL%U!M'U U\WNTAJZX44&X51_?V[_+?*6TC]*ZTM, 8WY511J%>V& MZ
GSCT\I0T*S">W(EK="2.2GK(J>0L0(TB:&G94>GM@!!P6=Y6R\Q D>*R^ M,K3V3'G!MI(4P5.ZLAN5U!M[?-]TO$_E%IL*4DK^J2@VM?=[Y]]S4C2+%L+5A+RNPQ)[(??
Q3@Y'\;HW#N2;X),0I0[&TT:(928CP M=Y \R5B_X-PZO_R=:BLQOZK7?":$]]I=.H##HUPC]@>"!VFV&E/8P6\"TEM]!5:!A M]+9\P*U.)T@.@1'0*T^^\EZF.V /A:DCZ!-U9!/$6RO;O)U
^"F(ZS42MM[3:WFTSNS?-[&5> MC#VZ"P"O"].'=*NXI[S2XQ)QMJB.U'\1N&55P/I-YI+TSB_%,QO5?[IB\8 MX=+CR9CXN\CI&IZYQR>#X.CVA4L#Z?\)0&G*R"A+BVDQ0-
OWGUERRW%4F&&R MML#MWD!:I!&%WFULV[Y]#NS%%FI$FR?+9[V)\T8&LJM5\DY/PH#>@H)I,BE!.@R81A\0$"\]46E #-Y D2 M-15AHV?XTMOMD.E)/>9[/A.>LDQ2?
X486\]8Z80@C:=/%\2> V05\35.3R M<+0ZFF; \(QDL_UZA@8C>$98G*Y5;NK*TWLZ--K6GBOB4KPZ+499!+??!*8] MK;24UED9L*+33K <5@>P#*4)I<6]\;Y4OP7YH:H\F!5G,4@?
2_A6^9=!O#F$ MIZ8^K3N\/U7:C$)/6G1[L^WZ])S59MOK3"7Y;+OYW>U@(.J+X.GP$<<+_)DF MZ52Y :+F,*"P_H$1NZ$9JXEQMSLX;$/QK+J3<'HQ3C%3K,F:O=NX(D?' M-
VO2ZX\",QYA[3\HS@5R$"V000\'@[TK92 E!EQ -UJGD(XZ.=2;KH_;QZ'= MAT"M-PEMT?LXH[MU]!;]%%*ED+-#0UNS'R$)>6]L@"STZS"A%4L'DA+P-1-@ M*P4?
7#@>)7%P;C@I#=^YH"+Y$5)>MXS"8J0.,CPF8CI(YNQLQK2(M"IZ=!9" MSB]AZH^_EIG 6&R'KIS3'@V%^Y"_L,(Q7+:!'R*<1J09$Q9B9KA.-\HG=+2XF_HP[3R MT [H+9C#K4]//2?
R]W/ N"][-WXIW5A%/<# M=DOYE7:;G%TG"#B,.P"M^[7L5^Q<\/R)[9\8Z]2GD;=Q.(O"9]'20XLQ2$:O M)4-JO'M(/HI)PBDM,KTL@?0BFT-4R1@+&[3\0?XU$D.*;_X/4$L#!!0 (M
$Z";5F8Q)P5=5D /5U!P 5 >G9R82TR,#(T,#DS,%]D968N>&UL[7U? M<^.XE>_SO57W,\R=^ZS,=":39%*;W;)E>]8;V_+:]NED7U(P"4F)RS[Z]9A668QY6=L1; Y^^G=U3>3;[[_\2_??
W][_>_R/[D)#G]1A"1Y=6/?_UV613KOWSWW?/S\^^^ M//+T=XPOOOO[!]]_\-UV]+>;X?*O'#[[D\:=BU[_YIMXZPB/.4GI'Y]]L_OGQ[O+]7B19 M\5VE<2>IV
R4%/\IG_[^]F<7+6K!!GJS6*?WVN^Y$ MQ6QQ%DFRRHJM'REN2U[B&65L4RKLE=BO5X5#[2R>L36U*L M6:G'/:9S4J9%]TU^NXZ2X"VUAZ3*9WVFJ_62\-7O(K;Z3DJR[W_ZX?
OO*H*% M("BH>%8QR5A!)]DD+Q!S^ELI?T.?Q/_G;Q\ZXF3R7:)BE3X"DK:!<8D2Z3T MN1(_;D9+\MRCJ&F@7PHJI/U&)FW)2%GT[FWEV!>=T^AW" ;T74R3ZN'R!5&
MU.^+)O\\SXJD>$#[U\&DY)&F?_U6]>>:FE2*7L8W6^*?FF8>ZX6J*[H@:?WL MDR]}WD"88D1KFN8D?ZR^LS*?+ A9UX31M,BWQ]E1N/G%/\^2/$I97G+Z(#CE
M5*S_^>0Q+SB)B@.*+69X17"__2#$!T4OQ3\/M]H\B977MZTBV31>1_U.+)[PZ!O&A7KZUV^%BEL?%G^1#$?COWY;\/)U,S;G M4$NM9<[9"L0:K 7GBR?[Q*?04FJ(.D'#3.+:+Q"-
\]DX76^_#@80]T!$'YR_ MFK?G3JMWTWQX=46T^27+"L'4YVFUKT)UH0OY#VO$>]9'FT],_<\?U5F]0&1 M!\Q:0.Y@_MMW#2]C'C6Y..A*!XG=R,)]168VZ< MZTTSUCP!.;!! SYJ#?
ARP_DO#80I($"F!/TWZ+!]_PWZ;]!_@_]K4O^%GST> MU=^8197W=$*R>$(K9A,:Y9SQ555S ->%@0OY4(RM2.E%2SX1CX\E"1Q;RA,67XC?->GSQK'>Z)1[!*/RW4@-/%[NOD*5O@L=
[I?:)FT7,M0# ME36WJ3\A[3@/]/UW27A!>?IR1]>,'IJ6@)$>:'S@1*AI\NT9B50-I4&E>(2. MLKT_]^YS.8EC3O-\\Q_Y=7Y0.F T8WW1*4^X&7]@SVHWD7*D+QIOF5!ATO])
MUHI3VCS8%Z65EC[CMYP]\76QI96O?#>]9V*CX*3]%*H=U_^1E^49"K&]4\? M6ZU8=E\(;]**\EG95$51"=9D](G]0_Y;5:5DM \6#YAAM5+LAP/YA7-1X M]%;7CSU?
4;X0K^9GSIZ+I6"R-T44B74!9<4-6ZJUM'M8[=?=+FJ:FC[MI4/^4K4B:GI:Y4 YS M]4'2.*IWVA[(E\M8^I'F2=V)PR!\#../*O((H(E)EB296J9K1K2(U7W-"JY MV(0/OW]\2(I&VUXUQ
-5YU^B)-31+] Z/Z$%MUIAS\0TI_10M*& M@(#H?D*+3A."@QI;_6>WM.9&;6 ,B@^K5])R*$)Q8=5(+'Q\4*CX-!0+MPP4 M)#Z5!1AKA0+$]I2 PK10>/AT%GC(%
(H1G^8"#6%#$>)39-2I=%!,^-07O7L6 M:I+CTUST#EXH+GP:B\8/"P6%3UTQ^[RAV+#]Y L"2A&K.H))#H+Q8A50[&$ M^*'0L&HGFO@K%!I6I020T@*%B$\K,07VH.DH/$D
M8IDP///Z7SE+DUC>;3)Y)*F\ZV.2+RDM\LF:2%FXI(4P3U.+*G0WS_%1F..2 MTE#=/E"^X#BJVZIV]^U9T[R3O+>$S7CDNXJK-Q[9; MG@H(?.90B.JSY*0LEHPG_Q*RQHA$-6-
8!)=Y7L*I?SMZ6,K5&?$V4[OBN!7+ M4&'6Q&T^"KO) ^("?AJP28/CT'X@Y@F#TV_^3("SANDELG^F->@4X/&A<\OP M%_F\MU3D;_[Y4>CJ>;+(I"Q[RXO7;ZS #3U6("
(PL!)X'88K=UO0)S] MARY;XW3R*?8?O^R(K\-WV'_@LB.V483U7H?F\]H2)K2Y*H398X#/\HDH0GVM M: Y!OQ#TT[BX3E8R<^I?%2/-YI>9$!6+1&C0)WE."Y5[#C8IN!;/K"GTL?CN
M@KL@N N.SUU@(Y0]ZG[5E1M$L%0>\60MGR"5E\=-0N3DD>1])D&E @WDF8;U3N,U^9*LRE5C %3Y]]ZINI/5%8KM>O+4E.3Q:*.1C1Y MDAK_ZRJ5VlG\ M=D^U-
=U2UGXAKWC'?X/<[(GDS1EA3PA9M5&:IG,.-XK]6_46W5@&[HF&@> M5![?DY1NTH6D!C&;/^PL4BT2^,1CP3/L>PKN\W[H+|_S)$X(?]EC %V^MFF\
M@[SBDV+UJN++I^3J=&+#4 ?$_-?UK3BG[TZGTVLU&>R#8*K^]<[+H\OPG@O.^V2%\ +$E%DB0?;E\=1R!1#Z39 M^\<,;CAL"+3N7M;)$X8)JE-KG]E8$1AWP:R&L/:J.B;
0)*SZ4B(ZMXL.?D0\W.Q[K#HF/_DN!WFM.DV4U!@,*;MP2<>"YYAD]UVDO?D5?#>;N2N*='8 M;G)(XAL^B4^1+R3THI246;3>2RLT4_%Z:7S!^)2LDT+\6-?4JE)-NJT4
MLHQ"EI&#E W0:'Z":FG_-T$%IUKK=](/'1O>@O'(FCM,&74?E M3->/]DIY9294LNH^4 V/JP<.2*^R10UT^!AI'Y;31Q\ZDM:5;#[E-$Z*"Q)) M@U\7-C(-'YSV*ZFJ?_E95)EHZ732.26(%
M/!B CCT-PH(!%&Z4?-E-6';B2SP] NPAX$WQD,PMS!R6WNE1D,'0A"/TM M#"D(J+C02W\+3S7S?78;P5,0#_.XHOE. #;FFPNB-3$25!]._L:^>=D;4[.YQ..'VB64DG&7VE&I@8WCC7
M6TZXYNDA?RD@X_P\L=;SN(R*F;\GO*G)%+1]!OFBT;9?W?S^%QYBYIQ[#BH M#9<<4 MYTC8J_IDX,8Q7JF\]_7^"V&,3879*G?K4U(LIV5>L!7EIFH6V^DA&?@(DH%E
M6X39?._DT0AR[5@'F9 G_W/_<'+WC_O-EP3U(U(3-<$':;R7-B^2)/BPI)VM: M%DFDNS_//-P%43Q9,2$G5RP|)YK;['3CW))Q>ZB5@(H@RS') XI2M5N3MV[@_
M4=,&&.Z$]"P71W*2+;9VE8XB_5@'Y-S1-*%S&'^;QCH@Y^]";X$+ O/HD!X= MTJ,[ID=K'4S,RK>###=I7=MN?7I-ACIP/&)%_U6G'7]5%(& E!E7H]RBO!G'$ MNN8 !RK6-
1^%#.0]0<>?G?2 (TM&!O@$T#!EUT.=M? ZH&+>QM4?#+*VM_,4 M9O/Z_9![PMV8(TN$_WXJWML/6LH1=2 %3_^,E2['D10KY??CI0_H63T8Z-Y MPV#]U*L.[JZA!!T:
(TH)!U[2CIN%^SVG84\GX@AJZ2ZD#>?D"R>2-80Y(Z[F+5/9BIZ0NQQREP\R**\$+]9MSZ=2FVC."E8/\DR?-+J5"9VFK6@ M== 5(C8T*#YMAG-D?N*&/<)IT'C?$&>@^LC?!
Y5KHQI#(G9E6[Q!O MZ"SXNX*_ZXC]75U,&]]>K\4D+P01E4?HN8J(%+:N+MT2WOQ;9B*"4^OKS^:>:=V;\3C:HT13H&,/L>Q>BB-M$:-R7'!R
M62$X_ZT4@D/LYIIEXCS0\HQV[+BH'I3'7]6W]RC<0$S0GN'>'=HP[H%#)A MR5*AIN?URY:=N>&Q >OY+IR_$>6;HT17;*H=9"=1Z=0]OO2N$'GJ(&\&084Y:@94#^Y)BO_SU].6=
MK*@$YTYZ9C$(=9^/"GL&?Q2.4. [P^*K#]*I8SSBES_(]Z<-[C0/=!2HJ7VH[;AR)9]_T"O7G]6C#:AIW"KJOK%?9SRS- M?)1?YB#'YY&T8 QQ+6M$(:
[EZTY/E\YAW]&NSY.4"K)L:XX.IWF+934_.(2N MOK[0E:')RS7YDJS*5:,C1?GW_JD2'X.6J]:_]T[5G50P%#V%WOW-#S7*'6KX M*QZ*PM5SP97MS95])0]"EHZ7PVG> M'"_-
#PZ.E^!X.3"6=3>:[5G-YKOI>J3QO.1LK;;HF_X<'%;!814<5MTIL[T1 M99_N=I>RCAV-]W=T7RN@/U.VX&2]3"*2*E$8QXZ#6O][O-6N]FE12#3C6+]U
M0%$DV327Q7OY%2.9;+)XD60DBY)L<4YVBW'3SO.- ,RT\-U^G%CV'T\.U#0_O6<2(8-HV!/A:7 M65[PLDIO5;.0>N"]!KK#TW#QTA[2'OIA*"^V6-?C$LE65"Y9IL?=Q0;6Q5T
M6\PK[K?&G);S=$/'1'.H%,:77M693OEZ9 ,]&U=S:&G'.D@*DUT5]^^QO\PB M?3==[6!'! W%%F2E,CEU?1HACD@XHZF"9VKG][T=P>/O?_TM\I)J7YP M\P@7CW[^O/6/;E^U@2-
@,]QT5O#2/1M(SB?&T_@YB>GYER@MXR1;;(*^%C-" MIFS(E#WR3%DS G-$BEF%!['ATR:GL$[1;$Q0G<;?F(VUAG$73,Y4UMHGCA&M MQGO&;+U5&/$=PXT",*1ZDY*UCL+B1ZZ-
OS*!B.?HBE&LHD#HKCAI39.2M0 M51GT<;1@]'AQV>/&6>$X,AI7]D'IKUR;'H"2H7UHC$?2NB84#1Y7T> /:#C+ M5<5=__RE],^,?7#W64+X!S1.!\V^0,-I8%.6 9SWJ!C0C2G?
B2[_1,>7YIQ< M=)QI,$!'RY?=S',_=HY+L6(.A:*#!N1+FY@S$.,?T8D50-X&/KG2TM_'NJ<] MH)1'?3E*.TF]/Z%A=5A5-AHN;O>#8\;4$%2LZSP8V8E7_XR*5X%ED:@8UAP/
M9Z86!.CXLWLR ')5#_SBK-.(4$'LM4^5(W^L0VO*(B\,B/$G-.+1LLH*C8BT MB<>'>^3Q2\XV[]/IS=RA]9I[AX===WP7]4B[/?#3FVTU63 FSO TG8@-$L>B
M]&E,B#Q8;!OE0Y;RUL,-3DSHZ_;U]76SJ'@*_4^,M_])Z!/1(0TK](DX^FKM M"WDDTZODB<;7KX=H973FIR_7Y%?&*VU7\SY;K(%X8XZ8. EJL$BOQ0D>^T(G^6KGGY1-
1UIXT#'SX M[T+:('9PU5281X?*UU#Y&LKL+-&VT?68(R4*XWX<8[%:*.:R+N;2G'DHXS6A M@$O)LJVM671LW%;8,I!)@9*O_1Y/1U+1]37GA$+-!)3"*%*5,P:=Y M4>]M1>>+ H[U?
+]Q6_I8U(\W!85_0RA3(3SWF!@3,-ITY[7LB3!DZ\=KQ7ZF_H\YYDXBP3_XQJ4Z(F M#P:J(3)^HZQO:3 (;.-HKY3?T9P*O7 IUM&RUB$+4P4L6O&1C\I*99,'[1HI&]QWKY MC,V^%"!
(1YV0G(-TY T#[H*C)CG.=\'HZP3B<[18Q1D^N)T%!.BH-8+S%]C- MR^8QL%C5[T:39";;9)2MD >G;3VR;@EO=\.RJ#],:KO.Y.ALL4+PL/6G_0^H/6'[3^KT'KAYW] MZ"+M-A#;*
"^K9O%)"\$$1.2Q9/G32"FG7T#6,F;A0.F)=@XP<8!V013MEQJ M[%YRU:PL!+MELN/^'4O3"\8%B\66QD'+]8*5$*RSCAG0.QX*8LEX\F_:'PO MQ*H\I?:X4F;3\"
<:"W:*,4Y1B_SO"191+74]_B$8" % RD82,% .DX#]7?! M.6I+JI.VY-ND6M;&QR.1VS<1HV7^:15F:6=709?S9ES9$10LK&!A@2RL<\&X M[(72>R:DHA6<+$N-PF^-33\X*%
M%BRT8*8$,R68*<%,.3XSQ?,QZEMU3R9SDO#)$TE+.F'SB7B8L*L2(N\Q>PU5 MM5/CVRSM3:5O3UQ0[X-ZKVN.)=CJ%\E5=00%DRR^2LACDE91T6M*9#?%>)0
MF5!R+DSZN@DJW_XH!$F2R_F5['B@T3)+?BMI#M+/O#Y[F%W5 ZH0?,S8HW07 MU=7/Z[*0\E=\VVFRP07-9"A:??MGW^)TE*P3]W\:B4^\HW+ M\9SP3 B"_):RRC\)M^-8[%>2
MU_[_&#O!WM?8]V=EKDX4_/\)/]M3/***6\YNY"2:5] &4+C32Z2Q,#%3V]R MDL3?RI5U(-GI4X*O*?B:@E,@. 6"4R X!8[7*=#KX3DB9X(3Q7-$WH3>54S?
M%C<1LB>/>+*N.@>Q^>1Q@V?R*/.UY6_6G.9B?-U;2+9RS1!\/,D(F*18N\F M2+%409(TGTB!4Y)7>0$TWWV0XLT7X],<"Q\)?8Z%G[=[:KSX:4>9^.&?4WG# M)>5KPHN7&
[*B#>29AO5.XS7YDJS*U?4;,:Q'7./?>Z?JC@A)K=BN=W_S0XUR MAQK^BH)#_FX4(*WF'@<:[^^H2C?K"0??VB"83?3JS-M<^-T?B/T MPOR*D>K*]#HD)[NGTH@F53WDZ'B8AGFE
M]4;&A(6"+^C(52^@<8Q7*F=/E,M^7H64[[/*S-!NK7&\5^K?LF6C=((,'1/- M[J6I%>W"@LQHO,W]%P*D7)6I,%GC,V'Y1DFA1 *=Z#>00J3OI9+Z4I^9S1]V M]K+VS< G'@N>0?
FN;ILN&Z/3^)8G$=T6G:C@F,:\,(1A!T/4 M+2CKEW]#GZL_]??:9K)?7.5CGL0)X2][GZ5&C3..]QOTY573CI>*BDVK_VI3 M5?%?T_BAJ:^:DL")?S/<07+^2;%Z-<#E^\T;]3/(4 ?
$O+FW8I'D!>4TWOC8 M9O,YK3XD*7";R+.>W!?!C?P(>Z]//?2NEI%LOSY+&LXE,[%\MJE>0R)'O! MY:D52=?^0GS4/W-A(EOOM8EN-ROV"VWSDD\6XA<+<7@8^:7K6@[@-
!C#FT=? M):MWVJ[-% ?$_=?UK;#7[TZGTVNU3% .W"E[(#71+=%^@)@22]D>V!!HXZZL M4T@*$U2GSFIFXQ#$N MF6X^U|UA A@N,R,W3';F-GH4E:=!VO04]J/T4&C>N@
M2MWU*;7ZR?L=C-&![BQT7&PA;9F-PP8E7SL^AS"P<#^O&*SMHTM?M@-K&2#V MB]:!=-*DIJ&11"KSA1ES(5')&*AYUDEH^*NP=R4TX-X,OUO@Z,.RIQ'C^LZL
M+6NF=XRB^P2=^A>0'_ =WZC>QPY$^0=4GR,T;Q;51PER S!KKSNZ3].-8Z33 M- DC&FX--;W6'IVQU?1ZM !!D#1YO?C,/! BVP1.?%JX%]9]Y-[OH>X&(#B[MO>\9T",X!-
,Q_O(^M5@W9!@:/_&DH&?L657FIQ[HG=Z\BF'EK[?^"B5"G@.EIJ8/ M-LDKCMOR44B8C\6F]OK[FIJM2!34& P%B?#QX+GF%+8$,1:2]T?IRS$WI=* M9?UG\8JEOW:6[8D:!>'
64Y*7FA*RBQ:[AAR28K_%FI,U2/R@O$I62>%)(;H M2R2ZK11*$KSD=X/.!]9>"OO%[# K%'YPHHE(MWA'S.&WBBKLV1]_8\@L"5'L
M$,4^OBBVC<4UTK"VE1XWLIBVV3TQLA@VU(OAVT<;"_'V6$R8.*D6Q$4+:_B" MWORMMB0%K^K7YU4=9:OF:_&9:*FJ^GOO5(4&TF@;2%OXEJH+//;N<-"U8M4,
M'91FK<]4/WAL=_**V?B>+W,XZE MU]LF=E$*S6DI"*MJ16]8%M4_* /JX)E>$4G;?S:?BOU5I-N&C(8C4+@5S=A M:\YLT_#!:;^2QCK72B/HM&/ JB$WL?L:E)4^0O :7ZQ\&15
M*7+:2P44HSQ3VI2L+D\L)=&F"7[S+:B0V;3[$) EBV6Q*V:2FAN;<^T;L)P= M,E^.(/-%6T*T?P^E$H+E?*_H]JU(S-0/R?1 M\HP3^4?W8-7/\ +_3*@W\F#ZX8.\QK.R5?
ZN#XM:29$9W6]L= A3FD6 M+5>$?[ZFS M=OBP7 $TWPG QMPOL-?E7]Z<+K9U@_)VL#QM]D8$ XJC#];9:8!L88[#$+W MA]#!00$)5M4TTKX/;8N<1M8"HH^,ASUC>@W?
\7O0=/G9G3+_0#N [9;%%H4 MI &18KM$P:XZ! @2UT*'3/2@6A1W:W0Y)?JE.@!U5*P7+W0_ E#"\FA:+$I M95?*PDK5K9 N@&(%2_7Q070+4&L?MD6)$ A8]&T?&2/
M0C%CT;GZJ=* [@(6I"#>-ALOG<2:02[=JR#[@4G_W/_<'+WC_L-MP&Z*\!F MN"#MMY+F52;5DG*RIF611)HN%(#A+HCBR8I%*5NQ])RL-=1HQKDEX_:0*@(1
M99CE@L2#0U*FQB6Q>#7RATK3JKW"Y^*EK63JX!W-A:U-5:>6VT4=)RRU8]\M9;?[$_7F X8[(2K+A0Z29(NMXT)'D7ZL&W+>G<73E#P_DNBS]D5;371 Z!U- M$SJ'21K36"?
D[*LIU0VE222K$&\N$0E L67P2Q]6O2;H9^L!.U:]1TS5=P*O\ M UME;!/8:Z19-] !(7\7FCO\Z#./#DU\>F_BHW5Y,RMO,S9HVH@#Z^34Q005 MIMLR1^XIC,B_ZN8XL-
B:Y]=F*-2V_NB8K=;GN1#9^EI1BJ@!^]+Y2T_O>A!!O4)^/]+^A)(QLH'F#8/U M7PMW.! ZE=RTLLT= RT#EH,<,5RV8EP(TU>]F.=I"?%E'#^ M(G[Y"TEWA]-AVKG-
7*^HMBWXQ)%6?63WM"AJVUR5/ V8$1+JAT^H'U]J^NZK MOZ.I- <>V#7E"\K5M &GA 3"WK/L-(<@LSF 1IEX9=(T(3;0.^!M?FX4/F[MNS$D\@B;U3O$F\\1@C
A"',\01AKY7BD(986AHQO#]ABDLN.VY7WY[E*.BBZ MNKULEO3FZ[(G*CBXOCX'ETV?@)3D^6S']>:E&;^3-QMIJJB-XX>G7MMP C!C MO B&!9O11-=-*0^?V;RZ.RNI(F%"?
Z#QZ$C[C]4TZE7YR2WEU^X:9?M/,H1!M M+IBR7CVJ8MQAG#(JBO18%2_W;TL)0#OF' %*\8SG\KA7HM#JS3&B1VI-% M.W9<5]Z$M[R39MFF\\6-LDSCMV%*)M3Z?

P+Y5&24V6<"#!EF,#+ 9OD&AT7 M-">$NX8/=SF@T_*:KG<06EWSA0'=#7VN_M0*VKO)+H*4$>5;!5T3F%2.;9K\F4RC:S;:8Z(/:")+Q2 MJD_B7\OZ]K?
9_+8L9FOYF=Q0\=,#^=)$J]U,!Z1N/N+7C=EHHK<\B53&A/4\ M!V0^+&E]DQ[;?A?JC\D7S$HQQXC3["MD+1QSHTL6L'2=HLD; ML'DS#'@\HPK.NN93##D$#OG5P@Q"QI-
ZB7E^%)>P$&&D:\@,(00&SXRH>A,0H@0"S5PVU MRWHXW;6.36/A9E-1/F=\)5O)U J0-I_6,-HOY2G)%+=[ZX8,0JV5;!Y$'8Z M!\UE;/[:]QJ]GK[LAFP*X;IO;6O1[7H0
A,A/3QQ7#OH:]_&TO5Y[W,VH+4+.4@K5&[J-?2F2K,K5]M"0]$DFJZDZ0.)@)0=0+K.(4_',RVS/ MQ:[I.AI?,%X]6.C93<3;SG65=_IH/L=X Y$5&#F"EJS,!;(+5O*"TJS.UQ%;(K8A
M>:(&VEK,#XF^?BXG;'0Z,)\]*,9M:706,)B9/MKL7[6'!%WRI&+_66>!@RI/ MK1TWCB1KTO0*]>?9:%.6-5Y>=%]9K[*?67]247Z9@QR?1W*?9<@9MO["0\YP MS]E
OAS[(\TY[MF!/]0]L9<3^AI&E17=P9(TT.[JKYW1D^=+.W*PCS9QV$AT8 M:39UF[03=),"N7>KSQ89,.7/!RG>L@3](@0F)A5]?8]'A9I_-L=(8EU#^O7^] MQ >FI:KI[[U3=2?
55<5%4N_^YH<:Y0XU_!4/18.FBEP+_;FLC8;+;%T6\FR- MQ,E[ECPEL1"/=T(X:W,ZI1= @>^.\]N8/RG[BH'BJ JM?6'H4(UG&805),N0'5'=)_OF"4V'8%52HNX4U%YH7&!2?(;_;-
'QPVK7I=.8)8Z4_)/4=85+?MOKO M1)Q553'NGHOLD!44*-HLX;RSXZ9Z\;6B[Q.5/]+XY(ERLJ"O-7$'&!RL%!)O M>K^4[KU"S0R:+28$X'.-
V9\BH\N=T=A':,+Y*LYB1H,35006^N5@R'IQF# " M4Q_1,)O%%Z\!"=7X43&H6\&(@8T|"!6U;PT-!#>L"K"[T47[NR&&.H70A?/= MP%;YC$("5DC LD,<$K .
(;6WO=')6.N.1>T,===^1\L^35";I=+VZU+2,MP@U MC) 070[1Y1!=#M'EH2D*,0M\,0N%/_^*YCFE5_)PJ5,Y']AY=8IL!(,T(Y]\ M]S;S^B%3/B')Q+98D-
@XQRUY=U2>/4(1E^CC$=&P6>%:,=7'^T(M48 0!0CNT^!F"FZFHW. M@UK_>[S5MO9I44@KXUBO?U:3*)LFM\(+3&_8B23X?N+NM(W6]S1B"9/TG0\ M?=G]VU
SXV))OWNPU|%)D'K#,K+[S8/X5R[L2EG5K"U\:KG*\2,=-.VU(JS. M8N\R/QW?:H8.2O-4;&4B+/BJY4*UO_7]DT 4YI15ZJF%^:2WS)*/Y_NVDU3^%QJG= M=O"\XT S+#\U4*<^=
RCAZ;\K:#<7"4ZXUM!^;8/VMM+K,U .RP^]+Y4-%75 M W"X[^<,@F+*5H_2RZXY'C\80-DL@15C(_,9-8P>GH!UAV;%DG('K/!V'01H
M"V&&5OZ9/7KW;9K*HS:;S\HB8BN:5XG;_YDLEE9;T?4A2/P!~OL.)\V:\6\DK MXL;T?J7ZC#X6EZ\-#34B0#UPO'HO2$1/5M+?"]+Z_? !:3=>!V@:/D;:!Y55
MFQ[6^0/&,R5CW[GAE=@@4[SBX6SB-(XO^!LM6TO/9M?L3HA3&Z_"@UXHE<\ M;X,A6M[2#1T3S8-^"W=TO6'KV;SB9\'EFF_-#Q4\PQ?S>. 3DVK[SU73[N+
M1)OFXT%W0Y^K/[6"]FXR!ER52=T25O-/27-HUR0$,=)4LCK8C;JT2R[2'A>G&19 M\D1Y3OBAC\1VF@LB#^)M2K\U<+0#DAQZ4,4\N65BTIV>*E M;FL-I%=V^VNU(&FU@
/"KXG8G&7%LH+UBD1&Q:3NJ:84-L,):16WW;$7DA8O M2G\:*QS3_6 3DWXL@A2Y(2N?GJMZ49YH"(,YHF=*Y^>M/?'3SV M_M/?]IP_I8_1=1[AX]//G;<+A]D,P?"^P7U3QI(@D<['
1B71W@>N'>N MG(_K.1>">*,#-!'1,/+!HW!Y)FLI^FE4RMM\Q0DL.T2=D9=#[18XV@%)GQA/ MXV=Q%IU_B=)2/D!34V(Q(W0H^.H[%)@1F!/"F55V/C9\VMHPUJD8!!/4UQ1'
M%^GOS,;9BW$73'EMS"*=#S]:36B0V8:S,.(S9S^P%]D&&)']/6G[-R-V*?? MB%Q; L#4XX9_LPX;MH/2<=&T!;*7H-ON"T ?+:KN+GT<+1@Z#3ED7W>E=^AX M7*L&
[;IR;9T&2H:VH3%V8G0\:<]#LI;C:M;FJ"41HDYG_?.7TC\SYL/=9^NV M/Z!A.FAJ*1K> YNR#.#]1\6 ;DSY3GSY(SJ^-)?$H^-,@WDZ6K[L9IYCL'-< MBA5CX!0=-"!?VL3Q@1C_B$ZL -
+5\,F5EOX^UCV%!*4\ZLM1VDE2_0D-J\.: M(J+A\G8Q.&9,)$'%NLZ#D9UX]<^H>!78E0P5PYKCX] *Z'L*IO\1ML;<+@8S(GP\;0#M9"POJTY=K\BOCE4-#Z7M,MLXGIJW
M[+5,QH"A[3)>L=Z2@JKN=]",\4IEN(NG'SJU!<:>[S^9I6M>/A%U.^C& 0X> M_"AM2A^ZUSM&UT3N9(F<.X\'?80S;T6+7NL:HY$Z!Y7\ZY M-O15;<6RK:U]=&S<5M@RD,J-
DJ_]'D!TFC50K-&Q^-=6S5!U6B4W(ZR+]/Q MM7D]OJZHK;R?N2""06KVL?D],9R!Z>98]"M.G(&V\6$#(6++B+9/&@ "Q98/ M'9,E!H2(+2G:/]T/"1+XG-OZ0[?92D205
MCGNDBR3+A'(U(5D\H9G4LR:/))5]A?+)G$D;CB=/1-;E54.>ZW*72;]M5!,; M3O*2TWA"BC=$9()QXF2H5\R3UY*$[4X!2S#&",U;"4H(02%%UBT+:T
M[+IF,\G(GY)B^3%CCSGE51>PRVQ=%K(KV!YSRQ|KYCN5O/=:4/NF3.TPGZC/ M9X7DN32Q29$FW?N^*U3\M5F582\WP^IU%Q$Ol:YL6^QVL_\<+[PT,>1W E M!U=R<"4?
6CO1'WXC\TL/*9Y]VXVIV">^H+S!1(A>:__E/W?%_Z\F0$+;FG2. MG^K-VNJ%[F (!4,HU 2'FN!!*;?K4[CM_U)W<)[-3=VL/AAVPM/3D>[LNZ9? MK7=)T3XL.!\0.A^,-R[O.PN
US,'XSX4:834_'Y2\\=X0WI(TP^>N.")&XLG MKK.>-S(_VZ!6@&|'6RR^R<=BPE[O.<@G\|(H.9VLQ&-7Y6JRYDD6)6N23K;=
M55MZUUP\RIM+S1VQP8\6_&@::^_M_5,:]XQZX(#T3@GG+T*\O;TS2TMY\Y0! M,1@;UYB&CY'V0?V2;XGZF)$Z?
9'&9TD>2:ZXY725E*N3+*Z&;BX4G+)=V+_AL1K4FQZ>.\W,K_='C.7&;!-H),U\>Z"H25>I[5PH]8UQ.NV&'+< MRG9X79;"BMFF"::K9;WN1=/5# >XU+K:!>X"MZP7D0D_
M(?/%)=WJNZ7G\M2=EE|(ZO.RV+)N'PYD|RZ3[:NPEBMA.I9SY-5(]M8*6R\3)@#<7&\<-3KPUC M V:.%\&@L?AD)42K6*G9)T4)*VO0; ;B-X+QB\JL:K5*E3XVJ[C-TXB:3HE
M0I\1l.H^2>_R|TY?=F-N;^N@^MQWWWP6WZ8D,V9>]/FHL&?P1PWZ=84X8EIT M2CFSQR/RG6MO5P+,\(I@LOR7#:/>RN0ZZ#+N=#TV0NEU7[= MECO:BD|-
[E7SY57.UNL;UF^ET"HOQ<^9[';0!9!QI1 +]A(+;M;"F<\3&..V MF%5]UD*O'FVP7&.KH8N3]\]PK,59B"I&.^AW?R11>4M_ +HO!"*O&$B!0LG: MKF0W!FY%
(.^.K[LI8X.5A11TC<1.WDGUY/L MV.TP^ EZP+ Q30L20Z0A"IAH9M:%,S*0G!@U33?*513@D.\F-QD,N3@,9G MI>S[>DMYPN+ZI:N5-
YWSO/UJ>)#7OQ=Y;TX,Q.AS+8!K%P$#\X;^ES]J16^ M=Y/QX&JV>]J U*^$"+'\XVQ=M2 Y_R+LFD20W JP;J$0L@@V9[Y@\VIMCD-
MZB(^#QGPG;4_YT=:_M+UD!AI\8L3%7:DU2]MM+V1E;LXT_E\^\E@-^61ZIK' MRI&T?W$#CCL.71/GS3\W)+S@VPN^/5T90L5TK[?]R$(O(5\%ORE,/^-XSYY) MOF9=0?3/:9$?
0',]MZK97C,&^2_+.V::9YRD 8KG9GB9'XAK%>]7Z5*[68V=P!%\.KA5[=PG9VSO(M3E^JZ57>BI8#^WYL__SA7)@:R,'I;R7-HB;MJL7,81#55RA6V_M!]I4 9@R.X/?6"'Z/#,$/
MU@A^P("@B;=APML\\W@0X3A9]NC+WPM::XS&-8X;);YW^JK^P$0)8&K(DSF" M/)F/]P^\>M4O0#>%>8*#2L;I$W^]($9=I:@>Y8"$35F!IDBR>43()!2Y6=I M%A@N5@>>5A@W
N3A86T\=!C1F@W;IC?=]QL%^389[4O#IZ%5OT>78]3: $=7 M"6CSKDS23ZO@H79WXELA8== MW+[H.+B=]MFT"R;O*DKV]J2C8Y#80S%#HZ,:72Y]+] ;/=SHWKK5(:;S*/C-
MMNU'DNMBD7B%=U_6X]X>09UJV,7\<#;YV X!#TQED5#F-Z<]U]%6]'CJQ4" M9*NA4\Q@R("YM;XK!U(!C2\HG|"\2%;B3W6.NI")Y;JNX)EPFHK?QY."'62Z M*W+:2?1;F:01-
0FJA3)T.:1@|"^92M'I.L4K:EZKW(Y-4KE[%LDS=/I,I2GXF; M/8]/LGCOT#^1LE'\LAIB .W^0:/=ERG)E^(/LB>A.$&DB\C#WJD?.MY|%(:D
M[']98C9P52V4JCY^"L<^WG*Z)DE_D66SD15&;Y^X-2VCW?7+K"#90K;= M]+&O#4\;\PC|&E>=VY+ ME +JX9]# O_P"?R*[/.3B/(':(>;(FI9%$N676:1.1#<.=D"04WLUJB[MW=YF
M*\:(W_"2;C7:0\X8C@!L&[=>< 94R>NXC(I9NN;E$^E]M[1/1;9%9W1.A5H0 M3UDJ]D.&/\5]%V533^!!GHULNV;BW!?^#.8.L((#W%+A3V!H*>_;< W?I3TAV:1!G"W'/
M_HQDCSL&;8%|\Q.RO6EVS4/5/H\W-'M_TQV$Q 05I_(?C2>9X#EZQ7*+L@#] M?#3H[N@3S4I5SHC%S)"QX5!I)\260I@JA*N^ZG 56#*//.9D>;)Z5-S+C)1Q M(FN*!;?"TJ-
1_2MG:1)7I<:/)"591"?YDLH*8[BJWG9E\IY-I[".AI4<=V% M:AN7X382+ Q[FE0-9G+QS6\"H HMRFKN(*C>.4+W'!$P;!8K^$98KLJJP4*U
M]_+F3DZ74EF1;2.WHE]\A]G\@7Q1HVRSBE^D<5S)49+>DB2^S*9DG10DW;N# M604./-$O'EU!U(!52QOGW6->M:/3TGE/JV$DG7^)4I+&7PVT&TSU3.F33:@4=AK1GJEV%SG
M/W1M_G[L-(NK#VK)TICR7!XAA:JM W0:*BP&[=-V^E#8]$H=$@M2^@+%P3CE M5)A))HK50_W2S++% ^4KJ1 :18Q^L%>ZF[-G7O2|#IN$ 8?Q58#G#8CF+EDL MB|G\8UX?JB
DBCE^4>P*,,SO03?6/]5@D6D8/2CEL$W730!*_RW?9#T:57C- M2-\4*VN6|'QC,=,S(D5MB+HA#62*5PQW,ODKH_$YX9F0A_F>+_F,SI,H42&! M3QPF<63?
8Z#I3VH<'|)TAN^CXX!.H+V%Q,*RMJF065&O%YZ8#B?U0 >]5'9- M^X6DW5R_8]9VVTQU06R25[%*\;P[^BB^&*-:93NM9R(-&VHUTP&I'[.8YLDB MDP?
26Q5(W6L+,B>D&'II7V,^FQD\HC&Z'$I+#=05=SQK-"V&MOC=4,...>#2T MIPGYOB'?M|]|C9JU8'2R4D\LONBPSSE 1^,+#MERJ!+V ;@M<^]1-?0QXS2
MVG^'KB,/X$UV1N.O7MB,QAC71]?OQIULZ0C97_.:R(<']3:CZSIC<1PT/7 M-\:,;BP]8R"RQ#;-"5\'& WFF.R^!JU0(\UY'H6S"|HEW:$SE2PAM&@;EJ7 MPZ S);KLPI4Q#PH=AW>!:Y.
A,ZX: .\75P$GV;]*O95Z;"],]NL6UD%*WS3R>V R M*^B6LZ=$\-'IR\=<7]'QZC,XB8KDJ98CAJY /3[*>V^7@T2I.RKH2:+B]:JQ MM[_8&RG UK')LR1?LYRD/W-
6KL6,RASD$">/9XUO*$R88 M)Y+**#VC]7]?89]_B99$&),W0GZ>S^=4R;'#$.%UG\^H4.BBI'K3XM\IK=27
M+#Y9,5XD_ZI^K]@=FZE>,=7;.9OO;_$L0_#5XB',Z_NX2#+9>;1R+M_R1(C] MM;2&7ZJC0+%5H#E^43!.DT561W^BEP=.LER<0&)7?Q:*A3R]3NE^/(>R2I, JL#8:@TD*'5I"]9P(8L-
C'N;A6D#KV'.P"A>M<.-9\V@A=HO M@ 7?V^"^-P;_8;\ M4GR&4ZO]0ACP2F[+BP[O4[, 4GSMWB=@(0QX&QQR=C@U"R#%U^Y|8O-<0JY. M&_YZM#I0_KE]
(5,V6Y4ID#$:@P0/;7#.J+\XSH+)<95BDE;)'WI#'T!NR7*_K]CLDE3;"1+/[JYNPJ8&IHO&@WVT%CNZF05&4] MC98+2O-:Q6XZFV"#'1!T01)>99+N$DAT,ME]3E_D;>[X#L
M]_Y773%,$^'M5NB%|(9>#6Q>-O=H[[*$ ^*E53W+[DLACDCEW=X&[F?SK:Z] MT7.[+.& ^)V=]QJ3GV670@1P]1=4^75V6,8%B'TMU)YVZ]FAFV=H M(!@:"
(8&@@>0NKJT16U=0#$0.YGA)5@H$Z1O><]HV.%7B$S._,9G7CPM3FF M&#^ZS\G7QIC"1NA*,'UMC'U&-[IRSKZWJ]/CJX>=+C]4GICT-6->MFC3D8]
MNEI4+UL&=#ZB:I7C2YRWKC= =P#"%.VVJ=WHU.<60+3; "[!0*,A-=MH=-3G7X?\%@>,N73 M^>*3]% MNJ?MT&]H%F_QP=-
JUHSWIF@F+3FZZV9>VA6WH].Y.QPBX7G$LQP@$ MD.+KT"7 C^78L(4/+1,:RX%AB5^?GSZ6P(NE.VW%A.@0[?OZJD IW$=\$& M71,^T?E:W I$:
$H.E=+G\=BUUWPYVIQLPL6+<_0^5C<[$#:;AY0=.@,65L4;V]:57>XV@'%UB&> MO>-#YQWBWS\"88=X%9&A0[RYF.8K[A OW3.SN;Q)N;HH@O*G)**O-RQWZ!_M
M;N'A]R._9VEKS,K)WG%)HC8Y4.(.RCHW$B"4YH)U4:/7CEZD'ZN&U+$ MGK)M-H>2>N.,T,?O/95[VU23LMD_%<6F\5ZI?\WPV9YT!DEM'#\,]48^T8ST M2_$FOZR9!4R;;S79<^^JG
KC6/I3SN@335F5)K2A[%7=W620Q#)%G0F5),=Z ME@*L@Q4|[\ 3S4JZ/?;DF/_B4%,NIT 3$._^*OSB29=RS^%ZMOT.BPDM^>3[0Z
MGW\6AQPGJ;1:XI6P^B47RGO&|6+0;G+H78/<(^45E_0..3)_'*%_2FE/Z[MV;S2^/-96>0%R21?Z^R<5FN@1'F6I*6\4#7)I3.TY#4#&4X MXL??]NRK4J[
MK7UZ!0Z'H6.1Z'CT0&DSMH;NK1 8*C5L:,;7:)@AVTP^+[1 MY0'"H)| >B"PV:Z60|F*#IQ9K4-;M5/*=EOYGK'DUP>+"47_U]7M1G>N<N6L%L9_O7'*\ZIAV I)UYV[UD,KD/Y4II&.$=
(R0CO%5IF-TTHW010PL MPF"N3RQT/@C7* $;V)O*B.[C&F!S6VF8Z+]0'C<.;+QZ=(1EK*'3:)+LVNM/ M\G*U(OQ%^G>VOWX19VC>]4XW$?U^Y#
4WY'G:_%I\2DQHUN&CL,U9\8_R:;6@BNW%P M<$0$1T1P1_1'1'!$>+JWS7B&H#-F+)%ICAET68B6T#0:%KI40TMH*CW,MQ49_M"
[GV6$S88YHLZBR_"5DLN)"+XH_K::O8"5G)"YM:&I2=GN'-MG1 93 $@YFI M46^KFPFR7$@@R74-A)H'#DCOE'#^(JNNJ@\ 1'GSE $QW) 5;>1=Z/ QTN[L M.^R.X6-
&ZGK,.CM1SSS6JM;W5=& M8V&FK)(KQ1@+84MUPANH%Z! !049GN8CL[-!=72T,7NC>^#.?GZ4'GYW'!L M)^>?/Y\8_ 6;#@_"_T(+O.?
B>C_W#+>%1^]";FV9C=0O#;+=1NJ85AMZOCW2 MRTDN\T,?25W&MI)%R94_5OE[6A-T^U8XJ#USIXK34>C9.T>A"- MMR7C-)[N\9:^X;#=9*^X#%VU>3K>8.
<'7"3N;+I\]31QUL ,S @$#K^@;- M&3>*0;WXVGY\VB_%8F;P*X?4N!'[1"%R]%WK()#(&]V'%'RTH'.5PMX.M&/I M\!XVH)?
4)0^/Q&=]_;9;Z'[!FQJ\<&;VLU!U<:2l.VZ^G62T:+]J#01G^_D MEY1,B&"]6];DDMV6E\4GN\=/_*2G6H MFL9U_]+5NBPJT3";'_8]U*8P.EU[3+MR^M*\@,9WY,&)"';0F'D)G78,6 ;U
M0P6O35]TLNCSOCIUFY),Z]<#S'"02KAM*?_ ;DMA7 NE;Z^<#I[T&):<(YY M<8[Y."A86X$\6O^:M^,7G7\,_()9"Y&%RKF!] L:B7?/AD_:'1W!MQ=\>\&W MU|&WY|[D]NWZ^SQ)J1
6^61%BJUGB\WK7T[2A#PF:1>W7]OEO;G\NA$8W'W! MW:2F:XVO/2B,$RU8X>G^I:\R(\F/RM5[@#H-%18;L07_/!,TR=Z M+4(]I$5Y96\BYR^W@MK
M>U+83D>)#7AR=%T.)7;#2=)V&;18=2=+ZW7PHE6>-"U7P8?4YN3IOB >]8G M4:>U_%[]TTRC I=A= @-#Q\:5@16&W6C!W9*;TD2G\P+RA5G4\O9#DC6?D1@ MTMNO$B+%
(7818A#ZZTN9&V@NCFR!QICP@W-C@0_(_(P+?R M#@*Q_A$9UD[V*1 SMAOD6WJV@6C_C QM1V\+$/5/R%"W"\U %1-_V6_NWW%[
MU%CTL4Z&*10L%BW,B2D+!3TVW:L=RK$J6^W0CD*[@GE&H9!'I62YA3X*7;L= M-&R*%<@E[C$YLO(ZM,K7BY8D6I!\DFQZ MR6UN:9[0W\H]%,:DQ5X>ZR.9L4?"6R0YO@86L,?
=1.P8G=>XK(U4WDD20.9V1_%KF M1272'IB"O"KI_O&P \>=E'FY$)WWE#\E$:UO7K^C$5O4LOD7DBI3F7P|UNM> MFFI5C>.\4GM>'5ER:UFFDH>@L>.B>M!Z]AM:
["ZJ5U#=.,9O4HA"V$]"!'6S M^0/Y)AD MDX-/0-?; S0GI/@,G^+CIOO#99Z#XKN6#5^@RM#LZ3]#Y>Y7V82@1VT]%@.Q>&)'NAM!JS+?
>51>$M@!K70H.Z_O4%XQN%J\I=M,PFA MN&N5 ./XX:C?"6G>N3:]\N*;%DJG8R6;J4*F2#C(,C;XR-*U0|)XSUL8/Y!F; M/GM2]R;>OR@\74D<]O>Q4,'1L"7,1<#
W@]4/&GW8E@KUP.Z/%CPF[3P9J++ M>@6#!![HZ/):P0 A;@MT":QP'FT70QBLKJ"AY*/-P8@7C5N1ZO;L"+43_29+ MF&PZ=*<$\"Y%M<<>W;$;-#E-
3R'[G2QX.9V#K.1UD0X<(B.M$*BHW-MI#42 M3D-V(ZV<:..$X'FFUA+W';ZR5$NTB6!ZS.-^V6*R;*D;B)73M]JE>R7_C2!_M MH4>DN5@\]
(BLTJXOA<'&A0FLOYL8,&,P!'?)8BG.TX\Y/,.01 M>3 TN "#"S"X (,+4.,6,^AM(W7\052[D?G\;$[_D?K]S$?92#U_CM3OD3H(
MG2GC&#Q5CR25KVF2+RDMM'X8A\ZJ]@\\=U%_5E>$@L@HN*UB'OC.ZYC1**N82 M_TYI)1*S>#^B>Z]ZO?SRKN0C)<'J M]DFFX8/3KFV59IXP5OH'[?
=V1!>93TNN:>X&F3(\AAN61?8PWL "DB8,0*&8 M,1B"3U021..3)Z&M+NC9INOYG3@C;BF/8*\OLB H9,Q7::IH$7_S<,F8UXVS]*_],'-E@URX3 U?"!*T5"NL(4 M.K" &EO+M9[O.
(^^$B9L7FZ$R<_\?0]CJSD.R-M:C/O&XDE1EZN]=A(Z)T3^ MO/2!,=K-S-Y*'5V$T\Z)XDFIUFW8@/?"6GU]J *[;CEV).W@+%YM^R/*+^J0 MD1 R%KQ6Z%RC72C(1^H@DCS6$
^_A&FL@ =RB/-*'|RM4\TK0%=PD9V&J; M+-QL(RUULO'N B%B:WAEZ?6%*@;8NEU9)@;IP6%1>]RX2J&HL:E"78)A4,S8 M-)YN 0#?B6^_3C):3,3&Y1-!]R27S5(G=--B>^]7[3+
<6]IN+96M$WTA9RWD MK.EN@-82NS=_D_\GKN,1O_S]O2P,$% M @ 3H)M65, FQAE@P)?4& !4 !Z=G)A+3(P,C0P.3,P7VQA8BYX;6SD MO7MS)+>1+ K_C:C? 4?GQO$HHBED-
MK>U_1PX>67LZ0E^1(NZNXX2A6H=FU MJBZTJZHYT_[T%PG4]]GU !*O'F_$KC4D4<@?$IE (I&9^*=__;S)R LMRI3E M__S5VV^^^XK0/&9)FC__\U1E^+'?_YJ757;/WW[[:-/
MG[[Y_%1DW]#B^=OOO_ONAV^;UE_5S>&O2=5^T&_\NV_E']NF1UU_^D&T??O' M/_[Q6_'7MFF9#C7DG;[]]C_>WSS$:[]SM(<,!(#EC+]4RE^>TWG\OD*\YU0B3K"I;1>[HB\-
^/]]>C-/_X+;3X M-J?/,$TWT1/-.&;1Q;[@J^'OLJ(X^ QP_!%PO/T]X/C?0[U5^RV7C3+=;#/Z MU;?&2.]HD;+D,K<,>;A;)]@?]JBH7*_[M@R_D=619E=Y,==VL;,ES!]&?-1 MEY8Q?Z"6Y>-
UA_:P(H!6QR 5T670ZH;_JVX('4XLJH)>O83W.J:?*\KWHWK5 M;/MF\<$@_O921&>P-7WWQ^^$S#A-W^Y8/%N0_JF?/%HDJK_76^8L5&K.\-
M&0%3]|#47L+*8)=@13W@@%K|GN6];FIQ*1C|A>T9+LBEILJ)PW;/LW//CY\ M]2\-;<*)$TF=]LC_T[<=VN.O+(N&SU$1SV"K6WP;,]ZC;JO#<:T*MM%A,M/F MG&0$!_%Z3EZ)"N
O&T-C%95/8@2[\NPYBK;?@@Q]2[.J;'XCI$I(5/V+O[S; ME6E.R_*<;9[27""YIS%[SM,_T>0ZX6#351H]9719EK0JE_%?=VE!$SZ"&_[K M-
$NKE);\;WQBW_Q@2/QO]8832A*YK47WH<)!EBX/< MU>3]BZ>526+6.>_-9KDK6$QI4EYQECQ$&7T?5;N"6U-\B3]G649CV!/*V]5U M_D++"D8T9H\8](2T-1
47=Y/K:B*#'4E=,E90I^] M,_:4I<_"8D9)WFPO5L5OE)H7&80SU06G3VX[^B%4 MYK(K\5Q+ '#CE9S%;+,E>2G|= @95>W.JJ#.$?4BK?_62.N9P$'.>SA.2&;5 M)VA6E:GL2CQ_/5?0
M;90FEY_!QJ&_6VUIH7\FX?[7VTL)W [K(S9M;;5M F5Q,.X>L-*@Z,K9>04 MN]IELK,-+9[Y!H?894:^M;K+O*+A99>!*.#W@NH)[3)CS)[=928Y^.7O,D)C M?
&\G!T1/;=\0X%PKBB!"8DF71(+PWI?T\UN\V&W>:+%[>]::R1HK?!F#(]] M64\82<=1="W0C>GXN1%+.V;9(\SC=1ME9M('H/I0O8$3!=:C(/))@
M823\5\L&';EKT)&E0'>2UH+93&,B472GSZ,6K7;5KJ!GFS0%>_AVT9[>).7 M**/C8>%^B)Z"7^D(G&O5]3,*'7O[5/F*.+$ V2_?23>N,*Z<=#.SY34$ED\O M+5YH6_O*_'0);M&!IG
C]CGXLQU%_R,32FSG4]AI,T;'S(%BZ:V(7 ?)%F4>NI M]F -'=$Z 2.HQ>1:^5M"7_P>?3R-SA+T!^?&ZXY\L!1$<96^I!7N^@S?O?O] M4 M,4=0&_BKD:IF$X,0A=#:6(^L
Q%DGYJ0"J;.*F_2#L47DUU&;U==<'OWMZH;E MSX^TV("#\A'V.BC^\8X3_W5$%[#=(#5%EYSS&ALU'CCG'-8C $QG $HZ>W\1 MN @ (P+9_Q=$2-'3Q6S-@?_$QI'?UU'$*
(O(&C5/J9.*](+G5D[!J8Y&/DD# MRIX\&&1JHB8Y;"JG#- 4MF%O_S[;T*C<%>#CJ ZZR<*"OL]5/7A TUQ=Y9A MH 5()4UA%-*2(4H!#$L<=KJF5/D?3TL$E4''>7DOAD6>0?
#.LD5))!06LJ/ M=2-I8=>F7IL(O#K;^N:9%,Y M6'V^W#7%4+PLK2 V9";L>L&7-#Y1'*"TNGB|)_J_H7V_6/M2/GP8 36Q_O#Y@"+=\U3!&FV:5@"K>X M)%/$PGG1,J7O*V_7T?W_"!ON-
*3)|OI|&J,*Y$P5&7+*|P_29< MAG;"S[&6:?(K9&#$,:_T@3>A.(_'+-*%>4OQ3Q7O $0T7YM%3EM9) MDZVA'@YA2L%>$ 062<"P3RQD2$>_CB&".AL\)(>X
4Y@$QZF!=$HB8M;"Q M"RM!C7'^HD^,M68ZYL3.Q'HM3L8W[31)LYW8R4O8F?N1,"[LN9S0)6.<, M_*(.WYL;O6W_6[=L3-%_?.K9/$6-V;X">NFGYUM!V
M?.MG;VL+1XK_G.6LQ&7H*_3CIF3H.3W/Y4.;?W!1+4\SIUYE;M0KC,XQW+FD MEKOM-I-_B*-R?;;*V*>SM/>\94&S"%Z)K5CSB9%$FI-S(_EX7/XUY*'%2B %
MDEQQK/W75,F]Q$HJUGQTTIID02;4-<[61/O4S/K2@!NCE)NK4V"M*2>>I'/] MU(<65$7K"T!^O.)P)]7TB]%2 ^% *;KIC#O7U4T;" X7?Q*):6P4MG,W^J<(MPK^FOF=H(-# G/LY<".
MWL==F\!VZAZ/5^**QMUH<1-2/1TU&=88[: M/CWB<5-8WQUNS\7ZX9ZA&8NXT.Z'$_=LX,.PNY$DAZ;JP$GNZSYE3OU] 5^" MY'QEV1;L3)C^D-
[%USX.A$OACEL:@)EMZP409VX;4W&S"NBB\:_;=P5774!8 M;\!<-^\E0E#CVQ;A:6LL>M;5]=!L*IUKUW$ *_^Y2O-GX2KK6QC6IUO+--UH MGADV_WIX'(]^WN)]90Z?
^OG8MGRHZZC-23?46)CA\I&UZ01!79MOC=&2 M\5Y]R'=)'EDQ_:(C[E]4%=C+-'GF3#R63V551/'KZ'O-K^R*2]-[4+$AOS0P M_!8?T>7\O"0-L].[^TX1H9[M;^>>;]%:+6P]TX,-
\)2,AG0Q)&.][4L6MM M^OA &M+!U GSSF]6*Y3@*NB:\|/?"[W.8[:A5ZR@Z7,N$R;C MO;AP@1J>+%_FB?@I$^XH_QC&0;@!UQN^TSQ?["]?3XD6*4L^T.IV]1A]'I%/ MCY1-LFW=
(G2M,374.GBY+[W904K6[@\7D\"#HGV.>LFAI6<$_1 ML]|&WEDTABEOE'GGR^(Y- >7A:FDKZ M;; V#TB0+XH_QC8Q;<=?O^G0ED_8BVHIXA:21-

V@R($'5]7&:RO<'H"/Z>>T6I_SO9!O \5Y%GUZBN)?)]=/K0\Q:Z02 2_KH!(2;5UV M-#[,PU0U$O*)0R$-%KZHU6@,%BQ'@S1>E.)F:(=K47S B;@&[' 5T5,NAF=V M\%,6V)&-T7C'"F%L5E61/NTJ45Z;W450KV;DML-1[Y9/2YHH/-4RZN,D;R [M^FN2"KQ_JG#$'8.%0X\1A/C376:IU$?61T6)X8#;^_(H^O8.YG*WR"%?;9_ M7W$ZPI*WJ2HQZ?D\SA7;3S M@B9I-?>@Y'A3]).2QUVZ5AN@"6>Q6! EVV@?3(XF.(J'!*$Q*S8LL*WAF! M7(\3<8\HBN74,J_#<<.[0!$76R[SI'G=659?%I&R=[00?QZZ"M3Y#G,3J-*_ MEXM %2#:5V1N1H])99%'0?>]Q^+BCW-G;<[>#CFI*M&&8[+(+&^ M=%QIWO4FJ4 9(!I!2],8FLG>K(%E'+,=1W0GC2B.D?^FX."47QE!)("T C0H M^;(-"!A=G^G(\;$7=5X&IM;*&4D(9'Z^=1\6OM"T=2.!^ZNO VQ8X\+#U#CK;2OZD;'D4YIE\-8(GZ3\ M.05-%!52+M(RSA@\T35W[X+K!+DAZ1%SK6@-&OF838NGJ?#3(2*_A+YM0S_QQP6$G54_4]5'UR4Q+D@-D+0(20.1G#HS\"?
#33WHJ!TT:P8M M#XV[/.''QHHWI9)]29]]4< <4&,M9U;GR=WZ=\XV&WXTY[^ZHG"RC6&FGSF6 M'PM6EN \&RRJ8]='RVNA N70*Z("1)M+@1..V%\=.YB$XUR0#BEXDP16\F7P
MQL"-=C#F9S'F$D#40?8MAU;T"UTX=18&A>53>_X,%|&[@GN45'^QUSHU5 M*+Q>5Z#GY?@)GP>KT*E_S5<52GXB$]1R
A(!LD;;"050.&1#TTVGKMMUM@#*"E"&)DAX[WY)![B-4UV&5\'H.S?4KE*:R/-F4RJ7 M'T5[WD)1?)NUH8$+&UT'F'2(&P=(6]+XJ-:QA'TJ MH:BNI(%YFF+3G;&^?[]=\:,+7P>V47:;
([9(?#>HO5*?G)?3 P*7_O;I=.Q& M<2I-_"%?&[8--L*-6OLFA(_Y-[\X MGRMNCL Q?KL9CTC1[\!66.HHH6 1]:.(K 2CVABOM3C4;0U&V/=4;9R^PE#G M)7 J E61S?Y.Q1"P]H[S/8&4?
IJ7PB#I[:+O]EV3>C3+3U&1?-A!?,'M:IDD M(CLIRNK0N%VU9@6<0L9.R.XI8D_+[I#Y6C0<#@&SRIP41[%1O&=/@([T1T!Z M0R!/>])O5P^#B'$LB!R)>)ZI'0NIHX.
[T8@88!D=&Z84M ^M9 $$X\M92'TM MGZ>V:'ZQ2^5)+) !E\5WBLOBN^EE\>]P+?2R I[(NM=W*.?)0\4/G6N6)5RH MY!7MC/M#]W-T;JL&??
YKMU=!9QMRAZ2W]1W]H&R7S7G@9DRUY^$,GZM7Z2 M*MZ+;(H6U;G45'L^2_%^YECXJGS+58V56CXVA65P&!V.D>C1.Q>@(3TH) : M2QBI!TQ(P9L1/;QKW,TV?UQ5-EB^TB)
[IX8YUNZO*BJ]|4.P\S7:\61?E?5W1 MS=AC7&XZ1^JL'1"NE;I!22()D^2MU55G8D+I!;;9<---[2==###%*ZT/+O, M[91YTZCK/(:'/N@%E?
^]SNM78O/&_AYK+HT^GND7BC3<5Z7M2%+,J#;EB8. M=86C/P',F*O^,H]%E,F(Z!W^$9LO+%_7]F0$26JH+%/DSHI54:9GQCS"]|+@ M?Z \W<.)9=-<\.>
(VVVWF3A!1]EY5*ZO,O:I5[1OQKK0_!KK-%.CXCS>K@># MQ!P'67$@).V0A#$"=">!&7+6XWUX!;>!DP^M#;9!WVKW^G(>V2V)A7T_;9A[M3(DE_L2 \^U#M*'+S^EHO?
&!)E@AZ'7E7 ;X3P2(D5^ 7" 9&.(=4V&(=PFX M8)LHS6=DX+"1H13(SCS*@2085A)><7! %H;8XDT:#FIEMS7*'MFY.)KW';KO MHC*-1\0%V0M2GC2I^3+=-6%A;'SG(T?X-
#^$K"&/%3QFB:<>CO9/F3Q_ l31 M$\10(_1!H=~9MZOO ZJH>VTL;I,0PAM:EG%B94VZ?G\GT %F4 :8&H.\R?-[M6CQSE>K7&%_FX/G]?62],CYE M^#H^AM/'[,Z)-Q7HH-
RN^H$8]S2#!>BD4JA2%YUZGH:B@ M7N!0<%6P-7O,T91X4XZK-$\K>I.^T*/*7._V[Z/_9O B(K?7QMT8B!Z00]!! MR;6 2RAG LM];:G/1%XB 4TE&"F1UF@>6G(, =OED_#+
(7^X(\1"VL,"\. M1#F\PP<[56I2/<__-4L+C?;C.TI?:#%2QK3D;C23,@A_U>_3L =+5(F-Q_U MNA:.Z!E7N+",*[5M""7L@:SK'%1UZ(%L/Q4L8&LU-.K<>%*,@:K73B=;L.Z
M%\MJTU:C$O6FQ@M"SS3%U*\B2=*U0"\?WW>EVV15-GR):&MC,*ZS $76EM59 MM:9GLA#TZT$&J*[7L_M8&M%?]7F28BV&G^I4X'%(RW M)6,D/HLNO1MX[5,<6
Y>_^P0DP/(I[)8 M5*)4];.:@Z,OE"RV>&";20A(E;R#B0NN=-DO]11*+3;$"5!D)$O#7R#Z-3|| MR1K/PK:L&+F+L&]PF8Y&/TC_=.)R9J-N0N6.M(O8^"W28!ML)DF_+Y][6;AK
MGF'V,26>G.)5#1=3_9N9WD?V+V)XY[YBL:918%9!V^-"+/)SET]S(_-_?=27 M)[7;HB-F>LP6/4)R^3G.=I#>VKRV-:)1.I^BGWY;SZ
MAR065D2&N<>46.)OO]H]96G\L:H+1%SG+URU6+&?RI|4^ 2[-P9@F9TJW-:88$Y\,[|>9PKS;#W'S+F??V3;".CBT]S#/+,#D!5;-V2@0U<^L*HG'Z(QA25^<0.Z',N=G MQ=8TD&
(D+/PC/,[\"4CDS]UC[Z.AX0K-,>'A$]VZ%IX^Z5X8-3I*W.I0C"/% MX=7M7NDT>+B[XB($8ZV8^.NN/_Z0CW&KB!;39;+'ZZV$KL;OW=2ONG#=H*^] M],CYNF#6Q86YW M3"
(5OBGO!LDSAQXY+N**3'#0$HI2J&F_;&VZ^V+F(.Q"_ABVV4)B+;K&T>LS*$<;"E M<@P]"=[.!0"15B*2>IDGW9L)W-#ORG+,^=EQG2!-!3UBKI>G'AJ9B]S'TRMB M%#ZW!3E)S
[G_7DF8KXT[43AF LX?L2I6*3XOS-:9^(L-ZRHTK_)6W;--W=M M=X_U=%B"X:UHO"6\]++S_GEU6*CO4=\DR$2UOJA#3I(>=+'21#W,85Q*ME6! MN9XS?
W=E8WC&H[55/L'>CTUT[3SD;_"QZG !I4IL9AC>-)8^,+T]+ M0XT24<\'YVG$I\9AGD!I L.'O!,R6S@B=TL]O2 6'P\D,$P*H=<|$"#.#B5]46AF&K;?'$F!:OZ)M
M19H\TQLVDP4YU@Q;<.U5=\[+J0EZ! B&35P;Y2-398XWR=#-&7*5^A,L@V

=.;^$$-3"><>&N<;4 M6.%- F[2& Y]DW=7@VV0\W_0E^OIKXF%O6\:YAY38HDW.;A

J1UZB(A$4D+O(FS4DI MZ@5HE4)S/WZ\Z9[O8#4'/GS]\:$;"6A+1\2R8>MP!? EL$H)#/EO*EU7Z0; M%F=LP[++:#MAV$^T0]GT_TY-^<[FN1R>6=@R%L!C[7AY>5\Q

D M@BESRV.D>ES *W\75/[W.E_&,3S>4-Y%>SA%PR5_'!<[FMRDT5.=GCABMIEU MAHY:QQ#U%[N.08>+8/?#!\2FW0 A6XE$ALY(+'RW$]^(A"E :2BQS"[[?6H]
MV]#'Z'/]A,L[FM/5D=M:L35>;X=Z]:B80^21FFM2M%7TN5&E4)HT M^21,DU\>@Z_SDF5I(HR.GZ(B!66]SODR1\OJ,]_2:G_ ' Q]O1[1#^WMTR+4B M'??1UCT@"]) (0T6(L$LB(1#?
]G_&]K?H3[1S)C[AF>1AY_'7QW$Z\S#;? MG#\.>W)>TN:G?Q3U4L(/Q8WD,G'VFUZN/.>0-_9Q6ZS1_2#^_9WFU?GV_L-LI1QJ-B7OQ]!FC MU%;R 'Q:'#
92_*;]'M18!T0216TH'E+59$XB42,.&(R9?#)-SBU81Z[:*, MI V+"@Y1I/6M=GE2DB=6%.P3O.(HB@&(52X!_K;E !8D7?$_ "N9]DLPK.?,V M8B@!UD%["P=S,Z&&]^V'B)-
:1UGT@55TW!28:(99$0>Z<_X.2$.2 $V\96 % MNA7SX'$ 71C2BB8*KN<6 NR@C/8U306U6T>BPB2^R'B?7G%B0,HBR'W21IC M^NGGY9VZR8#MV9]=H(L@H/&@"]72YNB>0S;-
B$5=*5V\+-D@)C5D IC)%;PQ MWJ&&JSG 3=[PO^I?.X9BFD%-0IYCJIHQ*3 &+(MX@#&BD$!C@U2,/%%98*"] MK"6\J \TI81)V-8:0O#;(*=`>H:W_9U[N1XA^[>
[D%/&T;@(Y\V7HOG M&@^\^VYB/)R18N"BM3[:M] +Z%0#DV6>2(JYCQED"SVPA63?W0/GPXM M].ZI8=9]=ZB\; /NX&LO;:?$2<0FT3Z'W<._>/5,?&\("R('T>XE)9'#$$$,
MS4!$'_50R)?/5K1WL6&!@ RF/I7,2UOFU6E&=:&!@F\/>5/ L+/S131CITTJ M&=Y4'H/+1KZ-Q_=3!GL2=/S43&_<\3' -N-A$62>!<=P$_H/MHENTA@N_!5*
M"\^WQFP"X[VZ7L3_X_;]DM2D;106MCD2K+DX54@8/@==CJ[7P)HH8(4,4V& M&FK!3Y^B[?#Y?D@+YEMCM@\"5R^FS#AY;2VP.1*$*0$NF F7X)O_I%&A[_NS M.2A' CP8> !U5E
'ILE$0W5NLA-D[,]86IM*4XPBCW3IZ=F^4C^RR^48K-S7 M;>6 0.;;Q)H ?(-*0/ MD\/QJ3(VAV*>]3X\NC=@V]$BVY-?<_8D)U$)CE#VP#)R_WE!;F[.OPZ17*,@
M7$R7S:;Z\5\VC\O[_WQ0/[JH?8'2DLF>G2M*3=WF,5>D<D/'$SW;&J40H[UZ.>F,D]=7!GCP61?_M 7G2HU'1! !0618)RS+HJ($!9$7^/HG'YN#Q)]\!'BR%0,[]F VSL@4-D5@
M2M3A#:'_\WK#-+EK>B2B659>1<4S>Q?EOWZ(QC?"Z9:H]%@C\[/0T"5"+($ MZ"[(AV^6W^ W/5NCL'(B^FIX=%\%.!5-
BPO3X)ZAB+_>/9&Q8C(Y';*Q3&DP(L)W@!).9\]Y0(]]'152MQ<77 M"S?0X<%2H?8'1N>F>72M90YWTR(O@T16=F8Q@=<:0&\4I8DA M&&JL&:
(*YCW;1UFUOWW*ZK/]L$Y,M\5IPW"?7@Y@8\01&F!K%(C#5U-PMJ9. M3F(<.!U>;] D!ARKFN*S13THUF()HKXS@L^T^&=Z@F)%EGQ*$]H^>'FY@Q=0
M)DY22E^@3E23/3L_6374H;A;$R8D 1@6I?H*HE3/;LKWH"'!Y:2\C0S+,])KL%%@:&&]+F M@II$,01+_56\B5N=14>RY O\49;O73GK4M]A*-RHT MO#R@
2(GGKZE'8XPM6NTV,Z,>&FX2M_3+*6K\35YZ.^8%;C?CVMAD+3P*ZL9 M5N-U5)(/L%H.SC6;98K'.GAU 2=9B.P#R^&AP0@>D!E9_Q2^0-?#&^W97TV\ M40BXNG@V1F16&Z^^M
M;&6]>9!B";U8=0UU"VKQCZ+BMN6.HZS. 8Z@C;NA0 M,1F%!<0\$]0@,2/^P1&F.<:2Q-DJ1IQ?(HNXOVP-S; "HM MRFJ9YRDD[$3%Z^]4NI^AMFOFN_<39C./0S\4Q<78,($W+0Y2
X&R& (*,;GQ MF?]$(PX*/N6#W7:#78G!1AVP$&$V&IK$T.P,6/3]MEK3@IL:\:XH.%),J??Y M+]P5>!\G%;ZL^S@F,\7<;8X9L0X)\B13'96W MU0O!T%X]W *S+1_VY&4'/B2IO1F9(D;
(/Z895Z_V2'SA[4O8"UL&RXU'I XRJ37;L6O. ^%](39[\^1O2 M0X!W55H>DNV$BU06-FA24@/(O9HP,7UV>C/_EIF0GBA^8\[SC=N3]ZM+Z8WH\G&V(UHL%_ FQ"0)@WM M!;E;?W-
AM@-9&LO?Y^XS+3U,CXW&J1 YO5V=%S1)JZLHAK/3OG:)OA.U 3F; MSJ,M_TO?.7J[NLY?:%F)6D]#2F*Q6US:A#%Y+^(/8W@ GG)0D M4M) 79#FUJ1%2QJX"W)X#?'%L3:
<'@N+^)+G913L^S=%6Q?-K@F&R,-3@&. 5B<-Q_0VK: MI"9N9FY8&LG?I[DQ+3M,CXT6!\/\#3;.K] %55' V3@3%S[7%BOU0GW[,;*!, MKKXA+7$SJ;,38/Y5%KT.3!
[]NZ;T' 7CO%Q80XP -;_3{\XS-LL(?UDZ;+,MZ)IR M/7FA\LGL#[2Z73U>>N9A2^P&;DC/?L*^)F @+F'L;JB"K&UP4][]0!?9*Q M,E!>D8+(, 37'"V$YVFU7Q8T.F?)Z_O)L3\CEL%^-\
[3S,!W!L0(4/.^"@YR MC,VQP=L:^+&DMZO+LDJY"3$:BCC<"+G2'7;F>O8Y-7"+&9K!KR)]^&[8G>T2%F2QG7,1L,O-B+36M\B!5F)AB]#40D, MQF1T-$H;
[QPV8)HXGN[EPR"]J2=SS(C%/L]C&Y:+F##Y3.MM=SDZ?B"; 01__M(AOMVKG-*FB3$H@OVL=Z>U?%;]HW?+5] +L9&T* Z@$^R $V3S_?GNH(MT)/ M'JHJ/3&^2[B/|:EFT]L-
)>Y9[JW]ECV&S" _+Z M0G.,?WVB6Q_+5O3ZH8N')=Z];G4L./_ZAV@##R.*Y*PMU_\]J=91)?Z9QND6 MCF2B4CE9I3E7CS3*P.&>EU$L*NV1R_19IN)1E"]BR([TZXB.:M(EFY2>""Y
M8@L1V)-S2DV03|<91/JDU2Y0V3X5&66ZD^7-H+CCW8A7&;5L"L6OD&;%3.^N M5;0E;\.X<+3]TX 0W+5<)F_8V4)]62O=M6NH.)A3SZD\B,\SWW)=9WM*14P M[O@YF-;8B
1'6G1$P",-/FE!D@8A$1#Q^XU? MEAA7G=HV7%0)+J4ME^1;\;3ADM!ULFVXM 74 783*Y+.K,^5X7IPP MPEKF2?U@7)/EO.\2GX=47 -3C)8KBQ]>9U92;O/;]>MI.!L(RCW48!$%#@)O!
MM7 6I -T.@~%& L M1=*4-"11FR6=''+BT^MI#K#*Z"H5, ^&[JVM82>LJ+>,H M@T=N^6G]@I\UAJYD9YIBKER'NG1^?JSE3!(F0)EPT@1H^[^XG>,KTV%6H)N,
M=U&9E@_<8(B2V_RG]$CA#?I[CNZMTF7& .=6[C/&R82YTAC'8WZK87.L-BXV M!!XB 4$MJ 82N?>M=&@1'+W>4.5U(.5LKEL T4,%"=6C-2+Q'5A1T"E"851T
M"I&YDMH=KPTU;>NL]0%D:"4RU%ZT50E:1S55766>]/69L6X@4)6YVPT &"T M'5+WCOISK6+MFI\'11*S0+?:XXQDRMSQ)AUS4F%+&KQ)P1%!S#I]@!81X L(MG 2D-
DR([Z2XAA;3XX)\=P7=1FER47O,ZW(M_,PK*O6)-VS5;U+]=&;M.J4* MT7!U*E70V;E8;9D/)G7@;RA-X2;YEHR\-8T41NRMFJ66O$[6M=1GOC>=OVW* MV8O%YV>:/]_YA"Y?^&^?
Z45:BGA,.+1]VMV[`=(/52L2%R2DL),<\'5Q&1ACE;1%Y6+.B@O?3YQ:1\8;(1>2X0^>E5H'B6<5) MAEY%)IC)U#GDW_S"%ZGN02WF=:F/]##7EW+C""[($"8_")(!\)DF^/OD.=E
MBFG>Q.@>K.[;U4=^1(2CX>T35.]@R75^^3E>0T7@*U9'F\$(Y5/:#D8@NMH0K'$$\\K4 M*3@U;0BLYK:@Q//3<-#?TXTLXB;^"$>@L6];#0.^A3#I2^A94779S[+:D8%SF5=<9:
[2C'[8#20S335!F#6ONW(M39(> 8)$ M4O1NRXQRCZFP.FL7VYH\"?:K64*4LRE_;(XJMT;(PV'LGL6AH$TF< MU-0#B<@T?YDFTP*%OUY%,97/[8UL;W/-
K82V=MV&"63MZ)N'K9J,Q4:0*M G M*H/Q$H\Z(#"CT:=CG'/L*GCDW4]X"/I_-G ,0#?>_ %+)@3X(!A;(X+3C?, MATV49>]V)3^)E$.7D!.MT!OD06^>-D9!DS1$
^V'PVQDBKQQ*P=KFF5S]M)0 M([P4]#KS)01 ,K!--,A#IL88Q\M\KT;[#9>_ZXININ(2IIH;; -#W7K;%OIE MZG\!\D30]WN)],QDILLY?
P(D+/C5A.>@]1W!$5V&$1I!^B3DY9"OX[(RP"QO M1ZVK*"U^BK(=?4^C@JL_I]7Z8\Z>2E]\ +3K?+NKRGL*'$BS5&"&'W=% MP0^,(GFR=92*OD;.:4YI(0]Y3C#Y.B$Z
8\Y7IX(%TW++W[QO\?6:@QR"G>[M'#"O4^3W-HTN!(W1@%[U8S8>.=9'>!/(1;K\ MG(ZEXHTWM.(6A0Z=VWF' D/R"Q -$U8XPFZ];SL+ B0)K(XJ>P_
QP>'01&F.;]R(9D#\X*47C#0W+9'0=>]N3 23# M2LP$-P=]98RQR++#R)=8 '[& SW>;728*\%VN5C2NELE_[^3;[I]$*@QQ3/5-
M;R"=E^83@710Z7S%AT1>8$QDTPU*N\KE"7,&5R=SV=:,$C%LLA HP)&K1D!4K M7E5WKZW?.(O*,EVE-"%12:*NA&;#YH3 [=4SV?4XQ#L %LF:]%Q5,Z &!>2I
ML#I^4Q+V*8<*#+O-5KA1HR>VDRVZ7Y9D$Q6_TEY1>R@N_(GM,B)GU:\-\' M>4/6OYJSL!+JL3I^NA$[PV!I\IE6Z,KW![VYKW;/R=6[M5)-<$>[!1@3F2)G M;.W3G5?#\>?
2Y5Z^ZKD\$H>+PMN[7?-/,(OD*2W^7YC_U M[!S^'5_F'=L&>H5%4PN/-C"-V?"7>Q^O:;++Z.WJ\$!;SF58JW^(S \ M5[]& ()WP_+G,XCQ)Z_\%N6II&1K3 C#"O^[2,JWH
S\WI#&5>:AP;'C.12]3X16^R"(EUS4\YXLMO!%S)L"1N(>N M,16";(6W.6>A)C)@ =3ZO>]RJ=7(@=)4'.?5ZYX]&&MW.D$K7!53B= V2EN M:F?4)C5-
&P2]6J:%ZBB]%315$<3).J;*?/9W-(#R[_*TM3<;VHU'#A"'. @$@@W^6HH@0X-R-EAEECN M-%2#GZJ0$_#K]8;) S^=(S[='!&B/]>HK6X-3)(?FP>=5S7&;:K',;[\.I M%U%VG2?T\
[_3\?C D7;X") _#_GR%]DBJ1) EG&ZHF)X1;C)E%CD5BGOZG,)R M)@,_1F5BN!E:) Z[\R01'5$1H!-('D8XR539XU0:!N-MQOZ,GGT_L37UK <) MJAEE&9OC@Z/IO>"E4Q2'7!!3K1
3/*KGMS7%.7D2#/;_OV.4\QC"AQQJM#+ M),&L*^O_W*3YT3N-2FW1]C[0IR>]KTDNFG\0($YN\U#K_A1WF1;+_*?\-2$G
M*2WKT)7D]E54RE$,RV$(R]P=G$M2I@E_%B&YEOWN.GY!>K!)@QO>XVR1RY%$XZ36 MGSCIU(;_\)[LLBL=BDU?)518]O](6I;::2C+9IVO=F"2N MHQ>61X%0!T[]#,@3H'_VEG
$$&TNZTG18I/F(D3K%P#D=R]3DQ[FQ41ON\EC M(7;!O;CAEH%@\5]W:0&7MV7UGE9KEHSL*3]?(G<6%1*^KC=5L&"V&LMC-+G, M%#?W)2GHEC=8BVB']01_[!04* :
&YE74#PYR+:!-F+M 20F7#O0M\CW2)C)O-_*+ M0E_C, 6)'Q*3 9$?Y9P/,_^,FR!1]E_I]IPEXY>W4XU-C8GW; Y(XX=0) MD]K$@RS=\@JF.!9F*/<.=MLID/&YYK:.++UN@UR3.O1-
SZ;&8T%L9XVQ(F@ M#B\L OT%41B-C /6D,2,G;%&6>=C014A@+<%/ZB^I'D\N2.-#==5%]UZWM9 M%>3AG-4 "+NPCC%Y;&F=Y)P?A_&T(3K?V-QE[-D<':=NZ#3V;91.>8T#&Z8*
M8C/L,[9KGJ*N(+.,?8+:H5>LN&"[IV]URYH4@2XU8.PJ4NMCJ)6D$A%?-HD: M&M0]I:-Q8NXKFTR8CNZ"M/A$39OS@B9I16Z8YT<@D*+'S/CL:&]Z7Q49.)+*
MV]5CD8"'9B001ZTQ8F\;[]2U0KWGID !-9$$>5&!HH@2"'SI+^R_A(IJ4>0X MTV-CP+M Y9L_Z_=\X6[U[-SA>;]Q:P^)I3PD1A6)61GF9:T)J9B\?/.R:DH- MN\Z3Q[0Z,DW&&R!6Q\..?
%CKAQ1U+713O"C7QM&BO8"LG00E37:PNL^/P* M/2(!;)Y-KF5V((]G].\F%NLC<^>((%]>E>@*OWU*/QR7\MK):3C>9DM;G@
M3%E^P3>S49D=:8>6W5?]^9/A5X1QLFR,WHY,DOX.,C\:9S()AQ,F6=.9?P! M@L5% /GR^7GY$]79-DW])(:*WI'1S"\13")"<"
MEDB7"/!NK:HH,4VNNLU+%Q<^PL27,86WNZJLHAP8/GH!H_(1/F-]HG-?Z>L" M0G.=5\=:IF"$RF9783O#\=+I0BS\X'.6QE C]++;[\S?:MNGBEMDS7!;LBX: M$"%-BT%I8&JL"EB,3-
1<^L '*!^(F!M2_Z_R%@V)%JE'\;^ ;;[K6ZSN< MAO5 V-$KW*A,M$EY"-Y4:$A)A5GE&F.[/MZ9W_8;YY8]DH91O^.L-H/^G$M MY(VY(JEYM\.'><9F&>&QV"
(W]:_+3BQWDR(@$U9]T%Z8."UQ5(*?[P=:#]DKI" MR8QY?QH:>[G99FQ/J6AT5V=RWO'91.GO?&\NM'FQ6-<_M_)M=UF;*-@"EOX;$%P8%;5==)E0GRE7].*Z/V=V;
MY72T\NQ8$TP%N5==.,2\A! 2((!BJHNPH]Y@*2T)O%5U>/,]V& W<[F9P1,:U M7 $$$<*;S@>[0Y_SG/:2Q\G)_2:BVV@?>T>*8%>?.!5935G6L1I2<>*F> [\82 M+S"F#-_>R?
JH/2?,CFXUGC:DWZ[NV@O;SL^106W>&KP4,CAG;;A M,RWSJC:.PN3Y"V^&*_RYJI7#C;!AS0>=>0MI/["*"FS5E M9.*9&E=";WAB/QX[4"!,M]F^'-AQHS2#&76QJE]-
G5M/:057G$%%,]Q6DY" M!2R8?//].!#](;?J-A#KMZ1D7=R FYJH:@R7E6P1Q[6ON$'I.?Z'3SQC/ C MDX?"P2?5=3[1E$.5KIV[95KRY+Y[5+D^)*L]O^YC4+BWI. IEO\5K/^L&V;O
M[>B-P!J3@;6A5>6(8?H9>]^N#!OSON]>/3](.^Y,].3GM#U(,<=P?<&*]T+(" M'SZ\;TX+OC-L8,NHWT*-X)1[XA[[F?E4/LDJ3)(_ 5: 9[^[Y1YK3(L[6>;), M-FDN'ABJTA=Z*5^E'9-
^K8^Q]$Q+6,UR@6Y%GB$*!T1@=(P@BLWA0P,[X: M6C"';Z^ Y]0VN\UY5*[?15ET7%%)ZQN,"3/7MVNA4@*A;K6#RT\D*+/'U>5U=ISM'P9>R>&YK0I*X?
T=RAM6I/"=YV,T!LS0CAMOJGS?;\9N^HS]BML6V$]>2].?W M=_A+.@.4QLLX!QY@53Z>7#;-B].X2OM /XD_H;*!CCYV<6'6$CF1.S*(#;K; M/65IW-E",N+[W==.8V,-
&.$HM8!Y:=T4TB_SU%2L> M:/'"C39,TL9H'PI"GHYHA4S?H)_C-=@$XB: RQ<$O8.(ES6V4Q+BF9E2#'Z: M87]HD9;Z9BC3,YVXV)Z\2_5(YD;:6[Q+@FZ=WR')R(HG$U^ 8*GA
MKJB@B(+:RG5J04K>#ZS#JUV>--%2,C@,W,=,N(S+KFQR;7=5ZZ@BW #A7R24 M;L2:_K0G:Y:!=O&_K=+/O)F(N:ID+6H(J]7H.,DJCCQC> -IR[8S$]ENZ):
M\V]+].ZPY[SBOX*GF:!)73NP_]=OZGU$I-W"TT$;&0&:YU"W?ROLD))\6M.\ M_7OS2XE]RPH(W@?=,[LOX4%"X2_G7Y@O)^!7HC(&V!^OZC*$)UMTHKBQ;!\#>V"$6XBY(7 M\+
<.O(C>K@.FO(=;Z?]O @4LNE1,QVC9TR_@!]W]I^0V&9$Y17^HH6M_Q'+^ M" >*3V >Y<_+YX(*VX'K/L3 1MQXJ>!GF8(Z[B5!=X*QK+6)N5:\/B#2(A*; M 6 Z:T'5!5?PCA(/0S?
VE.AR(X#EB1=79F]LXOI>LR23\]'A5@E92; KU94V0TVZ MH@.O%HD>1))(DQ@1V,1#$.M' (T.\]8_P!I*F M###6%B>,;Z"_#M@(CP M4\BN+^B;YF7Z0]]S?LRB\%
[\!UK=KAZCSR:.ANP%&^`K1\VG[DE_;-P'Q$^G M@(B\R3BF,#*+G1YFB><>MXB2T!>;L2WLX756?GOG)PJG%C2YSN* M%M.R/&?E^-YAW"-Z4T%3=IYM6$.3-P4=N$
+LOD,.0=L]R;T<%EPD98Q7U]V MQ6R%S9G62&$=Z=6U({]""1U=\@M0)H)TF'OC.>XR399Y$Z+7B;4BZ>@GOA=\ M<9\]F=ZC]2U2P)1HN!:W'@@B4"QDSAWI@(2M#* W$\R(O0$?
A+OE9^@(/%/G MT3:MHFSY! 5XXK$]7+\#:T %C1%R'I(J0ZG3O'ZB4.S4O8N\/YW(@VNS$S'] M;*$2=X.MH5"4X;]@'*@LR0 U-K06TOD.+*VFXX0"+*D A@ :TL"1I5=.:F55
MF)D)Y565WZ9NJ'A-DUU&;U?+7;5F1?HW6L)M7R;&&QF'6OP0M4F,D;-)>AO\BD!-ER _<$ M>8=$MG.INRPJ2-+9 YQQ4B0AW)N5(AYF%M_1]SC M<]*,S:?
P!?:H.]ZSKX"S"0@8K[_5$:$?GZA84VLMROBZ5P=YA@EO49$>AF"@ MQS.32)=XK^X84ODS?2X:[]IYT%A#^Z3\1$K,9A@.!COM@(LTAQNL]"5-:)YH MGW;F.[!TVADG%."TTX
A#9H3/.PHS,S$84>5W=XDMW4;W(;H8D(WG_@C)$Y M!B,"J_P=4DYG^WZ4D1WRH2' M; YS#E7&Q-/'XQ'09CUA/#HXBJZ%LD'UV@]3QP43B8RTT.I7M=$1T;ZX8!P6
MO6T8\][E4M;E&F6B$$3#U(S9 MP #A=#2686)R:TR:-GZ+@Q;WPY34;(8QPF MUD:"<);<'%MF[-!LFW&9N!X2-LV0C1N?IV1F:AB7@73]+DJ3Z_S?TSQIKI=& MU'R\
(5+#CSMT7\$E/Q/OB;1E[ZF,U HB,A,,9>I<"KTIG&,.P>'6[@X^D(6I=?2_G4'L+UPLMGICNZC5\]B\ RQE;G>WX#S(V MV=Q=83Q
LVLR[3%Y.1R,2=3HV6"2B_Y*C5%.G(Z<6NZBO0@*NMB-O:ZL^SFV M])@B&6\ER!3QH$]1.1LKOB29T+MM35O7 ^]']'FNZ#%3'IN&AT,8Z-/K-]5[MC_6\VW=-
;A!+>']>EKFX7S&5CL,7Z+]%8:O#ML&!.&+TL'X3L]9.2Y@ MZ[,&>;>QF'Y8PZ9<5!?GB:7GZ%(B:PVCSDYS_7EXA@1]O,DSM1CX*P?L"UP
MX5"='S$Q1V7YIS:N[U6DQ9=P^IX57]6CN-ILA+T3U+D)="_%_36S]I=7ZA@ M/ATKP.<]G_+MGE47U>,G]KAFNY+;K_#\145I/A!;.QZUCOD>X^K1H>-:/[[_
M[NUOA\/0\5'H;L=GY3!/*"]8+25S]TH$5M6 P9J2XT7*6FKDYA4]'8W;M/' MNM(>$\9KBP0L*]*M?,R(Y\'2)1\YX8G'$>>:6TJ-;+KUGA!)@\'+(=Q)G&3R1 M^CC,M=/PG?
2N7,'IM4=.TS3BX*@?QZ$'+;V3\)<, 7,9C& P>L2FR(7K'[X$ M/\BD."+"$4:X[-/ D58 K],4:5_$SM\7:WYGFZB%-(S M;U=7XI%*@# N+;'5,]ZW8HK HR?&%"K2;^.?0XC50>

(\$T!)AY0(J+V:!GW0 M"]+B!8-3(B;SG'+G$K*F#LSA# 8U1"\8X-,P10_L&B,RHY#F:.2^ND8I* 8 M/&.2#O'N)(W2@5> 3;OQ8)+Z>!D_<,7:(^^?A/;#H^]*> ' MO*!1!@56?^0K"#R'
NSKQVM*"Y'/#\7#UK9! I9N[;@W M]P_I\<-N0Q)_5VT#N)4;:3&>3S62)= $_+ %'EUHIX\X7?\Q*SX[E[UY<5; M5],\3?]<#A7XT"!9-4IA)W(?5L>%V\H7Z\K68_ZM,$^'-9;E\JO(ZOXK2
MXJ^,'1^3!]O%\ &EL\\-T[&\!F[+[8Q,2<7\O&! M?]X>/]'LA;[G"]QZ[#K9M#O'(2"OR9Y:*,AK?"Y#0LQY@0L-^=T7%AHR*JI(M$)%IGI^""6R7_O9'3=[:])
MPAA;)52^P2ZW"4WU!T_I"@5MC0]DV)H5YV3+6I1D(OFT!6\>%!'!XGPM_.? M]MM2,#-U;%SIIY*0,12/30O!K*F,165-O-)$T9>9MJ@^+R-!NE8/3I:)X \@!
ME5$,$U,N\T3\F(EY*N]8EO(&,\^=&/>'W8>P=)W7[)3 2(.,]*&)M;L[TDLAT MY)?ZOZ%?5C&?3F9]C@QW@WOn:I73%U;"(MG17I?%$5/1<6\QN,-:G:T&4=$F? M,'XSL#<([&8 9E)9M#
N *L_[.2PK0X9RCCC1GUR.XX]=127NA7./BKO$9 M1O(5NG>M!&V& !>&E/N@UF7U2<;(NT? ;[=/Z,U:OG!4.^7#7)4Z;%*&]"(X)HW[VNZC\B-=.- MD6(SW*DOC\TP=8RKQM8X,
^BP-IS-O"$1LAWQ&>$A>EQ[K0N-76*,)EWZ/*]_M,VC))3Q"9Q>@X0HL@222- 1SG.W@F1-9#A@BFEIS07B](]C=ES#N4%KA,H6KSBJ-[[MFOBON[2@R3)/&K I+?G?N,&<7- 5Y?
L\7^$R#I'):,ZKW>C3<;YI8XY1OC"Z M7HX:VGSO[!$GJQWN/:_398MIQ>]>C7^H'KP33(,BP#>L:A&, MN$Q%DR2]0I06][Y>+*APG-!"N(S%RR,E7\;%%SG\IMC!2R3"5AW,I0T"(/22
M, O4?2D+"0">VP,$XI(@DAB:HX5^TN^)L\C6&KD_7"$C%5ZV"V54_;TMDNI: MYV*EU)23$XC%^UC2U2Z[25?Z*Z[#8C9$S&:/]2#B)A@ < M\@9..C,5";P'OPU(G5*
(VQB;3\AD&3Z(INY-E5G"H4V448!>4HF]C"2H?6.1 MOX@EZ?;0LZ3^VNF7PQ5G)^+77KF^:?=W> :>7ZE2:NA-9!B=\\-M395L)5ER1FYO[NX _K0,>Z*UQ S3
MA4VL4:]8M&@XM)#+5 %WNYS-*(R3(ZK"Q/L+)6D6UN9\O'P]IR**R1)-YJMIC M0TK&^Z45XIM"9W VP^/[[?UC\\V0?-G[0?)VIJ*FO+B0PQ-0*8D^T1#]0 M!GITO<68 R06I:U>?
2@WK*&I:F<9 H"F%@ GWR)W/M",Q. YSGP?,]' M'=Q%9VNQLIBP,"83@>P6A<<(YS^P8L7X?)+P[K7]@GR5T(ME,?> GRH;?>== MZU@5J.Z\Y&(\M1BT\+E/4
YM#2AF:MO<]QUSQ6,"=W]C/M$;-=P]@,]K-MV* ME1;*.C3V.N<*0,N]CG'I[+3YM5&U! /E<(Y2@!5P#I*A>ML?L8UUK@EF;V"1 M&M>"G/#
S>+VNX>3TF;06XF)1'#WS:VRX<#]B!]Q8!FL<0=?PY2U=7C9TIL7 M;X>&#D^:?#BJ0#'3"GD\>-6;\P<,X#IGRVF)M)%&"H/8_V-\9(K,L;]!766, M%?=*
<7)'3!VQPDI4R+3T'=R,OV@E?#E7S\D45WNE4+2"E>B=I!E;(X/AL>G&_'RLPAWNO5G1\95$=)(70& C%TCE+]
M!G.@FNO;R\E]#H3VT<3^]!#KH02Q:,)S)1"X5F^A+,0_R1OP,FNM^HX&:?[^_MV)]*-\C]2-MFP%4#]WOX/-1CYLJZQ%!<-HV:S[:%[B4:K_$_V 5X=[OR'G< M^LW=_<>?
EO@I_89HC>6Z'D"(F.O!"6?S?/'H_7WA/&+%?LKU>]P$[??MNO)5 MJ+!/$V.;FV%&[#PM07$K'LA+/3#E3(4G]@VLR\\5S9/Z\D3#R!K]SI*A==1_M*&/K"(@-6\3"Z&P:71).=WUJV?
R,%KC76I3#VW]."WDF:7^-:-F&"S; [MD/K+NBH"^&W340H_QTMA,= R>$U!]$5Q]<8$>\.L#871/B$$I9E45'"5;WT M#YV">VAV0D;=1&I<]F^A 9.9>\K![.@5\LYRZLBB]N?
TVI]ON/ZNZ&%3(^%%$Z^ M-// 2QZCSR,"9= 34MH0%%V+8@UI :&?0<309!:81=9Z$^"V.-UUOMU5Y0T' MGOTPZ%C1^ (ID!,]>RG;^)-,NI34P3;F],D/83SO.MQF"!;Z$S!6T/0Y/]\5
MD#2U?RRBO.3]P,W3'Z,TOV%F^8ZN>)OQE1'1 U8 U2GYT> T%\,)H(T(4F05N^[>!K](\ M+=@%M8"'N;FD 4\P2+ !D2O9&;9 O+?
M4EIP$.O]8#R441^F1H8+*7]F!VDIB]HW'Y8_A8FG,IN2(4M$G\]!C=^WVL:O M6V?&[]O0QN ;TS-^7W-[QO@=9&%0 ?M>6\"^=R9@WX<6L.]/3\!>QJ=A-$@F[T?H/<4=.P9
L:O#5_S'B/OKTGI\!BS3* M9D\10VU-#Q'\/IT[+Z-/9-,0"WN$&&3ET EBG# _>9.4#K2!M*Y@+VE"DW?[MCR5-KO.N^B$_(+^D54K+Y5,I7*DC@H3O""EE^@2]Y%_VWK+H%=1LI?
PIB&@: M3 ZSQW%O0KV,1853>-[EMEK3XI[&-'V!VD8EC$$X@,;D6.M;I.@]T7 MK0T(ML1$S@ &U71L<0<14C ?,B*>A+%-D;M)0JKU13GQ@N4$-=^[I[F<* N6RQ.R9$U%^[X'8(
M%O5KG4LH$")*($'EAO.")FE%X$9B091&[`@IGI2P@65XGL7^]"D1"7R*(,Z M$]?Y>;1-JR@[9YL-RT4 MC3Y7I-UF)UY=%#8)1[0MZ)KF9?I"K\6SC).^2.WO\6N]&AWGXGA[?
DV6556D M3[M*5'&M&+F"F%.A/13ZL$,V:O1 ,4]\B:90G?T"[NDNK 0/8B<$F:)S Z\HBOOG7=R MC;Z4#R]/.3 GVF-]G&/]^C]$C0+ G, LCJ9BW,;3W]PB>UH^M- 3[VUT2^
MCQW&*3LK-$R;=]XT1-@RHZ!F3 B]CY&ZHT;$>5;YH+R%,2LTV<[,>,G %OZB M?5ZMG'L%2^D;TSOWH;X]7K7WR)-?0C^.I<;PH1OV>2YZDS2X 8+ !RN;FV-4 MN+]X[*"0%>:+/
M:9[#);M\3(3^'MEW&6NF""O4[CS5#(F:WF8L&&&V$!ET@="$"%/OP G!?5?%,2$^[/))Y9/),A EY!Y'(^9KD$T,OR4#"T# MX5%]B7Z8.W'DO4,MH%;7!?7 ;0?>9Z9DL M/#!I$"%^,-
M@OPANC/2KO;@4/ M?$?04\0$QVFHSS>,",GM),1(&,'B^/6] /EVU/ MOC:M'DG,CF*$&!TVD:F"=G8D/IYQIL"4T'F45VD>Y?%!;MQ8")%V!W;S)@<(M>0LR4D:$BCIR.%ZD^23,HVT-
B#SMR;H!T\L4/:5$T2DIG$\0G66UOX,CVVQ2 ML<]!JN"Y,- ^4XYM5"T5OL >R<9[=IZHW)&6YGJ?.'GS@5647(2I;IS";X9@ MHKIX^MU3F29I5.PAO/5V):*S)\[S+;'1M./]>L\=)F3]>>
(!BRNL<\9YDV MN_R)48?B0[3A_^R5*YRLYJ;^(5:P9@EXEK"0A=HTN,WP+/1WEC^,[X0,U+%3 M_'A+[/G]N$=?!N@ ;8RE:64$")-2%&WM5QR9#1YSY7:8$ JFP2>/]N!Q>?#F
M++FORXC?TY@]YQ-/PN(Z05N-.L2\,>*U4*$'B "B"0 M.ENL7YJK3OLE4;CX1)TI8 9\#;U?0,1M:;)?3'1@=[\8(1XOQA 9'& L#)> M& M%V@ YT?UB2@+G]XM9-
IMI:%E4/>WD/W6:"; :GT,)*5ILHZ+:@W=DP'(QITBZ*^ M1@W W!Y+EQ(NB>)9QPX+VH#*1"%[1(7R)N2M/YT,;)MDB5&>S3M:J<1MS@-#N9%H\\ MFA=)@A"B#1>(@ M-9!
QHJZ0#$#'GHT9\KJ=B6>;.1P'FCQDL:T?&!9LMRPHDK ,)I[/1^T:G8 1 M!HX*$?=F?\5 3*$*KW YDZA'/) IH,5\9L91KV?)4D0PJA?IF&QO<+(<[-?' M 5,2/LDZ'=.\9MH,]+K2@;S7%R C
<[#S0Q6KWYW_DYDAW1QAS!3[/BRI.T% M-%4:@,,U=E 8F"]7?);7+W8TN6?[*.L5#%:QDG4^Q1?5GR7A\2&562S(!U4< MC!'WL H (2V24*\$]$L5,V&COW"--;"?CF9%YY* 7TBM*
<)I=1 M 56'R\E:)],-D=HRW*EK/6FHDH9LV HG,YQE>NQ2E9Z_O121$(GQ_OC#=T(L MX#=_^9@GM$R?*,U)G$5EF;Y2_F?^[UT/\S=>%45/ MR!B*QT',E>NRW,%3J4KG4-
7O+!@N@_W]M8[3&@^'37Z:Z2,[O0(G MO4G>(U1=VQ5[@4'"F=SQ9]LC)6VT7^=Q'#5AN7HOB*0==O.?9S+3YIP_Q_7P M@[73;\&]?(-U54_U[;S<>O<$\5W]!"%-
/_"3KTH,GW^&.*BD]5;/2>D:;6=0 MV>B@/Q_UC/B:I&-?.BQ?-,Q*ILP??S5N.$K@NOE]['P,C'+12FEB7)%*M]@ M'\M,]>V)KF@23]BO4L7*7&9H5CG[X6 0RB358LFVV+KZ
UZ5N,PI8GFF8K MT^*5OVT+3M"W]K?=UEWI2\P++9Z8[EV2I BZ58E#=P$9=Z'7I^D?,Z;* ! ,&NT**1,A25A5_+; M7556401/(N@LYP.?V5S3>]U[BX*=P8&*BK4^-DQVXMC.M2
]*.1-FM>A28&] M%ZN*V=QV-LI?CWD)36U&<,G+RLH[#]=[.D=7;&"RG:/T6=:7GZNBH@5"14 M[* Y>;2$"$9(R&19)LH]RJR@$1WU0!&=&^$,F;]D.6=#P"79G1!'L257GP1$ M>
R)8R05@ R4IN)><5B N0MK5'S8@6OV=O5 XUTATH'/HRR#*DEUN]NJ.67 MT, 5IDFB3CVHQ:(.TYI!XY(S=NT=B534/V^Q$@D6GA)IX+9?E*=I%2$48RD%$"X73A9?'\^!PG]4P)TT
VSRP_/=8"DC&5\DTL">4# M'=L-9E]CZP$-]NI+9T;(8_3%VD@0.P=(%&E$B@C2W@+-8Y#G7]$;(2T+/]T M,GH^)_A,DW<>]9NO,WE9%2*P_&-
>ETVA\@'U75[=%723[C;PI/KK)6E]';#2 M*W]],*+N;UTQ@HG36U^<,=G3I6KO.G12S9,;XV)(ZT7I>5&,GA\>?TUS^*^* MN_9>F!' 9BCN?.8?
B;>6FD\;Z]+'W&YKO?/YVN1/'.$VZ7>1=EL-<]K"FM;D"14I9/1&#.-4=]Y%BWKM6O#:8&+TC] M>#4DJ+!2I'B0!LN"U A#&2T\ 9_7-3IW?_O+BKXV27;WL,M7VE?"9="
M2TVIFNC1M3@U9$E+ETC"7]5%A:5,@T^.Y.,RK)]#V$*!:C=>0J+@$.,"R(0 &7RC42 E"\2Y4,\QF2HX%.1^=14>SA MT:T- %,Z#@U_8N7\
<]BUQS#STB3.W.X8;!S:#C&$'Q.Z0NTFS=/-;@.S(Z[4 M3N#@-2+^HR>M*=YY4_H?;4Z+*%OFR3(!GG)PXMF)NISN9**VUK?(94")AFM=
MJD$() 0A#%+C")OFK3<1S(B[/BL]@UYP!1$%S%-;+I]*X5(<$'M]T^:754(@"]B8$4-%TY+)P=.1 M+NXNWW;YZ^;E)2 #X6.LE"IL*7P(5, M(0D!*[<.
M"MELZ=9QSOIV:)3"K7S#N"&YS.LP87X N:9*^1,DNRH;?KIAKIBD68]TY]^1F&>D1 M#7-?,,M+ILH@CXM'23F9M0A[?Z$9VXJRH@]W4QI?HI>660KN5QH)05Q-]4"<
MQKV4SA0P [YZKD+4!LDIQ*(]?&%4!6BP9Z]1@A+':46AJG#]I(2, BM#"]ID M\;3TC5UA"Q"4,BYN(2TM-=[/BUS0N]%@ -VNEE";Y%F@FEC7)MLBA6RP3_?% M^C/^
:O#.7K$9;1'[^?;:DT+>%XI)X!:?'6D8W?69(#XC3> &'7 M'W;D6G Z:B$$8()Q;)X;_DJ9U5F ',7M4Y8^'SQM]DK])]MBRXX-]>FMF-@0
M<52),#NCP!3^ZB@3U3&X*MLU*1Y,BUL>CZ ;MN:+0EGNN>;H@^IPM[X488P^ M1A?LC06A#AUQ,$7#5\B>E1>FRSA_MR%YE29IM@,+]JN0=_DYSG8)360&^6:[
MDX]AW]Z:YU+O:"&>=9],2[#:-_9^Q 8&YU|)'DA2=O4;0Y=HM#N!S.FL>-.8 MJR@M?HJR'7VW7Y8EK431R8DCVFQ[I&2/]NM<6H$;D;5(YZYYOG*M)GE7X@$ MFO*]>(R2)K?
Y/6A#P87]752FY<>9/)G M"D7);;)\H47T3-LRYN(\T'L)!E;=>$0X47T@I52+EFMQ%43$U8$X9M!$_2P5 M9'0()TB#B02LG;)P#D..%?L7P#N11O(+,.YH(\X3GD2(?___:.M;=M'/GY
M_@4_+- 6<'LMNMW=[KZ MYG11:4KBYY1*.93%)U4ML&&WO:V!T3Y^4P#?]V1H H9F+V?$UE)E+Z+/B./0GNH^(NBP-) M/!#K8D^!&G/8HR3FCCS\U2,K<[&?>7ZR^+-
,:LU@H.C=\-O82F3=HSH_1>MI M26O>H%7M1I#+-#'FC8;V'9A#.MO=NTCZZ1S3OPZ6"=F90H^TM9"$4M4XT%%"M*8DAK(.WWD)I;);6C-#,OC;+O"S&$>L,4Q730EM0T0L_BH-
VN"*DZG<6Q?', M^"$$\XPT, 0N!JF, !%Q/8#1L()[Q".D](U-0>[+!X01Z+]/1]H-^8$T\!K" M*7D:Y:MS81",U5Y2^<3<"7DPM%?G(\Q.Y/03ZX%>.= MW\!/5\NKLH!L@US>HOXKN5^-
]*]V)S'4=>T XRO4T2[4&/,S--X0=NO&]FC! M/"-;],D.V.VDC'Q&).1P/C>PSXB$?D;&,>C8$K,1QUFBXM-#]%GWH+*OF*I
M@#H_$^97\:RN<(Y_:ZYY]L_A505M@_&"5(!,2!E5V(ENK505O:'R+T>(<>1M M.SF7O@BN3K!LA?&$I:\QY/8G50:F(9DO".'$G*ZHD,B/M(+ODN70L>]I,8]^
M7,,MDQ#21<&3N[*0)3C8==11V='R]$B:-)S=->U6*9]+-GPDD0!B-"GOBT54 MP^]:\4OPC+U26K@CGK5%I,S19DS1S7&1@7DYA\M\<^=&QV#N71[M23TX,GZ=
MNDNB:P]PCHA>Q*K2\5^//)+$^?;C^[>20.')]_F*BH?OKP5J.TOI#+^D25#= M@SDO"+]BX,!Z3V!*Q6HX;N"-.2'D>2'2%/PQF'X]\RX[!HEG+VL$Z9)!(H*54N
M*C7MY"GBL5SF&Z^<,4(D3 V#TY7(YV)K; GD]EB^Y#',Z4$< W8WH^Q>F#X-\?VY?MHT1D)A#V3-6$.>V(,P/T _=9 M]!(KUG;O-=Y8M8N_+9#>;ON>V*3/,1[V)R?
76@&_!R\,+0^(I+;\Q=NE=0I/KKR(V,G<'M MI:DB@/!]IV,&K5PB/N\INRSLIO*&C4I*O61ZE<-2R->7%LW@(4,HF2UWN5N00 M&#^KYE2N)02 P=?7@-4IR!7(-4%?210\@^T
4Q;L>I\V59BCU(<-@BG"W:? M)7\)P1"7O$D[K,XP _A3,;&Q6$/5U?P2:VH-T;5C"PKT*KGX;7V0<+]4=W',>HO;6VQHG&9TJOE MYKKEJT! R7E33'9.?Q2?Q+S_Z^$RQ
C8%#;UF9PGLM6@5$W<:F"$>K@!IZX7 M3 B(D$*E-"&V!UF >5!SH8;J%QYM?R65]6U%>H]:GYMX:08F,5YP?5Y45! MN!Q >4-
5W'PJIW+ZKF^FZ*2S'K[V19%B6'S+ .:+4$K?]|T:%%1XAS3 MBM1P/QGK0S&L SN,(^LD5/"&+EPNK)=@(1K395H50M2P9B82F#$&YO"-M>;7 MCAC5\[VT(C@NV-+W[?-1<./
!30*G]BO8$$<>WO7?*?CS1P;8"<\2!NM3@N M_/5XN+ O^1V)TTEQXD!BL.[G#OG01_JO+CRNN!"W5AP3_G8T3-B7\HS#]#<6
MK#Q22KTOAEY%LE;7D,Z=C;+'RT1:7@SBE.D@RHQB"CJ\YN^?1PTE9K!B'*^?*#?)NCW 07VK2D<8,KLE* Q0=P>QTA0B9 M+&$A6V!(#GV6ROC*_R8CV=
<*,$,'#]J6';,)-OB2(\R6)9#:\[M@%<',W^EG<%[JM]@HO7&QO86FP[Q9DP60]QJ'D*)>PG$*UEC0#L>S_["K 3@ M15+]D:"?GPQ?03D'^7C")Z!XDG8 _203^C3G,G_$ N_,M!
M&CCA(;/N<[>T?ISW :"+5=4$>Z?W]1=!VROR_EW=P6KZ_GKE'E:F^^-]86" M#@WGA QZ%-9Q _GY6T[CBZR"7VS=';0AEZG$(QTV_A65]_0M>L+]L/+F7[M05EI;MF 0J(-
+&&:7AIL#K.\TU'H)B: M4W4$7)<^5^N83&L("^VU5.03AUM7:S "))::R$;*\/KHJB[R(M9%_/&Y:FYXQ#GP#--#7D>,9);YKS^DQAJT*K.K*1%G $H",U>--+:;"
MF]'V&%Z& #N"QH9%WE\FMOL-S$7'!DBNI:R9#5^HU11>W&W%1;9D_*$Z2" - M7E@ATCICY*F&)\"%0P\1, 5,!9#;YU'"95=.>1#EXDAIS#NA]GX1YEXI#I^K M[(9",JE
+G2+SS5EN<4YC.6[!5A\RGP MVDN6T$LM;$6S*0!&@IE:, F$N[I M'08V2:'S@+"^OWZ;-[: W:9P|S#8^ K18,##+%/]7 MG%..7T=)?%'ITUT*[>C+&-VV=U#G_LS-
O++S!UF+]4F202]3,*QR@$%\[6X M&IP2/-^)TUGLK1'N%)MUR@4&T(C]8CI(=.; #UE?,UX5-!/+(MO06>H]8@. M"U#K&Z0X'1S;/O4DQ.8G6RG5O$0;'4E7-7PS%!
(-9>U6&8W_6^9%U7D>:O14 M/^\'-6A]@Y&\8V,[C\$";^81 "#1!@("K40*8\((LSW9P](MB"TNSJ1Z ;&L MT>C,.=F<-W7P)Y18A3#)5^V5MM8O?EMN$2/C23=
!SB1E)F,H1!O''6]X'#1 M_IE6_[(KM;R1B"[W]908LNRKJ'4)4600^!BLK6FI :2O(QK,%^!OLO&\1$D(!W'FLS&CI@J-%UA0'/VB8*] M?K(L*.])4T=^C5)RE&?
Q(HK4P='7!ARN%"\7+WA2$"1,JQ?XYGEEIAI/2@5; MT1K,1;$#!'GL7] MQ*.T94\@OIIRI:V_OB%G,AI16%K-R2=YD!<#49:5XHTJVR8G3RN:;?[>/ 27 M *?"!
X96!7,WXND$;SDMUM!>,QFHO6@S&WTN!Q50&@:W7G$6+U:L0"IR^ M*&&&M.6]6T>KX_#-)]?I(A;;DRP3N+&HKSC 7WQ
M8:Z>I]D,^WE8ALIW@P_+X%MJ#QX&DXC:XMO;3Q!(7\&G7]V!-E!.I;&X58X9 M;CYN? -,^WW(\W!7!]77#?&CH+I^:,_F15?4!TN_\8>'E1OJCGMFF[IVZ&.- M@;3(?9,V!C?
C_Q5(1$\0+QAELC,4.5W:;]"R- 0.X'8E]@_[0P8'EK\A>R*U^X150JZVT1\4)O M*9^B+/R$8>$^RS1O)6@=A7DW<^$3!TY4_>R=KI46D_L>EE59_/K91V#:N)>
MUC'P/7I9[6,2(;4WC99;P, (%GS2AG_? WN0CE(O8D:4,3HM-ZTRRYF[:?5V MWZ/:53MQ3M,HSZ^64F0/U,(>?1^MA/6,Z]R! //)]N$RU39@2>QQU#)M?/D+ MGFZ!,9AYTO\B-
DSZ8$#?)!,RW60 G4P=1]I(Y))E]W/*'SI3NV(TYVWX922Y M=_]FF0N-UENL9@W"*6,8)/IH2A]O)9Q"'C.[^F7!:A@VS.A6R0GI;0SE$O M3ODUFG%&LM:L/G./&\"
(@(Q(T&8RK7@A=;X:O.FE&.-VL3.9V&!KCM*.K5[Q M8,+N3C0!Z[5ZY1@-UQ/MN.XIX6\ZYJH*'H_ 4MWC+$=&:M=V6T]Z&;]:Z+]& MPXU@)^5E:*;0UW):CG/1R2"/N3.]2Q?
Y0JQS6'D*;B^5IL M-ZP1[@36# T&H->Y)Z'8],+H6]HT$\ (&]:>21:CS>Q'?TZ.[!VCHU-Q0X^2 MF64!G*U[P]LY,3CO!)BX$SX_M92R;?R*2@;H$?#N\&8[XE]%'=SEV'^(?Q0X M-[>+-
?I\9]T$=?,NHBW"I^^3[G$92X/.'\T-%5OD<[EA][#5-#N@;SC7! MUG.2$RB0>"]O,O(9N8-ZP"RF,1EE.IHL :6@8EG'U]+[3GSZRX;)16FBK@# MG9R82TR,#
(T,#DS,%]P&UL[7UK<^,VUN;GW:K]#]GL9T[2 MD\E,.O7.;LE].^MW:,MKN],S[Y?/-T])(TP_MDA7^YA\7#S??!-]_^-?O__^_O:;3T_3;_[X_1__%'SX$'SX(0C^]W\D4-"E)@=$3-
#5Z@!KFY&N+NN$P]#ZAYP2K:W3R"R=^UWHLMR$]N:C+!]O0[U[_=]_LV_[M@& MF3V1]SAE!U:,;O04DQ.8G6RG5O$0;'4E7-7PS%!]'BH\ M$,OMOJ2,/;
\U/_*%Q.._O9M3HO]:T8T?'=^O!UHV^*[-:+\E B7<1+M>L\I M6>DS3F!SCSVX)UAR)K?A&R/8 #8$TFC'ZP\=,Y-&=K 2E2 P=N85TY\ Y XP M!!_&"@'T+'5E,D $-

]D]!A[0^8_O:K6(SI6CWX(4YP'C) O6F 89Z[7'"Z@= MR88PJ!ZIR?#ZD=>/;.1@(/WHMT3A?9/::/?+&HY'AE>Z_=#:_=>?W(ZT=> M/_+ZD57*@=>/O'XDUX^
LH5Y_2@.YBBFP0M*"AR0>3#?'0FE=XP6JP;N)*TQ M#6I0#>CR*I57]6SD8""5ZH]MGU_Y\CF0IG2/@/IXU?4]9*H%=X@1&F-=-:]VKT%U2?)\KQ9YM&-6)(A*67I8 I5& R\G+
ME(PYH:OR<7 %"3B0&6U)BYA>5*<)>WS$2;A*T*)&5:G]O4?E:'66*ICU2^7$[BZIGWV,:D^B*?5>G M>BK;&J.38P2C\EU+ S1>'U:A2*V!-C=+;9U2 VE]@.I]MHF7D+2= ?K^7X$H
MD^&3S0->$W]]AP%:&]#QB:(TB_G;4Q(I:F["2O8(&65'/ _=(S5;&C>D1V9&?; M? C[""T$4K:FJ*3GW S^D1>Q99,2M-U8VXUK(KGIK1U[[1>Q0F^*U;/F H)?-
_$"%5TRO:4!5.HI82]:]4[;==I2"B; MYJ4H6&Y\4U*P[64CW=1!O0S0SJ0O%.;Q"V8R(M]N6@G1LN:]4 N %$WN*3Y M'5]H:UOUCMUCTN<)*K%7=>H?
\]6*$DNBHR)89EXRZYUM3MQ=4C>0M-O.X M*ONCV'P4]9UR1P-H(MSXL"2I>,\6->F1]D<<%I2!\,&/STQ]7JM%BYH8H,KR M:[A$Z0(+]9LQZI8THFE^<>-ZMGDM205?
N[.SY*V?)QWMT$,BN=@]-)!PBX MQ=#1Z?&>6P)6<1V=* I(9((A&)$_NH&(Q!%AN(-'Z" >9S]/S)#52 #BXP M+#^Z"(O HP8&Y<]N@?+>'P%&XB]N(2%U;(%!^$
M6K6##0Z)4U(L)&8*#HU30BPD\ 0.C5-RK"3H"8Z(4S*L)) %CHA3HBL@I!". MC".RZZ4B'@.L.B",2[*5FL+'1M,4B1444YS@*0I)&.,VJOS*2Q!& .,"IX1@F _M2"[(EACG65#!LL1YS,1RC;
(OW3S'3-)CE[3Z;E JQ% M3MW0++V'_>(>T1DM+4=160UJ5VE7Q "\YU <53O@I,B7A,; QI&:$U&/83FX MSK("3OW;UL-2+LZ/T>EBE(?[G2S09%'H=1Z0+^#2@'4:G _I
E%W&)Q^]C !M]AJF@-3Q659S-H/;^W)=$'IG\WT5]'M2!1\HZKWI=#^5Z?2,F2 TRG_9@?F((MW4"5WN< T5==TM^&HX]U%]KEC38 M8IW#I\>T(4O=;;YG7;-
REDV43>>6BP9"X%PV.I\[HQ/!UM,Y9ZL%O"TFJ/L=1UW1*2D7AH]TTS?O,?6>,J MH:%'7ZWF$RWQVC:BVOMO+?'?3E8\>, .?Y2N;S:_9K$D7,=-
&)EF&$997(I[QS24EQEP0W:9ULH&X:5K,AX%SZ1! MN)C^]4_7 ,Z<$<+W[S0PU0H1J?NV?(KPN:+A&&9XL**[\AB>S MJ'9Y-NK;.S>EG>= UCTE"XI6@M>O;CP0O4+ (MA 2&
[@47#6;S^R/!0'4G:/.!C/+K]YRUX<[9V0NFDR0A>1G45DX6ZZ5)1MC=* M _=MM1IIJ(FMJUE2&$KR- .&G\&S">=)#KI1S .WI3Y7#AMNWI+)ZS.(H1W1R] M>%E@N:II!\'"DWRU%R?
Y4S)QC+"B:0?$._?M/3O7'BZFTULQ&<)&71"P6DL> M?/IC!P\<\KIH((GU8K 8)DC[CJ+4F* ;1D$X,?9PAP_+4;I"\&~$EU M-3C?
WPWN[P;WWBD=YNLM;$1AZG*!;ZD9EK2RG8T=GDZM/$1'\W(%.;4(3IJK M3=V=^=26TH.NM2FX(=@4U0$ &S);@#""0?1MNU7_F MB08,"UC==";31N>D!]K,G9DVPNU%XM@?
^U8BU:@DX17,Y$^UVRO@5C1G=A#I M*"'[FP8%3*N,R0/O;=$LZ_W(/AS 8B70_0>" 75@5,2=;TGCB7B-IC//U8 MDD/CSL]\5 MG-3F ;A\-
W9SFN[RH<@4X7Y#5F]N:FMN:*"KF36Q1$.'G/"!L@UB@)E4I MQ ,8-)>IB/!&L0$K1-A9?>$V3N54U?WN:T+T71-")\.?%P2:A+\7\?8""DGF MOJ3IH#1+S7?RQF9-
P6QI[K3G_1&9@>6OCE%^G()@N+I&4S!%QPP'I%18Y@38? MK\-@_!P,Y/+@8OAL/F5"=)O?H9 K?3)WAZKYX+3?<-&-2E)4H0!WZ('4629N?A/?
L)T58YQX)TF=91D#LD1_[SG#VY1.4.Z+:^CADD=1F-?"!HRI+;9U15L().D MD4\.#)!/DO=)\F/1RS6C=D&A2^;#="% \0M."QRD>$\W,$*WMJ_!X%S)\WU<
MKK^Y34KC/251$>8S^HCI2QR*:)0U,T4CK[VY?7PFO"9+V;; F-YQW;]F$UM+ M*5>A*]=O&MV1%!V^.:HN7!]:T'(4' GL:N2SCVFU(]8UQ&DFCZ2L;6.4RH=* MSKEB NB4I"5>G^-
\.2VRG*PP587-ZW;WD90.1%+R?.S9 .C4D6SFTK8=Q)9- M_NOQ:?+PS\?M2@+$UL%Z=':SV0/-%/RTQ16MOHW'B9@V0/-.B$]S(N%IN3M9 M7$:1O.UY!.<^X"3&
<]@25+7M@)Q _+$0OE>I6_N86!\3^\X@Z&-BTW.)B96: MD8B6!<<%./QE8-&):>0OPA!?A$ 6"<8.R*PF:%V>8P= M!\B)#++#]N1+VH7;I \Q#8Y\3V'-7VSHU]FD"WD=A>OG8PVC!<(
MA6-'O*P?^P2!"&8;1O.QSPR38;>CC;SU8:?2 ML--FKG_S<:CS@#59Q>4EE5F THA|+@O;XK3!)4S T0S&JFI1Y*-7!XQ>O6$" M6U7K=\H%LOJX4'$CP_2|K[HOI%)4H-
]0/,KT,/\G:30]GOWP J#-!AEO5-SX M.1@HKL]'E=72,;[XK,.>]H 3QG[T1&XQ7>#ZTI$Z748>63,N\=7'C?BX$1\W MHFL,D8B91$?$&SL6,.^E2B@?NW%9/2/TCS\73(8
3'IQV%DZ34R:#2V=%=YL MV-)LV$;/-F\\7 19SI@HS6JO9?A;KFLQE UAT$RH)L/:!BVYAGV:H"R;S3|7 M;VE&'W@Y%$F.E;+|\-1+4V+-'M3V&Z\-
K7QV'<8V>$)2)MEM0'V\179XBVP'=+)UM20)DT*SZF5S,QO< MI:+=OPM[.>-)3:IM7,>49'GV MR"8HON#$[AYM2@N(RN#7T:CC=3Z,GX.!W"?WF,X)7:$TQ.4$D1<\5K0V2WF"
M4D$IJ7J&YEU..SWAN/=X[@.T<7FW?Y1;J:''36-0-SV^2CO_!K> M^35]WPS[\@<^M:1.F?I&71#P2IZ6I,A0&EV1@N88IY74?\WVVY37G5#0U]"_M=R)Y)|(I'-Z)=&RB<=^)5*\5$9-
GMBM0UDJ?2 + ZN+ OO* *^HL:7479I C;O0?H2 M))@1IIOC<|K-H'^H M'>'31@G9 :V\^/BN=(;D?ODZJZN^B/J1+?5=\C5>^N MD#^BZ/WU\D:H$2)4\^MX'3WCY\#7_QF!P?
V&'T[JE!%0VY'; \SNV;L&0]R(+4<@.8^=:K3%+1+FQVX^DKUPB4{ =4B3G6ZS>C/U|F[2067KJ MO86LH85,0\0U; =*@E59RS03[G7:S:#=I_[1WNXUH-U+=M?$D1E%?4%
M%I2LQ2:>NI^]O=#;"^VQ%ZHHTKW<|)C>9A>C]LC-(UYP*G[!9$'1>AF'*!%2 MKVS;/[6[$^]8!L%<5;8UF[02AOQ%9Z6]YX:@E-?FVUI]TL4##G'\PL6\B\WA
M;U6.2P=#FL6@V76WIVRWN337%*>2*\1.V5'>]S80S=+@?LAEO(;HO]!QM,!\ M_DNGC:B965]+C&E]67;\OOF?[*R0P@WN-S@WXHFN:#U\!45?]&/P<#.33K][X'V]^7'AA=*
D)IN.!9F46 M<+O!C/+]5O24KAI94Q]_'S\06LZ^6L5WAU[0JZT;4=5+(O=IY.0WDQ2VEC M-\[JGEZPP/:4)TQ73*,LA37UQ5*-!NB \%M$4;XDZ92D+YCF,9O@I5(LIA36 MHXMP&/:FT!
(EB \OID?2;.0Q.4 2]POHQ0#5 _=[!8Q\ _[VTG(@?7-^BBT>_ M?MD9;7:S43%I83U&5+P62,YG0I/H-8[PY=6[&SL\G7];B(ZV[PIR*L,W:6SG=P4A
MB967Z%I57<'$%S67H2,W#Y&.O,6N"7U,1,]KZXKF*BC:T$.2U?BK0&'E(XI MU!58 +4[.HO"<06SKB5%>>2&^]'^/KNG^4L?;1&4]K)<+'WU"NM3+X?-G^R$ M G[8I,)AQCXI8
JATB\#AN%'NV$ 2]_*Z%%7IH1*A^EN4E@N* #6AM*;[H6 MH$FAX^L' -GNX%[QR !M7M@ZEL:AM\ H8J+ 8#91L,)D[*[@?&7[@Y Z:ZE>X8^(AW?H_IA])XY7 >F-I2SB[2@
W2F"N.L@@4A3&![MDB!FSTD77$$/$#]9=(M$0X8R6$ '3HXO[F/+W:)G4Z+ IZ+;D8KNTW-M2,^] MBM,XQS?Q"XZN]UMU]=UD%YM;]!NAI;@FF5,-1K'%PP-URLSVA],8Y?27[:'+
M=MY3&M5ELL-8I3/>R9LB))%I6U\,K5/INXTF7M$^:6S9$V+%R1,&:QMT,&# M_\$VPE/7DI@*=6N?M.B3%D_A\$F+.T36$EKT&450A)[XZ0C,=<5#'V.C<\G MZ3V?
1")VN0*%>F8TMAVX E'+[5]BY;KB+?0!?=H!?5!=RI5@#!/))*//H/"N MXU]%NHVYLPN7\1LG(@ZC"K+K-(L9VRY%$DQV+F6\=PK2N2CU+9T<+H8#Y3
M#]G*0=R4C]9NX'INV8= 39+D.HWBES@J4%)O+58U:^T6%E-W>&:- 5+Z24::L/18(?/ \XP?VZEUCF.KA*TJ*%4W+@#OZ4VK4]TE>9 4@]MC5 *
MAW1(/,%@#HADM2)*9'A%#B:]U.Y'IXT,TL8V0&X*$Y*U _=TL14]Q+MBYCQL8 MI.D1AP6-\QAGD\5B\H+B9+(Z=8LI6AND]BCS23KE3MHUHU#@.?NO7Q\FTR6-
MLQPEM[>W4[J+V2!-2V[Z(H,<7G/Y2,$E[B>G]\],<(&GCC@AZ MBEPF+CD&NK-B[-9/(!] A3MV M(Q\0">6),W9+'Q 'B"0 AL+2*B% * #'+!@)2ZL>)%0"T [(/[;6(\,J6&* MJ"UI,
"LEA^45B\"M>&Y(4M \8!:X?]3*0S&U^E.%95YI3_QPG)0!,:=_L0, M^_&HM2SU)VQ8"PC0LMN?\#$*9,3F9# PVE6%K 5&P_@)1D>[T([EZ"A,KF!<
MM"MH6(L+W"L'E^AL3@YHA0YDOS&0^1_%BS2>QR%B?Z,J8#3C(UB3) [9PM__ML2-170% =T0SA0":4>7K =A2#V#_RNZW+TJ1VJSN8)3^*4DS1D=43N9?$8VY MEGO-
"]SA+*^F>G<"-C1[F\V\QP_Y]7C5>F\DI9FL[ )Q6Q'F!;]$D9,4?) M$;S>)/^8E%AG,+Y:CV>4>U[%*&7/V<'84S4W3GN6\ST=3KRTO5'J[#KT<4I_((3LN;3 MXO+KFL??
2\\8C9Z&.6+;3X&OF,S-CL$2V\]QOIP664Y6F,)63+-!?(4&!RHT M?,KP;'Z9Y?&*D2+"M+Y1!\$FNQ**\FD*:=H!,4?Z4&/-Z)CB+L9S)VZF.TA\ MB051B07@83OV]"%?
7N&\;V7RB72G2*CT@ =7 2IM/ZY ^"7P"0=5Y:-'B) M$\'8@SB;@=/0\CCV.,]F8+71,L<>$=H4,4VCP]BC19MO46H3[-CC1YMATY'M
MO;\P#YO!4SID^HOOL!$6N!VFO_@,&W'IQO%@-+*A+/T?!0%VY^1VEIS++K]7 M&($ MF^]7[>:C.=G>]AA]4R*?(EH?& AVM'Q[V2%]PQ!;.5<', M-WR=905*0RREO\5X]M$0]O&
(O\%?^_B99 MAG->Z^ F1L]Q4L9*W&*4%6R_F:4/_!8'RHO3I]$=2>GN(UNV<<;[E|/]"8?+ M-/Z]P!E(;C;Z[&%0E3-4-1 A@K= M>5'RIAF&T.SO'"&R1LIM.,0:*)+
R3C07,MPW5#3"QALMO-'"&RV\T<(; M+72,%IT+C*Y,)S6(^AY8' M+[.J 6YO^]IYB]IO08KS@$&;!6M,@XP;")L9 MT C&;27@:GQYC%+S&-'45V,D"A.BCQ^P8<[32^_ADG!7E15K'?
%EM369'V) M:.]677:/:6G?AELFNG[04-$F)W3Q#2CD!7HY;U@W:Z31:-XPXPTS-M-IQC # M.'1 =ACPX>6^V04"A;>R> "N+M])X*XNWLNA86?H1?EV94UI!-LTE9O_* Y<@
MP2AK6EQ=T-N@8B^EP"OSEBCS-_P=\=@QD*RN:.V52Z]ECQF7RV<G=]YLZ^MLU)4'6@[5:76%\L'9!4HX%8]+C//K=$[HJK*&:Q11 M:#!0#XQ.4;:\2LAK*R; @_1ILQ"D"TV86*D%O
M@Q8]*07>0F6)A>]BR-C9FV63\/+;Q_$NHC $-!QEH$"1&F]S MB\W1)WX)-MLOV%3FUXC'4;E_]%'HX0D#(71(?]V.&(WQ/,;1-I22\\".@;RW8]4=8M/I4[QUU%M';;;33.B-X- %F;&D!I;
[9BP1^]Z,Y MC^43#-*#;.?*A%+#V$]=0IVK6.XVS08N*E:W>/6, M:0UQM; W3M4#8ONB *YWOYFA1HA0S:_]4X37!0V7*,.3!<7ESG(ZBVJ79Z,^ MO7-
31N8>R&)BQ8*BE>#UJQL/1*\0<$CS_FFNRNZ?PK8OTC]9\3GPH8Y\6,]F MMJ365J]0&/+'9W?L7,UN"#L7]QXU7B@?AS@N$[TO-H> GQB!-;,KRR'-^DMH M'"TPI[1VDU(U,TKK'?
<$,P&)T9&)7L";-D$ZS,2;O6#*]V F?(,Z/4OYV9M5L3I*EAFID@F^)HE[/!UF&Q*A(F.494+OZP%1 %]Y'U12>; MJ-5K_ECP0BM5A>+]]=_AU_(G,=:0SD/-F.(YBZ,8T<^#O.:L4"2-,.B'ESM]I8BSI@6AZ,MSCZ;SW&YG/C&6T<>N',G^-4^M796JIIW2M;E[P6W6K$'T/BY M*,W2! 5XM8]SC'UUA?D)%G+#W(([M[E\H$U#+%UM':}L133&W?=^3!?MPBOX2
MY:QI.E:G#-6H8]N'W\2K=X(BI$NGY/WG[3W3&1\NIM-:\>X@;-0% :NUY,&G M/W;P0*XL/Y&K7>75O4SRL):./[TU3A|3H]>S U+O*0DQCC*>1[^[= #-37M, M_ZPC%-
OVPN0:PU'XO<:=\%63MYC2^A2F)[6N)*:*LE2]*^4[P^I1&FK[Q8 M0KK8[TELB7'5' %4^7:#],6)EPHL;E\&^R5PP>)N6C@GIGOMXE1!2^&1>X MEOH-
22MGS]CAZ=243W1LI:X@I[9CD.;6RK&#!/1#$EW_W]AQ@8ND!WJYG9DVPNU% M$HDV]IU$]E%)X@'!?/_)3KX[VBO@MB)G=A#I*E&'M[]P8%3*N,SP/O;=$LZ_MW./AS 8B70_0
%875@5,2=9T7H"!^=%.8$SF,?YYK! ,G\=H;8]S/#RVOVW# M6D ;O' V=^1:AU*3X(?^)%,IX=$(,NI/2!D1-) @L?Z.;>N :A?)VM]A;B]0
MT+AP,#9_&3TVVK$R8&Q^<@.;)O%78(Q^=@.CKH(SX5+D^.7[']H)UX?"-7PIO MD2,*AVG\8KAVB@40ZR8K5"=,.+LG>&L1Z:8O49Q7E +#-G M%-)9B5W2(@P'Q(QO
"@Z%)?.AS0>DO0H/C,-[M#G&&L2(H.]@[Z12 M.;97(O/+QS.Q#UK0>C#G;@4=0Y)O/=,"<@5FDD9W) VK#T(/K[+G0#QQS6HV MGS*,A<6WCYM80"7;.,O[LR6GGZKYX+3?
<#6(2GS#O5]#\F>R/8^M;*6 MR2'C1.1.5W0;*L2!QJM2@)"6_1>T,DQI76 TW^>%1(LZ#%5E&[-]#I=Y\VF\ M6.:'=4N+Y YE;X#S=X^*,.!H QIJLWQE7M"%H#!!UH1QQJ,Y"P3-
1N,5NFI M)6[8063)B5+[@N*$/ZO2HCZE>9Q\^.F6I/DRNR))0E[9.Y\F)&/_?&3DU$68 MM!NQTPB?=J1LC7>7*%Q^C_V#V[[Y]A&(^/3&#@V_P/'WCO9@R^':-'!H36
MBL|+G+*MJ+Q0E9W*%S@-ERM$O]SB^]+4'0QK&YO7Z1W^FO\3H]JPKTX?T"/K M5PDA] &TL^R;]DC.L0'F.@UYG@7[!]04UBL1!=^E3 3A_/X!3]1%)6;\R8K8V^2D-=$8#+-
;/[K\)D!G$_ = MD7MD=GO*%E,MD:L>F-D@2'Q+]R5DU1MKQ "=^6 .2^Z],C@78X*54G $(@2'Z3E]7.!$: M$PG@)0KF*AS'E2A5ZXDP,CW5YA,]PH6
M@.M0E*&/KF"AVC64*LSYI$E/3+ .Q5:)< W)$M;B MI)O/ X9H_'<\M,X^ &/ER)T/=5;!EN%*8 C'?R5$VTQYN(SKCOQ_(\EGA>/A MCM /SQ6$H^.DE-\V/P@.GY,R?O?Y1G!
G93T]?.;X("-7ZCO)G =CMCXQ?N^ MTLW@&(Y? N\ZPP".G2/Z0* 9?W TQZ\;Z*0AP]VWXU<#.L@8@\)ECI;0H(01 M*;QJPN:%:O@T#BI"]AS'@\ F2K9BP.*7W!:X"!E[ZM=M5[068+I6K0XVOT M#EBC=\KU,$S9BLLW/!=%4()6UJQW&K>R[(P^8OH2AR(;9N8;863B5EDJ4=1M7GA,CB1V< MT0/9H(1?DD)1^!'2=2BNN,6-'IU7A'XDQ7,^+Y+WX(OX G4>BC-
*>9!MZ1N] MD$:';Y[87QD*2]^;M.977/VC:^?]0#]2/Y;7:S M^=$N+MD3?F ,Z;E8-')U .XVF"7I]1^$7ZJD$=NZT'-9Y23 \XB?$ZL+<$CM]*25 7?L\,
T+]*1.8R"MH]%UE ;5YVK/1Z"E&8T<$-C/4#LJQXP YD0%VT/Y2>VV9#AIF MP+'/"?"YJVV%'/LT >^C,$T?#(>E!:K <(MPF-'O!?]TQ=(&QG$Q[Z3Z.VQ M4-L1&!5+BX#!-Q2E4V?
L$P0BF&EX#L8^,TP6=!IM32M?T*D^L+QK!T9]-U M^'43S-/?9CQ.P,Z]L!/(-]??D64G*(W<[/T=:G:"U'G8"1C\ \>=NMPDX!\,T M_O3L)ED&8'C&GX'=+5>E3@Z\#!1*
(8YY>H23D,V^5MF\34 M7RL*?:;?@)E^-^R6Y0S8-]307 -)WH%R&7/Z!2Y*20B"-$Y M_L>.!2RF2"6PC=WMJYX1^IN]"\X\ ":]A-)8.DU,.O0LG17>H=?" *2ANIRA MNZZ1FFK>-
K<(,EX#OJ1*O9;Q^GE;@YS.D :M=-;GZ8WG6(8"(SFAU M\U1YDMYC6M[:HJ9?U'/X-[*!=I;(EX1*]_H(>]C"0W6E#I3^]K4MM /6LJ3+ M0%Q<_EZP YH1MB8I-P?
3A=I6[/NDIVHKS/]Y9V&,OOV(;QAD6 M>GXD789V_9Q,D4PB:X'Z> ?6\ ZL#N@$7I8F9'A96LV\'>'7\N?&C&W[]QI M\9-
)B.E.*):X&X46MNBAH]$:JW8GFNVWL#1)UM&ET[Q2YCVS(%\2SX29IM'WZ M/CQ16"U6IVNGY%ZAF):BZB3ZK:ANTYO-[XM\MN;+Y0ZS3T_H:QVUL)[G6CA]
MN_/LW^-6$+VG<2C2)\#]_L7T:8FKBQ3);BF+U[NJK7>(>X>XVPYQ/G,%%Q.1)Z,O4^(C3V3;ALK^>X:1)T# REEFA,,=-V>4$-[,LW)&R>%- MG?AGE!K>VLA_AEG@#8(2SC
)O.,PH3/*$V]LK 9C-/[[M]OY[^#2I3O"MT[< M_AR?\8O?;3V:<*S&+Y"W<:7"<1]_9-["B6L^E6!9!=@_(P88KWBQQFE6/JUE M/H'VN :3"AK2YC,++,DLX"5T0BYUEP?]!7^-
TZ.W>/F5_RFI7E?=>:CK=5\1 MC7B>K^RVV;HV9N,F,9T3NN)%"I12QI%KFAMEO($I8++WV5-!J%1&@YG!AZJAP*#B'M\XE#1BVTY,H7<6/#*!(P<=LTT M JVP/A_E(ZM=CZR^9&
(LV6!S<:HZ_+'2L_)]DIT$[9K M!^HT1E,([",WZ&]^*U6[IXQ3RB5;1=<)+BY$Z9>8Z#2EF3[U.CVS4VSJNT16A MY:.9%%9'K3O64<=/ZL/T&?Y 5J#:(D\;XZ2;4%GM,"S^12MXYQSQI>
,+G- M*MJZCIYF7_Y0KB!9V'1]HRX(>"5/2U)DC+1*V*H< M'KD@X

[?5G%$=N MM8WDC +66]D9SS!NO;UI_(PBV3NTP9]A3'M'SJX>_]4Q6GXNS+%<5,36.2%\YR[5FH'F!0_A0AUJKF
M@],NC5Q4=_#QAP[$'^[2U29LCR^39H_,3*=30,!%DR$Z+T"Z3;?;)Y%]QOPC MCB8OF*(%WB=2G?#0P4@=L')0!@90"XZ1&)00Q^*6AL72AT&Y'P95KPD1A4HR
M=][!XA71%V9QY[:(9T.4AL&&/G&QZ! --(7,&CS08!U3S"L_C M7S-B:^38^>YBC@ ,+ZX$-[6!"6I*[,\Y5ZL1.9)5Y:=CQ>T.EYP("3>\TFZ ML#*Y(L]HUZ!]9LDR'U;P)4AX-
%?;RX=5PQATY\-(\:YX[KWKGC'7/'>455+ MI\#S<8.S#.,;OEE6<:A/Y++<%;?+CPO"=8X*2+],.\EK'LB?$:<,& TBW_3I MB\ 'S'=W)A?QA\SF4Y+F%(6U=]]I>SE7]V%<0K)/@?>^'^_[\?
X-$_X-2XU& MO=NH+7W?)HUEEK[Z,1C+K,LJ;2C8G5&";&,5XMP27G4U&/.VPR188;K M*7M M4#6,0=LAC!1O.QS0=C@E!8\+8$LLWP@*%0:N;!4[C94'}6FPFJ_O9VURS=4> MFZN*
(KS>9A%/%A27^^?I>JO=R!KU]9V;1[S@5/R"R8*B]3(.42*D7MFV?VIW M)]8Q#8*Y[FQK]FJ$,.0O.N,6M>R&H)3[D[>&M73Q@$,E+U%2=-!:6;]
M6A8SG:*4,$M<*ZT"R(>H^U!7DP#)VY45K*(OJZ(;);M:FZT9%XQNB782-/S MY(V-TGU!XVB!^N;>U(LAU_M4+ %&<)^+FNGH)3[D[>&M73Q@$,E+U%2=-!:6;]
=JG&LXC=GRD"I9QY1?"Q#ESKT;#XK M\I"L<%8&9O[?>+'4]/I0ZQ':A #VA]. 4@#\5P;HBLYM97MAZ=>*CD!>@S/ M ?Q.<1TNF]|4;@]+K2NP0,GL.8D7Y0(1<5C7=B"Z/^+G_']?
R]9/.&))[MA4((67&;$8CJ0W,KT%9>>:=J;I3V;1'>[(ELU;722G25K:ICF]79ZS.;EO&"S13*71,T'NW3/ MQZ?W0Z>D^NV18M[HZL;C_C9>UGB'7\N?
&C&W[VPP79Z5RU"QMWT\XHMOD[/Y MD?HG92D;3L( )^$F#XQG1RM<9"87:=AN)+[Y2-.R)HX7+*:EOU04)413' M.;^[8BMNS-*KF&;Y)$WC%TPS1$^U76BW3G,V3CT-
0FNDHG6G1'5H%6/],&RL MTP/O6L=4?T_K%)0:I _VHN8F7L6U^3^*+IV2]PL3V&X(4Y-%IGIDN\^UZFT M6)_^*-VF6;&9G![%C;!7NXN(Y+:VW=?B+:71 !T0?HL8/,MRXK()F,?
R04F^$5HBI&T[?M.B?I,:!*]L@/T\FN8%/P1DN!AC1X^"Q=@GAA[M2J;/PCV[+%Q86" 1BE9V 1-IO@=I%7H^=GCV88M=!$L3':> *\BIHO=(XV!%
M5Q"2.'N)KGO2%4S4T2.D:B&*^C(K=[" 2U279P!2UIB@01MW-Y!JD+$X"B MKETI50$XI'0\/*[HIXEW261N8)9UY*B//W$ 4(IOC"2L]79310(LO35*ZQ/ MO1PVEM>?
5Q\|JJC8L4*F$*H],> 8="^^-ZV";%.?G9E2JATF.XFA>6" F!M M*+W)KF !FA0ZT1!@8/YL-S#JG0,0-^C*U]$T%K4-[P$#]1>[@9+K(,JB6&.? M,!!7D"(*!0S!3W9")L*P-)
+LP'L+M4'$H6=<#1(MTX=CY(CT#$WFA0/CCMP,JK<&!V;\LK+A2@QP:-V1L;7]",,!P[K?]*AS1 M\-] M\' (QZ\7=%3C[P"9J8N(5\&"D.@U3I(@9L])%SQ"/$!<*LI:7D[<9.@*!B,7
M%C#:-2>\:=:\\1?T^2B_BM,XQS=, XU. MUL"G#,^+Y":>BXKO0[H.M(|$I&7'Z_]RZYHG\=RQ\^GI%2,!\"45'A /:T2WVHL^_B^V-RBWP@MU5C)>=5@!%LX/%"GO,^JX2BV<'J'19*[O--
MI_*7K2HIH'GW\T#47;.3:BZ&;9^KIN!"=YBAKAMC:K[H>A1I&W^AE0,76MET M?=^(KAZ8)6M:O"!Q[?3:!AT\^!_L^#FM/B"F0MW:5V\'K,7<"^M*A
M7H%#/C,9V"5<@:KE=2W0Z>"B" MW0CYRF;:E&!,8(`=B=)O$K8%A&G\<;H_1'& 4W4<(+MF7!G-" O>'X M!?&LQ++):Y6V$B3[3+L51EG!2P2A_ T1*7\<.U*K$;-
XGQ:PPJ8"#%&U@PF M8HP7'\(8DDBR#ZZK9ZH7S*?(ISY:>4/&>8EL4(K]-UD?/BA$2B^`LO,% M?\OIY-MRK!->>WU6\">/6R/_G,]Q ME$^BWXHL7[W/]1KFX1T
=C@@'3@]CU^&4XPY%FGFUKOQ@7#G$PAWQA>)CL'E MN:Z*MN2(YE83:$S(\\|-LI(AQ2X^G.Z5O/W,HW.9 ;^*,+6E#4P84< 76!: M(U:$^]HJ_,]#
<96]V!#CIH:ZCI]JT(;6"^7>O&6)>;BFR>T);HW0HM3B,\758GKWAU'[#*;\-\&G)7MT:%WD< M9M=I*$Z-5#;NTS#9L?P!LAGV(O.X;\[K&C9O:3L?2YM/.?4)@+TD (/+U=@
M,6&Q'GT]F[=8=UA- BSMT8-]SF=]D.Y %S5O;HZ85/ND?O=CGB= FLQMQISH#*+6C0K MJ@ZW&LMNKF45AJL-9CG?PFK#38:R?X[KU!KO:EBC6!S?EB3@Z\V%2L,X$KV# M2<>?
PR=B_G8B;B9S]HU@O];KU &!?)7<$)1FG_@:F#(-.M" M>0*YPKK3TMSW?W6"E7=ZG8_32Z(&$UV%S15,U-9[E?' %0NT?$T.XUIO(5E;_Z-34U)]] - -I6[!E++=&.$7MOQ0(C-
I;2H]TB M]EZK!@.F7?K.)L":V!O R.A7NR,Y2FS"Z3.Q\V2467?-AVPL@BPGX9?CP@&\" '/>>3U HI\22A_PT'& MQL-9%=Z\6I%TVX_7']C:?>+MZVX8T6& $H,!'\;X\?$@EL2#3-
AKCG@Q?4DH M2&T;HU265S _YI^K*3FC# _%B*0M>4;8?GGIB @AUD.RD7^R-?X%*UC)@D] MEAO PW9KN"+TJESVN\-3Q%?3<7BGS773HQ>;0YKZ2V\M% M;@KH892#
[28FI;FV30?. MV7N29;P$[MM-I3+%7S)YBFPP+O&Z+VBX9$N,8U5 _>6QGX_7-UN\%DR>NV>>4 MUTUIPY!R1#[=YP9$49!WW9A([+[SW024WC= _/K[Y>KV$F)2N7(%2K3"1!MJ)
M*^BH_;@2%=D5?[YZM4$%3U<044\+H!W"%4"T=A&)S.]* (=PR70F>[OB;&Z! ME);;YAZ\EK972YQ\Q1"?]?\"\\A[]!W!WK T"XY#2*]
MI\!T23]O1^JL6WJS(V;LN*^.KW27ON@Q4M[!K+GPE0N>\%?S\P-"@M>7OJ^* MZ92O72RIR3P9S4>SA_/]>W; /K*3-F;2:Q.&A8.XSN= Z;]2(N_P;_E3(P[? M=;:'KWJ+:1,FY2-
9Q#' <;8N7?5^;BK_$U%5MML+*_[P,+GF'F6SN1TCS<'.L &*,>1VY;&SVQOQRWT2$$43)[R'D;RE>';NK>=\,[%I9E6&68_\/TJN-+ M*I?# OT"PU#G$&?TI ,>G\^4)?ZH2?EZ]U=
(\F18MG&Q-RLP?BG;& _9#T36A M;%9?D#1ZY!.OG)W2+ -0'\.U=7=W8/,RZ12%.8^!4=0&5G<9B(=#DO5#G'V1 MUI96=QF(AMZ@3]R4 [%3GQZ?:/FJ-T!U1MVA@ZB#Z0O=7]4D

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|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l$,,\V:&W\^XA>RM>CJW,21PM6UKZ.' M@/BQH:?PFK@2_ Y#"&BO<66/4K-+>K ON+)E::'71'WO;W<;(#!0"RV5=[2_M72;8!;=@,;;P _[IY 1^)0U 1^0Q5Q9CF5?-@=-SP/O6,ZE/FS- M3%BNR)T-\=(SJ/6WXP[Q'#9>F&S=D*0<0)E6/$RV ,C6.)EVTQ5T>_])=A.:HI M*@U:Z6\9VRCH:H0O|F>?&*'<'XQO%5"N5MN$S9T^W*'N&,$ZQJ8!ZC6^=YN3 M;MA0C)HE:O> X" YBB+K//E& "@KDW!4Y/ID'&N2<8Y>5"5@,$EC-A?'F$EZ M#!5+>RP:[2L)/I&CNA-+DK =.)/%!VF.,E"Z1REUKP"\7TB3'$N/R7H^':1 M"8TSOI47E/V_RB-7O'>#3[8"44[KCK![[A1D#.4YC9^+O)H8]^6!]HD6<-0A M8XR;4PT)0NYN=!_9":&7&Q# M\ZP(SAO L0N]=M&0'9N|DC!ZD76<64'ZAH<_Z];2G]3>NAW!-F7TQ#APUABUM*8DQT$8Q$?7,&7%:H7HAIL=U]O@@CG[*#1L'LV'-B,%;45 M<=YE?HG-=':*QZTN<50&D@LT3WGC8>@^7.&E(OK0G?+1H!6_(KMAD:'5L\P:'_H@$YOBK#$%%'> M=)=F;,67-5?>$ZIN,""[4T3IA]=*EU,-1/G;+L$'"[BX0RM<.VNAS0>D_5.*MJH('53@OQ_2>XE5BCB[]@FG=VC MC<2D<=QD(,.<-Q7IF(KN$#O"ERA! ,W=8A[^7F?ZD33K@HBC6;,O4U'>M(TC M)L^OXBPKQ38IA0W'Z-/.A"9W#?"M0/)V^/.QQXG$4)}KMCD"B9] M YU*A'?%?B6?'1V<0]Z8]2!]00*5R:"-1. Y=/!9A/ "Z;/Q,ZP5AW[0@^K MY6WQAB=;@W ;*/TI++#1H;S+)RAFT!FPC#O'U@R98;$7YY1E=>\XN4XRJ<) MO\?;@CK-? 6=/<^@WZ!CFKT/P1(?PB0I'X2C78T07*:,[=ZB_#(.O?:(NGL.:+8:UH[?VN'|IE;\:1U6E\=6ZJ&;/ M;'Y:K5<:%=OIV&-"Y6)3/X#$ &;@B18@] Q#AG;S1[?AC4X=T$G"+\<' 7V" M4JE9$M"C I/9[G:8)W)?,%V'B2-'Y:/$8:<:W?JT[;4YG$'FO/:GO_L6O%88 M>:/=^1CM3)SII.GYZ@K(:GWBMEY98 M+[XPEKZ[?V)$KT@A,F%!NUO,W1-[5M,INN|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|JI"@ !SM;#/@$9@!?GRQF;K-+S51V;/ M573Y=7KYM:IZ=46HSH7C<<;Z)HJ"+UZUW"U&'&HJ[K>B)"*N2MO[!T##C@& MW@C1VS<,,,B?-#5BZ&XO#N@9Q+L2\[(<-X!9-[[@WLWL#N#>P Z[%"'7!N MBFB82ELBXD2>#D1\/2]SNE|$Z\^@;FV9[\[4V/[,Z/&SL8RZD*I]1DE_$4' MV1+C7"]Y=FB2;?[0@:VR;0GWAEE+##+-'Q10^8C9WPKA\C>SO!)>;5QH=AR_< M4\(6=;[A.84Y^XTGK:PEIH.NAG]W7X

B9L

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|^O.U5ZQH9)=.W[M[VIGU>\DK,FZ0K2G[[_KCRYO;K[[OXM_?)I:\!J]IG?EZ;6-3_\.'EY>7L MI7&F&T\?;KU>[\,K?:?DO'1NX,G:BZ^/ALI>K5>K[0_PK?2^35ZL"7;_]P!L*T52BX?]|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}FMQ6D_@(M MI3 =1FT47>-$@<&$@A18H+%5E D%*:.W%-HUE:342;T52Y_/(+TR5O"\#^/ M("$9EQZQQ1R;0ZM9[E8;Y6]KO=\4VD$"+^X4#A-9SCP:Y7]4VZTFWO.(TA7 MQX748:1H-LHUL+0:[3W1U*XG.(4$2-&LE5N-9KG=[NZG0YL;I/"\ \ZF][- MW>W/=,,B?[,8\OWD1H,Y/-'8ZA$&%"S=:>DZD'3^9-*"/SR0!EM:KU|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|^)?*?*MY;KC2]VRK=.]/7LZYGD-)+_6- * MF$9U*6-\(F)-R.0V[$@BHY:/R-AO]&%2HY:/U(B*F*V"HY:5X!C>HBL::?A2 M)1-KE5,>76[4LL,$<<:*#9J(#:&9Y+;@N0VD?M V1&;2DSG)#"&[.$1AC& M!D:F;:0F/W;.()+XJ,G:R(]I0 T5"40' ;ET#;:&UT+>PPP0'6EX%BZ+%F8&KN&'$E2-/*1 M%/N,/4Q0-/(1%-&0LE5.--*0$ XQW.E:-.IWPZN%Q2\/%GU@H:3M[3LN|K>_ M#AW+ZL2:C$WXFQ;3/#=9Z4@8J<3*G)Y/#3IHF@)8H8.E-0#/7DVEY'Y-ZP=^M7S+);*YB5I%OLU'VMZG;AO,G*_]Z[JX'FTW82=L+]UW,:L9Y?['8!CUP:$AL MI#BPUNOES4_KM>XV?WSA/5IO?<[2SKR_P$PV+(K+B]4(O=^MOEL.4_&]2F>P MZL+YQOO;Z^3#VEHLUX9N);*%<3+EO/9GCD5UX7;/\LI\KSOO+I[$:MUF]56H.#!7;]DUH7]T$M&W*_V7?-@'/Z\E*9);9O[EVOE*$Y\3"LTCKMVR;M;NUNMNA6DSV'[^(2@Q>TKQ%C#N?4R=6-F/AY\WOZ\IK.M.>;YN-*B36FOBP/OI]X'M(R:244>$N!7ZB MHW/^5*"S5RHDB)OR2ED1FL:ZYH_)3ED1B56#_=\U[P^?0CL:KFNRQ'QP]]" M?EG1[S"Q$V0W;=]1^4O93;NIDXG=]&9MWI[YFUM&M'7II'XVFRF"O.W-E'M M[>369DTF#K'IR1_F"4BVJ2Z&>*X;(#_<3..ER".P=#C&[K& M"OG2G_M.O(I.4W#.M^8<^F"/MPU\5!1N;^P#E]YTD7 85W!+CB@6OKG7!I[2!7[&-YJLS! 6TR%&75ICQN MQP\<7L@4L%/46 M>%=/OXLD).F#+]^C$\['AB;V)7"A?B%?'I*C$+XQ_PJ.S M4%2B%\-GX,Z +RJY"VO%&HYA84O&U*Y+(V1-BZ&>RJ-Q)7)87-FD#Z&0[P3, _MPF;-*3J9/1&%[5E@X@D;LI!D$[9@9M')%(C+@4V7RAS#2K<(BRTU/R6G8Z][M$UE8>B=,?&$AGB#1A65Y4N06%FF&T#)^!.P,^].0NK!U? M!*.:6U!PD 6;]H08>NF?!%"HA4FA,V:SR4&.1!1V)X%)IZP(0M)-F$+9E78 M/@WBE3QY\7]\W@QQXR'/QM$>< +T5WRSZB&37''RYFS38]ANLE7PZI5]BR\P MNX-*<((M2K7)W1SIH!*>X^\C^]$D"D%@U2$5WT^8;>=H5&O6?S(PTTGT.]XM MH;")E"[^?C;0>UI,N=C$VS*E MU.(Z[D)'B>MLO)I /6U!XI1(O,ZC?]JEP*-#I#TYILU7]$IF]LP9^!;"WC|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|;_>_*\FM=VP)1.T%<.-A-5FJ%63G MC;$Q8T8NRT=T9E^0O.Q0NR_"G-*$YO)'.=1_'03)$R9A)MI%WXB[DB|\+^;_M0*9T,O1^]\;=H#K-+M;(T]1:'?J#-T;ZQ#A!H"2@Y2,NZW%A-0&=(@!ZO !- M11_NVE@32I#CC;<;8*!2[OD2GKM)R+.@9CZ?80'-L6T0V1WU72CP8NF++UKTQ MPL8SD9T?W,('S73][M_I\?3[2=\P]/>^A$/_M]&X/_QUY+[+.1)VI+IN6:'# M(AY!R[L2'6OK?+B,"B24EUF[E5PI@=Q%98+&>B?*@9(A5@F>^(D9&>P%PVW8_M3/,':0)F5]3*>0F?)Q'0.CYHI:X]Y)) ;|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|(Y*+1QJ:9.L7T]V=B=G/LJ45@V<(E10=04_5*O2?H$,.#HPN7 MH >W:+DO=ZO+:%E(8A-C QYV@=1@Y^QJL 9WMWKG-^*41[-MDQKMM<\887Y':-H'&'D"!/F (#^;+\" $R#(31+DY^YM&OX"!+E)@IRJ"NUI$WS! M&C:0"FO45V9$(Z9E(.HK'0\,(LU0V 4"",(V$$ 0]H$ 0H82@1\;8>-(!#8F MNC&CYP-&4V3P6CYBQXG;D%D>(,\,R6SNE|] M2,P_G<,FS\8M08]$A=FXIU.N$3%^1[J-/\,39-H&4V?7!O[+OI[\8#];ON-[MPQQBV38,HCWQ#8QMZ^%5_7]S*]'XB-QMA&5=H33*^]:W89!&5<$#4+C\^ /0 MG897%KS;;&RP62Y&=(+$(OA4@LNAB|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

H\4@2=C[0D$W_2G4=>8<7E!-E^RW/8X M@.CI,<0FL7C>\LARLR%_8]UMGW]&X*O+>#3%V+K59:8$&,$>#!W:M$#Z*X_
M;#*G$^Q;E[II\4E#3]V%3*1*2@:A9437@''YR&+N55WT>8I&Z#NW.G M6]B\U9%FPORNB08+ X[3$,N8/*-'%3RGU>=EGLAG@RA/F/[*S0KY;)M$PZ;9 MET&@F<2'%FR,I]A
EVS>:#+?T#AD659["9OK$S^#9-EB\ (O$1NRS&EZ MK%V?V-GAL783M/G2 7!!'#)>89I;?MP;M!)0?E6]_!*%EH!0,OJPFJ ^K%>] MT&+3 _$*/UJKFO#.3ODO/[%U<47$+7Y"ZH"-
MYBZ[>T47?6Q/M'X4D#!Y'QC ME7)34"Y=HRBHC5<3">HW:OZ/ ES'!2Z7KA&M' ^K*8"+%0O;-+S75YU7T 0- M?3_8%)*29(=LN /=AJ;@I%+=S#<%0]D^8
[I&8&U9'WE=]76]G\,Y+"OR$#6 M5-T9&Q8!\XB94GS3:PO';9]0FAQ(%SDB! I?38 #!7E3(.\Z; HI=KB# MYOC^E]1SP<8#)OO;4[R,+,$3G]@7K3_#]E,C(*48ZL&F@ MWGV-
NC[WDS[-$7C"2TE]2V0@ >X_&=AYJ+%S0^!%L=7W'O,)&NJE!ZVD"QC _M>O)AMD6:42@]G;"$GZB'A^4"4>':,R]L,A(41@.1$L!V[^OOSIT<^+^A=[IV+[A(Z+TFN6A-
@F\,R=/46O[&,X?*-VF3%LJ1.PY=/%_7ZTMXO.*!@Z,Z*;- MO>[&,XX +8;[1F;ENX1GV_VV87BL/FDB^5Z/3*65Z]V@F5!W)15X(I>B9T0 M.Q;_AP/_(M7;K9Q'V07A4I*A')R#%Z1-
@R=3*OH?1]U[=6[8SZC(%%];0C&H MLDNO":KD667@FFC$PK?D&2LW&K3X1/-76<3(_+SXBO[0C=4U] \@2KEWH/>8
MT"JXNC8S[MG*2QEL;I0XBTW+D&WE_^DSM+F;>++$CSR&;7NSX2N:H@/* IG!:7"3(6@->&M^C*1AJ^5,G$XK5O6QS&LG2G=X1=IJ,^0YCPL2^QQ63)AG!/W=R;Y&Y]+-
=I0Z<+I^=.' M.?3Y:6IXO4TQS; ZEQKSUX^2K*NZ<2[]L\K^]U%Z1/*?3X9N:TIE\ZL7HEA3 MVGCUW_">;L"$SR5-U_!'R9M 8VY)U=*'X/YJR?=7A?_S]9GI@@9W1B%202IY
M@@KSX=G!_]>O-:'1S?Y?X2'83$,;U2W_TP\W=E_!75FZ,KL\D^K55K,W MUUA4/-E!KMB\Z64U-[3"IFA)^QPA18Z-3 5]R$A[P\.XK M,OZ4[C7\WDS]
[0[3799>YZS^[SE["M=)R/5(X"ES^%G4D8\O).I_FN#R8P-=3'$ M<]VP2M"&,4,691]H"LOGC[JN/B)5U6&BK_NS7ZM*L=[K--L?WW(@T/73!TL)
M6+G>84OWAVV"9;Q(0%?]]UM_.!X,;W^5AH.'^^%8>O@V''WKWXVE\;T$"G8, M6E2]-:3[H51KO5/>2_?7TOB'@>33O4N]V[\29LZ(?)!@%
[OH _"89XU[#^E8\B]*HHB$FVN=4.RIECZR\,PQ/R%M?5] M(]+^.6' ,Q@84"9Q K'CKEQQ5H@[6S>G_UV<^L!\H8'CMZ[QZ;D'3RHS&,>4
M JRBH$5E@9%1P5H,AJV5+D9X;CDN8P,D/WWQ+>^N@^ZX@'4_S')B0K&EH=C& M!M*;HHY-51*O,28ZTEN@]OQ);D934 M"YN/@F7=8%6(SB50-* *"74(V-B<- %H]STN^F3\?
_*M"0_P MRMZ&RA@YZ'W3Q*019>F:@ X#^0=&P[EOG1[#!?6 18CI[YR?Q9# #1H6KU4: M[5ZMD;Q_GU1 *;BC P.RS,DTZK.U\A-C6 MT>WE9B_ Z'O4+4N?1;3[$K-
5=LACX$[=F+I*F-4[924DC<6EKN"W-K1)WY@; M^C-M)Y:[V2Q=7&$5O2 #AXP$%.ZSL>B^L 7,M#BD'^,7F_<;67GEMG8NKE5 MNJ4*?ZUNK]GH=7=0UO$1>.>
<=XP=)+#U[VG*LO2C;1!3(3*S]_5)PE:^BZK' MBS6.9+T;3TAS[_1]OVE^\LTJ2Q-^%VOS1/;;L^'9Z$P:S.;]O["9$"G1>8WO MI#O]+(2XQ>"6:'06N$QVP,7 Q@XEU%<4@Y8$$?
M9M%8-OHX!!:1.0Z+7J&^^Q'+X=O3;&2_AX;XSUESBF3Z=TX1M7 MW"$PK710/(11C0YQ@YYJUNZN+XMJ/%51,Z-1M<'G6:4_T;FCN6]-U5[I8M& MLT/3!1.UO:*'JI/3P.Z*4!
<]0K"&6B+DBW7NM\-*4Q6"-S.FTWDL^"MLVMB MFD7S$R M>#*AT5KM"2O2B%!%TBTR+=\CNFS.DQWRN]$(s=]N5]C3D#4E(!TE2B;69[.6R#;PU\[78R)I):-
M$8SDJ233VCDA=D4VPS$0$T.CQ>Q15 _;B?>22[_P 7M[2FSY*O,I)$$?/4R M)?!DQ7Q[22*O>\=QV3W,)&;L+BY%JLLTB9(L+40JE5=T;.HU1\9N&)HU7J) M[3G#*HXL7?
ZS+/VK>D8/1L' #.D9J3:F*8"2.0W<35C'3 *K&PDI.TB0U.JZ M#.+P1XRE;90NZ-FO7:OF[0.&SB=0?8;Y%\EEC8!]2>U$WL!E0\J;; >R*)/& MW<9J-RG'FPKZ;W.!':1*-
*,=6]+M!:5C^]6]'N^%)\Q$&A&CQK\3#';V]$FC[$TM<^E=[7W M248>ILB4)D0%PPNI*G1$K5)C_UE$VJ-@1'VB-T78'Q+@ZQ!=W^<5#S7+/-9 70
("WX+2I* .#2QCID)K=8GE"IO2.V@/N$ R;=!(YE2GV0U. M#C4,8HJLC7607M#Z*.D0G1^[U5)00OS+"P!:U<=]-(Y*>,8^U0D6LBRS1@\W2I= (K- M-PR]GK:=I!OF'I-
(ON&0A;S3UO/;4IE1\V-(>EQA_ <^I1+C,&"N&;$L8$!80K(,$L1 5 Q03C&H)@]\2E, *P%?F#,0/-"'X>E=8(T9 M$&=1IF8+- ;ZGB[1DP3S>+&FWM=G8,5@-C(%3V@17Y -
;*NG%#:R4N(+@5T M(I7"9U1B9DXI9$8EFC#*A!ZXNI6Z9ZSY+;2SDC'"LP[@$0C I MQB(@U,)>8A"0W9=B15TZI8N[(&VTSX&\+<1?FDV\,M0H3$-QCO8=Z&'3\FZ& M2?
S@9KL;I20!W^RW.^>< RKO'B0"SD(MN$X7]H=#.1-Z@N;TZ5GEB;-2+TH M)Z /W2Y/!(/IFQEOC0W^G,/)%C>L#$Y+H.](]D&!)Q9N G6KZ2RR;YN."P=3 M8T4U)&MU%-J-U]
X#NU+7=#.7PAT#=U*&LQ2IQKLF9A,?6M(DPE2]0E.3QI1 MEVE10 49BBG1HT9$V@>P9B$(Y\3G=@?^_5G>=6,"@FZ_8C-0&.4UT%UF M'EW^M)13I[I%.>6\+GM&37,/N
MAM(X5A=E+[A(>:/\5GU'KY#EZL$Y=X=**M0W2/Z3UU]['PV5S0;/P M=5%:EJGV?CZ=5,!D=YYO?D%C]=+#E[MO7TO^FM?LS57-;^_3ZL.*^@]+X/* MY^&@_U.E?
ST>#,\EI+Z@A;E9^R&0S/6]2DLPVFZLS 7P2OC.(&'K(,5<1(HM+A0Y5$%Q@_P/=VE_(2D]4&ESS]!0*QG![^\]2!5K1$ MB@,M^,L;FPV4UE?7'R62_L;T(^6YC*- M5;'H
MS5KZ66RO$NT.4= *@4@)(G!MB9BD<4[W(::7&%0LFN?]?G8A!,\ ;6[NK@;_M6]61"9MBS%+FF4 ;+SZ#YX+:;;+?!C\/^[0NW;# _/@VOKD(]@D12)'T9(N+BDY$]Y$ M-ZCRXGY-
M'*>FW-;7<\G#S1S-EYQ^Z'9U9M?N4]%Y5QO^@)L3"SD1BWI<\F> MS^G.FHD=2#Z E;962V(U22<\6S 2[-'"YOQVV/%5<)?]C>[2CO>/]ZCR_=] MJ?&62>*<+=\S5-
_O:$)I5< ?'R6@CDB^+'6\U-KR@NMI+958FR1147NCR, MD*\])LAX?$ ELL"[I,JIV]R3OA#UO]2H^H*V!KR%8(W1X"?T3!=R/ZZ?YN M='][5KUDK@(GH%)RTTT,[\]+S@?
NJ2.&CP<-X\/7S8+BLGU]VEI-FC5YA MV:VM7V/?-;(& OX7]2S7V(VK@# _KA)K6%_VBF831P+\F*'IKZ',S.\98"7;* M$?=S[%2Y6IWULF4F%U,=S=GUDYK@$=S-Y"^.B<^G.R!
9B&=='PBZ4$!79"ZA-6 M_Z(G3$V>&433+9R MK'@;8'A63XP_OB(-/3&1O&8IY$8_R7'B,@H"AH MD0P*7GB@>G]3[*NZ:=-$P?ZC;GLEE*0A,?\\ IWB+.5%4^B4 +9H%H\MFHFQ
M!^<\MV6VM>KDE]^22 M>YJ6ET9BB> ZP74G:I04++%$Q4 T#$]"1LDM:,8@,[6)B&<'YM4/^GPY3?-=Q7%"G.H'6A8 H?^E3P!-'(M>F*\=^4V*'V;TY*\6".ZX2LK?
@0\L%RRA@C@V%1/P:*<,Z+AY#;.H#'0.!-L M+?RA_B- /5LF(?,#$=\]%)N\6K\H,<@[=Y??:$[)#7;O;.'![JR0D.^!:&\7 M"^TNI).S< 9N@T> \^7:7#0;IR'811A=A=$SALI*%)GD*3DQ-
()>D/7&NBR< M#&*+-+AW+:>-%M;*%KW][DU%)]_ M59D<9XF7%7+6 UC[G&.)IS=KMF>5IQ@K%K 6D]=]4>L][8,* \?,ZS 1;GU5 MG@+
[W^3V56^LL[45U]@KHW[T=>FRH#LB?Z9[-T:0[*A"EC]X&K"S' MW?UX(T'7_K#]YN[+/ 0HTR_PL7)[? \3 7MU!,I?;BAXS&](&F74]S&^7:=@ MY&Q!=@!JUGG%
[30<2U[A3EI<]F(\)?0B+6]8A.9RTBO"U(5[U3>]:Y?>#L[] M,=$*U]YMYO3F:74=*[%IVFNO4Z:\N75.T^KW7H\^02HLO+#FNT85;H M$A'GB.P+,I2*]NM_NO6OO2-
!GZ";^C#B4VM"7K1&WU..]%MPWMJN/VQ2]*0 M@?VW,+*YHPF6IL@ N6]*LH'9U1D@Q=U"R?Y-DN5UDHTR/=Z.9NR,$;O4Z>VK
MSCFC"%=3!K:U5FB;$BY\%51:Z9E>0;FV"M",:Q%6M<1AR5F\0Y/QF?0+EIZP M!D2@]^016M,* +5MS1\7 $%C1C30<$\+YS8Y&/TZ7&9HL4G/]1=>B*KN>$.W
M567[*^9T]SOX=0Z4?H.N]9=)[X%X/HK-"U:)G-8AATORKO'1*B:4G:T8]&K MEZP=XS;T/W;/CI6,GUN;&Y@A>P<')@K]@Q'6:\= MO>E4]0.\=Z\%T6R0+1)E%18*-
F(;61(+SHML.]RH@9BAB7 .Z7/:75_X #S M;$W; D)%"+SSB.@Y+.>U+6S$KG,#E@.12)G4+2@K.7![UBP,@EF/_5K2M6-DR M*) B44FLAD))DZ.QWH7#Z#* MI)N;LN0EPD@E?T*
(UKF@VK^;;UGY8G4B>$5GZ6%AA@Y9Q(?5/TI.S>;\SN@6#Z8G!)&^O/ M#:)*SDO-,U $LL[4G;HH2PO=EAP!R*Z= /:6,55:-M5W*F%U6&RZC;F+.DP'
MR$BCK5!NA.6C;2]O%/4!3R:&;,]H06@94[TS<>']<#"P#0%4WM/K59$\I0A5 M&,?)@'JG(#<(%/H#6-30WN@3(%=;0^M3-1*"@&D&Q*52& W434V,?09-*N; M>
(U#5R(\PHBW:ES7-O':(:9[YY1K4^$RL)QC:=!%56%R%KN"M>QOA''W.8-> MMH9]W"*8>UC\CN_*7&9_1 '9EOYQ+:# GGC%BOT5,'W5%WVAH,WXSXPHBKKR MT>O__AA8]C"\
7I1D>_77@4'IZXG]_G?[O2B-K8QFE[[WUO,=2H]T"-1B;6@ M0I'JN"=Z:1MP.:#9?_T&2'7]Y3U]0U\3Y]3V LXP)S8%/;LV!CKZV[E[Q@]V M':GZ,%%?1+?]/&
M#6;']]ECZ>M$UE45E(%C=4D(1N]HB(]+W< U+H^#^8(;.%#Z,U!&O5]D0R%X MG@H+#4A/NG>?);69M=4=-'G+Y;0;X!L/0@+O+X'L,E%Y*S0G[)%F4L%]FCJX MII;G!U%^@&;
;9*G93!)GL$8F3.)RIP#?3;#!G5ER=^NX)3!1V"H$GX%FWN_+#(J=N^8!' M(ERR',7YVF:9+Q< *W0_VPVV.SMFNH&A#7_(QZ\7!,H%RKE$.7.GO9UM%D%$
M^96L[U>\HPUQ^WV:P'GC;8)Y;S-.V'(-^BFB..9CK\(:\ MW*N:L;J#;N(#S79X9'XTC3K1;:N%8 >&$!L:"5AY;#L)Q;AI"$>C/^D_P7O
M%CV]Q)RN<@Q7>F*I&^AND\G2(>AKBS5Q@=Y ;N$G4"5K^T\LZ8F6.-.P84[) M?%59W1^!A4>TD$)452.1B;O%AH73+?0.0[RVGGYG^G)]]-GRU[T25(I61(Z"Z92Z43%2'+7/
M"/ZH(T.19DZN*CO)25S)R *&$S"WIT[\A#X1V0A"P'$FX#82RIV32C@H4=S) MWSW;(<+\IWC]AWA/YH39UASO&0B/S81H]VR2KJELQ]O+[EXZ\HKSK?0R);*3
M^N[/D#8P;Y1EJ+/#%6Y^-4L?9]V!% (RTEQWFD,[HWW"Q)8D=]\,962S'79C ML78]P6ML? M@U<9S^DA"6_S@(6:5/12IN^YXW,.-+%A.)X[\\+GBK,5L?5H'9I8[I'#+6Q!
M#]-0Z)MA2TV[^8"3O5VHNAMEI3F0T\<+!,W=YU.3GQJ/*SHFC+YIJET MLX*)9WI \=5:P=#C+Y,Q%I4S%6AR4\;Y E^P\\&VG[DSR7"CM.F.XK@VN;&
MU]0$?G\%9/7&.ZY>B7XHFR6%4:S0#VQ[] B>M^<#]W&C1O%/G&D1?_J?7; IA)*]L>AYBE M-/[,RENX53MJ]:IK>7>:-(?:GOL/ASE15+;]SE-5?]+/I+ZJN@<35Q,L.Y\E
M#C\W2Q:D"M,E@;\35@RI-S9YI. G*#* MSJ21KM)#I-0. "8" 4_SI[!IFY%#S8YWXCCC8HATV 'V9@900^G0D>K5MR% M=;C# _IC;I-;9]15TSD?QXZ,+RTETW^:\9$)!=,R: (CU6],FRI
6XN9 M/,[1Q* U<4X:NHH84VO./>1/3TF!6I= T% MZJ["F,I5):2F5C(U[C;]XMLY ML)&[3ER)S%#W&^H$R'D?YJ/[!%]-ZLV'.1Y:H_5@P#Z:-)OWNFROD7PH MR!ZZ(<%
(;E!C[F6]@\U8H2I4Z9%ADRB$2AK OB,&WVV4HUBVMBYRWTM,:3/I M0\43#- [3N-G/CC5>ZSCKY/1[D4W8RK)V*+;Q^,IFE;JVL63H% MVOR9]& ;INT*2M\AON7PRY)S
ECR=U7V44-Z ?9BIK'K&!!E8HOGG$-DXW1> M9R-<3M]-,*9M(D>-FS;(P&>6DTF=)(?^S#C=1=X(+):1,YUVH9^$BW =7(-K M2T&I"!6XU@IP12BNE&OQK0-
K;^VY4H=7WBIVXN:V=:-A54RH+5HQ2Y^]@*+2\4N[ZYZ]^QLEAO+A7;E'$[M;8L#9Y%0A8$U;F?#)/1B:\O)&#EPC [^=M<8\.IB!I2;I Y%M%J3":WKCM##
MU@NQ'@,J4JVFN9;+LXS;UP^ML9G4O*-.&A9H=0VZ'@-NA1\ KC14@EZ+WB M_0?4[-R;JS(42;\>A[V)7IA8?]A\&U\+[=];=W5!B M_F6O!G\%KB:+%YM3ZCVS M'71D2.](I8>ZV?
E7\WTN(PU0A*YPW%=NNT;/A&C,%@@6Y,$^9V@EVS=R'Y;6 M8<-|"S.'B#+;GA)H)\CS%Y3/G_*-W"D?41"M_M7Q"2O"#RQ+!.=5OVU.YFHFP& U7ZIHD]1XA7Q9MK*
[!&7D./%WP,B:=6 I:' M&XV>T3Z=5.FMJM5#MY=N%5_$6.M<\)5H)5W;.'65M H3^H ?%@J4>DNN"77W MMW$@,!"M^.(4U91=*NB8)F ;"U)[@?S^U*E4;IH-!=']D?>*&RO0A' M)?
ZW=Y,?5W;BZH"^4U1*Q=>Z,0+.6Y'S"C]:][I<\S@F?S9:Y4:C([3!<8*O M&UK/<[G8+H1R.S2>@MY[8RUN]6":V@64,RA^(?ER. :_,V8NM&5S: M@
MPH.!YX@HZ]5^'64@KP5=>=0'^T6=US/S5]OX>NBVYCY!!F&YWFG'%@6<(4+P13'YHAY72Z;'%[5RE^9R%)$O,/&OLMN] M]#8OZQWG.(=,2^>GJ4X3ET/9&+ !B7I;V;(1VUU*@ %
[O7*S64_I2 U8C8RI M>B0P:<;V<1* 2;==[C72#&CM@$DA_9A=/LQF=Z6+&WHHW](-(B)5F<0-8N]C M>X1:W.F:?!AGE3NM^)Y!L0E_]/B*O7.=':+YZ91A)(8)0?.U$["^\P[>E55U[
M]M!Z1$*H9\!T]6],\R3[7*MVA(R_SCAE_K6]&[X3<@K5BI_8T/?1)Y;#* 0 M^]#HQOR#5Y*+W;GSETWF3HD=8L$I2P8,?8VM$DX8=:*O?>< LPZC9Q=R1,Q]>^7[\]F&-
$"I!1M%7U2886/N=U9/CK>B[W3 MNR3@+:?7D [X?O+-Q"Q6&C/#]%L7^45'BK/8.Z=IS"W/+83L=^_Z+I"R\,* M29X!A\7>!/6H%/<83[E3S3D\>NS=Y >]V%NFQ0?5B1CB-
YJ%M"='ZY Y9K<(MKV3%7 ?LG7HT]:F5RNW6FG&)0Y8KY3TEX!NLM!MQS]I?1!T. 5R M(U4W*R'H)NZ*;4 VGS]/1)-^>KRX)>B1]&X2+[VHT=+E/Z>Z2N^Y_XXE<5D+
M40.WM!51 W??Y>$D=L\:WFE;M45?XEZMZ*5N*UPHI!RJVTU1PMV!PZL.6 MV;VW7]T3'@.BL;OAKQII._YQ;9=Z#P[Q^IK2=TCG,SH.+CO7:,>/UO .AM/%
M7/RSW^ECKEMN5AMB RP'=7!+-':?]FQ@A5B>4C@[^< I5G0[=O(#I9EY/[ED M)-O!>9P?XSKV;O)#5^Q$AWW0M4VNMTH7C4ZY4RU&HOQF?F>LSS7#88-$/'Z
MQH%3GQ\MY'T&'!D (6'M (!G=2T.]V7;:H]3)D<*M/@[_HD#C5VI(BQ[3C2 M0DSFRK&8CX$?D26T0-;,N?>^_ =_/!C]_0T2TQW[M;;C7%N?+C!%MG M[YWV-,'6I(=:6BWA#^2A#>
[7"I=S+O1%SN=A,?=^&?:*4P28 =>(SZSFK8\C:K3G=B[W8FQ7Z-9 M;G8SS6H6%ZD6H5G!U8*Z:#LGL2\79[!5/"C.&V? M130@ H8ST&H,I*(U1
\ $MDM]ZHBP>A(,19 VSE1C)6K[6)4,>1KUV% ,?X+ M,@SDLY$70I)GP&5[;R4[<5ULD&=DD6>:P^<2;KG)=S#/U1H@U],\!8AG*!P] MXO;>4TX;<2U '*V!+[83LA#SF\5]?
2&1,CPRS66PQ-UN%FH@ Z:,?08\)-'C M8!W0[.;2&M6[L0]NI82WO*ZL.Q,* VIXT),1 ;BRY]R[OSNR.PYB2 MUB\O-_,N+'WLW>2'M[WW4E/&&RW666ZWBY%>6G@/8*-
RHD@A.NK$B6[L3=O- MQ(D$@KFM>OR]6\Z (-BAF.P0>U\Z<7;HE)NM^.6I12I15M444U>0_K7?6^[L MAP->N7YGQ;5XS'[R>PES>/NHM1KY@S M7)%5 K9.Q<"F;ALR-
BN7ICET_ZA,K9E:48F&;RP\]SS7GRM4#%!P<*S>+_ 79 MC%CTDDVGOB+E*Q!=6)-IQ<=W=[]%I:OWQU]9SIPCS6NB8F*Y0EXK4Z(H6#M? MRIKN]D_ZNJCB>,AB]E)
<3"'E"NQFC'QU95DQG\Y'M[JL*(LI6N%&)'#(/,M _M>]RG!P-/L&%@.E1@*<$]HI64N2< U;.?+Q6=DQIM^C[SA G8_O3U2F_YR)W7 M'[9ID6_A7%,.HU88&BO-)2],
MM1IQC+V([=5*%YJ^/H?@&1'3I 6$=4/2;X5)]P)RJI&D*"&B1.,9;^--VV, O:"->S>>^?O(M AZDSNPE]>;O)\RJ[+\2L^+GT:6*9%] 973;'C9; \7/E,^RKU%YX$KG"ILC
MQV30_K;CQ28S.>P**\!O;136VA 3]?V,#Z:W58KB@*%]]ID&! 03B=B?V H MU%N)6A_0:(]6\2MWJXURE2;=!BE^&@B-TE8;+(I6@]YW6VI!0.O-K;44Q'3V& MZP;@T6R4ZDX!&VB9
W]52D H]$:5"-$E&F] :W;]8%X60]H7 M_2S#V,#(M(V%Y_(A"!(@BB)$"77]:BOK!6521Y+U'M4.-JG *>SE<5#YO[E4UU>B/6T41=4[B]26$\'=0T?ZA]!7KG3 MB7\>*R.!7W2+W2 P=>
<-]TE MV.10-@FJ"1;UFN2 6^'RXA).G*ML4J/K'=]99M-WU. [!Y !AX>:= _>2 MG5C8/994#GIVZD&%VB+I2?]YD@$C<YYL0J!TM]L%ZU)4% 0O!^Q?2/R00Y IY=CX%1P[!8) QK+VQ?
0YEYT%9 M,K%!)D&*S!O7/-MN/Y&+$<82DFDD$VD+FD&LZ18T8NF '60KA$8[5*.,#. M)V8=L"#HA&A(DPGSS=S#$N89T/UB.0^ZCO!?27+FQ\?B0O _>*8.'+Y] *FT"
MLEK]=Q#&W">,^=FC$FMNH[WK\7#98-!,?)VXQU]K8#]I&/J+]\WF5S)65>GA MR]VWKUO[IV#>P[?0E24VOOR3)UC[!/TZ7MM]#_\N@\GDXZ/]4Z5^/!\-S":DO M:&%Z3$F-*PVO3?
RC-,7.*M9I!,0U&?]99?^#W[VQ)MVO2A^"5OR'J^ 5IZ1+ M8KW']Y>W1/MSV8="S+F*8"&)1@^95!Y5$)SKL&5=+QN5/B%I:E A_$^0L;4U
M@ 7%70@"CLG1S=PGB\ $B>S7P>/'WKO MQ(N[^^N M!GRFO4[X@F65/=-L$Q M^QJXSGEG,LAOEJZ+Y?#2 /PZO 0LSE<0?E]B4;-0.*XAO+R M;W.,Y.?
CFP"SPB*M:/T56:O?W+-)7#^5V/Y 2,ZXM*.>,"! M0>F#)%R$,@L'M!\M!@=K0<]M?5]]JU;?20P]?K G1N6&G:,)CK@$+^8=#5> 4>F'?AG\U!H&+I1D\G9H2!A0KZT?Y/GW
LPOW7ZY02 T?AT5/ M!4R/&*9W8$06&*7+6+!0!W'YK"[X+"D^HP%=CIE%0.VHH-804!-0$U)-0.VH MH.;S5,LF\R !Y":3A!Y](*6+(7[&&]WEH^`]#B*E,-O$$F[C#B!L+[=W6#)M
MW.%%L!M;&0E*&Y60I=2K>UQM(D1_]K09S2$3 OYA5C32]L$H&/C1I-5FPZL M;YH8_E^)G3O[T2BW>ZDDEQ<6:[D/H$A@;P2 O;$">X,OL-?+70%VQ@90)+ W
M@R5[C4_)7]N56^V>0#M/ R@2VEO!HKW&IVBO-P.<< MS&>L+B1SJK_T/ <&>!QPA><&2#L&/OBL8OH!WNOO[0!G;)&Y44SDV>9SXRWT /#))P$G M,#<&]#7C'] Z.?3E/@ >X=]-
P"W,#?[M ML\TK _7N6*C7>+/-/Q,N5,$D2#,DLG]X"V6.=#41*]&)+/ I)\0 "@'RD(#] MX6Y29)#G<@/5<0(L]P'PB/"02-CAGE!28MP-\P]0%V0 /((\)-IUN+=S &*< M^VVP+%,[U],X[^?8
)K3Q)^G=/B#&:$.\,/FFZ*;^B?=&^:%^T+]I/HOTC MBP1*O:1SY4V,#'G*4C$4 (Q5?4[+%XE 8-&,ZZ"MA/V3YQTT@&5]M<+"P#&K MEEL??DOFQA8N=$>#!V,;Y/:Y ?
(1^T&G! ;/LLX9^O5MN=+DU M>+@/,^;K+8VP]D+G9>D):]A *O.:D#(C&C$M&H\]O]?H.*5SWT!V,B?V^+?* MIZ #GOLZ9"[@OCAPHVE;:V!S!55< [1=A]'F+(2!NBM*<-H)
<5I0#M2^_E^[MG-8]=VN"T02C%9W1@O*P]O4V4V6T1I<#QU)P6OZK571.\"H'V]>Y3==X]7; MK;RCEXE@A_L=PIQ2:Y;_U+KSU25@^IMLFZP]WH.N]SND_T((IG1N!&P%I>[%
M.69 D_90)?4NN64[CX77,(3 MEZ1(M0 &3(1+0C)5]C[KD "7=.KE9C>?4ZR"2X0NV<(E[9"DEKT/2R3)>9Z=KP],[$OGR;]N "4D=VLNE6YZ]N=%D M?88IF.+)&,F$M8-
/S+UK5(NFDM\+;CER;@G)-MK+M4N!6V]M]7+P4N*53*[>Z^6Q:"&X1NB6,6T+R5_9R]5+@ED:SW&P6E%0$ MIE[X>7EKB@U:))K%!-Y+A %&G)D7[8OV1?NB?=$^]^'2?$^!W-
#+!+%]>1DP MIWCD@_NC8]LM[B0N'O(X&ZNW.G;C2BI!CT0EUD+X M+463&YV@I+!]_18*F)\7OI+N-Q/?G% $CM+8K-SAZS(0H0\YP_566 >E(NWK MN*0 :]166+G=R?L
=X$PEOL > 1Y4 ;1OIY,XB!O^D#>+++?;50'RP@R 1Y ' M)?[LZ]BD*LF;Y7I.AP=%^:W471VB/6/G:>8Y[$)T'"HZ#KG)[.]G P7+C9L5 M) [5CSVA'(LS !X1?L@U9]DA?"V;O"YN="[.
'Bs^"'WF&4"9P.2Q028+D/ M@$>$'W*)628(.)[*[G8RHF66$:W;G26INDT2^RMKZ/P5D[<1W6-+C;\Z MC;SWHP1_Y;]:!>>>O;D@^0W1W,27^JI?K3<^?
@K^*SE\AB171G=64^*M9;C3R M|E*S+!Y\!))*14YZ(:DO^R5NNC/<5Z31(?&S%KE7BT? M?U74!3EEEMQ*,2&Y-'ME12;.?3@2Z=HY:9$O=0CJ3FUE5M"TD?V2]],FEMJ
MY:ZHP7W\W%) W1*2BK)7GF:BW-(L773+]9Q2K#*M,GR*-:=8E>%'#&# WI:F MA5ZSNSLF0["'F[S8Y9BS2VB..#9(A?ME2>G/C/;.>V-*^<&K M92!@,](A8W%CX9D)XH0.Q-
#9K55>X,G@DSN-C(%,KC" MNC!N58MUWC1H*>(]4R]IEU83Z9P!E=87\OC]D4['4[NI#A%K',EUY,II\$M MUNOMW,K-A&.=^YVO_7(YD\WC]#R<4RX1*';D
T15+XD*'DL1Y,9;/F,-3TBH MF)F05ZQ4_L:&'BIA_O//;KU6_W@,. *"OXZ=O[:; KTD:HGLR6"[=@$Z>9>* MB]W4IU9&YV1Y:BM+)5&Y1.@LH;,$?P7S5Q)%4P1_B9VYO7?
FEO_TV!CNL"6I MNIG? 9^-C#, =N[!PH D1;6&0'82O#Z*8YV M[]O8D6BSX1O!-"-\<4BDF%;[A:4=1\(W@ MFQ"^..3^3"I\P]/NY-Y\P_TNYG'=+":%^V+]D7]HOUX[8M
9N@1@\ ()#*K MG*80U:8%4WG"G-,2S8%!E8TB=@/,UF8%.9EB[_*2Z]%NV+]D7[HGW1/O>> M8+ZU2?/;&RO"UH(ORO"H FQR##L=-.CM@:>@)/M=&X0/V!A1PVLS #5 A@;#
M-+WOF?&V#$15(P>B;NZN?9&HZEF;]Z*C :LNCLW!>5[[[IBS%HW=?*^;C@^ M-W$?Q-V/(T6OHE?1]^A5]"IZ%;TFU2OWX>C\=GI_P=24QHJ$8+KH"4M@-CYB M@V[NLEU>?Z,?
&O,<> CIX'11L\T[#N6 MX1TS#.\G[%WS?F4%'A*%O&AVRMUJMRM\5[695_T'"XI=B[.^[!J?ES6:)8[M]6:Y7U LX1,Y&&$L(1D\ 3G2%K#&DJ9;T)2E ^R0#E5AS&^U=CX?+!H-
FY>O$_?U:]-)Q=!?O&\VOY*QJDH/7^Z^?=W: MQ_; QL8BPOHX?4E2R^MUB?RUS_Z/TV6 Z:'_95#Y/!ST?ZKTK\>#X;F$U!>T M,#T^I#L>&EZ;^$=IBIU5K%-
^=>-2_ZRR_\'OWH2LW*]*'X)6_(>KX!6GI$MB MOJ]7Q#X-A_V'P;7QS.2I+-W>7(#@?Q::<;;P[:[_]>IF M//+B2+N_OK@9W(^?3Z/[VYJH/CYTE'HWA\]?!W7@DW5_#]U\?AH,?X.6;GP?2
M[?UHE-?HWQ%-LJ:Z;8*18[[/910!V'3XA5D6KE!DUA:5+]X9L_S;G"-Y^;,Z/"70SML1W\I+U/> M)$FQG]T70/H[AS4"@FO?E]][]7DFM65'"*X]FEQ<1M #KN1)4T.*9?SA4)TZA
M% 9M^%=CD+Q8FL'3]2EA@+HBC? H]*&YOFF=PCT<^5'^O0 []V /R="(M?S5&^F#?=GF& +L >SC8NTG?9Y$^V+?=>"' +L >#O:@6H '74*1/MBW75/! M"=CW](%X".KGY??
<6^#ETD/>W' *:C.,W%XLP]FB'Y$ M/Z(?T8_#I[C]%" "F>O\(&O=P#!32;8- VOR0K(,])DJ8L8H4OZP38NFS&<= M^(QP%BCS@21Q1W9^5C<"\]CJK-1#BL/N%7-E]N:EW]QT?!
<7I9KX(RXE0^#DBN3"A"DRH4R.4?-;F:"H++N.&R1IQ+QS/D,G;X MBG-[7'"9X+(=7!;G,O(,N:S=*W>;(9TM#:(WZG>7EDUJ/#9=?E)+? M_N^/]U+R[26?B5+RHI3\150TI])2XB2F2 +

G4E<^W0&N:LSCOVQB+9;UY;T_MDZDM+W7.ZI'TVT%(B5!M7MHH-/]# _^[+8 23@" N+W_ZX?[V:C <_>>?W7]M M\U$: /?;S?A7?F:W9S7Z;.8EZM/SF11X_(=% ?
VDS'OA!02]8;$2@FFO <@ MK[_'#+KCM0YED0I,]MW;]9&;;9G)W!E3H&0/E(P-C$S;6)P81H22$$I"L+][M=N+$>%\ 9!]H%M9&Q@#+\%0]9$-'W+@BN"!;+G"J'@HY*1 2AI '1)0*$1 1
M$ F%""N:6A8($0@)#=G(LCVS5;I;+& B8++%&EDEQ@B@"*!LU3ANF>[OA!-7 M6&X0MW5QP4F%N:Y+8/ 8,7B)YB3[8)Q H4"A'X7(@F4U+8%"@<(<47B%)T0F M
H4"A7FBT#F4(KVC=1G>"RP*+.:(Q0'+F^82A/O' K8[_OE7ZO!F5 _F>;WP M9Z0B3<82,NDIA1^19B-C(=5@7=CUYB=:]#(^LW- &C-6X;W6QHEGXAS K-4K MC=KO0[P\?]9)69E!*
('0*< &/B9Z+:I+H9XKAL65K[BV2,V?A]YKSORAH:B M=8T>CF$]]T.Z+R _82G/SXY<,]]Q*K0Q_F!:5&A3W#I+BZM9\>E]\QPFK5P MH[F!I6PYME,OM]N";P7?
\L^W6TL=M!K9,;Z7K,^XT-&U63+M6BV@7OO5&^*[A6<&UQN;;5H9F\RL8+*\B; M#R,WA>85/,PU#V]EX7:"+)R1M]JNE;LQG%56R8<#,G@]P"[GO?I;8QSM MH(L
]D9[G)AC)*A'WB-HE]MUSNX+R#8$(2 ?4;ZW=Q?ECV+0)!.Q$>@#]; M=]4+/\M^QD7W2F'N\3U;DF$L)CU6WE$3GGZV1S$(V*0Q* T<^:7I0LY$55) M-G((;?
65/VS38M<3C/60B,%HB@S, '7IP].0%O(VB85'V'@F,GZ 5="5(9;U M)XVU\C-2;2ST]^";M/FFF7.T+"\>VK&G52_7:CW!1MQVR1L;M7*,P0DU)/BG MZ/S3SBNJ)YA',$_1F2>1;?V$
H2"GP0_%9V?HF40\,D'J?@UJ<0@', M&].TV;%W?4(#F.!!P)# FY (C6'*4Z0]88H7=OFFK5KTDD[3P9G(V^-6("62 MX1'G^#F%$U:N; -
PXL@A)GRZX8HHL1,HF"!M)N@DDOAQZ.GN0QEBAWIN MM05#<-LE;PR12%[((:>FA7;@!)F"&3K1TD32.HHL.($36 I.Z"22"9'D\5[! M')P@53!')UJZ0R$= ?
Z#=/EG&7KGWF%*OBC:6NC.'UOK+4-P;V)R^P]F2W , MF3 PPZ+/0=A*@]EE2LW5RRW(E^Q!I*V& H9 MVU91E$C*2O!/0]UI!T/\B
M]GD<4BB1U)4$8Y_LNWL';P,/;D*%BX'PR#R)I+]D%/?E3Q6'] !O193+4OKC46#!]'0?,^ M548P]V!6P:P1F37/&W$$HPI&%8P:C5%[N5WF([A4<*G@THAH5LN];J,@O)CE-=F"#;EE
MPW9L-HR=ZWPP#[9\/-BLMUIKYEO@2 MIJE@QX/9L1O.CEEY>=URM]8]W=!Q_GG6^5:4N,.6I.IFYI=9B6,<*1WCZ(4D MUCM2].:;-074+3:Y"IFLL=1X)&;@?#'&+UJ2/+4?
HQO0&16,(D8"/=, M$I*[M!^3Q R;=*8I$4J6VVY(;>P!QK2V:Q+I[MI6JYU^6BSE9&%,WI4C\A,(3 Z#7JL05&[(-"B4J+9J-=;O!Q6:<0%\>YX*<6>U5=Y+?]&7+4N!L(]8X3DQN[']
M& ?L/@@F$0/AGDE"TCOW8Y*8 7?!(&(@/##(]K!R2"KB?AP2)\($'RW$N1D(C[P64@,M\NU1D>PWM$,A$?6"RD2F$G@4]B[MHX4Z-P/AD>=";N>E'PH5#'>T..=F(#PR7"*Y'0E%5?
_>^ ;G+B1!0Q ?WZ% MRKMY,E,%#F#CR\RLJQA?$F]F;+^V)WEVOVP):(PR0F(E88_WU[_GG+ZH!4((M$"!PIS99&PMU]^ESOQH:W%G4+\U&RDB#^=)(RDD[*['3S&"
K?'Z3AV6ZGC6 M<:1VG0!%I<=P^H1Q .*PRHDI:? F:AP9OK+P@,=C8#?F8V4D5X*2?!9MDO% MBFCGZ+#2K!\9 MJ9C921@ K)_5G!U-.9Q&-.R]>SD1(23C-?"M:IYP;]C$;
M*375%)+@LH:IIH:0S$9*34CYLEE9ODGV8]_W .:>&&(,XFDX M&F@GUG^% AJ3P%.BSYQU=^(&(N1H";C922< K)QUF1YS(W$[E%-^F'<+&@@@ .!U9M70Z&KO *F$4X M9]V-
@D[?#IEUY]]>\7'N"E,D)$>F0!^GQ#IZ1N(H(2RSD:TBK'P)(EMM^*S*(SH# 4RB9S',4$SN](=XTZ'%?K"@XX2L M:]R>N* -C&<*
(MAT=]N.;Y=2G0STMMLI(S$L^D!1H41TJP&#TW3+'1W-E)& M2MKDE",CCK8'=TNSD3(2T<8&(1D*VA[$+W"Y-!LI(5$= M%S%'JQ8I[LI'BQF;,^);D8L"'HLJ#*D0*>'_ZP0M|UNH1*
MM8]%_WN?FH.\49ZT\#DR^="65(VY!V2:&W[:2]R9%3A]P-69<4>MM. MUAN;:F5HVM!T2:&W!32=.5W]N$R3LU9$YWGGNC3(X\EW#FK3?;N^R[L.>3O6S
TVRR#CK2NN]NL+F,XA.$0QR<+=QL0^]T8::O3/)^ 0PC-O3]M87@&\(R3VL(\8^%:A:49Q[*&, Z/3BO-<@Q!,!QC5R%N.(;&,>]+FR8% MUF84]W74WY1_PS 0PT VYMHX:4SG'^M1'LY
93@^+DEW\%_BZB-U,!G**@%!]*,R6AZ)S65]L+/Y0 MIZ0.[)(%&@"&\)YTFSR92UBLPG/7)D5M-/6Q1X-X[>V#,LCM8I&-[KX!TEN=' M\)[(!ZJT1UT'Q#92+D]Y#]11E!.EN=5S/-
OK.+8KH>R3-U04*!,7.X$0@,=6QI5#X!%WOWI^?6^<^FNUG^0; M%#4J9(EI-A)!V.3[KA[O]Q((-X8MVB(RB*N_H-^K!OZ+"N^. .;G#7->Z^_7F MV]?.-;+!. 9 @(]@A-
;QXA>2%21^UG_L]S#V7>O7R^KG^\O6[]76U>/E_0?+ M=E LUU!RK ^ 7!Y+/RCU6<K*P+>C[?G M7QSONJCZX1#UP9 .IX+5G&U[8*P2K(&6E]+T=M6/T!1]S>0:WL)9'\1@'!
M&@)1R;O#)\8_?+8#Q_8FGBV$(3RB&, 8^CG*:Z#33[_89WFQ(4UR)+;V\]BN M?IXI$!*,>1RRTSF\7M=XO-\8_W*"/@]!VZ?VV;\O_[AO68^_7=ZW[BZ_/5Z? M/U2LZYMS8'3M%
ZWB1U^NVE]N[A^O+RPSF]O+BYO'OA/#[=?KB]:^/'#(_$? MU\N;QP?K]LHZ ZUU\^OE QP" G![OMOMU\N+N*&?V^*-U^?]]NW[\5P?? M\'A]\^WRHCP'?
>=X5M3W1Z'M=Y5YO4XQ)Y M:?K+QM\5OXK>E)#!'IJ@[D=M?V)[@KTHZ&5<5QR^%UJQ?ZO"R+(,@!D$R^$?%LB, 4!@9/#%XDHXG%ZSG M=!R#(9!IB
(3ZRWWF&KEO<&30R:I*,)SZ@N,7YLIN7^[)L7B3;-DY^F7V:. MUR0NU!(W,I:RFNQL\T ;#&]G!]U6GMC8"'[6U*9BVEEYM<3(JHL1BE?N;7A/1 MJ-72;]H:U7]C>E# SSU3B=)41?4 M
UHXM\%[-QOI2Z'!>L^&?A^Q+B^>*FD' MF946=1=Z4ZO";4-):Z"DM.]B%5%2&3]M'!X<51!'IX:V#&T5LK",TE\@KH/U M$5=I.I(<5U;<(;;0^YN[M-
>05CE(ZW!]I+6YQATZ71TT#RK'C>V17(:R2DM9 MF8357*-*6*[^%F?UU;;@,XJAH3%.8T<%TMB:>D <-RNP^RTFC!)FHJS0!:K^ M/:65;EBTDBFB\^?7K'.1TZ)Q<)*MS"#WXY2! @?
56ET,%(?#Y#R" 5#PEW' M$P=*,=LG7)<>?#HC2#K21'(NH2KSR"N0=R%$/>T",1=T(WVMI%VZ73;5;]X M1<;
#!]5O58$1B[B?/WO*'[8Z8D41O1A)EXG;;C.]U^D@VA>GA\NWA5_HLLK# M=]\(+,@QY&A"V,!K,," MR!N;H\6;W)VS@@!0BM@PU'0Z9-WRPZMH1U$6-((G-*B)ZQ[!8!U%_A/
M@3U837WCVZW0F++,P;X% M.EJCD%#"T$AZK+4%FHV2MF>MF!OP:A82D%W0S+8.QLT]['X>'98@;&IZ[4IZ; M+UR] N>08;8&HU>"T87$= ORI!@D-QK% .I!%OLCMF]<,3#
[1V748CJAYE- # M?"+0&F%AN'#+P92B3M_VGAA>+0UV';D1#H -N3MN#056A=9I[]:P*B1&O4CW M)\0AEVS,M MB :S.CIHF2X?H& 3>' H54[2[%^(<'9
M(GL1&7(P!L!:#8"#?.%=H\3/@4PES3U2^X_\(9[H1_P)H=W89_+@/W17UX^D M(TWW@9TJ5]F$[RS/!8BAQU2 I[CGXCV/NDXIO=2M%-O\K7BN MM-
Y#9C*\0C(#YG3N3=,+L)+XAD6WO4?[QYT?X&9;410X[5%DMUWVZ-_9 :RY M+=*^A%AL&(-A##D90R%)%TNX0@V3,$QB%Z"YTTRBD#R6!9W%AD$8!K$+T-QI M!E%
(@X=%W.F&.QCNL O0W';ND)E%>%!(:E%!$8<5<8S<+="_USWL9[V(L+HQ M)H9MO#6VD2]-RY![6TUDRT=_MITRC65UVM)F-:PAFRPGF9&&"*<<(W.-*H[D](SH-
"6TG"67KP]<+TU!I)MW6 M:Y73D^T1124?R&E(:$X2.]PM3$(EF6A[=%0Y/=P>060(:,<(]+ZX'E>NR;4Q M31T9>63(:2-
6T6%C.C6MR;)IGE8:1\NW3]B<85/RG',XG^8KG)I#KO=1F)%+ M/KXTGU'K$ -=>:<9XXBQK#+@LM/3*(B/CN\FD\2F)4X=0Q!..H>E SDVR+Q3*# MU"M%ZBG)/O,A]5N;>&L0?'L0?
$]ZRGP(_I8FXQKD+A5R9UOQ4[(]YL/NC4_9 M;52:Q^NVW:> >Z4I3P;#YV;?4UK;S*F?O.'!O(:=EPK9L]GYE$XV8]AN.'-9 ML]/6Z2Q:RM!QD,Z4QS%I\74;,&'K9-
G]9TB]E]=XS0RR&6+:-6 H)?YM)QZ7!*D,_MZZ6??)'V-\#"M9*2LD*?!3/2,V F_!ABV %B.,]7 M&& 4^<+<8>O.G%O1:) 5N, L$#841/@Y,%7K4C :D&)BR+0\8-I.,BTD_V0%[D\C2
V%&@I%"BVDET31/EI#GH8\ M#7DB>1;2-;(&1[*A6$.QAF*18O.EO!CK<@4X5/*LT16YR7.XQ[/N9^^_9 *5 MHRNA8+E^N/HLTAU@96::5-YVIT>%I$+-Z4PWTRG-
=,I=@.9.,X9"TL26\,4; M)F&8Q^Y 91"$9=0M&$@R#, QB%Z"YRPSBN)#V0XL$,@QW,-QA%Z"Y[=PA MLTOG<2&I? 4%4C8]$ONHL=.\8Z7MH W;>%-L(U^>H2'WLI#
[FZR4F+\ZXK/M M4G&$'6(=Q#]"K,.)Z(T2;J4R!NKG]67HDLLH/T^7HK*IDH8A[?AK]FETF< M&](VI#V;M \7)NUE:RZ*(//#@]-*\W3==V+.-H.;"U+Y,Z4:A M8Z;KM +$?
+4SL"U>!%$KI!T<@W.NGAM0-]1M2SR;UX\6U M^ (K2@JE_L:FFK@8RM\N0.XZY6<2_LETPE^3"=X\]9QL:DCAQBSPDM>G?%A#
M5_,;%]VGML3T;4O;3297F))B>1S'.D\+=]V;\;P&]5>)U"=3T@+G0^HEG-8& MP0V"KQ3!IR2VS8?@" _II#7(;Y%[IRUVN5@Z,-Q1O' MX;U2#X)!\;GY]Y06:7,]*,7XXPP_-
\B^6GX^I=W8&+8;UESZ3-9U.(M(&ZW2 M6$1]3R+G(EKL! [,C!.I?.)L2L.RE3]1S&19(PFWC4ZFM E;FU^]C%-I#T$< M5PX;X9I2GC2&*!]>[&
MCYCUY;WQ)):/FQ22V%@\+U6A ,7V*B)C1E\+QS?"TEU6+:\>@G)\O)6+-$]@,TAND7R72%Y(FL(:Y M9H8.#!VLD@[RI0$8Q:THW10+ M@1M%?
FM3P58S_V0Y]QEQ3*HO52S3@N=-,HI",F07]PX9!& :Q"]#<:0912$>1 M17SHACL8[K+T-QI[E!(4E%!<8:-#,0^V^W!,(9?&'Y1)+ (EX]EZ'SSF%GR M#.ARCKQ_8,.()-7;Y]X?
[!# _A+-877\$-+NCXI6F'S"3>9ZFS]=;4=IV$?,X M=F(4U_3;6IMV9*A[YZF[7EN8NI?-3R^"T@^;CV-A>E^X!*%08C\X/IVQ.FE M'#P10=#1&L\8;W0XMFKB:UHP19V1O\OONB
;]/A$CNN9N>?4.(XMU]:6%T?I MP!Y80)A_I[*897>PML7V7N$N+<^/8 N1#\AMC[I.1)/5<-M>QII(;2<4:%;/ M\6ROX]@N $$(P7 ?\/1L5\ S=MF ;U;'M4.@R[M?/,-TYQM=I/$G\412B,
MBNDF$]&SY/NN'N 5"U,V8VF+R-"; H)^KQKX+RHH- .G#G=Z^[7FV]?,]>8 M-V FF(]UHFA6DF/B9 W'O@H^WK5^O:O^OK]L 5YM73U>WG^P;/?%?@TEU @
MF.BQQ,$ 6GW&H=A [B(N\V\U^B?MGL6?]GY)@ AO%^D0QZLK MZ/M^=?'.^[M6J/KA$/7!D ZG@L68+7M@H"8Y#$?M
MIKXT03=3R&0V##^US^"B2>GH[5F1$^&:-*^.X>W@"@/KORS_N6];C;Y?WK;O+ M;X_7YP\5Z_KF'/AM>Q:_76.>W-Q>7-P_\IX?;+]<7+?B8 M@_3A$7[^>GGS^&#=7EGGK8??
K*LOMW\^;&K7[QS/BOK^*+2]:OA^(]M(P4%. M%Z36",:WCST,(0$7$]1J6^CTI^-I+'R9W22EEX<6DYM.D3K)^O 59DFS;- M&8/. 0-DZS@N\SPA]/!3_+F#>OL(@]"-TUI?T,*N\XC$(),
[W5]S-*L8RZM M!$UE"W"W?<@W?2E'V]C\F]D[H]RP*LVGI[:R.C; ?N,V'*N(P;KP0]>+;\=^BX+.PR[>'0 M>YZ,)-T=EI+6WG1>2:IPY<_
B=B% [(H.VE6&H>'V\%.S$:V%>.G].N<2XCF MQ_B-=M/]5R;7F8,8$"R-C@^X<'TGK[#FOY.3M:'YW//@O1Y1%
M]4]0Q$^W@Y68C6PKQD_I33F7Y,R/\6]3:6HCC/PL\NHLZW7;6FHL["#Z_API4,'WPCJE68C):2!@RE3 MP,>2]RND@49]2S1+8Z3.)6JO;">PGG$^]V6K?!$K8-18!Q-$7NP@L.$C%,/G
M?]Q;KF,W'=>)7HW\W2;>DYF)=I"6B997 / O.;_(!K1E\XZ>BV]R=\G1 X MT/ES\$4BSK(-E@XK1T^%XY<*CWL,7A^:#M4D=BAT2VP ; SW8C=
MG>$VRZ1.$;>)\>4*T(7GE%#YUZ)C^$Y+Z4?;,E0KS4;*B//+)$^M!.=A2]N! M\\:]G=^]??=D.]Y[-&X!(Q@+ >CT;<\4\>P0:RDBB>]*X\FY
M0)/'P/9"OM:O@$](5)\9XM*C_6/IH7B'6Z+%FXV4F"(R_14K9@D#'D^O M+'\RP]99LIOKNG-.D 3 1C M\G%T(K8&8\XS3KHPV21;I?YD:C]I:6SS5_5W<(HVNV#_Z\]B3XMC_=O(]Q
M9UF3X+32/#%&P0YMI)1&05J.U?RE_RLGB[-ZY:A12N?<=+EL&FQ6^=P&CL):H M8=2%,#<7C/S=`4Z3ELZVO 6&'3!>BP(6/>28Y+D.RW"HD4+'9NE[.-ETCNW
MA1XRR2$MSVIYP;LZEC'29Q,TEY>BM&AG!*RB(&*I^ MKSK"<@ICUNX6FTG+89LK;W.2QR@$^H* W^,A 1X@#VGORRKO!Z8GWBYMI(PD MD99Z-
5=:YXI)HG%XL!TD80S;^00Q.9)=WWNJ1BP8&-F[8XRF6<3TPQ1>@VAS MXWL\.SC*]IE-K5*,V8LI5]RYC931T=,L8G[BDM0PP^5S6DHY:P*%!61/#>U7 MC.[S]K2=3C!B<5372-
S=83*KS:*ZXUB$/3HY#GV),X67=K?5*LUR>MR,PWE; M:".3-%;;254T:31QM-!AK90$82S?)<7RA1,2UI X#EC;CIC15+N#+&>9E*HI MGC:).L!H[@EQEN0S%.D]:92R4=Z686!I-
E)&4E@FG6I]I'!0.3EM;@'_ZP0M]UNH1#M8]%_WL_LV)]_8QH MX8-D,ZUE\K5R1\F6-A0TMW6E=E"6+ML+7\E;E_B&*#-I7]G\B W/&!5!]+O/S3B*W,=VL31^LU67
M]2)^O<6H%T=%!*0!GIT#FMT%_K/39=W/K]\ WS3#]*60;5GEHGE0.:QOUD>P M^$5L0]DP5%8**BLBU6U]5%8_KAP<;]9FNB JVSH'Q5MH^&;6,>NL2V M&#ZUSU#&6#W7?
PFM7N /Q*C*I,WPX=,O[3/3"+74Z\!5RJ7;4T7W]AUKU!;9 M>DU;]+ILBFO=C8).W\9V;*69][E^YZN)2@%M:1'L;N)UM^"\$$KE+_M<:F1KC0;*27V M+S/E=N78WZR BEAZ[-
\ZT[(D\C1DG5' NH!_P= /L$;-\R.3Q;==W"63N2PS MU'8]LO8Q!6BTC]DR+"S-1DHI;)<9>%LP M/^Z[+]-EP]O>\F9#X[!R?%H6HWG%F&7H\@W3Y7$1$WW71Y>'!Y7#T[+H
M%)M+H=^_5^B%/]T=!B30K\5S&U%R;W':QV+T<0;..66>K4NC?LL60 MDD+?@W"]B9]2,!P!QV(8>.FR=E2Q M/!;A+R[S0(.T>LQD/6Q7F#?3M"IBT+GNE;T6Z'/;6S2@>
[AWUCRIG):S ?V6 M85QI-E)&U"]B]'FQ[(-=T]D)[52IA'N@&6P01G+$V%0CD9])^A6AS;6]:& MC25NQP]-AL-V,9ALOV41#7AE"A7G*I+'G",]+)IR4*F=EI++#F#3];4']3*PO MHM7NEB)56(FV4*TB":X"D"'Q97SYM[98:-R M7,XI5$9T[@:R%]%=MB!DKS? $BT_LALC=%%'KQ>. K([M1A5)\\,9-JOW5L M)8NKG"S3Z)7F327<7!)OKB3:M#2L6=
FK5=]DXTR\IHMP[[2;*2,9+!,)]9U MD4&C69:DKD;N7@Z&KO_*F/40^9WOEJPRM["CCY&Y,\-LBA@^GBAW06Q! M'%F4MQP=`FP'9S$;V5;
<+V*]>*$XWZB?;@?,&RMVWE"J:/CI@.HUM%T+4=$8 MM#O$:#+]9"=++Q./ TQW$H=NO97H(>E&8EF/,8[2 E+SQ)?'R4TCS;;]O1T M:5F-((Y*V!#:<>&?3N
;]NAA3E./,)C%W\U+]/'P,][RFP!T8H;Q,KRN1$ M168[7?E!C"NWO7-_/],@?>2O[V4B)Z2!;)!>9 #4_() MZ]ZI?"=$-#$"=IL82R9?*2(3*KU@87FV962Z.;[?
<>%R[$;>F$6(V$SLM8NPV=\NQ+XA^RFTG M;8:=,9%-/|(20V\+R##33#\M8C#W0G0XRTV^[=2WW99\"1]..#D63.JO]FMI
MR#0=W0H.MG@7ODR^541FV91NB'&T;\ENB&+2MO7R-5V()K\1EK\U="@R]!P2]]9 CXK^7,4+>LS * MG$[$NOB'EM=-?]]>>UUW!&> ,()AWYHN[\"6QC"-^!WW* CC5CW=LB
%G (MQ-)=G.MEB9(68X<90C>$/D;H131 VWY"/Z@9A\L;=K@X7B>@(,X[P _ZZ3W. M>BF-!K4!%EH6!CAA7\RPVXI(0%R*<]W!07RP\C@>70A\4OQ.YY&<;RYH^]5K
M&^^/FG(WI<73MT$:V;*^B)S$\M-&0H%O5.#892.2[2XVV)RH/I\FCRM6F\%S M'D9(,$N#T,P$2+;"PEF1_W8L3]+A#*[>]![45\C@UF*VX%S*VN%F\RQ-7,70
MY4)T>9I"EXT=HS88CGG+3H0,S83!I^7120XVQ/MFXB5LS.KZ MH[;+QA'SJZ7GA-/WGL$*&[5:"BM5BI'91<19E^;9O740R=E. MZZFFQ&
[0*9@2C:,=HM,M]*LVC@^LXY9QTRKW1+#Y5/[[&$T'+K4T\=VN?V" MHVLMQ^-B!,2!F55; G7,K-]M6&=W9M5NV-DRM)TN*KK IR(6@!+]!G(RTF*)
MY;,Z9EA3:8GU\R9H7(L[OP,DN&$+C]FL'!V=E,OT*7$V@\'C)!ZG94C/FTQ1 M#!X?;GA<0"XLUN4;_-SVNZ_\3_"+#;8]_?+IEZ[SS']*+Z#0$:##$'ICYQ@[M07[D[ZYWV4_,V0-
CEMWI^(,A[;UBYH+G1XP:*8X\>]1U(M9%#.LR+^0_4=C& MQH]%/2CHZV$$'U"A\3[@P-G:SS$&/K@^]^/:(6#FW:^??]\);1M:I;OF6ND M*RQ3P ?
P$11HG2HRD!B>^%G_L:]TO[O6KY?5S_>7K=^KK:O'R_L/ENV^V*^A M])"A@N2QQ,$_6GW&H=C Y&&A,OZM1O_]R:T2?&GO5_2(/[;13K$\>]*@/?C M[?D7Q_NNUN@ZX="U
9".YSH>][9=O _]B;:TM*;8VE8_0.[ZM\CO["74T1U;D1+BL^$W<,3P'P/OWY1_W+>OQM\O[UMWE MM\?K\X>*=?USQ[^\%&O>^,WMX^4#X++U[:;U[>+Z\?+".K^]N;B\>> _/=Q^
MN;YHP<<GGS^##GUCG]%%LGG_Z>U'0^CT(@Z#"\8&$G<(:HB[2[F<[=*CG- O1_82?/L*+/[O4&8O4 MK<;QR>DI9G/!%^TA\]%@Q*1X(,U!,,_ [&$\%;B*"*6IW\.AW9& IXFC HU[
MKM:]7XV]7(=_L2QI;6O3/.)ATZ/Q%,:G)!W2/!5+ (9?]0#K4*Y!P^ &T[/ MZ0 GLQX#VPNY+AC&ZY$.)K4O7?"@W1_C<+(Z;T6BW<+^!!R>PU2-S_A_@1- M[#9XLCWG?
P1*KD7%U#AE@Q-\]V.*=I38DMB1V+M$L+AW^PYL*W'/@N QD:1 MTX$;O/8Z^]8[[-N]=\Z5U+WW%N">#?0_ $:_^B>(4_N)\:,(318VT1FAQ@]8 M"Y0(6!JBM9G]A OQ_4%
!8#]DB#VP(.GB; M!5:C5K&0!U:_=[+!&9[QV_[#OG7E^UU:XB(8/5FM[@_V$48\N1NWCS47K$W U;ZJ\&\]^H>W\FK4/[Y' MD'_Z!;\C\.[K]=V7?UU=M>"!PY/&1^L=(,W [[C^P'??
5SZ%(X6.8Z[%R!]^_M)-U,Z)E@#O^D83-\\0PVY@>VZ[Z"P>KBI>&9Y%?S!Q$#;AP&N.Q5[YS.=WGQ M5O0ZA'N/3WIW+HZ0\#OU8TC20#%1JXX.D\"2F@FD.6)D/.9 5]. '78$ _H
MG/ZL$#'G[OQ]^+B,A&TE]R7AE_'6,["LYP3HXP2LL@!=]C&R*!HBF-Z=5\0N M$ (.T$&'6XSP1Z!*]FKS!YVP'PFC7IRH;PV<)W>$AF0Z81)P7/(^)R 9NS.FQ MD(L=DD.P)+
[5[H[8@'&S8-(B\'EP@)0K@-<<[D>@U#!P?UL7O/3M M8L _^]_[X8L3;+R_1EXGA@VNQ6&-/1][EKS; 7$RPM^(3[FA;[49\ZPGV ^" MW@^&?4"# 6P&]!!XC613P(^
HOA%$(>0=M^I<\OX0Z&#%Z#/4H=P%K?DTB7 M#\]ENO[S=?_NC)9!C?@+/C\O'AQ\MN0SQ@YQ??1?Z762 ZY,.:_ E! 'G ,$O5N>UXQ)QD\H8 N_=GX1]KU/ MRANZ0RYTE(" -
SC>,V"^\T0WIMVC1+FXO'1]SO@/0UDCOYU(?2E1N^R9N?Z0CC8!FI@KMQE"1SR, MA!L2[>IQR Y>"38HT>%]W>K$N ;ZU:]WOTE,1"Q&!)0\).?V!:NA969R ME^O?]F,Z?
4O*KD[JO."P:SE 8&BQ\@;ZO[/!7=\.!D()CGQK]H+,J$X150:; M!%>6HGC%VL$(4:%1)SWQ8)_KB3/TRZ^ QWU+?$6HE] N_X+4I+:.3 *. 9V M]*>U16, L$H.T ,$)7$H^)A433OLVO^U?
G7]-A#2 W.QL1"L^1WT=> 63* , M:&GP8_@Z:/NNM??O/^Y;>_L[A#=I=F%>_OFKC^ \[T."SQ%4F_1CD322L0T M5"A#VHBYXQG_X"H2),:!FQH!*DM)X(VAT,;N-_A"I])-
C:C!T:0]DP%Z MW[G"L">MD@PZ$@[XUQ#^$/9$< _^K+7P1LF<"SPXM':'K",VWAB=FW+D8! M;F2&WN!'TY]""[08]4,L"GFE_X%1*>\77I^Q_&&MPD5 QC-DF?*G$ +93QZ(
M)W5E&Y2;41"0LNT!,[&\X[IX!X@)V1>3UE%C M@4Z(Q5U,XVA_L]FH("]^]@K_#Y07?Y++7=PB$-9FP M(,]/8"==HS!CQEV!(3HK<(^6S\L?@ LC+V*Q9W%@ \7M?;#3;
(M2"@]%/#1+[M#]A"H((AWK,?B!X4.B:X'!FT(4 M/AVTV%RT=6#7/00?*M^P!MC%Z,<$B<;%F:*.;8]507TC1R3UMFJ0!'KI>H/ M"6VT)*(/01/B&>KSX{[<[14K% I QP#@/@:
(*1"G!.B]" M3%578]VI V> GR/N-P=%!9 R T!!V\%IG*,V4(R'D6TJI(D0A+!FE!/T*0!' M0K,C>29;$]7V@_%GKV.,QQ50(G K!0]HN%YC_W(^"H,];E1O-B[^KZF>];
M+YRN(H)@D7^HB^@KY[IV 0P#])3!G8?H U6'1$<1BCPQ_33$#0+L$+=0PUP; MG4^AN[(1/]BJKO/?D=-%[.-QHA>0YG#/E@LO0D],ET4L&!#G%]Z^<-3I@#*.
M(-8O)NJ#R'SBSEOEYN7:?7OD?4JKI.!]V@0 24-\7%&,=*(=?H>^R[>%B"5!GC?(G[I M2\5)H^QX<(GD>3&PQEN\:W9>EQY('N $+; "B$9IV3O7)B59?).RW)
(O4\^K%"HBYA8(R$084*3)B2_CG^,] MV-80HXAVAQXE.WTB14Y7W9)):%K<(]('>'@4BE,KM-C55":&; ?TFSC]+D9 MEW,#&AIEK-6/^?6
]B>O9^ <]4E#OX#7[B5#VG0"ET6"1]H=T %"1VX33[]O MW6GV!#XT#M"*##SJZU0T#+!>0'<9X*]=D?3@B7LDZ/.41/XX;B^^%TW!M4-A M'P;/H"K!![
P:C[X*M)X9B$7Y1S!"SW& 2UX!0R7]@CD(RL0;"=@RGB5\N;) MB1(B%R6W;EOX VX (':?=FWK7!@[7VT/]%T.D"]?SH&5WYQ_C7%GS)*S03%T M'3)/"4OD7TGC!*%%4N(=)H)(AS>'"
]RS(C%;[4&AM#2X;#+9NOS: SSX^N0M7XX8?4S[0]_[96P M/=WS_3\XWH>45WZU?SB#T>"+,UC,YWT$YOK) F2';DL$*>#&^08MW"%B,J A M61F:(8\.#W'EH(4X7%\F6TK0" L!=
(G!1+]FG\-$'FV<*UM!K'.!FAL[5.WN M>4X]SZMO>HY((@U#^ZS@!3BCT%$+E&:U:KBP%52O2$]N,)1U.I)U@PM6^A<5O M>*?6E]B6ZXT"0FF53A-*W?:<,G;LC5OJC,=F/,9\X4;/

L%$=:\F;3" MIJ07%QI*;0.)%RMCZ/'"E!8O H4I:3*@11Y?FG"QV[$2.^DV'U>40&-C]){0 M=EGR=.MSD'IEKOKO#@&< _=^/LS\R4.#OC;LM9K'!^=8.\#X9K&C3/R76!VQ1/< MPQ-Z[#&G(DO]/$Y/E6A4:TU-87P 2XXE5,9SNI$'O)![L3;KTF-QADLMM[IX M?7,%!\)FC)7C1GU2:0SIQ|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|K8[KW\=&1S%]= M)DU:-PKKFLMHK=9H?5 C#@FLFI>U;+]AFB0J8YG.89F.\;/%K-*3-& =&MG _M&[-.DW=6#,/?GY58H+X\EAX<">5\=F8!YU[UA*>=8J9F'5;2S=$CZOUNO[C M&I"L# :II6S1;K8INLA-QJ5%D69PH50J2:AMO58GW:%UKXH^K#O>+.^MFHF9 MM'W!.HFI9O5IA4^\>CRBXB="9JVL1K8C%%U;IEW WOM9;2BQ7D)4O&IOSV" MG#92!5FJ46U,:84=!M$'42 B%Q+;;(U 5# _M#VUP\KY0#*3 *9\L>$056JO"M5YK'S#CK>CDTV).[5H&VVI#5T6O(M08?!=S M=\+T8;:GNS/,]G.N8;8/H\%]-;29]3&\+(DP H:55O\?.3%!^0N=PF\)DLK MKUH>8[^%H"5?BBS-<$]C&HX,:F%/4EEJF#")X&*U<#^SE1R;RB:YX4C7CTMFX.2 MBTVT+. IPK=/XBX1VCQ5]JTFNY^HUGPV.0X&E&G4NRVCS(2^W-W'7*F"]>- M'VK;?F.6S]U'=2UBC(08CY7(?GL&HON.42U9FRRL77 .OZ3 MI\UE'86L-W(M5];MX0!$%HC&BXAEPSC3![^,F?JB*34,X)O M5UT^S5>=?$' MJ5\=?@]:ISR8^);.F:?ZB%4 1_#=A16ZER M7R BZ"GF*GNT,0B*])_+&1GNT$%H)/FP<:(.^QD$ B);|>B#Q>3R>S"(M"^HHXFD69&,+WJ*M!$0B=<#(6)[=O1$CHW2QG..7SQP M#3X5AWJ48@IQX# 9J(__(A;ZHU!X-B<8@!-9H^R0@VO9'G*UT (+$!1E.6+;NA"OH3KX"N^%:B3NRUE[C5MI0AQ.-R'6AO%G?Z)'_!VP.AT?;8=%ZFE"E*Z2AT0 MM"^AY)YTUN*0/AHCS";5(EYOS8,:F@/@(0)A;@=:=K 3NDH,@XBV26P\XWR"K M*4:C*1,EG;,K94A<4T27JQ*(O2F&> 9XXD$8&)@$+ 3KXBY7=[!"4"@CQ!T M(OUD9%*-/#YQ%O[Z1+ F%87/#Q03Q'C)!Z#KF#KNJ4_U8I20W5C4THS MH!)#L;@:J)UD&(#Z%P VDBD&^A\U9]Y R.NPA1<*?Y_V5J6H)BI-X]+%MH]E MGJ2C!RP!$1W&";A.MR%33M^V74JQ"?N,14G5]^

K %@WVM3AVTH3)\C$?C _M MS3]F5&/25[>^8DOP*P!6AD%"WF,FYA8LG\X.;%WKIFZ$@(" *IM6W*(+DD)/# ?P!ICS3CG0RM-#U;.MXE,F#>F)!#,-2KZMF]KOK[!=`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|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|'%U5BCZGTX8F$7+;_MM%^Q)MG\>T[?J(\AQ/D.$;8[=@8WP;M5DG8QF8$9CJ#X/T0?W*-D0V!KA)[QS4$]#C2=#PLGU2%>4X87Y)TEW=I3 6@ M9SR"AMR^TS17S>DI'<%8]/:4,I$K-L]B?C/]LB=GI,HS*FU:?H!.0_QZCP5IM%"R#=NH#)VXH@HW%\.\B;A'O1SR\CSWPY"]:B*$-$D@-.Q,0@]Z(1N3>Z/(M<>G(NC 3@1A\SN.9QX)? *FWZ3+RL$(]CC/KBTZHL4K%%)%S3/+-72*S/*DX MSME7Q=/N!$_3Z*N5D])!XDI#=.$_EW'=%%7X73I7?3^M0%>_7/6Z<"*T0I*7 MUS/Q/,8 M\;9IZ88B 3!$4>_=C+ /IW\>!*BBNNZSG?,PQ0OX8F((#=Z<=" M;X132"+.$U<,XR!N8$!<,&4H.IX?"7,$$UXJ,C"[!>0S%X19U ./L\^];7 MR4M1Y)QG+Z(X((V]BG"H9##:N$LO"GRWPO4TJ9UYOE=5N8QR9I6F;MFNB(@KMY8G2]>&L(8^M/4GM,M>^,]%%F&38:PP8E0S]R^4LWM&)0KMPVX(2F-=5-,#K M_4E[)>TH9;Y2P*H*K>/VP)K.2)0TC34,%[=D8" Z+68"]Z6!F8K"6&=IM & M(?G$E36EI40J5\IC]+S::)SRHIUD(;6:4L:GSZ5A7\M[%;M213*O%PYP]1P MJS,:X*4#O$6)BQUU^M714(RJXB7]HMLI49'HP8##;^VV+U0U)5Z)"]B!1X/%M'.6#@HLBH*NM[%OW3/I"IZ@0XV>=Y!BY+!<;RQG;U!Z&C#%Q8-*XSK_Y68)D MA?&RMUY4W3!%U::HNFQ%U<6'=]MG=]R9:(FH#[SKAD5Y,K17SGQ6&^Z;HC3C MM-*D$2>\K(,U:;$DT1&2^0!=O@VA3 H.5>^C[@+.!M MP# _##4G/(+GL0I90V^(C37&5B1KWF9'>./2 A^8/6C6"AN9"0\[ZJX4/ >;GI$3L<9"H=OQ\B[IVZ4F%%T#.+MPUD;9#$YR]Q6EU^U'E>153T5J;O5NM9#NMA*MGN1LMGRNA>Q:7K)'?FI-6S' MFZEAFP*-5D=445W?W?]?>S#\>$'H _#4VK,59\A:S[9A?\9JZ\5$]F64CK$(1 M7U'N)Q!MHX#[91P_X"QVPN=#_F(.:BW?WO&J-&$@#"T)?/CI+\K0)8G 0<]E M2?I%:1X0&3UR%(^=5H.K[/&1YTH7MEB8:@CPQ"[P98];:)B>A0JT4711962 M(',)<#]ZP#$[ET">(N'T.:BY4'$KMFP$H_FF+@,(:^$]J;!5VRF@K)TA+(- MCP&[_(54 YRVP34 !I*@PV,J(M?@3PQIZ5W^9IR+A!TO6,]0%]*^$W2YNB"* M;RJ96"/K=%ZY1TT+V"2P0^G?\<9DQSX[4D;770/Q4LDDX,ZA%;Y*6KA984G;W CKXC/5N_Q$ K1 M8GLD1!K5P#(N>=?BM_C===>=D37#>31><3X]"=>LBJVIO1NI>=I+S24[QNZ(S MRUTZF=V0MU6@YNQWG.CRE5TX6K@EA.O-,$&*!6\(&>@+R4S3[2L'R[Q.(^@ MX$+$VU4H;$M/@PKOQ=2F MZH"BD.[)-#$H,+!+<=N5$=#<47?]9%BUG]O (DJ::)R)6&C M:5522N*2*8BF--;R*_M-:!-D]LIODR$MJR-Y,5>*:!,MVO0-:GL;)FS"8<"J MKCWR"",5$7C/OOLLL#EPPN^36\F9[Y@GI-B6,4+AO>'6+>$Z8CBEB[W*!M28 MG?2,?C6J.:2]P8O0!J44<_I=Q8KM3ZK#LNR%S!T?'9EY0=\ W"&$\51O!XE(VDTGVD?+C8M#^4,,M6+/IU=,V()Q3ZS?9]F=^,R)6LKH."F5]5,7E_RR6)OAM#UEW43,YK'-DP(ZY!9S&SS%R7G.*ZSI'>&"[WXI==WR%5XR4%^,E#:SWD'RM?' M.)DK;'E=^E7TK,QVHT_,P%P3-,3^16I7YS6G$WV-,9T2F&&M]/:GJ%Q'XH9Y MFHHO;#%I5TFH:G4C8$_Q4L.CYSS5.5CSO;/B9$.Y& %6F[0M'&H7$?FBR6W MACZ^. %(%*FB93>,LV_B"DCL,$X)]PP=.MAI2DQB$\8C/HT3'%0(0#A8>?ZZ M,$A%"VQE.]GM\#Q'H8/+=B&4U2X\;-,.$<.0Y_?BN=#D?1H#]I5MDQN?PH^D MJ@@2>TFDC<7E-*HA"NK-(HJ*3BA!+QB7=;]'4A$4";F& !YX"1D)'+8_(*V MHJH/U <[SMD"G";V]7T7NP$*@XI&"T;OY6N7\:9;@]\E@^]"M3,'4IW6-C20 M:LKI<;_6=8BS[CMH](71IOI\EUL($9P<"2>5,<1SI?@T6X]Q=9]XEY@A,Y,M,RNG5L_0H/$30BPEI4XRG41EC2231*0%D[X3722]@0ZI'Z0HI2P/ FQ)9LG* MURI0A?[?YM%E+5)NA1WP 1I=_ =[3Q='$F?E]D0RRC/,??2N2H2WXDU#8> 3>04L4? 2,"\ MYGK?T\CA[>Z 7UZU'CY3-<*C/X1O9S5'.ZG%$ 4NJ!4$O(CW0/^BV0-4\<,U M<40+;^:(/7CQ7MS0;HX=G=2U&7\7\.$SG8^? C?6A>MZRK<%>),:\O?83S1D MCSM,ZV7W\2T'V.6/9FOH TMUR]S. I09)$[?S8X*IKWG-))6, A 1YYKW*% M.XN]E]>UI!R&%A3-@[GTHM!%7)3!,5G-@NS,4=(27U9%-TZ_\LHD)/51,Y.=F/3HK!:,'-I.MXIZ+H]K5W([3&(7 MQ!1;6?@XQG%)XA /DB7//T\44 [=*!94M%Q&F!9T"]GB,&)R&F;*?O71;3:6JE>)Z^01)+^PNDAIO_(/";@ M3@O>Z/A(UXP-OMAZ0#0V0#Z[=N=[|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|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|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|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|";S5-8WIY*V.W6.V5, M[<70M(=W M!!E_]6_G]]9#9/= [G>M*^ HUO5UQ?JR?[=?L?!O=WX$L_J,_PGE'JG%0PI" MB85^\UV4I]%\U<)>&>]0P,_QU/=5RX3Q&]]>7+.5F4=G> 0P\BT%K)T?4T?M!6\H'6DW;8 _I6G(\?,86OS\,48(PH<$M.@AL$,BP;IL^AX/AF]*MT*48RDC'."KPVQ#7@![W9Z>+1C-P/\\!6UD&*,A> M[@EM$\U?'1=%:HQ!&]]0HMB[MR6XRF5C _9IKK$"F%"(6.0^ESK3N7)<3 M4 UJM0P/?<5ZZ3L=06E,:($@("@3]68&K>]$0G<-0"_M \H &?#0:OB! D/9 M8$WS^$NPKAC"=R)Z!\?'>V5$6B#F$R<+HH?(>>]5%\$* M;Q4AL6PH3O%K0PZZ%#=WZ]EV7-0W.'I^PS!L 81[L:]DB%T+Q(,8!E0C "W9ES; ME#9<9;PVX7^Z!'A<<.@L>)'U;#YD)[R<*MKL#PEZ/,B?90&=)%.3$CD>4RF, M1W]GDMG)E#8PF[HOZ;DYQ,_^-D18Y%2PARB809JV>>+!U46+RQ*9OB! 1^_V MU^N[+ ^ZNM(^(24@8#9W(L)W;N[.ET:%"<>6U&2GZGHQ?BB5+)?&M&,*V6, _M73\(R=*Z6KN+?:YW?]-1QM-;T>!%^;V4$B6];F[E[VWQ%(YM7\YZA56)8 M?%#=T1V7Z9_N*3@U7]'9-N8Y%+?_O, @]=!+S$$$!$]:1^+UB1 M.WFNZ/'Q?DK#'2WI=-^ZYEC@L0@U\>ZH$UDA+!2]]!4NZW7A6E_Q;D66WSQ$ MVA3>YSSR\R0MWWQ-_/B&17<< @\(# Q"?>6DW^Y5I5<'ST=A1B6BLF\EAE3:;BQ2GS"??>5+T MZ%0$0I'[1D%VHP(]\F. #6\T)=US<*>R7D)/E,9E,&9 M>>I(/6X2I_+<[>F4R;HEN=MK[P9V]B^@A85S%[,*@4K(<$_3;1.\W9[%>L&3@*CMVB.&5Q

1Q*^;P[<+,ELW)4TR2>:-C-TLTM?!@SK&;ZV01/!OA\86YSVRL M9<]6\(=MGW&X4=YP9'C#QGE#VD33TO &U!<>7_SM8@E"9="MW*+XQ%N<^P;X M>/SF+9*RC)K*;Y9D3#@M"5_!\,I68N,9'Q^67FXR>3.,EG* ME)3>\K"4*W]DW!L;XRC5R!*I)*?B,!-XC.I@DW@WNHYT*-J6+\!/C3\0?_6 MYV4'IU"-
E[JI!9K/N::S9C+,M686(=>,DESSM84X/XM#SIB9=E2KG-8W.II^_M VA;>G5N<_ZC1Q\3PU3FAY#)QJ.T<8_2NLL\DN\\%\G@8UV>MH;7;+NC:',,
MX0L+PP]8L])R^2G+KNN$U&NU(BI;1(B2S 87EE"YM!.K MG1X5O9Q D0K6$8XG\:925*E&-V$; *D.XF(TB;B7OWYN51 91 M#;+RS;SES>1H@HSWB6;V,4?
(_U6YE7;:'2T$!O[>UK\?'EOW_WJP^ FU\92(M,BD]]N,?5W]#_V<<7%.63P?6Q!.SH966@]M*QW[#I0 MUYGOGO^"0T^MSV#JP"[N^C:K2IG-RE:E&_
M9_TZ"K!&^0[']ECGO'I4]K#G+2OD^(9\U5N8$E_%?U25*MUOI'IB,J;V ^P MJKR;]!?F7WRBNN>NJH>5T+%)D*,["JG,^,4/W.X+U]^[XOWP]*@+Q*I0;]0#
M$4NUDV,%@BRYI&CX*NNV.]A_"V$1RN)\[A_"V5(RN)&@(&8C M#BTU(A+JH5#[LMIDV+WH@X2.]5:K8O?+1F*]UQ!N _TX MI*Z)LQS/P
SV;KV.OO4##RRP^^\F%5 4T'797:75YU.U%!213>?TX/MY]2% MQD6#T^]X'^?GHG4>R:+.+'Q05XP?=66=*!_0VQG6KTBM4E"M%9-]@&M!=)F M%I ?I+7!!IVM6:T=_^<X!K@
M//0%<3#QR./KD-WV6EAD ,24E2&A()[-'S@2RL$];T*$Q_I]P?.5VFFT5)L M\>BC_UD^_C_67;!DO7F:V;F9BL"IFU6'5RWS4OYP"" I.7"5<$DCUX[\0+O. M1+UO3#%:GP-
*!]!O7:QB=_H.'$[6D-6U:MT%K,8AOA[X MKSB-.GZ_FF^/K8%QXBO6J*O>5E0-C6R3O_\=D%,7RZAY:Z!LU'Z_KW#;"65Q
MOC9]G<_)&M\/[43PC&K[M2K9!PU=$SVIV8^A$ZA:9RJX%]^A/D5]9NUP"/R1 M[_7QEOV4H3Q+BT]=0RKFS8QO2MDZUD*:0U*9B4^24_5D"Q_982?]\W;A(4M'
M[,H$#A(*3EPP;Q/')0 .&8&S QYWD%N./%&9C\UXPM#O.(0PI"28LAT -5N@_ML7N(0!6QI9A?IBZ*70VPP0>(#T)>F[>?09K&5@ULJ/0:U5I(3A/"]>Q;D2" M-K26)%B WF&JO#S1X,(?
N=V)-?5Z\&K(.E7G1[7O=+O,^R#9^N&)V #5@B?O MBU^7@U$-1/XV44$2V@&C1EJNFMVB>B1U1@.\7VR\$W!^JC> PTX'BVRW69O< M+K%.N,B
_+:B&#%QG7B%4]:95B:_=\;X9,9HHH\-[^Y#C1FH@VR*'C8:SY@ZXDPE"SWI<]$@Z&Y\:TMNEZ\!D S!GW1B\QUOC/W_V?O79O31K:%X>_G M5Z@\)V>2*G"X&9MD3JJ(8V>R)XG]V,
[LYWF_[!*H,=HC)+8N=IA? ZZUNEL7 M:(0 @016:I*Q09?NU>M^-<>.PYM-3724;WA\@J]-'9PNQOL2R8@IW:]70LV MEZU1T(HF0%C_& K_">!8 MS:3F4X3>
(UUG*G_95]FQ+*D7;:CHG)U\:)XV5S1V0^Q)A_J2CKG-"NI+AZ:> M=M.AGN@I(AN-2#Z0Q1"I =&@GB@FY?+$Y7C22/L8QUP!8SJI))MBZ^PGZYTD31U\:)] .]4!]H-SK0
M;G6@B1;TZ@;T@K $145V;]3=D1J-7J0)H]ZWF9@3=E2.Z4.9;):LC.^674S(X MOG0M0R3&3L,&IH+K2Z;BA0^NC=DO(E8AXQ MO$F&(U9@/)]'TB(EJ-D22E#T*MEQGT+3O
OBD/'VNM+@#X>!Q5Z8(GS..XO" MI]FJ-]KU5B/^8PF%ST*C_SMNMPLA(UKZ;]+/OXEM=-7]_$D1%?X!;#V[Z-B? MZ,,"T#^%ESC!!--
PXH_;9N/\G'.R3/&*!9Z<(,MTFITN4NR6#>Y20^W[\MTN M"2.'NU4F">P(!_+PHKBTY#-F%[4TE@X];RA,R5O4O_^4H RK85U-RZD!>N(
M>S'#9K(>;ZO,/:C"03L4RALZRG@37V%OZIAR:4ZI?_.WO-6 ! W M<e3)\;%0[-]=)AVQF-RS[,74P]$&,S0U'5;NF]Y?P2;-GW8VZQL9B>C38)E-, M>T'6H*ZJ]>H^$431>Y-W=V/Q[
+1&O+V_7#W8EJF4,* H=]&3%K*IEC()XP M'M5=YWDN3!%]A[E8VNWG[S^^I;XE'19S4(C+\+16YF<)_6VIPI;X>1PF:-WV M/U_5/]Y=]?^H]Z\?
KN[>:;KUK,\\F0^(7,5F"0"]U\;.9WVUL))+)![_TJ__M<-]"3K+XZN2M\FA^_Z0^&LPUR^=@'FXNOYKV7^%;#-,#=)\A%+&Y>7V B7B+ M:82)]"UL8OR]!??&9XDV.^S
(;)MB^R7WI*>,7\AR&G3GZ<2RX.]6I%\D;; MDJ<_Z4M!8GR! W%B4K2V\(UR?2H^!$ESB2IS[F2U8]9H-UXDV#;.V?3S[<,]#Q6?+7ZT\,G\][F5T0SZ6YCHG)*HESL%[R4U=/%U
M%7\X((Z0T5&4>%8VGM$7JCI/,-)HR(;/P]"4Y(D:\#>:AQ('/'6'C ^.$2QG M+CU3>BWXMR=OYO)&8]F*88IBY&YT4N?H:/W@$4>GR+B.F"D?FW\NEKO0TL70Q
M_V[9'37Y#4UO&#N6$5OXZD$+Y%3A"8)BX(+,I;@*7+"[X_; H6?#79< R: MB,^)S!V8,FT75@)6W3=]R P'KM=>GWQFSB,@P9C2
M;OD.3]XD!SQR.&+*E]K|'E"1BO'/G8Z/56<(VM0F9_L1GZFHEU&X$UR!>PN3U-LBP1XQ?!2XE'^% M=?L!#064Q+*G!,@^?RGED8M7W6Q&'B&2HRR:!+2;KL<0QZ?
R8ABCR^118X.0X9&W* M#PX5(E"=,#$[6A@'UUX9&V-.E"/3+H_F$YI(HN1AJ4U#9 M>0R&/X9*Y0P>*Q%(Y0S1"NT&
<"7Q@P_PE^^"2^#]IT$-.38_7@8:MS2/B2IBX5SD5G)U.: M,8=9+'<]F'J@IW()7D.(#18>1\G::SV2IV\C?/BX3;(\")XV3O\$J SY #]/ M'S$QX94-
#A3'*B6HT/IDBFX[%YW4Z$Q.CB8^.8PB$(+.1R!Z7(&.8 M-0IIAFD5E#GFLI"%ACX/I$ITYTN4]311Z>W/*;\TLI=I1N5P3'59G$(<0/Z% ME=#,6H/YE'N"ZR=(T2ME?-49B%G+T<[\
<5@7E9Q<*1?IA8.R!8=Q7"\^V31> M#R'O'>N<<5*0.\(R &HH="(@!8^Q?0MJJ9XBSN+UZFHXK:.,T@,BA%$;X,\ MO6B09KAU&G@<6VKTO1+?PAU<-D#@FP)>>-4]H#((6-
YQ&B68_4=6>:&G#>>_M (ML*^9ACN@ :TE]\5(T^-IWS4'@HT433C07.%[GY7B^_A-.M23#NU.;'92S MEEVH +\SW4+N$P#5\ ;-!&F]WHE*I%V.0&'UK9S4S(4!$ITXZ\ -Y[!'ZT4M0
MSZAI<)KA#'AKL>P+$&7*;(.*&Z,,,NY3%'Y93WH.95*%%R6_*I-&T_!9) MUS38?$&&K7Z.5-=PDF@DZB(Y)W@G|2CBGV*M_&7 GT S40"6Q':,(OGE M+A
MJL9).7IL6PZZ"C9904HIF1268KT/A+G@S#%%3OV<9>D*[MQD_X3:1H2SI;^ MC$YSS9*IQMIK3JY"7P3,FH@::SNF!.I+=Z+VE&,302>*Q'F8'=]YRYPS< M3TS(171!3"H>.
.[!>$$O(.? >Q+@,[Q-SI;V0[2?*82>.YR?4./ZBN):%5[.$ M81&" +40!KKE.=$K014+)M,8#[#?1K@G&X96> OCK-'.>$97X2_8[TA M(0IQ1XYZ6 #-3YV_09P9:;O
/YF.\0303",\.-6^Z;;.DP*)F\=.7+%C3M," M(7%8M&7)$>_\0^3Q)G MW4T@H9=T=V-=\Y0$.HI#OE]N4P_2F]<<1[Z.V\ %"5BZFI>SDP^M506&]\LZ+S*6=1XH
MD+HG'RX4A4%9*KT\:0KH*0&\$OG:!2 ?Q2]50+T4&PB!NW$=\6+_QG413E%= ML'.$VSE@.]L (Y!,A*A"7$-P\=9'P.6XH0&Q3C=0&DQXEX,#$.*2]PL$<75
MEU+=;VJK@$RB)2I^RZ,Z\Z*GKLX\GRNW/5R>V5K%,U?3>:^1K2;Y0(%$)<0K MFBHHJ_-SD2X]E6]S:PS<@W19"M!D'6^,N:6#2:7<[!H'=PNF+LJ;Y3#YG69
M+/(%;4B?)JI(@PVY*KJ>6=S_$2\AWJ%02,:DL^>+<9%C90NJ),%]>US4] !;I M>'=6E(XS_\3+>$3B(?*A7\F3ON,'O2U.-L_3)(:@WGG:S4,6[[JK2+S9JK>; MQP)IY)
(M1>N*N=2G!&0WRL!>[,TK3U,>YB*[H9YM>V$2>V4/?MQ3IF*-(H#D MHM:,_1-%>B?=#C'%Z,SF_AZPQL/3#(<8"9 H[2\+2A2,VX2F5[G.A,HOH0=C[S\O8 M;
[>G3O<%A\U^&X399/?H;=Y7DM$&$;U"%W.37@T0DEWKG,BN%7,E7G_J1R$A MF2/]VG,,[/\['3-[9@T"?X;T@ VA*2P]=$W>['"" Q 4#X)=@%VA L_#'IS
MS_TL$;N@4#S1J&$ROQ8&5"+:BES",:8@X]^\0AO[Z&.WQ9$^% &4]&3@ MYFEKT@H]L(@'BG#@BG/[#H=*Y]8\7][?2Q]21,F(Y[<#C[,9%^1AB%"4I[SF MB;QORM;Z<-
[+O9"V_YQ5<\28D,'XZ$+3.PW3O$M!]%65N:2*;E5E7E69%U=E M7DAR_IV'S'#U+[SO(Z5%&<\YQ$]T.OWVY_?K_KJ_[M=^\(-SWW PWWYF^ M)ZP21
*VWZL8OXG;/\";'1>;@8#99($U0FD!,N8>92M_O[W,N,Q8'$@7C3H# M:J,>11\QK5"4E5YF#DFSP0274Z_I&/9-WV&;;Z:8B$WIG2L_PU6RD+Y*39N]K6IL-IC]4^D4WS5_MC;N?
0+7N5$PVD:=)I^!A\B$/%?S?FV^@4/ZX?Z-]_7]D&N3SV$$DPNQ#]_N MP*0W=9<\LG1M!]G;ZQ/\"$>1F,F[PG:!\5)7NF_)\!0LN R'C?!W*]I>Z',T M2VW*]HSRVJ1N&U47I*%F?SAT M
V;-[XXM/ (;.O*Z:0,QC("%N$$&*Q$U")"QEOG Q$#'$SJ M6(]T[-%4,-EB?P/OR-),VMUG$.WV?4LRA!:G.(3E'X%O6I14CL, B'"IJH5W MK^>#E69408&^2G17888[@'4N;QG^4@]
[:>$@>4:D'4^1H]1&I\B*U"/L%RD M#XH,T"&*3/E],7]YYK@>3Y47W]"[T%,NC;1'<")G|C(')^ZYA\#EN52;!, MNMD6LQ4IWT*":!@BMD6,<= _W EN65;8GO<=2#-*1A^-9
MDOGUE&P>F)9 Z;"P1$S0|"7!#Q9'XUT$W/N0]B3K.(N!A>KA*(#E!DW6?# ML4UW#O5IY%&$A9K899#*6!;!G\[3=<0 @=LXL:+'D3-A1C5$!8A%$=D)2G) M"'P0>;P<>6_H7.ZHH
M!2_6E*?0@LE#\Q FH,JQW8V@RC-]/4%,49O\Z (] M.I%9Y(+$XM]G[O.GA1/0KQIWM;!)HLP>!AGF@"[]ZS\3CU>OF@O+.%\XC>-*
M]D6)98C\HENZ(,G(5%)^Z,71PKMI!L60PBBH&99@/I5B#W)C/CFE;*+]PB-(/0P5(' MH2#@^!VL! 2%#IYD@L9 \X'FYL48E*GO+OX(C2ALPD@\9]ANED\R A#::?3C?E=)3
QM!]8"7)]Z M!8&P==K.A.6R8 N!MI*K*P+;,::U"2]:R6/.%2<@,S'*S&/.%Q,KLKF\U'B> M RM:Q8DNUH;T2^!$*7G[<(BXR&$>N$"VY):Z0]*4#F'Y#F5FR2JAO*:?
7:BV7*"O.0ZJAUX[[R0D& BBP%L]HR8%P_VY!2][?9C^#M0 MTE#^+N"=B _G%]7\S<EUQ50Q61'T) M:$4/> NO^B_XE[_W+
<%C'KE2L2,][K]ZRUM[.S9'[LAI>TVM,:NO(\D^5EPR*S+?9P#K$UG MG]@<\M!C 1P% ,.UJC:.I2UFZ6$DA\O2U'< &B,[U&VX!NU]+ =V;+AF%DN3 MI!:E5 0-G(?5*&:'80O=
(O=HEC<33\+9*;?:[\XSCD7E^5@7SUILB7="F1N# MN]!Y9DP=%VQ!N'X-S!,9G%8?W;M7:(P]<*Z1C MD%;OP3_T0U/VV\MJTMW[P$RQ/R^(YZ^F+]O\W"6-#YXG%F9-
F:LRIQ:$U/ND M^_B]PM_[7NRHA'[2%2D:-T/?H82\5B(A[R.HE]Y?,^U_],GTO78/#'MSKE;;@3O:>_V,/3FH9%*A;\/V6_WYW3E=IA\UVK MS1V:PZ=ZRG6-BUY/C!:141W>7?
G>I[C2)XK/)3 IG+],"OTW@F0Q=G1]] M#Q@#_SGN7IKO.2D3ZK9R1O4Q=@C[QH"[E;NMH&3DD$Q8-H^,X##.H""%-D-FT!%[2D(-L+1)*3)RE/-X MA,OG43$7@,WW0|"+ M
RLUH>'3U76STY<%]V((O9A(+[(K:!Y[M&$7Y+LK!Z,+0,]P^<1Q?-'>)-H8 M9N*9V%V(PU/B*T>SE;L.;:"+Q*X39#FW^R&AO Z,RA>-4V Q$]/#R?("L_I1 M/B]0!*9A_SLPL,U,Q9\5&-
=*8MQ73$S_IC_7, >)I+H_=- D,/FGMY2;M))A M_\&> !4> M?F")03PXX_MDP,N[F\V(!AQ_GT)] MGBF+[] 9#))C4*"$O>QP:/'_MNZ>Z]9)30\P.OX3\"R3H>,Z5"]%5D!("C0(
5N'\H$;_W9@DUQVH)F'!$;) M& EZF5 6$C!/!8WBOT*$DMEDCN)5$=S]"7?B(4N)E:$\=(O^AA-+.R?2"Q: MG^B/]^V0B@'/,^
,G/8;F)YCV,0_')O.)2]6FWANR7AMM^*UQ\UKN1I70G[+ MJ2$ _=]L5PVGWP@(7/#"'Q)TI2[[96Y]JG2P!0,MJ9!K(/ &!1RQ> \ -[VN6 M2*NG+'7F^Y;P[
T0'^+H8D5N)^E<=%7N)TX%L71)2F"*OPPXA,OBN?F$,(^/ M:.OYB8QRPLN?Y#,$U$\-(9XMZ2C6B<(97B@]!:\?]BK[H>X(A?;1A1+&AB"ARB0@UL]2K:\[XJ)/ 8IHES7@*,
MQ/6YR%T1-SR-Y625A$9*M9@U_+?+?;;+DR"R^W%?)O0S@GY%256\<$)5P=L MJ%.%U:,N_$FZB#IA46?@LSD?U6_:$"THOD4)^$QW@=EY/HE-[9], MAI*F+J;%^XDB?
7^6Z&#A:I@3P=LV!SYEXY)>|P^/O0KSX3'1W_&%>#!AIT.: M2P@::A@@JU&O8)NF<81]NMD6LQ4IWT*"[T%,NC;1'<")G|C()^ZYA\#EN52;!, MNMD6LQ4IWT*":!@BMD6,<= _W:-N?/98K%V(C"?IEI@/(@*H?
J+UDN<,>9V#<,IQWEE6=1)WO$=*]I@#=BS.'^B0GT!%&,8^L\8T*T M3!'$\;L7"Z?&]UYH*7$(31R0H9AC$0V5%*U>PL,2C1HLKH-[HAQU$B2-4-.3 MBC\|:Q(@[W4\$-
,QDHL2(_RB*1,4\DR,6N!TC9?8'F]SL=B.80XON#Q.XS 3 M?<:YBK0G@+IUCFQ AF%.RB)%*?93#G_%]J_I>^OT,9:2<*UJ1IZVE$MM:BT M(5$^RJS/N6S?O]1==P8? HE]^G/+
MO%ISR\#T92M87)5'%H.I%C,2W4R'+,W/F;(T"4PD. Y) MQ<%^7]F9R98T^6=G[OK%Z-\8?!!SDOY&C _?2P+&#+X2*H4#GS0XFTR MH='6P/28L>YBCJQP@0R6N4$.!?A;
(7O?6Z>^<4 ;Z44^RFNSSKU*X:[5KC;-E, M%D*IM+VH*G-%C=">]])IUYK-1]W=7=;4>0E>/0.95_AJ,8C^>&A5T3Y[^_%";3]N8$ *C\C(M!]$%6@*CY >Q"?" MR+L(KM\[,
!_%/V_>:W,M/#&TY#N3 MD[B=FC]G2=K[>3U?$X=8YWN 3PDRR6Q3O%<_*N/)XZM5BA]CS05U.V8[5'@ !:. M?'"%U;Y7-=:E/35^WN!*T5, 9U!"[]/4NSFN]G]*#3EF1HEI
&S*UG!D35=?17)X7 M*8Q4S\ZBY\I092!!6BV-"2V?\ZU_LI3V5O:Z+0UV)O +V)3MP*[RLGD6IU6 M&=,JFLGEC7\5F1XUF78:^6@AAT.F[4ZCUCPOVPQ#9Q.KS6&VOZ M!-
BPCU-Y=(OG+S#M(S8@KM\/QXX%M/ZD6P&3U4A3QZ5EBE^3CX7;:0WX7ECE# M:[SB?WZY:+4:[V\#7^,N8_]@^?[--:FX3]GDPQ=U&/@;Z<"&+X[U0HJ.I/%[?^X_X3[&N5O7VKNS?
NO8\LY4]\=73+9EMOG(+2V5S< M=\B,N"*O#X<<29"U*D5O,,5?4^&P9-Q-,WU,8Q]P4*I&O)7\OVC_$U N^>@; MQ% 0<>%[NB$&K8RMYU7O!IL;;KT9W8=RY%*W+&9\G,G%B
OWBW6#IA(H\4BPG\!:[$=L>^L28(?H0+>$8H0&L6%*4Z4 M"N$E;:UW!-:_,$NKUFLU:NW&8O>6&,03T(;?D5RYDAGA[W*]G"; 9R:2 =9 MU8X6>7@3NKGJ$===G
XS\XA&C2CQUG2%C!O=Y3.&WG[Y6D ZFU)E4*U%/8L< M*\F!%IU!?*'7KC,1]\G\A^CLNIG/KMX]^=]5;B 0-FT<+ !!*63@2!F/ MS&8NS<%P01M'-
@.D,'5@#?/&$QVHQT!O63S/P2RNP&N@ZH.]!$_XY]B$;^.Z M/3TE;D*^'H R']AAEM";FNI1H+=:EA89:0Q)G*N=3Z;!)W0^00WNO")Y[LF M/#5F60A,06NA>?
X>%N%YC*L@\ZQ#O@|V] RF$-SO,C]PZ4E#WHP^?-4SK/=4 MZY? ![E+1R]4]X27M X6;]W\61^;!D#S74@5W9-LUYU+3Z'HLTW F]?KM+'^ M!+C"F!TEA7&FH;H"E6,R?
N&4#.8S=P+]!SV/R!]T#T0U"W!Y"1G! ""VE&; M(W/(V3S@,DX((!:/UGL*G#H7C9C%CL]:<<-%'R4G\!G3D/6K 9$QEB(VN&N MO+$36 ::LW)]W*9 ;;[1+%,?F!9QPF/SV92'Y+S,
((/E')>:RT=%3$< #L9(WTB;5*> XQN\GSN[&UD6Y* Q%^8 IP##>2 MPP15;U*P3K5+4G$\Z6])W4-(DC40$B%';#5N;*7^&&Y\Y(Z#P-8#P\15@KP$
M)N#QGR@;A!;O23V=L,B!M>H\$Y3V&|^7^8 GQ',9)6@| 4F"R>6?=|&Z]"(> M*M-5G1*+0]WSG*%)H)">FH0(7L2K9X1J3,\1O'>6]>Q3U:+S1C8 _=4R]
(!LI%Q]55N\KMC@^[JPK%OHN:<@>W/ETT> DQ3\3VZ4W)A@ $\ M;)VJQAP2.!+82":X#>H"BP("*QQ-(% 8R\1*PVDQXI7.NB-CUN/ JT,[D1#8
M$PVFHE!3U6BB'=%6NU@4:I\NBR9.LK+HIMJOU6B68X>=T\6V&4NH0SMDPEBA M&+55-+%,C|_5S+'$F"7VEG84S0M^#G)A;V%EX0YB MOR1^'HN'][MW8",^ZS-/9B>B_62S!
(#>;V/&LQQ; MF,4H,FU^:= ?57:.^,KDK?)H?O^D/AJ>&Y3'YS7<'XU|; "MQBF-[7T&4+1 M]JI#W!:5M) I)?'#T?@$Z!U?P"QO%) K>?!3!,X$8F&IK\E/&*^0]#FS3Y M<2YYF#2-
BP| F0#6?;6WTMK""FE]"A.%%)>IN[1I5SBD?P@9XN$L+^* Z> M[0>B?3*](:AE@BH3!5C$5;?RK:7*YQ MHY%CMG%G)DBL;GSBN>$_7ZJFG0+NIUQ544NJD39+0X*)
[4Q*,BQ^;6+17 M"!.B,,4!'1OD)Q-E;(D^'L!<[$3ZRA<;)0"(2-F%%RZ0B2SHCS|O Y(JI:Z)^X=#;+1;W?W^YO3E=D8=YQ'Z\+YDS
M6YJ=6DPKHNPE!V"/8/P4PCD94|!>GX37G;SA"0\K4FGZ<%(6ONUL_FWS<8IX M2*+&S8(G$>N:NS2#W=+LQ-1%'D/7(E2\E5BZ\DD"B^<>&$?BFLB '+ AL&]-
MC49<)82'K'QZ##JG,>@\9%B88D48#L0 D1?JWH_D5YRO4[^)X!$[_G3"PG<> M)V1^MK&;4^%N)^H\!5"NWALU1@-1UEQR\+\FCSPZ<=A)?\)U>US$'>..XOQ.
M73OI_X\^F;Z_VP3*B/?1=%ETC>L&!ZR,#'(RRD@72?!P5-+!OGD4A^2/*9,2 MY&\(@=4QJO-N^XRU6D]FRL?<&"+D(9SH$QTL[V"BV11D)TQ1A[UY@](=^,9 MHI34B"#E 6Z?
GQC%K&P;YX.F R:ART!8>-IK4$"'@8=R8Q2XM,,! M UB^@8=F=33YII4!^^*C%-M-[I&FE5KFQ*1D?KB<([JXUD<1$9C@@9)8 G2T MS,1FL^)1S* EI!C|"@[(C!M"2$AM&91?B+
|"7*,4 @I]V2QU'N8*+;E2[IT M0$3>BU3'-"NIVZ*EO9[(S-&'M4'>=K :W!-]%D-C%:IL07+PL+1 MO _!WX$S_249^=A[0>(,*U _C'F,W91,@E*,F4#*4N@^>KL>*23T<;:@
MBO<1**TEIQI8GJU'O:SNECFFRDL<5W,H"7N$T,JE2@'GS$7)0%2@RGFWB^B M4B:"C&$1I56$3 ECV"%CTIPL DVRE|B44'IBN'+&=+>F87#>BH+]\'2P%L.(
MZ1KL*BX3!I*R4BC@7,49;6(K2&Y.-GE7R%R(X390918.5A/"()T0[L2I7SON M%W'F7 !X\'+=NF4N+DI_1,N7YZ;,3P,/Z:?>RDQ *"<7R.85![C0?7T\V!4 M2*O28F7>C-
"X8LD *Y* 8E'4)'Z1G 5]G-%3<(>VH;L"XZ@B'5TZ,JX7KL("-I(B:!$V"L4J1?(M)<0ESI1)3X1>SIBQW+$%;0U>:)\-TN)F,OIDO*LR1>S|%OJ4?\ M. WOK-C#LX8/-
C2R3LPPE5"6C/.9BY/O4'W;6Z.NUKFR49 M_1-X^,\.6,/,3@24VYA'JTB\7SCL6 9M29A][23/KIUQ:7TA# _MZ%O[V-G?'M6*SZ8>_>"MP0?+K\KKH*P/S?0F_*2K+9TU]XWO51I'I+,-
+,9I;W/-[6Q) MVPR>S),"K9'I>KYLBR'+X8@=S,-KP!X!(U;8.3=#W\$SY%9 LQ9YYE;PZM@Z MP@HF@VK%AI2":*QZ\S=|)E-46P*W=I9:NX::E%5QS("+V?2%DHU(;)V=U\[. M%YL
1OYJV; M:T'NGC R%26&X^Y<"ZUEAB0;G=*-\$"D"?=M"BY(>Y3B/>\R+O)[D[4T[W2 M\U5V9IC+UYZW\,\,OSI UW.;6%F|=]=LXKZT2(Q\]C#OO0>8,10<(EX;/* M?
E!8^2;]O!2>"]N,5^*1&F>RQH02[Z"2O%1\444Q7@R^K.B)<-Y;,IN\56_U MC@4ZG>70R>92.S[YE]$!S0H^C@%MGVW01[7IEVH'UW[!H LG,F$0*F7;K M69.9PELA[RGQ7V-
6'))PB%8/G0DWG7/;95T5AKX%(!LDK)*O"Q!VV2R^50G6_M+/F-_<2?8Z6$$:A5:7"UM0*9XA8RM%;X]N8DC^F)2"3O,4]E>:&=CEG 8*RS MB2>_2W2PV;P \C4]CONCO#?
O2G)VBMSY(3)R[X=C9@06NQF%EA&?3;5$[@#< M>;WVS>@.T.311H'!#2S*WE7GZC:5N;H;).N*|/"1:5/2]$F2=F4+W[-7$FZB M@2]^(--IP_S>/"H;YOI?
DQD,96^SO318AWB9U<]#B)90VS\WI^V%$YUI5^ M\:4 "S25J:YG53%&'HM*(EO4)JQ=_X&?&#E:E9S!0F Q:ZBR[EIVEV*6,T77WTL<09E8P\O>W>S='-N+SKGV1)OOU ;E[/]5?
AMJ00FT2$OFU\ MBM#@BKN_L_2#%6Y09JB|I.))81RMG;U+31N#C)W.8D^QEXR?A2 ,@H A$E9FN M2+X]4 +IG'PX;Y5V;/3+7,!!D4?&HH0#)0^0'^U;NZ5]!OAR\;/P!1P2@9PM
MZ5+8/]YT<:[*63"E9- ,MIOQ84&BK/?[IEEP8MKX2 $&KMB3$P;QPA0B]^7 M:,KE,O^]2-T\092V9BJ%>F:=]Z(8%@!!>1:DOB5)7]P$HJKYUX*ZE:T>K!TZIJE,>:AGS9 M:;59:YQ=*
,MECYLN\\0_5P39R=L2)92M;)ORS\\WK8J\6*'[U^98P$+T@PG MP,J*.80KS VYQ9I3.=R2F3R9AA7M1^NO-=O%Z/U;@'SO(DH$1+04G>+X41[
MDO7MBXJ6*EH]QYI3:6E)CE*F67'[H:5&[>*B&,6Y(J:*F-8BIB7Y3)EFRNTI MX:)Q44S"7DZTE#(W2#$DJAPE\/&N8XEES"T@:Z6;%LY#+T6A?^'M>+7-6X3&
MVB&%DW?)T#3G5YF&,'<-6]/6Z4 ZR5;@%BX;IJJU7MP1C'%.-3,25 M!\FT3^/#)M9L[5@JQE5-]Q2'W,Q5TSVKZ9Y[FNY9HAF?X03G:-CGDJY K>,9 MX/DETP1/!(U&L$%\N#9MD#Z
;=H7VP, 3#AR',0PSS5?O!T!B:9>,)T(I#$- ML,$&>-C2,C;$?<)TQ#7>RRL<):AK(Q?0$Y2(O^@&^A4^)S|_'71B%UO7T=29 M*&TU[+/I&G-7QU]TJEU'7Y@XLF9$\VIT3\R],8=,=-'-U LO
/G8X"L=\XDJ(MAUP0NX-Z'O-Q&,Y4-_GL>5>WO1&CZ3BF/C M[*IGXJPZC>@"%&>Z1.AW ^8_M8U=A.):_X$%3'<."YI3/K??Y]+QHU=1VNJ9QK<>QE7. 8.4V/L&"]]7HS0-0

MPH:$N'KT;0UT'L_7=.-)I^%&3N#)1<@ACCC5P!P!+PDW&>YH11>^G6-6:=!; M6DF!1RB;R9*K^R9+$, 8?L>D^QF-Z$-)"RL5!^!)[*"'CB@;N$0T@#,F3C?%P0;TK$T>!_*EOO!(0#'>E=W3O !P[3]! MU"P7;A>"_8[&O.-DM,N0@N-V)SP@P/EH QPB1(+%M*F[Y<7+BSJO#N!{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|'I7X??MMI7K;]_6;GO-[K?;R^_'C7Z*?ER$8(KK[_OR>?MKJY:U_U>]|Z\/+NN=SJ7';BWUZM?7WQJ7/6[9V?]3FO7TQB:C?EQ#/2)4#8O M|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|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|<_1WU<+D9"39SXQ*3D9GV M,XD1?8X084[^YOSXK-)(*IQ6X_29 J?;$4X+&5Q*G.Z5$]=7%,]%U3GD+!_2 MZCW1DZ2>7"BH4]00L9]#*S"8+,4QS"=9N'+[^?KA+C4A7L*\T7@E:WD23QB/ MZ[]S"XU_QT6^&BWG[__^+8ZI7YINE&8FO3MXJC^;W3^]C05S-YV >;BZ_FO9?X5L,TYM:^@RA:)DVMJP^PO"O)W^CE\0/0M;&+?.07WQF>)++#_60 #S!G?1!3FIXQ7S\\88GORXUSD M!E6281GB)?)%&YM-Z6MA!5%Z@H;B1)6DNH4K\U=",U:S1O6BO/3.]#2=]E'M M(7!P*NA##DT5GT-GH]IHC6I$3)Z)4,%[FK4V,ZQVI4KP-(KEQ9@@FD0AIS, M&#SQU5,MN?:,M&'!3N"![>:]65FV^>L M/9HX374]9C>U'I.SLK 4\YA*,\O><^]BSQ5>22OUHV[I][*)FU%8=?+ME2[M)=/[4YR.Z:TP5,TT_FGZXP5>XB69B9=D/:'>GU3RUVB(=7;RH=FM@;927BV_MS--&EDQ#V_U(LERQNT2LF\0D0[9]=^XLPT"Z5>.-^-VP&O6NFD\,&7J=RMJ=X&_K2$SV%3;K6$65T&DP!3+Y_8U6C$AG[?0!49'[I92S_-@W.!G\"VK#5[MQ;3VR^$0WQQ*=^)<9G'O@TDFM2E5YX6],TDX?/S;7@3'_MN_[6F6>F':W)[WMF<:#NRG)H@>B*;9!4VS7>HUB$M'W?);Y^9KSL*8X-F)Z@[:\W[?$ET77-750I M7B/;M!EW'$W@F[&G,1O[K96@VUC87RS[@\D;-Y:MY$#$]N94[Y1&;E,72,B% M,]!HEO7^X,[X(]??C;ZZZT8=W*K%# MA;'HR)<;_V MXU@S?6VL&YKI>=B5,1KN6=,<6 HR0V ER=OA(Y\(" 5E &"8 0_T3=]BG);' MC@58[N&JIC]J[^84B)8_HG@F"JFD#-M3%YKWH?EQ[%K Y S@KG9*<_M%]ZH$S!X2\NUP8I]8DTXV7"E802#GSN^;\ 0$9PAO7__&?&[$46%ZT*(Q,1 ME+6!CLTT@ZE#C_8+KP.L]# B.1Z(X'194.&GQBFY[OF(*!\"W@L,/78)W*5MIRN(9"%,\3XB#**+!%D(JA#X7'):_ 'RU^4K A"!64]:GXY/^\:'\DZ6=0 M1HF:3!N.D]7PJ$!P1)\LIS_?@EZ!)R8<;27[4Z39Q9[%Q(HG8^H0N45U0= MX!WT_F_A;4Z47:@9@2M?Q#=RJOU8]L*Y57K!@"@:[R=!'KN4GN>XI/_CZT$# M!Y*79!"2!W&&I;C^[06,$C8%Q *4G-"(,GP:N%Z"F 9]Q@I \0Y(#N\8#C6]-#Q@]L(EP3PGN@&DV>40#0]8MRZE^"BC&H5]HGTYK'DFQ8'N1%A(B)46_@[8AA:@6>0%V,Q)MPU 9N$!&- MD8N.[A7" "OL^GH8?P$S5%=7,B,Q)D^MCU$HZM:0_*/(I@2>"1Q[C?CW)DUE 5'^/#;'I*|@:@'VD8O(:Z#.]KX(7M M1AL3WZ'YX M-_P*7#.LQ%AD+.+0YPEX<6LO2YWI>W UL;R!\\2X3K(#4P,M\[_7-3%QELF/ MC#@1*2?J$@@C9 M_7.:B52.C"*3Z6UQ$SFB1<3T))#1=GS2+50"\6#@ZICFRW/V8@ZS4#AR!7L[MO2=F3H,"+?0"E)IQ3-O+$((,T,TlQ^T>Q)H16.QFU(?]RNU&,VZO!/"O ?:7MI+\2V&|&V1Q\% O-<#N;3W [B_+;>[48/5"Z|)6=|WW/-/HZ[#?+7<'^-*U M?4\1_BE?/8PQ7) (R23"+CPPPO_9=1?Y[?)S*C0]8C3];MJ'C*5A$D\E#C:EMLY(/!#DD.HLBZ:4DE@K5C@K5VA6J5:A6<;4*U8X*UW7\+N+30]2K1OR.<@[W=LOH3H.R-^V%=U'H7Y[5> M;["8&DQL%I&6E05576CFBP7='@4AH\K[6ZK5]C74QGNL,D@<(74$(:[#56 M5G9V*QI,Y,#1+*",--AK\A3+&U_H>E.]2%-Z1UTG]L?]-MY M*EMXPC+;'+ V"/9[7.1;MVUBY:1=D1AE?\X"7Q M@W;O[H)#YP>=6NNL5>OTBNG55?D'KT/E!IWC7Q;'S@TH_]/C!T?"#E0WR M*_W@1>D'I<]I**Y)\(/CZU:\%G"W95+[=NK$VW/M54ALU!UL_YQX9<+59BWJM>MU,'IM2<\!FI]8Y;X)*5)*A)7FA5$5E1T-EYYG\(.6F,] PH+2S5DDFZU54 M5E'9')4M21"<\RZ4F\HJ65916>%GF4IE2U(FY4LVS.5E6<,=2?)FN#X17-A;!DGW?S@95(*WJMQ*8MX,#87Q1XS:T\=VS%&[;_RX(7$[&R;QNB"R&U15$W8>E535BJ MJONJNT4A18-5$Y8*30\;3:LF+"]=%0UY%6[@G&K5#A#5RMRNH$*UHT*UBJM5 MJ%9QM?(G+$E'3*=3Y(1S...2YVJRQMJO]OYH>^:<1S^\^'HY"L6QZ0=SC8. M ?G5,93B^=4QE.+YBF,H?=7VX4.]>G[U .KYU?.KYV__-(;CH4:B[^%:5A; MS,59:A+N(%-KGUF%"\Z<+7;]YV?MRI@!NJJ+T_G]N4Z^NM!0**F%7!H?W5Y!4TEXBFT>K4|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|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|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|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|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|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|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

M[74OY&&+BH@>.&==4=@]K:]#^Z0"_6@C;.I>)+,MW&PM.M/6Z PO5SWI+]B+ M6Y]Z\ET.E],CNW/:N'@WK9H\=HIX,WI|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|C M,L'I$*_MH4]48G[+C=6O%<5RTBVYE0\,QUU157_91^]Q11>YM5$-MWW2P&T_M# [CMFN&3Q\V'K+>*>D$0>!YESC]VNLL[T*YOZ?=W@*_/#URU33.^X<6*0>6[M/lP%N!G%0E@?X?-18KV#*^KI7@C*(=ULEMHL;%VHU.2=]V>FQ5F-/M05/Y.+J;V6PFBSPRV)DYG/6GC7EUUW9319[UJL M>?]\%9_0[3.7%_:++V>VO:[Z0/[[T<][[;OT++G@"PJ$*QW_Z'"3_6 NM/(M090\QUK!)5,]/G_87<@@JGOX/IS@^B32"TI)^0#'>[\2&PMS#N"OG=?=(ML M>XIM]C9//5M J,HQP3MS]CVF6IU-7TS-U2V0'T]3^_@ :?V*,,!]TXN@N=Z\4 MOL/0D"7YZZ$,?Q3^'YBZ|+WZ[O6 MFZMWO=];O?A;/3R:!,\5=Q 2E5A]CB$4.1L; M!^!8HQBYPM_2R-TI$/:=W P?&(>/F@R?,OZB_*%6>HH?/TP @L*;T< Z1RX7 M(KJYLQ)5T"4NW"'S4JG[-O.;S06>K1:(%/ZCHSUX_NMS;N#-"8"P'Q3REYWH M8?VY=^W%),U\7IR@HM.+NEUV0]JGU*%T8D0BL7=SQ'?72.WN4CDS4 M#, ,?\1[. &EKU)BH/PI_E#GZRX\E;GU8H]R%)4C@I(CWX>7 L7C@=3U\^=M(!#>F37M)O1T!2IZ7-(RI\0B0D4%)O=]V[U|\ O_)ZV!L MW9@%'\;+!'W053V?4\(GL<\]GW -Q258N^:;WE9NA(;4SAV-V#W'1%2.GZ"[D?HR[;$1 ;N*U,UMVM*%@=\$W4%KFG7 MW[/VVUN9]\;9*B*3!R??XX06T $)0EIJ_,;,TGM9^&FX8"[/LR%C45P9-9% M@(<06END?HD*C0M4]LV?UQIVT;N/NR*G):OEFZ^DE2_)0X+1S*.XL)LNN$* M\ .43Z&94?+]Y+B]7ZSU8):B&|(_;#= =]D<2L-!TW)*V*T:L%KA+2FY92& MQD 73WI=<_9,O8*/"U]4/5UX94\2]S_.U7IXC?]5V#C90"^":M\B,D+[/ M(?F=;]'5F@%!"ZF_X2?:T%&O:LNH3)RDN&VM?-N*:[L\M[E:2M51XZ<9>27P M,B]<8:;ML3\,,@R:5$LR6E80#,]>[2=&A0Z]$/!\S<+5(M2^\BF5>.3@GI!R,.WJ:_GTY \2KIFYRB!$LN_KJNY";8PTQGHT_1G1F&06M&X"FP MVX$-D*0:.*XR_("L+J((1KK]P\=W\QU5CR]"3VE="*#C67]R4%*GW?\W-J#:;[G$3R3Q:1$4@YX^\8SKN MI?RMZ+:5+GY!!G#)02Y3F?L1!>W)%S5+>NI7A12$.0>'C5!182<*$]0,IB&J MTC-!)<2<$U%106P_LE^L9#1P^#-]5*5?"#D@B7B<- G#MR]$&E0G?3R*)R?#=.CB)>4&].L);"&909P4(?NLC<@Q0%NF.^E-C5#9#"., M@%KJ$ 4L1>YHT<\M53@E8KC9X%PY"#=\DDQ!U]3+@28??CTP!&Q)-^0O-TF\QCZE-$= M"S:^.(&%-7?8,- P\U0BY$ %H-(*B@^\+3A#Z0DQ!K1<1H>!R4-61C2^'E9 M^F.&IZ;]':3S#QUR$=ICDFZ&3"ZDY@ @4B3L C-X_]!E+9 M)).25"1IT_5E"<*^&$:KP9Z$0,GL7BF'[*]>S9O9'6^[0QA"Z6/MD[,WX+T][2,37M@"'B+<]B&U8,WRZ]I[!Y&+[S55PA MF\CT(7ZS4FTTTGD" TX&LF(8.(;98@>S8?=D*1U57(]$HPQASB8WB &F5M%U M,$U$K527:0UC7?EB\L:I-+)C3EVB M'%&2,5:5BY0GPW3BB, \(3Y"YL8R1%;) MCSQ=*1!\+SB;'X\292GF'O0E] A-)!5)9%BZ[[@_00EX S^K8T42G[-K (M=%KR+43#E+GJ0SP9C[GH]"#'B'H[4%:EAU%ROY^IWL5Y8-G)B_(396>A]DMM M?F46$JZ\+)Z(_)%@01%= _2(9!S;>.2O,V5P%JH#X3=2FWDW$B%%RCCZAD>5 MIE1W?ZN/ZLZ0ST!]KJ]Y#YPIHFT"IR0OF!/H5%Z73,](Y,T<]5PZ=6A[).N8 MQZ:62>D-&7N%\IPWOU?77M1HT6"6"7]/)=:">I_UU&&I*]#N27W0@(V66'UG MA=6*& [|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|/E^;/ARCKC\YF\3\.6MY4M/S.M]ES[M*I\,F1767ZJF>4Q]ENMTKF6=SF-R9BP >C:L^0E2V+(W4D& EG6)A:C6P7-Y M_.DZ*F?K12FP16-?P,J^C44ZF@9H4L_VA,YX<'K7'A^A' :OON(+.LWT%;C M)!ICOOONQ6 /AGFI@.-S>9\9UM5]+F_VCI%U9'Q<9U"O5\.4[/,FUC. $#7S MN3+/3TX,IR(FR?3)K+\61_OT7%YGAJ%U?GRF+"W$"$V2 BURVULCXKVN!6$+ M&5V:4F!VE+\]3U@^:[5Q:=AH/C-5Y,.1>2O1'"!87I$^HE*+^T:* MK2S4F*XA6F;M]M[^]GRB91]#\9F\C^F79=SE=:]77"Z?#$"US*XY5 M.]]U|VI>S_9=4/KF(I]0)G.=2FHJ-,(".=>?4.JO 72"F9.DCEC4O\@ D_ 3M,8N%4XP%*+\VD-RYKY^]\Z"$S+RWH15FA \">E !A=TVX-EE8NL8,ZP1]D5! MKE/^+)?Z&%CBV#-6UDG1&DP()QY3 DV]/A#Z_#]JF&H0Z492_[D!BZ]R0BQ& MB%]6Y_(R]@F=B$W8V7@-X+!4:)59F SIG."%?H$U7*K@&"I])'@Q!R"(9;H M|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

{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|&-F%K>:A&G/M*;T]#I&HY)%;$2=!(Q1$I0/ M1-_L,R7^AOGF;FI$?NF%$ZXV- +7QLM3<%@*07,:.E/= =1 J,)6)7I(7U4HQ MRM/"%0\T>6P?ZT[0-]>"M;>_8B-W@ID\!+*HIQTD%F<.HAL5/G8E NBO? M0T3QK*W0LN-*5X6W$(<E)>T=F|$*E"-7.L$BS^.A:*%.M)BK:AK)===NB<%]?`M$7<.F.R!:K6HFMOEBCL'5]3|JO/C7RF"+56? %-5NI667HRDR/JA#*F:38:/3 MACID8BI$\C*:K8"]3.9=?G1>SDT.,&B4\JO34+'0'->3Y3^R>*X'JF#L>9X' MN11\"1U28/C=Y"[\"T-6USI&TKF$YPMK=>7>-*

_KHT2G%U+B'UX;.@RU[+RZ5_M>O\';-254XOH9$"RF=2D<'Q:(+7EQ?:NW*:614*\,WM<&X>&^"_H_]>^Q>VKB:F[\]E MP]#"RO%*2K4KCR[MWS>C[$9]'GY(@J8F_0D$#L;^VP58I1Z"%I.8'9U+ CUGTC;EC;D[G^_W4_ M :G;ZK,W%V_W[E7?PK1]#X+'^I>MM6K,8A[%/_3"=FI<(4FD^AU^>$B']BK5 M;87+W'W09=Q@8"P]\^77<>=UM *S*[_$V^^2O;)ECKY& M3]F<8[TTS*%A=D_Y9C3,81YS^)B74EC & *K5B68V5ALX#GBN+G2'C& M.F<\+_127|4AA)@*[33%SS3 GYL9C&!&5 M#/0 RX)/6>"FBD<107-*;A,.$M+#VUMGWUCR+I*2UPG1E0U!9H)A5.V42*\[M9V)+[RZYL+#:A>)T"C/J^EK=(8HLX&=',OD$NY_LW<++Y7-#;,I"NOBA>SR M.&9HOQ#9YU'09585^FD\ HT8?]{RK|'C<|4X5LMP(GY#P63$D.I[T]+:"!G ME@S"<.S_R$+&0O[&SQ^,QM^-[&YD]W;(IEZ]@GE(I"3XVX;<3M M4Y8UC;A=1=P6I>U9^Y!# <|@>3MNG)-k.]+&=68@X0@V.@-I%4OH'+<{ M.4_H=-L'+5-HF,+3OQ$-4UC(%,A,],('W:/VF<$/3MK=AA\T_.#\7X,&\!10 M$MZ\OI.?TU6\X0!- !I4;NM^E*S3^N,8?]_#^N!N=[Y]D+N)!#S+TJ<%_#_Q M]0>/")S*Q^5"5RYIP8C45S$M%+,H[UI5DKTNZY:9M*HD4Q6D|+[7>8&!>L"H M.*#<.(;DPU15>$;5KA,85#&1/R\GV-[KMFEH-RR@"L1"C;T;T5>=-(!U-K=LH MR,)48#5V7G^2=S(OEBPI8C Q&4.%1=C&5IJ.K.:*G:&*C!9KRY@P%:4@)&|<~M#6-GC&IJH0:8*%<:.6B&). Y_T_I.,;2G.MW3U09#)YU/[H5A ,14\MD! ?-M"2&TVM4D;167\6V.K>Z\K FC0D4#YQQN^.;'GD&%5ZIO$Y41(9I0AA?? MI]X0$0+CC?U4EXY]>MO3A&.)(8(]D*F(S5T,617!!=]BF9A5"6.51G=. M[.&@/ NAYG+= (-8HVI1])V)$@/3_,GJYO!""R=L!?2'!"0M4;<2<.KC1#5NUK MG"7\KO<_US>]fW]?6Q]\(/"R@GMXP%I2#8>U2:>" PQ\RH5_>15F MP$]2(M(YG(#$L8M%%H).\H(+L98$*S$F%1$_#)AHV\9ALXG,U]GE)IWTC] N)E8P)Q0S[0,E+F'>8LLS&S :(.H^@ MD-3E#9H'ICX7&/.?.;B\' (OK7&? %"B\|.:.4KL^&O@)&D+EPM|E80SE1A'NFN5G'>N5XB6FI(R>Y2==]KUZOW>3F>]7YH/=KH&D4M2DK)2148="\]*

M"11/HO$1*EXG%ZY:J]=SD5U.Z)>,O9.+40(O2V7O5O)@NWI*K5_0PW2+2&NZ M<]MN[^UO;ZF%GU"%,)0H>XG_S9H*)Y8=-0-T9^NM)A!=()3Y#B_WTEA2>M[;UA>:,NDS(N_X MDKOM04^A3M[89!A^'$\6!=X>@5P7@[.Q H:60)@-8$>S6&(6F.$78W9"P@L9 M#E42 AH9NBE)HN@&=Y"Z![&GPLM;9N(A<9_BJ?2NG'^ZEIY&/\'L#>]Y\5|9 M0(U6|NGI2$)JO.(1XV(B0#DZ0W240VY>[&=C&SL(M;&?!_US9|_<0<>D><4? M(M-4@^CMS*TN/FO6K.0#^9R?0%B*IEP9[X\'IU^NSZ%M4Y6?-K;MD=FU[AR;&,(U'#N2V@7U _63D1D0R.VK.BK#"XZBA*)_2<%_)!NF\2P%-I;DG05I$.5:0*=7'"/@XCAO MYLQEP[CK4>AWYQ7!?<;%PD-$90OB?@^QU"D?@GGfG%%0.C]2 YY_Y8Q3T.Q MC*B\%PV9/K&KJBC,) .. [' T@46(N+:.G4QABJON1[H.4RSI&*$"U9;T+3-.M1YL-)#M_)#-W"<9;*Y-M8*> ^C1V?X[? M1AU)O?/H(?_1,4H"[,>[BL)<1S,^BG@H8E->]US!T35YG*.&8EWWK-T=_F)G MKQ1M-Y)9\9.Q-)N\(G=BI;(BMNO|8 A|P,HP<6#9TMX+O MR|C$BGEU!VCB"#//)SZ=?9!SZ=?9!SUZ'`M\U1K]HSX"S3V&4:|GM TE\PEZ^B#W4U2|P_CA1*0B0V+##&HKL*TD;M?KO>1 M#Q_.095',(H@F+:BMNO#&&7S/QS)4"/]UA@3;@-^M,-)FM0TF=G1SK^ >5A]F,"6$FQ.Q-NN=*_\AA2S$/A7%=%%OZ".2<,'4,9:6F$= M^]F^E64-2-*

*]&!9:VMU+PZNF6DMH2[VK]!9$5=)6C#GW&1%Y*V2A80;@C_ZMX M?,[7]U9:W7)/VB_^PT/]PGD>Y2]FZ8#/R3 \4Z13%4 1#-3!D2?2) ZZ?X/RV[,#" 94;X/ M-!-2-.7;.IGC[BI#(#E^7-U]!/5AG1K1^E:32N@H5;1X=?]O7[&W=Z79!SZ=?9!SZ"'M\U1K]HSX"S3V&4:|GM TE\PEZ^B#W4U2|P_CA1*0B0V+##&HKL*TD;M?KO>1 M#Q_.095';(H@F+:BMNO#&&7S/QS)4"/]UA@3;@-^M,-)FM0TF=G1SK^ >5A]F,"6$FQ.Q-NN=*_\AA2S$/A7%=%%OZ".2<,'4,9:6F$= M^]F^E64-2-*

*]&!9:VMU+PZNF6DMH2[VK]!9$5=)6C#GW&1%Y*V2A80;@C_ZMX M?,[7]U9:W7)/VB_^PT/]PGD>Y2]FZ8#/R3 \4Z13%4 1#-3!D2?2) ZZ?X/RV[,#" 94;X/ M-!-2-.7;.IGC[BI#(#E^7-U]!/5AG1K1^E:32N@H5;1X=?]O7[&W=Z79!SZ=?9!SZ"'M\U1K]HSX"S3V&4:|GM TE\PEZ^B#W4U2|P_CA1*0B0V+##&HKL*TD;M?KO>1 M#Q_.095',

*M9>2FCW)6$%9>L.ZP]DSWD=B3C^*;9$!)?N<5]+!E/QL'5Z$"DGM'QY_/]^OM M>LW;A16#E0_W-I,08(L;GX4;/]CBQK>X\2UN_!%;H5A0PW.^*FA'^Y7V0S%@-M Q.3P@(]1-C$8W!(M]C[R3LII2=:2FT*0_Z M_]9@W;K8$^^R/&"'-S/]U?]!YW*8=W/!_4,SL!^9ZDO3+6?E_=)%]X O2KG M*EK3O#H%<(3%KRT9*O?=6[5.L[7G_G;M:.8"-BN718:,8[\\X!<>[90'HM^M,\+^4>_M.*:LJ8K\-ZN-JI4G("MQ'0:#\76/\P.]"=.UZ&@(%9/;IN)4R]\==<("W1WP>F.,>-L%"=)!&FKHB=%>@"IZGFYZO8O=*I MURJ-VL&N,T["0M?+2X6>/EN(|),\?D,2QD-"]X_S2N+U*EEH(M)*1^9--Q+B%;3/O!)Z4$,G+ 'CH88<>2A%.[2.(]$RZ{%X;^0*$Q(3$ MUE*&8DQ)"KI.5#^=>O!M:U*388#S.FF]V+MLU_8[';693|P>I#G MH|_9&:VVNN#KH>M!FH$\!..NM^93GW@]&M$B4F/:>(V=G*8:2SE%%#:-XDH'& M;S&GR/XHBN1UIQ_625/GWCI)/+C_OK\3E6'&*!:=\[M0:?D]!3Y <^]%0__=I9@M6P,^O R$>!!B#CO{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{SI<=AY55DKTRH[.0--@X/+HD1PG;0P13(DN(Y MU2 G532L@$2&238-1XIMR/|+]*["-V-1'/D[-@2;#]W-CE<7B*/'0YA/#0]BJ$3R3DS*5Z8=$%.A>35I&VG M)$J80I%X=2"]OKB;AA8P9.'E,G!0 ,%D,+8KQ1$C9^%{(@VLM>[2 M>Z\$5#V7>F_ML!O> ^"LH_)-4=;^/>E?49R3V&!!!)'7(NC=,4>PZ4R@"$,D M3X]K[V<64$UINZ9B,1F"X39*#,8:LQD!"\A48A{&)),7-GI**37/, WE4VEDJ^3M,"A "B:Y=U.6A6-%9QC@[?-GAOQ)<0@'IK0+D5SN.;*)ED"#U0 M97GVB<@:1;2DZ>].D]33$[NMMTD3W5H\|+N 'LZ#5N8EI4YH]7^%?C#LW&&3S M=77C6W?C/?N?6]#=0M#=X19TMP7=;4%W2S-,';.9/\&PXI{]@%?1BW766CS]`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

0001434647 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001434647 us-gaap:TreasuryStockCommonMember 2024-06-30 0001434647 us-gaap:RetainedEarningsMember 2024-06-30 0001434647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001434647 2024-06-30 0001434647 us-gaap:CommonStockMember 2024-07-012024-09-30 0001434647 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001434647 us-gaap:TreasuryStockCommonMember 2024-07-012024-09-30 0001434647 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001434647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001434647 us-gaap:CommonStockMember 2024-09-30 0001434647 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001434647 us-gaap:TreasuryStockCommonMember 2024-09-30 0001434647 us-gaap:RetainedEarningsMember 2024-09-30 0001434647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001434647 srt:ScenarioPreviouslyReportedMemberus-gaap:CommonStockMember 2022-12-31 0001434647 srt:ScenarioPreviouslyReportedMemberus-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001434647 srt:ScenarioPreviouslyReportedMemberus-gaap:TreasuryStockCommonMember 2022-12-31 0001434647 srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember 2022-12-31 0001434647 srt:ScenarioPreviouslyReportedMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001434647 srt:ScenarioPreviouslyReportedMember 2022-12-31 0001434647 us-gaap:CommonStockMember 2023-01-012023-03-31 0001434647 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001434647 us-gaap:TreasuryStockCommonMember 2023-01-012023-03-31 0001434647 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001434647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0001434647 2023-01-012023-03-31 0001434647 us-gaap:CommonStockMember 2023-03-31 0001434647 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001434647 us-gaap:TreasuryStockCommonMember 2023-03-31 0001434647 us-gaap:RetainedEarningsMember 2023-03-31 0001434647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001434647 2023-03-31 0001434647 us-gaap:CommonStockMember 2023-04-012023-06-30 0001434647 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001434647 us-gaap:TreasuryStockCommonMember 2023-04-012023-06-30 0001434647 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001434647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0001434647 2023-04-012023-06-30 0001434647 us-gaap:CommonStockMember 2023-06-30 0001434647 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001434647 us-gaap:TreasuryStockCommonMember 2023-06-30 0001434647 us-gaap:RetainedEarningsMember 2023-06-30 0001434647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001434647 2023-06-30 0001434647 us-gaap:CommonStockMember 2023-07-012023-09-30 0001434647 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001434647 us-gaap:TreasuryStockCommonMember 2023-07-012023-09-30 0001434647 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001434647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001434647 us-gaap:CommonStockMember 2023-09-30 0001434647 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001434647 us-gaap:TreasuryStockCommonMember 2023-09-30 0001434647 us-gaap:RetainedEarningsMember 2023-09-30 0001434647 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001434647 2023-09-30 0001434647 2022-12-31 0001434647 us-gaap:BridgeLoanMember 2023-08-30 0001434647 2024-02-05 0001434647 2024-06-04 0001434647 zvra:AtmAgreementSalesMember 2024-06-04 0001434647 zvra:UnderwritingAgreementMember 2024-08-082024-08-08 0001434647 zvra:UnderwritingAgreementMember 2024-08-08 0001434647 srt:MaximumMemberus-gaap:OverAllotmentOptionMember 2024-08-082024-08-08 0001434647 zvra:UnderwritingAgreementAndOverallotmentOptionMember 2024-08-082024-08-12 0001434647 zvra:JmpMemberzvra:AtmAgreementSalesMember 2024-07-12 0001434647 zvra:JmpMemberzvra:AtmAgreementSalesMember 2024-01-012024-09-30 0001434647 zvra:JMPAndRBCCMMemberzvra:AtmAgreementSalesMember 2021-07-02 0001434647 zvra:JMPAndRBCCMMemberzvra:AtmAgreementSalesMember 2024-07-112024-07-11 0001434647 2021-12-20 0001434647 zvra:ShareRepurchaseProgramMember 2023-12-31 0001434647 2023-01-012023-12-31 0001434647 zvra:PrelaunchInventoryThatQualifiedForCapitalizationMember 2023-12-31 0001434647 zvra:PrelaunchInventoryThatQualifiedForCapitalizationMember 2024-09-30 0001434647 zvra:NotesPayableExcludingSecuredPromissoryNoteMember 2024-09-30 0001434647 zvra:NotesPayableExcludingSecuredPromissoryNoteMember 2023-12-31 0001434647 zvra:NantahalaNoteMember 2024-09-30 0001434647 zvra:NantahalaNoteMember 2023-12-31 0001434647 zvra:NantahalaNoteMember 2023-08-30 0001434647 zvra:NantahalaNoteMember 2023-08-302023-08-30 0001434647 zvra:SWKLoansMember 2023-08-302023-08-30 0001434647 zvra:NantahalaNoteMember 2024-03-01 0001434647 srt:MinimumMemberzvra:WellsFargoBankNaMember 2023-01-26 0001434647 srt:MaximumMemberzvra:WellsFargoBankNaMember 2023-01-26 0001434647 zvra:WellsFargoBankNaMemberus-gaap:PrimeRateMember 2023-01-262023-01-26 0001434647 zvra:WellsFargoBankNaMember 2023-12-31 0001434647 zvra:TermLoansUnderCreditAgreementMember 2024-04-05 0001434647 zvra:TermLoansUnderCreditAgreementMember 2024-04-052024-04-05 0001434647 zvra:TermLoansUnderCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrMember 2024-04-052024-04-05 0001434647 zvra:TermLoansUnderCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrMember 2024-04-05 0001434647 zvra:TermLoansUnderCreditAgreementMember 2024-09-30 0001434647 zvra:CommaveTherapeuticsSAMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember 2021-05-07 0001434647 zvra:ReliefTherapeuticsMemberus-gaap:LicenseMember 2024-07-012024-09-30 0001434647 zvra:ReliefTherapeuticsMemberus-gaap:LicenseMember 2024-09-30 0001434647 zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember 2024-07-012024-09-30 0001434647 zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember 2024-01-012024-09-30 0001434647 zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember 2023-07-012023-09-30 0001434647 zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember 2023-01-012023-09-30 0001434647 zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember 2023-06-012023-06-30 0001434647 zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember 2012-03-202012-03-20 0001434647 zvra:ReliefTherapeuticsMemberus-gaap:LicenseMember 2024-01-012024-09-30 0001434647 zvra:ReliefTherapeuticsMemberus-gaap:LicenseMember 2023-12-31 0001434647 zvra:ArimoclomolPurchaseAgreementMember 2024-07-012024-09-30 0001434647 zvra:ArimoclomolPurchaseAgreementMember 2024-01-012024-09-30 0001434647 zvra:ArimoclomolPurchaseAgreementMember 2023-07-012023-09-30 0001434647 zvra:ArimoclomolPurchaseAgreementMember 2023-01-012023-09-30 0001434647 zvra:ArimoclomolPurchaseAgreementMember 2023-01-012023-12-31 0001434647 zvra:XomaLicenseAgreementMember 2024-09-30 0001434647 zvra:ArimoclomolEapMember 2024-09-30 0001434647 zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember 2024-09-30 0001434647 zvra:ConsultingServicesMember 2024-09-30 0001434647 zvra:ArimoclomolEapMember 2023-12-31 0001434647 zvra:AquestiveTherapeuticsMemberus-gaap:LicenseMemberzvra:AZSTARYSLicenseAgreementMember 2023-12-31 0001434647 zvra:ConsultingServicesMember 2023-12-31 0001434647 zvra:LitigationRelatedToMergerMember 2024-04-012024-06-30 0001434647 zvra:AZSTARYSLicenseAgreementMember 2023-12-31 0001434647 us-gaap:StockCompensationPlanMember 2024-09-30 0001434647 us-gaap:StockCompensationPlanMember 2023-12-31 0001434647 us-gaap:WarrantMember 2024-09-30 0001434647 us-gaap:WarrantMember 2023-12-31 0001434647 zvra:PossibleFutureIssuancesUnderEquityIncentivePlansMember 2024-09-30 0001434647 zvra:PossibleFutureIssuancesUnderEquityIncentivePlansMember 2023-12-31 0001434647 zvra:PossibleFutureIssuancesUnderEmployeeStockPurchasePlansMember 2024-09-30 0001434647 zvra:PossibleFutureIssuancesUnderEmployeeStockPurchasePlansMember 2023-12-31 0001434647 2023-11-012023-11-30 0001434647 2023-11-30 0001434647 zvra:AcerWarrantsMemberus-gaap:CommonStockMember 2023-11-30 0001434647 zvra:TheInvestorWarrantMember 2023-11-012023-11-30 0001434647 zvra:TheInvestorWarrantMember 2023-11-30 0001434647 zvra:AcerWarrantsMember 2023-11-012023-11-30 0001434647 zvra:AcerWarrantsMember 2023-11-012023-12-31 0001434647 zvra:AcerWarrantsMember 2024-01-012024-09-30 0001434647 zvra:TwoThousandFourteenEquityIncentivePlanMember 2021-06-012021-06-30 0001434647 zvra:TwoThousandFourteenEquityIncentivePlanMember 2024-09-30 0001434647 zvra:TwoThousandFourteenEquityIncentivePlanMember 2024-01-012024-01-01 0001434647 zvra:TwoThousandFourteenEquityIncentivePlanMember 2024-07-012024-09-30 0001434647 zvra:TwoThousandFourteenEquityIncentivePlanMember 2024-01-012024-09-30 0001434647 zvra:TwoThousandFourteenEquityIncentivePlanMember 2023-07-012023-09-30 0001434647 zvra:TwoThousandFourteenEquityIncentivePlanMember 2023-01-012023-09-30 0001434647 2021-06-30 0001434647 zvra:The2023PlanMember 2023-01-31 0001434647 zvra:The2023PlanMember 2024-02-29 0001434647 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001434647 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001434647 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001434647 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001434647 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001434647 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001434647 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001434647 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001434647 us-gaap:PerformanceSharesMember 2024-07-012024-09-30 0001434647 us-gaap:PerformanceSharesMember 2024-01-012024-09-30 0001434647 us-gaap:PerformanceSharesMember 2023-01-012023-09-30 0001434647 zvra:CvrLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 zvra:WarrantsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 zvra:WarrantsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 zvra:WarrantsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 zvra:WarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001434647 zvra:CvrLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 zvra:CvrLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 zvra:WarrantsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 zvra:WarrantsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 zvra:WarrantsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 zvra:WarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001434647 srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001434647 srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001434647 srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001434647 srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001434647 srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001434647 srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001434647 srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001434647 srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001434647 us-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001434647 us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001434647 srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001434647 srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001434647 srt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001434647 srt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001434647 us-gaap:StockCompensationPlanMember 2024-07-012024-09-30 0001434647 us-gaap:StockCompensationPlanMember 2023-07-012023-09-30 0001434647 us-gaap:StockCompensationPlanMember 2024-01-012024-06-30 0001434647 us-gaap:StockCompensationPlanMember 2023-01-012023-09-30 0001434647 zvra:WarrantsToPurchaseCommonStockMember 2024-07-012024-09-30 0001434647

zvra:WarrantsToPurchaseCommonStockMember 2023-07-012023-09-30 0001434647 zvra:WarrantsToPurchaseCommonStockMember 2024-01-012024-06-30 0001434647 zvra:WarrantsToPurchaseCommonStockMember 2023-01-012023-09-30 0001434647 2024-01-012024-06-30 0001434647 srt:MinimumMember 2024-01-012024-09-30 0001434647 srt:MaximumMember 2024-01-012024-09-30 0001434647 zvra:PropertyAndEquipmentAtCostMember 2024-09-30 0001434647 zvra:PropertyAndEquipmentAtCostMember 2023-12-31 0001434647 zvra:AccumulatedDepreciationAndAmortizationMember 2024-09-30 0001434647 zvra:AccumulatedDepreciationAndAmortizationMember 2023-12-31 0001434647 us-gaap:BridgeLoanMemberzvra:AcerTherapeuticsIncMember 2023-08-302023-08-30 0001434647 srt:MinimumMemberus-gaap:BridgeLoanMember 2023-08-30 0001434647 us-gaap:BridgeLoanMember 2023-10-31 0001434647 zvra:SWKLoansMemberzvra:AcerTherapeuticsIncMember 2022-03-142022-03-14 0001434647 zvra:SWKLoansMemberzvra:AcerTherapeuticsIncMember 2023-01-312023-01-31 0001434647 zvra:SWKLoansMember 2023-01-312023-01-31 0001434647 zvra:NantahalaNoteMember 2023-01-31 0001434647 zvra:MarathonConvertibleNotesMember 2023-06-162023-06-16 0001434647 zvra:MarathonConvertibleNotesMember 2023-06-16 0001434647 zvra:ReliefMembersrt:EuropeMemberzvra:LicenseAgreementAndTerminationAgreementMemberzvra:AcerTherapeuticsIncMember 2023-08-30 0001434647 zvra:ReliefMemberzvra:LicenseAgreementAndTerminationAgreementMemberzvra:AcerTherapeuticsIncMember 2023-08-302023-08-30 0001434647 zvra:ReliefMemberzvra:LicenseAgreementAndTerminationAgreementMemberzvra:AcerTherapeuticsIncMember 2023-08-30 0001434647 zvra:ReliefMemberzvra:WorldwideExcludingEuropeMemberzvra:LicenseAgreementAndTerminationAgreementMemberzvra:AcerTherapeuticsIncMember 2023-08-30 0001434647 zvra:ReliefMembersrt:MaximumMemberzvra:LicenseAgreementAndTerminationAgreementMemberzvra:AcerTherapeuticsIncMember 2023-08-30 0001434647 zvra:AcerTherapeuticsIncMember 2023-11-17 0001434647 zvra:AcerTherapeuticsIncMember 2023-11-172023-11-17 0001434647 us-gaap:BridgeLoanMemberzvra:AcerTherapeuticsIncMember 2023-11-172023-11-17 0001434647 zvra:SwkLoansAndMarathonNotesMember 2023-11-172023-11-17 0001434647 zvra:NantahalaNoteMember 2023-11-17 0001434647 zvra:AcerTherapeuticsIncMemberzvra:AcerWarrantsMember 2023-11-172023-11-17 0001434647 2023-11-17 0001434647 zvra:TheInvestorWarrantMember 2023-11-222023-11-22 0001434647 zvra:TheInvestorWarrantMember 2023-11-22 0001434647 zvra:AcerTherapeuticsIncMember 2023-12-31 0001434647 zvra:AcerTherapeuticsIncMember 2024-01-012024-09-30 0001434647 zvra:AcerTherapeuticsIncMember 2024-09-30 0001434647 zvra:AcerTherapeuticsIncMember 2024-09-30 0001434647 zvra:OlpruvaMember 2023-12-31 0001434647 us-gaap:PatentsMember 2024-09-30 0001434647 us-gaap:PatentsMemberzvra:XomaLicenseAgreementMember 2023-04-012023-09-30 0001434647 us-gaap:PatentsMemberzvra:XomaLicenseAgreementMember 2023-01-012023-09-30 0001434647 zvra:ZVRATimothyJSangiovanniMember 2024-07-012024-09-30 0001434647 zvra:ZVRATimothyJSangiovanniMember 2024-09-30 0001434647 zvra:ZVRASvenGuentherPhDMember 2024-07-012024-09-30 0001434647 zvra:ZVRASvenGuentherPhDMember 2024-09-30 0001434647 zvra:ZVRAJoshuaSchaferMember 2024-07-012024-09-30 0001434647 zvra:ZVRAJoshuaSchaferMember 2024-09-30 0001434647 zvra:ZVRAChristalMMMickleMember 2024-07-012024-09-30 0001434647 zvra:ZVRAChristalMMMickleMember 2024-09-30 0001434647 zvra:ZVRARLaDuaneCliftonMember 2024-07-012024-09-30 0001434647 zvra:ZVRARLaDuaneCliftonMember 2024-09-30 0001434647 zvra:ZVRANeilFMcFarlaneMember 2024-07-012024-09-30 0001434647 zvra:ZVRANeilFMcFarlaneMember 2024-09-30 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:D utr:Y0001434647ZEVRA THERAPEUTICS, INC.false--12-31Q32024 0.00010.000110000001000000000000.00010.000125000000250000000548030565322736443110360415346681545000461900064500000000P20D0090000000000000025000000246200047000002000000P13Y0065000006500000065000000650000065000000October 15, 2024Timothy J. SangiovanniSenior Vice President, Finance and Corporate ControllertruetrueApril 15, 2025October 15, 2024Sven Guenther, Ph.D.Chief Scientific OfficertruetrueOctober 15, 2024Joshua SchaferChief Commercial Officer & Executive Vice President, Business DevelopmenttruetrueApril 15, 2025October 15, 2024Christal M.M. MickleChief Development OfficertruetrueApril 15, 2025October 15, 2024R. LaDuane CliftonChief Financial Officer and TreasurertruetrueApril 15, 2025October 15, 2024Neil F. McFarlaneChief Executive OfficertruetrueApril 15, 2025falsefalse10-Qtrue2024-09-30falsefalse001-36913DE20-58943981180 Celebration Boulevard, Suite 103CelebrationFL34747321939-3416Common Stock, $0.0001 par value per shareZVRANASDAQYesYesNon-accelerated Filertruefalsefalse533759254039000430490003533700024688000779000017377000227600018240009944200086938000875600098410006105000060700073600082000079646955000-399778000-115000-430006977000061864000191551000172327000369500028950001156900014541000230300014400060510009460001545000046190000109450001229700033743000283850006273060000-15364000-71587000-344470002312000366000515700074500047460000-3678000-4660000-4253000-90000-124000-64000-451000104900017380002248000433100059190000517400018150008290000-33225000-10190000-69772000-26157000-0177000-0-0-33225000-10367000-69772000-26157000-0.69-0.3-1.59-0.76478088173472461443843851343640 75-33225000-10367000-69772000-26157000-5360005000-72000-333000-5360005000-72000-333000-33761000-10362000-69844000-264900004000472664000-10983000-399778000-430006186400000 0-166220000-166220000211900000021190000560000005600007100000071000011460000001146000000018400018400004000476056000-10983000-41640000014100048818000000-199250000-199250000263200000026320000193000001930000480000004800000028000028000040004793610000-10983000-436325000421000324780000000-33225000-33225000061370000006137000100064516000000645170000150000000150000092000000920000157000000157000000-536000-536000500055041300010983000-469550000-115000069770000300043626900 00-7536000-353729000113000751200000000-132170000-132170000094500000094500000-0-03447000-0-034477000042000000420000000-176000-176000300043725600 0-10983000-366946000-6300059267000000-25730000-257300002151000000215100002500000025000016500000016500000000-162000-162000300043959700 0-10983000-369519000-225000588730000000-103670000-103670000014400000001440000011500000000115000000710000007100000005000500030004526080 00-10983000-379886000-220000615220000-69772000-261570001088800044820005244000014890000474100021900 0-4660000-4159000-64000-451000015700039900013800 0-1470003000 0-958700016280004520000-270004159000-190000-389000-243000-093000-105900005400000482400038950 00-395000-326000-103100071600 0-53415000-17377000-022400041488000458210000-025426000247980004349600 0-16690000-279750005899000038801000209100 0-042700000128000001082000012560006430002190004310005640000-034470006581900000-050008131200023460000-217000-305000109900 00-221970004304900065466000540390004326900036880004560 00 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr><td style="width: 4%;">A.</td><td style="width: 96%;">Description of Business, Basis of Presentation, and Significant Transactions</td></tr></tbody></table>   Organization   Zevra Therapeutics, Inc. (the "Company") is a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases. The Company has a diverse portfolio of products and product candidates, which includes clinical stage pipeline and commercial stage assets. On September 20, 2024, the U.S. Food and Drug Administration ("FDA") approved the New Drug Application ("NDA") for MIPLYFFA™ (arimoclomol),an orally-delivered treatment for Niemann-Pick disease type C ("NPC"), which is an ultra-rare and progressive neurodegenerative disease. MIPLYFFA, the first FDA-approved treatment for NPC, is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients two years of age and older. In addition, the Company received a transferable rare pediatric disease priority review voucher in conjunction with the approval of MIPLYFFA. MIPLYFFA has also been granted orphan medicinal product designation for the treatment of NPC by the European Commission. OLPRUVA®(sodium phenylbutyrate) for oral suspension is approved by the FDA for the treatment of urea cycle disorders ("UCDs"). The Company also has a pipeline of investigational product candidates, including celiprolol for the treatment of vascular Ehlers-Danlos syndrome in patients with a confirmed type III collagen mutation. KP1077 is the Company's clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia ("IH"), a rare neurological sleep disorder, and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate ("SDX"), the Company's proprietary prodrug of d-methylphenidate ("d-MPH"). The FDA has granted KP1077 orphan drug designation for the treatment of IH.   The Company changed its name from KemPharm, Inc. to Zevra Therapeutics, Inc. effective as of February 21, 2023. On March 1, 2023, following its name change, the Company's common stock began trading on the Nasdaq Global Select Market under the ticker symbol "ZVRA".   Going Concern   The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the nine months ended September 30, 2024, and 2023, the Company incurred a net loss of $69.8 million and $26.2 million, respectively, and as of September 30, 2024, has an accumulated deficit of $469.6 million. The Company has sustained operating losses for the majority of its corporate history and expects to continue to incur operating losses and negative operating cash flows until revenues reach a level sufficient to support ongoing operations.   The Company's ability to continue operating as a going concern is contingent upon its ability to generate revenue from approved products or obtain product candidate regulatory approvals, which would generate revenue, milestones, and cash flow sufficient to support ongoing operations and the satisfaction of financial covenants. These factors raise substantial doubt as to the Company's ability to continue as a going concern for at least one year from the date the unaudited condensed consolidated financial statements are being issued. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.   The Company's liquidity needs will be largely determined by the success of operations through the progression of its products and product candidates in the future. The Company also may consider other sources to fund operations including: (1) out-licensing rights to certain of its technologies and product candidates, pursuant to which the Company would receive cash royalties and milestones; (2) raising additional capital through equity or debt financings or from other sources; (3) obtaining product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (4) reducing spending on one or more research and development programs, including by discontinuing development; and/or (5) restructuring operations to change its overhead structure. The Company is in the early stages of its commercialization effort for OLPRUVA and MIPLYFFA and does not yet have a substantial basis to project future earnings, and its other sources of revenue are not sufficient to sustain its present activities on their own. Accordingly, the Company's ability to continue as a going concern may require it to obtain additional financing to fund its operations.   Basis of Presentation   The Company prepared the unaudited condensed consolidated financial statements in accordance with U.S. GAAP and the rules and regulations of the Securities and Exchange Commission ("SEC") and, in the Company's opinion, reflect all adjustments, including normal recurring items that are necessary.   Merger   On August 30, 2023, the Company and Aspen Z Merger Sub, Inc., a wholly-owned subsidiary of Zevra ("Merger Sub"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Acer Therapeutics Inc. ("Acer"), a pharmaceutical company focused on development and commercialization of therapies for rare and life-threatening diseases. On November 17, 2023 (the "Closing Date"), the Company completed the acquisition of Acer. Pursuant to the Merger Agreement, on the Closing Date, Merger Sub was merged with and into Acer (the "Merger"), with Acer continuing as the surviving entity and as

a wholly-owned subsidiary of Zevra. In connection therewith, Zevra also purchased Acer's secured debt from Nantahala Capital Management, LLC ("NCM"), certain of its affiliates and certain other parties (collectively with NCM, "Nantahala") through a series of transactions and Zevra agreed to provide Acer with a bridge loan facility for up to $18.0 million ("Bridge Loan"), subject to certain terms and conditions. The Merger expanded Zevra's rare disease portfolio, as well as increased and diversified its revenues with the addition of a U.S. commercial asset, OLPRUVA, indicated for the treatment of UCDs. See Note L for further discussion related to the Merger.   Registration Statements on Form S-3   In connection with the Merger, Zevra and Nantahala concurrently entered into a registration rights agreement, pursuant to which Zevra agreed to file a resale registration statement with respect to the resale of the Zevra common stock issuable to Nantahala. On   February 5, 2024, Zevra filed a registration statement on Form S-3 (File No. 333-276856) registering an aggregate of 2,269,721 shares of Zevra's common stock. On   April 5, 2024, we filed an amendment to the registration statement on Form S-3 (File No. 333-250945) covering the issuance of the shares of our common stock issuable upon the exercise of warrants issued in connection with the Merger (Note L) and remaining unexercised as of the date of the amendment, which was declared effective on   April 8, 2024.   On   June 4, 2024, the Company filed a registration statement on Form S-3 (File No. 333-279941) (the   "June 2024 Registration Statement") under which the Company   may sell securities, including as   may be issuable upon conversion, redemption, repurchase, exchange or exercise of securities, in one or more offerings up to a total aggregate offering price of $350.0 million, $75.0 million of which was allocated to the sale of the shares of common stock issuable under the 2024 ATM Agreement (as described further below). The registration statement was declared effective on   June 13,2024.   August 2024 Offering   On   August 8, 2024, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Cantor Fitzgerald & Co. and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the "Underwriters"), in connection with the offering, issuance and sale by the Company of 9,230,770 shares of the Company's common stock at a public offering price of $6.50 per share, pursuant to the   June 2024 Registration Statement and a related prospectus supplement dated   August 8, 2024 filed with the SEC (the   "August 2024 Offering"). Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 1,384,615 shares of its Common Stock at the public offering price, less underwriting discounts and commissions, which the Underwriters exercised in full on   August 9, 2024. The   August 2024 Offering closed on   August 12, 2024. Total shares issued were 10,615,385. Net proceeds from the offering were approximately $64.5 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the offering to support the commercial launch activities for MIPLYFFA, continued commercial support for OLPRUVA and the continued development of celiprolol and KP1077 through potential NDA filings and other general corporate purposes.   Based on the planned use of proceeds, the Company believes that the net proceeds from the   August 2024 Offering and its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into 2027, subject to continuing compliance with the Company's debt covenants.   Entry into 2024 ATM Agreement   On   July 12, 2024, the Company entered into an equity distribution agreement (the "2024 ATM Agreement") with Citizens JMP Securities LLC ("Citizens JMP") under which the Company   may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0 million through Citizens JMP as its sales agent. The issuance and sale, if any, of common stock by the Company under the 2024 ATM Agreement will be made pursuant to the   June 2024 Registration Statement, the accompanying prospectus, and the related prospectus supplement dated   July 12, 2024. Citizens JMP   may sell the common stock by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415 of the Securities Act. Citizens JMP will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company   may impose). The Company will pay Citizens JMP a commission equal to 3.0% in the aggregate of the gross sales proceeds of any common stock sold through Citizens JMP under the 2024 ATM Agreement. As of   September 30, 2024, no shares have been issued or sold under the 2024 ATM Agreement.   Termination of 2021 ATM Agreement   On   July 2, 2021, the Company entered into an equity distribution agreement (the "2021 ATM Agreement") with JMP Securities LLC ("JMP") and RBC Capital Markets, LLC ("RBCCM") under which the Company   may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0 million through JMP and RBCCM as its sales agents. The issuance and sale, if any, of common stock by the Company under the 2021 ATM Agreement will be made pursuant to the registration statement on Form S-3 (File No. 333-257661) which was declared effective on   July 12, 2021, the accompanying prospectus, and the related prospectus supplement dated   July 12, 2021. JMP and RBCCM   may sell the common stock by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415 of the Securities Act. JMP and RBCCM will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company   may impose). The Company will pay JMP and RBCCM a commission equal to 3.0% in the aggregate of the gross sales proceeds of any common stock sold through JMP and RBCCM under the 2021 ATM Agreement. The 2021 ATM Agreement terminated on   July 11, 2024, and no shares had been issued or sold under the 2021 ATM Agreement as of the termination date.   Share Repurchase Program   On   December 20, 2021, the Company initiated a share repurchase program (the "Share Repurchase Program") pursuant to which the Company was able to repurchase up to $50 million of shares of its common stock through   December 31, 2023. On   December 31, 2023, the Share Repurchase Program ended, and the Company had repurchased 1,575,692 shares of its common stock for approximately $11.0 million. -69800000-26200000-469600000180000002269721350000000750000009230770 6.513846151061538575000000000.030750000000.030500000001575692110000000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr><td style="width: 4%;">B.</td><td style="width: 96%;">Summary of Significant Accounting Policies</td></tr></tbody></table>   Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.   On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the useful lives of property and equipment, the recoverability of long-lived assets, the incremental borrowing rate for leases, and assumptions used for purposes of determining stock-based compensation, income taxes, the fair value of investments and the fair value of the warrant liabilities, contingent value right ("CVR") liabilities and discount and rebate liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.   Investments   The Company maintains investment securities that are classified as available-for-sale securities for which the Company has elected the fair value option under Accounting Standards Codification ("ASC") 825, Financial Instruments ("ASC 825"). As such, these securities are carried at fair value with unrealized gains and losses included in fair value adjustment related to investments on the unaudited condensed consolidated statements of operations. The securities primarily consist of U.S. Treasury securities and corporate bonds and are included in securities at fair value in the unaudited condensed consolidated balance sheets. The Company's investments in corporate bonds mature within one to five years. As of   September 30, 2024, and   December 31, 2023, the Company held securities with an aggregate fair value of $41.4 million and $24.7 million, respectively, that contained aggregate unrealized gainsof approximately $0.1 million and $0.6 million, respectively. Applying fair value accounting to these debt securities more accurately represents the Company's investment strategy due to the fact that excess cash is currently being invested for the purpose of funding future operations. Interest income is recognized as earned using an effective yield method giving effect to the amortization of premium and accretion of discount and is based on the economic life of the securities. Interest income is included in interest and other income, net in the unaudited condensed consolidated statements of operations.   Variable Interest Entities   <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;

text-align: justify;">The primary beneficiary of a variable interest entity ("VIE") is required to consolidate the assets and liabilities of the VIE. When the Company obtains a variable interest in another entity, it assesses at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE, and if so, whether the Company is the primary beneficiary of the VIE based on its power to direct the activities of the VIE that most significantly impact the VIE's economic performance and the Company's obligation to absorb losses or the rights to receive benefits from the VIE that could potentially be significant to the VIE.   To assess whether the Company has the power to direct the activities of the VIE that most significantly impact the VIE's economic performance, the Company considers all the facts and circumstances, including the Company's role in establishing the VIE and the Company's ongoing rights and responsibilities. The assessment includes identifying the activities that most significantly impact the VIE's economic performance and identifying which party, if any, has the power to direct those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) are deemed to have the power to direct the activities of a VIE.   To assess whether the Company has the obligation to absorb losses of the VIE or the rights to receive benefits from the VIE that could potentially be significant to the VIE, the Company considers all of its economic interests that are deemed to be variable interests in the VIE.   This assessment requires judgement in determining whether these interests, in the aggregate, are considered potentially significant to the VIE. As of September 30, 2024, and December 31, 2023, the Company identified Acer to be the Company's sole interest in a VIE (Note 1). As Zevra is the final decision maker for all of Acer's research, development, and commercialization of drug candidates that it is producing, the Company directs the activities of Acer that most significantly impact its performance. Therefore, the Company is the primary beneficiary of this VIE for accounting purposes.   Revenue Recognition   The Company recognizes revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers ("ASC 606") and, as a result, follows the five-step model when recognizing revenue: 1) identifying a contract, 2) identifying the performance obligations; 3) determining the transaction price; 4) allocating the price to performance obligations; and 5) recognizing revenue when the performance obligations have been fulfilled.   Licensing Agreements   The terms of the Company's licensing agreements typically include one or more of the following: (i) upfront fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales of licensed products. Each of these payments may result in licensing revenues.   As part of the accounting for these agreements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probability of regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the licensee which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.   Up-front Fees: If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.   Milestone Payments: At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or the licensee's control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the licensee's control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company's estimate of the transaction price may also result in negative licensing revenues and earnings in the period of adjustment.   Product Revenues, Net   Net revenues from product sales is recognized at the transaction price when the customer obtains control of the Company's products, which occurs at a point in time, typically upon receipt of the product by the customer. Our current single customer is a specialty pharmacy provider.   The Company's net revenues represent total revenues adjusted for discounts and allowances, including estimated cash discounts, chargebacks, rebates, returns, copay assistance, data fees and wholesaler fees for services. These adjustments represent variable consideration under ASC 606 and are recorded as a reduction of revenue. These adjustments are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the factors that impact such allowances. Adjustments for variable consideration are determined based on the contractual terms with customers, historical trends, communications with customers and the levels of inventory remining in the distribution channel, as well as expectations about the market for the product and anticipated introduction of competitive products.   Acquired IPR&D and Milestones Expenses   In an asset acquisition, payments incurred prior to regulatory approval to acquire rights to in-process R&D projects are expensed as acquired IPR&D and milestones expense in the consolidated statements of earnings unless the project has an alternative future use. These costs include upfront and development milestone payments related to R&D collaborations, licensing arrangements, or other asset acquisitions that provide rights to develop, manufacture and/or sell pharmaceutical products. Where contingent development milestone payments are due to third parties, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Regulatory and commercial milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product.   Inventories   The value of inventory is recorded at its net realizable value. The Company determines the cost of its other inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis.   The Company may scale-up and make commercial quantities of its product candidates prior to the date it anticipates that such product will receive final regulatory approval. The scale-up and commercial production of pre-launch inventory involves the risk that such products may not be approved for marketing on a timely basis, or ever. This risk notwithstanding, the Company may scale-up and build pre-launch inventory of product that have not received final regulatory approval when the Company believes such action is appropriate in relation to the commercial value of the product launch opportunity. Inventory manufactured prior to regulatory approval is recorded as research and development expense until regulatory approval for the product is obtained. Inventory used in clinical trials is also expensed as research and development expense, when selected for such use. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign. The cost of finished goods inventory that is shipped to a customer to support the Company's patient assistance programs is expensed when those shipments take place. As of September 30, 2024, and December 31, 2023, the Company did not have pre-launch inventory that qualified for capitalization.   The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded as a component of cost of product revenue in the statements of operations and comprehensive loss. The determination of whether inventory costs will be realizable requires the use of estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. Additionally, the Company's product is subject to strict quality control and monitoring that it performs throughout the manufacturing process. In the event that certain batches or units of product do not meet quality specifications, the Company will record a charge to cost of product revenue, to write-down any unsaleable inventory to its estimated net realizable value. For the three and nine months ended September 30, 2024, the Company recognized a charge of approximately $2.0 million and $5.2 million, respectively, related to write-downs for unsaleable inventory. No such write downs were recognized for the three and nine months ended September 30, 2023.   Foreign currency <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal;

margin: 0pt -9pt 0pt -1pt;"> Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the unaudited condensed consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income/loss in the accompanying unaudited condensed consolidated statements of stockholders' equity.   Debt Issuance Costs   Debt issuance costs incurred in connection with financing arrangements are recorded as a reduction of the related debt on the balance sheet and amortized over the life of the respective financing arrangement using the effective interest method.   Warrants   The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity ("ASC 480") and FASB ASC Topic 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own stock and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.   For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital, on the unaudited condensed consolidated statement of stockholders' deficit at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in other expense, net, on the unaudited condensed consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model.   New Accounting Pronouncements Not Yet Adopted   Segment Reporting (Topic 280); Improvements to Reportable Segment Disclosures   In November 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280); Improvements to Reportable Segment Disclosures, which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. This update is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on the presentation of its consolidated financial statements and accompanying notes.   Income Taxes (Topic 740): Improvements to Income Tax Disclosures   In December 2023, the FASB issued ASU No. 2023- 09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity's income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on the presentation of its consolidated financial statements and accompanying notes.   Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.   On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the useful lives of property and equipment, the recoverability of long-lived assets, the incremental borrowing rate for leases, and assumptions used for purposes of determining stock-based compensation, income taxes, the fair value of investments and the fair value of the warrant liabilities, contingent value right ("CVR") liabilities and discount and rebate liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Investments   The Company maintains investment securities that are classified as available-for-sale securities for which the Company has elected the fair value option under Accounting Standards Codification ("ASC") 825, Financial Instruments ("ASC 825"). As such, these securities are carried at fair value with unrealized gains and losses included in fair value adjustment related to investments on the unaudited condensed consolidated statements of operations. The securities primarily consist of U.S. Treasury securities and corporate bonds and are included in securities at fair value in the unaudited condensed consolidated balance sheets. The Company's investments in corporate bonds mature within one to five years. As of September 30, 2024, and December 31, 2023, the Company held securities with an aggregate fair value of $41.4 million and $24.7 million, respectively, that contained aggregate unrealized gainsof approximately $0.1 million and $0.6 million, respectively. Applying fair value accounting to these debt securities more accurately represents the Company's investment strategy due to the fact that excess cash is currently being invested for the purpose of funding future operations. Interest income is recognized as earned using an effective yield method giving effect to the amortization of premium and accretion of discount and is based on the economic life of the securities. Interest income is included in interest and other income, net in the unaudited condensed consolidated statements of operations. 41400000247000001000006000000 Variable Interest Entities   The primary beneficiary of a variable interest entity ("VIE") is required to consolidate the assets and liabilities of the VIE. When the Company obtains a variable interest in another entity, it assesses at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE, and if so, whether the Company is the primary beneficiary of the VIE based on its power to direct the activities of the VIE that most significantly impact the VIE's economic performance and the Company's obligation to absorb losses or the rights to receive benefits from the VIE that could potentially be significant to the VIE.   To assess whether the Company has the power to direct the activities of the VIE that most significantly impact the VIE's economic performance, the Company considers all the facts and circumstances, including the Company's role in establishing the VIE and the Company's ongoing rights and responsibilities. The assessment includes identifying the activities that most significantly impact the VIE's economic performance and identifying which party, if any, has the power to direct those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) are deemed to have the power to direct the activities of a VIE.   To assess whether the Company has the obligation to absorb losses of the VIE or the rights to receive benefits from the VIE that could potentially be significant to the VIE, the Company considers all of its economic interests that are deemed to be variable interests in the VIE.   This assessment requires judgement in determining whether these interests, in the aggregate, are considered potentially significant to the VIE. As of September 30, 2024, and December 31, 2023, the Company identified Acer to be the Company's sole interest in a VIE (Note 1). As Zevra is the final decision maker for all of Acer's research, development, and commercialization of drug candidates that it is producing, the Company directs the activities of Acer that most significantly impact its performance. Therefore, the Company is the primary beneficiary of this VIE for accounting purposes.   Revenue Recognition   The Company recognizes revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers ("ASC 606") and, as a result, follows the five-step model when recognizing revenue: 1) identifying a contract, 2) identifying the performance obligations; 3) determining the transaction price; 4) allocating the price to performance obligations; and 5) recognizing revenue when the performance obligations have been fulfilled.   Licensing Agreements   The terms of the Company's licensing agreements typically include one or more of the following: (i) upfront fees; (ii) milestone

payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales of licensed products. Each of these payments may result in licensing revenues.   As part of the accounting for these agreements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probability of regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the licensee which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.   Up-front Fees: If a license to the Company's intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.   Milestone Payments: At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or the licensee's control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the licensee's control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company's estimate of the transaction price may also result in negative licensing revenues and earnings in the period of adjustment.   Product Revenues, Net   Net revenues from product sales is recognized at the transaction price when the customer obtains control of the Company's products, which occurs at a point in time, typically upon receipt of the product by the customer. Our current single customer is a specialty pharmacy provider.   The Company's net revenues represent total revenues adjusted for discounts and allowances, including estimated cash discounts, chargebacks, rebates, returns, copay assistance, data fees and wholesaler fees for services. These adjustments represent variable consideration under ASC 606 and are recorded as a reduction of revenue. These adjustments are established by management as its best estimate based on available information and will be adjusted to reflect known changes in the factors that impact such allowances. Adjustments for variable consideration are determined based on the contractual terms with customers, historical trends, communications with customers and the levels of inventory remining in the distribution channel, as well as expectations about the market for the product and anticipated introduction of competitive products. Acquired IPR&D and Milestones Expenses   In an asset acquisition, payments incurred prior to regulatory approval to acquire rights to in-process R&D projects are expensed as acquired IPR&D and milestones expense in the consolidated statements of earnings unless the project has an alternative future use. These costs include upfront and development milestone payments related to R&D collaborations, licensing arrangements, or other asset acquisitions that provide rights to develop, manufacture and/or sell pharmaceutical products. Where contingent development milestone payments are due to third parties, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Regulatory and commercial milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product. Inventories   The value of inventory is recorded at its net realizable value. The Company determines the cost of its other inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis.   The Company may scale-up and make commercial quantities of its product candidates prior to the date it anticipates that such product will receive final regulatory approval. The scale-up and commercial production of pre-launch inventory involves the risk that such products may not be approved for marketing on a timely basis, or ever. This risk notwithstanding, the Company may scale-up and build pre-launch inventory of product that have not received final regulatory approval when the Company believes such action is appropriate in relation to the commercial value of the product launch opportunity. Inventory manufactured prior to regulatory approval is recorded as research and development expense until regulatory approval for the product is obtained. Inventory used in clinical trials is also expensed as research and development expense, when selected for such use. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign. The cost of finished goods inventory that is shipped to a customer to support the Company's patient assistance programs is expensed when those shipments take place. As of September 30, 2024, and December 31, 2023, the Company did not have pre-launch inventory that qualified for capitalization.   The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded as a component of cost of product revenue in the statements of operations and comprehensive loss. The determination of whether inventory costs will be realizable requires the use of estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. Additionally, the Company's product is subject to strict quality control and monitoring that it performs throughout the manufacturing process. In the event that certain batches or units of product do not meet quality specifications, the Company will record a charge to cost of product revenue, to write-down any unsaleable inventory to its estimated net realizable value. For the three and nine months ended September 30, 2024, the Company recognized a charge of approximately $2.0 million and $5.2 million, respectively, related to write-downs for unsaleable inventory. No such write downs were recognized for the three and nine months ended September 30, 2023. 2000000520000000 Foreign currency   Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the unaudited condensed consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income/loss in the accompanying unaudited condensed consolidated statements of stockholders' equity. Debt Issuance Costs   Debt issuance costs incurred in connection with financing arrangements are recorded as a reduction of the related debt on the balance sheet and amortized over the life of the respective financing arrangement using the effective interest method. Warrants   The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in FASB ASC Topic 480, Distinguishing Liabilities from Equity ("ASC 480") and FASB ASC Topic 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to our own stock and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.   For warrants that meet all criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital, on the unaudited condensed consolidated statement of stockholders' deficit at the time of issuance. For warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in other expense, net, on the unaudited condensed consolidated statement of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model. New Accounting Pronouncements Not Yet Adopted   Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures   In November 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. This update is effective for annual periods beginning after December 15, 2023, and

interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on the presentation of its consolidated financial statements and accompanying notes.   Income Taxes (Topic 740): Improvements to Income Tax Disclosures   In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity's income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on the presentation of its consolidated financial statements and accompanying notes. <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> C. </td><td style="width: auto;"> Inventories </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Raw materials </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">4,549</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,938</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Work in progress </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,084</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,884</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Finished goods </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">1,123</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total inventory </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,756</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,841</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Raw materials </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">4,549</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,938</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Work in progress </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,084</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,884</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Finished goods </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">1,123</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,756</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0,

0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,841</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>
45490002938000308400018840001123000501900087560009841000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; height: 15px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr><td style="width: 4%;"> D. </td><td style="width: 96%;">Debt Obligations</td></tr> </tbody></table>   Long-term debt consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Notes payable </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt, padding: 0; margin: 0">$</td><td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt, text-align: right; padding: 0; margin: 0">61,035</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Secured promissory note </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt, text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt;">5,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Unamortized original issue (discount) premium </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">(959</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt, padding: 0, margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; padding: 0, margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">148</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt, padding: 0; margin: 0"> Less: debt issuance costs </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt, padding: 0, margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: "Times New Roman", Times, serif, font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(1,172</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt, padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt, padding: 0, margin: 0"> </td><td style="width: 1%, font-family: "Times New Roman", Times, serif, font-size: 10pt, padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif, font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(82</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%, font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%, font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,066</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt, border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>   Secured Promissory Note   In connection with the Merger (Note L), on August 30, 2023, the Company and Nantahala, entered into a secured promissory note payable by Zevra to Nantahala in the original principal amount of $5.0 million (the "Nantahala Note"). The Nantahala Note initially bore interest at 9.0% per annum, payable quarterly in arrears in cash. The interest rate increased to 12.0% per annum effective March 1, 2024, as the Nantahala Note remained unpaid six months from its issue date. The additional 3.0% interest would have been paid in shares of Zevra's common stock based on the volume weighted average trading price ("VWAP") of Zevra's common stock during the twenty consecutive trading days ending on the date before such interest payment date. Beginning on the first interest payment date following the second anniversary of the Nantahala Note, and on each interest payment date thereafter, Zevra was required to make $0.6 million amortization payments on the Nantahala Note until it was paid in full. All principal and unpaid interest on the Nantahala Note would have been due on August 30, 2026, the third anniversary of the Nantahala Note. Zevra was entitled to prepay the Nantahala Note at any time without penalty. The Nantahala Note was secured by Zevra's interest in (i) the loan assets under the Loan Purchase Agreement described in Note L, (ii) the note assets under the Note Purchase Agreement described in Note L, (iii) the Bridge Loan described in Note L, and (iv) the proceeds therefrom. The Company used the proceeds from the Nantahala Note, along with $12.0 million in cash and 98,683 shares of Zevra's common stock, to acquire Acer's term loans, as more fully described in Note L. In April 2024, the Nantahala Note was repaid in full and terminated. At the time of repayment, Nantahala elected to receive a cash payment in lieu of shares of Zevra's common stock in exchange for the additional 3.0% interest accrued for the period from March 1, 2024, through April 5, 2024.   Line of Credit   On January 26, 2023, the Company and Wells Fargo, as lender, entered into a revolving margin account agreement. The Company's investments were used as collateral for the loan and the amount the Company was able to borrow was limited to 80-90% of its outstanding investment balance held with Wells Fargo. The margin account bore interest at the Prime rate minus 225 basis-points. As of December 31, 2023, $37.7 million was outstanding under the margin account. In April 2024, the Company repaid the outstanding balance under the margin account with Wells Fargo, and upon such repayment, the margin capabilities were removed from the account.   Term Loans   On April 5, 2024 (the "Term Loans Closing Date"), the Company entered into a credit agreement (the "Credit Agreement") with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the "Lenders"), and Alter Domus (US) LLC, as administrative agent (the "Administrative Agent").   Under the terms of the Credit Agreement, the Lenders provided a senior secured loan facility to the Company in the aggregate principal amount of $100.0 million, which is divided into three tranches as follows: (i) $60.0 million which was funded in full on the Term Loans Closing Date; (ii) $20.0 million which is available to the Company in up to two drawings, each in an amount not to exceed $10.0 million, at the Company's option until 18 months following the Term Loans Closing Date; and (iii) $20.0 million which is available to the Company upon approval by the FDA of the NDA for MIPLYFFA for the treatment of NPC, at the Company's option until December 31, 2024 (collectively, the "Term Loans").   The principal amount of the Term Loans outstanding (the "Outstanding Principal Amount") will bear interest at a rate equal to 3-Month Term SOFR plus 7.00% per annum. If the net product sales for the calendar year ending December 31, 2025, exceed $100.0 million, the Outstanding Principal Amount will bear interest at 3-Month Term SOFR plus 6.00% per annum. If the net product sales for the calendar year ending December 31, 2025, do not exceed $100.0 million, then for any subsequent period of four consecutive fiscal quarters ending on or after March 31, 2026, in which net product sales exceed $125.0 million, the Outstanding Principal Amount will bear interest at 3-Month Term SOFR plus 6.50% per annum. In all cases, the 3-Month Term SOFR rate will be subject to a floor of 4.00% per annum. Interest will be payable quarterly in arrears on the last day of each calendar quarter. The Company has the option to pay up to 25% of the interest in-kind beginning on the Term Loans

Closing Date, through and including June 30, 2026. The Company has recognized approximately $0.9 million of interest-in-kind as of September 30, 2024, which is included in long-term debt in the unaudited condensed consolidated balance sheet. The Term Loans will mature on the fifth anniversary of the Term Loans Closing Date. In connection with the Credit Agreement, the Company incurred approximately $2.2 million of costs, which primarily consisted of underwriting, legal and other professional fees, and are included as a reduction to the carrying amount of the related debt liability and are deferred and amortized over the remaining life of the financing using the effective interest method.   The Credit Agreement contains customary affirmative and negative covenants by the Company, which among other things, will require the Company to provide certain financial reports to the Lenders within 60 days after the end of each of the first three fiscal quarters of each fiscal year and 105 days after the end of each fiscal year, meet certain minimum net product sales amounts, and limit the ability of the Company to incur or guarantee additional indebtedness, engage in certain transactions, and effect a consolidation or merger without consent. In addition, as long as the line of credit remains active, the Company must maintain a minimum cash balance of $20.0 million to ensure the Company can meet its immediate capital needs. The obligations of the Company under the Credit Agreement <em style="font: inherit;"> may be accelerated upon customary events of default, including non-payment of principal, interest, fees and other amounts, covenant defaults, insolvency, material judgments, or inaccuracy of representations and warranties. The Term Loans are secured by a <em style="font: inherit;">first priority perfected lien on, and security interest in, substantially all current and future assets of the Company. The proceeds of the Term Loans were used to refinance certain existing indebtedness of the Company and its subsidiaries. The Company will use the remaining proceeds to pay fees and expenses related to the debt financing and fund the development and commercialization of OLPRUVA and MIPLYFFA.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Future minimum principal payments under the Term Loans as of <em style="font: inherit;"> September 30, 2024, were as follows (in thousands):</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Year Ending December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">2024 (excluding the nine months ending September 30, 2024)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2027 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2028 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Thereafter </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">60,919</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total minimum payments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60,919</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: unamortized debt discount, debt issuance costs and paid in kind interest </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,015</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">) </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Note payable </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size. 10pt; margin. 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left. 10%; width: 80%; font-size. 10pt; font-family; "Times New Roman", Times, serif, text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Notes payable</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">61,035</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Secured promissory note </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Unamortized original issue (discount) premium </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; padding: 0; margin: 0">(959</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0;

margin: 0">148</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Less: debt issuance costs </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(1,172</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(82</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,066</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 6103500000500000095900014800011720008200058904000506600050000000.090.120.036000001200000098683 0.030.800.900.022537700000100000000600000002000000010000000200000000.071000(<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%; border-bottom: 1px solid rgb(0, 0, 0);"> Year Ending December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2024 (excluding the nine months ending September 30, 2024) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">2027</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">2028</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Thereafter</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">60,919</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total minimum payments</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60,919</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: unamortized debt discount, debt issuance costs and paid in kind interest</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,015</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Note payable</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,904</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 0000060919000609190002015000589040 00 <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">E.</td><td style="width: 96%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Revenue, net</td></tr> </tbody></table>   Licensing Agreements   AZSTARYS License Agreement   The Company entered into a Collaboration and License Agreement (the "AZSTARYS License Agreement") with Commave Therapeutics SA (formerly known as Boston Pharmaceutical S.A.) ("Commave"), an affiliate of Gurnet Point Capital, L.P., dated September 3, 2019. Under the AZSTARYS License Agreement, as amended, the Company granted to Commave an exclusive, worldwide license to develop, manufacture and commercialize the Company's product candidates containing SDX and d-MPH, including AZSTARYS, or any other product candidates containing SDX and developed to treat ADHD or any other central nervous system disorder. Corium Inc. was tasked by Commave to lead all commercialization activities for AZSTARYS under the AZSTARYS License Agreement. Pursuant to the AZSTARYS License Agreement, Commave agreed to pay milestone payments up to an aggregate of $590.0 million upon the occurrence of specified regulatory milestones related to AZSTARYS, additional fixed payments upon the achievement of specified U.S. sales milestones, and quarterly, tiered royalty payments based on a range of percentages of net sales (as defined in the AZSTARYS License Agreement). Commave is obligated to make such royalty payments on a product-by-product basis until expiration of the royalty term for the applicable product.   The Company concluded that these regulatory milestones, sales milestones and royalty payments each contain a significant uncertainty associated with a future event. As such, these milestone and royalty payments are constrained at contract inception and are not included in the transaction price as the Company could not conclude that it is probable a significant reversal in the amount of cumulative revenue recognized will not occur surrounding these milestone paym ents. At the end of each reporting period, the Company updates its assessment of whether the milestone and royalty payments are constrained by considering both the likelihood and magnitude of the potential revenue reversal. For the three and nine months ended September 30, 2024, the Company recognized $1.1 million and $3.6 million of revenue under the AZSTARYS License Agreement, respectively, primarily related to royalties. For the three and nine months ended September 30, 2023, the Company recognized revenue under the AZSTARYS License Agreement of $0. 9 million and $7.2 million, respectively, which includes recognition of a $5.0 million net sales milestone that was met in June 2023. There was no deferred revenue related to this agreement as of September 30, 2024, or December 31, 2023.   In accordance with the terms of the Company's Termination Agreement with Aquestive Therapeutics ("Aquestive") dated March 20, 2012, Aquestive has the right to receive an amount equal to 10% of any royalty or milestone payments made to the Company related to AZSTARYS or KP1077 under the AZSTARYS License Agreement.   The AZSTARYS License Agreement is within the scope of ASC 606, as the transaction represents a contract with a customer where the participants function in a customer / vendor relationship and are not exposed equally to the risks and rewards of the activities contemplated under the AZSTARYS License Agreement.   <div

style="font-size:10pt">   Relief Exclusive License Agreement   As a condition to entering into the Merger Agreement, Acer and Relief Therapeutics SA ("Relief") entered into an exclusive license agreement on August 30, 2023 (the "Relief License Agreement"). Pursuant to the Relief License Agreement, Relief will hold exclusive development and commercialization rights for OLPRUVA in the European Union, Liechtenstein, San Marino, Vatican City, Norway, Iceland, Principality of Monaco, Andorra, Gibraltar, Switzerland, United Kingdom, Albania, Bosnia, Kosovo, Montenegro, Serbia and North Macedonia ("Geographical Europe"). The Company will have the right to receive a royalty of up to 10% of the net sales of OLPRUVA in Geographical Europe. For the three and nine months ended September 30, 2024, the Company did not recognize any revenue under the Relief License Agreement. There was no deferred revenue related to this agreement as of September 30, 2024, and December 31, 2023, For further discussion of the Relief License Agreement, see Note L.   Product Revenues, Net   Expanded Access Program   Net revenue includes revenue from the sale of arimoclomol for the treatment of NPC under the remunerated expanded access compassionate use program in France ("French nATU"). An expanded access compassionate use program is a program giving specific patients access to a drug, which is not yet approved for commercial sale. Only drugs targeting serious or rare indications and for which there is currently no appropriate treatment are considered for expanded access compassionate use programs. Further, to be considered for the expanded access compassionate use program, the drug must have proven efficacy and safety and must either be undergoing price negotiations or seeking marketing approval.   In accordance with ASC 606, the Company recognizes revenue when fulfilling its performance obligation under the Expanded Access Program ("EAP") by transferring control of promised goods or services to its customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. In determining when the customer obtains control of the product, the Company considers certain indicators, including whether the Company has a present right to payment from the customer, whether title and/or significant risks and rewards of ownership have transferred to the customer and whether the customer acceptance has been received. Revenue is recognized net of sales deductions, including discounts, rebates, applicable distributor fees, and revenue-based taxes.   The French Health Authorities and the manufacturer have agreed to a price for sales during the French nATU, but the final transaction price depends on the terms and conditions in the contracts with the French Health Authorities and is subject to price negotiations with the French Health Authorities following market approval. Any excess in the price charged the manufacturer compared to the price agreed with the health authorities once the drug product is approved in France must be repaid. The repayment is considered in the clawback liability (rebate). An estimate of net revenue and clawback liability are recognized using the 'expected value' method. Accounting for net revenue and clawback liability requires determination of the most appropriate method for the expected final transaction price. This estimate also requires assumptions with respect to inputs into the method, including current pricing of comparable marketed products within the rare disease area in France. Management has considered the expected final sales price as well as the price of similar drug products. The Company is operating within a rare disease therapeutic area where there is unmet treatment need and hence a limited number of comparable commercialized drugs products. The limited available relevant market information for directly comparable commercialized drugs within rare disease increases the uncertainty in management's estimate.   For the three and nine months ended September 30, 2024, the Company recognized revenue related to the EAP in France of $2.6 million and $8.0 million, respectively, which is net of a clawback liability of $1.4 million and $4.4 million, respectively, and other gross to net adjustments. For the three and nine months ended September 30, 2023, the Company recognized revenue related to the EAP in France of $2.0 million and $7.1 million, respectively, which is net of a clawback liability of $1.1 million and $4.0 million, respectively, and other gross to net adjustments. The total estimated reserve liability as of September 30, 2024, and December 31, 2023, w as $17.0 million and $12.2 million, respectively. As of September 30, 2024, and December 31, 2023, this estimated reserve liability is recorded as discount and rebate liabilities in the unaudited condensed consolidated balance sheets and is separated into current and long-term based upon the timing of the expected payment to the French regulators.   Product Sales   On December 27, 2022, the FDA approved OLPRUVA (sodium phenylbutyrate), a prescription medicine used along with certain therapy, including changes in diet, for the long-term management of adults and children with UCDs weighing 44 pounds (20 kg) or greater and with a body surface area of 1.2m2 or greater. On November 17, 2023, the Company acquired OLPRUVA in connection with the Merger (Note L). For the three and nine months ended September 30, 2024, sales of OLPRUVA were de minimis.   On September 20, 2024, the NDA for MIPLYFFA, an orally-delivered treatment for NPC, which is an ultra-rare and progressive neurodegenerative disease, was approved. For the three and nine months ended September 30, 2024, sales of MIPLYFFA were de minimis. In May 2011, Orphazyme entered into an asset purchase agreement with LadRx Corporation, which was assigned to XOMA (US) LLC, a wholly-owned subsidiary of XOMA Corporation ("XOMA"), in June 2023 ("XOMA License Agreement"). Under the XOMA License Agreement, XOMA is entitled to certain net sales and regulatory milestone payments in addition to a mid-single digit royalty with respect to sales of MIPLYFFA. For the three and nine months ended September 30, 2024, the Company recognized a regulatory milestone payment of $6.0 million due to XOMA under the XOMA License Agreement, which is included in intangible assets, net in the unaudited condensed consolidated balance sheet.   The Company currently utilizes a single specialty pharmacy provider as its sole distributor for both OLPRUVA and MIPLYFFA. The Company also enters into arrangements with health care providers and payors that provide for government mandated and/or privately negotiated rebates with respect to the purchase of its products. To commercialize OLPRUVA for oral suspension and MIPLYFFA in the U.S., the Company has built marketing, sales, medical affairs, distribution, managerial and other non-technical capabilities or is making arrangements with third parties to perform these services.   Accounts and Other Receivables   Accounts and other receivables consist of receivables from product sales, receivables under the AZSTARYS License Agreement and EAP, as well as income tax receivables and other receivables due to the Company. Receivables under the AZSTARYS License Agreement are recorded for amounts due to the Company related to reimbursable third-party costs and royalties on product sales. Receivables under the EAP are recorded for product sales under the French nATU. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. As of September 30, 2024, the Company had receivables related to the EAP of $4.4 million, AZSTARYS License Agreement of $1.1 million, and other receivables of $2.3 million. As of December 31, 2023, the Company had receivables related to the EAP of $4.7 million, AZSTARYS License Agreement of $11.4 million, and other receivables of $1.3 million. As of September 30, 2024, and December 31, 2023, no reserve or allowance for doubtful accounts had been established.
590000000110000036000007200000500000000.100.10260000080000001400000440000020000007100000110000040000001700000012200000600000044000001100000230000
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr><td style="width: 4%;">F.</td><td style="width: 96%;">Commitments and Contingencies</td></tr> </tbody></table>   From time to time, the Company is involved in various legal proceedings arising in the normal course of business. For some matters, a liability is not probable, or the amount cannot be reasonably estimated and, therefore, an accrual has not been made. However, for such matters when it is probable that the Company has incurred a liability and can reasonably estimate the amount, the Company accrues and discloses such estimates.   Stockholder Litigation Related to the Merger   On October 12, 2023, Brodsky & Smith, purporting to act as counsel for Jerry Beavee, who was asserted to be a stockholder of Acer, filed a complaint entitled Jerry Beavee v. Acer Therapeutics Inc., et al., No. 1:23-cv-08995 in the United States District Court for the Southern District of New York (the "Action") alleging that defendants violated Section 14(a) and 20(a) of the Securities Exchange Act of 1934 by filing the Preliminary Merger Registration Statement which allegedly omitted certain information that such counsel asserts is material to Acer's required disclosure. On October 30, 2023, Acer filed with the SEC a Schedule DEF14A that contained additional information regarding the Merger, which mooted the disclosure claims alleged in the Action. On December 8, 2023, Jerry Beavee filed with the court a notice of dismissal of the Action without prejudice.   On October 20, 2023, Long Law, LLC and Acocelli Law, PLLC, purporting to act as counsel for Kevin Turner, who was asserted to be a stockholder of Acer, filed a complaint entitled Kevin Turner v. Acer Therapeutics Inc., et al., No. 1:23-cv-

01185 in the United States District Court for the District of Delaware alleging that defendants violated Section 14(a) and 20(a) of the Securities Exchange Act of 1934 as well as SEC Rule 14a-9 by filing the Definitive Proxy Statement which allegedly omitted certain information that such counsel asserts is material to Acer's required disclosure. The complaint prays that, if asserted omissions are not adequately corrected, then Turner will seek to enjoin Acer from holding a stockholder meeting to approve the Merger and, if the Merger closes, will seek to rescind it and seek an award of damages.   On October 20, 2023, Long Law, LLC, purporting to act as counsel for Matthew Jones, who was asserted to be a stockholder of Acer, filed a complaint entitled Matthew Jones v. Acer Therapeutics Inc., et al., No. 1:23-cv-01186 in the United States District Court for the District of Delaware alleging that defendants violated Section 14(a) and 20(a) of the Securities Exchange Act of 1934 as well as SEC Rule 14a-9 by filing the Definitive Proxy Statement which allegedly omitted certain information that such counsel asserts is material to the Acer's required disclosure. The complaint prays that, if asserted omissions are not adequately corrected, then Jones will seek to enjoin Acer from holding a stockholder meeting to approve the Merger and, if the Merger closes, will seek to rescind it and seek an award of damages.   On June 19, 2024, the Company entered into a confidential fee agreement (the "Fee Agreement") to settle the above stockholder litigation matters related to the Merger. The parties to the Fee Agreement were entitled to an aggregate payment of approximately $0.3 million, which was paid during the second quarter of 2024.   Litigation Related to the AZSTARYS License Agreement   In September 2024, the Company became engaged in a legal dispute regarding the AZSTARYS License Agreement. The litigation is in its early stages. We cannot predict with certainty the timing or ultimate outcome of this litigation or its potential impact on our business, financial condition, or results of operations. At this time, we have not recorded any accrual for contingent liability associated with this matter. The AZSTARYS License Agreement remains in effect during this litigation, and both parties continue to perform their respective obligations thereunder. However, there can be no assurance that this dispute will not have an adverse impact on our relationship with Commave or on the Company's business. The Company will continue to monitor developments in this matter and will assess the potential impact on our financial statements in future periods. The Company expects to incur significant legal expenses in connection with this litigation, which may materially affect its results of operations in future periods.   As of September 30, 2024, and December 31, 2023,no accruals were made related to commitments and contingencies.   3000000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr><td style="width: 4%;">G.</td><td style="width: 96%;">Stock and Warrants</td></tr></tbody></table>   Authorized, Issued, and Outstanding Common Shares   As of September 30, 2024, and December 31, 2023, the Company had authorized shares of common stock of 250,000,000 shares. Of the authorized shares, 54,803,056 and 43,110,360 shares of common stock were issued as of September 30, 2024, and December 31, 2023, respectively, and 53,227,364 and 41,534,668 shares of common stock were outstanding as of September 30, 2024, and December 31, 2023, respectively.   As of September 30, 2024, and December 31, 2023, the Company had reserved authorized shares of common stock for future issuance as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">September 30, 2024</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">December 31, 2023</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Outstanding awards under equity incentive plans </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">8,987,997</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">8,023,142</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Outstanding common stock warrants </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">5,483,537</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">5,603,729</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Possible future issuances under equity incentive plans </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">4,536,410</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,728,885</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Possible future issuances under employee stock purchase plans </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;">1,242,425</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;">1,340,172</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total common shares reserved for future issuance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,250,369</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,695,928</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>   Common Stock Activity   The following table summarizes common stock activity for the nine months ended September 30, 2024:   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">Shares of Common Stock</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> Balance as of January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family:

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">41,534,668</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued as compensation to third parties </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">9,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Common stock issued as a result of stock options exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">306,826</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Balance as of March 31, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">41,850,494</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued as a result of the Employee Stock Purchase Plan </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">97,747</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued as compensation to third parties </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">41,820</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Common stock issued as a result of stock options exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">1,403</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Balance as of June 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">41,991,464</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued as compensation to third parties </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">32,820</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued in connection with the Public Offering (Note B) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">10,615,385</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued as a result of stock options exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">39,750</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued in connection with vesting of performance-based awards </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">547,945</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Balance as of September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">53,227,364</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>   Authorized, Issued, and Outstanding Preferred Stock   As of September 30, 2024, and December 31, 2023, the Company had 10,000,000 shares of authorized preferred stock, none of which were designated, issued, or outstanding.   Warrants to Purchase Common Stock   The Company has issued warrants to purchase common stock to various third parties, of which 5,483,537 remain outstanding as of September 30, 2024, and are immediately exercisable. These warrants qualify as participating securities under ASC Topic 260, Earnings per Share, and are treated as such in the net loss per share calculation (Note J). The Company may be required to redeem these warrants for a cash amount equal to the Black-Scholes value of the portion of the warrants to be redeemed (the "Put Option").   In connection with the Merger (Note L), in November 2023, the Company directly issued to certain investors an aggregate of 1,382,489 shares of its common stock, par value $0.0001 per share, and accompanying warrants to purchase up to 1,382,489 shares of its common stock (the "2023 Warrants") at a combined offering price of $4.34 per share of common stock and the Warrants and an aggregate of 917,934 shares of its common stock in exchange for the cancellation of a warrant to purchase 2,920,306 shares of common stock of Acer. The Warrants are immediately exercisable and expire on November 22, 2028. The Company used the net proceeds of approximately $6.0 million from the offering for general corporate purposes. These warrants are separately exercisable by the warrant holders. While the warrants are outstanding (but unexercised), the warrant holders will participate in any dividend or other distribution of the Company's assets to its common stockholders by way of return of capital or otherwise. As of September 30, 2024, and December 31, 2023, none of the warrants have been exercised. The warrants have been evaluated to determine the appropriate accounting and classification pursuant to ASC 480 and ASC 815. Generally, freestanding warrants should be classified as (i) liabilities if the warrant terms allow settlement of the warrant exercise in cash and (ii) equity if the warrant terms only allow settlement in shares of common stock.   The Company determined that its outstanding warrants and the Put Option should be recorded as a liability and stated at fair value at each reporting period. Changes to the fair value of the warrant liability are recorded through the unaudited condensed consolidated statements of operations as a fair value adjustment related to warrant and CVR liability. As of September 30, 2024, and December 31, 2023, the fair value of the liability associated with these warrants and the Put Option was approximately $13.9 million and $16.1 million, respectively. The fair value adjustment related to these warrants and the Put Option was approximately $6.0 million of loss and $2.2 million of income for the three and nine months ended September 30, 2024, respectively. The fair value adjustment related to these warrants and the Put Option was approximately $3.7 million and $4.3 million of income for the three and nine months ended September 30, 2023, respectively.   25000000054803056431103605322736441534668 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-

size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">September 30, 2024</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">December 31, 2023</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Outstanding awards under equity incentive plans </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">8,987,997</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">8,023,142</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Outstanding common stock warrants </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">5,483,537</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">5,603,729</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Possible future issuances under equity incentive plans </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">4,536,410</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,728,885</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Possible future issuances under employee stock purchase plans </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;">1,242,425</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;">1,340,172</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total common shares reserved for future issuance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,250,369</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,695,928</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 898799780231425483537560372945364101728885124242513401722025036916695928 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">Shares of Common Stock</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> Balance as of January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">41,534,668</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued as compensation to third parties </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">9,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Common stock issued as a result of stock options exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">306,826</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Balance as of March 31, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">41,850,494</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued as a result of the Employee Stock Purchase Plan </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">97,747</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued as compensation to third parties </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">41,820</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Common stock issued as a result of stock options exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">1,403</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Balance as of June 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">41,991,464</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued as compensation to third parties </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">32,820</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued in connection with the Public Offering (Note B) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px;">10,615,385</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin:

0px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued as a result of stock options exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">39,750</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock issued in connection with vesting of performance-based awards </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">547,945</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Balance as of September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">53,227,364</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>
4153466890003068264185049497747418201403411991464328201061538539750547945532273641000000005483537313824890.000113824894.34917934292030666000000139000

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr><td style="width: 4%;">H.</td><td style="width: 96%;">Stock-Based Compensation</td></tr> </tbody></table>   The Company maintains a stock-based compensation plan (the “Incentive Stock Plan”) that governs stock awards made to employees and directors prior to completion of the IPO.   In November 2014, the Board of Directors of the Company (“the Board”), and in April 2015, the Company’s stockholders, approved the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), which became effective in April 2015. The 2014 Plan provides for the grant of stock options, other forms of equity compensation, and performance cash awards. In June 2021, the Company’s stockholders approved an Amended and Restated 2014 Equity Incentive Plan (the “A&R 2014 Plan”), following its adoption by the Board in April 2021, which among other things added 4,900,000 shares to the maximum number of shares of common stock to be issued under the plan and extended the annual automatic increases (discussed further below) until January 1, 2031 and eliminated individual grant limits that applied under the 2014 Plan to awards that were intended to comply with the exemption for "performance-based compensation" under Code Section 162(m). The maximum number of shares of common stock that may be issued under the A&R 2014 Plan is 9,932,883 as of September 30,2024. The number of shares of common stock reserved for issuance under the A&R 2014 Plan will automatically increase on January 1 of each year, until and including January 1, 2031, by 4% of the total number of shares of the Company’s capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Board. Pursuant to the terms of the 2014 Plan, on January 1, 2024, the common stock reserved for issuance under the 2014 Plan automatically increased by 1,661,386 shares.   During the three and nine months ended September 30, 2024, 27,750, and 761,500 stock options were exercised, respectively. During the three and nine months ended September 30, 2023, no stock options were exercised.   In June 2021, the Company’s stockholders approved an Employee Stock Purchase Plan (the “ESPP”), following its adoption by the Board in April 2021, The maximum number of shares of common stock that may be issued under the ESPP is 1,500,000. The first offering period under the ESPP began on October 1, 2021, and the first purchase date occurred on May 31, 2022. As of September 30, 2024, 257,575 shares have been issued under the ESPP.   In January 2023, the Board approved the 2023 Employment Inducement Award Plan (the “2023 Plan”). The maximum number of shares of common stock that were initially available for issuance under the 2023 Plan was 1,500,000. In February 2024, the Board approved an amendment to the 2023 Plan to increase the aggregate number of shares of common stock available for issuance under the 2023 Plan from 1,500,000 to 4,500,000 shares.   In May 2023, the Board approved the Ninth Amended and Restated Non-Employee Director Compensation Policy (the “Non-Employee Director Compensation Policy”). The equity compensation made pursuant to the Non-Employee Director Compensation Policy will be granted under the A&R 2014 Plan.   Stock-based compensation expense recorded under the Incentive Stock Plan, A&R 2014 Plan, ESPP and 2023 Plan is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Research and development </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,441</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">720</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,322</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,023</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Selling, general and administrative </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">4,696</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family:

"Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">667</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7,566</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">1,058</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,137</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,387</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,888</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,081</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family: "Times New Roman, Times, serif; font-size: 10pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> During the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> September 30, 2024, the Company recognized approximately $2.5 million in stock-based compensation expense related to performance-based awards. There was no stock-based compensation expense related to performance-based awards recognized during the <em style="font: inherit;">nine months ended <em style="font: inherit;"> September 30, 2023. </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p>
99328830.0416613862775076150001500000257575150000015000004500000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Research and development </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,441</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">720</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,322</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,023</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Selling, general and administrative </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">4,696</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">667</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7,566</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">1,058</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total stock-based compensation expense </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,137</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,387</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,888</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,081</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>
144100072000033220002023000469600066700075660001058000061370001387000108880003081000250000000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr><td style="width: 4%;">I.</td><td style="width: 96%;">Fair Value of Financial Instruments</td></tr> </tbody></table>   The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company's principal or, in

absence of a principal, most advantageous market for the specific asset or liability.   The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr><td style="width: 2%; vertical-align: top;">   </td><td style="width: 2%; vertical-align: top;"> ● </td><td style="width: 96%; vertical-align: top;"> Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; </td></tr> <tr><td style="width: 2%; vertical-align: top;">   </td><td style="width: 2%; vertical-align: top;"> ● </td><td style="width: 96%; vertical-align: top;"> Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and </td></tr> <tr><td style="width: 2%; vertical-align: top;">   </td><td style="width: 2%; vertical-align: top;"> ● </td><td style="width: 96%; vertical-align: top;"> Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. </td></tr> </tbody></table>   The carrying amounts of certain financial instruments, including cash and cash equivalents, investments, and accounts payable and accrued expenses, approximate their respective fair values due to the short-term nature of such instruments.   Assets and Liabilities Measured at Fair Value on a Recurring Basis   The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2024, and December 31, 2023 (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">Balance as of September 30, 2024</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">Quoted Prices in Active Markets for Identical Assets (Level 1)</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> Significant Other Observable Inputs (Level 2) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">Significant Unobservable Inputs (Level 3)</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding: 0; margin: 0"> CVR liability (Note L) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">4,800</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">4,800</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Warrant liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">13,902</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">13,902</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Total liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">18,702</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">18,702</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> Securities: </td><td style="font-

family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%; text-align: right;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%; text-align: right;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%; text-align: right;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> U.S. Treasury securities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">35,337</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">35,337</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding: 0; margin: 0"> <p style="margin: 0pt 9pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Corporate bonds</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">6,105</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">6,105</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> <p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Total assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">41,442</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">35,337</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">6,105</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; width: 36%;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">Balance as of December 31, 2023</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px; text-align: center;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">Quoted Prices in Active Markets for Identical Assets (Level 1)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px; text-align: center;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">Significant Other Observable Inputs (Level 2)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px; text-align: center;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">Significant Unobservable Inputs (Level 3)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> <p style="margin: 0pt -9pt 0pt 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">CVR liability (Note 1)</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">7,262</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">7,262</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Warrant liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">16,100</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-

family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">16,100</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Total liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">23,362</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">23,362</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Securities:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">U.S. Treasury securities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);">24,688</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);">24,688</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> Total assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">24,688</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">24,688</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>   The common stock warrant liabilities were recorded at fair value using the Black-Scholes option pricing model. The following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option pricing model as of September 30, 2024, and December 31, 2023:   <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.51% - 3.81</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.76% - 4.12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> <p style="font-family: "Times New Roman", Times, serif; font-size:

10pt; font-variant: normal; margin: 0pt;">Volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61.76% - 82.44</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">62.01% - 92.42</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Expected term (years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.27 - 4.14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.0 - 4.9</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Weighted average fair value </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.54</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.94</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr></tbody></table>   The following table is a reconciliation for the common stock warrant liabilities measured at fair value using Level 3 unobservable inputs (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> Balance as of December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,100</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Change in fair value measurement</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(2,198</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Balance as of September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">13,902</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr></tbody></table>   For thenine months ended September 30, 2024, and 2023, the changes in fair value of the warrant liabilities primarily resulted from the volatility of the Company's common stock and the change in the risk-free interest rates. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">Balance as of September 30, 2024</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">Quoted Prices in Active Markets for Identical Assets (Level 1)</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding-top: 0px; padding-right: 0px; padding-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> Significant Other Observable Inputs (Level 2) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">Significant Unobservable Inputs (Level 3)</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding: 0; margin: 0"> CVR liability (Note 1) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">4,800</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">4,800</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding: 0; margin: 0"> Warrant liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">13,902</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">13,902</td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Total liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">18,702</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">13,902</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr></tbody></table>   The Company's warrant liabilities are classified as Level 3 financial instruments because the Company utilizes significant unobservable inputs in determining the fair value of the warrant liabilities. The Company's CVR liability is classified as Level 1 financial instruments because the Company utilizes quoted prices in active markets for identical assets in determining the fair value of the CVR liability. The Company's Warrant liabilities are classified as Level 2 financial instruments because the Company utilizes significant observable inputs in determining the fair value of the Warrant liabilities.   The Company's CVR liability is valued using a Monte Carlo simulation model. The Company's Warrant liabilities are valued using a Black-Scholes option pricing model. The Company's CVR liability and Warrant liabilities are valued using the following assumptions: <table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; width: 100%;"><tbody><tr><td> </td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">Quoted Prices in Active Markets for Identical Assets (Level 1)</td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">Significant Other Observable Inputs (Level 2)</td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">Significant Unobservable Inputs (Level 3)</td></tr><tr><td> </td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">September 30, 2024</td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">December 31, 2023</td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">December 31, 2023</td></tr><tr><td> </td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">Level 1</td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">Level 2</td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">Level 3</td></tr><tr><td> </td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">Fair Value</td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">Fair Value</td><td> </td><td colspan="2" style="text-align: center; font-weight: bold;">Fair Value</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td>

0);"><td></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">18,702</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"><p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Securities:</p></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%; text-align: right;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%; text-align: right;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%; text-align: right;"></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"></td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"><p style="margin: 0pt 9pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">U.S. Treasury securities</p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">35,337</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">35,337</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"></td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding: 0; margin: 0"><p style="margin: 0pt 9pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Corporate bonds</p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">6,105</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">6,105</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"></td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"><p style="margin: 0pt 0pt 0pt 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Total assets</p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"></td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">41,442</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"></td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">35,337</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"></td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">6,105</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"></td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"></td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; width: 36%;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Balance as of December 31, 2023</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px; text-align: center;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Quoted Prices in Active Markets for Identical Assets (Level 1)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px; text-align: center;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Significant Other Observable Inputs (Level 2)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px; text-align: center;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 13%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">Significant Unobservable Inputs (Level 3)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"></td></tr><tr style="background-color: rgb(204, 238, 255); vertical-

align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> CVR liability (Note L) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">7,262</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px;">7,262</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Warrant liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">16,100</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">16,100</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Total liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">23,362</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">23,362</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Securities</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 13%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">U.S. Treasury securities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);">24,688</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 36%;"> Total assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">24,688</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">24,688</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; padding-left: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>
480000000480000013902000001390200018702000001870200035337000353370000061050000610500004144200035337000610500007262000007262000161000000016100000
<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.51% - 3.81</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3.76% - 4.12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61.76% - 82.44</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">62.01% - 92.42</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Expected term (years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.27 - 4.14</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.0 - 4.9</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Weighted average fair value </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.54</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.94</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>
0.03510.03810.03760.04120.61760.82440.62010.9242001.274.1424.92.542.94 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> Balance as of December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,100</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Change in fair value measurement</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(2,198</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Balance as of September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">13,902</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 16100000-219800013902000 <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%;"><tbody><tr><td style="width: 4%;">J.</td><td style="width: 96%;">Net Loss Per Share</td></tr> </tbody></table>
  For all periods presented herein, the Company did not use the two-class method to compute net loss per share of common stock, even though it had issued securities, other than common stock, that contractually entitled the holders to participate in dividends and earnings, because these holders are not obligated to participate in a loss. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.   Under the two-class method, for periods with net income, basic net income per share of common stock is computed by dividing the undistributed net income by the weighted average number of shares of common stock outstanding during the period. Undistributed net income is computed by subtracting from net income the portion of current period earnings that participating securities would have been entitled to receive pursuant to their dividend rights had all of the period's earnings been distributed and subtracting the actual or deemed dividends declared. No such adjustment to earnings is made during periods with a net loss as the holders of the participating securities have no obligation to fund losses. Diluted net income per share of common stock is computed under the two-class method by using the weighted average number of shares of common stock outstanding plus the potential dilutive effects of stock options, warrants and other outstanding convertible securities. In addition to analyzing under the two-class method, the Company analyzes the potential dilutive effect of stock options and warrants, under the treasury-stock method and other outstanding convertible securities under the if-converted method when calculating diluted income (loss) per share of common stock, in which it is assumed that the stock options, warrants and other outstanding convertible securities convert into common stock at the beginning of the period or date of issuance, if the stock option, warrant or other outstanding convertible security was issued during the period. The Company reports the more dilutive of the approaches (two-class or treasury-stock/if-converted) as its diluted net income (loss) of common stock during the period.   As noted above, for all periods presented herein, the Company did not utilize the two-class approach as the Company was in a net loss position and the holders of the participating securities have no obligation to fund losses. The Company did analyze diluted net loss per share of common stock under the treasury-stock/if-converted method and noted that all outstanding stock options and warrants were anti-dilutive for the periods presented. For all periods presented, basic net loss per share of common stock was the same as diluted net loss per share of common stock.   The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average number of shares of common stock outstanding because their effect is anti-dilutive:
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <em style="font:

inherit;">2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Awards under equity incentive plans </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">8,987,997</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">7,262,039</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">8,987,997</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">7,262,039</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-0; margin-0"> Common stock warrants </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5,483,537</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">4,252,490</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5,483,537</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">4,252,490</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total securities excluded from the calculation of weighted average number of shares of common stock outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,471,534</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,514,529</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,471,534</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,514,529</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>   A reconciliation from net loss to basic and diluted net loss per share of common stock for the three and nine months ended September 30, 2024, and 2023, is as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> Basic and diluted net loss per share of common stock: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss, basic and diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(33,225</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(10,367</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(69,772</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(26,157</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average number of shares of common stock outstanding, basic and diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,809</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,725</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">43,844</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,364</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Basic and diluted net loss per share of common stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">(0.69</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">(0.30</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; padding: 0px; margin: 0px; border-bottom: 3px double black;">(1.59</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">(0.76</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">)</td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Awards under equity incentive plans </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">8,987,997</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">7,262,039</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">8,987,997</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">7,262,039</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Common stock warrants </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5,483,537</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">4,252,490</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5,483,537</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">4,252,490</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total securities excluded from the calculation of weighted average number of shares of common stock outstanding </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,471,534</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,514,529</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0,

0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,471,534</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,514,529</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr></tbody></table>
898799772620398987997726203954835742524905483537425249014471534115145291447153411514529 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> Basic and diluted net loss per share of common stock: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net loss, basic and diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(33,225</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(10,367</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(69,772</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(26,157</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average number of shares of common stock outstanding, basic and diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,809</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,725</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">43,844</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34,364</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Basic and diluted net loss per share of common stock </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">(0.69</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">(0.30</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">(1.59</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">(0.76</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">)</td></tr> </tbody></table>
-33225000-10367000-69772000-261570004780900034725000438440000343640000-0.69-0.3-1.59-0.76 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr><td style="width: 4%;">K.</td><td style="width: 96%;">Leases</td></tr></tbody></table>   The Company has operating and finance leases for office space, laboratory facilities and various laboratory equipment, furniture and office equipment and leasehold improvements. The Company determines if an arrangement is a lease at contract inception. Lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company does not separate lease and non-lease components. Leases with a term of twelve (12) months or less at commencement are not recorded on the unaudited condensed consolidated balance sheets. Lease expense for these arrangements is recognized on a straight-line basis over the lease term. The Company's leases have remaining lease terms of less than 1 year to approximately 3 years, some of which include options to extend the leases for up to 5 years, and some which include options to terminate the leases within 1 year.   <p style="margin: 0pt; text-align: justify; font-family:

"Times New Roman", Times, serif; font-size: 10pt;">Effective <em style="font: inherit;"> June 1, 2021, the Company agreed to sublease office space in Florida, comprised of <em style="font: inherit;">one of the <em style="font: inherit;">two contiguous suites, under a non-cancelable operating lease, which expires in <em style="font: inherit;"> February 2026.</p> <p style="margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The components of lease expense were as follows (in thousands): </p> <p style="margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three months ended September 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine months ended September 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease Cost</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finance lease cost:</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 9pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Amortization of right-of-use assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">36</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">90</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Interest on lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total finance lease cost</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">36</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">90</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Operating lease cost</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">119</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">113</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">330</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">340</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Short-term lease cost</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">59</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">55</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">177</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">165</td><td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Variable lease cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">13</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Less: sublease income </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(128</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(117</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total lease costs </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">166</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">168</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">454</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">517</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr></tbody></table>   Supplemental cash flow information related to leases was as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> Cash paid for amounts included in the measurement of lease liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Financing cash flows from finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; font-family: "Times New Roman"; font-size: 10pt; text-align: right; padding: 0; margin: 0">5</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating cash flows from operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">405</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">426</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating cash flows from short-term leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">177</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">165</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating cash flows from variable lease costs </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Right-of-use assets obtained in exchange for lease liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0;

margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> </tbody></table>   Supplemental balance sheet information related to leases was as follows (in thousands, except weighted average remaining lease term and weighted average discount rate):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%; border-bottom: 1px solid rgb(0, 0, 0);"> Finance Leases </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Property and equipment, at cost </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> less: accumulated depreciation and amortization </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(917</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(882</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Property and equipment, net </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">114</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">149</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Other current liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Other long-term liabilities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total finance lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Operating Leases </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating lease right-of-use assets </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">820</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">790</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total operating lease right-of-use assets </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">820</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Current portion of operating lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">540</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">543</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating lease liabilities, less current portion </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">483</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">456</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total operating lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;

margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,023</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Lease Term </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating leases (in years) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding-left: 9pt;"> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Discount Rate </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">0.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">14.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">%</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">9.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">7.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">%</td></tr> </tbody></table>   Maturities of lease liabilities were as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Finance </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Operating </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%; border-bottom: 1px solid rgb(0, 0, 0);"> Year Ending December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Leases </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Leases </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2024 (excluding the nine months ended September 30, 2024) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">167</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2025 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">536</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2026 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">146</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2027 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">136</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> 2028 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">161</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Thereafter </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">49</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total lease payments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,195</td><td style="width: 1%; font-family: "Times New Roman", Times,

serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Less: future interest expense </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(172</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Lease liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,023</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>   P1YP3YP5YP1Y <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%; border-bottom: 1px solid rgb(0, 0, 0);"> Lease Cost </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Finance lease cost: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Amortization of right-of-use assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">36</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">90</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Interest on lease liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total finance lease cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">36</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">90</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Operating lease cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">119</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">113</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">330</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align:

right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">340</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Short-term lease cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">59</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">55</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">177</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">165</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Variable lease cost </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">13</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Less: sublease income </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(39</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(128</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(117</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total lease costs </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">166</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">168</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">454</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">517</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>
120002600036000900000000120002600036000900001190001130003300003400005900055000177000165000260001300039000390005000039000128000117000166000168000
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> Cash paid for amounts included in the measurement of lease liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Financing cash flows from finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; font-family: "Times New Roman"; font-size: 10pt; text-align: right; padding: 0; margin: 0">5</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating cash flows from operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">405</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">426</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating cash flows from short-term leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">177</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">165</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating cash flows from variable lease costs </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Right-of-use assets obtained in exchange for lease liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size:

10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> </tbody></table> 05000405000426000177000165000390003900000041900000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman, font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%; border-bottom: 1px solid rgb(0, 0, 0);"> Finance Leases </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Property and equipment, at cost </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> less: accumulated depreciation and amortization </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(917</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(882</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Property and equipment, net </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">114</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">149</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Other current liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Other long-term liabilities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total finance lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Operating Leases </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating lease right-of-use assets </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">820</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">790</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total operating lease right-of-use assets </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">820</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Current portion of operating lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">540</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">543</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family:

"Times New Roman";">Operating lease liabilities, less current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">483</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">456</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total operating lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,023</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td

margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">49</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total lease payments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,195</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Less: future interest expense </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(172</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Lease liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,023</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 0167000053600001460000136000016100004900001195000-017200001023000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr><td style="width: 4%;">L.</td><td style="width: 96%;">Merger</td></tr> </tbody></table>   On August 30, 2023, in connection with the Merger Agreement with Acer, the following transactions occurred prior to Closing: <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:47pt;"> </td><td style="vertical-align:top;width:18pt;"> ● </td><td style="vertical-align:top;"> Bridge Loan - Zevra and Acer entered into a bridge loan agreement (the “Bridge Loan Agreement”), providing for Zevra to make loans to Acer up to an aggregate principal amount of $16.5 million. The Bridge Loan was provided to Acer to support its termination agreement with Relief Therapeutics Holding SA and to provide Acer with working capital, including for payments of accounts payable to support the commercial launch of OLPRUVA and the development of celiprolol pending the Merger’s closure. On October 31, 2023, the Company and Acer entered into an amendment to the Bridge Loan Agreement, which increased the aggregate principal amount available under the loan from $16.5 million to $18.0 million. </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:47pt;"> </td><td style="vertical-align:top;width:18pt;"> ● </td><td style="vertical-align:top;"> Purchase of Acer’s Term Loans - Zevra purchased certain indebtedness of Acer held by Nantahala. Under the loan purchase with Nantahala, Zevra purchased (i) an original senior secured term loan facility made available to Acer in an aggregate amount of $6.5 million and funded on March 14, 2022, and (ii) an additional senior secured term loan made to Acer in an aggregate amount of $7.0 million in a single borrowing which funded on January 31, 2023 for (1) $12.0 million in cash, (2) 98,683 shares of Zevra Common Stock; and (3) a secured Promissory Note payable by Zevra to Nantahala in the original principal amount $5.0 million. These were recorded as receivables from Acer and were treated as a settlement of a preexisting relationship in connection with the closing of the transaction and recorded as a component of purchase consideration. </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:47pt;"> </td><td style="vertical-align:top;width:18pt;"> ● </td><td style="vertical-align:top;"> Purchase of Acer’s Convertible Notes (“Marathon Convertible Notes”) - Under the Note Purchase Agreement with Nantahala, Zevra purchased the Marathon Convertible Notes that Nantahala had acquired on June 16, 2023. Zevra acquired the Marathon Convertible Notes in exchange for the issuance of 2,171,038 shares of Zevra Common Stock at $5.0667 per share for a total purchase price of $11.0 million. </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:47pt;"> </td><td style="vertical-align:top;width:18pt;"> ● </td><td style="vertical-align:top;"> Amendment to IP License Agreement and IP Termination Agreement - As a condition to entering into the Merger Agreement, Acer and Relief entered into the Exclusive License Agreement and the Termination Agreement terminating the collaboration and license agreement, dated March 19, 2021, by and between Acer and Relief. Pursuant to the Exclusive License Agreement, Relief holds exclusive development and commercialization rights for OLPRUVA in Geographical Europe. Acer has the right to receive a royalty of up to 10.0% of the net sales of OLPRUVA in Geographical Europe. In accordance with the terms of the Termination Agreement, Relief received an upfront payment from Acer of $10.0 million (which payment was funded with the Bridge Loan described above) with an additional payment of $1.5 million due on the first-year anniversary of the $10.0 million payment. Acer also agreed to pay a 10.0% royalty on net sales of OLPRUVA worldwide, excluding Geographical Europe, and 20.0% of any value received by Acer from certain third parties relating to OLPRUVA licensing or divestment rights, all of the foregoing which are capped at $45.0 million, for total payments to Relief of up to $56.5 million. </td></tr> </tbody></table>   In connection with the closing of the Merger on November 17, 2023, each share of common stock of Acer was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable CVR to be issued by Zevra, which will represent the right to receive one or more contingent payments up to an additional $76 million upon the achievement, if any, of certain commercial and regulatory milestones for Acer’s OLPRUVA and celiprolol products within specified time periods. Certain additional cash payments are also possible pursuant to the CVRs with respect to milestones involving Acer’s early-stage program ACER-2820 (emetine). <p style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; margin: 0pt; text-align: justify; font-size: 10pt; font-family: "Times New Roman", Times, serif;"> The assets acquired and liabilities assumed were recorded based on their acquisition date fair values. Consideration for the Merger was $72.6 million and consists of (i) approximately 2.96 million shares of Zevra common stock valued at $12.8 million, (ii) the Bridge Loan advances of $17.8 million, (iii) $12.0 million in cash paid to Nantahala; (iv) 2.27 million shares of Zevra Common Stock issued to Nantahala valued at $11.5 million based on the VWAP of shares of Zevra Common Stock during the 20 consecutive trading days ending on the trading date prior to August 30, 2023, (v) a secured promissory note payable by Zevra to Nantahala in the original principal amount of $5.0 million, as disclosed in Note C, (vi) $8.5 million in the estimated fair value of contingent consideration related to the CVRs, (vii) approximately 0.9 million shares of Zevra Common Stock issued to a former holder of Acer warrants valued at $4.0 million based on Zevra’s common stock price on the Effective Date and (viii) $1.0 million in notes payable paid by the Company on Acer’s behalf. In addition, effective as of immediately prior to the Effective Time, all of the outstanding and unexercised Acer stock options were automatically cancelled and ceased to exist without any cash or other consideration being paid or provided in respect thereof. The following purchase price allocation reflects the preliminary estimates of and assumptions related to the fair values of assets acquired and liabilities assumed:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">575</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">278</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other current assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Inventory </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,376</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Property, plant, and equipment

</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other noncurrent assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">209</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Approved product - OLPRUVA </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">68,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> IPR&D - celiprolol </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Goodwill acquired </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,701</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">85,185</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Liabilities </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accounts payable and accrued expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,881</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred collaboration funding</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">175</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,556</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair Value of Net Assets Acquired</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">72,629</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>   The preliminary fair values assigned to the tangible and intangible assets acquired and liabilities assumed were determined using an income approach based on management's estimates and assumptions, as well as other information compiled by management, including third-party valuations that utilize customary valuation procedures and techniques. These preliminary fair values are subject to change within the one-year measurement period. The estimated fair values were developed by discounting future net cash flows to their present value at market-based rates of return. The goodwill acquired represents the excess of the purchase price and related costs over the value assigned to the net tangible and identifiable intangible assets of the business acquired. The useful lives of the intangible assets for amortization purposes were determined by considering the period of expected cash flows used to measure the fair values of the intangible assets adjusted as appropriate for entity-specific factors including legal, regulatory, contractual, competitive, economic and other factors that may limit the useful life. The marketed product asset is amortized on a straight-line basis over its estimated useful life. As of September 30, 2024, the in-process research and development ("IPR&D") project had not been completed or abandoned and, therefore, the IPR&D intangible asset is not currently subject to amortization.   The results of operations and changes in stockholders' equity for Acer were included in the Company's consolidated financial statements beginning November 18, 2023.   The following pro forma combined results of operations present the acquisition as if it had occurred on January 1, 2023. The pro forma combined results of operations do not necessarily represent the Company's consolidated results of operations had the acquisition occurred on the date assumed, nor are these results necessarily indicative of the Company's future consolidated results of operations. The Company expects to realize certain benefits from integrating Acer into the Company and to incur certain one-time costs. The pro forma combined results of operations do not reflect these benefits or costs.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">   Nine Months Ended   September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 54%;"> Pro forma revenue </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,267</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">14,913</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Pro forma net loss </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New

Roman", Times, serif; font-size: 10pt;">(25,900</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; padding-left: 9pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(54,763</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr></tbody></table>   Cancellation of Acer Warrant   On November 22, 2023, the Company sold an aggregate of 917,934 shares of its common stock to a healthcare focused investment fund (the "Investor") to cancel a warrant held by the Investor to purchase 2,920,306 shares of common stock of Acer. The shares of common stock were offered and sold to the Investor in a registered direct offering without an underwriter or placement agent.   Contingent Consideration   Contingent consideration liabilities relate to our liabilities arising in connection with the CVRs issued as a result of the Merger. The contingent consideration is classified as Level 3 in the fair value hierarchy. The fair value is measured based on a Monte Carlo simulation or a scenario-based method, depending on the earn-out achievement objectives, utilizing projections about future performance. Significant inputs include volatility and projected financial information, including projections representative of a market participant's view of the expected cash payments associated with the agreed upon regulatory milestones based on probabilities of technical success, timing of the potential milestone events for the compounds, and estimated discount rates.   The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration liabilities for the CVRs (dollars in thousands):   <table cellpadding="0" cellspacing="0" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 50%; margin-left: 25%; margin-right: 25%;"><tbody><tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 81%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at December 31, 2023 </td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> $</p> </td><td style="vertical-align: bottom; width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7,262</p> </td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align: bottom; width: 81%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0pt;">Change in fair value recognized in earnings</td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="vertical-align: bottom; width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black; text-align: right;">(2,462</td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;">)</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 81%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Balance at September 30, 2024</td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double black;">$</td><td style="vertical-align: bottom; width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double black; text-align: right;">4,800</td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double black;"> </td></tr> </tbody></table>   For thenine months ended September 30, 2024, the Company recorded a $2.5 million gain on the change in fair value of contingent consideration, primarily due to changes in market data and revenue projections.
1650000016500000180000006500000700000012000000986835000000217103850.066711000000001010000000150000010000000000.100.204500000005650000000.1210.000176000
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> Assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">575</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Prepaid expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">278</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other current assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Inventory </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,376</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Property, plant, and equipment </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other noncurrent assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">209</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Approved product - OLPRUVA </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">68,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> IPR&D - celiprolol </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Goodwill acquired </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,701</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">85,185</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Liabilities </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accounts payable and accrued expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,881</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred collaboration funding</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">175</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,556</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair Value of Net Assets Acquired</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">72,629</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>
575000278000110009376000350002090006800000020000004701000851850001088100015000001750001255600072629000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">   Nine Months Ended   September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 54%;"> Pro forma revenue </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,267</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">14,913</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Pro forma net loss </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">(25,900</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; padding-left: 9pt; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(54,763</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> 326700014913000-25900000-54763000917934292030 6<table cellpadding="0" cellspacing="0" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 50%; margin-left: 25%; margin-right: 25%;"><tbody><tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 81%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at December 31, 2023 </td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> $</p> </td><td style="vertical-align: bottom; width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7,262</p> </td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align: bottom; width: 81%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0pt;">Change in fair value recognized in earnings</td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="vertical-align: bottom; width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black; text-align: right;">(2,462</td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;">)</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 81%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Balance at September 30, 2024</td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double black;">$</td><td style="vertical-align: bottom; width: 16%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double black; text-align: right;">4,800</td><td style="vertical-align: bottom; width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double black;"> </td></tr> </tbody></table> 726200048000002500000 <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="vertical-align: top; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="width: 45pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> M. </td><td style="width: auto; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Goodwill & Intangible Assets</td></tr> </tbody></table>   The Company's goodwill balance was $4.7 million as of September 30, 2024, and December 31, 2023.   As of September 30, 2024, and December 31, 2023, non-amortizable intangible assets include IPR&D of $2.0 million   As of September 30, 2024, and December 31, 2023, the Company had a definite-lived intangible asset, net related to the acquisition of OLPRUVA as a result of the Merger of $62.6 million and $67.2 million, respectively. This is amortized on a straight-line basis over the OLPRUVA patent life of thirteen years and is reviewed periodically for impairment. Amortization expense is recorded as intangible asset amortization in the unaudited condensed consolidated statements of operations and was $1.5 million and $4.6 million for the three and nine months ended September 30, 2024. No amortization expense related to definite-lived intangible assets was recognized for the three and nine months ended September 30, 2023.   In accordance with its policy, the Company reviews the estimated useful lives of its intangible assets on an ongoing basis. This review indicated that based on recent facts and circumstances, including detailed analysis on sales experience and prospective product strategy, the actual life of the definite-lived intangible asset related to OLPRUVA was longer than the estimated useful life previously established at the acquisition of the asset. As a result, effective September 30, 2024, the Company changed its estimate of the useful life of this intangible asset to better reflect the estimated periods during which this asset will remain in service. The estimated useful life was previously 11 years and was increased to approximately 13 years. The change in estimate had no effect on depreciation and amortization expense, net income, or basic and diluted earnings per share for the three and nine months ended September 30, 2024.   In connection with the XOMA License Agreement, the Company owed XOMA a royalty payment of $6.0 million upon approval of MIPLYFFA in September 2024, which is included in intangible assets, net in the unaudited condensed consolidated balance sheet as of September 30, 2024.   This definite-lived intangible asset is amortized on a straight-line basis over the MIPLYFFA patent life of approximately five years and is reviewed periodically for impairment. Amortization expense is recorded as intangible asset amortization in the unaudited condensed consolidated statements of operations and was de minimis for the three and nine months ended September 30, 2024 . No amortization expense related to definite-lived intangible assets was recognized for the three and nine months ended

 September 30, 2023 ,   For intangible assets subject to amortization, estimated amortization expense for the five fiscal years subsequent to September 30, 2024, is expected to be $6.5 million per year. 47000002000000626000006720000015000004600000OP11YP13Y60000000<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><tbody><tr><td style="width: 4%;">N. </td><td style="width: 96%;">Subsequent Events</td></tr> </tbody></table>   The Company evaluated events and transactions occurring subsequent to September 30, 2024, through November 13, 2024, the date the accompanying unaudited condensed consolidated financial statements were issued. During this period, there were no subsequent events that required recognition in the accompanying unaudited condensed consolidated financial statements, nor were there any additional non-recognized subsequent events that required disclosure.   30008000April 15, 2025105006300110009181 7